<SEC-DOCUMENT>0001564590-21-012531.txt : 20210311
<SEC-HEADER>0001564590-21-012531.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311161951
ACCESSION NUMBER:		0001564590-21-012531
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			C4 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001662579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475617627
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39567
		FILM NUMBER:		21733556

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 231-0700

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cccc-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;line-height:6pt;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December&#160;31, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39567 </p>
<p style="text-align:center;margin-top:2pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47-5617627</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">490 Arsenal Way, Suite 200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Watertown, MA</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">02472</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (617)&#160;231-0700 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.0001 par value per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCCC</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:10.71%;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second quarter, there was no public market for the registrant&#8217;s common stock. The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on March 1, 2021, was $1,334,088,669. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 1, 2021 was 43,119,385. </p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:1pt;line-height:1pt;margin-left:10.74%;margin-right:10.71%;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
</table></div>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, or Form 10-K, including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-K include, but are not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the initiation, timing, progress, results, safety and efficacy, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials, the period during which the results of the trials will become available, and our research and development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ultimate impact of the current novel coronavirus pandemic, or the COVID-19 pandemic, or any other health epidemic, on our business, manufacturing, clinical trials, research programs, supply chain, regulatory review, healthcare systems or the global economy as a whole;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">risks related to the direct or indirect impact of the COVID-19 pandemic or any future large-scale adverse health event, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to mitigate the impact of the pandemic, and our ability to execute business continuity plans to address disruptions caused by the COVID-19 pandemic or future large-scale adverse health event;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain funding for our operations necessary to complete further development, manufacturing and commercialization of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain regulatory approval for any of our current or future product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the period of time over which we anticipate our existing cash and cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to identify and develop product candidates for treatment of additional disease indications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the potential attributes and benefits of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the rate and degree of market acceptance and clinical utility for any product candidates we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the pricing and reimbursement of our product candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the effects of competition with respect to any of our current or future product candidates, as well as innovations by current and future competitors in our industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the implementation of our strategic plans for our business, any product candidates we may develop and our TORPEDO platform;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability and willingness of our third-party strategic collaborators to continue research, development and manufacturing activities relating to our product candidates, including our ability to advance programs under our existing collaboration agreements with F. Hoffman-La Roche Ltd. and Hoffman-LaRoche Inc., or Roche, Biogen MA, Inc., or Biogen, and Calico Life Sciences LLC, or Calico, or other new collaboration agreements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">future agreements with third parties in connection with the manufacturing and commercialization of our product candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the size and growth potential of the markets for our product candidates and our ability to serve those markets;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our financial performance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory developments in the United States and foreign countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the success of competing therapies that are or may become available;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to attract and retain key scientific or management personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments relating to our competitors and our industry; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">other risks and uncertainties, including those discussed in Part I, Item 1A - Risk Factors in this Form 10-K. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Form 10-K represent our views as of the date of this Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-K.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY OF RISKS FACTORS</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in Part I, Item 1A - Risk Factors in this Annual Report on Form 10-K. These risks include, among others:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We are an early-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. To date, we have not generated any revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years and may never achieve or maintain profitability. Our net loss was $66.3 million and $34.1 million for the years ended December&#160;31, 2020 and 2019, respectively.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We will need substantial additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our approach to the discovery and development of product candidates based on our TORPEDO platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Most of our product candidates are still in preclinical development. Our business could be harmed if we are unable to advance to clinical development, develop, obtain regulatory approval for and/or commercialize our product candidates or experience significant delays in doing any of these things.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. In addition, the results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of later-stage clinical trials.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization of our current and future product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We have entered into collaboration agreements with Roche, Biogen and Calico and may in the future seek to enter into collaborations with third parties for the development and/or commercialization of certain of our product candidates. If we fail to enter into these types of new collaborations, or if our existing collaborations are not successful, we may be unable to continue development of our product candidates, we would not receive any contemplated milestone payments or royalties, and we could fail to capitalize on the market potential of our product candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The continuing effects of the novel coronavirus, or COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates in a timely manner, or at an acceptable cost or quality.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we are unable to obtain required marketing approvals for, commercialize, manufacture, obtain and maintain patent protection for or gain market acceptance of our product candidates, or if we experience significant delays in doing so, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_I"></a>PART I</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a>Item 1. <a name="ITEM_1_BUSINESS"></a>Business.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company focused on harnessing the body&#8217;s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases in collaboration with our partners. We leverage our proprietary technology platform, TORPEDO (<font style="text-decoration:underline;">T</font>arget <font style="text-decoration:underline;">OR</font>iented <font style="text-decoration:underline;">P</font>rot<font style="text-decoration:underline;">E</font>in <font style="text-decoration:underline;">D</font>egrader <font style="text-decoration:underline;">O</font>ptimizer), to synthesize a new class of small molecule medicines that are designed to selectively and efficiently destroy disease-causing proteins, including targets previously considered to be undruggable. Less than 15% of proteins are considered druggable with traditional small molecule inhibitors because of limitations, including lack of accessible active binding sites. By contrast, targeted protein degradation fundamentally enables access to a high proportion of the potential target proteins that are currently considered undruggable. Our degraders are designed with a focus on catalytic efficiency to optimize the overall degradation process. We believe this enhanced catalytic activity offers many potential advantages over existing therapeutic modalities, including improved potency, faster response, higher selectivity and avoidance of known toxicities. We are using our TORPEDO platform to build a robust pipeline of oral protein degradation drug candidates, with our lead product candidates focused on oncology indications. Our most advanced product candidate, CFT7455, is an orally bioavailable degrader of a protein target called IKZF1/3, for multiple myeloma, or MM, and non-Hodgkin lymphomas, or NHLs, including peripheral T-cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL. We submitted an investigational new drug application, or IND, for this product candidate to the U.S. Food and Drug Administration, or the FDA, in December 2020 and received clearance from the FDA in January 2021; we expect to begin a first-in-human Phase 1/2 clinical trial for this product candidate in the first half of 2021. We believe CFT7455 has the potential to eventually replace therapies in the class of molecules, known as IMiDs, as the standard of care in multiple indications, including MM. IMiD therapies were estimated to represent worldwide sales of approximately $15 billion in 2020 for a number of indications, including MM as well as MCL, marginal zone lymphoma, and follicular lymphoma. We are also developing CFT8634, an orally bioavailable degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-delete solid tumors, and we expect to submit an IND for this product candidate to the FDA in the second half of 2021 and begin a first-in-human Phase 1/2 clinical trial for this product candidate in 2022.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our TORPEDO platform to synthesize a new class of targeted investigational small molecule protein degraders, which employ a natural protein disposal system, specifically the ubiquitin-proteasome system, or UPS, to catalyze the destruction of target proteins. The E3 ligases targeted by our degraders are a family of proteins that identify and tag proteins for degradation. Since our approach is to optimize overall catalytic efficiency&#8212;rather than specific steps in the catalytic cycle&#8212;our degraders are designed to destroy target proteins as quickly as possible. Our robust chemistry engine and proprietary analytic models of pharmacokinetics, or PK, and pharmacodynamics, or PD, enable us to efficiently design and synthesize degraders for a selected target that are optimized for overall catalytic efficiency and properties such as solubility, permeability and oral bioavailability. These PK/PD models allow us to predict the depth and duration of target degradation <font style="font-style:italic;">in vivo</font> and select candidate degraders with confidence. For example, we believe our PK/PD models for CFT7455 may be predicative of the target level response as a function of time at a 1mg / kg oral dose, showcasing the predictive capability of our TORPEDO platform. We observed a similar predictive relationship in a PK/PD model for CFT7503, which is the parent compound of our lead BRD9 compound, CFT8634. As a result of data such as these, we believe our approach maximizes our potential to create effective drugs across many targets. Another aspect of TORPEDO platform is that we have developed a rich toolkit of 14 novel, structurally distinct binders targeting the E3 ligase, Cereblon. The IMiD class of molecules, which includes approved therapies thalidomide, lenalidomide and pomalidomide, harness Cereblon to effect the degradation of protein targets, resulting in anti-cancer activity. To date, Cereblon is the only E3 ligase known to be targeted by an approved drug to cause protein degradation. Notably, Cereblon is widely expressed across tissues, potentially allowing for therapeutic Cereblon-mediated targeted protein degradation in a wide variety of clinical settings. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFT7455 is an orally bioavailable degrader designed to target IKZF1/3 for the treatment of MM and NHLs, including PTCL and MCL. We have selected IKZF1/3 as our initial targets because they have a strong mechanistic rationale, well-defined biology and targeting them with a novel degrader may address a significant unmet need. In our preclinical studies, CFT7455 has demonstrated potent and selective protein degradation with favorable pharmacological properties. We believe that the differentiated pharmacology of CFT7455, including its high potency, may translate into improved clinical outcomes over the current standard-of-care agents in each of the indications we are pursuing. We submitted an IND for CFT7455 in December 2020, for which we received clearance from the FDA in January 2021, and expect to dose the first patient in the first half of 2021. We expect the results from this clinical trial will help us better understand the disease characteristics of those patients who may derive benefit from CFT7455, which will enable us to design future clinical trials more effectively for the drug. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFT8634 is an orally bioavailable degrader </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designed to target </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid malignancies. BRD9 has been considered an undruggable target using currently available modalities. BRD9 is a component of the non-canonical BAF complex, or ncBAF, that plays a role in regulating gene transcription. In normal cells, this complex is not required for cell survival. However, some tumors, including synovial sarcoma, encode genetic mutations that render the ncBAF complex&#8212;and thus BRD9&#8212;essential for tumor growth. CFT8634 has shown potent anti-tumor activity in synovial sarcoma cell lines but does not appear to affect normal cells. Further, CFT8634 has shown </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> activity in synovial sarcoma xenograft models when dosed orally. We expect to file an IND for CFT8634 with the FDA in the second half of 2021 and dose the first patient in a first-in-human Phase 1/2 clinical trial of this product candidate </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our lead product candidates, we are also developing degraders specifically targeting V600E mutant BRAF to treat melanoma, non-small cell lung cancer, or NSCLC, colorectal cancer and other solid malignancies that harbor this mutation, as well as degraders of a protein target called RET to treat lung cancer, sporadic medullary thyroid cancers and other solid malignancies that harbor oncogenic RET lesions. We expect to have product candidates from our two other lead programs, BRAF V600E and RET, in the clinic by the end of 2022. Beyond these four initial product candidates, we are further diversifying our pipeline by developing new degraders against targets where we believe degradation offers potential advantages over existing therapeutic modalities. We have engineered degraders that have successfully achieved blood-brain barrier penetration in preclinical studies, which is a key step in developing medicines with the potential to treat brain metastases in oncology as well as therapeutic areas such neurodegenerative diseases. We also believe there are many other therapeutic areas and indications where leveraging our TORPEDO platform to develop novel degraders may be advantageous. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk57707871"></a>We have been a pioneer in the field of targeted protein degradation since our founding in 2015. Our technology originated from research at the Dana-Farber Cancer Institute by Jay Bradner<a name="_Hlk57707871"></a>, M.D., Ken Anderson, M.D. and Nathanael Gray, Ph.D., leading researchers in the field of protein degradation who co-founded our company along with our Executive Chairman, Marc A. Cohen. We have assembled a scientific team with extensive knowledge and translational medicine expertise in the protein degradation field. Our management team draws on experience in all phases of drug discovery and development gained at large pharmaceutical and biotechnology companies. In addition, we have entered into key strategic collaborations with each of F. Hoffman-La Roche Ltd., or Roche, Biogen, Inc., or Biogen, and Calico Life Sciences LLC, or Calico, that help us address targets across multiple therapeutic areas. Through these collaborations we have received upfront and milestone payments in an aggregate of $167.5&#160;million through December 31, 2020.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Pipeline </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have leveraged our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platform to generate a robust pipeline of orally available, potent and selective protein degradation drug candidates that may be capable of treating diseases in a wide range of organ systems and tissues. Our pipeline focus is on establishing clear clinical proof-of-concept for targets with well-established biology and a defined regulatory pathway. As shown in the table below, we currently have a number of preclinical programs in development. We anticipate that we will start dosing patients in our Phase 1/2 trial of CFT7455 in the first half of 2021. We expected that CFT8634, BRAF V600E, and RET programs will be in the clinic by the end of 2022. We are currently in the process of assessing our EGFR program in the context of the EGFR treatment landscape and determining the appropriate next steps for this program. Our three strategic collaborations with partners provide additional pipeline optionality and an expansion of our potential targets for protein degradation.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing two types of protein degraders. We refer to the first type of degrader as MonoDACs, which are <font style="text-decoration:underline;">Mono</font>functional <font style="text-decoration:underline;">D</font>egradation <font style="text-decoration:underline;">A</font>ctivating <font style="text-decoration:underline;">C</font>ompounds. MonoDAC degraders function by binding to E3 ligases and creating a new surface on the E3 ligases that enhances the binding of the E3 ligases to target proteins. We refer to our second type of degrader as BiDACs, which are <font style="text-decoration:underline;">Bi</font>functional <font style="text-decoration:underline;">D</font>egradation <font style="text-decoration:underline;">A</font>ctivating <font style="text-decoration:underline;">C</font>ompounds. BiDAC degraders are designed so that one end of the molecule binds to the disease-causing target protein and the other end binds to the E3 ligase. Each of these types of degrader is intended to result in the same end point: the specific degradation of the target proteins of interest. These two approaches have complementary requirements for target engagement: BiDAC degraders utilize specific binding sites where chemical binding moieties, which are portions of a molecule, can be identified, which enables a rational drug discovery approach, while MonoDAC degraders, in contrast, rely on ligase-to-target protein surface interactions to drive the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ubiquitination process, which is the process by which an E3 ligase tags a target protein for degradation using a molecular tag called ubiquitin, rather than specific compound-binding</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sites.</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000001.jpg" title="" alt="" style="width:656px;height:244px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the programs identified above and our early-stage development collaborations with Roche, Biogen and Calico, we are conducting exploratory research and development work on various other wholly owned targets. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are committed to transforming the treatment of cancer, and other diseases through the discovery, development and commercialization of novel therapies that destroy disease-causing proteins. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key elements of our strategy are to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Continue rapid progression toward clinical development of our lead programs developed with our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platform. </font><font style="font-size:10pt;color:#000000;">Our two lead product candidates are CFT7455, targeting IKZF1/3, and CFT8634, targeting BRD9. We expect to initiate a Phase 1/2 open-label trial for CFT7455 in patients with relapsed or refractory MM or NHLs such as PTCL and MCL in the first half of 2021, and we expect to initiate a Phase 1/2 open-label trial for CFT8634 in patients with synovial sarcoma and SMARCB1-deleted solid tumors in 2022. Using our proprietary TORPEDO platform, we have generated novel product candidates for the treatment of cancer, and we believe favorable trial results from our lead programs would offer important validation for both our platform and for the future development of those programs themselves. Based on the results of these planned Phase 1/2 trials, we will work with the FDA to discuss potential expedited development and accelerated approval pathways for the product candidates in these lead programs. Additionally, we will leverage the knowledge gained from our lead programs to strengthen and improve our TORPEDO platform for our other pipeline candidates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Rapidly advance our late-stage discovery programs to generate product candidates.</font><font style="font-size:10pt;color:#000000;"> In addition to our lead product candidates, we have progressed programs targeting BRAF V600E, in collaboration with our partner Roche, RET, and EGFR. We are also pursuing several other earlier-stage research programs. We believe that our platform and approach are broadly applicable to address unmet medical needs in a variety of indications and we aim to continue expanding and advancing our pipeline. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Leverage our TORPEDO platform to generate discovery programs for previously undruggable or challenging targets.</font><font style="font-size:10pt;color:#000000;"> We believe that we can apply the principles and approaches used to advance our lead programs more broadly to develop novel degraders for diseases where traditional small molecule inhibitors and other therapeutic approaches have been unsuccessful. We believe our degraders offer potential broad tissue distribution, oral delivery, relative ease of manufacturing and well-established development and regulatory pathways, which are all critical characteristics across disease areas. Additionally, our targeted protein degradation approach has the potential to address many protein targets that are currently considered undruggable, as our degraders can theoretically destroy proteins using any available conserved binding site, including low-affinity binding sites or non-functional binding sites, bringing biological utility to ligands that would otherwise be inactive. We are focusing our current programs on selected oncology indications, but we believe our platform has broad applicability beyond cancer that we plan to capitalize on in the future. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Strategically invest in our TORPEDO platform. </font><font style="font-size:10pt;color:#000000;">To date we have invested significant time and resources into the experimental and analytical components of our TORPEDO platform. This platform enables us to quickly develop novel protein degraders. We will continue to invest in the latest experimental tools to improve our capabilities and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">continue to enhance our proprietary computational and predictive models. We believe that this investment will support our continued discovery and development of degraders against technically challenging and high-value targets. Additionally, we plan to continue expanding our intellectual property portfolio, including through the identification and optimization of additional binders with unique and desirable drug-like properties. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Engage with strategic partners to accelerate program development and maximize the potential of our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platform. </font><font style="font-size:10pt;color:#000000;">We have entered into strategic collaborations with Roche, Biogen and Calico, under which we are working to identify and develop novel degraders across multiple therapeutic areas. These collaborations provide us with access to the resources of larger biopharmaceutical companies and expertise that enable us to further develop and maximize the potential of our TORPEDO platform. In the future, we may opportunistically enter into additional strategic partnerships around certain targets, product candidates and disease areas, which could advance and accelerate our development programs, allow us to access additional capabilities and expand the utility of our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platform. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Maximize the potential of our product candidates with selective use of development and commercial collaborations.</font><font style="font-size:10pt;color:#000000;"> We retain worldwide commercial rights to CFT7455, CFT8634 and our RET and EGFR programs. In the future, we may selectively evaluate development and commercialization collaborations for our drug candidates with partners whose capabilities complement our own while retaining meaningful commercial rights in key geographic territories. We evaluate potential collaborations based not solely upon their ability to generate additional revenue streams for us, but also based on how they might increase our ability to reach a broader set of patients in our targeted disease areas or expand the breadth of indications that our product candidates are approved to treat. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview of Protein Degradation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Protein Degradation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteins are large, complex molecules that play many critical roles in the human body. Due to their central role in biological function, protein interactions control the mechanisms leading to healthy and diseased states. Diseases are often caused by mutations that alter the normal function of proteins and in turn lead to protein dysfunction and then disease. Recent scientific advances continue to implicate the role of specific proteins in multiple disease states.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As proteins age or are damaged, the human body has a highly conserved homeostasis system, which maintains a stable equilibrium, and relies on specific machinery to identify and break down proteins into their component amino acids, known as the UPS. This process is mediated in part by E3 ligases. The primary role of E3 ligases is to act as a quality control inspector by identifying proteins that are old, damaged, misfolded or otherwise deemed ready for degradation. When an E3 ligase identifies a target protein for degradation, it attaches a molecular tag called ubiquitin in a process called ubiquitination. This ubiquitination process typically continues until the target protein is tagged with multiple ubiquitin proteins, known as poly-ubiquitination. Once the target protein is poly-ubiquitinated, it is released by the E3 ligase and is then quickly recognized by a proteasome, which is the cell&#8217;s recycling plant. The proteasome degrades poly-ubiquitinated proteins into their component amino acids, and these amino acids can then be recycled to form new proteins or can be excreted by the cell. This process is illustrated in the following graphic.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000002.jpg" title="" alt="" style="width:617px;height:246px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately five percent of the human genome is dedicated to the ubiquitin-proteasome system. In addition, many proteins of therapeutic interest are often regulated by E3 ligases, which normally function to achieve rapid control of protein </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concentration across multiple steady states. Collectively, these factors underscore the essential role E3 ligases play in normal cellular function and how they can be leveraged against therapeutic protein targets.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our approach represents a novel modality that seeks to harness this natural degradation machinery to destroy disease-causing target proteins. Both our MonoDAC degraders and BiDAC degraders follow the same catalytic process, with the first step being the formation of a complex between the native E3 ligase, degrader and target protein, which we refer to as the ternary complex. Formation of an appropriate ternary complex that can undergo ubiquitination results in poly-ubiquitination of the target and then degradation of the target protein by the proteasome. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000003.jpg" title="" alt="" style="width:657px;height:248px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, both the natural protein degradation process and the targeted protein degradation mediated by our degraders occur rapidly, on the order of milliseconds from initial target-ligase encounter to poly-ubiquitination and release for degradation by the proteasome. The process of targeted protein degradation mediated by our degraders is illustrated in the following graphic.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000004.jpg" title="" alt="" style="width:672px;height:326px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the targeted protein degradation process occurs for one molecule of a target protein, the degrader is released, and the process can be repeated with the same degrader molecule. This recursive process&#8212;binding the target protein, ternary complex formation with the E3 ligase, ubiquitination and release for degradation&#8212;can occur thousands of times with a single degrader molecule before it is eventually cleared by the body. We refer to this process as the catalytic cycle and it is a crucial differentiator between degraders and traditional protein inhibitors, which must remain bound to the target protein to remain effective.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many current targeted therapies are based on small molecules that inhibit the biological function of a protein of interest. One of the main limitations of inhibitor-based treatments is that high doses of the inhibitor are often needed for adequate, sustained target occupancy levels that are required for efficacy. Since the pharmacological effect is driven by the drug exposure profile, the overall timing and duration of drug action is dependent on drug absorption, distribution and elimination. These exposures can be challenging to achieve and may increase the likelihood of significant off-target side effects. A further limitation of this approach is the requirement to find compounds that bind to specific active sites on the protein that result in functional inhibition. However, there are many sites on a target protein where small molecules can bind</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but have no effect on the overall function. The following figure illustrates the use of a small molecule inhibitor to block the function of a targeted disease-causing protein. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000005.jpg" title="" alt="" style="width:617px;height:240px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advantages of Targeted Protein Degradation Over Traditional Protein Inhibitors </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe targeted protein degradation is a novel modality that could offer significant potential benefits over traditional small molecule inhibitor approaches, including improved and sustained potency, fast and recursive catalytic effect, high selectivity and an expansive target landscape. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Improved and Sustained Potency </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Degraders have the ability to offer a many-fold amplification of effect because a single degrader molecule can exert its effect recursively on a large number of target proteins, thereby boosting the catalytic cycle, known as catalytic amplification. In contrast, traditional protein inhibitors rely on one-to-one binding of an inhibitor molecule with a target protein, with the protein only deactivated while the inhibitor is bound. This means that much higher concentrations of a protein inhibitor drug are needed to achieve the same level of therapeutic effect as a protein degrader. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to requiring significantly less drug than a protein inhibitor, the catalytic amplification of degraders means that targeted protein degradation is able to achieve a level of potency necessary for a therapeutic effect in situations that may otherwise be impossible with traditional protein inhibitors. The effect of rapidly reversible traditional inhibitors on target protein is transient and the target protein typically resumes its disease-causing activity as soon as the inhibitor is no longer bound to the target protein. In contrast, because targeted protein degradation leads to destruction of disease-causing proteins into their component amino acids, the effect of a degrader can persist well after the degrader is cleared from the body because it takes a period of time for the cell to resynthesize disease-causing proteins. Additional potency amplifications can result for target proteins that form complexes with other cellular proteins, since removal of the target protein disrupts the overall complex, not just a specific functional activity of the target protein. In these cases, cellular recovery from the degrader effect requires not only re-synthesis of the target protein, but also its incorporation into a larger molecular complex. This effect can be observed even in cases where the target protein complexes are as small as two proteins, or dimers, as well as larger multi-protein complexes. This means that degraders may help to achieve a more durable biological effect and better clinical outcomes. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fast and Recursive Catalytic Effect </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One degrader molecule can rapidly degrade many target proteins. Each catalytic cycle initiated by our degraders and ending with degradation of a disease-causing target protein occurs in a matter of milliseconds. The speed of the catalytic cycle combined with the catalytic amplification of our degraders could result in clinical impact on the disease mechanism that cannot be achieved with traditional inhibitors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">High Selectivity </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the primary challenges of protein inhibition is attempting to identify and develop molecules that only target cancerous cells or mutant proteins without having deleterious effects on normal cells or proteins, commonly referred to as off-target effects. We believe degraders combine the advantages of small molecule therapies with the potential of gene therapies. Degraders have drug-like properties, including oral bioavailability, and are easier to manufacture than other therapeutic modalities involving complex macromolecules, such as antibodies and genetic material. Similar to gene therapies and gene editing strategies, degraders can eliminate the presence of a pathogenic protein. However, treatment with degraders may be halted at any time, in contrast to the long-lasting effects of gene therapies. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each step in the protein degradation cycle requires specific positioning of the target protein and E3 ligase to progress through the catalytic cycle, and these positioning requirements can serve as filters to increase selectivity of a degrader molecule so that only the target protein is ultimately degraded, even if the molecule binds to multiple proteins. For example, degraders are created with the shape, or conformation, of the target protein in mind because a degrader and its target protein must assume a conformation amenable to forming a ternary complex with an E3 ligase. As a result, even if a degrader were to bind to a non-target protein, the resulting ternary complex may not have a conformation that is appropriate to facilitate ubiquitination and subsequent degradation. We are able to leverage these intrinsic properties of the ubiquitin-proteasome protein degradation pathway to design degraders to be highly selective for disease-causing target proteins. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expansive Target Landscape </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since targeted protein degradation does not function by inhibiting the target protein&#8217;s active site, in theory any conserved binding site on a target protein may be used for degrader binding to facilitate formation of the ternary complex and eventual protein degradation. In contrast, inhibitors are only able to have a therapeutic effect either by binding directly to a protein&#8217;s active site or by binding to an allosteric site in such a way to cause a conformational change in the protein that inhibits the active site. This inherently limits the number of druggable targets addressable with traditional inhibitors, as many drug binding sites are physically inaccessible or weakly bind with small molecules. Additionally, whereas an inhibitor requires high affinity and a strong bond to the binding site to remain active, degraders can bind with weak affinity for only a short amount of time and still enable ubiquitination and destruction of the protein. Specifically, less than 15% of proteins are considered druggable with traditional small molecule inhibitors because of limitations, including lack of accessible active binding sites, while targeted protein degradation fundamentally enables access to a high proportion of the potential target proteins that are currently considered undruggable. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000006.jpg" title="" alt="" style="width:596px;height:294px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ a comprehensive approach to product candidate selection and development to maximize the potential therapeutic benefit of our protein degraders. We seek out indications with high value protein targets that may benefit the most from degraders, with catalytic degradation turnover as the key metric by which to assess protein degradation. To that end, we have invested heavily in experimental tools, computational and predictive models and team expertise to analyze and optimize the catalytic ability of our degraders through our TORPEDO platform. Additionally, we leverage our platform to optimize the ability of our degraders to initiate the ubiquitin-proteasome protein degradation cycle and predict their function <font style="font-style:italic;">in vivo</font>. Due </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the rapid optimization allowed by our TORPEDO</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">platform and the ability of our platform to predict degrader effects </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we are able to quickly and efficiently advance programs from target identification to the candidate development</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our oral, small molecule targeted protein degraders are designed to leverage the body&#8217;s natural degradation machinery and repurpose it to recognize disease-causing proteins and tag them for destruction by the proteasome. Both our MonoDAC and BiDAC protein degrader approaches are complementary, and this provides us with additional flexibility to design degraders for each application and specific target. Since our degraders are fundamentally small molecules, we are able to deliver them through any route of administration available to traditional small molecules, including oral, intravenous and subcutaneous. Furthermore, our approach emphasizes the value of rapid catalytic degradation to increase the rate with which degradation of disease-causing target proteins occurs. Our approach focuses on minimizing biology and toxicity risk and pursuing diseases with significant unmet medical need and defined regulatory pathways.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>Platform</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000007.jpg" title="" alt="" style="width:512px;height:232px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary platform, TORPEDO, allows for informed and efficient drug design and discovery through a robust chemistry engine and proprietary assays, culminating in predictive models that enable us to maximize catalytic turnover and predict <font style="font-style:italic;">in vivo</font> performance. Key elements of the platform include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Structural biology and ternary complex model development:</font><font style="font-size:10pt;color:#000000;"> We have invested heavily in structure-based approaches, such as x-ray crystallography and Hydrogen-Deuterium Exchange Mass Spectrophotometry, or HDX-MS, to evaluate degrader binding interactions and enable structure-based design in both the solid-state and solution. These approaches enable, among other things, the ability to dissect the distribution of ternary complexes formed by degrader complexes, allowing us to quickly evaluate and optimize prospective compounds. Our proprietary ternary complex model library incorporates target structure, Cereblon E3 ligase structure and chemistry data to provide insight into differences in activity between degraders and drive the medicinal chemistry optimization process. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Purpose-built chemistry engine:</font><font style="font-size:10pt;color:#000000;"> Our TORPEDO chemistry engine is designed to facilitate development of degraders with drug-like properties, leveraging structural insights generated by the platform and our deep drug development expertise. Traditionally, small molecule inhibitor optimization has often been guided by an emphasis on specific property enhancements, such as the Lipinkski &#8220;rule of five,&#8221; which stipulates limits on the molecular weight and hydrogen bond donors and acceptors to ensure drug-like properties. Degraders often fall well outside of these traditional boundaries and therefore require a reevaluation of these guidelines, commonly referred to as the &#8220;beyond-rule-of-five&#8221; space. By applying these principles in our chemistry designs, we are able to improve drug-like properties, including permeability, solubility and oral bioavailability, while maintaining potency and </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> activity. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Enabling quantitative degradation assays:</font><font style="font-size:10pt;color:#000000;"> We have developed high-throughput cellular degradation assays that produce quantitative data showing the relationship between degrader concentration and target protein degradation. This approach, along with similar robust cellular assay systems, allows protein degradation quantitation with greater precision and higher throughput than traditional western-blot approaches. The application of our experimental data to our robust and proprietary models then allows us to predict protein degradation kinetics, and the high throughput of both approaches allows us to rapidly iterate and improve on degrader candidates and design for properties that optimize catalytic degradation turnover. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Predictive pharmacology founded on an enzymology framework:</font><font style="font-size:10pt;color:#000000;"> We have established an enzymology framework that assesses and balances the relationship between degrader concentration, time and target protein degradation to identify the key kinetic parameters of degrader induced protein degradation. We have extended this </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">framework to proprietary PK/PD models, which integrate these kinetic parameters with metabolism and PK exposure profiles to predict </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> degrader performance. Our predictions of degrader performance are routinely validated through </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> PD experiments with measurements of target degradation from tumor samples using standard western blot assays. We have observed that these models linking cellular assays with predicted </font><font style="font-style:italic;font-size:10pt;color:#000000;">in vivo</font><font style="font-size:10pt;color:#000000;"> performance have significantly accelerated our discovery process, and we believe that this will increase the likelihood of successfully transitioning from preclinical models to the clinic. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These features help focus our platform on the creation of candidates that we believe will present minimized biology and toxicity risk and address unmet treatment needs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Minimizing Biology and Toxicity Risk </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We place a significant emphasis on minimizing risk in our current and planned programs by focusing on candidates with well-established biology and toxicology profiles, which allows us to select degraders that we believe have the best chance of being successful clinically. To reduce biology risk, we pursue targets that have been clinically validated or that have strong preclinical data suggesting that successful target degradation would result in therapeutic benefit. To reduce toxicity risk, we seek to minimize predictable preclinical safety liabilities early in the drug development process. In furtherance of these objectives, we consider the following during program development: </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ligase selection: <font style="font-weight:normal;">Our lead degraders exclusively utilize Cereblon as the E3 ligase. There are over 600 E3 ligases in the human proteome, of which the biology has been well characterized in no more than 50 of them. To our knowledge, only a limited number of E3 ligases, including Cereblon, VHL, MDM2, IAPs and &#223;-TRCP, are currently suitable for targeted protein degradation. We have chosen to focus on Cereblon as the E3 ligase target of our protein degradation approach for several reasons: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Extensive clinical experience with the approved drugs thalidomide, lenalidomide and pomalidomide has shown that using Cereblon can effect target degradation. The mechanism of action of these molecules is to degrade disease targets, specifically IKZF1 and IKZF3, by bringing them into complex with Cereblon. Lenalidomide and pomalidomide are both approved drugs that have served as part of the standard of care for the treatment of MM for the last 15 and seven years, respectively. Together, this experience clinically validates that Cereblon has been harnessed both safely and effectively by other drugs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We have developed methods to obtain high resolution structural data with Cereblon bound to novel chemical binders, which allows us to rationally design improved binders with unique chemical features. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Cereblon is widely expressed across tissues and is present in all of the cellular compartments, including the cytoplasm and nucleus, potentially allowing for Cereblon-mediated targeted protein degradation across a wide variety of clinical settings and potential targets. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We have developed multiple distinct, proprietary Cereblon binders that we have designed for improved drug-like properties, such as enhanced oral bioavailability, solubility, permeability and stability, and all of our product candidates and programs benefit from these properties of our proprietary Cereblon binders. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our library of Cereblon binders offers a proprietary and powerful toolkit for degrader discovery. This Cereblon binder toolkit enables a more modular approach to identifying and optimizing degraders, as each of these binder classes encode distinct drug-like properties and, importantly, unique &#8220;exit trajectories&#8221; from the Cereblon surface following protein degradation, which can promote better target degradation turnover. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimizing target toxicity and maximizing potential degradation<font style="font-weight:normal;">: We select target proteins where we believe degradation of the target in adult humans will likely be tolerable by patients generally, often by selecting target proteins that have already been targeted by traditional inhibitors with good tolerability. Three of our lead targets, IKZF1/3, BRAF V600E and RET, have been previously targeted clinically with inhibitors, and their inhibition has been tolerated. One of our lead programs, BRAF V600E, specifically targets only the mutant disease-causing protein that is found only in cancer cells, which means that on-target protein degradation should only impact cancer cells. We also aim to limit on-target toxicity risk by specifically targeting proteins that are only critical in the setting of genetically driven cancer but not normal cells, as is the case with BRD9 and proteins that are minimally expressed in healthy adult cells, such as RET. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degrader design: <font style="font-weight:normal;">We seek to optimize catalytic degradation turnover and high selectivity, while also managing safety risk, by focusing our analytical techniques and predictive models on the relationship between degrader properties and ultimate protein degradation. Our degraders activate the E3 ligase and facilitate target protein binding and ubiquitination, resulting in rapid overall target degradation. The ability of our degraders to repeat this process recursively with many copies of the target protein with the same single degrader molecule allows us to optimize our product candidates for catalytic degradation turnover and, as a result, create candidates that have the potential to provide a greater therapeutic effect. Our MonoDAC degraders and BiDAC degraders need to achieve sufficient binding affinity to initiate brief ternary complex formation, but, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">unlike traditional inhibitors, they do not need to achieve prolonged stable binding to achieve desired physiological effects. In fact, in a number of our pre-clinical research activities, we have observed that even weaker binders can still result in very efficient degraders since they may allow for higher rates of catalytic degradation turnover, which is something we prioritize to achieve potentially greater activity. We can target disease-causing proteins to which traditional inhibitors have been unable to sufficiently bind because we are not restricted to selecting compounds that have high target binding affinity. Moreover, in some instances we are able to repurpose molecules developed for traditional inhibitor approaches as the target-protein-binding end of our degraders and improve upon their biologic properties by incorporating them into a BiDAC. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We address toxicity driven by degradation of proteins other than the intended target, or off-target toxicity, by developing degraders with high selectivity. We confirm selectivity by global protein expression studies and validate the results through standard good laboratory practice, or GLP, toxicity studies. We also minimize the risk of toxicity driven by the chemical matter making up our MonoDAC and BiDAC molecules that is independent of the specific toxicities described above, or molecule-related toxicity, with high quality chemical matter optimized to minimize known chemical and metabolic liabilities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Focus on High Unmet Medical Need </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently focus on indications where there is a clear and high unmet medical need. Given the broad potential applicability of our approach, we believe it is important to prioritize treating diseases where traditional therapeutic modalities have failed or had a suboptimal therapeutic impact. In some cases of significant unmet need, there can be opportunities for expedited product development and a path to accelerated regulatory approval. Pursuing these types of accelerated pathways is a focus of our approach and provides the potential to address patients&#8217; needs expediently while also validating our platform. We believe our platform has broad applicability beyond cancer that we plan to address in the future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leveraging our Differentiated Platform and Approach </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that these features differentiate our platform from other drug development approaches, including those of others in the targeted protein degradation space. We believe these differentiating features, as exemplified in our four lead programs, will help us succeed in developing novel degraders of disease-causing proteins to address unmet medical need. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our four lead programs will be delivered orally because, in these indications, against these targets, oral delivery provides potential therapeutic and commercial advantages. Also, oral delivery helps mitigate the risk of adverse events associated with intravenous or intramuscular administration, including pain or extravasation, or leakage into the extravascular tissue, at the infusion site. By focusing on targets with reduced biology and toxicity risk and pursuing conditions with high unmet medical need, we have selected four preclinical programs to advance into the clinic. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidates&#8212;Highly Selective Protein Degraders </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have a number of preclinical product candidates in development. We anticipate that CFT7455 will be in the clinic by the first half of 2021, and that CFT8634, BRAF V600E, and RET programs will be in the clinic by the end of 2022. These programs are directed towards targets that remain inadequately treated with available therapies or are undruggable. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CFT7455: A IKZF1/3 Degrader for Multiple Myeloma, Peripheral T-Cell Lymphoma and Mantle Cell Lymphoma </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing CFT7455, an orally bioavailable degrader designed to target IKZF1/3, for the treatment of MM and NHLs, including PTCL and MCL. We have chosen IKZF1/3 as our initial targets for degradation because of their strong mechanistic rationale and well-defined biology. In preclinical studies, CFT7455 has shown robust activity in MM, PTCL and MCL subcutaneous xenograft mouse models, providing preclinical proof of concept. Specifically in MM, we have observed in preclinical studies that CFT7455 remains active in <font style="font-style:italic;">in vivo</font> and <font style="font-style:italic;">in vitro</font> models that are relatively insensitive to standard of care agents that have a similar mechanism of action, such as pomalidomide. We believe that the differentiated pharmacology of CFT7455, including its high potency, may translate into significantly improved clinical outcomes over current standard-of-care agents in each of the indications in which we are pursuing its development. Additionally, our first-in-human Phase 1/2 clinical trial is designed to capitalize on potential opportunities for expedited product development and accelerated approval in MM, PTCL and MCL. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">IKZF1/3 Is a Well Understood Biological Target for Certain Blood Cancers </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IKZF1 and IKZF3 are transcription factors central to the differentiation of lympho-myeloid multipotent progenitor cells through mature immune cells, including T cells and plasma cells, such as B cells. In particular, by preventing the maturation of B cells there is an antiproliferative effect in B-cell driven blood cancers, such as MM, B-cell lymphomas and myelodysplastic syndrome. In addition to these cell-intrinsic dependencies on IKFZ1/3 for B cell maturation, degradation of IKZF1 and IKZF3 has been shown in third-party research to lead to enhanced IL-2 expression in T cells, meaning IKZF1/3 degradation also induces T cell activity and may exert anti-cancer effects. IKZF1/3 has been previously validated as a target in clinical practice. Lenalidomide and pomalidomide primarily target IKZF1/3 as their mechanism of action. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Multiple Myeloma </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, MM represents nearly 1.8% of all new cancer cases. The National Cancer Institute estimated 32,270 new cases of MM in the United States and 12,830 deaths from the disease in 2020. Although overall outcomes for patients with MM have improved substantially over the past several decades, patients with MM have a poor prognosis and the predicted median five-year relative survival rate is only 53.9%. As such, there remains a significant unmet need. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most patients with MM will have an initial response to treatment. Based on fluorescence in situ hybridization, or FISH, studies on bone marrow, patients are stratified into high-risk or standard-risk categories. High-risk patients eligible for hematopoietic cell transplantation receive induction therapy with a combination regimen, often including an IKZF1/3 targeting drug like lenalidomide, to reduce the number of tumor cells prior to stem cell collection. Alternatively, patients who are ineligible for hematopoietic cell transplantation immediately receive a combination regimen, often with three to four classes of drugs, including an IKZF1/3 targeting drug and a steroid, typically dexamethasone, until progression or unacceptable toxicity. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, current therapies are not curative, and most patients will ultimately progress. Despite the likelihood of an initial remission, there is a significant unmet need because most patients experience serial relapse and will be treated with most available agents at some point during their disease course. In our clinical program, we will initially focus on treating patients with relapsed/refractory MM who have received at least two lines of specified prior therapy, including lenalidomide, pomalidomide, two proteasome inhibitors and/or an anti-CD38 monoclonal antibody, or mAb. Ultimately, our intention is to seek approval in earlier lines of therapy, replacing or complementing current IKZF1/3 targeting drugs. We believe that the high potency and activity we have seen <font style="font-style:italic;">in vivo</font> has the potential to translate into a meaningful benefit for patients. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Peripheral T-cell Lymphomas </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTCLs are a heterogeneous and typically aggressive group of NHLs. The Surveillance, Epidemiology and End Results Program or SEER Program, of the National Institutes of Health, or NIH, estimated 77,240 new cases of NHL in the United States and 19,940 deaths from the disease in 2020. PTCLs comprise approximately 4% of all NHLs in the United States and Europe, with an incidence that increased from 0.1 cases per 100,000 in 1992 to 0.4 cases per 100,000 in 2006, potentially reflecting improved diagnostic methods. The median five-year relative survival of patients with PTCL is 50%. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTCL is a heterogeneous malignancy with many subtypes. The outcomes in these subtypes vary, but many patients with PTCL do poorly. In patients with PTCL in whom no subtype is defined, which is often referred to as PTCL not otherwise specified or PTCL-NOS, the five-year overall survival is approximately 20% to 32%. In other subtypes, outcomes vary greatly, though most patient with these subtypes do poorly. For instance, patients with angioimmunoblastic, natural killer/T-cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic, enteropathy type or ALK-peripheral T-cell lymphoma all have a median five-year overall survival of less than 50%. Although initial overall response rates for chemotherapy are approximately 40% to 75%, most patients either relapse or fail to achieve remission. Median progression free survival or PFS, following chemotherapy is 12 to 14 months with a median five-year survival rate of approximately 20% to 30%. There is a significant unmet need for relapsed/refractory disease as there is no accepted standard of care for this population. Lenalidomide has been tested clinically in PTCL in a Phase 2 trial and shown to have an overall response rate of 22% to 26%. Cereblon modulators, such as lenalidomide, also known as IMiDs, are not widely used nor approved for treating PTCL. Based on our preclinical data, we believe CFT7455 has the potential to create a meaningful benefit for these patients. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mantle Cell Lymphoma </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCL is one of the mature B-cell NHLs. MCL comprises approximately seven percent of adult NHLs in the United States and Europe with an incidence of approximately 0.8 cases per 100,000 persons per year according to recent SEER Program estimates. Median overall survival for patients receiving intensive therapy is four to five years. There is no universally accepted standard of care for MCL. Outside of agents being tested in clinical trials, treatment options typically include some combination of conventional chemoimmunotherapy, rituximab and radiation therapy. Most patients with MCL experience serial relapse and are treated with various agents, including IKFZ1/3-targeting drugs, BTK inhibitors or the BH-3 mimetic venetoclax. Lenalidomide is approved for use in patient with MCL whose disease has relapsed or progressed after two prior therapies, one of which included&#160;bortezomib, based in part on an observed overall response rate of approximately 26%. However, lenalidomide is not widely used to treat MCL. Accordingly, we believe that CFT7455 has the potential to meaningfully improve outcomes and become an established standard of care for these patients. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Development </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted a comprehensive preclinical program across multiple mouse models to study CFT7455 as a potential treatment for MM, PTCL and MCL. We submitted an IND for CFT7455 in December 2020 and received clearance from the FDA in January 2021. We intend to initiate a Phase 1/2 first-in-human trial in the first half of 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We performed an </font><font style="font-style:italic;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> analysis of CFT7455 at varying doses in cells lines across MM and PTCL. The figure below on the left depicts CFT7455, in a MM model, degrading up to approximately 90% of the IKZF1 target protein within 24 hours in a dose-dependent fashion. The figure below on the right depicts CFT7455, in a PTCL model, dose dependently degrading up to approximately 90% of IKZF1 in six hours. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000008.jpg" title="" alt="" style="width:500px;height:200px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFT7455 is a highly selective degrader of IKZF1 and IKZF3, as demonstrated by the figure below. The figure depicts the standard method for determining degrader selectivity is a global proteomics experiment, which utilizes mass spectrometry to quantify cellular protein levels in DL-40 xenograft tumor cells following drug treatment. Specifically, the total cellular protein pool is extracted and processed from cells treated with a degrader, then each protein is individually identified and its level quantified. Using this process, we analyzed the effect of CFT7455 on over 8,000 proteins. These data were then compared to control samples from cells treated with the dosing solution alone, or vehicle, to provide the relative level changes for each protein in the entire cellular protein pool. The x-axis in the graph represents the relative level of proteins in the treated cells compared to control samples, and the y-axis shows the level of statistical confidence in the difference in relative levels of each protein. The figure below depicts cells treated with CFT7455 degrading only a small subset of the cellular proteins with statistical confidence, which are the proteins highlighted in red falling outside of the shaded area. This analysis shows that CFT7455 is a highly selective degrader of IKZF1 and IKZF3.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000009.jpg" title="" alt="" style="width:258px;height:368px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we have profiled known Cereblon targets of pomalidomide and lenalidomide, including GSPT1, GSPT2 and SALL4, using target-specific assays. We observed that CFT7455 has no detectable activity against GSPT1 or GSPT2, but it does degrade SALL4, which is not expressed in the cell line used in the analysis reflected in the figure above, and accordingly, its downregulation is not detected in this assay.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to IKZF1 and IKZF3 degradation and selectivity, we have observed potent activity </font><font style="font-style:italic;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> across a panel of relevant cell lines. In multiple subcutaneous xenograft mouse models of MM, PTCL and other NHLs, CFT7455 treatment resulted in complete regression at doses that we believe could be clinically active, as shown in the graphs below. Significantly, 30 &#181;g/kg of CFT7455 administered once daily, or QD, demonstrated complete regression and clear dose responsiveness in a widely used MM xenograft model, H929, as shown in the graph below. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000010.jpg" title="" alt="" style="width:320px;height:218px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in the RPMI-8226 MM xenograft model, a MM model that is relatively insensitive to treatment with pomalidomide, CFT7455 demonstrated tumor regression and dose responsiveness, as shown in the graph below, and the combination of dexamethasone and CFT7455 resulted in increased activity compared to either CFT7455 or dexamethasone alone.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000011.jpg" title="" alt="" style="width:302px;height:202px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the RPMI-8226 MM xenograft, we observed that pomalidomide at the clinically relevant dose of 3,000 &#181;g/kg was indistinguishable from treatment with the vehicle as shown in the graphic below. A low dose of CFT7455, 30 &#181;g/kg, was active in the model, even when administered to large tumors that had grown despite treatment with 3,000 &#181;g/kg of pomalidomide for 21 days and were insensitive to pomalidomide and then were switched to treatment with CFT7455.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000012.jpg" title="" alt="" style="width:355px;height:230px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figures below, in preclinical studies evaluating various doses of CFT7455 and pomalidomide in MM H929 cells, CFT7455 was up to 10,000-fold more potent than pomalidomide, as measured by impact on cell viability after 96 hours. Further, CFT7455 exhibited a high catalytic turnover rate, as measured by CFT7455&#8217;s cellular degradation rate of up to 75% at 1.5 hours. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000013.jpg" title="" alt="" style="width:363px;height:394px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on its pharmacological properties, we believe CFT7455 may have a favorable therapeutic index and has the potential to replace or follow existing standard of care therapies. We have also evaluated varied dose regimens, as shown in the figure below, which suggest the possibility of intermittent dosing of CFT7455. This could further increase the therapeutic index if adverse events are observed, by incorporating drug holidays in the dosing schedule. Preliminary data from 28-day oral toxicity studies conducted in rats and monkeys demonstrated that exposures well above the modeled efficacious exposures in humans have generally been well tolerated. Definitive GLP-toxicity studies are ongoing. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000014.jpg" title="" alt="" style="width:406px;height:210px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Planned First-in-Human Phase 1/2 Trial</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65527925"></a>We filed an IND for CFT7455 in the fourth quarter of 2020, for which we received clearance from the FDA in January 2021, and we expect to dose the first patient in an open-label clinical trial of this product candidate in the first half of 2021. Our planned Phase 1/2 trial is designed as a dose escalation trial of CFT7455 in approximately 40 to 60 adult subjects with MM and NHL, followed by an expansion trial consisting of four arms. The four arms in this expansion trial will include: a single agent CFT7455 arm in MM, a single agent CFT7455 arm in mantle cell lymphoma, a single agent CFT7455 arm in PTCL, and an arm including CFT7455 in combination with dexamethasone in MM. We have designed the trial to identify a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maximum tolerable dose and a recommended dose for expansion in patients with MM, and a discrete dose for patients with NHL. Identifying discrete doses </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these two patient populations </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is done </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it has been observed in prior clinical experience that patients with MM may tolerate a higher dose of IKZF1/3 targeting agents than do NHL patients</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Additionally, specifically in MM, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are exploring </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFT7455 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sin</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">le agent as well as CFT7455 in combination with </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dexamethasone</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the clinical activity or therapeutic index of CFT7455</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be increased by dexamethasone</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFT7455 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may also be sufficiently active and tolerable as a single agent to be developed as a dexamethasone</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sparing agent</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This trial will primarily investigate the safety and tolerability of CFT7455, and key secondary endpoints will be to characterize its PK/PD and anti-tumor activity. We expect the Phase 1/2 results will help us better understand the disease characteristics of those patients who may derive benefit from CFT7455, which will enable us to design future clinical trials for this product candidate more effectively. The initial cohort will enroll </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to six subjects with relapsed/</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refractory MM or NHL and we will administer CFT7455 over a 28-day cycle, evaluating the window for any potential dose-limiting toxicity. We anticipate Phase 1/2 initial topline safety and PK results </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in 2022</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65527925"></a>. In the expansion stage, we expect to enroll an additional </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 patients with relapsed/refractory MM,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20 patients with MCL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 20 patients with PTCL</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> treated with single agent CFT7455, and 30 patients with relapsed/</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refractory MM treated with CFT7455 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in combination with </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dexamethasone</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CFT8634: A Novel BRD9 Degrader for Synovial Sarcoma </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing CFT8634, an orally bioavailable protein degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid malignancies. We have chosen BRD9 as a target for our approach because of the strong mechanistic rationale, the well-defined biology, the unique opportunity to target BRD9 with a degrader (traditional protein inhibitors are infective in this setting) and a significant unmet need in these patient populations. We plan to initially pursue development in synovial sarcoma, which is defined by a gene translocation SS18-SSX that results in dependency on BRD9 and is therefore potentially addressable by a BRD9 degrader. There are currently no clinical stage molecules targeting BRD9, as BRD9 has been considered an undruggable target with standard modalities. There is limited benefit of existing treatments for metastatic or locally advanced synovial sarcoma, with patients having a median survival of approximately 18 months. We believe that the ability of our degrader CFT8634 to drug BRD9 has the potential to offer a benefit over currently available therapies for patients with synovial sarcoma. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BRD9 Is a Well Characterized Driver of Cancer with No Currently Available Targeted Therapies </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRD9 is a component of the ncBAF, which is one of three types of BAF complexes in human cells. The BAF complexes, also known as SWI/SNF complexes, are responsible for regulating gene transcription. Critically, BRD9 and the ncBAF complex of which it is a component, is not normally required for cell survival. Normal cells rely on another complex, cBAF, for cellular growth, and BRD9 is not a member of this complex. However, in certain genetic settings, ncBAF drives malignancy and these tumors are dependent on BRD9. Genetic settings in which BRD9 is critical share the same feature: the function of the cBAF complex is compromised because SMARCB1, a critical component for normal function of the cBAF complex, is removed from the complex. This situation, referred to as BAF perturbation, is seen in both cancers in which SMARCB1 is deleted, such as malignant rhabdoid tumors, or MRTs, and epithelioid sarcoma, as well as when a pathogenic fusion protein referred to as SS18-SSX results in the ejection of SMARCB1 from the BAF complex. This SS18-SSX fusion protein is the defining genetic lesion that drives synovial sarcoma. In each of these settings, BAF perturbation results in a central dependency on the ncBAF complex, and as a result BRD9, for tumor growth. This is an example of synthetic lethality, in which the cancer cell has a specific vulnerability to BRD9 degradation in the setting of the underlying genetic lesion. In contrast, normal cells, which do not harbor this genetic lesion, are relatively unaffected by the degradation of BRD9. Thus, BRD9 is a critical dependency of the cancer in these genetic settings and depriving the cancer cell of BRD9 effectively stops tumor growth. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRD9 has previously been considered undruggable because existing small molecule inhibitors of the bromodomain are inactive against synovial sarcoma. This is because inhibition of this domain is not sufficient to block BRD9 from driving cancer cell growth, preclinically. Inhibitors of other protein functions, such as that of the critical domain of unknown </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">function</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or DUF, have not been described. We believe that our approach to targeted protein degradation of BRD9 has the potential to offer a major benefit over currently available therapies for synovial sarcoma and SMARCB1-deleted tumors. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000015.jpg" title="" alt="" style="width:648px;height:330px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Synovial Sarcoma </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Synovial sarcoma is an aggressive tumor that accounts for approximately 900 cases in the United States each year, or approximately 10% of all soft tissue sarcomas. While it is prevalent in patients over a wide range of ages, it is more common in younger adult patients, with a median age of onset of 36 years. Like many sarcomas, synovial sarcoma is characterized by recurrent chromosomal arrangements and is referred to as a fusion gene driven malignancy. Specifically, nearly all synovial sarcomas contain a fusion of the SS18 gene on chromosome 18 to the SSX1, SSX2 or SSX4 gene on the X chromosome. This type of mutation is referred to as a t(X;18) chromosomal rearrangement, or an SS18-SSX fusion. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SMARCB1-deleted Tumors </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SMARCB1 is a key member of the BAF chromatin-remodeling complex and assists in the control of gene transcription. The function of SMARCB1 and the BAF complex in cancer has only recently been established. SMARCB1 is a tumor suppressor gene, meaning any decrease in function could potentially result in tumor proliferation. The inactivation of both alleles of SMARCB1 has been shown to result in several types of tumors, including malignant rhabdoid tumors, or MRTs, as well as epithelioid sarcoma, renal medullary carcinoma, undifferentiated pediatric sarcomas, a subset of hepatoblastomas and others. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MRTs typically present in infancy or early childhood and are often aggressive. If the MRT is found in the central nervous system, MRTs are referred to as atypical teratoid/rhabdoid tumors, or AT/RT. Whether the tumor is classified as MRT or AT/RT, the vast majority of these tumors are characterized by the loss of function of the SMARCB1 subunit of the BAF complex. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRD9 has been shown to be an attractive target in pediatric MRTs because the loss or inactivation of the SMARCB1 subunit of the BAF complex leads to a dependency on BRD9. Mechanistically, SMARCB1 loss results in the reprogramming of the cBAF complex and makes the ncBAF complex essential, in a similar mechanism to that which drives synovial sarcoma. As a result, SMARCB1-mutant malignant rhabdoid tumors are dependent on the BRD9-containing ncBAF complex. Thus, we are able to target this tumor by degrading BRD9. We believe our BRD9 degrader could reduce tumor cell proliferation and improve patient outcomes. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intensive, multimodality treatment approaches have improved the clinical outcome of these young patients in a stepwise manner. However, their prognosis remains poor even on these treatment approaches and the median duration of survival in clinical trials does not exceed nine to 17 months. New therapeutic strategies are urgently needed and we believe CFT8634 may have a potentially meaningful clinical impact in these patients. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Development </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted preclinical studies of CFT8634 in two mouse models. CFT8634 is highly selective for BRD9 relative to other bromodomain containing proteins, including BRD7 and BRD4, as shown in the dose dependency of target degradation in H293T cell lines expressing the individual proteins, as reflected in the graphs below. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000016.jpg" title="" alt="" style="width:282px;height:273px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also observed meaningful <font style="font-style:italic;">in vitro</font> dose-dependent inhibition of cell proliferation of synovial sarcoma cell lines over time. Cell proliferation is measured by analyzing the occupied area of cells in a sample over time and densely packed cells are considered confluent. Cell growth inhibition is evidenced in cultures that show a growth plateau below 100%. The figure below on the left shows the effect of CFT8634 on BAF perturbed Yamato cell lines, which is a mouse xenograft model of synovial sarcoma, compared to the effect of a BRD9 inhibitor, shown as BRD9i or the vehicle, dimethylsulfoxide, or DMSO, which were ineffective. CFT8634 had little impact on the growth of a BAF wildtype SW982 cell line, as shown in the graph on the right, showing that its effect was limited to cells with BAF perturbation.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000017.jpg" title="" alt="" style="width:496px;height:322px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The below graphic shows CFT8634 was active and tolerated when dosed orally in a mouse xenograft model of synovial sarcoma (Yamato) and a PDX model (SA13412), with dose dependency observed between 3 mg/kg and 50 mg/kg QD, as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well as 20mg/kg twice daily dose, or BID,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for Yamato, and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mg/kg QD</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25mg/kg </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BID, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 16.6</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mg/kg </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thrice daily</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for PDX, with all doses </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">well</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tolerated, indicated by limited weight loss. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000018.jpg" title="" alt="" style="width:533px;height:224px;"><img src="gjnp4w4lrub1000019.jpg" title="" alt="" style="width:531px;height:239px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Planned First-in-Human Phase 1/2 Clinical Trial</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to file an IND for CFT8634 with the FDA in the second half of 2021 and dose the first patient in a first-in-human Phase 1/2 clinical trial in 2022. We expect to design our Phase 1/2 trial to be an open-label dose escalation trial in approximately 12 to 18 adult patients with synovial sarcoma or a solid tumor with SMARCB1 loss. The Phase 1 portion of the trial will primarily investigate the safety and tolerability of CFT8634. If a well-tolerated dose is identified for further development, we expect to enroll two expansion cohorts, one which will include 30 patients who are known to have synovial sarcoma and a second with patients having solid tumors harboring SMARCB1 loss. Assuming CFT8634 has a favorable profile in these early clinical trials, we initially intend to pursue approval in patients with synovial sarcoma after failure of first-line therapy. Depending on the results of the Phase 1/2 trial, we will work with the FDA to discuss potential accelerated approval pathways for this product candidate. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BRAF V600E Degrader Program </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing orally bioavailable degraders of BRAF V600E as part of our ongoing strategic partnership with Roche. We have chosen BRAF V600E as a target for our approach due to strong mechanistic rationale, well-defined biology and unmet need. We plan to initially pursue development in locally advanced or metastatic melanoma and NSCLC, in which approximately 50% and 2%, respectively, of cancers are driven by BRAF V600E mutation. In these patients, there remains a high unmet need for those who relapse after, or do not respond to, approved BRAF inhibitors. BRAF V600E mutations also occur in 10% to 20% of colorectal cancer patients, so we may pursue development of our BRAF V600E programs in other indications in parallel with, or sequentially to, development in our lead indications of relapsed/refractory BRAF V600E-positive melanoma and NSCLC. We believe that a mutant-specific BRAF V600E degrader could offer a significant mechanistic benefit over currently available BRAF V600E inhibitors and could have the potential to confer significant improvements in clinical outcomes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BRAF V600E is a Common and Well Understood Oncogenic Mutation </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRAF is one of several protein kinases involved in a signaling cascade to initiate cell proliferation, known as the mitogen-activated protein kinase, or MAPK, pathway. The MAPK pathway conducts extracellular proliferative signals to the nucleus of cells, signaling them to proliferate. Many cancers are characterized by activating mutations in components of this MAPK pathway, including BRAF V600E mutations, which confer constitutive activation of the MAPK pathway and promote oncogenic transformation and can cause tumor growth. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Single base substitutions for the amino acid valine at codon 600 in the BRAF gene are known as V600 or Class I mutations, and when those V600 mutations result in substitution of glutamic acid for valine, they are referred to as V600E mutations. BRAF mutations occur in approximately 15% of all cancers, and approximately 70% to 90% of BRAF mutations are V600E mutations. Melanomas have been shown to contain a particularly high prevalence of BRAF mutations at 50%, of which greater than 90% are driven by a V600E mutation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRAF V600E mutants activate the MAPK pathway constitutively, meaning that cell proliferation is activated without receiving the extracellular proliferative signals necessary to activate the pathway normally. Constitutive activation occurs because BRAF V600E mutants are able to signal as a single protein, or monomer, while wild type BRAF proteins must form a complex of two proteins, or a dimer, before downstream signaling can occur. This constitutive activation leads to overactivation of the MAPK cell proliferation pathway, causing oncogenic cell proliferation and tumor growth. Approved small molecule inhibitors of BRAF V600E&#8212;vemurafenib, dabrafenib and encorafenib&#8212;block the constitutive activation of the MAPK pathway by the mutant BRAF monomer. However, BRAF inhibition with these molecules can lead to an alternative activation of the MAPK pathway, known as paradoxical activation. Under these conditions, BRAF inhibitors bind and inhibit BRAF V600E, but this inhibited form can form a protein dimer with other RAF proteins, including both wild type BRAF and BRAF mutants, activating the second molecule for signaling. This BRAF driven paradoxical activation activates, rather than inhibits, the MAPK pathway. BRAF inhibitors are frequently used in combination with MEK inhibitors, a protein downstream of BRAF in the MAPK pathway, which improves response rates and clinical outcomes. However, patients frequently do not respond sufficiently, or they develop resistance to this approach. Many known mechanisms of resistance to approved BRAF inhibitors result in the promotion of BRAF dimerization, and in these settings the BRAF inhibitors are ineffective. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that targeted protein degradation of BRAF V600E offers the potential for a fundamental improvement over current BRAF inhibitors due to the advantages of degraders over inhibitors in general and because degrading mutant BRAF removes the possibility of incorporation into a BRAF dimer and subsequent paradoxical activation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Melanoma </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the National Cancer Institute, approximately 100,000 patients were diagnosed with melanoma in 2020 in the United States, and approximately 13% of those cases, or about 13,000 patients per year, will have locally advanced or metastatic disease. Moreover, approximately 50% of late-stage melanoma patients carry BRAF mutations, and approximately 90% of those are BRAF V600E mutations. Taken together, we estimate that there are over 5,000 incidents of newly diagnosed melanoma patients per year with BRAF V600E-mutated locally advanced or metastatic disease. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The recommended first-line treatment for patients with BRAF V600E-mutated unresectable or metastatic melanoma is anti-PD-1 monotherapy, such as pembrolizumab or nivolumab, or combination therapy with a BRAF inhibitor, such as dabrafenib, vemurafenib or encorafenib and a MEK inhibitor, such as astrametinib, cobimetinib or binimetinib. However, a significant number of patients undergoing this combination therapy do not sufficiently respond or have a durable response as resistance to the therapy occurs. Specifically, across several double-blind randomized controlled trials conducted by others evaluating BRAF and MEK inhibitor combination therapy in patients with previously untreated locally advanced or metastatic melanoma, median PFS has ranged from 9.9 to 14.9 months. After each of these lines of therapy is used, there are no approved single-agent therapies that effectively target BRAF. In preclinical models of resistance to BRAF inhibition, our degraders remained active when dosed in combination with a MEK inhibitor, in contrast to the approved BRAF inhibitor, encorafenib, which is inactive in this setting. Thus, a BRAF V600E degrader may be active clinically in the setting of resistance to approved BRAF inhibitors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, in the A375 BRAF V600E melanoma model, we have observed that one of our BRAF V600E degraders, CFT7977, showed deeper and more sustained response in comparison to the standard of care BRAF inhibitor, dabrafenib, as shown in the figure below. </font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000020.jpg" title="" alt="" style="width:433px;height:216px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, two or our BRAF V600E degraders, CFT8442 and CFT8905, showed sustained activity in the A375 model encoding the NRAS Q61K activating mutation, in combination with the MEK inhibitor, trametinib, which is shown in the following figure. The NRAS Q61K activating mutation is a clinically observed mechanism of resistance to BRAF inhibitors. Both BRAF V600E degraders, in combination with trametinib, also showed improved activity compared to trametinib in combination with the BRAF V600E inhibitor, encorafenib.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000021.jpg" title="" alt="" style="width:306px;height:258px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our BRAF V600E degraders have the potential to improve upon current clinical outcomes, as our novel protein degraders could offer a potent and selective mechanism to degrade V600E-mutant BRAF and prevent constitutive activation and oncogenic cell proliferation. Furthermore, degrading BRAF V600E may offer a fundamental improvement over inhibiting BRAF V600E because degrading the mutant proteins with our approach may avoid the possibility of paradoxical activation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RET Degrader Program </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing orally bioavailable degrading compounds of RET for the treatment of NSCLC, sporadic medullary thyroid cancers and other solid cancer indications. We have chosen RET because of its well-defined biology and the known drawbacks of RET protein inhibitors that we believe our degrader approach will be able to overcome. Our initial target population is relapsed/refractory patients with RET-altered cancers after treatment with RET inhibitors and we plan subsequently to pursue first-line treatment of RET-driven cancers. We believe our RET degrader has the potential to overcome resistance to standard of care RET inhibitors to effect deeper and more durable responses due to the unique advantages of protein degradation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RET is a Well-Characterized Protein Target for Oncology with Known Resistance Mechanisms </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RET is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET typically plays a role in normal development, but when mutated it can cause cancers, including NSCLC, medullary thyroid cancer and other solid tumors. Two RET-specific inhibitors have been developed to target these malignancies. Eli Lilly&#8217;s selpercatinib and Blueprint Medicines&#8217; pralsetinib were recently approved, both as RET-specific kinase inhibitors to treat RET-altered NSCLC and medullary thyroid cancer. While these molecules showed in their Phase 2 trials that they are effective in the majority of the patients treated and generally well tolerated, patients are observed to relapse, at which point there are currently no approved targeted therapies. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goal of our RET program is to design a degrader that covers the full landscape of observed and anticipated resistance mutants to current and emerging RET therapies in these relapsed/refractory patients. In particular, we have identified compounds that exhibit activity against the wild-type RET fusions and fusions encoding gatekeeper mutations, as well as similar potency and activity against a solvent front resistant mutant, or G810R, which is a mechanism of resistance to selpercatinib. We believe there may be an opportunity for our RET degrader as a viable alternative in front line therapy where we hope the RET degrader will effect deeper and more durable responses due to the advantages of a degrader over a standard protein inhibitor. </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000022.jpg" title="" alt="" style="width:566px;height:273px;"><img src="gjnp4w4lrub1000023.jpg" title="" alt="" style="width:560px;height:268px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-Small-Cell Lung Cancer </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung cancer, in particular NSCLC, is often driven by alterations in a single driver oncogene, making these tumors well suited for precision therapies. One such example is RET translocation, which is present in one percent to two percent of NSCLC. The NIH SEER Program estimated that there are approximately 10,000 incidents of RET-driven disease across lung, thyroid, and other cancers in the United States each year.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NSCLC patients with mutated or rearranged oncogene drivers can be treated with first-line selective inhibitors and achieve fairly high response rates and longer survival than with chemotherapy. However, in some cases, resistance develops to clinical RET inhibitors, due to mechanisms including new RET mutations that make the inhibitors inactive. Our RET degraders are designed to overcome these types of mutations. We believe that our RET degraders have the potential to improve upon current clinical outcomes, as they could offer an alternative to RET inhibition that is less susceptible to resistance mechanisms and potentially able to achieve similar efficacy in front-line settings with an improved pharmacodynamic profile. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Development </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted preclinical experiments to characterize the activity profile of our RET degraders and have observed that they inhibit tumor growth comparably to the leading RET inhibitors, selpercatinib and pralsetinib, and retain activity in the setting of the solvent front mutation, G810R. As shown in the figure below, one of our RET degraders, CFT2521, with daily intravenous, or IV, dosing, has comparable activity to both selpercatinib and pralsetinib dosed orally twice a day in the KIF5B:RET fusion murine xenograft model. We are working to identify RET degraders with similar activity using oral dosing.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000024.jpg" title="" alt="" style="width:340px;height:272px;"></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to identify a drug candidate, file an IND with the FDA, and begin a Phase 1 trial in patients with RET-altered tumors by the end of 2022. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Other Discovery Programs</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the programs discussed above, we are also progressing several other discovery-stage pipeline programs. In line with our strategy, we assess on a target-by-target basis whether our degraders would provide a compelling and differentiated approach over standard of care or other approaches to the same disease and are consistent with our focus on minimizing biology and toxicity risk and focusing on high unmet medical need, including rare diseases. These early-stage discovery programs include compounds that have already shown the ability to cross the blood-brain barrier in preclinical models, and we are also evaluating degraders for additional oncology targets. Our discovery programs are a combination of internal programs, over which we have full control and ownership, and programs in collaboration with our partners. One of these internal discovery programs is our EGFR degrader program, which reverted to us from Roche in November 2020, as is more fully described below in the section entitled &#8220;Collaborations and License Agreements&#8212;<font style="font-style:italic;">Roche Amended and Restated License Agreement</font>&#8221; below. With that program now back within our control, we are currently in the process of assessing the EGFR treatment landscape and determining the appropriate next steps for this program.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaborations and License Agreements </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Roche Amended and Restated License Agreement</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64888649"></a><a name="_Hlk64887780"></a>In March 2016, we entered into a license agreement with Roche, which was amended in June 2016 and amended further in March 2017. We further amended and restated that agreement (as so amended) in December 2018. We refer to this amended and restated agreement as the Roche Agreement. Under the Roche Agreement, we agreed to collaborate with Roche in the research, development, manufacture and commercialization of target-binding small molecules using our proprietary TORPEDO platform for the treatment of cancers and other indications. In November 2020, we signed a further amendment to the Roche Agreement that provides a mechanism through which we and Roche can mutually agree to terminate the Roche </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement on a target-by-target basis by the entry into a mutual target termination agreement. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon a termination of this nature, the Roche Agreement, as amended, provides that </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all rights in know-how and intellectual property in support of products that use inhibition as their mode of action</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">referred to as the Roche Field</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will revert to Roche and all rights in respect of know-how and intellectual property in support of products that use degradation as their mode of action</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> referred to as the C4T Field</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will revert to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, this amendment </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">states that, following the entry into a mutual target termination agreement, Roche will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the Roche Field and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the C4T Field. In support of this allocation of rights, under the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mendment, Roche provided </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided Roche, with a perpetual, irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that are allocated to a party under the mutual target termination agreement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and a perpetual, irrevocable fully paid up, non-exclusive, sublicensable (including in multiple tiers) license to the know-how that is allocable to a party under the mutual termination agreement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, through the entry into </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this amendment</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we and Roche </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mutually agreed to terminate the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement as to the target EGFR. As a result, Roche </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> now free to pursue the target EGFR in the Roche Field and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">free to pursue the target EGFR in the C4T Field and all rights in and responsibility for know-how and intellectual property related to EGFR in the Roche Field reverted to the Roche parties and all rights in and responsibility for know-how and intellectual property related to EGFR in the C4T Field reverted to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with Roche assigning the patents in the C4T Field to us</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Roche Agreement, we are responsible for conducting preclinical research and development activities for a number of targets selected by Roche in accordance with a target selection and replacement procedure set forth in the agreement. We are also responsible for conducting Phase 1 clinical trials for products directed to certain targets and for manufacturing activities in connection with the applicable research plans, subject to Roche&#8217;s right to assume manufacturing responsibilities at pre-defined times. We and Roche each share in the costs of these research activities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Roche Agreement, we granted Roche an exclusive option to obtain an exclusive, worldwide license, with the right to sublicense through multiple tiers to develop and commercialize products directed at each target that is subject to the collaboration. Upon the exercise of its option for a particular target, Roche is responsible for the manufacture, development and commercialization of products directed to that target, at its sole expense. However, we have the option to co-develop products directed to certain targets, in which case we would be responsible for a portion of the development costs associated with such co-developed products and eligible to receive increased royalties on sales of such co-developed products. We also have an option to co-detail products for which have exercised our co-development option. If we exercise our co-detail option, we will be responsible for a portion of the co-detailing costs. We generally have the right to opt out of these co-development and co-detailing activities.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon signing the Roche Agreement, we received upfront consideration of $40.0&#160;million from Roche. In addition, we receive annual research funding from Roche for each active research plan and we are eligible to receive additional payments upon the achievement of pre-determined research and development success criteria with respect to certain targets. If Roche exercises its option right for a target, Roche is obligated to pay an exercise fee ranging from $7.0&#160;million to $20.0&#160;million, depending on the target. For each target option exercised by Roche, we are eligible to receive milestone payments up to a range of $260&#160;million to $275&#160;million upon the achievement of certain research, development and commercial milestones with respect to corresponding products, subject to certain reductions and exclusions based on intellectual property coverage. Roche is also required to pay us up to $150&#160;million per target in one-time sales-based milestone payments upon the achievement of specified levels of net sales of a product directed to such target. Finally, we are eligible to receive tiered royalties ranging from mid-single digit to mid-teen percentages on net sales of products sold by Roche pursuant to its exercise of its option rights, subject to certain reductions. For sales of products for which we exercise our co-development right, the applicable royalty rates will be increased by a low-single digit percentage. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Roche Agreement expires on the date when no royalty or other payment obligations under the Roche Agreement are or will become due. We and Roche each may terminate the Roche Agreement in its entirety or on a target-by-target or product-by-product basis and, in our case, on a country-by-country basis, for the other party&#8217;s uncured material breach of its obligations under the Roche Agreement or upon the other party&#8217;s bankruptcy, insolvency or similar proceedings. Roche may terminate the Roche Agreement for convenience on a target-by-target, product-by-product or country-by-country basis. In the event we are acquired by a competitor of Roche, Roche has the right to require us to terminate our research, development and co-detailing activities under the Roche Agreement, after which time we would not be eligible to receive payments for such terminated activities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Calico License Agreement </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, we entered into a Collaboration and License Agreement, or the Calico Agreement, with Calico, whereby we agreed to collaborate with Calico to discover, develop and commercialize small molecule protein degraders for diseases of aging, including cancer. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Calico Agreement, we and Calico each agreed to conduct joint research activities with respect to a number of targets selected by Calico in accordance with a target selection and replacement procedure set forth in the agreement. During the research term, which ends in March 2022, Calico is responsible for the costs of these research activities and has the right to approve targets for advancement to lead optimization activities to be carried out by the parties under the corresponding research plans. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of our research activities for each target selected by Calico for lead optimization activities, Calico is responsible for, and agrees to use commercially efforts to carry out, all further pre-clinical development, regulatory affairs, manufacturing and commercialization for products directed against each such target. We refer to these products as Collaboration Products. We granted Calico an exclusive license to manufacture and commercialize Collaboration Products under certain of our intellectual property rights. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this agreement, Calico paid us an upfront amount of $5.0&#160;million and certain annual payments totaling $5.0&#160;million through December 31, 2020. Upon successful nomination of a target following a target evaluation phase and initiation of the applicable research plan, we are eligible to receive target initiation payments from Calico. For each target, we are eligible to receive research, development and commercial milestone payments totaling up to $132.0&#160;million. Calico is also required to pay one-time sales-based milestone payments aggregating up to $65.0&#160;million upon the achievement of specified levels of net sales of a product directed to such target, subject to a reduction based on intellectual property coverage. We are also eligible to receive royalty payments on the net sales of Collaboration Products, at percentages in the mid-single digits, subject to certain reductions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the Calico Agreement expires on the date when no royalty or other payment obligations under the Calico Agreement are or will become due. We and Calico each may terminate the Calico Agreement in its entirety or on a target-by-target or product-by-product basis and, in our case, on a country-by-country basis, for the other party&#8217;s uncured material breach of its obligations or its bankruptcy or insolvency. Calico may terminate the Calico Agreement for convenience in its entirety or on a target-by-target or country-by-country basis, subject to reimbursement of costs and return of materials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biogen Collaborative Research and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into a collaborative research and license agreement, or the Biogen Agreement, with Biogen, whereby we agreed to collaborate with Biogen and use our proprietary protein degrader platform to research, develop and identify small molecule protein degraders. In February 2020, we entered into an amendment to the Biogen Agreement that provided further clarity around Biogen&#8217;s ownership of target binding moieties, which are portions of molecules, and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provides that Biogen licenses to us rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Biogen Agreement, we granted Biogen an exclusive license under our intellectual property, with the right to sublicense through multiple tiers, (a) for the purpose of performing candidate development activities in accordance with research and development plans agreed upon by the parties and (b) for the purpose of exploiting all degraders and products for any use in the world. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, we are responsible for conducting research and development activities for a number of targets selected by Biogen in accordance with a target selection and replacement procedure set forth in the agreement. We are required to provide all resources necessary to perform candidate development activities, perform those activities with reasonable care and skill and in accordance with applicable law and the Biogen Agreement and use diligent efforts to complete the activities as set forth in the applicable development plan and deliver to Biogen a certain number of degraders directed to each target that meet a range of pre-defined criteria. We and Biogen are also responsible for research activities designed to inform Biogen&#8217;s target selection process, for which Biogen will pay for its own costs and will reimburse our costs up to a certain amount. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon Biogen&#8217;s commencement of the IND-enabling study for a degrader directed towards each target selected by Biogen, Biogen is responsible for, and agrees to use commercially reasonable efforts to carry out, all further development, regulatory affairs, manufacturing and commercialization for at least one product directed against each such target in certain territories. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon execution of the Biogen Agreement, Biogen paid us an upfront payment of $45.0&#160;million as prepayment for candidate development activities, and if Biogen elects to extend the collaboration term by a pre-determined period and obtain the right </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to elect a certain number of additional targets, we are eligible for an additional payment of $62.5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million. Upon Biogen&#8217;s receipt of degraders directed to each target that satisfy pre-defined criteria, we are eligible to receive payments ranging from $2.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million per target. Upon Biogen&#8217;s commencement of the first IND-enabling study for a development candidate directed towards each target, Biogen is required to pay us $8.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million. For each target, Biogen is required to pay us (a)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development and commercialization milestone payments totaling up to $35.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and (b)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales milestone payments totaling up to $26.0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million for the achievement of certain amounts of net sales of all products directed to such target, each subject to certain reductions. The total development, commercialization and sales milestone payments will increase if Biogen extends the collaboration term and elects additional targets. In addition, Biogen is required to pay us royalties on a product-by</font><font style="font-weight:bold;">-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product and country-by-country basis on the net sales of each product, at percentages in the mid-single digits, subject to certain reductions. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Biogen Agreement expires on the date of the last product-by-product and country-by-country basis upon the expiration of the last-to-expire valid claim of a patent right covering the composition of matter of method of use in the approved label of the applicable product in the applicable country. We and Biogen each may terminate the Biogen Agreement (a)&#160;with respect to one or more development candidates, products or collaboration targets or, only in the case of Biogen, the entire agreement, for the other party&#8217;s uncured material breach of its obligations and (b)&#160;in its entirety upon the other party&#8217;s bankruptcy, insolvency or similar proceedings. Biogen may also terminate the Biogen Agreement in its entirety or with respect to one or more development candidates, products or collaboration targets for convenience. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63857199"></a>Competition</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, expertise, scientific knowledge and intellectual property estate provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Not only must we compete with other companies that are focused on protein degradation, but any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our focus is on the discovery and development of protein degradation therapies using our TORPEDO platform. Other companies developing chimeric small molecules for protein degradation include Arvinas, Inc., BioTheryX, Inc., Cullgen Inc., Foghorn Therapeutics, Inc., Frontier Medicines Corporation, Kymera Therapeutics, Inc, Lycia Therapeutics, Inc., Monte Rosa Therapeutics, Inc., NeoMorph, Inc., Nurix Therapeutics, Inc., and Vividion Therapeutics, Inc.. Further, several large pharmaceutical companies have disclosed preclinical investments in this field, including Amgen, AstraZeneca plc, Bristol-Myers Squibb Company (and its subsidiary Celgene Corporation), GlaxoSmithKline plc, Genentech and Novartis International AG. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, T cell or gene therapies. For example, we understand that Adaptimmune Limited, Foghorn Therapeutics, Inc. and GlaxoSmithKline plc are pursuing the development of therapies for patients with synovial sarcoma.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates target oncologic indications. The most common methods of treating patients in oncologic indications are surgery, radiation and drug therapy, including chemotherapy, hormone therapy, cellular therapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection and others are available on a generic basis. Many of these approved drugs are therapies and are widely accepted by physicians, patients and third-party payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these therapies are all limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer remains high. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to currently marketed drugs, there are also several product candidates in preclinical development for the treatment of oncologic indications. These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain market approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved for the indications for which we expect to conduct clinical trials, they will compete with the foregoing therapies and currently marketed drugs, as well any drugs potentially in development. It is also possible that we will face competition from other biologic or pharmaceutical approaches, as well as from other types of therapies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate and currently have no plans to establish any manufacturing facilities. We rely on and expect to continue to rely on third-party <font style="color:#000000;">contract manufacturing organizations, or</font> CMOs, for both drug substance and finished drug product. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term committed supply arrangements with respect to our product candidates and other materials. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements. For additional information, see the section titled &#8220;Risk Factors&#8212;<font style="font-style:italic;">Risks Related to Dependence on Third Parties&#8212;Manufacturing pharmaceutical products is complex and subject to</font> <font style="font-style:italic;">product loss for a variety of reasons. We contract with third</font> <font style="font-style:italic;">parties for the manufacture of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third</font> <font style="font-style:italic;">parties increases the risk that we will not have sufficient quantities of our product candidates or products or that we will not have the quantities we desire or require at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</font>&#8221; </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our drug candidates are organic compounds of low molecular weight, which are often referred to in the biopharmaceutical community as small molecules, but our BiDAC degraders tend to be larger than traditional small molecule therapeutics. We have selected these compounds not only on the basis of their potential clinical activity and tolerability, but also for their relative ease of synthesis and reasonable cost of goods. In particular, CFT7455 and CFT8634 are manufactured using reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale up and does not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost effectively at contract manufacturing facilities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Plans </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet established our own commercial organization or distribution capabilities because our product candidates are still in preclinical development, with our lead candidates expected to enter the clinic in 2021. We have retained full commercialization rights for all of our programs in development other than those subject to our collaboration agreements. If any of our product candidates receive marketing approval, we will need to develop a plan to commercialize them in the United States and other key markets. We currently anticipate that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. We expect to utilize a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States or for situations in which a larger sales and marketing organization is required. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates advance through our pipeline, our commercial plans may change. Some of our research programs target potentially larger indications. Data, the size of the development programs, the size of the target market, the size of a commercial infrastructure and manufacturing needs may all influence our strategies in the United States, Europe and the rest of the world. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to secure and maintain patent and other proprietary protection for our protein degradation technologies, including our TORPEDO platform, our solely-owned product candidates, our product candidates co-owned with Roche and&#160;know-how&#160;related to our business. To protect our core technology and products, we will need to successfully prosecute, defend and, if necessary, enforce our intellectual property rights, including, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, pharmaceutical compositions, methods of use, including combination therapies, processes of manufacture and process intermediates, where relevant. We continually assess and refine our intellectual property strategies as we develop new technologies and product candidates. We currently plan to file additional patent applications based on our intellectual property strategies, where appropriate, including where we seek to adapt to competition or to improve our business opportunities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions for biopharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. Further, the laws governing the protection of intellectual property may change over time due to the issuance of new judicial decisions or the passage of new laws, rules or regulations. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued and its scope can be reinterpreted and challenged even after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by valid, enforceable patents. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exclusivity terms of our patents depend upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. The term of a U.S. patent may be extended to compensate for the time required to obtain regulatory approval to sell a drug (referred to as a patent term extension) or by delays encountered during patent prosecution that are caused by the United States Patent and Trademark Office (referred to as patent term adjustment). For example, the Hatch-Waxman Act permits a patent term extension for FDA-approved new chemical entity drugs of up to five years beyond the ordinary expiration date of one patent that covers the approved drug or its use. The length of the patent term extension is related to the length of time the drug is under regulatory review and diligence during the review process. Patent term extensions in the United States cannot extend the term of a patent beyond a total of 14 years from the date of product approval and only one patent covering an approved drug or its method of use may be extended. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks may also be available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions for our products on any of our issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however, there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will agree with our assessment of whether extensions of this nature should be granted and, even if granted, the length of these extensions. Further, even if any of our patents are extended or adjusted, those patents, including the extended or adjusted portion of those patents, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patents and Patent Applications </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, in total, we solely owned three issued U.S. patents, twenty-one U.S. patent applications (which include provisional and U.S. utility applications), six patent applications filed under the Patent Cooperation Treaty and over thirty patent applications that are pending in foreign countries. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, as part of our collaboration with Roche, we co-own one U.S. patent application, two patent applications filed under the Patent Cooperation Treaty and one patent application pending in Europe. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio is generally organized into two categories: platform patent filings designed to cover inventions generated through our proprietary TORPEDO platform and protein target-specific product candidate filings, each of which categories is described in more detail below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TORPEDO Platform </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We solely own our platform patent estate, which, has been designed using our proprietary TORPEDO platform. As of December 31, 2020, our platform patent portfolio included three issued U.S. patents, thirteen pending U.S. patent applications, four patent applications filed under the Patent Cooperation Treaty and more than twenty pending foreign patent applications. This patent portfolio covers a variety of our toolbox ligands that bind to the Cereblon E3 ubiquitin ligase, or CRBN, either alone, as part of a MonoDAC molecule, or as part of a BiDAC molecule that includes a protein ligand to a disease-modifying protein target. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, this platform consists of sixteen patent families covering the TORPEDO platform with composition of matter claims directed to various classes of CRBN ligands and degraders derived therefrom, as well as claims to associated methods of use, pharmaceutical compositions and processes of manufacture. Patent applications for several of these patent families have been filed in the United States, China and Europe. Patents in these families, if issued and maintained, will expire between 2037 and 2041, without taking potential patent term extensions or adjustments into account. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product Candidates Solely Owned by Us</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent applications directed to our solely-owned product candidates are focused on composition of matter, pharmaceutical composition, method of use and process of manufacture claims covering novel compounds designed to degrade specific proteins. As of December 31, 2020, we solely owned eight U.S. patent applications and two patent applications filed under the Patent Cooperation Treaty covering our solely-owned product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, as of December 31, 2020, we solely owned three patent families presenting composition of matter&#160;and pharmaceutical composition claims to compounds that cause the degradation of the IKZF1/3 protein target, as well as associated methods of use to treat cancer and processes of manufacture. Two of these patent families include claims directed to compositions of matter generally and specifically covering&#160;CFT7455, one of our lead product candidates and associated methods of use, which if issued and maintained through the payment of all required fees, will expire in 2040 and 2041, respectively, without regard to any possible patent term extensions or adjustments. The third patent family covering our IKZF1/3 degraders is directed to a separate genus than that covered in the previous two families and, if granted and maintained through the payment of all required fees, will expire in 2039, without regard to any possible patent term extensions or adjustments. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we solely owned two U.S. patent applications, with claims directed to compositions of matter covering&#160;our BRD9 degraders, including our CFT8634 product candidate, and associated pharmaceutical compositions, methods of use, and processes of manufacture. U.S. and foreign patents claiming priority to these patent applications, if granted and maintained through the payment of all required fees, will expire in 2041, without regard to any possible patent term extensions or adjustments. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we solely owned one U.S. patent application with claims directed to compositions of matter covering&#160;our RET degraders and associated methods of use, pharmaceutical compositions and processes of manufacture. U.S. and foreign patents claiming priority to this patent application, if granted and maintained through the payment of all required fees, will expire in 2041, without regard to any possible patent term extensions or adjustments. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we solely owned two U.S. patent applications, one PCT patent application and eleven foreign patent applications, with claims directed to compositions of matter covering&#160;our EGFR degraders and associated methods of use, pharmaceutical compositions and processes of manufacture. This portfolio of patent applications was previously co-owned with Roche and exclusive ownership of this intellectual property was transferred from Roche to us in connection with our entry into an amendment to the Roche Agreement in November 2020. U.S. and foreign patents claiming priority to this patent application, if granted and maintained through the payment of all required fees, will expire between 2038 and 2040, without regard to any possible patent term extensions or adjustments. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product Candidates Co-owned with Roche</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we co-owned one U.S. patent application with Roche, two patent applications filed under the Patent Cooperation Treaty and one patent application filed in foreign countries pertaining to our product candidates. Our rights to these patent applications are governed by the Roche Agreement, which is described above. above. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Target Platform Collaborations</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We work with three strategic partners to expand our platform potential: Roche, Calico and Biogen. Under the agreements with each of these partners, we generally assign our solely or co-invented patent rights in development candidates to the applicable partner in exchange for financial benefits in the products under development under those agreements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trade Secrets </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secrets, technical&#160;know-how&#160;and continuing innovation to develop and maintain our competitive advantage. Under the agreements we enter into with our employees and consultants who are identified on any company-owned patent applications assign any rights they may have in any such patent application to us. We also rely on confidentiality or other agreements with our employees, consultants and other advisors to protect our proprietary information. Our policy is to require third parties that receive material confidential information to enter into confidentiality or other agreements with us that contain appropriate protections for our confidential and trade secret information. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trademarks </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own various registered and unregistered trademarks in the United States and overseas, including C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC degrader and MONODAC degrader products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Government Regulation of Drug Products </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">nonclinical laboratory and animal tests that must be conducted in accordance with GLPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adequate and well controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an NDA and payment of user fees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of an FDA advisory committee review, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with current good manufacturing practices, or cGMP, and GCP; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of an NDA to permit commercial marketing for particular indications for use. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing and approval process requires substantial time, effort and financial resources. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Studies </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, a sponsor must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data and any available clinical data or literature, among other required information, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the clinical trial and imposes a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Trials </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#8217;s or the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to subjects. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 1&#8212;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 clinical trials may also be used to gain an initial indication of product effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 2&#8212;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3 clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 3&#8212;These clinical trials are generally undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done at trial sites outside the United States as long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, clinical trials are designed in consultation with the FDA or foreign regulatory authorities during these development phases. The indications under development can influence the study designs employed during the conduct of clinical trials, such as for a first-line cancer treatment indication which may require head-to-head data demonstrating clinical superiority or non-inferiority to currently available therapies. The timeline for first-line cancer indication development programs may also be longer than for indications sought in third-line treatment or beyond due to a desire for regulatory authorities to expedite access to later-line treatments for those whose cancer has progressed despite available and earlier-line treatments. As such, many new oncology products initially seek an indication in treatment for third-line treatment, a smaller available treatment population in any oncology indication, and any later approvals sought for those products in earlier lines of treatment which target a larger treatment population might require the conduct of additional clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 trials may be made a condition to be satisfied after approval. The results of Phase 4 trials can confirm the effectiveness of a product candidate and can provide important safety information. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial and the review and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the NIH for public </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dissemination on their website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country, as well as U.S. export requirements under the FDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if serious adverse effects occur. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate, as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Special FDA Expedited Review and Approval Programs </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including fast track designation, breakthrough therapy designation, orphan drug designation, accelerated approval and priority review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#8217;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from the FDA on an efficient drug development program, organizational commitment to the development and review of the product, including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough therapy products may be eligible for accelerated approval and/or priority review, if relevant criteria are met. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post approval studies or confirm a clinical benefit during post marketing studies will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior review by the FDA. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under the Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six- and ten-month review periods are measured from the 60-day filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not ultimately expedite the development or approval process. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NDA Submission and Review by the FDA </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce and the applicant, including its affiliates, is submitting its first marketing application. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#8217;s identity, strength, quality and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are in compliance with</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission during the review period that amends the original application. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the FDA&#8217;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing or other information or analyses in order for the FDA to reconsider the application in the future. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information, require post-marketing testing and surveillance to monitor safety or efficacy of a product and/or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a boxed warning. A boxed warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect of approved products and may limit further marketing of the product based on the results of these post-marketing studies. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Post-Approval Requirements </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for approved products, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to the manufacturing process are strictly regulated and often require prior FDA approval or notification before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a REMS program, among other consequences. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy that are consistent with the FDA approved labeling. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. However, manufacturers and third parties acting on their behalf are prohibited from marketing or promoting drugs in a manner inconsistent with the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with any of the FDA&#8217;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#8217;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Marketing Exclusivity </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA provides periods of non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#8217;s approval of the NDA. Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds or other noncovalent bonds not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate (i.e., a chemical compound) or clathrate (i.e., a polymer framework that traps molecules) of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regulation outside the United States </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be subject to similar foreign laws and regulations concerning the development of our product candidates outside of the United States. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency and patient data privacy and security laws and regulations, including but not limited to those described below. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bride or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward or in return for, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">either the referral of an individual for, or the purchase order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid</font><font style="font-size:10pt;color:#000000;">.</font><font style="font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">A</font><font style="font-size:10pt;color:#000000;"> person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation</font><font style="font-size:10pt;color:#000000;">. </font><font style="font-size:10pt;color:#000000;">There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution</font><font style="font-size:10pt;color:#000000;">; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, which prohibit individuals or entities from, among other things, knowingly presenting or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using or causing to be made or used a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity need not have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, imposes, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, for certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members.&#160;Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made and investment and ownership interested held in the previous year to certain non-physician providers such as physician assistants and nurse practitioners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party-payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to drug pricing and payments and other transfers of value to physicians and other healthcare providers and restrict marketing practices or require disclosure of marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that govern the privacy and security of health information in some circumstances. These data </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pharmaceutical manufacturers may also be subject to federal and state consumer protection and unfair competition laws and regulations, which broadly regulate marketplace activities and that potentially harm consumers. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of drugs and biological products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued to increase their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product and the level of coverage and reimbursement can differ significantly from payor to payor. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which, among other things, included changes to the coverage and payment for products under government health care programs. The ACA included provisions of importance to our potential product candidate that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expanded the types of entities eligible for the 340B drug discount program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There remain numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court, and the Trump Administration has issued various Executive Orders that eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or biologics. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, effective as of January&#160;1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance, eliminating the implementation of certain of the ACA&#8217;s mandated fees and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act, or TCJA. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and held oral arguments on November 10, 2020. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. These reductions have been suspended from May&#160;1, 2020 through December&#160;31, 2020 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. For example, at the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change, which was effective as of January&#160;1, 2019. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More recently, on </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021 and ending December 31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, HHS finalized a regulation removing the safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although a number of these and other measures may require additional authorization to become effective, Congress </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, it is possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on April&#160;18, 2020, CMS announced that qualified health plan issuers under the ACA&#160;may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June 2020 given the challenges healthcare providers are facing responding to the ongoing COVID-19 pandemic. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 99 full-time employees, including 62 employees with an M.D. and/or Ph.D. degree. Of these full-time employees, 80 employees were engaged in research and development activities and 19 employees were engaged in general and administrative activities. We presently have nine senior leaders, five of whom serve as executive officers, one of whom is a consultant. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our future success depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lives, including health care, retirement planning and paid time off. As part of our promotion and retention efforts, we also invest in ongoing development.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce, from working with managers to develop strategies for building diverse teams to promoting the advancement of leaders from different backgrounds.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, Kelly Schick was appointed as our Chief People Officer to lead our Human Resources function. In this role, in addition to other areas of focus, Ms. Schick will focus on human capital, oversee our employee engagement and retention, and foster and develop our culture.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in October 2015 under the laws of the State of Delaware. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472, and our telephone number is (617) 231-0700. We have one wholly owned subsidiary, C4T Securities Corporation, a Massachusetts corporation.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is www.c4therapeutics.com. Information on our website is not incorporated by reference herein. We will make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an Internet site, http://www.sec.gov, containing reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics and the charters of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee are posted on our website, www.c4therapeutics.com, under the heading &#8220;Corporate Governance&#8221; and are available in print to any person who requests copies by contacting us by calling (617) 231-0700 or by writing to C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to use press releases, our company website, including our Investor Relations website, and our LinkedIn, Twitter, and Instagram accounts, which are listed below, as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000025.jpg" title="" alt="" style="width:20px;height:20px;"> www.linkedin.com/company/c4-therapeutics-inc.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000026.jpg" title="" alt="" style="width:20px;height:20px;"> twitter.com/c4therapeutics</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gjnp4w4lrub1000027.jpg" title="" alt="" style="width:20px;height:20px;"> www.instagram.com/c4therapeutics</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item1A"></a><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an early-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an early-stage biopharmaceutical company with limited operating history. Our net loss was $66.3 million and $34.1 million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $183.8 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, including our initial public offering, proceeds from our collaborations and debt financing. We are still in the early stages of development of our product candidates and expect to initiate our first clinical trial in the first half of 2021. As a result, we expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing approval for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including, without limitation, successfully completing preclinical studies and clinical trials of our product candidates, discovering additional product candidates, establishing arrangements with third parties for the conduct of our clinical trials, procuring clinical- and commercial-scale manufacturing, obtaining marketing approval for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing approval, identifying collaborators to develop product candidates we identify or additional uses of existing product candidates and successfully completing development of product candidates for our collaboration partners. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">initiate, conduct, and complete a planned first-in-human Phase 1/2 clinical trial of our lead product candidate, CFT7455, in patients with multiple myeloma, or MM, or non-Hodgkin lymphomas, or NHLs, such as peripheral T cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">initiate, conduct, and complete a planned first-in-human Phase 1/2 clinical trial of our second lead product candidate, CFT8634, in patients with synovial sarcoma or SMARCB1-deleted solid tumors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">leverage our TORPEDO platform to identify and then advance additional product candidates into preclinical and clinical development, including, without limitation, product candidates arising out of our BRAF, RET and EGFR programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expand the capabilities of our TORPEDO platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">initiate, conduct and successfully complete later-stage clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expand, maintain and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">hire additional clinical, regulatory and scientific personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our ongoing research and development and potential future commercialization efforts.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses could increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform trials in addition to those that we currently expect, or if we experience any delays in establishing appropriate manufacturing arrangements for, completing our clinical trials or the clinical development of any of our product candidates. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, expand our business or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause you to lose all or part of your investment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need substantial<font style="font-style:normal;"> </font>additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we prepare for and initiate, conduct, and complete our planned first-in-human Phase 1/2 clinical trials of CFT7455 and CFT8634, advance our TORPEDO platform and continue research and development and initiate clinical trials of, and potentially seek marketing approval for, our current and future preclinical programs. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Further, we expect to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65602179"></a>We had cash, cash equivalents, and marketable securities of approximately $371.7&#160;million as of December&#160;31, 2020. We believe that these funds, combined with anticipated payments from collaboration partners, will be sufficient to fund our operating expenses and capital expenditure requirements <font style="color:#000000;">through the end of 2023</font>. We have based this estimate on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing, progress, costs and results of our planned first-in-human Phase 1/2 clinical trials for CFT7455 and CFT8634 and any future clinical development of CFT7455 and CFT8634; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs, including, without limitation, product candidates arising out of our BRAF, RET and EGFR programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the number and development requirements of other product candidates that we pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the success of our ongoing collaborations with Biogen, Roche and Calico; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs, timing and outcomes of regulatory review of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval and the timing of the receipt of any such revenue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any delays or interruptions, including due to the COVID-19 pandemic, that we experience in our preclinical studies, clinical trials and/or supply chain; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">our ability to establish collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current cash, cash equivalents, and marketable securities will not be sufficient for us to fund any of our product candidates through regulatory approval. As a result, we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. We may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2015 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, developing and advancing our TORPEDO platform, undertaking preclinical studies and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. While we anticipate commencing a clinical trial of CFT7455 during the first half of 2021, at this time, all of our other product candidates are still in preclinical development or in the discovery stage. We have not yet demonstrated our ability to successfully initiate or complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product directly or through a third party or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had already successfully completed some or all of these types of activities in the past. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as an early-stage biopharmaceutical company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in making that transition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The ongoing global COVID-19 pandemic could continue to adversely impact our business, including our preclinical studies and development programs, supply chain and business development activities.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic, which began in December 2019 and remains ongoing, has spread worldwide and caused governments worldwide to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny, business shutdowns and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. While COVID-19 vaccines are now being distributed in the United States and around the world, it will take time to widely administer the vaccines and achieve herd immunity locally and globally. Further, new strains of COVID-19 have accelerated and expanded the spread of this outbreak. As a result, the future progression of the outbreak and its effects on our business and operations, as well as the potential timing of a return to a new normal, remain uncertain. In addition, any delays in foreign shipments coming into the United States could also impact our preclinical study or clinical trial plans. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CMOs and contract research organizations, or CROs, may face disruptions that could affect our ability to initiate and complete preclinical studies or clinical trials. For example, because of ongoing efforts to address the pandemic, we may face disruptions in procuring items that are essential for our research and development activities, including, due to shortages arising in raw materials used in the manufacturing of our product candidates, laboratory supplies for our preclinical studies and clinical trials or animals that are used for preclinical testing. We and our CROs and CMOs may face disruptions related to our clinical trials arising from potential delays in IND-enabling studies, manufacturing disruptions and/or the ability to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain necessary IRB or other necessary site approvals, as well as other delays at clinical trial sites, including delays related to site staffing. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2020, due to COVID-19, we closed the office and laboratory spaces in our Watertown, Massachusetts facility and transitioned our employees to work from home. During the spring of 2020, we also experienced closures at the locations of some of our Indian CROs due to local lockdown requirements. These shutdowns resulted in delays to our preclinical studies. Due to the COVID-19 pandemic, we have also seen the risk of delays in production of components used to manufacture our lead degrader candidates increase due to previous delays at one of our China-based manufacturers, which we remediated by working with that manufacturer to change the location of future work to another of the manufacturer&#8217;s sites. In June 2020, we reopened our office location to enable a subset of our employees &#8211; those whose work can only be performed in our laboratories &#8211; to return to the office, and we have required our remaining employees to continue working from home, an arrangement that we expect will continue for some time. While the ongoing impact of this pandemic is uncertain, we believe the redundancies we have in place between our China and India based CROs and our Watertown, Massachusetts-based laboratory staff, as well as the transition of the majority of our employees to remote work arrangements, have mitigated the impact of these disruptions on our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to the COVID-19 pandemic may result in the redirection of resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. For example, since March 2020, foreign and domestic inspections by FDA have largely been on hold with FDA announcing plans in July 2020 to resume prioritized domestic inspections. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. Should the FDA determine that an inspection is necessary for issuing any future marketing approvals and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter.&#160;Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications.&#160;Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. Additionally, as of June 23, 2020, the FDA also noted that it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals, including for oncology product development with its staff teleworking full-time. However, FDA may not be able to continue its current pace and review timelines could be extended. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we were successfully able to raise capital twice during 2020, the pandemic has caused significant disruptions in the financial markets and may continue to cause these types of disruptions, which could impact our ability to raise additional funds through public offerings and may also contribute to volatility in our stock price and otherwise impact trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could adversely affect our business prospects, financial condition and results of operations. Any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19&#160;and actions taken to reduce its spread continue to rapidly evolve. The extent to which&#160;COVID-19&#160;may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our pre-clinical studies or clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the&#160;COVID-19&#160;pandemic adversely affects our business prospects, financial condition and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and results of our planned and future clinical trials and our financing needs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Credit Agreement with Perceptive Credit contains restrictions that limit our flexibility in operating our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we entered into a credit agreement and guaranty, or the Credit Agreement, with Perceptive Credit Holdings III, LP, or Perceptive Credit, an affiliate of Perceptive Advisors LLC, or Perceptive Advisors, which is one of our significant stockholders. The Credit Agreement provides for a $20.0&#160;million senior secured delayed draw term loan facility, or the Delayed Draw Loan Facility. The Credit Agreement is secured by a lien on substantially all of our and our subsidiaries&#8217; assets, including, but not limited to, shares of our subsidiaries, our current and future intellectual property, insurance, trade and intercompany receivables, inventory and equipment and contract rights. The Credit Agreement requires us to meet specified minimum cash requirements, as described below, and contains various affirmative and negative covenants that limit our ability to engage in specified types of transactions. These covenants, which are subject to customary exceptions, limit our ability to, without Perceptive Credit&#8217;s prior written consent, effect any of the following, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">sell, lease, transfer or otherwise dispose of certain assets; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acquire another company or business or enter into a merger or similar transaction with third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">incur additional indebtedness; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">make investments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">enter into certain inbound and outbound licenses of intellectual property, subject to certain exceptions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">encumber or permit liens on certain assets; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">pay dividends and make other restricted payments with respect to our common stock. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors or management team could believe that taking any one of these actions would be in our best interests and the best interests of our stockholders. If that were the case and if we were unable to complete any of these actions because Perceptive Credit does not provide its consent, that could adversely impact our business, financial condition and results of operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are required to deposit into controlled accounts all cash or other payments received in respect of any and all of our accounts receivable or any other contract or right and interest and, at all times, to maintain a minimum aggregate balance of $3.0&#160;million in cash in one or more such controlled accounts. These accounts are required to be maintained as cash collateral accounts securing our obligations under the Credit Agreement. Until our obligations under the Credit Agreement have been discharged, our ability to use the cash amounts held in these controlled accounts in the operation of our business will be limited. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we drew down on $12.5 million of the Delayed Draw Loan Facility. Our ability to draw on the remaining Delayed Draw Loan Facility is contingent on our compliance with the covenants described above and certain other covenants. Even if we meet these conditions, we may elect not to draw on the remaining Delayed Draw Loan Facility.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a default under the Credit Agreement, including, among other things, our failure to make any payment when due or our failure to comply with any provision of the Credit Agreement, subject to customary grace periods, Perceptive Credit could elect to declare all amounts outstanding to be immediately due and payable and terminate all commitments to extend further credit. If we are unable to repay the amounts due under the Credit Agreement, Perceptive Credit could proceed against the collateral granted to it to secure this indebtedness, which could have an adverse effect on our business, financial condition and results of operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perceptive Credit&#8217;s interests as a lender may not always be aligned with our interests or with Perceptive Advisor&#8217;s interests as a stockholder. If our interests come into conflict with those of Perceptive Credit, including in the event of a default under the Credit Agreement, Perceptive Credit may choose to act in its self-interest, which could adversely affect the success of our current and future collaborative efforts with Perceptive Advisor. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until the time, if ever, when we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Biogen, Roche and Calico, we do not currently have any committed external source of funds, other than our ability to draw on the Delayed Draw Loan Facility if the necessary preconditions have been satisfied. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of any securities we may issue in the future may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. Pursuant to the Credit Agreement, we granted Perceptive Credit a warrant that now enables Perceptive Credit to purchase 338,784 shares of our common stock and Perceptive Credit could elect to exercise this warrant in the future. Covenants in the Credit Agreement impose certain limitations and obligations on us, including restrictions on our ability to incur additional debt and to enter into certain business combinations without Perceptive Credit&#8217;s prior written consent. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery and Development of Our Product Candidates </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our approach to the discovery and development of product candidates based on our TORPEDO platform for targeted protein degradation is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treating diseases using targeted protein degradation is a new treatment modality. Our future success depends on the successful development of this novel therapeutic approach. Very few small molecule product candidates using targeted protein degradation, such as those developed through our TORPEDO platform, have been tested in humans and none have been approved in the United States or Europe. The data underlying the feasibility of developing these types of therapeutic products is both preliminary and limited. If any adverse learnings are made by other developers of targeted protein degraders, there is a risk that development of our product candidates could be materially impacted. Discovery and development of small molecules that harness the ubiquitin proteasome pathway to degrade protein targets have been impeded largely by the complexities and limited understanding of the functions, biochemistry and structural biology of the specific components of the ubiquitin-proteasome system, including E3 ligases and their required accessory proteins involved in target protein ubiquitination, as well as by challenges of engineering compounds that promote protein-to-protein interactions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scientific research that forms the basis of our efforts to develop our degrader product candidates under our TORPEDO platform is ongoing and the scientific evidence to support the feasibility of developing TORPEDO platform-derived therapeutic treatments is both preliminary and limited. Further, certain cancer patients have shown inherent primary resistance to approved drugs that inhibit disease-causing proteins and other patients have developed acquired secondary resistance to these inhibitors. Although we believe our products candidates may have the ability to degrade the specific mutations that confer resistance to currently marketed inhibitors of disease-causing enzymes, any inherent primary or acquired secondary resistance to our product candidates in patients, or if the scientific research that forms the basis of our efforts proves to be contradicted, would prevent or diminish their clinical benefit. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we plan to commence a clinical study of CFT7455 in the first half of 2021, to date, we have not yet initiated, conducted, or completed a clinical trial of any product candidate and we have not yet assessed the safety of any of our product candidates in humans. Although some of our product candidates have produced observable results in animal studies, there is a limited safety data set for their effects in animals. In addition, these product candidates may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, there could be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better-known or extensively studied product candidates. Although other companies are also developing therapeutics based on targeted protein degradation, no regulatory authority has granted approval for any therapeutic of this nature at this time. As a result, it is more difficult for us to predict the time and cost of developing our product candidates and we cannot predict whether the application of our TORPEDO platform, or any similar or competitive protein degradation platforms, will result in the development of product candidates that make it through to marketing approval. Any development problems we experience in the future related to our TORPEDO platform or any of our research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate, as well as from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an early-stage biotechnology company and, while we plan to commence a clinical trial of CFT7455 in the first half of 2021, all of our product candidates are currently in preclinical development or in the discovery phase. If we are unable to advance to clinical development, develop, obtain regulatory approval for and commercialize our product candidates or experience significant delays in doing so, our business may be materially harmed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an early-stage biotechnology company and all of our product candidates are currently in preclinical development or in the discovery stage. As a result, their risk of failure is high. We have invested substantially all of our efforts and financial resources in building our TORPEDO platform and identifying and conducting preclinical development of our current product candidates, including CFT7455 and CFT8634. Our ability to generate revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates will depend on several factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">sufficiency of our financial and other resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful initiations and completion of preclinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful submission of INDs and initiation of clinical trials; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful patient enrollment in, and conduct and completion of, clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">receipt and related terms of marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and maintaining patent or trade secret protection and regulatory exclusivity for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">making arrangements with third-party manufacturers for both clinical and commercial supplies of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developing product candidates that achieve the therapeutic properties desired and appropriate for their intended indications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishing a continued acceptable safety profile of the products and maintaining such that a profile following approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">effectively competing with other therapies. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not successfully achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience as a company in completing IND-enabling preclinical studies, submitting INDs or commencing and conducting clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience as a company in completing IND-enabling preclinical studies and, while we plan to commence clinical development of CFT7455 in the first half of 2021, we presently have no experience as a company in commencing and conducting clinical trials. In part because of this lack of experience, we cannot be certain that our preclinical studies will be completed on time, that we will submit INDs in a timely manner, that any INDs we submit will be cleared by the FDA in a timely manner, if at all, or if our planned clinical trials will begin or be completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and reliance on third-party clinical investigators and consultants. Relying on third-party clinical investigators, CROs and consultants may cause us to encounter delays that are outside of our control. In addition, relying on third parties in the conduct of our preclinical studies or clinical trials exposes us to a risk that they may not adequately adhere to study or trial protocols or comply with GLP or GCP, as required for any studies or trials we plan to submit to a regulatory authority. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. For each of our lead product candidates, CFT7455 and CFT8634, we have entered into a master services agreement with a CRO to lead our planned first-in-human Phase 1/2 clinical trial for the applicable product candidate. There can be no assurance that we will be able to negotiate and enter into additional master services agreement with these or other CROs, as necessary, on terms that are acceptable to us on a timely basis or at all.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approval for the commercial sale of any of our product candidates, including CFT7455 and CFT8634, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete. Further, the outcome of these activities is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes and, because our product candidates are in an early stage of development and have never been tested in humans, there is a high risk of failure. In addition, because targeted protein degraders are a relatively new class of product candidates, any failures or adverse outcomes in preclinical or clinical testing seen by other developers in this class could materially impact the success of our programs. We may never succeed in developing marketable products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective or safe in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing in humans and, therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purity</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and efficacy profile despite having progressed successfully through preclinical studies and/or initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we expect that the first clinical trials for our product candidates may be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. This will be the case with the first-in-human clinical trial of CFT7455. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies or clinical trials are inconclusive with respect to the safety, potency, purity and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for those product candidates. In some instances, there can be significant variability in safety, potency, purity or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we plan to commence a clinical trial for CFT7455 in the first half of 2021, we have not yet initiated clinical trials for any of our product candidates and, as is the case with all drugs, it is likely that there may be side effects associated with their use related to on-target, off-target toxicity, or other mechanisms of drug toxicity including chemical-based toxicity. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects of this nature. If unacceptable levels of toxicity are observed or if our product candidates have other characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Further, if we were to observe unacceptable levels of side effects, or if other developers of similar targeted protein degraders were to find an unacceptable severity or prevalence of side effects with their drug candidates, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could also affect patient recruitment or the ability of enrolled patients to complete an ongoing trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and prospects and many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we plan to commence a clinical trial of CFT7455 in the first half of 2021, all of our other product candidates are presently in preclinical development or the discovery stage and their risk of failure is high. We are unable to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs in the United States or similar applications in other jurisdictions. We cannot be certain of the timely initiation, completion or outcome of our preclinical studies and, other than in the case of CFT7455, where the FDA has cleared the IND for our planned first-in-human study of this drug candidate, we cannot predict if the FDA or similar regulatory authorities outside the United States will allow us to commence our proposed clinical trials or if the outcome of our preclinical studies ultimately will support the further development of any of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the timing and outcome. A failure of one or more clinical trials can occur at any stage of the process. We may experience </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">numerous unforeseen events during or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trials, which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in reaching, or the failure to reach, a consensus with regulators on clinical trial design or the inability to produce acceptable preclinical results to enable entry into human clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidates to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in reaching, or the failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or CROs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the failure of regulators or IRBs to authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well studied and for which the natural history and course of the disease is poorly understood; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the selection of certain clinical endpoints that may require prolonged periods of clinical observation or analysis of the resulting data; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or the failure to recruit suitable patients to participate in our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the third parties with whom we contract may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the requirement from regulators or IRBs that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or unacceptable safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">clinical trials of our product candidates may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; &#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the cost of clinical trials of our product candidates may be greater than we anticipate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">disruptions caused by the evolving effects of the COVID-19 pandemic may increase the likelihood that we encounter these types of difficulties or cause other delays in initiating, enrolling, conducting or completing our planned clinical trials. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns related to our product candidates, we may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be delayed in obtaining marketing approval for our product candidates, if at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be required to perform additional clinical trials to support marketing approval; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">have regulatory authorities withdraw or suspend their approval, or impose restrictions on distribution of a product candidate in the form of a modified risk evaluation and mitigation strategy, or REMS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">be subject to additional post-marketing testing requirements or changes in the way the product is administered; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">have our product removed from the market after obtaining marketing approval. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. While we plan to commence a clinical trial for CFT7455 during the first half of 2021, we do not know whether any of our other preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business, results of operations, financial condition and prospects. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, cancer therapies sometimes are characterized as first-line, second-line or third-line. The FDA often approves new oncology therapies initially only for third-line or later use, meaning for use after two or more other treatments have failed. When cancer is detected early enough, first-line therapy, usually systemic anti-cancer therapy (e.g., chemotherapy), surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second-line and third-line therapies are administered to patients when prior therapy has been shown to not be effective. Our planned clinical trials for our lead product candidates&#160;CFT7455 and CFT8634 and other drug candidates will be with patients who have received one or more prior treatments and we expect that we would initially seek regulatory approval of these product candidates for second-line or third-line therapy. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved for second-line or third-line therapy, may not be approved for first-line therapy and, prior to seeking and/or receiving any approvals for first-line therapy, we may have to conduct additional clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Targeted protein degradation is a novel modality that continues to attract substantial interest from existing and emerging biotechnology and pharmaceutical companies. As a result, we face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face, and will continue to face, competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, immunotherapy, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition we face and will face is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeted protein degradation is an emerging therapeutic modality that has the potential to deliver therapies that improve outcomes for patients. As a result, a number of biotechnology and pharmaceutical companies are already working to develop degradation-based therapies and the number of companies entering this space continues to increase. We are aware of several biotechnology companies focused on developing product candidates based on small molecules for targeted protein degradation including Arvinas, Inc., BioTheryX, Inc., Cullgen Inc., Foghorn Therapeutics, Inc., Frontier Medicines Corporation, Kymera Therapeutics, Inc., Lycia Therapeutics, Inc., Monte Rosa Therapeutics, Inc., NeoMorph Inc., Nurix Therapeutics, Inc., and Vividion Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed investments and research in this field, including Amgen, AstraZeneca plc, Bristol-Myers Squibb Company (and its subsidiary Celgene Corporation), GlaxoSmithKline plc, Genentech, Inc. and Novartis International AG. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, T cell or gene therapies. For example, we understand that Adaptimmune Limited, Foghorn Therapeutics, Inc. and GlaxoSmithKline plc are pursuing the development of therapies for patients with synovial sarcoma.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors, the scale of which could be difficult to compete against. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expensive than any product candidate that we may develop. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuing</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards and research and development tax credit carryforwards may be limited. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had $58.8 million federal net operating loss carryforwards and $105.1&#160;million gross in United States state net operating loss carryforwards, which expire at various dates through 2040. Under legislation enacted in 2017, informally titled the TCJA, as modified by the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, federal net operating losses generated after 2017, if any, will not expire and may be carried forward indefinitely, but will generally limit the federal net operating losses deduction to the lesser of the net operating loss carryover or 80% of the corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended). The CARES Act temporarily allows us to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior years. In addition, net operating losses generated in those years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA. It is uncertain how various states will respond to the TCJA, the CARES Act or any newly enacted federal tax law. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, including a recent California franchise tax law change limiting the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we also had United States federal and state research and development tax credit carryforwards of $4.7&#160;million and $1.1&#160;million, respectively, which expire at various dates through 2040. These tax credit carryforwards could expire unused and be unavailable to offset our future income tax liabilities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. In 2020, the Company completed a study of ownership changes from inception through December 31, 2020, which concluded that we experienced ownership changes as defined by Section&#160;382 of the Code. However, there were no net operating loss carryforwards that were limited or expired unused. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership, including as a result of our recently closed initial public offering, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, that would harm our future operating results by effectively increasing our future tax obligations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect and, even if we are able to, the FDA may not permit us to proceed with our planned clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience as a company in preparing, submitting to and receiving clearance from the FDA on INDs. We submitted our first IND to the FDA in December 2020, for CFT7455 and, in January 2021, the FDA informed us that we are permitted to proceed with our first-in-human clinical trial for this product candidate. We plan to submit an IND for CFT8634 in the second half of 2021. While this is our current expectation, we may not be able to file this planned IND or INDs for other product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies, we may determine that additional IND-enabling studies are warranted, or we may face delays due to the ongoing global COVID-19 pandemic. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing us to commence clinical trials or that, once begun, issues will not arise that lead to the suspension or termination of our clinical trials. Additionally, even if the applicable regulatory authorities agree with the design and implementation of the clinical trials set forth in our INDs, we cannot guarantee that those regulatory authorities will not change their requirements in the future. These considerations apply to the INDs described above and also to new clinical trials we may submit as amendments to existing INDs or as part of new INDs in the future. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our clinical trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk62158767"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are planning to commence a clinical trial of CFT7455 in the first half of 2021, we have not yet evaluated any of our product candidates in human clinical trials. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that any of the product candidates developed through our TORPEDO platform will not cause undesirable side effects, which could arise at any time during preclinical or clinical development. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A potential risk with product candidates developed through our TORPEDO platform, or in any protein degradation product candidate, is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in and of itself could cause adverse events, undesirable side effects or unexpected characteristics. There is also the potential risk of delayed adverse events following treatment using product candidates developed through our TORPEDO platform. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidates we develop are associated with serious adverse events or undesirable side effects or have other characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The occurrence of any of these sorts of events would have an adverse effect on our business, financial condition, results of operations and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates or limited their competitiveness in the market. For example, single agent BRAF inhibitors can cause a secondary malignancy called keratocanthoma, which is a skin cancer caused by paradoxical activation of BRAF upon inhibitor binding. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results of preclinical studies may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when those trials are completed or in later stage clinical trials. In particular, the small number of patients in our planned early clinical trials or the designs of these trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of the dose escalation portion of our future first-in-human Phase 1/2 clinical trials of CFT7455 and CFT8634 may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any setbacks of this nature in our clinical development could materially harm our business, financial condition, results of operations and prospects. In addition, we may conduct some of our clinical trials in a combination Phase 1/2 design and, if the Phase 1 portion of the trial is not successful, we will not be allowed to proceed into the Phase 2 portion of the trial. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our timelines for submitting for and receiving necessary marketing approvals could be delayed or prevented. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials, as required by the FDA or similar regulatory authorities outside of the United States. We are preparing to advance CFT7455 into first-in-human Phase 1/2 clinical trials in MM and NHLs, including PTCL and MCL. In addition, we are planning to advance CFT8634 into first-in-human Phase 1/2 clinical trials in patients with synovial sarcoma or SMARCB1 deleted solid tumors. While we believe that we will be able to enroll a sufficient number of patients into each of these clinical trials, we cannot predict with certainty how difficult it will be to enroll patients for trials in these rare indications generally and during the COVID-19 pandemic, specifically. Our ability to identify and enroll eligible patients for our CFT7455 and CFT8634 clinical trials may turn out to be limited or we may be slower in enrolling these trials than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates and, as a result, patients who would be eligible for our clinical trials may instead elect to enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment in clinical trials is also affected by other factors including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the severity of the disease under investigation; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the eligibility criteria for the trial in question; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the perceived risks and benefits of the product candidates offered in the clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the efforts to facilitate timely enrollment in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the patient referral practices of physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the burden on patients due to the scope and invasiveness of required procedures under clinical trial protocols, some of which may be inconvenient and/or uncomfortable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability to monitor patients adequately during and after treatment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the proximity and availability of clinical trial sites for prospective patients; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the impact of the current COVID-19 pandemic, which may affect the conduct of a clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials or by interfering with patients&#8217; ability to return to the clinical trial site for required monitoring, procedures or follow-up. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for our planned clinical trials, or our inability to do so on a timely basis, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may also result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The conclusions and analysis drawn from announced or published interim top-line and preliminary data from our clinical trials from time to time may change as more patient data become available. Further, all interim data that we provide remains subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. In addition, preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being different, potentially in material ways, from the preliminary data we previously announced or published. As a result, interim and preliminary data should be viewed with caution until final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation, business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may develop CFT7455 in combination with other drugs for MM. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of these other drugs or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with CFT7455, we may be unable to obtain approval of or market CFT7455. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a recommended dose is identified from the dose escalation portion of our first-in-human Phase 1/2 clinical trial of CFT7455 for the treatment of MM, we plan to conduct a portion of that clinical trial in combination with a dexamethasone inhibitor. We did not develop or obtain marketing approval for, nor do we manufacture or sell, any of the currently approved drugs that we may study in combination with CFT7455. If the FDA or similar regulatory authorities outside of the United States revoke their approval of the drug or drugs we intend to deliver in combination with CFT7455, we will not be able to market CFT7455 in combination with those revoked drugs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate certain of our clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for CFT7455, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with CFT7455, we may not be able to complete clinical development of CFT7455 on our current timeline or at all. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if CFT7455 were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with CFT7455 or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combination therapies are commonly used for the treatment of cancer and we would be subject to similar risks if we were to elect to develop any of our other product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify or discover additional potential product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our four lead programs are focused on oncology targets, a key element of our strategy is to apply our TORPEDO platform to develop product candidates that address a broad array of targets and new therapeutic areas, such as neurodegeneration, diseases of aging and infectious disease. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance;&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">potential product candidates may not be effective in treating their targeted diseases; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the market size for the target indications of a potential product candidate may diminish over time due to improvements in the standard of care to the point that further development is not warranted. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify suitable product candidates for preclinical and clinical development, we will not be able to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. Each of these milestones is and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our revenue may be lower than expected or the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Dependence on Third Parties </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect to rely on third parties to conduct our future clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to rely on CROs to conduct our planned first-in-human Phase 1/2 clinical trial programs for CFT7455 and CFT8634 and our other clinical trials as we currently do not plan to independently conduct clinical trials of our other product candidates. Our agreements with these CROs might terminate for a variety of reasons, including a failure to perform by the third parties. If we were ever to need to enter into alternative arrangements, we would experience delays in our product development activities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on CROs for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities for how these activities are performed. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with standards, commonly referred to as GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, these CROs may have relationships with other entities, some of which may be our peers or competitors. If the CROs with whom we work do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing pharmaceutical products is complex and subject to product delays or loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or that we will not have the quantities we desire or require at an acceptable cost or quality or at the right time, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on CMOs for both drug substance and finished drug product. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or that we will not have the quantities we desire or require at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to establish agreements with CMOs or to do so on acceptable terms. Even if we are able to establish agreements with CMOs, reliance on third-party manufacturers entails additional risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reliance on the third party for regulatory, compliance, quality assurance and manufacturing success; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the possible breach of the manufacturing agreement by the third-party CMO;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the possible risk that the CMO will cease offering the services we require or shut down operations altogether, either temporarily or permanently, due to a regulatory concern, financial insolvency, non-compliance with applicable law or another reason; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us or the inability of the CMO to provide us with a manufacturing slot when we need it. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have only limited technology transfer agreements in place with respect to our product candidates and these existing arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If we receive marketing approval for any of our product candidates, we will need to establish or have established an agreement for commercial manufacture with one or more third parties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our molecules are highly potent and, in the absence of additional safety data, they receive a high occupational exposure band, or OEB. These assigned OEBs dictate the contaminant and other precautions that must be taken as part of the manufacture of our product candidates and limit the number of CMOs who are qualified to manufacture our molecules. Our failure, or the failure of our CMOs, to comply with applicable regulations, including the ability of our CMOs to work with our highly potent materials and the safety protocols in connection therewith, could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. &nbsp;&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us, particularly given the potency of our compounds and the fact that only certain CMOs can manufacture compounds of this nature. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure or delay in performance on the part of our existing or future manufacturers could delay clinical development or marketing approval. For example, our contract fill/finish manufacturer had a mechanical issue arise in connection with a manufacturing step for a manufacturing run for our CFT7455 product candidate. While this issue did not ultimately delay the timing of submission of our IND for CFT7455, in the future, we could experience a manufacturing issue that would have a material impact on development of our product candidates and the occurrence of an event of this nature would largely be outside of our control. We do not currently have arrangements in place for redundant supply or a second source for drug substance or drug product. If our current CMOs cannot perform as agreed, we may be required to replace </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any replacement manufacturers or we may not be able to reach agreement with any alternative manufacturer. While we have identified alternate vendors for CFT7455 and CFT8634, switching vendors could result in significant additional costs of materials and significant delays to our operations</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and we may be constrained in the vendors we can select based on the high OEB designation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of our molecules</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we currently rely on single source suppliers for certain of the raw materials for our preclinical study and clinical trial supplies. If our current or future suppliers are unable to supply us with sufficient raw materials for our preclinical studies and clinical trials, we may experience delays in our development efforts as we locate and qualify new raw material manufacturers. These third-party manufacturers may incorporate their own proprietary processes into our product candidate manufacturing processes. We have limited control and oversight of a third party&#8217;s proprietary process and a third-party manufacturer may elect to modify its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost of and significantly delay the manufacture of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our product candidates progress through preclinical studies and clinical trials towards approval and commercialization, we expect that various aspects of the manufacturing process will evolve in an effort to optimize processes and results. These types of changes may require that we make amendments to our regulatory applications, which could further delay the timeframes under which modified manufacturing processes can be used for any of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as we advance our product candidates into later stage clinical trials and plan for the potential commercialization of our product candidates, we may determine that it is necessary or appropriate to bring on additional suppliers of drug product and/or drug substance, which could result in changes to the manufacturing processes for our product candidates and may require us to provide additional information to regulatory authorities. If we were to bring on additional CMOs for our product candidates, we may also be required to conduct additional bridging studies or trials, all of which would require additional time and expense. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have existing collaborations with third parties under which we are engaged in the research, development and commercialization of certain of product candidates. If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. In addition, these collaborations could impact our intellectual property rights.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Previously, we entered into the following collaborations, which involve our research programs: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaboration agreement with Roche in December 2015, which we amended and restated in December 2018 and further amended in November 2020; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaboration agreement with Calico in March 2017; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a collaboration agreement with Biogen in December 2018, which was amended in February 2020. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under these collaboration agreements, we are generally responsible for developing drug candidates leveraging our TORPEDO platform based on partner-selected targets. Further, these agreements provide that our collaboration partners have exclusive rights to develop degraders for their selected and reserved targets. As a result, we are not permitted to pursue a target of potential interest &#8211; either alone or with another partner &#8211; while that target is bound by these restrictions.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, if our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us or elects not to pursue a program within a collaboration, we may not receive any future research funding or milestone or royalty payments under that collaboration or in respect of that terminated program. If that were to happen, we might decide to abandon the program or to move the program forward on our own, which would require us to have to devote additional resources to the program on a going-forward basis. In addition, if one of our collaborators terminates its agreement with us generally or with respect to a specific target, which they are permitted to do for convenience on between 90 and 270 days&#8217; notice or in connection with a material breach of the agreement by us that remains uncured for a specified period of time, we may find it more difficult to attract new collaborators and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing<font style="font-weight:bold;font-style:italic;"> </font>approval and commercialization described in this report apply to the activities of our collaborators.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that our c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollaborators may not properly obtain, maintain, enforce or defend </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual property or proprietary rights </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arising out of our licensed programs </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or may use our proprietary information in a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, Roche, Biogen and Calico have the first right to enforce and Roche also has the first right to defend, certain intellectual property rights under the applicable collaboration arrangement with respect to particular licensed programs and, although we may have the right to assume the enforcement and defense of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> intellectual property rights if </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> collaborator does not, our ability to do so may be compromised by their actions. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any licensed program were later to revert to us, our ability to protect any intellectual property or other proprietary rights associated with that program would be impacted by the intellectual property filings made or other steps taken by our collaborator prior to program reversion. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollaborators may own or co-own intellectual property covering our products that results from our collaborating with them and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in cases where that applies, we would not have the exclusive right to commercialize the collaboration intellectual property. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future and we may not realize the benefits of those collaborations, alliances or licensing arrangements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Our likely collaborators in any other collaboration arrangements we may enter into include large and mid-size pharmaceutical companies and biotechnology companies. However, it is possible that we will not be able to enter into a collaboration agreement of this nature or that the terms of any potential new collaboration arrangement may not be favorable. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we may seek to enter into collaboration arrangements to advance our CFT7455 product candidate in MM or other indications or we may form or seek to form collaboration arrangements to enable our development and commercialization of a product candidate in a specified geographic area. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process for these sorts of transactions is time-consuming, complex and expensive. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. Additionally, our existing partners may decide to acquire or partner with other companies developing targeted protein degraders, which may have an adverse impact on our business prospects, financial condition and results of operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business prospects, financial condition and results of operations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies the entry into the transaction in the first place. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Commercialization of Our Product Candidates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well-established in the medical community and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the prevalence and severity of any side effects, in particular compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to offer our products for sale at competitive prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the willingness of the target patient population to try new therapies and of physicians treating these patients to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the strength of marketing, sales and distribution support; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the availability of third-party insurance coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing of any marketing approval in relation to other product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">support from patient advocacy groups; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">any restrictions on the use of our products together with other medications.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company, we currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company, we currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue arrangements with third-party sales, marketing and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain these types of arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of these third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of these third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be relatively small as we expect that they will initially be approved only for those patients who are ineligible for or have failed prior treatments. In addition, our estimates of the prevalence of our target patient populations may be inaccurate. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may target cancer, but cancer therapies are sometimes characterized as first-line, second-line, third-line or subsequent line and the FDA often approves new therapies initially only for a particular line of use. When cancer is detected early enough, first-line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first-line therapy &#8211; usually chemotherapy, antibody drugs, tumor-targeted small molecules, immunotherapy, hormone therapy, radiation therapy, surgery, other targeted therapies or a combination of these therapies &#8211; proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third-line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect initially to seek approval of our product candidates in most instances as a second- or third-line therapy, for use in patients with relapsed or refractory cancer. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second-line therapy and potentially as a first-line therapy, but there is no guarantee that any of our product candidates, even if approved as a second- or third- or subsequent line of therapy, would subsequently be approved for an earlier line of therapy. Further, it is possible that, prior to getting any approvals for our product candidates in earlier lines of treatment, we might have to conduct additional clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, who may have their tumors genetically sequenced, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our reasonable beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect or out of date. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second- or third-line of therapy, the number of patients that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each of those tumor types.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive marketing approval of any of our product candidates, our products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">any of </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which would harm our business. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which would negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may, therefore, hinder our ability to recoup our investment in one or more of our product candidates, even if our product candidates obtain marketing approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs. In addition, coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if or when we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">decreased demand for any product candidates or products that we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">termination of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">withdrawal of clinical trial </font><font style="color:#000000;">participants;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">significant costs to defend the related litigation and/or increased product liability insurance costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">loss of revenue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reduced resources of our management to pursue our business strategy; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the inability to commercialize any products that we may develop. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we plan to put coverage in place prior to commencing our planned first-in-human clinical trial of CFT7455 in the first half of 2021, as a preclinical company, we do not currently hold product liability insurance coverage. We will need to purchase product liability insurance coverage as we initiate our clinical trials, as we expand our clinical trials and if and when we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62163138"></a>Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, our ability to successfully commercialize our technology and products may be impaired or we may not be able to compete effectively in our market. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our intellectual property and prevent others from exploiting our platform technologies, our pipeline drug product candidates, any future drug product candidates we may develop and their use or manufacture. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patents and other proprietary protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties or that we license to our collaborators. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of the biopharmaceutical industry generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned, co-owned or licensed patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights or those of our collaborators are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our owned, co-owned and licensed patent estate consists principally of patent applications, many of which are at an early stage of prosecution. Even if our owned, co-owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us with any competitive advantage. Our competitors may be able to circumvent our owned, co-owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned, co-owned and licensed patents or patents obtained by our collaborators may be challenged in the courts or patent offices in the United States and abroad. These challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our drug product candidates might expire before or shortly after they are commercialized. As a result, our owned, co-owned and licensed patent portfolio, or that of our collaborators, may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of our patents in general or increase third party challenges to our patents, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law and made a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent and Trademark Office, or the USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act, including the first-inventor-to-file provisions, became effective on March&#160;16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business and financial condition. The first-to-file provision of the Leahy-Smith Act requires us to act promptly during the period from invention to filing of a patent application. However, even with the intention to act promptly, circumstances could prevent us from promptly filing or prosecuting patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, which can impact our ability to receive patent protection for an invention. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act created, for the first time, new procedures under which third parties may challenge issued patents in the United States, including post-grant review, <font style="font-style:italic;">inter partes</font> review and derivations proceedings, all of which are adversarial proceedings conducted at the USPTO. Since the effectiveness of the Leahy-Smith Act, some third parties have been using these types of actions to seek and achieve the cancellation of selected or all claims of issued patents of their competitors. Under the Leahy-Smith Act, for a patent with a priority date of March&#160;16, 2013 or later (which is the case for all of our patent filings), a third party can file a petition for post-grant review at any time during a nine-month window commencing at the time of issuance of the patent. In addition, for a patent with a priority date of March&#160;16, 2013 or later, a third party can file a petition for <font style="font-style:italic;">inter partes</font> review after the nine-month period for filing a post-grant review petition has expired. Post-grant review proceedings can be brought on any ground of challenge, whereas <font style="font-style:italic;">inter partes</font> review proceedings can only be brought to raise a challenge based on published prior art. Under applicable law, the standard of review for these types of adversarial actions at the USPTO are conducted without the presumption of validity afforded to U.S. patents, which is the standard that applies if a third party were to seek to invalidate a patent through a lawsuit filed in the U.S. federal courts. The USPTO issued a Final Rule on November&#160;11, 2018 announcing that it will now use the same claim construction currently used in the U.S. federal courts&#8212;which is the plain and ordinary meaning of words used&#8212;to interpret patent claims in these USPTO proceedings. As a result of this regulatory landscape, if any of our patents are challenged by a third party in a USPTO proceeding of this nature, there is no guarantee that we will be successful in defending the challenged patent, which could result in our losing rights under the challenged patent in part or in whole. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of this legislation, the issuance, scope, validity, enforceability and commercial value of our patent rights, or those of our collaborators, are highly uncertain, which could have an adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our issued patents, the patents of our licensors or collaborators or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive, time-consuming and unpredictable. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensors or collaborators is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at risk of being </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actually </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalidated</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, held unenforceable or interpreted narrowly. Even if we successfully assert our patents, a court may not award remedies that sufficiently compensate us for our losses. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to license intellectual property from third parties and licenses of this nature may not be available or may not be available on commercially reasonable terms. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products or our collaborators&#8217; products. It may, therefore, be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products or those of our collaborators, in which case we or our collaborators would be required to obtain a license from that third party. A license to that intellectual property may not be available or may not be available on commercially reasonable terms, which could have an adverse effect on our business and financial condition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party intellectual property rights is a competitive practice. Companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biopharmaceutical industry, as well as administrative proceedings for challenging patents, including reexamination, <font style="font-style:italic;">inter partes </font>review or interference proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may become party to or threatened with future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including derivation, reexamination. <font style="font-style:italic;">inter</font> <font style="font-style:italic;">partes </font>review, or interference proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. As the bio-pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found by a court of competent jurisdiction to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from the applicable third-party intellectual property holder to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A number of other companies, as well as universities and other organizations, file and obtain patents in the same areas as our products, which are targeted protein degraders, and these patent filings could be asserted against us or our collaborators in the future, which could have an adverse effect on the success of our business and, if successful, could lead to expensive litigation that could affect the profitability of our products and/or prohibit the sale or use of our products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our MonoDAC and BiDAC product candidates are small molecule pharmaceuticals, which degrade specific proteins. A number of companies and institutions have patent applications and issued patents in this general area, such as, for example, Arvinas, Inc., Cullgen, Inc., Kymera Therapeutics, LLC., the Dana-Farber Cancer Institute and its Center for Protein Degradation, the University of Michigan School of Medicine, Foghorn Therapeutics, Inc., Nurix Therapeutics, Inc., Monta Rosa Therapeutics, AG, BioTheryX, Inc., Bristol Myers Squibb, Roche, Novartis AG, Amgen Inc., AstraZeneca PLC, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GlaxoSmithKline PLC</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Vertex Pharmaceuticals, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and others. If any of these companies or institutions or others not included in this list were to assert that one of its patents is infringed by any product we might develop or its use or manufacture, we or our collaborators may be drawn into expensive litigation, which could adversely affect our business prospects, financial condition and results of operations, require extensive time from and cause the distraction of members of our management team and employees at large. Further, if litigation of this nature were successful, that could have a material and adverse effect on the profitability of our products or prohibit their sale. We may not be aware of patent claims that are currently or may in the future be pending that could affect our business or products. Patent applications are typical</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> published between six and eighteen months from filing and the presentation of new claims in already pending applications can sometimes not be visible to the public, which would include us, for </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a period of time</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, even after a patent application is publicly available, we may not yet have seen that patent application and may, therefore, not be aware of the claims or scope of filed and published patent applications. As a result, we cannot provide any assurance that a third party practicing in the general area of our technology will not present or has not presented a patent claim that covers one or more of our products or their methods of use or manufacture. If that were to occur, we or our collaborators, as applicable, may have to take steps to try to invalidate the applicable patent or application and, in a situation of that nature, we or our collaborators may either choose not to do so or our attempt may not be successful. If we determine that we require a license to a third party&#8217;s patent or patent application, we may discover that a license may not be available on reasonable terms, or at all</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could prevent us or our collaborators from selling a product or using our proprietary technologies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our products are subject to The Drug Price Competition and Patent Term Restoration Act of 1984, which is also referred to as the Hatch Waxman Act, in the United States, which can increase the risk of litigation with generic companies trying to sell our products and may cause us to lose patent protection. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our clinical candidates are pharmaceutical molecules that will be reviewed by the Center for Drug Evaluation and Research, CDER, of the FDA, after commercialization they will be subject in the United States to the patent litigation process of the Hatch-Waxman Act, as amended to date, which allows a generic company to submit an Abbreviated New Drug Application, or ANDA, to the FDA to obtain approval to sell a generic version of our drug using bioequivalence data only. Under amendments made to the Hatch-Waxman Act, we will have the opportunity to list our patents that cover our drug products or their respective methods of use in the FDA&#8217;s compendium of &#8220;Approved Drug Products with Therapeutic Equivalence Evaluation,&#8221; sometimes referred to as the FDA&#8217;s Orange Book.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, in the United States, the FDA may grant five years of exclusivity for new chemical entities, or NCEs, which are drugs that contain no active portion that has been approved by the FDA in any other NDA. We expect that all of our products will qualify as NCEs. A generic company can submit an ANDA to the FDA four years after approval of any of our drug products. The submission of an ANDA by a generic company is considered a technical act of patent infringement. The generic company can certify that it will wait until the natural expiration date of our listed patents to sell a generic version of our product or can certify that one or more of our listed patents are invalid, unenforceable or not infringed. If the generic manufacturer elects the latter, we will have 45 days to bring a patent infringement lawsuit against the generic company. If we were to do so, that would likely initiate a challenge to one or more of our Orange Book listed patents based on arguments from the generic manufacturer that our listed patents are invalid, unenforceable or not infringed. Under amendments to the Hatch-Waxman Act, if a lawsuit is brought, the FDA is prevented from issuing a final approval on the generic drug until 30 months after the end of the data exclusivity period (7.5 years) or a final decision of a court holding that our asserted patent claims are invalid, unenforceable or not infringed. If we do not properly list our relevant patents in the Orange Book or if we fail to file a lawsuit in response to a certification from a generic company under an ANDA in a timely manner, or if we do not prevail in the resulting patent litigation, we can lose our ability to benefit from a proprietary market based on patent protection covering our drug products and we may find that physicians will switch to prescribing and dispensing generic versions of our drug products. Further, even if we were to list our relevant patents in the Orange Book correctly, bring a lawsuit in a timely manner and prevail in that lawsuit, the generic litigation may come at a significant cost to us, both in terms of attorneys&#8217; fees and employee time and distraction over a long period. Further, it is common for more than one generic company to try to sell an innovator&#8217;s drug at the same time and, as a result, we may face the cost and distraction of multiple lawsuits from generic manufacturers at the same time. We may also determine that it is necessary to settle these types of lawsuits in a manner that allows the generic company to enter our market prior to the expiration of our patent or otherwise in a manner that adversely affects the strength, validity or enforceability of our patents. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A number of pharmaceutical companies have been the subject of intense review by the U.S. Federal Trade Commission or a corresponding agency in another country based on how they have conducted or settled patent litigation related to pharmaceutical products. In fact, certain reviews have led to an allegation of an anti-trust violation, sometimes resulting in a fine or loss of rights. We cannot be sure that we would not also be subject to a review of this nature or that the result of a review of this nature would be favorable to us, or that any review of this nature would not result in a fine or penalty. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Federal Trade Commission, or FTC, has brought a number of lawsuits in federal court in the past few years to challenge ANDA litigation settlements reached between innovator companies and generic companies as anti-competitive. As </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an example, the FTC has taken an aggressive position that anything of value is a payment, whether money is paid or not. Under their approach, if an innovator, as part of a patent settlement, agrees not to launch or delay its launch of an authorized generic during the 180-day period granted to the first generic company to challenge an Orange Book listed patent covering an innovator drug, or negotiates a delay in entry without payment, the FTC may consider it an unacceptable reverse payment. Companies in the pharmaceutical industry have argued that these types of agreements are rational business decisions entered into by drug innovators as a way to address risk and that these settlements should, therefore, be immune from antitrust attack if the terms of the settlement are within the scope of the exclusionary potential of the patent. In 2013, the U.S. Supreme Court in a five-to-three decision in </font><font style="font-style:italic;">FTC v. Actavis, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> rejected both the pharmaceutical </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry&#8217;s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and FTC&#8217;s arguments </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with regard to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> so-called reverse payments. Instead, the Supreme Court held that whether a &#8220;reverse payment&#8221; settlement involving the exchange of consideration for a delay in entry is subject to an anti-competitive analysis depends on five considerations: (a)&#160;the potential for genuine adverse effects on competition; (b)&#160;the justification of payment; (c)&#160;the patentee&#8217;s ability to bring about anti-competitive harm; (d)&#160;whether the size of the payment is a workable surrogate for the patent&#8217;s weakness; and (e)&#160;that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing the generic drug to enter the market before the patent expires on the branded drug without the patentee paying the generic manufacturer. Further, whether a reverse payment is justified depends upon its size, scale in relation to the patentee&#8217;s anticipated future litigation costs, and independence from other services for which it might represent payment (as was the case in </font><font style="font-style:italic;">Actavis</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), as well as the lack of any other convincing justification. The Supreme Court instead held that reverse payment settlements can potentially violate antitrust laws and are subject to the standard antitrust rule-of-reason analysis, with the burden of proving that an agreement is unlawful on the FTC. In reaching this decision, the Supreme Court left to the lower courts the structuring of this rule of reason analysis. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are faced with drug patent litigation, including Hatch-Waxman litigation with a generic company, we could be faced with an FTC challenge of this nature, which challenge could impact how or whether we settle the case and, even if we strongly disagree with the FTC&#8217;s position, we could face a significant expense or penalty. Any litigation settlements we enter into with generic companies under the Hatch-Waxman Act could also be challenged by third-party payors such as insurance companies, direct purchasers or others who consider themselves adversely affected by the settlement. These kinds of follow-on lawsuits, which may be class action suits, can be expensive and can continue over multiple years. If we were to face lawsuits of this nature, we may not be successful in defeating these claims and we may, therefore, be subject to large payment obligations, which we may not be able to satisfy in whole or in part. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States and, as a result, our product candidates, if approved, may not have patent protection for a sufficient period. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits one patent term extension of up to five years beyond the normal expiration of one patent per product, which if related to a method of treatment patent, is limited to the approved indication. The length of the patent term extension is typically calculated as one-half of the clinical trial period plus the entire period of time during the review of the new drug application, or NDA, by the FDA, minus any time of delay by us during these periods. There is also a limit on the patent term extension to a term that is no greater than fourteen years from drug approval. Therefore, if we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. We might also not be granted a patent term extension at all, because of, for example, our failure to apply within the applicable period, failure to apply prior to the expiration of relevant patents or other failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States and any equivalent regulatory authority in other countries, may not agree with our assessment of whether extensions of this nature are available and may refuse to grant extensions to our patents or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have an adverse effect on our ability to generate product revenue. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1997, as part of the Food&#160;&amp; Drug Administration Modernization Act, or FDAMA, Congress enacted a law that provides incentives to drug manufacturers who conduct studies of drugs in children. The law, which provides six-months exclusivity in return for conducting pediatric studies, is referred to as the &#8220;pediatric exclusivity provision.&#8221; If we were to conduct clinical trials that comply with the FDAMA, we could receive an additional six-month term added to our regulatory data exclusivity period and on the patent term extension period, if received, on our product. However, if we choose not to carry out pediatric studies that comply with the FDAMA, or carry out studies that are not accepted by the FDA for this purpose, we would not receive this additional six-month exclusivity extension to our data exclusivity or our patent term extension. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, supplementary protection certificates are available to extend a patent term up to five years to compensate for patent term lost during regulatory review, and this period can be extended to five and a half years if data from clinical trials is obtained in accordance with an agreed Pediatric Investigation Plan. Although all countries in Europe must provide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplementary protection certificates, there is no unified legislation among European countries and, as a result, drug developers must apply for supplementary protection certificates on a country-by-country basis. As a result, a company may need to expend significant resources to apply for and receive these certificates in all relevant countries and may receive them in some, but not all, countries, if at all. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Weakening patent laws and enforcement by courts in the United States and foreign countries may impact our ability to protect our markets. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Supreme Court has issued opinions in patent cases in the last few years that many consider may weaken patent protection in the United States, either by narrowing the scope of patent protection available in certain circumstances, holding that certain kinds of innovations are not patentable or generally otherwise making it easier to invalidate patents in court. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed. For example, we could become a party to foreign opposition proceedings, such as at the European Patent Office, or patent litigation and other proceedings in a foreign court. If so, uncertainties resulting from the initiation and continuation of such proceedings could have an adverse effect on our ability to compete in the marketplace. The cost of foreign adversarial proceedings can also be substantial, and in many foreign jurisdictions, the losing party must pay the attorney fees of the winning party. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that we, our employees, consultants or contractors have misappropriated the applicable third party&#8217;s intellectual property or claiming ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at universities as well as other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning any resulting intellectual property to us, we may be unsuccessful in executing an agreement to that effect with each party who in fact develops intellectual property that we regard as our own. Assignment agreements of this nature may not be self-executing or may be breached and we may be forced to bring claims against third parties or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, an employee or contractor could create an invention but not inform us of it, in which case we could lose the benefit of the invention and the employee or contractor may leave to develop the invention elsewhere. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Litigation or proceedings of this nature could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or proceedings of this nature more effectively than we can because </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices and the protection of our patents could be reduced or eliminated if we fail to comply with these requirements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with many procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have an adverse effect on our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information. In that case, we could not assert any trade secret rights against that third party. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome of a dispute of this nature is inherently unpredictable. Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights and our failure to obtain or maintain trade secret protection could adversely affect our competitive business position. In addition, some courts outside of the United States are less willing or unwilling to protect trade secrets. The Defend Trade Secrets Act of 2016 is a U.S. federal law that allows an owner of a trade secret to sue in federal court when its trade secret has been misappropriated. Congress passed this law in an attempt to strengthen the rights of trade secret owners whose valuable assets are taken without authorization. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate them, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We only have limited geographical protection with respect to certain of our patents and we may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. As a result, our intellectual property rights in some countries outside the United States can be less extensive than the protection we might have in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if these in-licensing opportunities are available to us at all. Further, in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding that may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example, relative to other countries, China has a heightened detailed description requirement for patentability. Further, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business and could additionally put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Further, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in these countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting or are otherwise precluded from effectively protecting the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Matters </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future (independently or with one of our collaboration partners), will ever obtain marketing approval.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates could fail to receive marketing approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">results of clinical trials may not meet the level of statistical significance required by the FDA for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain marketing approval in the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, that data may not be sufficient to support approval by the FDA. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a&#160;country-by-country&#160;basis regarding safety and efficacy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not guarantee regulatory approval in any other country. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience as a company in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our CMOs will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient&#160;follow-up,&#160;a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may also have programs similar to REMS. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">fines, warning letters or holds on clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">product seizure or detention or refusal to permit the import or export of our product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for&#160;off-label&#160;uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturers&#8217; communications on the subject of&#160;off-label&#160;use of their products. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Breakthrough Therapy designation for our CFT7455 and CFT8634 product candidates and some or all of our future product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to candidate products considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA of a product candidate. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for CFT7455 and CFT8634 and some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive Breakthrough Therapy designations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A Fast Track designation by the FDA, even if granted for CFT7455 and/or CFT8634, or any of our other current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Fast Track designation for one or more of our future product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for CFT7455 and/or CFT8634 and certain of our future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receipt of a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether or not</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to grant </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we decide to seek Orphan Drug Designation for any of our current or future product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Orphan Drug Designation for one or more of our current or future product candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant an Orphan Drug Designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. In the United States, receipt of an Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has an Orphan Drug Designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan drug exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan drug exclusivity if we are unable to manufacture sufficient supply of our product. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Orphan Drug Designations for CFT7455, CFT8634 and some or all of our other current or future product candidates in additional orphan indications in which there is a medically plausible basis for the use of these product candidates. Even when we obtain an Orphan Drug Designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek Orphan Drug Designation for other product candidates, we may never receive these designations. For example, the FDA has expressed concerns regarding the regulatory considerations for Orphan Drug Designation as applied to tissue agnostic therapies and the FDA may interpret the Federal Food, Drug and Cosmetic Act, and regulations promulgated thereunder, in a way that limits or blocks our ability to obtain an Orphan Drug Designation or orphan drug exclusivity, if our product candidates are approved, for our targeted indications. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accelerated approval by the FDA, even if granted for CFT7455 and/or CFT8634, or any other current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek accelerated approval of CFT7455 and CFT8634 and may seek approval of future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval for any of our product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we may not experience a faster development or regulatory review or approval process. Further, receiving accelerated approval does not provide assurance of ultimate full FDA approval. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, sell, market and distribute our product candidates, if we obtain marketing approval. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our business arrangements and practices with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government funded healthcare programs such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the physicians or other providers or entities with whom we expect to do business are found not to comply with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Litigation or proceedings of this nature could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates in the United States will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid or TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS will decide whether and to what extent our products will be covered and reimbursed under Medicare and private payors </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a covered benefit under its health plan; &#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">safe, effective and medically necessary; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">appropriate for the specific patient; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">cost-effective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">neither experimental nor investigational. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for our products and related treatments will be available from third-party payors. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. A decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician utilization of our products once approved. We cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates or for any procedures using our current or future product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, no uniform policy for coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. We cannot be sure that coverage and reimbursement will be available for or accurately estimate the potential revenue from our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause payor organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lastly, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, countries in the EU Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between EU Member States are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the Economic Committee for Health Products. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices in the European Union tend to be significantly lower than prices in the United States. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Affordable Care Act, or the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a licensure framework for follow-on biologic products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">creation of a new Patient-Centered Outcomes Research Institute to oversee and conduct comparative clinical effectiveness research, as well as funding for such research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishment of a Center for Medicare&#160;&amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There remain judicial, Congressional and executive branch challenges to certain aspects of the ACA and we expect there will be additional challenges and amendments to the ACA in the future. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January&#160;1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and increasing the&#160;point-of-sale&#160;discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Further, the 2020 federal spending package permanently eliminated, effective January&#160;1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. On December&#160;14, 2018, a U.S. District Court Judge in Texas ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the TCJA. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and has allotted one hour for oral arguments. Oral arguments on this case have not yet been held. It is also unclear how this litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional action is taken by Congress. However, pursuant to the CARES Act, these Medicare sequester reductions have been suspended from May&#160;1, 2020 through December&#160;31, 2020 due to the&#160;COVID-19&#160;pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the Bipartisan Budget Act of 2018, or BBA, among other things, amended the ACA, effective January&#160;1, 2019, by increasing the point-of-sale discount (from 50% under the ACA to 70%) that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare and review the relationship between pricing and manufacturer patient programs. The Trump administration&#8217;s budget proposal for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower&#160;out-of-pocket&#160;drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary&#160;out-of-pocket&#160;pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly&#160;out-of-pocket&#160;expenses and place limits on pharmaceutical price increases. On May&#160;11, 2018, President Trump laid out his administration&#8217;s &#8220;Blueprint&#8221; to lower drug prices and reduce&#160;out-of-pocket&#160;costs of prescription drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out-of-pocket</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. The Trump administration&#8217;s recent budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Although such measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, we may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the FDA issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. Further, legally mandated price controls on payment amounts by third-party payors or other restrictions could adversely affect our business prospects, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that the federal and state governments will pay for healthcare products and services. This could result in reduced demand for any product candidate we develop or could result in additional pricing pressures. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the United States can have a significant impact on the profitability of a given market, and further uncertainty is introduced if and when these laws change. For example, in Canada, price control legislation for patented medicines is currently undergoing significant change that may have significant effects on profitability for companies selling products in Canada. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. It is possible that additional governmental action will be taken to address the&#160;COVID-19&#160;pandemic. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or these third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may face potential liability under applicable privacy laws if we obtain identifiable patient health information from clinical trials sponsored by us. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1966, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under&#160;aiding-and-abetting&#160;or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, in the future, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations and/or directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement these types of programs. As a result, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. Further, the California Data Privacy Protection Act of 2018, or the CCPA, went into effect in January 2020. The CCPA provides new data privacy rights for consumers and new operational requirements for companies, including placing increased privacy and security obligations on entities handling certain personal data of consumers or households. These requirements could increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. The new California law may lead to similar laws in other U.S. states or at a national level, which could increase our potential liability and adversely affect our business, which exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU General Data Protection Regulation, or GDPR, also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and liability in relation to personal data that we process where that processing is subject to the GDPR. In addition, we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including GDPR requirements as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices. Despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European data protection laws also generally prohibit the transfer of personal data from Europe, including the European Economic Area, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data.&#160;One of the primary safeguards used for transfers of personal data from the European Union to the United States, namely, the Privacy Shield framework administered by the U.S. Department of Commerce, was recently invalidated by a decision of the European Union&#8217;s highest court.&#160;The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries.&#160;At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses. To the extent that we were to rely on the EU-U.S. Privacy Shield Framework or the Standard Contractual Clauses, we may not be able to do so in the future, which could increase our costs and limit our ability to process personal data from the European Union. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United Kingdom&#8217;s decision to leave the EU, often referred to as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brexit</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has created uncertainty </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with regard to</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> data protection regulation in the United Kingdom. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the EU</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We may, however, incur liabilities, expenses, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other operational losses under the GDPR and applicable EU Member States and the UK privacy laws in connection with any measures we take to comply with them. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators may obtain health information, as well as the providers who may share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state/provincial or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly&#160;clean-up&#160;and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party CMOs for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Upon an event of this nature, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Further, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of any changes of this nature and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act of 2001 and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractors</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, w</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We may also have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">universities</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractors</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other collaborators, even if we do not explicitly authorize or have actual knowledge of these activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other consequences. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters, Managing Growth and Operational Matters </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical personnel, sales and marketing and other personnel. We are highly dependent on our management, scientific and medical personnel, including our President and Chief Executive Officer, our Chief Scientific Officer, our Chief Medical Officer, our Chief Financial Officer and our Chief Legal Officer. Our Chief Financial Officer is presently a consultant. While we expect to engage in an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties relating to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. In addition, the loss of the services of any of our executive officers, other key employees and other scientific and medical advisors and an inability to find suitable replacements could result in delays in product development and harm our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct our operations at our facilities in Watertown, Massachusetts. The Massachusetts region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens. For example, the former President Trump&#8217;s Proclamation Suspending Entry of Aliens Who Present a Risk to the U.S. Labor Market Following the Coronavirus Outbreak, which was initially issued in June 2020 and is effective until March 31, 2021, may adversely affect our ability to hire and retain highly qualified personnel who are not U.S. citizens or permanent residents. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to our employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may, at any time, be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our executive employees, these employment agreements provide for at-will employment, which means that any of our executive employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers, as well as junior, mid-level and senior scientific, medical and general and administrative personnel. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have scientific and clinical advisors who assist us in formulating our development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to grow the size of our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, manufacturing, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. In addition, in connection with our transition to being a publicly traded company, we expect to increase the size of our general and administrative teams to support the growth of our business and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements of being a publicly traded company. To manage our anticipated future growth, we must continue to implement and improve our managerial, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operational</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Future growth would impose significant added responsibilities on members of management, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">identifying, recruiting, integrating, maintaining and motivating additional employees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">managing our internal development efforts effectively, including the clinical and FDA review process for CFT7455, CFT8634 and any other product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">improving our operational, financial and management controls, reporting systems and procedures. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to advance into clinical development and, if approved, commercialize CFT7455, CFT8634 and any of our other product candidates we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with this type of anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. Further, research at our Indian CROs also exposes us to various risks, including regulatory, economic and political instability, potentially unfavorable tax, import and export policies, fluctuations in foreign exchange and inflation rates, international and civil hostilities, terrorism, natural disasters and pandemics. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any of our collaborators, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any material system failure, accidents or security breaches of this nature to date, if an event of this nature were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications or the inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Additionally, we may have data security obligations with respect to the information of third parties that we store. Unauthorized access or use of any third-party data or information of this nature could result in fines or other penalties that may impact our relationships with these third parties and our operations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, CMOs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA or similar foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">healthcare fraud and abuse laws and regulations in the United States and abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">violations of United States federal securities laws relating to trading in our common stock; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">failures to report financial information or data accurately. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ethics and other corporate governance and compliance documents, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and charters applicable to all of our employees. However, it is not always possible to identify and deter misconduct by employees and other third parties. Further, the precautions we take to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege fraud or other misconduct, even if none occurred. If any actions of this nature are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business prospects, financial condition and results of operations. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we were to determine to raise additional capital in the future, you would suffer dilution of your investment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to raise additional capital in the future through the sale of shares or other securities convertible into shares, depending on market conditions, strategic considerations and operational requirements. To the extent we raise additional capital in this manner, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that sales of this nature may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be difficult for you to sell your shares of our common stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, there was no public trading market for shares of our common stock. Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our business or the targeted protein degradation space. We currently have limited research coverage by securities and industry analysts. If no or few securities or industry analysts cover us, the trading price for our common stock could be impacted negatively. If any of the analysts who cover us were to issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and future clinical trials and results of operations fail to meet the expectations of any of these analysts, our stock price would likely decline. If one or more of these covering analysts were to cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of shares of our common stock is likely to be volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and the market for smaller biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you acquired it. The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the degree of success of competitive products or technologies or changes in standard of care regimens; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">results of preclinical studies and clinical trials of our product candidates or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">regulatory or legal developments in the United States and other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the recruitment or departure of key personnel; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the level of expenses related to any of our product candidates or clinical development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the results of our efforts to discover, develop, acquire or in-license additional technologies or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">effects of public health crises, pandemics and epidemics, such as COVID-19; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">general economic, industry and market conditions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the foregoing matters were to occur or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Litigation of this nature, if instituted against us, could cause us to incur substantial costs to defend these claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects. Further, our director and officer liability insurance cost may increase as a result of litigation of this nature and our insurance deductible may be significant before our insurers are required to provide any coverage to us. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have broad discretion in the use of the capital we have raised and may not use them effectively. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management has broad discretion in the application of the net proceeds from our prior financings, including our initial public offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from our prior financing activities in a manner that does not produce income or that loses value. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders will have the ability to control or significantly influence matters submitted to stockholders for approval. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers and directors, combined with our stockholders who have reported through filings made with the Securities and Exchange Commission that they own more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 27% of our capital stock as of March 1, 2021. As a result, our executive officers and directors, combined with our greater than 5% stockholders, have the ability to control us through this ownership position. As a result, these stockholders, if acting together, will continue to control matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delay, defer or prevent a change in control; &#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">entrench our management and the board of directors; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a board of directors divided into three classes serving staggered three-year terms, the result of which is that not all members of the board will be elected at one time; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">a prohibition on stockholder action through written consent, the result of which is that all stockholder actions will have to be taken at a meeting of our </font><font style="color:#000000;">stockholders;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Upon the closing of our initial public offering on October 6, 2020, 31,855,560&#160;shares of our outstanding common stock became restricted as a result of securities laws or lock-up agreements. However, those shares will become eligible to be sold at various times in the future, including upon the expiration of these lock-up agreements on April 1, 2021. Further, securityholders holding an aggregate of 30,694,163 shares of our common stock outstanding or issuable upon the exercise of outstanding options have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which means that those shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements signed by holders of our securities prior to our initial public offering. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an EGC until the earlier of: (1)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1.07&#160;billion or more; (2)&#160;the last day of 2025; (3) the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years; and (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the last day of the first year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of June 30. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this report; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">reduced disclosure obligations regarding executive </font><font style="color:#000000;">compensation;</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of these available exemptions. We have taken advantage of reduced reporting requirements in this report. In particular, we have presented only two years of audited financial statements and correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also are a &#8220;smaller reporting company,&#8221; meaning that either (i)&#160;the market value of our stock held by non-affiliates is less than $250&#160;million as of the prior June&#160;30 or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million as of the prior June 30. If we are a smaller reporting company when we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an EGC, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance and insurance costs and will make some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of these costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of Sarbanes-Oxley, or Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we have started a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. In the preparation of our consolidated financial statements to meet the requirements for our initial public offering, we determined that a material weakness in our internal control over financial reporting existed as of December 31, 2019. The material weakness identified in our internal control over financial reporting arose because we did not maintain effective segregation of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duties in the process and recording of journal entries. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">communicated the material weakness to our audit committee and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of December 31, 2020, remediated </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the material weakness </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taking a number of actions including </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">engaging </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">system controls </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that prevent one person from initiating and approving the same journal entry</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and performing </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional reviews and other post-closing procedures</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we believe that this material weakness has now been remediated</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we cannot assure you that the measures </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we take to address internal control over financial reporting </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be sufficient to prevent future material weaknesses or </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will prevent any </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant deficiencies in our internal control over financial reporting from occurring. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we cannot assure you that the measures we have taken in the past or will take in the future will prevent the occurrence of future material weaknesses or significant deficiencies in our internal control over financial reporting. If we identify one or more material weaknesses in the future, it could result in an adverse reaction in the financial markets and restrict our future access to the capital markets due to a loss of confidence in the reliability of our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (3)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. We refer to this provision in our bylaws as the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended, the Securities Act, or the Exchange Act of 1934, as amended, or the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, as our headquarters are located in Watertown, Massachusetts. We refer to this provision in our bylaws as the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of our Credit Agreement with Perceptive Credit also preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. Similarly, the recent significant volatility associated with the COVID-19 pandemic has caused significant instability and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our business, including weakened demand for our product candidates, and could also impact our ability to raise additional capital when needed on acceptable terms, if at all. Our general business strategy may be adversely affected by any economic downturn of this nature, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costly</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and dilutive. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to secure any necessary financing in a timely manner and on favorable terms could have an adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could adversely affect our business prospects, financial condition and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item1B"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We occupy approximately 45,400 square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in 2028. We believe that our facilities are sufficient to meet our current needs for the foreseeable future and that suitable additional space will be available as and when needed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us because of defense and settlement costs, diversion of management resources, and other factors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market information</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;CCCC&#8221; since October 2, 2020. Prior to that time, there was no public market for our common stock.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <font style="color:#000000;">March 1, 2021</font>, there were approximately 181 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities authorized for issuance under equity compensation plans</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans is incorporated herein by reference to Item 12,&#160;<font style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font>, of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent sales of unregistered securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following list sets forth information regarding all unregistered securities sold by us since January 1, 2020. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issuances of capital stock</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June and July 2020, we issued and sold 142,857,142 shares of Series B preferred stock to investors at $1.05 per share. Jefferies LLC, one of our underwriters, acted as one of the placement agents. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we issued a warrant to purchase <font style="color:#000000;">2,857,142</font> shares of Series B preferred stock to our lender Perceptive Credit Holdings III, LP at an exercise price of $1.05 per share.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All sales of securities described above were made in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering. Each series of Preferred Stock automatically converted into shares of our common stock upon the closing of the IPO of our common stock in October 2020 on an 8.4335-to-1 basis.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Grants of stock options and restricted stock</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, prior to our IPO, we granted stock options to purchase an aggregate of 1,467,424 shares of our common stock, to employees, directors and consultants pursuant to the 2015 Plan. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuances of the securities described above were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of proceeds from registered securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, our Registration Statement on Form S-1 (No. 333-248719) was declared effective by the SEC pursuant to which we issued and sold an aggregate of 11,040,000 shares of common stock, including of 1,440,000 shares of sold pursuant to the underwriters&#8217; exercise of their over-allotment option, at a public offering price of $19.00 per share for aggregate net cash proceeds of $191.2 million, after deducting underwriting discounts, commissions and offering costs. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.<font style="color:#000000;"> The sale and issuance of 11,040,000 shares closed on October 6, 2020. Jefferies LLC, Evercore Group L.L.C., BMO Capital Markets Corp. and UBS Securities LLC acted as joint book-running managers for the offering. </font>Upon commencement, the offering did not terminate until the sale of all the shares offered.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our use of the net offering proceeds through the date of the filing of this Annual Report on Form 10-K, is consistent with the use of proceeds described in our prospectus filed with the SEC pursuant to Rule 424(b)(4) </font><font style="Background-color:#FFFFFF;">in October</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2020</font><font style="Background-color:#FFFFFF;">, and there has been no material change in our planned use of the balance of the net proceeds from the offering described in </font><font style="Background-color:#FFFFFF;">the </font><font style="Background-color:#FFFFFF;">prospectus.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of equity securities by the issuer or affiliated purchasers</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of our common stock during the year ended December 31, 2020.<font style="font-size:12pt;color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item7"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Item 1A, Risk factors, in this Annual Report on Form 10-K.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company focused on transforming the treatment of cancer and other diseases in collaboration with our partners by developing novel therapeutic candidates engineered to harness the body&#8217;s natural regulation of protein levels to target and destroy disease-causing proteins. We leverage our proprietary technology platform, TORPEDO (<font style="text-decoration:underline;">T</font>arget <font style="text-decoration:underline;">OR</font>iented <font style="text-decoration:underline;">P</font>rot<font style="text-decoration:underline;">E</font>in <font style="text-decoration:underline;">D</font>egrader <font style="text-decoration:underline;">O</font>ptimizer), to synthesize a new class of small molecule medicines that selectively and efficiently destroy disease-causing proteins. We are using our TORPEDO<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>platform to build a robust pipeline of orally administered protein degradation drug candidates, with an initial focus on oncology indications. Our approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced product candidate, CFT7455, is an orally bioavailable degrader of a protein target called IKZF1/3, for multiple myeloma, or MM, and non-Hodgkin lymphomas, or NHLs, including peripheral T-cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL. We submitted an investigational new drug application, or IND, for this product candidate to the U.S. Food and Drug Administration, or the FDA, in December 2020 and received clearance from the FDA in January 2021; we expect to begin a first-in-human Phase 1/2 clinical trial for this product candidate in the first half of 2021.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing CFT8634, an orally bioavailable degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-delete solid tumors, and we expect to submit an IND for this product candidate to the FDA in the second half of 2021 and begin a first-in-human Phase 1/2 clinical trial for this product candidate in 2022.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our lead product candidates, we are also developing degraders specifically targeting V600E mutant BRAF to treat melanoma, non-small cell lung cancer, colorectal cancer and other solid malignancies that harbor this mutation, as well as degraders targeting RET to treat lung cancer, sporadic medullary thyroid cancers and other solid malignancies that harbor oncogenic RET lesions. We expect to have product candidates from our two other lead programs, BRAF V600E and RET, in the clinic by the end of 2022. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in October 2015, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, establishing development collaborations with Roche, Biogen and Calico, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests and proceeds from our collaborations. Through December 31, 2020, we have raised approximately $224.0&#160;million in gross proceeds from the sale of our preferred stock, $209.8&#160;million in gross proceeds from our initial public offering, and have received an aggregate of $167.5&#160;million in payments from collaboration partners. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses were $66.3&#160;million and $34.1&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $183.8 million. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our total operating expenses were $93.6&#160;million and $56.8&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. We anticipate that our expenses will increase substantially in the future due to costs including those associated with the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our preclinical activities for our lead product candidates and the advancement of these candidates into first-in-human Phase 1/2 clinical trial in the United States, which we expect to initiate in the first half of 2021 for CFT755 and in 2022 for CFT8634; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">development activities associated with our other product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">research activities in oncology, neurological and other disease areas to expand our pipeline; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hiring additional personnel in research, clinical trials, quality and other functional areas; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">increased activities by our CMOs to supply us with product for our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the management of our intellectual property portfolio; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">operating as a public company. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our net losses and cash flows may fluctuate significantly from period to period depending on, among other things, variations in the level of our expenses and the execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under these types of arrangements.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these anticipated expenditures, we will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, debt offerings, reimbursements and potential milestones earned under our existing collaboration agreements and potential license and development agreements with third parties, including but not limited to our existing collaboration partners. Adequate funding may not be available to us on acceptable terms, or at all. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of the COVID-19 coronavirus outbreak on our financial performance will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. There are multiple causes of these delays, including laboratory closures, reluctance of patients to enroll or continue in trials for fear of exposure to COVID-19, local and regional shelter-in-place and work from home orders and regulations that discourage, hamper or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of COVID-19 patients and the FDA and other regulators making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to the pandemic. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of the impact on our operations, we have seen increased risk of delays in production of components used to manufacture our lead degrader candidates due to previous delays at one of our China-based manufacturers, periodic shipping delays and resourcing constraints and, therefore, somewhat higher costs to compete our discovery activities on one or more of our lead projects, and one of our contract research organizations, or CROs, in India was forced to temporarily shut down due to local lockdown orders. In addition, we temporarily closed the office and laboratory spaces at our corporate headquarters in Watertown, Massachusetts, and we transitioned our employees to work from home. We are working closely with our CROs, manufacturers, investigators and preclinical and clinical trial sites to assess the full impact of the COVID-19 pandemic on the timelines and expected costs for each of our programs. While the ongoing impact of the pandemic is uncertain, we believe our CRO redundancies in China, India and Boston and the transition of the majority of our employees to remote work arrangements have helped mitigate the impact of these types of disruptions on our business. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the breadth and duration of the global COVID-19 pandemic, it is possible that our directors or employees could, at any time, have been or become infected with this novel coronavirus, especially since<font style="font-size:12pt;"> </font>methods and availability of testing are continuing to evolve. To date, we have not experienced or had to impose any material shutdowns as a result of positive test results for this novel coronavirus.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We note the high level of difficulty in projecting the effects of COVID-19 on our programs and our company, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously discussed, to date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. We recognize revenue over our expected performance period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of our existing collaboration agreements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roche Collaboration and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, we entered into the&#160;Original Roche Agreement with Roche, whereby Roche provided us with a non-refundable upfront payment of $15.0&#160;million, which was creditable against our target initiation fees of either $1.0&#160;million or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.0&#160;million, depending on the compound selected. Pursuant to the terms of the Original Roche Agreement, we collaborated on research activities to develop novel treatments in the field of targeted protein degradation using our degrader technology. We initially developed therapeutics that utilize degrader technology for up to ten target proteins. On a target-by-target basis, after successful completion of a defined preclinical development phase, Roche had an exclusive option to pursue a license from us for further clinical development and commercialization. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2018, we amended and restated the Original Roche Agreement, or the Roche Agreement. Under the Roche Agreement, we have a more active role in the manufacturing and commercialization of the targets included in the collaboration, whereby if we opt into certain co-development and co-detailing rights, the parties will split future development costs in return for our having rights to a larger share of future earnings from commercialization of the relevant target. The target structure was revised to six potential targets, three of which had been nominated as of the execution of the Roche Agreement and represent continuations of the initial preclinical research and development efforts begun under the Original Roche Agreement, and three additional targets that were not nominated as of the date of execution of the Roche Agreement. At the time of entry into the Roche Agreement, Roche maintained its option rights to license and commercialize these six targets. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Roche Agreement, we received additional upfront consideration of $40.0&#160;million from Roche. Roche will make annual research plan payments of $1.0&#160;million for each active research plan. Finally, adjustments were made to the option exercise fees, whereby targets that have progressed through GLP toxicology studies at the time of exercise now have option exercise fees of $7.0&#160;million to $12.0&#160;million and those progressed through Phase 1 trials have option exercise fees of $20.0&#160;million. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For certain targets, Roche is required to pay us fees of $2.0&#160;million and $3.0&#160;million upon the identification of a lead series and the commencement of GLP toxicology studies, respectively. For each target option exercised by Roche, we are eligible to receive up to $275&#160;million in research, development and commercial milestone payments per target. Roche is also required to pay us up to $150&#160;million per target in one-time sales-based payments if the target achieves certain levels of net sales. Roche is also required to pay us royalties, at percentages from the mid-single digits to the low double-digits, on a licensed product-by licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we signed a further amendment to the Roche Agreement that provides a mechanism through which we and Roche can mutually agree to terminate the Roche Agreement on a target-by-target basis by the entry into a mutual target termination agreement. Upon a termination of this nature, the Roche Agreement, as amended, provides that all rights in know-how and intellectual property in support of products that use inhibition as their mode of action, referred to as the Roche Field, will revert to Roche and all rights in respect of know-how and intellectual property in support of products that use degradation as their mode of action, referred to as the C4T Field, will revert to us. Further, this amendment states that, following the entry into a mutual target termination agreement, Roche will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the Roche Field and we will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the C4T Field. In support of this allocation of rights, under the amendment, Roche provided us, and we provided Roche, with a perpetual, irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the patents that are allocated to a party under the mutual target termination agreement and a perpetual, irrevocable fully paid up, non-exclusive, sublicensable (including in multiple tiers) license to the know-how that is allocable to a party under the mutual termination agreement. Finally, through the entry into this amendment, we and Roche mutually agreed to terminate the Roche Agreement as to the target EGFR. As a result, Roche is now free to pursue the target EGFR in the Roche Field and we are free to pursue the target EGFR in the C4T Field and all rights in and responsibility for know-how and intellectual property related to EGFR in the Roche Field reverted to the Roche parties and all rights in and responsibility for know-how and intellectual property related to EGFR in the C4T Field reverted to us, with Roche assigning the relevant patents in the C4T Field to us.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Biogen Collaboration Research and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;28, 2018, we entered into the Biogen Agreement, with Biogen, whereby we agreed to collaborate on research and development efforts for up to five targets to discover and develop potential new treatments for neurological conditions, such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. The Biogen Agreement also has an option for Biogen to nominate additional targets and extend the Biogen Agreement. In February 2020, we entered into an amendment to the Biogen Agreement that provided further clarity around Biogen&#8217;s ownership of target binding moieties, which are portions of molecules, and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provides that Biogen licenses to us rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We granted Biogen a non-exclusive research license under our intellectual property to perform research activities, select and optimize degraders and develop products including the degraders, as well as a commercial license to manufacture and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize the targets once the initial research and development work is complete. The research under the Biogen Agreement will take place over a 54-month research term with Biogen having an option to extend the Biogen Agreement for up to four additional years. If Biogen elects to extend the term of the Biogen Agreement, Biogen would be required to make an additional payment of $62.5&#160;million and would be entitled to nominate up to five additional targets. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biogen Agreement provides for three initial targets, with Biogen having the right to initiate up to an additional two targets and to control all post-discovery activities. Biogen paid us a nonrefundable upfront payment of $45.0&#160;million for access to our technology and research services through the discovery research phase. The nonrefundable upfront cash payment of $45.0&#160;million is not creditable against any of the target development milestone fees. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the achievement of development candidate criteria, prior to any IND-enabling study, for any target, Biogen will bear all costs and expenses of and will have sole discretion and decision-making authority with respect to the performance of further activities with respect to any degrader under development under the Biogen Agreement and all products that incorporate that degrader. Biogen is also required to pay us up to $35.0&#160;million per target in development milestones and $26.0&#160;million per target in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay us royalties on a licensed product-by-licensed product basis, on worldwide net product sales, at percentages in the mid-single digits. All milestone and sales-based payments are made after we have met the defined criteria in the joint research plan for that target, at which time Biogen will have control of the targets for commercialization; the receipt of these payments is contingent on the further development of the targets to commercialization by Biogen, without any additional research and development efforts from us. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen also has the option to fund additional discovery activities, whereby we will perform discovery-type research at Biogen&#8217;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or two additional targets under the Biogen Agreement. Revenues earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price at the outset of the arrangement. These research activities will be reimbursed on a full-time equivalent, or FTE, basis at specified market rates. These additional discovery activities can be purchased up to a maximum amount by Biogen on an &#224; la carte basis at an amount consistent with standalone selling price. If Biogen were to exercise these options, we would recognize revenue as those options are exercised. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Calico License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we entered into the Calico Agreement, with Calico whereby we agreed to collaborate to develop and commercialize a set number of targets for small molecule protein degraders for diseases of aging, including cancer, for a five-year period ending in March 2022, or the research term. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provided Calico with a non-exclusive research license under our intellectual property to perform research activities and select and optimize degraders and develop products including the degraders. We also granted Calico a commercial license for any licensed products resulting from the development candidates supplied by us. We are required to perform research and development activities for the nominated targets over the research term, with the intent to provide a development candidate for each target to Calico once the agreed-upon research is complete. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico is obligated to reimburse our research and development activities for each target at specified levels through the identification of a development candidate, after which Calico shall assume full responsibility for candidate development. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the initiation of each target, the Calico Agreement does not contain any options for Calico to license the individual targets; once we complete the initial research and development activities required, Calico controls and directs the targets with no additional work required to be performed by us. There is no exercise price or incremental fee payable to us to progress the research further, though Calico is required to pay an initiation fee with the commencement of each research plan. Once Calico nominates a target and pays the applicable target initiation fee, we will commence research and development activities for that target. The Calico Agreement provides for up to five initial targets. Research activities performed are reimbursed at specified levels for the five-year term of the Calico&#160;Agreement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this agreement, Calico paid us a nonrefundable upfront amount of $5.0&#160;million and certain annual payments of $5.0&#160;million through December 31, 2020. Upon our completion of the required discovery research and development services on any target, Calico is entitled to pursue commercial development of that target. For each target, we are eligible to receive potential research, development and commercial milestone payments aggregating up to $132.0&#160;million. Calico is also required to pay one-time sales-based payments aggregating up to $65.0&#160;million for the first product to achieve certain levels of net sales. In addition, Calico is required to pay us royalties, on a licensed product-by-licensed product basis, on worldwide net product sales, at percentages in the mid-single digits. All milestone and sales-based payments are made after we have met the defined criteria in the joint research plan for that target, at which time Calico will have control of the targets for commercialization; the receipt of these payments by us is contingent on the further development of the targets to commercialization by Calico, without any additional research and development efforts required by us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with third parties, including contract research organizations and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical and potential future clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs of outside consultants, including their fees, unit-based compensation and related travel expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third-party licensing fees. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, legal, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future to support our growing operations, including additional personnel to support our operations as a publicly traded company. We also expect to incur increased expenses associated with being a public company, including higher costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance costs and investor and public relations costs.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other (Expense) Income</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense) primarily consists of change in fair value of warrant liability. Prior to the closing of the IPO, a warrant issued in connection with our long-term debt was classified as a liability with changes in fair value of the liability recorded within other (expense) income. Upon closing of the IPO, the warrant was determined to be an equity instrument. Refer to Note 9, <font style="font-style:italic;">Long-term Debt and Warrant Liability</font>, accompanying our consolidated financial statements for additional discussion.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to changes in the fair value of our warrant liability, other income (expense) also includes interest expense and amortization of the long-term debt, which is discussed in greater detail in Note 9, <font style="font-style:italic;">Long-term Debt and Warrant Liability</font>, accompanying our consolidated financial statements.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, other income (expense) also includes interest income earned on our cash, cash equivalents, and marketable securities and accretion of discount on marketable securities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of years ended December&#160;31, 2020, 2019, and 2018 </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from our collaboration and license agreements consisted of the following for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,112</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,913</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,540</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,195</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,364</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $11.8 million increase in revenue in the year ended December&#160;31, 2020 as compared to the year ended December&#160;31, 2019 is primarily driven by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$2.6 million increase in revenue recognized under the Roche Agreement due to increased effort made on three targets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$7.5 million increase in revenue recognized under the Biogen Agreement due to the consideration to be recognized as revenue increasing by the $4.0 million milestone earned in June 2020 and as a result of increased effort made on the initial three targets nominated and an increase in sandbox related revenue of $2.3 million; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$1.7 million increase in revenue recognized under the Calico Agreement primarily related to additional FTE reimbursement received in 2020 resulting from increased effort made on Calico targets.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $2.0&#160;million increase in the year ended December&#160;31, 2019 as compared to the year ended December&#160;31, 2018 primarily stems from:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$2.4 million of revenue recognized under the Biogen Agreement for collaboration efforts conducted under Biogen agreement, which was executed in December 2018, including sandbox revenue of $0.5 million;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">A $2.3 million increase in revenue recognized under the Calico Agreement due to additional collaboration efforts conducted in 2019;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">offset by a $2.7 million decrease in the revenue recognized under the Roche Agreement executed in December 2018. The Roche Agreement was considered a modification of the Original Roche Agreement and upon its execution we identified additional performance obligations that have yet to be satisfied, resulting in additional revenue being deferred pending the satisfaction of those performance obligations.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,504</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,135</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,085</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,496</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,816</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,573</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">866</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,059</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,592</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $30.4 million increase in research and development expense in the year ended December&#160;31, 2020 from the year ended December&#160;31, 2019 is primarily driven by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $19.8 million increase in preclinical and development costs, consisting of $11.9 million increase in external FTEs used in preclinical development of our various programs, and $9.1 million of costs related to the IND submission for our CFT7455 and CFT8634 programs;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a </font><font style="font-size:10pt;color:#000000;">$6.1 million </font><font style="font-size:10pt;color:#000000;">increase </font><font style="font-size:10pt;color:#000000;">in personnel expenses, </font><font style="font-size:10pt;color:#000000;">representing </font><font style="font-size:10pt;color:#000000;">salary and benefit </font><font style="font-size:10pt;color:#000000;">costs</font><font style="font-size:10pt;color:#000000;">, including</font><font style="font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a </font><font style="font-size:10pt;color:#000000;">$0.6 million increase in stock</font><font style="font-size:10pt;color:#000000;">-based</font><font style="font-size:10pt;color:#000000;"> compensation expense</font><font style="font-size:10pt;color:#000000;">,</font><font style="font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">primarily </font><font style="font-size:10pt;color:#000000;">due to </font><font style="font-size:10pt;color:#000000;">the buildout of our clinical development team</font><font style="font-size:10pt;color:#000000;">;</font><font style="font-size:10pt;color:#000000;"> and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $3.2 million increase in professional fees, which primarily consists of consulting costs for our development activities. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $19.5 million increase in research and development expense for the year ended December&#160;31, 2019 from the year ended December&#160;31, 2018 was primarily due to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $13.7 million increase in preclinical and development costs, driven primarily by an $8.3 million increase in external FTE resources used in preclinical development of our various programs, and a $5.7 million increase in external preclinical studies for our product candidates; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $4.4 million increase in personnel expenses, related to personnel costs attributable to an increase in headcount. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our general and administrative expenses for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,929</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,587</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,949</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,036</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">351</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">722</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $6.4 million increase in general and administrative expense in the year ended December&#160;31, 2020 as compared to the year ended December&#160;31, 2019 is primarily driven by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $2.3 million increase in personnel expenses, representing salary and benefit costs, including a $1.2 million increase in stock-based compensation expenses, resulting from additional G&amp;A personnel hired during the year; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $4.1 increase in professional fees, which primarily includes a $2.3 million increase in consultant fees, and higher legal and audit and insurance expenses, resulting from our transition to a public company.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $1.6 million increase in general and administrative expense in the year ended December&#160;31, 2019 from the year ended December&#160;31, 2018 was primarily due to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $1.6 million increase in personnel expenses resulting from $0.8 million increase in stock-based compensation expense due to increase in personnel expenses and a $0.8 million increase in other personnel-related expenses.&#160;</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other (Expenses) Income</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our other (expense) income for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability&#8212;related party</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,676</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense and amortization of long-term debt&#8212;related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,229</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,512</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $8.7 million change in other (expenses) income for the years ending December&#160;31, 2020 as compared to the year ending December&#160;31, 2019<font style="font-size:12pt;">&#160;</font>was driven by the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $5.7 million charge due to the increase in fair value of warrant liability associated with our long-term debt, which, prior to our IPO, was revalued at each reporting period</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $1.2 million change resulting from interest expense and amortization of the discount related to our long-term debt; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $1.8 million change in interest and other income resulting from lower interest rates earned on our investments.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $1.5 million increase in interest and other income (expenses) for the years ending December&#160;31, 2019 as compared to the year ending December&#160;31, 2018<font style="font-size:12pt;">&#160;</font>was primarily due to increased interest income resulting from a higher average cash balance. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our income tax benefit (expense) for the years ended December&#160;31, 2020, 2019, and 2018 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63360639"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk62678631"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December&#160;31, 2020, we recognized $0.6 million of income tax benefit related to an anticipated refund to be received for federal taxes under the corporate provisions of the CARES Act.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, we recognized income tax expense of $0.8 million resulting from taxable income primarily caused by the Roche Agreement and Biogen Agreement, both entered into in December 2018. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sources of Liquidity </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and, if successful, the clinical development of our programs. <font style="color:#000000;">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of preferred stock, our IPO, and through payments from collaboration partners. Through December&#160;31, 2020, we have raised approximately $224.0&#160;million in gross proceeds from the sale of preferred stock, $209.8 million in gross proceeds from our IPO, and have received an aggregate of $167.5&#160;million in payments from collaboration partners. As of December&#160;31, 2020, we had cash, cash equivalents and marketable securities of approximately $371.7 million.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020 and July 2020, we closed our Series B Financing with both existing and new investors. As part of the Series B Financing, we issued 142,857,142 shares of redeemable convertible Series B preferred stock, or Series B Preferred Stock, at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&#160;million, or net proceeds of $145.5 million when taking into account offering costs of $4.5 million. Upon completion of the IPO, every 8.4335&#160;shares of our preferred stock was automatically converted into one share of common stock.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in June 2020, we secured a $20.0&#160;million credit arrangement with Perceptive Credit Holdings III, LP, or Perceptive Credit, an affiliate of one of the Series B Financing investors, whereby we borrowed $12.5&#160;million at closing, bearing a variable interest rate of 11.25%, and have the opportunity to draw down another $7.5&#160;million subject to the satisfaction of certain milestones relating to the filing of an IND for certain of our pipeline targets, which was met with the filing of our IND for CFT7455 in December 2020. Our ability to draw down on this second tranche expires on June 30, 2021. In connection with the Credit Agreement, we issued Perceptive Credit a warrant to purchase 2,857,142 shares of Series B Preferred Stock exercisable for $1.05 per share. Upon completion of the IPO, this warrant converted to a warrant to purchase 338,784 shares of our common stock for $8.86 per share. The loans extended under the Credit Agreement will be repaid beginning in December 2022 in monthly installments of interest plus principal equal to 2.0% of the initial principal amount through June 2024. We paid a closing fee of $0.3&#160;million related to the loan and have the right to prepay the loan in its entirety prior to the maturity date by paying the applicable prepayment fee. Per the terms of the Credit Agreement, the prepayment fee is $5.0 million, less any interest paid as of the prepayment date, which totaled $4.2 million as of December&#160;31, 2020. If we do not prepay the loan, the entire unpaid principal balance becomes due on the maturity date, which is June&#160;5, 2024. We are also subject to customary financial covenants in the Credit Agreement that dictate accelerated repayment upon the occurrence of certain events of default, none of which are expected to occur based on our current liquidity. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we completed our IPO in which we issued and sold 11,040,000 shares of common stock, including 1,440,000 shares of our common stock sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, at a price to the public of $19.00. The proceeds from our IPO, including the full exercise of the underwriter&#8217;s overallotment option, were approximately $191.2 million after deducting underwriting discounts and commissions of $14.7 million and expenses of $3.9 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the period presented (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,614</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,921</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348,932</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,901</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2020 was driven primarily by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our net loss of $66.3&#160;million;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $12.2 million change in deferred revenue due to the recognition of revenue under our collaboration agreements in 2020; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $3.3 million change in prepaid expenses and other current assets. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These were offset by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $11.9 million of non-cash expense related to depreciation, stock compensation expense, reduction in right-of-use asset, and change in fair value of warrant liability; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a $2.6 million change in accrued expenses and other liabilities.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities for the year ended December&#160;31, 2019 was driven primarily by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an $81.8 million decrease in accounts receivable related to the collection of up-front payments from our collaboration partners received in 2019;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$8.0 million due to changes in operating assets and liabilities, including increases in accounts payable and accrued expenses, stemming from increased clinical and preclinical efforts to advance our product candidates in 2019; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$4.3 million of non-cash expenses related to stock-based compensation expenses, depreciation expense, and reduction in right-of-use asset.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These were offset by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our net loss of $34.1&#160;million and a $3.2 million; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a change in deferred revenue due to the recognition of revenue under our collaboration agreements in 2019. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2018 primarily consist of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our net loss of $15.7&#160;million; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a change of $84.9&#160;million in accounts receivable, offset by a change of $81.0&#160;million in deferred revenue both changes driven by $85.0&#160;million in up-front payments due to us under the Roche Agreement and the Biogen Agreement, both of which were recorded as accounts receivable and deferred revenue as of December&#160;31, 2018. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $190.5&#160;million of net cash used in investing activities for the year ended December&#160;31, 2020 was attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$189.9 million for the purchases of marketable securities, net of maturities; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$0.7&#160;million for the purchases of property and equipment. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $1.6 million of net cash used in investing activities for the year ended December&#160;31, 2019 was attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$1.3 million for the net purchases of property and equipment; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$0.3 million for the purchases of marketable securities, net of maturities. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $36.9 million of net cash provided by investing activities for the year ended December&#160;31, 2018 was attributable to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$39.6 million from maturities of marketable securities, net of purchases; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$2.7 million for the purchases of property and equipment. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $348.9 million of net cash provided by financing activities for the year ended December&#160;31, 2020 is primarily driven by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$191.5 million of proceeds from our IPO, net of underwriting discount and offering costs paid in 2020; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$145.5 million of proceeds from our Series B issuance, net of issuance costs; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$12.0 million of proceeds from issuance of long-term debt and warrant, net of issuance costs.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $0.2 million of net cash provided by financing activities for the year ended December&#160;31, 2019 was primarily attributable to net proceeds received from the issuance of common stock in conjunction with the exercise of stock options.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $2.0 million of net cash provided by financing activities for the year ended December&#160;31, 2018 was primarily attributable to net proceeds received from the issuance of Series A redeemable convertible preferred stock in December 2018.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. In addition, subsequent to our IPO, we expect to incur additional costs associated with operating as a public company. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, we anticipate that our expenses will increase substantially in the future, if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">initiate planned first-in-human Phase 1/2 trials of our lead product candidates, CFT7455 and CFT8634; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">advance additional product candidates into preclinical and clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue to invest in our proprietary TORPEDO platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expand, maintain and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">hire additional clinical, regulatory and scientific personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel to support our ongoing research, product development, potential future commercialization efforts, operations as a public company and general and administrative roles; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek marketing approvals for any product candidates that successfully complete clinical trials; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital and operating costs associated with our current and anticipated preclinical and clinical development. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the progress, costs and results of our planned first-in-human Phase 1/2 trials for&#160;our lead product candidates and any future clinical development of&#160;those lead product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number and development requirements of other product candidates that we pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the success of our collaborations with Roche, Biogen and Calico, including whether or not we receive additional research support or milestone payments from our collaboration partners upon the achievement of milestones; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs, timing and outcome of regulatory review of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our willingness and ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of current or additional future product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the anticipated expenditures described above, we will need to obtain substantial additional financing to support our continuing operations and pursue our long-term business plan. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt offerings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future milestone and royalty payments under our collaborations with Roche, Biogen and Calico, we do not have any committed external source of funds, as of December 31, 2020, other than an additional $7.5&#160;million under our Credit Agreement, which we may elect to draw down at any time prior to June 30, 2021. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity securities, each investor&#8217;s ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as making acquisitions or capital expenditures or declaring dividends. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contractual Obligations </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our significant contractual obligations as of December&#160;31, 2020 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 to 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4 to 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease commitments <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,277</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,839</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,540</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,277</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>Represents future minimum lease payments under our operating leases for office and lab space in Watertown, Massachusetts that expires in April 2028. </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with third-party CROs for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material and they are not included in the table above. We have not included milestone or royalty payments or other contractual payment obligations in the table above if the timing and amount of such obligations are unknown or uncertain.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in <font style="color:#000000;">Note 2,&#160;</font><font style="font-style:italic;color:#000000;">Summary of significant accounting policies</font><font style="color:#000000;">,</font> <font style="color:#000000;">to our consolidated financial statements in this Annual Report on Form 10-K, </font>we believe that <font style="color:#000000;">the following accounting policies are those most critical to the judgments and estimates</font> used in the preparation of our consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues from Contracts</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63852959"></a>We account for our revenue in accordance with Accounting Standards Codification, or ASC, 606,<font style="font-style:italic;">&#160;Revenue from Contracts with Customers</font>, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <a name="_Hlk63852959"></a>606, the entity performs the following five steps at inception of the agreement or upon material modification of the agreement: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identify the Contract</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining whether a contract is within the scope of ASC 606, we consider the following criteria:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The parties to the contract have approved the contract, whether written, orally, or in accordance with other customary business practices, and are committed to perform their respective obligations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The entity can identify each party&#8217;s rights regarding the goods or services to be transferred.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The entity can identify the payment terms for the goods or services to be transferred.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The contract has commercial substance (that is, the risk, timing, or amount of the entity&#8217;s future cash flows is expected to change because of the contract).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>It is probable that the entity will collect substantially all the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining whether the criteria above have been met, management confirms that the agreement has been signed by both parties or approved in another acceptable manner, reviews that the agreement identifies rights and obligations of each party, both written and implied, determines whether the contract has economic consequences for all parties, and whether we will be able to collect substantially all the consideration that is due or will become due under the contract. The determination of collectability requires the most judgement and, in establishing collectability, management considers payment terms, ability to stop transferring goods or service to customer in the event of nonpayment, experience with the customer, class of customer, and expectations about the customer&#8217;s financial stability, as well as other factors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identify the Performance Obligations</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a contract is determined to be within the scope of ASC 606, we identify all promised goods and services in the contract, which includes those that are explicitly stated within the contract and those that are implied. Once all promised goods and services within the contract are identified, we evaluate whether each promised good or service is immaterial in the context of the contract. In assessing materiality, management considers quantitative factors by comparing standalone selling price of the promised good or service to the total consideration in the contract and qualitative factors, such as the importance of the promised good or service to the customer.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assess whether each material promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. We also consider the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights requires judgments related to the determination of the value of the underlying license relative to the option exercise price, including assumptions about technical feasibility and the probability of developing a candidate that would be subject to the option rights. The exercise of a material right is accounted for as a contract modification for accounting purposes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Determine the Transaction Price</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the transaction price, we consider fixed considerations, variable considerations, non-cash considerations, significant financing components, and any consideration payable to the customer. If the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assess our revenue generating arrangements in order to determine whether a significant financing component exists.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Allocate the Transaction Price to the Performance Obligations</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the transaction price is then determined, it is allocated to the identified performance obligations in proportion to their standalone selling prices, or SSP, on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, we consider applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. We validate the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Determine When to Recognize Revenue</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time recognition is based on the use of an output or input method.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements with research and development services to be performed by us, revenue allocated to our performance obligation is generally recognized based on an appropriate measure of progress. We utilize judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure, such as costs incurred. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the arrangement.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prepaid and Accrued Research and Development Expenses</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of preparing the consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of the accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. In addition, there may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense, in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expended in each period. If the actual timing of the performance of services or the level of effort varies from </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> estimate, we adjust the accrual or the amount of prepaid expenses accordingly. </font><font style="Background-color:#FFFFFF;color:#000000;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for all stock-based compensation awards granted to employees and&#160;non-employees as stock-based compensation expense at fair value. Our stock-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis. Stock-based compensation expense is classified in the consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. We recognize stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option pricing model includes various assumptions, including the expected term of the award, the expected volatility and the expected risk-free interest rate over the expected term of the award, expected dividend payments, and estimated forfeitures.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Expected term: </font>We use the &#8220;simplified method&#8221; as prescribed by Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107,&#160;<font style="font-style:italic;">Share Based Payments</font>, to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches. We utilize this method due to lack of historical data and the plain-vanilla nature of our share-based awards.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Volatility: </font>We use a weighted-average of expected volatility for a period equal to the expected term of the option grant, based on the volatilities of a representative group of publicly traded biopharmaceutical companies. For options granted subsequent to our IPO, the volatility is based on volatilities of a representative group of publicly traded biopharmaceutical companies and our own volatility.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Risk-free rate: </font>The risk-free rate is based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Dividends: </font>We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Forfeitures: </font>We account for forfeitures as they occur and, therefore, do not estimate forfeitures.</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above, inputs, the fair value of the underlying common stock represents the exercise price utilized in the Black-Scholes option pricing model. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, stock-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, stock-based compensation cost could be materially impacted in future periods. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Determination of the fair value of our common stock issued prior to our IPO</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there has been no public market for our common stock prior to our IPO, the estimated fair value of our common stock was determined by our board of directors as of the date of each stock award, with input from management, considering our most recently available third-party valuations of our common stock. Valuations were updated when facts and circumstances indicated that the most recent valuation was no longer valid, such as changes in the stage of our development efforts, various exit strategies and their timing, and other scientific developments that could be related to the valuation of our company or, at a minimum, annually. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,<font style="font-style:italic;"> Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </font>Our common stock valuations in 2019 were prepared using a market approach, specifically the guideline public company method, which &#8220;back-solves&#8221; to a common stock price. We allocated equity value to our common stock and shares of our redeemable convertible preferred stock, using either an option-pricing method, or OPM, or a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method. The hybrid method estimates the probability-weighted value across multiple scenarios. In addition to the OPM, the hybrid method considers liquidity scenarios in which the shares of our redeemable convertible preferred stock are assumed to convert into </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common stock. The future value of the common stock in the applicable scenario </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounted back to the valuation date at an appropriate risk-adjusted discount rate. In the hybrid method, the present value indicated for each scenario </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">probability-weighted to arrive at an indication of value for the common stock. </font><font style="color:#000000;">In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant </font><font style="color:#000000;">date including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;font-size:10pt;">prices at which we sold shares of our preferred stock and the superior rights and preferences of the preferred stock relative to our common stock at the time of each grant;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the progress of our preclinical and clinical development, including the status and results of preclinical studies for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our stage of development and our business strategy and the material risks related to our business and industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">external market conditions affecting the biopharmaceutical industry and the material risks related to our business and industry; and trends within the biopharmaceutical industry;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">our financial position, including cash on hand, and our historical and forecasted performance and operating results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the lack of an active public market for our common stock and our preferred stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">the likelihood of achieving a liquidity event, such as an IPO or sale of our company in light of prevailing market conditions; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management judgement. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Determination of the fair value of our common stock issued subsequent to our IPO</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following our IPO, the fair value of our common stock was determined based on the quoted market price of our common stock.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For information on new accounting standards, see <font style="color:#000000;">Note 2,&#160;</font><font style="font-style:italic;color:#000000;">Summary of significant accounting policies</font><font style="color:#000000;">,</font> <font style="color:#000000;">to our consolidated financial statements in this Annual Report on Form 10-K</font>. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance&#160;Sheet Arrangements </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered into any&#160;off-balance&#160;sheet arrangements and do not have any holdings in variable interest entities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Internal Control over Financial Reporting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the preparation of our consolidated financial statements to meet the requirements of our IPO, we determined that a material weakness in our internal control over financial reporting existed as of December&#160;31, 2019. The material weakness identified in our internal control over financial reporting arose because we did not maintain effective segregation of duties in the process and recording of journal entries. As of December 31, 2020, we remediated the material weakness by engaging system controls that prevent one person from initiating and approving the same journal entry. In addition, we implemented and performed additional reviews and other post-closing procedures. While we believe that this material weakness has now been remediated, we cannot assure you that these measures will be sufficient to prevent future material weaknesses or significant deficiencies in our internal control over financial reporting from occurring. See &#8220;Risk Factors&#8212;<font style="font-style:italic;">We will incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices</font>.&#8221;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an &#8220;emerging growth company,&#8221; the <font style="color:#000000;">Jumpstart Our Business Startups Act of 2012, or the </font>JOBS Act, allows us to delay adoption of new or revised accounting standards applicable to public companies until such standards are made applicable to private companies. We have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of this extended transition period. Accordingly, the information contained herein may be different from the information you receive from other public companies that are not emerging growth companies. in which you hold stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">being permitted to only provide two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reduced disclosure about the compensation paid to our executive officers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">not being required to submit to our stockholders&#8217; advisory votes on executive compensation or golden parachute arrangements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may take advantage of these exemptions for up to the last day of 2025 or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (1)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more; (2)&#160;the last day of 2025; (3)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years; or (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission. We may choose to take advantage of some but not all of these exemptions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item7A"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, and marketable securities. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of December&#160;31, 2020, we had marketable securities of $190.0 million which consisted entirely of U.S Treasury securities. The contractual maturity dates of our marketable securities are less than one year. These interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item&#160;15,<font style="font-style:italic;">&#160;Exhibits and Financial Statement Schedules</font>, of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements with <a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures&#160;as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the preparation of our consolidated financial statements to meet the requirements of our IPO, we determined that a material weakness in our internal control over financial reporting existed as of December&#160;31, 2019. The material weakness identified </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our internal control over financial reporting arose because we did not maintain effective segregation of duties in the process and recording of journal entries. We</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> communicated the material weakness to our audit committee and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> took measures to remediate the material weakness during 2020, including engaging system controls that prevent one person from initiating and approving the same journal entry. In addition, we have implemented and performed additional reviews and other post-closing procedures.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on that evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or an attestation report of our independent registered accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as noted above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W<font style="color:#000000;">e cannot assure you that the steps and measures we have implemented to remediate our material weakness will be sufficient to prevent future material weaknesses or significant deficiencies in our internal control over financial reporting from occurring. </font>The design of any system of control is based upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated objectives under all future events. <font style="color:#000000;">See &#8220;Risk Factors&#8212;</font><font style="font-style:italic;color:#000000;">We will incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices</font><font style="color:#000000;">.&#8221;</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;10 will be included in our definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information required by this Item&#160;14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1. Financial Statements</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a list of the financial statements included herein, see&#160;<font style="font-style:italic;">Index to the Consolidated Financial Statements</font>&#160;on page F-1 of this Annual Report on Form&#160;10-K,&#160;incorporated into this Item by reference.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2. Financial Statement Schedules</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">3. Exhibits</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:0.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="top"  style="width:8.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p></td>
<td valign="top"  style="width:6.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex33.htm"><font style="text-decoration:underline;">Fifth Amended and Restated Certificate of Incorporation of the Registrant, current in effect </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8211;39567</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/06/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:6.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex35.htm"><font style="text-decoration:underline;">Form of Second Amended and Restated Bylaws of the Registrant</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex41.htm"><font style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement among the Registrant, its warrant holder and certain of its stockholders, dated June&#160;5, 2020 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex42.htm"><font style="text-decoration:underline;">Warrant Certificate issued by the Registrant to Perceptive Credit Holdings III, LP dated June&#160;5, 2020 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1662579/000119312520255106/d772024dex43.htm"><font style="text-decoration:underline;">Form of Specimen Common Stock Certificate </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/28/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.4</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex44_220.htm"><font style="text-decoration:underline;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex101.htm"><font style="text-decoration:underline;">2015 Stock Option and Grant Plan, as amended and forms of award agreements thereunder </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1662579/000119312520255106/d772024dex102.htm"><font style="text-decoration:underline;">2020 Stock Option and Incentive Plan and forms of award agreements thereunder </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/28/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1662579/000119312520255106/d772024dex103.htm"><font style="text-decoration:underline;">2020 Employee Stock Purchase Plan </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/28/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex104.htm"><font style="text-decoration:underline;">Senior Executive Cash Incentive Bonus Plan </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex105.htm"><font style="text-decoration:underline;">Form of Director Indemnification Agreement </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex106.htm"><font style="text-decoration:underline;">Form of Officer Indemnification Agreement </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex107.htm"><font style="text-decoration:underline;">Form of Executive Employment Agreement </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex108.htm"><font style="text-decoration:underline;">Employment Agreement between the Registrant and Andrew Hirsch, dated September 6, 2020 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9#</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex109.htm"><font style="text-decoration:underline;">Consulting Agreement between the Registrant and MBJC Associates, LLC, effective March 31, 2020 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1010.htm"><font style="text-decoration:underline;">Collaboration Research and License Agreement between the Registrant and Biogen MA, Inc., dated December&#160;28, 2018 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:0.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="top"  style="width:8.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p></td>
<td valign="top"  style="width:6.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex1011_218.htm"><font style="text-decoration:underline;">Amendment No. 1 to Collaborative Research and License Agreement between the Registrant and Biogen MA, Inc., dated February 25, 2020</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1011.htm"><font style="text-decoration:underline;">Amended and Restated License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated December&#160;20, 2018 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex1013_217.htm"><font style="text-decoration:underline;">First Amendment to the Amended and Restated License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated November 12, 2020</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1012.htm"><font style="text-decoration:underline;">Collaboration and License Agreement between the Registrant and Calico Life Sciences LLC, dated March&#160;13, 2017 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15&#8224;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1013.htm"><font style="text-decoration:underline;">Credit Agreement and Guaranty among the Registrant, Perceptive Credit Holdings III, LP and the guarantors and lenders party thereto, dated July&#160;5, 2020 </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1014.htm"><font style="text-decoration:underline;">Lease by 480 Arsenal Group LLC to the Registrant, dated July&#160;5, 2017, as amended </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8211;248719</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/10/2020</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex211_216.htm"><font style="text-decoration:underline;">Subsidiaries of the Registrant </font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex231_219.htm"><font style="text-decoration:underline;">Consent of KPMG LLP, Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex322_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:0.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="top"  style="width:8.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p></td>
<td valign="top"  style="width:6.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:6.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  style="width:0.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top"  style="width:8.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:78.57%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or any compensatory plan, contract or arrangement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the Securities and Exchange Commission. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act, or the Exchange Act, except as otherwise stated in such filing.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew J. Hirsch</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer, and Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew J. Hirsch</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)<font style="font-size:8pt;"> </font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;William T. McKee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">William McKee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer) </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Laura J. Wahlberg</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance and Corporate Controller </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Laura Wahlberg</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Principal Accounting Officer) </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Chairman and Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Kenneth C. Anderson, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kenneth C. Anderson, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Alain J. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alain J. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bruce Downey</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce Downey</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Elena Prokupets, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Elena Prokupets, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Malcolm Salter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director </p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Malcolm Salter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><font style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors<br />C4 Therapeutics, Inc.:</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of C4 Therapeutics, Inc. and its subsidiary (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2020,<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>and the related notes collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2016.</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts<br />March 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Balance_Sheet"></a>C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66103801"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,549</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,836</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381,009</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,767</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,683</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,385</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:47.9pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,852</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,641</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,617</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, net of current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt&#8212;related party</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (See Note 6 and Note 9)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock (See Note 10)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, par value of $0.0001 per share; 10,000,000 and no shares authorized, and no shares issued or outstanding as of December&#160;31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value of $0.0001 per share; 150,000,000 and 21,343,452 shares authorized, and 43,059,632 and 1,426,641 shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464,597</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,823</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,488</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,791</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,963</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Operations"></a><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from collaboration agreements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,059</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,774</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,452</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability&#8212;related party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense and amortization of long-term debt&#8212;related party</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,512</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,961</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,295</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of net loss to net loss attributable to common stockholders:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual of preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,468</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.03</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common stock outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,370,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371,905</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Stockholders_Equity"></a>C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a><a name="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"></a>Consolidated Statements of Stockholders&#8217; Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Redeemable Convertible Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,145,900</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,956</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,639</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,389</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,750</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,797</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,112</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,145,900</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,426,641</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,525</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,488</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,963</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $4.5 million</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,857,142</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,525</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(256,003,042</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(256,520</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,355,379</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,517</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,520</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,001</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,001</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon closing of initial public offering, net of issuance costs of $18.6 million</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,040,000</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,172</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,173</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281,584</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,972</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested stock option settlement</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on investments</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.4%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,059,632</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464,597</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(183,823</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,791</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Cash_Flows"></a>C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to cash (used in) provided by operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on disposal of fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of (premium) discount on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction in carrying amount of right-of-use assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,224</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,257</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(814</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(881</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,235</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows used in investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds received from maturities of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(293,855</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(650</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,349</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows provided by financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series B shares, net of issuance costs of $4.5 million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from long-term debt and warrant, net of issuance costs of $0.5 million</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering, net of underwriting discount of $14.7 million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,074</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of initial public offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercises of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested stock option settlement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348,932</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,888</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,304</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,126</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents and restricted cash:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,304</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,577</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,577</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of the year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,549</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Cash Flows &#8212; Continued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering costs in accounts payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital expenditures in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option repurchases included in accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying notes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>
<p style="text-align:center;margin-bottom:1pt;margin-top:1pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notes"></a>C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 1. Nature of the business and basis of presentation</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc., or, together with its subsidiary, the Company, is a biopharmaceutical company focused on harnessing the body&#8217;s natural regulation of protein levels to develop novel therapeutic candidates to target and eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company was incorporated in Delaware on October 7, 2015 and has its principal office in Watertown, Massachusetts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company&#8217;s primary activities have been focused around research and development activities, building the Company&#8217;s intellectual property, recruiting personnel and raising capital to support these activities. To date, the Company has funded its operations primarily with proceeds received from the sales of redeemable convertible preferred stock, sales of common stock through an initial public offering, through its collaboration agreements, and debt financing.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred recurring losses since its inception, including net losses of $66.3&#160;million and $34.1&#160;million for the years ended December 31, 2020 and 2019, respectively. In addition, as of December 31, 2020, the Company had an accumulated deficit of $183.8&#160;million. To date, the Company has not generated any revenue from product sales as none of its product candidates has been approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 6, 2020, the Company completed its initial public offering, or the IPO, at which time the Company issued 11,040,000 shares of its common stock at a price to the public of $19.00 per share, which number includes 1,440,000 shares of common stock that were issued to the underwriters for the IPO when they exercised in full their overallotment option. Upon the closing of the IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into 30,355,379 shares of common stock. Net proceeds from the IPO, including the exercise in full of the underwriters&#8217; option to purchase additional shares, were $191.2 million, after deducting underwriting discounts and commissions of $14.7 million and expenses of $3.9 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its cash, cash equivalents and marketable securities of $371.7&#160;million as of December 31, 2020<font style="color:#000000;"> will be sufficient to fund its operations for at least the next twelve months from the date of issuance of these consolidated financial statements. </font>Accordingly, the<font style="Background-color:#FFFFFF;color:#000000;"> </font>consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2020, the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock and stock options, and a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock. Additionally, upon closing of the IPO a warrant issued to purchase up to 2,857,142 shares of the Company&#8217;s Series B redeemable convertible preferred stock converted into a warrant exercisable for 338,784 shares of the Company&#8217;s common stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented, except as otherwise stated.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks and Uncertainties </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the early development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with the Food and Drug Administration, or the FDA, and other government regulations. If the Company does not successfully advance its programs into and through human clinical trials and/or enter into collaborations for its programs and commercialize any of its product candidates, the Company may be unable to produce product revenue or achieve profitability. There can be no assurance that the Company&#8217;s research and development efforts will be successful, adequate protection for the Company&#8217;s intellectual property will be obtained, any products developed will obtain necessary government regulatory approval, or any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutic</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al and biotechnology companies.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Pandemic </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of the coronavirus, or COVID-19, pandemic on the Company&#8217;s business, results of operations and financial condition is uncertain and will depend on future developments, including the duration and spread of the outbreak, the impact of vaccines and new strains of COVID-19, and any governmental advisories and restrictions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 2. Summary of significant accounting policies</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America, or U.S.&#160;GAAP. <font style="color:#000000;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in consolidation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company&#8217;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. The Company&#8217;s cash equivalents are measured at fair value on a recurring basis.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity (deficit) until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&#8217;s lease agreements for its Watertown, Massachusetts facility (see Note 6, <font style="font-style:italic;">Leases</font>). </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, t<font style="color:#000000;">he Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC&#160;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash are Level&#160;1 assets which are&#160;comprised of funds held in checking and money market accounts.&#160;Marketable securities are Level 2 assets which are comprised of US treasury funds with maturity dates of less than one year. The carrying amounts of accounts receivable, which relate to the Company&#8217;s collaboration agreements, accounts payable, and accrued expenses approximate their fair values due to their short-term nature. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulting gain or loss is included in the determination of net loss. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation on equipment is calculated </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the straight-line method over the estimated useful lives of the assets as follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment, furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. As provided by ASC 842, the Company elected to combine lease and non-lease components as a single component for all leases. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over&#160;the expected lease term. <font style="color:#000000;">Certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company&#160;typically only includes&#160;an initial lease term in&#160;its&#160;assessment of a lease arrangement; options to renew a lease are not included in the assessment unless there is reasonable certainty that&#160;the Company&#160;will renew. </font>The interest rate implicit in lease contracts is typically not readily determinable. As such, in calculating the lease liability, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease expense is recognized over the expected lease term on a straight-line basis. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commitments and Contingencies </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&#160;reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue in accordance with ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC&#160;606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees; (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (ii)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Upfront License Fees </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if&#160;necessary, adjusts the measure of performance and related revenue recognition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further discussion of accounting for collaboration revenues, see Note&#160;8, <font style="font-style:italic;">Collaboration and License Agreements.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology are expensed as&#160;incurred and are included in research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes stock-based compensation expense based on the grant date fair value of the awards, which consist of option grants. The fair value of each share option grant was determined using the expected term, expected volatility, risk-free interest rate, dividend rate, and the fair value of the common stock underlying the share-based award. Prior to the IPO, the fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&#8217;s board of directors. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font>. Each of these inputs is subjective and generally requires judgment and estimation by management. Subsequent to the IPO, the fair value of the common stock underlying shared based awards is the quoted market price of the Company&#8217;s common stock on the date of the grant. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrant Liability Expense</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s completion of a financing involving the sale of shares of Series B redeemable convertible preferred stock, or the Series B Financing, in June and July 2020 and the entry into the Term Loan (see Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>), the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability, determined using Black-Scholes, as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63865862"></a>Upon completion of the IPO, the warrant converted into a warrant to purchase shares of the Company&#8217;s common stock, as described in Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>.<a name="_Hlk63865862"></a> Upon conversion into a warrant exercisable for shares of the Company&#8217;s stock, management concluded that the warrant meets the definition of an equity instrument and the fair value of the warrant at the time of conversion, determined using Black-Scholes, was recorded as an increase in additional paid-in capital.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible Series B Preferred Stock or common stock issuable upon exercise of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrant, remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequence of events that have been recognized in the consolidated financial statements or the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive income is unrealized gains and losses on marketable securities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss per share attributable to common stockholders is calculated using the&#160;two-class&#160;method, which is an earnings allocation formula that determines net loss per share for the holders of shares of the Company&#8217;s common stock and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the&#160;two-class&#160;method or (b)&#160;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balance. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016 the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This standard limits</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This standard became effective for the Company on January 1, 2020 and, based on the composition of the Company&#8217;s receivables and available-for-sale debt securities, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on its consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12, <font style="font-style:italic;">Income Taxes</font> (Topic 740): <font style="font-style:italic;">Simplifying the Accounting for Income Taxes, or </font>ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of ASU 2019-12 is not expected to have a material effect on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <font style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</font>, which provides temporary optional guidance for a limited time to ease the potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as the London Interbank Offered Rate (LIBOR). Optional expedients in Topic 848 are generally available until December 31, 2022. The adoption of ASU 2020-04 is not expected have a material effect on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 3. Fair value measurements</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,040</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its money market funds, which are valued based on quoted market prices in active markets, with no valuation adjustment, as Level 1 assets within the fair value hierarchy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of U.S. Treasury securities and are classified as available-for-sale pursuant to ASC 320, <font style="font-style:italic;">Investments &#8211; Debt and Equity Securities</font>. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies on a recurring basis.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further discussed in Note 9, <font style="font-style:italic;">Long-term debt and warrant liability,</font> during the year ended December 31, 2020, the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock to Perceptive Credit Holdings III, LP, an affiliate of Perceptive Advisors LLC, or Perceptive. Perceptive is a considered a related party to the Company based on its ownership of the Company&#8217;s common stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date. The warrant is considered within Level 3 of the fair value hierarchy because the fair value uses management&#8217;s own assumptions </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">about the assumptions that market participants would use in pricing the liability. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the Company&#8217;s IPO on October 6, 2020, the warrant was automatically converted into a warrant exercisable for </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338,784</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and was reclassified as equity</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the warrant was determined on October 6, 2020 using the following assumptions</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in Level 3 instruments, redeemable convertible preferred stock warrant, for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,676</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the warrant has not been exercised.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no transfers between fair value levels during the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Marketable securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities at December&#160;31, 2020 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,949</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, none of the Company&#8217;s marketable securities were in an unrealized loss position. During the year ended December&#160;31, 2020, the Company did not recognize any other-than-temporary impairment losses. The contractual maturity dates of the Company&#8217;s marketable securities are less than one year.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any marketable securities at December&#160;31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Property and equipment</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment as of December&#160;31, 2020 and 2019 consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,207</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,766</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,955</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,323</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,617</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Leases</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the Company entered into a lease of office and laboratory space for its headquarters in Watertown, Massachusetts, or the Watertown Lease. The Watertown Lease has a non-cancelable term of ten years with an option to extend for one additional five-year period and is subject to rent escalation throughout the term. Additionally, the Watertown Lease required the Company to provide collateral in the amount of $2.6 million, which is recorded as restricted cash on the accompanying consolidated balance sheets. The Watertown Lease commenced in April 2018, with rent commencing in May 2018. The Watertown Lease was classified as an operating lease and, upon the commencement in April 2018, the Company recorded a lease liability of $15.1&#160;million and a right-of-use asset of $16.7 million, which is inclusive of $1.5 million of construction costs funded by the Company. In calculating the lease liability and the right-of-use asset, the Company did not include the additional five-year period option as management does not believe there is reasonable certainty the Company will exercise the option. In addition to rent, the Company is also responsible for paying its pro rata share of costs incurred for common area maintenance, real estate taxes and property insurance related to the leased space, which are accounted for as variable lease costs.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The elements of lease costs for the years ended December&#160;31, 2020 and 2019 were as follows (in thousands):<font style="font-size:9.5pt;font-family:Arial;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future lease payments under non-cancelable leases as of December&#160;31, 2020 for each of the years ending December 31 are as follows (in thousands):&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,339</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,471</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability at December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,868</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Accrued expenses and other current liabilities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2020 and 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,799</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,615</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,724</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Collaboration and license agreement</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2020 (in thousands): &#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,913</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,958</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,195</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,220</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,164</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,934</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,075</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,540</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial information related to the collaboration and license agreements for the years ended December&#160;31, 2020 and 2019 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in the contract liability at the beginning of the period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,570</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized from performance obligations fully or partially satisfied in previous periods</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,923</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Roche Collaboration and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Original Roche Agreement Structure </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Company entered into a license agreement, or the Original Roche Agreement, with Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche. Pursuant to the terms of the Original Roche Agreement, the Company and Roche agreed to collaborate on research activities to develop novel treatments in the field of targeted protein degradation using the Company&#8217;s degrader technology. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for a $15.0&#160;million nonrefundable upfront payment and additional fees for dedicated personnel, the Company performed initial research and development services for drug discovery and preclinical development, provided a non-exclusive research and development license to its technology and participated on the joint research committee, or the Roche JRC. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restated Roche Agreement Structure </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2018, the Company and Roche executed the Amended and Restated Roche License Agreement, or the Roche Agreement. Under the Roche Agreement, the Company has a more active role in the manufacturing and commercialization of the targets, whereby if certain co-development and co-detailing rights are opted into by the Company, the parties will split future development costs in return for the rights to a larger share of future earnings from commercialization of the target. The target structure was revised to six potential targets, three of which were nominated as of the execution of the Roche Agreement and represent continuations of the initial preclinical research and development efforts begun under the Original Roche Agreement and three additional targets that were not nominated as of the execution of the Roche Agreement. Roche maintained its option rights to license and commercialize these six targets. For certain targets, Roche is required to pay the Company fees of $2.0&#160;million and $3.0&#160;million upon the progression of targets to the lead series identification achievement and GLP toxicology, or Tox, study phase, respectively. For each target option exercised by Roche, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company is eligible to receive up to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275.0&#160;million</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in research and development milestones per target and commercial milestone payments, with the commercial milestones being dependent on underlying net sales. Roche is also required to pay the Company up to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150.0&#160;million</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per target in one-time sales-based payments if the target achieves certain levels of net sales. In addition, Roche is required to pay the Company royalties, at percentages from the mid-single digits to the low double-digits, on a licensed product-by licensed product basis, on worldwide net product sales. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Roche Agreement: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the Company received additional upfront consideration of $40.0&#160;million from Roche; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the Company has an option for co-development and co-detailing rights, whereby it would be required to provide additional financial support in return for the rights to a larger share of future earnings from commercializing one or more of the six targets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Roche will no longer provide FTE reimbursement; rather, it will make annual research plan payments of $1.0&#160;million for each active research plan; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Adjustments were made to the option exercise fees, whereby certain targets now have option exercise fees of $7.0&#160;million to $12.0&#160;million (those progressed up to Phase 1 or through the GLP Tox studies, respectively) and others have $20.0&#160;million (those progressed through clinical trials). </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is managed by a joint research committee. The Company has control over the committee and may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&#160;days&#8217; prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company signed an amendment to the Roche Agreement that provides a mechanism through which the Company and Roche can mutually agree to terminate the Roche Agreement on a target-by-target basis by entry into a mutual target termination agreement. Upon a termination of this nature, the Roche Agreement, as amended, provides that all rights in know-how and intellectual property in support of products that use inhibition as their mode of action, referred to as the Roche Field, will revert to Roche and all rights in respect of know-how and intellectual property in support of products that use degradation as their mode of action, referred to as the C4T Field, will revert to the Company. Further, this amendment states that, following the entry into a mutual target termination agreement, Roche will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the Roche Field and the Company will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the C4T Field. In support of this allocation of rights, under the amendment, Roche provided the Company, and the Company provided Roche, with a perpetual, irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the know-how and intellectual property rights that are allocated to a party under the mutual target termination agreement. Finally, through the entry into this amendment, the Company and Roche mutually agreed to terminate the Roche Agreement as to the target EGFR.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roche Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Roche Agreement is a modification of the Original Roche Agreement under ASC 606 as both the scope and price of the contract were changed under the Roche Agreement and new, distinct performance obligations were created for targets that have different standalone selling prices based on the Company&#8217;s revised obligations. The Roche Agreement was not determined to be a separate contract for accounting purposes. The modification was accounted for as if it were a termination of the existing contract and the creation of a new contract, for which the unrecognized consideration from the Original Roche Agreement is added to the new transaction price promised as part of the Roche Agreement and will be recognized as revenue prospectively, as the new performance obligations are satisfied. The Company made this determination after considering the performance obligations under the Roche Agreement. When the amendment was signed, the contract was restructured such that the Company would pursue some of the same targets, but would have additional material responsibility to potentially develop the targets beyond the option exercise point, to either Phase 1 completion or to a point where the Company will exercise its co-development and co-detailing options and more fully share in the costs and future revenues. The $40.0&#160;million upfront payment, $13.5 million of expected research plan funding payments, plus $6.4&#160;million of remaining deferred revenue from the Original Roche Agreement represent the transaction price as of the outset of the arrangement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Roche, is a customer. The Company identified the following promises at the outset of the Roche Agreement: (1)&#160;a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities; (2)&#160;research and development services under the research plan for the three initial targets; (3)&#160;participation on the Roche JRC; (4)&#160;option rights to initiate a research plan for three additional targets; (5) an option to obtain a non-exclusive commercial license to intellectual property and know-how generated from the collaboration, subject to certain exclusivity requirements; (6) option </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights to develop, commercialize and manufacture products related to any of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> targets; and (7)&#160;rights for Roche to substitute targets prior to completion of a research plan, limited to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> exchanges in total across the arrangement and subject to approval by the Roche JRC. The Roche JRC has equal representation from both parties, but the Company holds final decision-making authority in the event of a disagreement until the time at which Roche licenses a target and leads development efforts. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The six potential targets were determined to be distinct from one another, as Roche can derive benefit from each target independent of the others. For each target, the Company determined that the research and development license and research and development services were not distinct from one another, because the research and development services are essential to the license. Roche would receive little to no economic benefit from the license if it did not obtain the research services. Participation on the Roche JRC to oversee the research and development activities and the technology transfer associated with the Original Roche Agreement were determined to be quantitatively and qualitatively immaterial. The Company evaluated Roche&#8217;s option rights to initiate a research plan for three additional targets as well as the option rights to license and commercialize each target to determine whether they provide Roche with any material rights. The Company concluded that each of the options were issued with an option exercise fee that represented a significant and incremental discount and therefore provide material rights for six of the six targets&#8212;three material rights from the option to license the three initial targets at the end of their research terms and three material rights from the option to initiate a research plan for the three additional targets along with the option to license such at the end of their research terms. The consideration allocated to the option rights to initiate the three additional targets is deferred until the underlying option is exercised, at which point the Company will begin recognizing revenue for these targets. The non-exclusive, limited commercial license to the intellectual property and know-how generated from the collaboration was determined to be immaterial and, as such, no consideration was allocated to it. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified twelve performance obligations, including three research services performance obligations, six material rights for the options to purchase a commercial license for six targets, and three material rights for the option to initiate research services for the uninitiated three targets as of the outset of the arrangement. The first three performance obligations primarily comprise: (1)&#160;the non-exclusive research and development license and (2)&#160;the research and development services for the target, including the related substitution rights. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company included the $40.0&#160;million upfront payment, $13.5 million of expected research plan funding payments ($1.0&#160;million per active target per year, for a maximum of $3.0 million per target), and $6.4&#160;million of remaining deferred revenue from the Original Roche Agreement in the transaction price as of the outset of the arrangement. The Company also achieved a milestone for the identification of lead series for target 2 in April 2019, resulting in a milestone payment of $2.0 million, which was added to the transaction price and recognized cumulatively. The transaction price of $61.9 million was allocated to the performance obligations based on the estimated stand-alone selling prices at the time of the amendment. For each performance obligation, the stand-alone selling price was determined considering the expected cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the amendment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocated the following amounts of the total transaction price to the performance obligations as of the amendment date, including the $2.0 million milestone achieved in April 2019: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$29.0&#160;million to the research and development performance obligations for targets&#160;1-3; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$4.1&#160;million to the three material rights, related to the three targets initiated at the outset of the Roche Agreement, which will not begin revenue recognition until the option is exercised or expires; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">$28.8&#160;million to the option to nominate targets 4-6 and the three material rights related to these options. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biogen Collaboration Research and License Agreement </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2018, the Company entered into a collaboration research and license agreement, or the Biogen License Agreement, with Biogen MA, Inc., or Biogen. Pursuant to the terms of the Biogen License Agreement, the Company and Biogen agreed to collaborate on research activities to develop novel treatments in the field of TPD using the Company&#8217;s degrader technology. In February 2020, the Company entered into an amendment to the Biogen Agreement that provided further clarity around Biogen&#8217;s ownership of target binding moieties, which are portions of molecules, and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provides that Biogen licenses to the Company the rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement. Under the terms of the Biogen License Agreement, the Company will initially develop TPD therapeutics that utilize degrader technology for up to five target proteins over a period of 54 months. On a target-by-target basis, after successful completion of a defined target evaluation period, Biogen assumes full rights and responsibility to each degrader to meet certain criteria against a target. Biogen also has the option to pay an additional $62.5&#160;million to extend the contract and select up to five additional targets for development. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the non-exclusive research license from Biogen as well as a $45.0&#160;million nonrefundable upfront payment, the Company will grant a license to develop, commercialize and manufacture products related to each of the targets, which is contingent on not cancelling the contract, will perform initial research services for drug discovery, provide a non-exclusive research and commercial license to its intellectual property and will participate on the joint steering committee, or the Biogen JSC. The Company will also be obligated to participate in early research activities for other potential targets, referred to as sandbox activities at Biogen&#8217;s election up to a maximum amount; any work performed for these services will be reimbursed by Biogen, and Biogen will reimburse the Company for certain FTE costs. Biogen is also required to pay the Company up to $35.0&#160;million per target in development milestones and $26.0&#160;million per target in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay the Company royalties on a licensed product-by-licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is managed by the Biogen JSC, which Biogen has control over, and Biogen may terminate the Biogen License Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&#160;days&#8217; prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nonrefundable upfront cash payment of $45.0&#160;million is not creditable against any of the target development milestone fees. The research will be performed by the Company over 54 months according to the research plan approved by the Biogen JSC. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Biogen License Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Biogen, is a customer. The Company identified the following promises under the arrangement: (1)&#160;a non-exclusive, royalty-free license to use the Company&#8217;s intellectual property to conduct research activities; (2)&#160;an upfront license to develop, commercialize and manufacture products related to each of the targets (which is contingent on not cancelling the contract); (3)&#160;research services for preclinical activities under the research plan; (4)&#160;participation on the Biogen JSC; and (5)&#160;substitution rights for Biogen via sandbox activities to replace targets prior to a program reaching completion of a research plan, limited to five exchanges in total. Substitution is dependent on the original target failing to meet certain criteria; Biogen may only replace a target in this specific scenario. The Company also determined that Biogen&#8217;s ability to terminate the Agreement at-will with 90 days&#8217; notice is not representative of a substantive purchase option to continue to the research and does not provide a material right in the form of a continuous renewal option. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the licenses and research activities were not distinct from one another, as the licenses have limited value without the performance of the research activities by the Company. Participation on the Biogen JSC to oversee the research activities and the technology transfer associated with the Biogen License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified one performance obligation at the outset of the Biogen License Agreement, representing a combined performance obligation consisting of (1)&#160;the licenses, (2)&#160;the research activities for the target evaluation phase for all five targets and (3)&#160;the joint research plan phase for each target. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize the transaction price as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen also has the option to fund sandbox activities in exchange for consideration, whereby the Company will perform discovery-type research at Biogen&#8217;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> additional targets under the Biogen Agreement. Revenues earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price. Sandbox research activities will be reimbursed on an FTE basis at market rates, which is adjusted for changes in the &#8220;Consumer Price Index&#8221; each year. The sandbox activities constitute additional research that can be purchased on an a la carte basis at an amount consistent with standalone selling price. The Company recognizes revenue as the services performed for the sandbox activities are performed and recognized $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of revenue for the years ended </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, related to the sandbox activities. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes FTE reimbursement related to sandbox activities as revenue as the hours are incurred each quarter. Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company achieved $4.0 million in milestones under the Biogen Agreement in June 2020, which amount was recorded as accounts receivable and deferred revenue at that time. The Company received payment of these milestones from Biogen in August 2020. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Calico Collaboration and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, the Company entered into a collaboration and license agreement, or the Calico License Agreement, with Calico Life Sciences LLC, or Calico, whereby the Company and Calico agreed to collaborate to develop and commercialize small molecule protein degraders for diseases of aging, including cancer for a five-year period ending in March 2022, the research term. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Calico License Agreement, the Company will initially develop and commercialize small molecule protein degraders for up to five target proteins over the research term. On a target-by-target basis, after successful completion of a defined target evaluation period, Calico has an exclusive option to pursue further pre-clinical development and commercialization via a joint research plan for each target. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Calico License Agreement, Calico paid an upfront amount of $5.0&#160;million and certain annual payments totaling $5.0&#160;million through December 31, 2020 and pays target initiation fees and reimburses the Company for a number of FTEs, depending on the stage of the research, at specified market rates. Upon completion of the required discovery research and development services on any target, Calico is entitled to pursue commercial development of that target. The Company will perform initial research services for drug discovery and preclinical development, provide a non-exclusive research and commercial license to its IP and will participate on the Calico joint research committee, or the CJRC. For each target, the Company is eligible to receive up to $132.0&#160;million in potential research, development and commercial milestone payments, on sales of all products resulting from the collaboration efforts. Calico is also required to pay the Company up to $65.0&#160;million in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Calico is required to pay the Company royalties, at percentages in the mid-single digits, on a licensed product-by-licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Calico License Agreement is managed by CJRC. Calico has control over the CJRC and may terminate the Calico License Agreement on a target-by-target or product-by-product basis under several scenarios, upon prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nonrefundable upfront and certain annual payments are not creditable against any other payments. Calico will reimburse the Company for a contractually defined number of FTEs per target depending on the phase of development, unless otherwise agreed upon by the CJRC. The research will be performed by the Company over the research term in accordance with the research plan. For the year ended December&#160;31, 2019 the Company received $2.0&#160;million in cash consideration for milestone revenue and no additional consideration in the form of cash received for target initiation fees. The Company recorded an accounts receivable of $1.0&#160;million for additional target initiation fees in 2019 and received payment in 2020.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Calico License Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Calico, is a customer. The Company identified the following promises under the arrangement: (1)&#160;the non-exclusive, royalty-free research license and commercial license, which function for purposes of the arrangement as a license and are therefore analyzed together; (2)&#160;the target evaluation research services for all five targets; (3)&#160;the joint research plan research services related to targets 1 and 2, which were nominated at the execution of the Calico License Agreement; (4)&#160;the target initiation rights or options associated with targets 3, 4 and 5, subject to nomination; and (5)&#160;the joint research plan services associated with targets 3, 4 and 5, subject to nomination and payment of the target initiation fees from (4). The Company determined that the license and research activities were not distinct from one another, as the license has limited value without the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance of the research activities by the Company. Participation on the CJRC to oversee the R&amp;D activities and the technology transfer associated with the Calico License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. The Company determined that the option rights to nominate the targets were not distinct from one another or from the other promises in the arrangement, specifically the research license and research services. The Company evaluated the target initiation rights for targets 3, 4 and 5 and the research services associated with the joint research plan nomination for these targets to determine whether they provide Calico with any material rights. The Company concluded that these options were not issued at a significant and incremental discount and therefore do not provide material rights. </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified one performance obligation at the outset of the Calico License Agreement, which consists of: (1)&#160;the non-exclusive license and (2)&#160;the research activities for the target evaluation phase for all five targets and the joint research plan phase for targets 1 and 2. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Calico License Agreement, the transaction price determined by the Company is the upfront amount plus the committed anniversary payments and the target initiation fees related to the targets nominated at the execution of the Calico License Agreement. Based on the ability of Calico to cancel the arrangement for any reason, Calico effectively has an option for continued access to the Company&#8217;s research license and procurement of research services that they can cancel at any time. Under the Calico License Agreement, the Company amortized the upfront fee received on a straight-line basis over the period services are available to the counterparty (i.e., the contractual term of five years). Straight-line amortization of the upfront payment was considered the best measure of progress because the customer has access to research and development services throughout the period. Incremental fees for research and development services are paid at agreed upon FTE rates and recognized in the period incurred.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Long-term debt and warrant liability</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 5, 2020, contemporaneously with the completion of the Series B Financing (see Note 10, <font style="font-style:italic;">Stockholders&#8217; equity</font>), the Company entered into a Credit Agreement, or the Credit Agreement, with Perceptive, which is a related party as previously noted, that provides for an aggregate principal borrowing amount of up to $20.0&#160;million, available in two tranches of $12.5&#160;million and $7.5&#160;million, or the Term Loan. In June 2020, the Company drew down on the first tranche of $12.5&#160;million. The borrowing bears interest at a variable rate using the greater of LIBOR or 1.75%, plus 9.50%. If LIBOR cannot be determined, an alternate rate of interest will be established giving consideration to then-prevailing market convention for determining a rate of interest. The Credit Agreement is secured by a lien on substantially all of the Company&#8217;s assets, including, but not limited to, shares of the Company&#8217;s subsidiaries, its current and future intellectual property, insurance, trade and intercompany receivables, inventory and equipment and contract rights. The Credit Agreement requires the Company to maintain a minimum aggregate cash balance of $3.0 million in one or more controlled accounts and contains various affirmative and negative covenants that limit its ability to engage in specified types of transactions.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to make interest-only payments until December&#160;5, 2022, after which point the Company will be required to make payments of principal equal to 2% of the Term Loan until maturity on June 5, 2024, or the Maturity Date. If the Company pays off the Term Loan prior to the Maturity Date, it will be required to pay a prepayment fee. Per the terms of the Credit Agreement, the prepayment fee is $5.0 million less any interest paid through the prepayment period. As of December&#160;31, 2020, the prepayment fee would be $4.2 million. The Company paid issuance costs of $0.5&#160;million in connection with its entry into the Credit Agreement.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Credit Agreement, the Company issued a warrant to purchase up to 2,857,142 shares of the Company&#8217;s Series B preferred stock to Perceptive at an exercise price per share of $1.05. The fair value of the warrant at the time of issuance was determined to be $2.3 million. The warrant is exercisable at any time prior to the ten-year anniversary of the closing date of the Credit Agreement. At issuance, the Company determined that the warrant is liability-classified and would be remeasured to fair value each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the Company&#8217;s IPO on October 6, 2020, the warrant was effected for one-for-8.4335 reverse stock split and automatically converted into a warrant to purchase up to 338,784 shares of the Company&#8217;s common stock at an exercise price per share of $8.86. Based on information available at that time, the fair value of the warrant was determined to be $8.0 million on October 6, 2020. Upon the conversion into a warrant exercisable for shares of the Company&#8217;s common stock, management concluded that the warrant meets the definition of an equity instrument and the warrant was recorded, at its fair value on October 6, 2020, as an increase to additional paid-in capital. For the year ended December 31, 2020, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company recognized $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in change in the fair value of the warrant liability as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the outstanding long-term debt was $12.5&#160;million. The outstanding amount is reduced by the unamortized portions of 1) issuance costs, and 2) the issuance date fair value of the warrant to arrive at the carrying value of long-term debt as of December&#160;31, 2020, which was determined to be $10.1 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had met the criteria to draw down on the second tranche of $7.5 million. It has the ability, but not the obligation, to draw down the second tranche until June 30, 2021.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt for the years ending December 31 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum long-term debt payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Unamortized debt issuance costs, and debt discount related to warrant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,448</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value of long-term debt&#8212;related party at December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Stockholders&#8217; equity</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certificate of Incorporation</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the terms of the Company&#8217;s equity securities were defined in the Company&#8217;s Fourth Amended and Restated Certificate of Incorporation, which was filed with the Secretary of the State of Delaware on June 3, 2020, or the Fourth Charter. Under the Fourth Charter, the Company was authorized to issue Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock, each of which had a par value of $0.0005 per share and which are referred to collectively as Preferred Stock. On October 6, 2020, in connection with the consummation of the IPO, the Company filed its Fifth Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware. The summary below relates to the Company&#8217;s Fourth Charter.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 1, <font style="font-style:italic;">Nature of the business and basis of presentation</font>, on September 25, 2020 the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock, stock options and common stock warrant and a proportional adjustment to the existing conversion ratios for the Company&#8217;s convertible preferred stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Fourth Charter, the Company&#8217;s common stock had a par value of $0.0001 and the holders of common stock were entitled to one vote for each share held at all meetings of stockholders and written actions in lieu of meetings provided. The Fourth Charter also provided that all dividends shall be declared and paid pro rata according to the number of shares held by each holder of common stock. In the event of a liquidation, dissolution or winding up of the Company, the common stock ranks behind the Preferred Stock in terms of distribution of assets. The holders of the common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June and July 2020, the Company closed a $150.0&#160;million Series B Financing with existing and new investors. As part of the Series B Financing, the Company issued 142,857,142 shares of its Series B preferred stock at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&#160;million. Of the amounts above, 138,571,428 shares were issued for gross proceeds of $145.5&#160;million, less related offering costs of $4.5&#160;million in June 2020, and 4,285,714 shares were issued for proceeds of $4.5&#160;million in July 2020.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the Company&#8217;s IPO on October 6, 2020, all outstanding shares of the Company&#8217;s Preferred Stock were converted into 30,355,379 shares of common stock using the exchange rate set forth in the Fourth Charter, as amended, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which provided that every </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4335</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Preferred Stock converted into one share of common stock. As a result, as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">referred </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock are presently outstanding</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, Preferred Stock consisted of the following (in thousands, except share data): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,145,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FF Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,760,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,760,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,145,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,416,155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Stock-based compensation</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2015 Incentive Stock Option and Grant Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;28, 2015, the Company&#8217;s board of directors adopted the 2015 Incentive Stock Option and Grant Plan, or the&#160;2015 Plan, and reserved 2,525,327 shares of common stock for issuance under this plan. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options and restricted stock awards to eligible employees, outside directors and consultants of the Company. Options generally vest over a period of five or eight&#160;years with a cliff vesting at one&#160;year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again. The contractual life of all options is ten&#160;years from the date of grant. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Stock Option and Incentive Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 8, 2020, the Company&#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan, or the 2020 Plan, which became effective on September 30, 2020. Upon adoption there were 6,567,144 shares of common stock reserved for issuance under the 2020 Plan. The Company&#8217;s Board of Directors, the Compensation Committee of the Board of Directors, and the Chief Executive Officer of the Company are authorized to grant a broad range of equity-based awards under the 2020 Plan, including stock options, stock appreciation rights, or SARs, restricted stock awards, or RSAs, restricted stock units, or RSUs, performance awards and stock bonus awards to the Company&#8217;s officers, employees, directors and other key persons, including consultants. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63867441"></a>Following the effectiveness of the 2020 Plan, the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2020 Plan.<a name="_Hlk63867441"></a> <font style="color:#000000;">As of December&#160;31, 2020, the Company had 8,880,367 shares reserved under the 2020 Plan and 2015 Plan, and 3,851,003 shares available for future issuance under the 2020 Plan.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing until the expiration of the 2020 Plan, equal to the lesser of (i) 5% of the outstanding shares of common stock on the immediately preceding December 31st, or (ii) lesser number of shares determined by the administrator of the 2020 Plan, which is the Company&#8217;s Board of Directors or the Compensation Committee of the Board of Directors. On January 1, 2021, the annual increase for the 2020 Plan resulted in an additional 2,152,981 shares authorized for issuance being added to the 2020 Plan.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the year ended December&#160;31, 2020 and 2019 was classified in the consolidated statement of operations and comprehensive loss as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">972</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans for the year ended December&#160;31, 2020<font style="color:#000000;">: &#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,801</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,222,179</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,222,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to the option activity of the Company is as follows for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised (in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the unrecognized compensation cost related to outstanding options was $37.5&#160;million, which is expected to be recognized over a weighted-average period of 3.7 years. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.23 - 6.35</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.35</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32% - 0.57%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71% - 2.36%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.54% - 83.76%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.50% - 76.80%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 8, 2020, the Company&#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective on September 30, 2020 for use by the Company following its IPO. Upon adoption there were 437,809 shares of common stock reserved for issuance under the 2020 ESPP. The 2020 ESPP provides for an annual increase to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing thereafter through January 1, 2030, equal to the lesser of (i) 1% of the outstanding shares of common stock on the immediately preceding December 31st, (ii) 656,714 shares, or (ii) lesser number of shares determined by the administrator of the 2020 ESPP. On January 1, 2021, the annual increase for the 2020 ESPP resulted in an additional 430,596 shares authorized for issuance being added to the 2020 ESPP.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To participate in the 2020 ESPP, eligible employees may authorize payroll deductions of up to 15% of their eligible compensation during an offering period. The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the 2020 ESPP. As of December&#160;31, 2020, the Company had not held any offering periods and no shares had been issued under the 2020 ESPP.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">President and Chief Executive Officer Termination </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;3, 2020, or the Separation Date, the employment of the Company&#8217;s then current president and chief executive officer, or the Former CEO, terminated. The Company repurchased all of the Former CEO&#8217;s outstanding shares of common stock, which had been issued upon his exercise of previously granted stock options, for total consideration of $0.1&#160;million. The Former CEO also relinquished his right to purchase shares of common stock upon the exercise of stock options that were vested as of his Separation Date, in exchange for total consideration paid by the Company of $0.7&#160;million. The Company recognized the repurchase price of these shares of common stock and the relinquishment of these vested options in additional-paid-in-capital.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Income Taxes</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense consists of the following for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current tax provision:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current federal provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">669</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current state provision</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred federal provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred state provision</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total tax provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a) Tax Rate Reconciliation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) expense computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows for the years ended December&#160;31, 2020 and 2019: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at federal statutory tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax&#8212;net of federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate change</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax attributes true up due to net operating loss carryback</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b) Significant Components of Deferred Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of (a)&#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and (b)&#160;operating losses and tax credit carryforwards. Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows as of December&#160;31, 2020 and 2019 (in thousands): <font style="font-size:9pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start-up costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,859</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and investment tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,578</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,157</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,580</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,801</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,967</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(744</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain/loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,866</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of the deferred tax assets. As of December&#160;31, 2020 and 2019, based on the Company&#8217;s historical operating losses, the Company has concluded that it is more-likely-than-not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">full valuation allowance for the deferred tax assets as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The valuation allowance for deferred tax assets as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.9</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.1&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, respectively. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net valuation allowance increase of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million during the year ended December 31, 2020 was primarily due to the increase in net operating loss and tax credits carryforward and a decrease in deferred revenue recognized during the year.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had $58.8 million and no gross United States federal net operating loss, or NOL, carryforwards, respectively, which may be available to offset future income tax liabilities. The Tax Cuts and Jobs Act, or TCJA, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended, or IRC). In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#8217;s NOL carryover or 100% of a corporation&#8217;s taxable income and be available for twenty years from the period the loss was generated. For U.S. federal income tax purposes, the Company has federal NOLs generated after 2017 of <font style="font-weight:bold;">$</font>58.8 million, which do not expire. The Company does not have any available NOLs generated prior to 2018 as they were fully utilized in 2019. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA. The Company is anticipated to carryback a portion of FY2020 NOL to the tax year ended December 31, 2019 which will result in a refund of approximately $0.6 million. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has total gross United States state net operating loss carryforwards of $105.1 million and $8.2&#160;million, respectively, which may be available to offset future income tax liabilities that expire at various dates through 2040. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020 and 2019, the Company has United States federal research credit carryforwards of $4.7 million and $0.4&#160;million, respectively, which are available to offset future federal income tax liabilities, which expire at various dates through 2040. At December&#160;31, 2020 and 2019, the Company has United States state research credit carryforwards of $1.1 million and $0.1 million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2035. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the IRC, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. In 2020, the Company completed a study of ownership changes from inception through December 31, 2020, to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The result of this study indicated that the Company experienced ownership changes as defined by IRS Section&#160;382 of the Code, however there are no net operating loss carryforwards that will be limited and expire unused as a result of such ownership changes. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize interest and/or penalties related to uncertain tax benefits in income tax expense as they arise. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax benefits. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, California, and Massachusetts. The federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2017 through present. To the extent that the Company has tax attribute carryforwards, the tax years in which the attributes were generated may still be adjusted upon examination by the Internal Revenue Services or State tax authorities to the extent utilized in a future period. The Company is not currently under examination by any tax authorities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CARES Act was enacted on March&#160;27, 2020. The CARES Act contains a significant number of provisions that may impact on the Company&#8217;s accounting for income taxes. The Company has considered several key corporate provisions within the CARES Act, has evaluated its potential impact and as a result recorded a tax benefit of $0.6 million related to an anticipated refund to be received for federal taxes incurred for the tax year ended December 31, 2019. The refund is expected to be received in 2021 after the Company files the tax year 2020 net operating loss carryback claim upon the completion of its tax year 2020 tax returns, which are due October 15, 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Consolidated Financial Statements &#8212; Continued</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss per share</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted in Note 2, <font style="font-style:italic;">Summary of significant accounting policies</font>, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for each of the years ended December 31 because including them would have had an anti-dilutive effect:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,368,148</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,727,041</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All redeemable, convertible preferred stock, including those that were outstanding as of December 31, 2019, as shown above, were converted to shares of the Company&#8217;s common and effected for a one-for-8.4335 reverse stock split.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding for the years ended December&#160;31, 2020 and 2019 (in thousands, except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual of preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,468</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common stock outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,370,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371,905</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.03</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14. Defined contribution plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) retirement plan, the&#160;401(k)&#160;Plan, whereby all full-time employees may contribute up to 90% of their pre-tax compensation, up to the maximum allowable amount set by the Internal Revenue Service. The Company, at its discretion, matches 100% of contributions to the 401(k)&#160;Plan up to a maximum of $6,000 per year for each full-time employee. During each of the years ended December&#160;31, 2020 and 2019, the Company contributed approximately $0.5 million and $0.4&#160;million, respectively, to the 401(k)&#160;Plan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>cccc-ex44_220.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex44_220.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.4</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF CAPITAL STOCK</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary of the general terms and provision of the registered securities of C4 Therapeutics, Inc. (&#8220;<font style="font-weight:bold;">C4T</font>,&#8221; &#8220;<font style="font-weight:bold;">we</font>,&#8221; or &#8220;<font style="font-weight:bold;">our</font>&#8221;) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fifth Amended and Restated Certificate of Incorporation (our &#8220;<font style="font-weight:bold;">certificate of incorporation</font>&#8221;) and our Second Amended and Restated By-laws (our &#8220;<font style="font-weight:bold;">by-laws</font>&#8221;), each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.&nbsp;&nbsp;We encourage you to read our charter documents and the applicable provisions of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight:bold;">DGCL</font>&#8221;) for additional information.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000&#160;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;<font style="font-weight:bold;">CCCC</font>.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our Common Stock is Computershare Trust Company, N.A. </p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000&#160;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are currently outstanding and we have no present plan to issue any shares of preferred stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, options to purchase 5,029,364 shares of common stock at a weighted-average exercise price of $12.72 per share were outstanding under our 2015 Plan and our 2020 Plan. </p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we issued a warrant to purchase 2,857,142 shares of our Series B preferred stock to our lender, Perceptive Credit Holdings III, LP, at an exercise price of $1.05 per share. Upon the closing of our initial public offering, this warrant converted into a warrant to purchase 338,784 shares of our common stock on an as-converted basis at an exercise price of $8.86 per share. If unexercised as of June 5, 2030, this warrant will automatically net exercise if its exercise price per share is greater than the fair market value per share or otherwise expire.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Certain Provisions of our Certificate of Incorporation and Amended and Restated By-laws</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and by-laws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue&#160;non-negotiated&#160;takeover attempts. These provisions include the items described below.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Classified Board</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of&#160;two-thirds&#160;or&#160;more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No Written Consent of Stockholders</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our by-laws or removal of directors by our stockholders without holding a meeting of stockholders.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Meetings of Stockholders</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and by-laws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our by-laws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advance Notice Requirements</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our by-laws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our by-laws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment to Certificate of Incorporation and By-laws</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors and, if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our by-laws and certificate of incorporation must be approved by not less than&#160;two-thirds&#160;of the outstanding shares entitled to vote on the amendment and not less than&#160;two-thirds&#160;of the outstanding shares of each class entitled to vote thereon as a class. Our by-laws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the by-laws; and may also be amended by the affirmative vote of at least two-thirds of the outstanding shares entitled to vote on the amendment or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Undesignated Preferred Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides for 10,000,000&#160;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directors</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deterring</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or preventing a change in control of us.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;<font style="font-weight:bold;">business combination</font>&#8221; with an &#8220;<font style="font-weight:bold;">interested stockholder</font>&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">before the stockholder became interested, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least&#160;two-thirds&#160;of the outstanding voting stock that is not owned by the interested stockholder.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;203 defines a business combination to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Choice of Forum</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our by-laws provide that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii)&#160;any action asserting a claim arising out of or pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or by-laws; and (iv)&#160;any action asserting a claim governed by the internal affairs doctrine; <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font>, that this choice of forum provision does not apply to any causes of action arising under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight:bold;">Securities Act</font>&#8221;) or the Exchange Act of 1934, as amended. Our by-laws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Our by-laws also provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. We recognize that the forum selection clause in our by-laws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clause in our </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by-law</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">officers</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more or less favorable</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to us than our stockholders.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>cccc-ex1011_218.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex1011_218.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***] Certain information in this document has been omitted from this exhibit because it is both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 1 TO<br />COLLABORATIVE RESEARCH AND LICENSE AGREEMENT</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT <font style="font-weight:bold;">("Amendment") </font>is made as of February 25, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation <font style="font-weight:bold;">("C4") </font>and Biogen MA Inc., a Massachusetts corporation <font style="font-weight:bold;">("Biogen").</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">C4 and Biogen are Parties to that certain Collaborative Research and License Agreement, having an Effective Date of December 28, 2018 (the </font>"Agreement")<font style="font-weight:normal;">;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">the Parties contemplate that Biogen will provide one or more target binding moiety compounds, developed by Biogen pursuant to internal Biogen non-Degrader activities and programs, to be used in the discovery and/or development of Degraders pursuant to the Agreement;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">Biogen owns certain intellectual property, including know-how and patent rights, covering Biogen's target binding moiety compounds;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">Biogen and C4 understand and agree that Biogen will retain exclusive ownership of any target binding moiety compound provided by Biogen, including any improvements, modifications, and/or enhancements thereto, and to any intellectual property thereon, as well as the exclusive right to use any such target binding moiety compound and intellectual property thereon in connection with research and development programs other than degrader programs;</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">pursuant to Section 13.2 of the Agreement, no amendment of the Agreement shall be effective unless in a writing signed by C4 and Biogen.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, <font style="font-weight:normal;">the Parties hereto agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10.5pt;"><font style="text-decoration:underline;font-size:10pt;">General</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated herein, words and terms which are defined in the Agreement shall have the same meaning where used herein.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10.5pt;"><font style="text-decoration:underline;font-size:10pt;">Amendment of Article 1 "Definitions"</font><font style="font-size:10pt;">:</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1&nbsp;&nbsp;The following definitions are to be added:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.193&nbsp;&nbsp;<font style="font-weight:bold;">"Biogen Target Binding Moiety" </font>means any moiety that is directed to and binds to a particular Collaboration Target and that is Controlled by Biogen or its Affiliates and includes any improvement, modification or enhancement to such moiety made by either Party or its Affiliates.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.194&nbsp;&nbsp;<font style="font-weight:bold;">"Biogen Target Binding Moiety Intellectual Property" </font>means Intellectual Property Covering a Biogen Target Binding Moiety. For the avoidance of doubt, Biogen Target Binding Moiety Intellectual Property shall be excluded from Joint Technology and Assigned Platform Technology</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2  The definition of <font style="font-weight:bold;">"Degrader" </font>shall be replaced in its entirety as follows:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.77 <font style="font-weight:bold;">"Degrader" </font>means with respect to a Collaboration Target, a compound comprising (a) a C4 Target Binding Moiety or a Biogen Target Binding Moiety, (b) optionally, a Linker, and (c) an E3 Ligase Binding Moiety that degrades such Collaboration Target.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3: The definition of </font><font style="font-weight:bold;">"Biogen Know-How" </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall be replaced in its entirety as follows:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23 <font style="font-weight:bold;">"Biogen Know-How" </font>means (i) any Know-How Controlled by Biogen or any of its Affiliates, whether or not developed or acquired by Biogen or any of its Affiliates before or after the Effective Date, including all Biogen Collaboration Know-How, Product&#173; Specific Know-How, and Target Specific Know-How; and (ii) any Know-How relating to a Biogen Target Binding Moiety Controlled by Biogen or any of its Affiliates and/or developed or invented during the Term by C4's or its Affiliates', licensees', Sublicensees', or Subcontractors' employees, agents, or independent contractors, or any Persons contractually required to assign or license such Know-How to C4 or any Affiliate of C4, and such Know-How shall fall within the scope of Biogen Target Binding Moiety Intellectual Property.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4 The term "Target Binding Moiety" shall be replaced with the term <font style="font-weight:bold;">"C4 Target Binding Moiety" </font>throughout the Agreement and the term <font style="font-weight:bold;">"C4 Target Binding Moiety" </font>shall have the same definition of "Target Binding Moiety" set forth in Section 1.182 of the Agreement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Amendment of Articles 5, 10 and 12</font>:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 5.1 of the Agreement is amended by adding the following sentence: C4 will provide to Biogen all Know-How relating to any Biogen Target Binding Moiety that is made, conceived, discovered or otherwise generated by C4.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 10.1 of the Agreement is amended by adding the following as Section 10.1.3: <font style="font-weight:bold;">Biogen Target Binding Moiety and Biogen Target Binding Moiety Intellectual Property</font>. C4 hereby agrees that Biogen will solely own all rights, title and interests in and to (i) any Biogen Target Binding Moiety and (ii) any Biogen Target Binding Moiety Intellectual Property. For the avoidance of doubt, any Biogen Target Binding Moiety Intellectual Property that is made, conceived, discovered or otherwise generated by C4 or its Affiliates', licensees', Sublicensees', or Subcontractors' employees, agents, or independent contractors, or any Persons contractually required to assign or license such Know-How to C4 or any Affiliate of C4 whether solely or jointly with Biogen, shall be owned by Biogen.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 10.2.1(a) of the Agreement is amended by adding the following sentence: For the avoidance of doubt, Biogen retains sole ownership of Biogen Target Binding Moiety Intellectual Property and does not assign to C4 any right, title or interest in or to any Biogen Target Binding Moiety Intellectual Property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 10.2.2(a) of the Agreement is amended by adding the following as Section 10.2.2(a)(iii): C4 will and hereby does assign (and shall cause its Affiliates licensees', Sublicensees', or Subcontractors' employees, agents, or independent contractors, or any Persons contractually required to assign or license such Know-How to C4 or any Affiliate of C4 to assign) to Biogen all of its rights, title and interests in and to all Biogen Target Binding Moiety Intellectual Property, and Biogen hereby accepts such assignment of Biogen Target Binding Moiety Intellectual Property. C4 agrees to the supporting covenants and further assurances described in Section 10.2.2(b) to support such assignment of Biogen Target Binding Moiety Intellectual Property to Biogen.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 12.5.3 is amended by adding the following sentence: Provided, however, that Biogen's assignment obligation under this provision does not apply to any Biogen Target Binding Moiety or any Biogen Target Binding Moiety Intellectual Property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 12.5 of the Agreement is amended by adding the following as Section 12.5.4:</p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5.4 Biogen Target Binding Moiety and Biogen Target Binding Moiety Intellectual Property License. For the avoidance of doubt, the Parties agree that upon termination of the Agreement in whole or in part with respect to one or more Development Candidates, Products, or Collaboration Targets in accordance with Section 12:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="margin-left:36pt;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all rights, title and interests in the Biogen Target Binding Moiety and Biogen Target Binding Moiety Intellectual Property shall continue to be owned by Biogen; and</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>To the extent Biogen's rights to Biogen Target Binding Moiety Intellectual Property permit, Biogen will grant to C4 a limited, non-exclusive, non-commercial, research license, with no right to sublicense, under Biogen Target Binding Moiety Intellectual Property, solely to make and use a Biogen Target Binding Moiety that was provided to C4 by Biogen under the Agreement for C4's internal, non-commercial, research purposes and limited to the extent that such Biogen Target Binding Moiety is an essential component of a Degrader and solely for the purpose of making such Degrader (the "C4 Research License"). <font style="font-weight:bold;">[***]</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>In the event that Biogen, pursuant to an internal non-Degrader activity or program, identifies as a development candidate a Biogen Target Binding Moiety that had been provided to C4 under the Agreement, the C4 Research License described in Section 12.5.4 with respect to such Biogen Target Binding Moiety shall terminate immediately upon written notice by Biogen to C4 of such identification.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section 12.8 of the Agreement is amended by adding Section 10.1.3 (Biogen Target Binding Moiety and Biogen Target Binding Moiety Intellectual Property) and Section 12.5.4 as provisions that will survive termination or expiration of the Agreement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Continued Validity of Agreement.</font> Except as specifically amended hereby, the Agreement shall continue in full force and effect as originally constituted and is ratified and affirmed by the parties hereto. All references in the Agreement to" this Agreement", "hereunder," "hereof," "herein" or words of similar import referring to the Collaboration Agreement shall mean and<img src="gfvy2su3zcnu000001.jpg" title="" alt="" style="width:2px;height:64px;"> be a reference to the Agreement as amended by this Amendment. Provided, however, that solely with respect to Biogen Target Binding Moiety and Biogen Target Binding Moiety Intellectual Property, to the extent there is a conflict between the Agreement and this Amendment, this Amendment is controlling.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Successors and Assigns.</font> Except as otherwise provided herein, the terms and conditions of this Amendment shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Counterparts.</font> This Amendment may be executed in two or more counterparts, any of which may be delivered by facsimile, email or other electronic transmission, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, <font style="font-weight:normal;">the parties hereto have executed this Amendment as of the date first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4 THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:77.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:77.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andy Phillips</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:77.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andy Phillips </p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:77.36%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BIOGEN MA INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:77.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:77.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Anabella Villalobos</p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:77.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anabella Villalobos </p></td>
</tr>
<tr>
<td valign="top"  style="width:22.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:77.36%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Biotherapeutics and Medicine Science</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>cccc-ex1013_217.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex1013_217.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.13</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41062859"></a><font style="Background-color:#FFFFFF;">[***] Certain information in this document has been omitted from this exhibit because it is both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">First Amendment To <br />Amended and Restated license Agreement</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This First Amendment (the &#8220;<font style="font-weight:bold;">First Amendment</font>&#8221;), effective as of November 12, 2020 (&#8220;<font style="font-weight:bold;">Amendment Effective Date</font>&#8221;) is an amendment to that certain Amended and Restated License Agreement by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (&#8220;<font style="font-weight:bold;">Roche Basel</font>&#8221;) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, NJ 07424 USA (&#8220;<font style="font-weight:bold;">Roche US</font>&#8221; and, collectively with Roche Basel, &#8220;<font style="font-weight:bold;">Roche</font>&#8221;), on the one hand, and C4 Therapeutics, Inc., with an office and place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (&#8220;<font style="font-weight:bold;">C4T</font>&#8221;) (the &#8220;<font style="font-weight:bold;">Restated Agreement</font>&#8221;).&nbsp;&nbsp;Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Restated Agreement.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Roche and C4T are Parties to that certain Restated Agreement, effective as of March 4, 2016; and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Restated Agreement contemplates the Parties&#8217; collaboration with respect to certain Targets, and their respective rights and obligations regarding Collaboration Patent Rights resulting from such collaboration; and</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties wish to amend such rights and obligations with respect to Targets that are terminated by the Parties&#8217; mutual written agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:6pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendment</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Restated Agreement is hereby amended by adding the following new Section 21.2.5 immediately after Section 21.2.4:</font></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.2.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Mutual Termination of Research Plan</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties may terminate this Agreement on a Target-by-Target basis upon their mutual written agreement.&nbsp;&nbsp;In such event, the Parties shall each execute a written termination agreement referencing this provision and identifying the Target(s) to be terminated (each, a &#8220;<font style="font-weight:bold;">Mutual Termination Target</font>&#8221; and such notice, a &#8220;<font style="font-weight:bold;">Mutual Target Termination Agreement</font>&#8221;).&nbsp;&nbsp;The Mutual Target Termination Agreement shall include the following, called out in separate sections or schedules: (a) a listing of any Collaboration Patent Rights directed to the Mutual Termination Target(s) that Cover the Exploitation of products targeting the Mutual Termination Target(s) using inhibition as their mode of action (such Patent Rights, the &#8220;<font style="font-weight:bold;">Inhibitor Patents</font>&#8221; and such field, the &#8220;<font style="font-weight:bold;">Roche Field</font>&#8221;); (b) a summary of Know-How made, conceived or reduced to practice by either Party in the conduct of the Research Program that Covers the Exploitation of products in the Roche Field; (c) a listing of any Collaboration Patent Rights directed to the Mutual Termination Target(s) that Cover the Exploitation of products targeting the Mutual Termination Target(s) in the field of targeted protein degradation (such Patent Rights, the &#8220;<font style="font-weight:bold;">Degrader Patents</font>&#8221; and such field, the &#8220;<font style="font-weight:bold;">C4T Field</font>&#8221;); (d) a summary of all Know-How made, conceived or reduced to practice by either Party in the conduct of the Research Program that Covers the Exploitation of products in the C4T Field (all such Collaboration Patent Rights in the Roche Field and C4T Field, collectively, the &#8220;<font style="font-weight:bold;">Terminated Target Collaboration Patents</font>&#8221; and all such Know-How in the Roche Field and C4T Field, collectively, the &#8220;<font style="font-weight:bold;">Terminated Target Know-How</font>&#8221;); and (e) a listing of any Collaboration Patent Rights directed to the Mutual Termination Target(s) that Cover the Exploitation of products targeting the Mutual Termination Target(s) using both inhibition and degradation as </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their mode of action </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;</font><font style="font-weight:bold;">Combined Patents</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;A Mutual Termination Target shall not be subject to exchange pursuant to the provisions of Section 4.1.3 hereof. </font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Restated Agreement is hereby amended by adding the following new Section 21.3.8 immediately after Section 21.3.7:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.3.8<font style="margin-left:36pt;">Licenses Upon Mutual Termination of Target</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon execution by both Parties of a Mutual Target Termination Agreement pursuant to Section 21.2.5, each of the Mutual Termination Targets terminated thereby shall be deemed Reverted Targets and the following provisions shall apply in addition to the non-exclusive licenses granted to C4T under Section 3.1.5.1 and Section 3.1.5.2, and notwithstanding clause (d) of Section 3.1.5:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Roche hereby grants C4T (i) a perpetual, irrevocable, fully paid up, exclusive (even as to Roche), sublicenseable (including in multiple tiers) license, under Roche&#8217;s rights in the Terminated Target Collaboration Patents to Exploit products in the C4T Field and (ii) a perpetual, irrevocable, fully paid up, non-exclusive, sublicenseable (including in multiple tiers) license, under Roche&#8217;s rights in the Terminated Target Collaboration Know-How to Exploit products in the C4T Field. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) C4T hereby grants Roche (i) a perpetual, irrevocable, fully paid up, exclusive (even as to C4T) sublicensable (including in multiple tiers) license, under C4T&#8217;s rights in the Terminated Target Collaboration Patents to Exploit products in the Roche Field and (ii) a perpetual, irrevocable, fully paid up, non-exclusive, sublicenseable (including in multiple tiers) license, under C4T&#8217;s rights in the Terminated Target Collaboration Know-How to Exploit products in the Roche Field. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Notwithstanding anything to the contrary in Article 16, from and after the execution of a Mutual Target Termination Agreement C4T shall be responsible for Handling the Degrader Patents and shall have the right to initiate suit or action in the Territory regarding known or suspected infringement by a Third Party of any Degrader Patents or any Terminated Target Know-How Covering the Degrader Patents in accordance with Section 17.8, <font style="font-style:italic;">mutatis mutandis</font> as though C4T were Roche and Roche were C4T.&nbsp;&nbsp;Roche shall assign such Degrader Patents to C4T and C4T shall Handle such Degrader Patents at its sole cost and Roche will Handle any in-process matters required to be completed by Roche or its counsel prior to the transition of those projects to C4T and its counsel.&nbsp;&nbsp;Where a Party has lead decision-making responsibility with respect to the Handling or enforcement of a particular Terminated Target Collaboration Patent and such decision-making could adversely affect the validity or enforceability of a Collaboration Patent Right for which the other Party has such lead decision-making responsibility, the Parties shall consult with each other on such decisions; provided that Roche shall have final say with respect to the Inhibitor Patents and C4T will have final say with respect to the Degrader Patents.&nbsp;&nbsp;If Combined Patents exist for a Terminated Target, the Parties shall work together in good faith to separate the patent claims in Combined Patents that relate to the C4T Field from those in the Roche Field through the creation of separate patent applications, with any resulting patents in the C4T Field Handled by C4T and any resulting patents in the Roche Field Handled by Roche.&nbsp;&nbsp;Following the separation of claims in a Combined Patent as contemplated in this Section 21.3.8(c), any Terminated Target Collaboration Patents that relate to the C4T Field shall be deemed to be Degrader Patents and any Terminated Target Collaboration Patents that relate to the Roche Field shall be deemed to be Inhibitor Patents.&nbsp;&nbsp;If C4T and Roche determine that separation of the patent claims as contemplated in this Section 21.3.8(c) is not possible or would result in either of the Parties being significantly disadvantaged, then the Parties shall cooperate in good faith to determine how best to proceed to ensure, to the greatest extent possible, that C4T Handles patent claims in the C4T Field and Roche Handles patent claims in the Roche Field.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Restated Agreement is amended by amending and restating Section 1.98 thereof to read in its entirety as follows:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98<font style="margin-left:36pt;">Reverted Target</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;Reverted Target&#8221; shall mean (a) a Target for which Roche did not exercise its Roche Option Right within the applicable Roche Option Period, including any target that became a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 2</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Target pursuant to Section 4.1.3, (b) any Terminated Target and (c) any Mutual Terminated Target.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:6pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination of EGFR Target</font><font style="color:#000000;">.&nbsp;&nbsp;As of the Amendment Effective Date, the Parties hereby terminate the Restated Agreement with respect to EGFR such that EGFR shall be deemed a Mutual Terminated Target in accordance with Section 21.2.5 of the Restated Agreement (as amended hereby).&nbsp;&nbsp;This First Amendment, when executed and delivered by both Parties, shall serve as the Mutual Target Termination Notice with respect to EGFR.&nbsp;&nbsp;Attachments A1 through A5 hereto set forth a listing of Degrader Patents, Inhibitor Patents and Combined Patents, and summaries of the Terminated Target Know-How, in the C4T Field and Roche Field, respectively.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:6pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Miscellaneous</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as herein provided, the Restated Agreement and all its terms remain in full force and effect.&nbsp;&nbsp;The Restated Agreement shall, together with this First Amendment, be read and construed as a single agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Restated Agreement and this First Amendment constitutes the entire agreement between the Parties with respect to the subject matter of this First Amendment and supersedes and replaces any and all previous arrangements and understandings, whether oral or written, between the Parties with respect to the subject matter hereof.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This First Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.&nbsp;&nbsp;Facsimile and electronic transmission signatures shall be treated as original signatures.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.4</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This First Amendment shall be governed by and construed in accordance with the laws of England, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this First Amendment to the substantive law of another jurisdiction.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of this page is left intentionally blank.]</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 3</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">IN WITNESS WHEREOF<font style="font-weight:normal;font-variant: normal;">, the Parties hereto have caused this First Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C4 THERAPEUTICS INC.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President &amp; CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">F. Hoffmann-La Roche Ltd</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Stefan Arnold</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Markus Keller</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Stefan Arnold</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Markus Keller</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Head Legal Pharmaceuticals</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Alliance Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Hoffmann-La Roche Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John P. Parise</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: John P. Parise</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Attachment A1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 5</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A2 &#8211; EGFR Inhibitors Collaboration Patent Rights</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 6</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A3 &#8211; Combined Patents</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 7</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A4 &#8211; Summary of the Terminated Target Know-How in the C4T Field</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 8</a> -</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">A5 &#8211; Summary of the Terminated Target Know-how in the Roche Field</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[***]</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 9</a> -</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>cccc-ex211_216.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex211_216.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:71%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4T Securities Corporation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>cccc-ex231_219.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex231_219.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:20pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors<br />C4 Therapeutics, Inc.:</p>
<p style="text-align:left;margin-bottom:10pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statement (No. 333-249286) on Form S-8 of C4 Therapeutics, Inc. and its subsidiary of our report dated March 11, 2021, with respect to the consolidated balance sheets of C4 Therapeutics, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements), which report appears in the December 31, 2020 annual report on Form 10-K of C4 Therapeutics, Inc.</p>
<p style="text-align:left;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:10pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts <br />March 11, 2021</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>cccc-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Andrew J. Hirsch, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of C-4 Therapeutics. Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;margin-right:11.97%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:46.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>cccc-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, William T. McKee, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of C-4 Therapeutics. Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.48%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:11.97%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:46.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;William T. McKee</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">William T. McKee</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:11.97%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>cccc-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of C4 Therapeutics (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.68%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.68%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.68%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.68%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew J. Hirsch</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>cccc-ex322_6.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex322_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of C4 Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;William T. McKee</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">William T. McKee</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr style="height:3.25pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gjnp4w4lrub1000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /P!A # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  NC_J ?^3G_ -A7J]-Q:W!-/8****D84444 %%%% !1110 445Q/@_X@_\
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M1_PC_P#;OVO_ (EO_/?RW_O[/NXW?>XZ573QGX>?1I-7&I*+&.7R#(T;@E\
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M1K?3;?9OP99&.YY"!C)/Y\# &3@#->2>./ ]QX6NQJVDF7^SO,#*R,=]J^>
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M63XEUK_A'O#]UJOV?[1Y&S]UOV;MSA>N#CKGI6M16"-3YR\'^)_^$3U>6_\
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M:+6VU:XM[6]F>1Y)([J(-'(S9R2HP.IS]<5T>K?$K5-:TZ6QOM-TF2*12 3
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MKVV\T;2]1F$U]IMG<RJNT// KD#KC)'3D_G5VGSI:I"Y7U84445F6>)^'?\
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MKS[X+_\ ,<_[8?\ M2M8.T61)7:,?Q)\4;S7=)ETZVL%LHIUVS/YQ=R,@X!
M7 ."#G.0>U=M\,O#-UH&C3W-\C175\RMY+'E$4';D8X8[FR,],=#D5UEGHVE
MZ=,9K'3;.VE9=I>"!4)'7&0.G _*KM2Y*UDAJ.MV>+>+-)UCP?XTD\2:="TE
MJ\K7"S%=ZH7X='P!M!+$#V(P<@XT)?C/(87$.A*DI4[&>ZW 'L2-@R/;(^M>
MLUGVV@Z/97"W%KI-C!,F=LD5LBLN1@X(&>AI\Z:U0<KZ&3X.US7-=T]+K5-)
MBM(GCWQSK*1YV2<8C.2HQW)YX(R#QYSX=_Y+;-_U_7G\I*]LJE'HVEPWQOHM
M-LTNRQ8SK HDR<Y.[&<G)S]:2DE<&MB[7B?P?_Y&VZ_Z\7_]&1U[95*ST;2]
M.F,UCIMG;2LNTO! J$CKC('3@?E24K)H;5V>9_&#1+I[FTUN)6DMUB%O-M7B
M(AB5).>AW$=, @<\BL^7XMZE-X>>Q:S47[Q&(WR2E>3QO"@##8]#C/.,<5[3
M6?;:#H]E<+<6NDV,$R9VR16R*RY&#@@9Z&J4U:S0G%WT.#^$OARXL;>YUJ\M
M_+-U&J6I8D,8\Y8XZ8)"X)YX]#SS_AW_ )+;-_U_7G\I*]LJE'HVEPWQOHM-
MLTNRQ8SK HDR<Y.[&<G)S]:.?5WZAR[%;Q1_R*6L_P#7C/\ ^BVKPCPMK^L>
M&WO-0TRW\Z$1JEQYB.T29;Y2VT@ YR 3ZGUKZ*EBCGA>&:-9(I%*NCC(8'@@
MCN*JV^C:7:0SPVVFV<,4Z[9DC@51(.1A@!R.3U]32C))68.-V>,>)OB'J7BN
MU&DVNGK;P3L@:)"99)6#9 !P."=O &<CKSBO1OA_X3D\+Z-)]KV_;[M@\P4Y
M" #Y4ZX)&6)([G'( -=#9Z-I>G3&:QTVSMI67:7@@5"1UQD#IP/RJ[1*2M9
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M8SK HDR<Y.[&<G)S]:OG2320N5]3B_C!_P BE:_]?R?^BY*UOAK_ ,D_TO\
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MO=1311^7N@<#<N<@$$$<$GICK],=-11=WN*RV*FF:=;Z1IEMI]JNV&WC"+P
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M.*J#2O<4DV=S1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<MX[GNH=)L5@O)[
M.";4(8KNY@;88H6)RV_^ 9V\_AWQ3;#P<V@:A82:#?RV]FORWMK.S2).,??
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M83Q-X:M-'NFAENFN$?G* ;5RY7(#% 68 ]Q1K7ADZ5X>NM0L-9U9-2LXC/\
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M[@7_ +7JOHMC:S?$[Q/>RPJ]Q;+:K#(W)0/%\V/<X SUQD=S6Q_8]Q_PG/\
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M*5UH)(P;)8=/^)E_9VMO%%'?::EY.5!RTJRLN>N!D-SQR1GKG/5UB?V/<?\
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M$B#?UAR VW&.%P/NL>,BKT%YX4UF^M;/P]H&G7S/*/M,[:;MBMXQR2Q*#YF
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ML9/BC_D4M9_Z\9__ $6U'A?_ )%+1O\ KQ@_]%K6M12OI8?4Y30/^2@>+_\
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MTWPA::?J$5_-?ZGJ-S!GR'OKHR>3N!#;0,#D'G.>@KH***&VP"BBBD 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\ '* .@_X3OP?_ -#7H?\
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MOAY_T+W_ ).W'_QR@#H/^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
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M>A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (JN?_X4E\//^A>_\G;C_P".4?\
M"DOAY_T+W_D[<?\ QR@#H/\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
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M\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*KG_^%)?#S_H7O_)VX_\
MCE'_  I+X>?]"]_Y.W'_ ,<H Z#_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0
MUZ'_ .#&'_XJN?\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#H/^
M$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\ @QA_^*KG_P#A27P\_P"A>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P!
MW7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\
M=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&
MCO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_
M +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\
M':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'
M_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_
M /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^
M_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X
M:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!_
M_0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0
M_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@
MHH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#A
MH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-
MUS_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_
M ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'
M_P#0-US_ +\0_P#QVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-U
MS_OQ#_\ ':]@HH \?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#Q
MVO8** /'_P#AH[P?_P! W7/^_$/_ ,=H_P"&CO!__0-US_OQ#_\ ':]@HH \
M?_X:.\'_ /0-US_OQ#_\=H_X:.\'_P#0-US_ +\0_P#QVO8** /*])^/GA76
M=9L=+M]/UE9[VXCMXVDAB"AG8*"<2$XR?0UZI7C_ ,7_ /DH?PQ_["I_]&V]
M>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5X_\ LX_\D\U#_L*R?^BHJ]@KQ_\ 9Q_Y)YJ'_85D
M_P#145 'L%%%% #)IHK:"2>>5(H8E+R22,%5% R22>  .]<K%\3_  7-J1L$
M\06PF#,FYU98LKG/[P@)CC@YP>,9R*T?&?\ R(OB'_L&7/\ Z*:O$_ACHG@#
M4O#=Q-XJEL$OEO&2,7&H&!O+V(1\H=<C);G'\J[L/AZ<Z4JD[Z::&<Y-221[
M[8:GI^JP-/IU];7D*ML:2WF610V <94D9P1Q[UB:W\0O"OAS4FT_5=72&[50
M[1+%)(5!Z9V*0#CG!YP0>A%>5_!.-8OB%K\>ES7,VBI!(L<K A7 E7RB_ &X
MKO(R ?O8 YK'\<V<&H?'[[%=1^9;W%]912IDC<C)$",CD<'M6\,!3^L2IR;L
ME?SZ$NH^5-'N>B>-_#/B-UCTK6;::9F*+"Q,<K$#<<(X#$8YR!C@^AK4U+4K
M+1]-GU#4+A+>T@7?)*_0#^9)/  Y)( YKYX^,7A+P_X5O]*30X_L\EQ%(9[?
MSS)M (VOAB6&<L.N#LXZ&NM^+DM[/\(/#LVHAQ?23VSW(D38PD-O(6RN!@YS
MQ@8J7@J<G3E!OEF^NX>T:O?='=Z=\2?!NJ>9]G\0V:>7C=]I8V^<YZ>8%W=.
MV<<9ZBNCL[VUU"U2ZLKF&YMY,[)H9 Z-@X.".#R"/PKR'X??#3PKXD^'5A?Z
MAI[F^N5F5KF.XD5E(D=00,[<@ =01QR#6'H\5[\*_C!%HL!>YTW56BA3S7VE
MXY' 5R%.-R-N7)'(#8"[@0I82C*4X4I/FC?1VUMOJ"G)).6S/<]6UG3="L&O
M=4O8;2W7/SRMC<<$[5'5FP#@#)..!65H7CSPOXDNC:Z5K$,UP.D+JT3OP3\H
M< M@*2<9QWKR7QC'_P )1\>K;0-8OMNEPRQ)'%(VU #$LC(,$?-(WRYSGE>N
M *J?%?PQI?@+5O#^H^&XGLIF9Y ID,JJ\3(RL-^3G+<@G' XZYJG@J4N6$F^
M>2NNWS!U'JULCVGQ/XST3P@EJVL7+Q&Z;;$J1,Y(!4,>!@!0P)[XS@$\5L65
MY!J%A;WMK)YEO<1++$^"-R,,@X/(X/>O*_BAXI\/MH7AN[U/PS_:]OJ,375N
M)+HV\D VH<90$\AQD9QE1UP,>FZ+<VM[H6GW5C!Y%G-;1R00[ OEQE057 X&
M 0,#BN2I14*,9V=W?M;3\?O+4KR:+U%%%<Q84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'C_P"T=_R3S3_^PK'_ .BI:]@KQ_\ :._Y)YI_
M_85C_P#14M>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5X_\(/^2A_$[_L*C_T;<5[!7C_P@_Y*'\3O^PJ/_1MQ
M0![!1110 5QW_"U/!'V_['_;\/F^;Y6[RI/+SG&?,V[=O^UG&.<XKL:^9OA7
MI/@W5/[6_P"$NDLT\OR?LWVF]-OG._?C#+NZ+ZXX]:[<+0IU(3G4O[MMO,SG
M)II+J?1UAJ>GZK T^G7UM>0JVQI+>99%#8!QE21G!''O67X@\;>'/"T\,&LZ
MFEM-,I=(Q&\C;0<9(0$@9Z$]<''0UX[X%L;*W^.\\7A6X>;1;=96D9)LJ8_+
MP1DXWJ)64#KG"G)QNJU\5K.#4/C-X9LKJ/S+>XBM8I4R1N1KAP1D<C@]JV6"
MI^W4&W:U_/T)]H^6YZCI'Q#\):[/Y%AKELTVY46.;="SLQP H< L<]AGMZBM
MO4M2LM'TV?4-0N$M[2!=\DK] /YDD\ #DD@#FO"?B_X-\)>&-)LGT9$M-2:<
M![873.SQ,K?.5<EL!DP",#D@YXQU7B>;4+G]G19]3E26[EL[5VD5F;>IEC*E
MBW)8KMW'^]GM4RPE*7).FWRR=M=QJ<M4^AU5A\3_  7J4[0P>(+9&5=Y-PK0
M+C('WI H)YZ9S^5=-9WMKJ%JEU97,-S;R9V30R!T;!P<$<'D$?A7A_PB\">&
MO%'A.ZO=9TW[3<1WSQ*_GR)A D9 PK =6/YUCW!O?@M\2$AMKU[G2KE4EEBV
MY:2W+,,,.!YBX;# C\ Q6KG@J,JDJ5*3YET?7YB5222<MCZ(O+VUT^U>ZO;F
M&VMX\;YII B+DX&2>!R0/QKG-)^)'A#6[];*QUN%KA\;$E1XMY) "J74 L21
M@#D^E>9?%OS-<^*?ASP_=^=%8-Y**5V GSI=KNAY/15'S=T/&#DL^+_@#PYX
M8\-V6HZ-9O:3->"!U$SNKJR,V3O).04XP1U.<\85+!TFH*HWS3VMLO4)5):V
MZ'L7B7Q/I?A+23J.K2ND);RXUCC+-(^TL%&. 2%/)('J16C97D&H6%O>VLGF
M6]Q$LL3X(W(PR#@\C@]Z\V\9^(+*/X2Z#J'B'2$UL7RVIEC:;R")&A+F0,HR
MIR".,<,1TX/?^'[J*^\-Z7>06J6D,]G%+';QXVQ*R A!@ 8 ..@Z5R5*/)24
MK:W:\O\ ,M2N[&C1117.6%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!X_\ %_\ Y*'\,?\ L*G_ -&V]>P5X_\ %_\ Y*'\,?\ L*G_ -&V
M]>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5X_^SC_R3S4/^PK)_P"BHJ]@KQ_]G'_DGFH?]A63
M_P!%14 >P4444 8?C/\ Y$7Q#_V#+G_T4U>/?"[X>>'_ !CX)O;C4X)EO%OF
MB2YAF*NB!(VP <KW/53U^F/;]:T[^U]"U#3/-\K[9;26_F;=VS>I7.,C.,],
MUY?8?!G6M*@:#3OB!?V<+-O:.W@>-2V ,X68#. .?:O1PM:,*,H<_*[KO^AE
M.+<D[7.5T2YO?AS\8D\-65_<W.E2WD<#02/M5A,J88CD;EW)\P )V8X!Q5'Q
M_81:M\=Y=.G9UAN[RS@D:,@,%>.)21D$9P?2O6_ _P +-(\&3_;C,]_J>TH+
MB5 JQ@DY\M.=I((!))/!Q@$BH-0^%D6I?$E/%TVK.JI/#.+1( #NC50HWENF
M4!/R],CCK75'&T56<[_9M>V[]"'3ERV\SRC5]!_X5/\ $O3+N:/[?I:RBX@>
M6'<3'DAAV4RIG((.,[&XS@>A?'::*Y^'NFSP2I+#+J$3QR1L&5U,4I!!'!!'
M>NJ\?^!HO'6DVMF;M+.:WG\U;@VXE8+M(*#D$ G:3S_"*S=0^&?]J?#G3_"E
MUK<SRV,HDBO3%G."P"E"Q^4(^T ,,8'88K-8NG.5*K4?O1T?IW'R-)Q6Q/\
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MJ\9X:$+^\F[_ 'EQBU-LMT445PF@4444 %%%% !1110 4444 %%%% !1110
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M.AKH^MTE64N;:+5[;LGDERV/)?&G@>#X:^(]+U6.V_MC1'E!,%X#]]<$H[*
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M 5X_^SC_ ,D\U#_L*R?^BHJ]@KQ_]G'_ ))YJ'_85D_]%14 >P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >/_M'?\D\T_\ ["L?_HJ6O8*\?_:._P"2>:?_ -A6
M/_T5+7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>/_  @_Y*'\3O\ L*C_ -&W%>P5X_\ "#_DH?Q._P"PJ/\
MT;<4 >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%>5>//$7_"0_"OQC_HOV?\ L[4_[/\ ]9O\SRYXOGZ#
M&<].<>M=/+XREAU3QE";-&A\.V<4Z@.0T[-$\I!.,*,!0.#W/.<#T'EM;V?/
MUNTUVMR6UOU<T1SJYUU%5-+U"+5M)L]2@5UANX$GC60 ,%=0P!P2,X/K5NN"
M47%N+W184444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /'_ (O_ /)0_AC_ -A4_P#HVWKV"O'_ (O_ /)0_AC_
M -A4_P#HVWKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /"/&G[0T5I>0P>#HH+V-=WVB>^MW"/D*5\L!U;CY@=P'08X
MYKUOQAXEA\'^$]0UZ>WDN$M$4B%" 79F"*,GH-S#)YP,\'I7CG[37_,K?]O?
M_M&NG_:&OKBT^&L<,$FR.[U"*&<;0=Z!7D YZ?,BGCT],T <X_Q8^)^G^'[3
MQ-J/A/3?[!E="941T9D8\'_6,4#=G9<?,O7(SZ'X\^(EOX5\ P>)+"'[;]O\
MM+#<"J$R(75W!PP7:"<=3P.,Y'+^,O\ DUZV_P"P5IO_ *%#7(:S=W$6F?!.
MZUD06?DR@LQ<!%@62W\MV.2!F,*QR>,G@=  =/H_Q4\:V'BW1-*\:^&8+*UU
MK8EL]O&R.&=@JD[G8<$@,APR[@3V!]HKP3]I.>:UN/"5Q;RR0SQ/=/')&Q5D
M8&$@@CD$'O7?^-=5^)%CK,,7@_P_INH:>;=6DENI K"7<V5&94XVA3T[GF@#
MO*\?_9Q_Y)YJ'_85D_\ 145'_"0_'/\ Z$S0_P#O\O\ \D4?LX_\D\U#_L*R
M?^BHJ /8**** "O)_$?A;1O%WQUCL-<L_M=K'X:$RIYKQX<7) .4(/1C^=>L
M5R^L^"8-7\0OKD6LZKIM\^GG3F>Q>)<PERYP7C8JV3]Y2",#&* /(/$)N/"_
MASXG>%-,GOET;3_L+V@,P(MA<.ADB#9W[6#$ <C"MN.6.Z/PCXSF^'G@77='
MO;^19SIEOJ6AEXB&9KF)=PC#DHR1R,"0.N)6P>0/4U^%7A]?"&I^'?-OF75)
M1-?:@\JM=W#B0."SE<'!&.G<GJ227?PJ\/W>H^&K]Y;Y;KP_%!#;.LJ_O4A(
M*"0%<'!!^[MSN/M@ \XT#P=JFG6'Q)\*:#Y":F-/TR%@'RDKM 3.%9QQOS(!
MG&-P^[CBYX5?0_#FE^(S9^%[OPSXWL-"N9I!*TLD4BKG]Y"9&963>B'D=\ N
M 37H^I>!8;I_$UU8:OJ6G:AKR6XDN;>4*8&A7"%, '!_B&[D$@$9J/3? :>;
M=WOB35)]=U.\T]M,GN'C6V3[,S,Q14CQC.X9))/'!'2@#@/^%:>'?^%2_P#"
M5XOO^$C_ +*_M?\ M3[9)YWVC9Y^[KM^]QG&<<YW?-7J_A.^N-3\&Z'?WDGF
M75UI\$TS[0-SM&I8X' R2>E<7!\'+:&PBT)_$NLS^%D<3-I,C(-\H?=S*J@^
M4?\ GF /F^8$&O2(((;6WBM[>*.&") D<<:A510,  #@ #M0!)1110 4444
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MP!10!]_T5\ 44 ??]%? %>P?LX_\E#U#_L%2?^C8J /I^BBB@ HHHH ****
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MIO\ T?!6Y>?\ACXO_P#8,M__ $DDK#U?_DE?Q(_[&:;_ -'P5N7G_(8^+_\
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M["I_]&V]>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%:1_R2OX;_\ 8S0_^CYZ^KPZM3BG_P!._P#TFJ8/?[_T#5_^25_$C_L9IO\
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M^PJ?_1MO7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\T__ +"L?_HJ6O8*\?\ VCO^2>:?_P!A6/\ ]%2U[!0 4444 %%%% !1110
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MNHIJ-_9S6L%G>_9$CPTT;.=R@XPJH<=?FZY' Z:.!JUHKE:UZ:WM>U]K6O\
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MAJ)S]]K]S?Z!I>CO!;1V^FM,T;QH0\AE8%BYS@D;0!@#@=ZSH)Y;:42PN4D
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M.WS[?*SL^7G_ %9ZX[5C.."G.TWOY[>Z[;**>MEMY%)U$M/ZU^93T7Q3K/\
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MN7__ ")'C#_L,R?^C(Z/#7_,B_\ ;_\ UK0LM)DUS0?$^FQRK$TVMRY=AD*
M\9)QW. >/Y5\Y6FHUN>3T3O_ .5)&J6G]=CJ+O1+6>'5?*'DW&I0^5--DMG"
M%5.,XX![8S5JSL(+*UM8(UW?9H1!'(X!?: !U]]HS]!5FBO =6;7*W_5K?D:
MV"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% 'C_[1W_)/-/_ .PK
M'_Z*EKV"O'_VCO\ DGFG_P#85C_]%2U[!0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&QU*SN957<4@G5R!TS@'IR/SJ[0 4444 %%%% !1110 4444 %%%% !1110
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M1TR#Z^G>OL4HP@YRTBO^'*2MHCU7P)90"'QZY59?-T>TE5GC&0LUJTA7OQR
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MU'5[BZEMFB3+-YH();!8?<3@'''UK%U+7[_Q!J&HZIJ[)>7]W&JO.R;"I4*
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MC*3;LCF9O]2U>Q^&;2#P)I?Q0\.:YJFG1:@VF1I"HN HG9K>5@(PVTL?G48
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M ,7_ /DH?PQ_["I_]&V]>P5X_P#%_P#Y*'\,?^PJ?_1MO7L% !1110 4444
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M&LY/W%_6Y6OH[34+O4KNQCMK"UA4216QD;++O5 J[BQ9_FW$9Z!B.!BNFM?
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MS>@;;G SC.,X% &A7C_P@_Y*'\3O^PJ/_1MQ7L%>/_"#_DH?Q._["H_]&W%
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MHP>XZY(%=W7,^)_ ^D^)T,DJ?9KT9(NH5 9CMP-_]X# ]^, C)KB=-\2Z_\
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M_P!GVW_".KJ/VW-TUR\/V4(#M150[RV[(R7P!MYVMSQBN]9++XA>.M>DS/\
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M_P#85/\ Z-MZ]@KQ_P"+_P#R4/X8_P#85/\ Z-MZ]@H **** "BBB@ HHHH
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MY&<_X(^#]5\*:)JE_K%O):S7YB*6S@;EC120QP>"3(1M(!&WGKQL_%#QC?\
M@[P_IVK:;!;23RW(B*W*LRA61C_"0<_**PQ%:>)Q"H4K/=+YH:M%79:\?^-D
M\&>'H]4FLFNV.H);11(^P$X9LLW.!A6Z \X'N/F#QGXC_P"$M\6ZMKGV3[)]
MJ6/]SYF_;MB5/O8&<[<].]6O%7Q!\0>+;?[-JE[&]F+W[0MND*(L;X8<'&[
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M07<UY!<PQS0MLW1R(&4XY&0?>KU( !G Z]:6O+<FS9*P4445(PHHHH ****
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MB@ HHHH **** "BBB@ HHHH *X/7_$,NI6OQ#T4P)'#I.E *X)+2-+!(Y)[
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MPP!XZ$Y_.OGOQC\3];\9:=9:7J-M8100R^:K6\;JQ(4J =SD8^8]JXR1L1N
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M=Q.AQ<C855D/S%=K$G&,XQN%?37AS3IM(\,:3IEPR--9V4-O(T9)4LB!21D
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MC7:I/:GT45F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI[PD$,&RDBL#T((W ],8'7/'H%>56K*"Y(>7X77ZEI!1117$4%%%% !1110
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M% !1110 4444 %>/_LX_\D\U#_L*R?\ HJ*O8*\?_9Q_Y)YJ'_85D_\ 145
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >/_M'?\D\T_\ ["L?_HJ6O8*\?_:._P"2>:?_ -A6/_T5+7L%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M9&OZQ#.((V$\+S,5:>4D,'YY9><YSR<=>13C'DU8F^;1'LE%%%8F@4444
M%%%% !1110 4444 %%%% !1110 5X_\ LX_\D\U#_L*R?^BHJ]@KQ_\ 9Q_Y
M)YJ'_85D_P#145 'L%%%% !17.^-?&%EX(\.2:M>QO*2XB@@3@RRD$A<]%&
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M/!WA_P .Z/-I.F:9''832^=)!(S3*SX49.\G^ZOY5NT4TVG= %%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \?\ VCO^2>:?_P!A6/\ ]%2U
M[!7C_P"T=_R3S3_^PK'_ .BI:]@H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C_[1W_)/-/_
M .PK'_Z*EKV"O'_VCO\ DGFG_P#85C_]%2U[!0 4444 %%%% !1110 4444
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \?^+_\ R4/X8_\ 85/_ *-MZ]@KQ_XO_P#)0_AC
M_P!A4_\ HVWKV"@ HHHH **** "BBB@ HHHH **** ,3Q?'ITOA34(]5G\BS
M>,*TVQF\MBPV-A>3AMIQ^?%>/>"/%T/@_4[R.>/[597&%>2 '=E-VUE#8R#D
M\'!Y![8/LWB71?\ A(?#]UI7VC[/Y^S][LW[=KANF1GICK7GW_"E_P#J/_\
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M:$1NMXVY!L<F1RHRP&04^\>>,CH_^$A^.?\ T)FA_P#?Y?\ Y(H ]@HKQ_\
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M)!@@$YP/NCGL0#Z#HKQ__A(?CG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\
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M^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D4 >P45X_\ \)#\<_\ H3-#_P"_R_\
MR11_PD/QS_Z$S0_^_P O_P D4 >P45X__P )#\<_^A,T/_O\O_R11_PD/QS_
M .A,T/\ [_+_ /)% !^T=_R3S3_^PK'_ .BI:]@KYD^+.J_$B^\*VL7C#P_I
MNGZ>+U&CEM9 S&78^%.)7XVECT[#FOIN@ HHHH **** "BBB@ HHHH ****
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MT:%W4,T4EQ(60D?=.V,C(Z<$CW-:<\E%/3[E_P .(YZY^,OQ NH6BD\12JK
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MQHOV[?9SVY5W\YF49R05P,'H<YK-_P"&<?!__02US_O_  __ !JC_AG'P?\
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MYRY[^E 'TW17C_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5
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M[3P,G;ANORMC'.=()6YF1)N]D2_#?Q-K.O\ BVX&IZA+.B6+;8^%0$2)SM4
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M2(V"0<,.#@@C\* +%%%% !1110 4444 %%%% !7C_P 7_P#DH?PQ_P"PJ?\
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MAAAE&X@$XZ"NTKR/X!>'[O3_  UJ6O7]M);W&LW"R(FQ(T:%02CHB@;06>3
MX& N !@GUR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?.GQ%^)=SXB\5:AX2BUJ/PYH-L[VE[<2PO))<E7"R "-6('#87*AAG<WS;0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM7F3B'9YNS&58YS@_P!W]::5W8&[$/Q!M;B]\#ZC;VL$L\S^5MCB0LS8D4G
M'/05X=_PB_B#_H!:G_X"2?X5Z!_PNC_J ?\ DY_]A1_PNC_J ?\ DY_]A6T5
M.*M8S?*^IPEMX/\ $EW<+!'HE\KMG!EA,:\#/+-@#\37HG@;X:SZ;?6^L:TR
MK/"S&.S 5PIZ*S-R,CD@#H=ISU%5O^%T?]0#_P G/_L*MZ7\6_[2U>RL/[#\
MO[3.D._[7G;N8#.-G.,T2<VM@7*>F4445@:!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>/+?0K
MG0X$\0WL]I:"Y4I) I)+[6P/NMQC=V[5U-<#\5= NM7T:SNK&VGN;BTE(,4(
MW'8XY.WJ2"J=.Q/U%1W%+8QO^$#\$?\ "/\ ]N_VOJ?]F_\ /?C^_L^[Y>[[
MW'2C1? ?@CQ#Y_\ 96KZG<>1M\SHFW=G'WHQGH:\_P#^$EU?_A'_ .POM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#
M_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]
M_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4
M>P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-4 >P45X_
M_P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\
MH):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W
M_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_
MPSCX/_Z"6N?]_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H
M):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'
M_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45
MX_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-4 >P45X__P ,
MX^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y
M_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^
M-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX
M/_Z"6N?]_P"'_P"-4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-4 >P45X_\ \,X^#_\ H):Y_P!_X?\ XU1_PSCX/_Z"6N?]_P"'_P"-
M4 >P45X__P ,X^#_ /H):Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-4 >P45X_\
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M^-4?\,X^#_\ H):Y_P!_X?\ XU0![!17C_\ PSCX/_Z"6N?]_P"'_P"-4?\
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M[!17C_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5 'L%%>/\
M_#./@_\ Z"6N?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-4 >P45X__ ,,X^#_^
M@EKG_?\ A_\ C5'_  SCX/\ ^@EKG_?^'_XU0![!17C_ /PSCX/_ .@EKG_?
M^'_XU1_PSCX/_P"@EKG_ '_A_P#C5 'L%%>/_P##./@__H):Y_W_ (?_ (U1
M_P ,X^#_ /H):Y_W_A_^-4 >P45X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\
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ME\4-$OM$U358K74!!IOE><K1IN;S&VKM^?!Y'.2*2KTWLR5B:3VD=M17F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7C_P (/^2A_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\ L*C_ -&W% 'L
M%%%,EECMX9)II$CBC4N[NP"JHY))/0"@!]%>,MX[\:^,-5N(O"%KY%K;Y;[D
M98J< >8TF5!."0JX[_>QFNJ\%:AXX_MF;3?%5I^Y^SM/'<^6OWMRJ$W1G9TW
M'&-W?I6$:\9.R3]>ASPQ,9RM%.W>VAWE%>)S>*?'^J>,M8TC0;SS?LMQ-LB\
MJ!=L:R;1RX&<9 ZYKI-'_P"%H_V;J_V_[)]H^SC[%YWE;O,SSM\OY?N[OO\
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M 4444 %%%% !1110 4444 %%%% !7C_[./\ R3S4/^PK)_Z*BKV"O'_V<?\
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M R?4U&%]IR+:WXF6"]K[..W+KZGFGQT_Y@/_ &\?^TZ]@KQ_XZ?\P'_MX_\
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M:CI]NDTME:Q.S13((H[D,68HLC=.%ZCD 9Z5PWCK_A,_] _X2[_II]F_U/\
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MBO8*\?\ A!_R4/XG?]A4?^C;B@#V"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&.U2QZ 9H 6D!##(((]
M143-NF@(SA@?Y5'&Q6WAP<9?!_6HY]?Z\C/VFO\ 7E_F6J*:C[]V!]UL4ZK3
MN6G<****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >/\ Q?\ ^2A_#'_L*G_T;;U[!7C_ ,7_ /DH?PQ_["I_]&V]>P4
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MGFH?]A63_P!%14?\+?\ &'_1)M<_.;_XQ1^SC_R3S4/^PK)_Z*BH ]@HHHH
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MI(ZIL M9C;KC)/*Q[03SUQGIZ"J?_"=^,/\ H:]<_P#!C-_\50!]OT5\0?\
M"=^,/^AKUS_P8S?_ !5'_"=^,/\ H:]<_P#!C-_\50!]OT5\0?\ "=^,/^AK
MUS_P8S?_ !5>J? /Q+KVL^.KZWU36]2OH%TR1UCNKIY5#>;$,@,2,X)Y]S0!
M]%T444 %%%% !1110 4444 >/_M'?\D\T_\ ["L?_HJ6O8*\?_:._P"2>:?_
M -A6/_T5+7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@W@[<^Y )QZ8]17E6I3,/AQX^<@';XAE 'MYT-4=7^)5KHWB;Q9)I2_;'O\
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MFY:YNU7<$";MSC(R0#]T<]2.:?9>"/%.M7<C-IMTCM(#+/>YCY8G+'=RW<G
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M_P!A63_T5%7L%>/_ +./_)/-0_["LG_HJ*@#V"BBB@ HJGJEO>W>FRP:??\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP' !!STK.2@Y:[^IE.--S7,]?7]#G]-\#7$-_HL^K:PFHPZ+"8[. 62Q@-P
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MW%;5K=0WMG!=V[[X)XUDC;!&Y6&0<'GH:Y#Q1JUT-2UW1LJ;,^&YKH K\RR
MNO!]"".#Z#&.<[WA7_D4-%_Z\(/_ $6M>E0C&$I1CU;?S/8PT8TYRA#9MOYF
MO11174=@4444 %%%% !1110!X_\ M'?\D\T__L*Q_P#HJ6O8*\?_ &CO^2>:
M?_V%8_\ T5+7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %>/_"#_DH?Q._["H_]&W%>P5X_\(/^2A_$[_L*C_T;
M<4 >P4444 0W<<TUE/%;3_9YWC98YM@?RV(X;:>#@\X/6N,\/> ;_1=8O;RX
MU]+ZWU%F:_M7L$5;DD/U.XX&7)P!@].E=M++'!"\TTBQQ1J6=W. H'))/85F
MZ+XETCQ#Y_\ 95W]H\C;YG[MTV[LX^\!Z&LY*#DN;?H93C3<US/7IJ<W8_#Z
MXM$TNRDUYY=(TR^-[;VWV55DW EE5I,\@$D_=&=S=/EV];JUC_:FC7VG^9Y7
MVJWD@\S;NV[E*YQQG&:R[;QMH%WJ:V$-[EY)#%%*8V$4L@ZHKXP2/E]CO7!.
M:+GQMH%IJ;6$U[AXY!%+*(V,44AZ(SXP"?F]AL;)&*B,J,5HU;U(C*A&.C5M
MMR.Y\*?:-&\.Z?\ ;=O]C7%M/YGE9\[R5VXQGY<_CCWJG<> ;:\T'6]+N;O?
M_:6H27\<PA&;=VQ@#).<8P2,9!(XS6GJOC'1-&OC9W=TWG(H>811-(($/1GV
M@X!.T>N77C!S6U%+'/"DT,BR12*&1T.0P/((/<52C3DVD-1I3;2U9QDGP[A\
MKPK%!?>2F@R>:1Y);[0Q9'8\M\N64GOC=[5VU9^L:WIV@6B76IW'D0O((U;8
MS98@G&%!/0&C^W-,_L3^V?ML7]G>7YGGYXQTZ=<YXQUSQC/%./LXMI%1]G!M
M)V9H45GZ/K>G:_:/=:9<>?"DAC9MC+A@ <88 ]"*T*M--71I&2DKIW04444Q
MA1110 4444 %%%% !1110!C>*]:D\.^&[G58H5F:W:/,;' 8&15(SV."<'U[
M'I7'7C$ZI\4U)X73H<?^ KUN_$W_ ))YJG_;+_T:E8%W_P A;XJ?]@Z#_P!)
M7KFJ-\]OZVD<E5MU+?UM(\P\6W%IK,_A^&SO;=I+;1+2W<,^U?-SRFX_*" X
M))( P03D8IGASPM>_:/#^M7EM"VDWFJV]L@D96\[,A##;SP-C [L9R,9YK&L
M_#NM7][!9VVEW;W%Q&LT2>41NC8X$F3P$R?O'CWKU/2@3\-/A_@$X\0Q$_\
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M2A_#'_L*G_T;;U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDFI/T-924GZ#D0L(&&,*O/Y5-3(O]2G^Z*?6D5H;15D%%%%44%%%% !1110
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M9P2KMDC@1'&<X(4 U:HJZ&$IT/@OV-,-@:6&MR7VMKZW_KR"BBBND[ HHHH
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MKC';7\S7HHHKK.X**** "BBB@ HHHH \?_:._P"2>:?_ -A6/_T5+7L%>/\
M[1W_ "3S3_\ L*Q_^BI:]@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH \?^+_\ R4/X8_\ 85/_ *-MZ]@KQ_XO_P#)0_AC_P!A4_\
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MG^(UA80^3:Q6$6Q-Q;&;>0GDDGJ35RU_Y"?PT_Z\)O\ TF2NJE047>6NJ_\
M2K';1PR@[RU=U_Z58R--_P"2>>!?^P]%_P"C9:-2_P"2>>.O^P]+_P"C8J--
M_P"2>>!?^P]%_P"C9:-2_P"2>>.O^P]+_P"C8JO['_;O_MII]C_MW_VTU_%7
M_(WZU_V*4_\ Z,:NL\*_\BAHO_7A!_Z+6N3\5?\ (WZU_P!BE/\ ^C&KK/"O
M_(H:+_UX0?\ HM:ZJ7\5G91_C2^?YFO11172=@4444 %%%% !1110!X_^T=_
MR3S3_P#L*Q_^BI:]@KQ_]H[_ ))YI_\ V%8__14M>P4 %%%% !1110 4444
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M!'F9_OFI:VCL=,/A"BBBJ*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \?^+_\ R4/X8_\ 85/_ *-MZ]@KQ_XO_P#)0_AC
M_P!A4_\ HVWKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBL?Q5XAM_"GA?4-<NEW1VD1<)DCS')PB9 .-S%1G'&<G
MB@#8HKQN#XS>*KJWBN+?X5ZS-!*@>.2.25E=2,@@B#!!'>NH\7?$N'P=X*TS
M6[_2Y/[0U!(S'I;S"-T9E#.&)&0$Z$[>I4$#/ !WE%>+Z%\7/%EIXHTS1O&O
MA3[$NJRQ16LT$3Q;2X'4.6#\O&& (*<Y!/%>T4 %>/\ [./_ "3S4/\ L*R?
M^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_145 'L%%%% !2!@PRI!^AH8!E(/0U .(9L
M#^(\4F[$MV9.'5CA6!^AI:JXVFW*@ GK@?2D$LIA\S>/E.",=:GG[D^T[EK<
MN[;N&[TS065?O,!]35:129)6&,H5;]*9.?,RX/R [12<["=1I,NT445H:A11
M10 4444 %%%% !1110 4444 %%%% !1110 5\H?$?XP?\+ \/6^D_P!A?8/)
MNUN?-^U^;G".NW&Q?[^<Y[5Z?\6OBUK'@3Q#9:3I-A8R^;:"YDENP[9W.RA0
M%9<8V$Y).<CICGYD@@FNKB*WMXI)IY7"1QQJ69V)P  .22>U 'H'P[^$VI>.
M[>/5$N[2'2XKT6]TK2,LY4!&<I\C+G:_&3UZU]<R-LC9N. 3S7EOP#TG4M&\
M"WUOJFGW=C.VIR.L=U"T3%?*B&0& .,@\^QKT=V8M?J6)54&!GI\IJ)RY414
MGRK^NUQ)9RLB,I&YH@>/K52*5W2V5CD><#^IIJ,QD3)/^J Z]J><1:;;S*HW
MB3.3[$UQ.;D[_P!=#SG4<W?M_P  9/<;4N+<+RTS$GVS_P#6J0/%/--*B!2;
M=BP]&KG?$&NKI%EYS(LL\L@V+D GG+?AC\B16G>ZSINGVD]Q%*&4:<+A%((,
MBNV$/3/)P.G&1G%91K)R=WM_P3"-=2D[M67_  2_?7T&FV=M>W#8BAA9VY&3
M\HX&>Y/ ]S7E;^+;H>'=/TZW9XYK:Y:>28G=YAW;T/O\Q)((/*J:FU[Q0/$)
MTNT:5[2U2-$NFVG&\D;FVACN48! Z]:M0>#K2WAT_4;B_6XLYKSR60QF,&/<
MPW%MV1D+GVSUXK@Q&(G5DU1>B7^5_P!#S<5BZE:;5!Z):N_3W;^>Z1SEJ;XS
MM=!I'\XGS6,G,@)R<\\\C//< UW5A8Z9J?C1HK.>*2U5?M1BQ@[<@;=I7IN(
M'3&.^:HZCI>EVTNI'3984BA>(Q1B;<) R_-MSDD@X[\<UH^'],_LKXCQ0,,3
M-H/F2_[QGZ=3T&!QZ9KEPF&E4Q')-)Q3W]&U;YZG%@L)*MBN2HDXIIW]&TE\
MW?U2,[1]>"0^!+B[GAM+64WS3-(RJN5#*/F/09/3/7'4@5S>K>*].30?%>AH
M)99[[5Y;B&:/:T13S$(.[.>0AZ ]161KEU;R^!?"EO'<1//!]K\V-7!:/=*"
M-PZC(Z9KF*]&57DBH1VLO_24CU95O9Q5.&UE_P"DI%XZUJK-<L=3O2UVH6X)
MG;,P P _/S#!QSVJC73Z/X,N-1L->GNY9;"?2+<3-;RVYW/E'8 Y(*\*.QZU
MV?PXT3^Q/%]O_I'G?;M!6]^YMV;Y$^7J<XQUX^E*%&<VK[,5/#U*DDI;/^OS
M,#3_  AIC^&_#&KRM<22ZCJL=K<0LX$9C,CJ<8 8'"#G/<ULW%K#9?#'QG:6
MZ;((-:>.-<D[562$ 9//05-IO_)// O_ &'HO_1LM&I?\D\\=?\ 8>E_]&Q5
MTJ$5&Z7V?T.R,(QA=+[/_MIKW7_(3^)?_7A#_P"DST6O_(3^&G_7A-_Z3)1=
M?\A/XE_]>$/_ *3/6SH6BQWVG^$-5>9U;3M.&R-1PYDB1<D^@ /'J1SQ@]$8
MN3LN_P#[<=48N4K+O^4SC]-_Y)YX%_[#T7_HV6C4O^2>>.O^P]+_ .C8JFT:
MUN+KX>>"OL]O+-Y6M)+)Y:%MB"67+''0#UK1TO1/^$C\/>,-)^T?9_/UZ?\
M>[-^W:\;=,C/3'6LU%RBDNJ_0QC%RBDNL?\ VTEU^UFO?'>J6ENF^>?PM+'&
MN0-S-*0!D\=375>&XI(/"VD0S1O'+'90JZ.N&4A ""#T-6?[,L_[8_M;R?\
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M&#VP((/((/:O5O#?_)5/B7_N:=_Z3M6\TG%W.JI%.+N=U$ 19G'(3C\A0O\
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M"K*>#@XR,]#P30!X9I-M\8? 7@Z"XAM=-CTO2$F,NG2M&[/'\\K3.P.2 6(
M5P?E'RGDF/XF>+/^$U^!&A:S(D$=T^JK'<PPR;A'(L<P/NN1A@IY 8<GJ=">
MS^,Z>"[[PE)H\%^LF^W_ +5>^CDEEA8OOSYDF3N#  D*548QG!7?N/@Y]H^#
MUIX1^VP1:G;2F]^TQ1[8Y;@[N'XW,NU]F[KA5..-M &?\:(=&D^"FD/IUUY-
MA%+:OIJ>6[><GE,$3+<K^[);+?W,'DUL#Q?K'A3X>>"O[)\)7VO_ &G2H?,^
MR%_W&V*/&=L;?>W'KC[IZUQEUX/^*'C#0=#\'ZUHVFZ7H]@\(^W+*KNBQQE
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M** "BBB@ HHHH **** "O'_V<?\ DGFH?]A63_T5%7L%>/\ [./_ "3S4/\
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M([%B<4W4M371=&U&[N //\L)&K8RSL#@=1GU/? )KDO?6]DO^"<'-?6]DO\
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M^2A_$[_L*C_T;<4 >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU7AR\S=CH_%__(E:]_V#KC_T6U'A#_D2M!_[!UO_ .BUKSGX@?%6RDTC^S=
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M_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\ L*C_ -&W% 'L%%%% !1110 4444
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MP#>+"9O)74F* XXR<G.#@ 9/X5#\(+FXN/%LJW%Q+,(=,,,?F.6V()(\*,]
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M4445L= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >/\ Q?\ ^2A_#'_L*G_T;;U[!7C_ ,7_ /DH?PQ_["I_
M]&V]>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5X_\ LX_\D\U#_L*R?^BHJ]@KQ_\ 9Q_Y)YJ'
M_85D_P#145 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !7'^.?'.C^
M'/#VM*NO6-OK,%H_D6_FH\RS,G[O]UR3R5/(QCD\9KG_ (H_$R#PQIUC+H>L
M6-Q?0:K''?6,,\3R-"H?S(V&&*9*A2V,@U\V>,/$LWC#Q9J&O3V\=N]VZD0H
M20BJH11D]3M49/&3G@=* (_$?BG6?%NHQW^N7GVNZCB$*OY21X0$D#" #JQ_
M.J^B:)J'B+5X-*TJW^T7L^[RX]ZIG:I8\L0!PI/)[5>\.>'[?78[XSZDMDUN
MB&-3%O\ -8MC'48P,G/MBNILK2RTN2PNM-@DM-0MHBLEW%<.&D<Y!8#/RY4X
MP*Y:V+ITY..[.*OCZ5&3@]6C;T?P+IGAOPMX<\7W3WAUR.^6=[/SX_*(CE;&
M,*3T5,G)^][UO:U\1[[6+74+8VD<<=TT93+;FB"@9&0!NR0#DCC)'/&.'>X3
M(8ODL>N?UJ&2Z4*X0_,.A]:\RI6JU=);'CU<16KZ2V[=.QMZAK^JZK<FXO+V
M1Y6C$3%0$RH.X A0 >>:S 0PR""/457ENE"_NCDGVZ5<\.7^F6FL6S:W:R7.
MF+N\Z*$D.V5.W'S+_%@]1TK-4W)ZF,:4I.[ZC4 :159U0,P7<YP!DXR3Z5WV
MB>!H$O\ Q-::T\;MHULDI>*4A=S(7') ^7 YSBN&U?7UNEGL;"TM;?3/,?R0
M;6,SE#(SKND(+[@"%X;&% YY)8/%FNBYU2X_M*9I-4C:*\+ $2J1C&",# R!
MC&T<# K14H:J1M&A3LU-W]/G_P  ]UT>;2;;Q'IZYCC":$-0:7=A%!;!=FSC
MD,?8 =L"L2Q^),,7AWPNZ76FVMY=ZD4OK6/[D5N7=6)R28^J,,D>WR@BO']9
MURYUS^S_ +3'"GV&RCLHO*!&43."<D_-SSC ]JI06=S=8^SVTTN9%B'EH6R[
M9VKQ_$<' ZG!K6DXT5RTU_6G^1O0<,.N6DOZT_R/;;7QY:Z7X?\ $]Z;RPO;
MF+79'M;5YD!FA\R/!0#D\;B&P>1GG%9<OQ:MK;6/%4UO<:C+'=QHFE':&2%U
MC92^UV^4%L-TR1U&>*\@K3LO#VKZA'>26UA,R65O]JN&8;!'$5W!LMCJO( Y
M(Y&:T566BBOZU-(UYI)05K?\'_,]?T3XT:?)<Z?:ZFLT4(L@+N\>+):Y &2%
M3.$.&Y SEAPH!KG[SXO3W>AZ3G[6NK6VHBZNQ"1##-"&<^4""3C!0<@].<]^
M)M_!VOW>H6=C;Z<\EQ>6BWL*JZ8,)SAR<X4<8^8CG ZD5#;^&=9NM/L[^&Q<
MVM[=K9V\C,JB64YP!D],@C=TR",\4W5JM6*=>NU;^NAT=O\ $S4+*PURWLK?
M[-)J.HG4(9TE^:W8NK,IXPX(4+C ZG.0<5IZS\7)]3DO1'93):7VE/92VC3@
MK%,6?$JG;S\K#(PN>A^Z#6,GPYU.;P_JNH6TGVF[TS47L9;."%G,FW:"R$<G
MENA4< G/:JNH_#_6],UF[TR<6[26M@^H/*DN4,*@Y(R,YW#;C'7VYHYJR0<U
M=(K)XV\0I+I4JZAA])C:*R/DQ_NE*!"/N_-\H YS5G2?&MW:6>B:5>*DFF:9
MJ<=^NQ/WH"L25!R 1\S'GG)ZXK9TKX;1/J7A.+4KYVBUZ&:=DME"M"JQ!UPS
M9R2&7/R\<CGK7.CP;J[Z'I&K0I#-;ZK<&UMU63#"7<556!P!DJV""1QSBIM4
M6O\ 73_@$6JK7^NG_ -S6_'-CJR>,2MK<1-K36@M@=I"K"1DN<\$@ X&>3C/
M>N<_X2WQ!_;7]L?VO=_;^GF^8?N[MVS'39GG9C;[5=U/P/J>E?V[Y\]HW]B_
M9_M&QV._SL;=F5&<9YSC\:W].^%%R_BN;P]J>H0PW!T[[;%-; R*/WJIA@P4
MGC=TQV.>U-JI)_UW?_!&U6F_Z[O];G%7FLW=]I6FZ9,4^RZ<LBP*JX.7<LQ)
M[DG ], <=260:3J%QIESJ45G,UC;8\VXVX122JXW="V77@<X.>E=9X;\"6VJ
M7/A5KR]F^SZY]KWI"H5HO)!QACD') [?XUZ?%\.YXO!6N^&X9[>"*_U/S[=E
M9G$4&^,@'(R6"H>,\G'/>G"C*>K_ *TT'##SJ*[_ *TT/%W\$^(4EU6)M/P^
MDQK+>CSH_P!TI0N#][YOE!/&:I7'A[5[7RO,L)F\VR%^OE#S,6YZ2';G:/7.
M,=Z^@=2\.WT'_">:@H29=7L%2VAAW-(62!D((QU)(QC.:Z/PY:3V'A?2;.Y3
M9<6]E#%*F0=K*@!&1P>1VK585-V_K<W6#3=MO^'/G'P5X'OO&6H-%&SVME&K
M&2\:%G0,,?(.@+?,#C(XR?8]9:_ O6'1S>:O8Q,&0((5>0%2?G))"X('('.3
MP2O6O=:*UCA8):ZFT,%32][4YSPWX,TWPIJ&HSZ5OCM[U8A]G8EA&R;LD,22
M0=PX/0@\X( VIM.M)]0MK^:W1[JU5U@D;DQA\;L>Y"@9ZXR.YS9HKH44E9'4
MHQ2LEH%%%%,H**** "BBB@ HHHH **** "BBB@#Q_P#:._Y)YI__ &%8_P#T
M5+7L%>/_ +1W_)/-/_["L?\ Z*EKV"@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O'_A!_P E#^)W_85'_HVXKV"O
M'_A!_P E#^)W_85'_HVXH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 9)+'"H:6144LJ@LV!DD #ZDD >YKR+QL08/B0 1D?V9D?BM=GX[_P"9:_[#
MUK_[-7#^,O\ FIW_ '"O_9:Y:TKZ=O\ )G'B)<UUV_\ D6=E_P UJ_[EW_VX
MKYUNM6O;R"T@FN',%FK+;Q9^6,,Q9L#U)/)Z]!T QZ]_PL?PW_PM7^U?M,W]
MG?V5]B^T^2V-_F>9G;]['\/3.>V.:\;B6-VB7&2<[NOX5S8B<7MY_H<>+J1>
MJUW_ $-/PY;Q7^OZ3;7*;X;C488Y5R1N5F (R.1P>U>L^5I7AJ3XA:= 4M;?
M['"D$1<L2S0OP,DD_,WX9]*YSPP([7P/I,LS;8HO%T,I(R< 1J?Y53^(%U'J
M>L>*Y[*02P-:AMV,?=@P>O/!S7/*I&E!--<S:^YZ'+.K"C!.+7,VON>GW:_>
M8ND?;V\?V3V]K)<O#I22K#Y9=2!(!RH[' !]:\GEO;N>TM[2:ZFDMK;=Y$+R
M$I%N.6V@\+D\G'6O0#XHUOP#K&C:I!;VTEQ=Z!"%%T"X:-VW;OE8'.5[GUXK
M ^'?ARS\7>.]-T._DGCM;KS=[P, XVQ.XP2".JCM7;@J#IQN^MOPN>CE^'=*
M%WU2_"Y8T[P+]O\ A?JWC3^T?+_L^[6V^Q^1GS,F(;M^[C_6]-I^[[\>T:M<
M>3K_ ,94"Y:33+8?0?8WS_.N9EL;?1/@5\0M)@D=HK7Q&]M"9""[*DMN 3@
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M% !1110 4444 %>/_LX_\D\U#_L*R?\ HJ*O8*\?_9Q_Y)YJ'_85D_\ 145
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M **EKV"O'_VCO^2>:?\ ]A6/_P!%2U[!0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7C_ ,(/^2A_$[_L*C_T;<5[
M!7C_ ,(/^2A_$[_L*C_T;<4 >P4444 %%%% !1110 4444 %%%% !1110 5#
M)=6\5Q#;R7$23S[O*C9P&DVC)VCJ<#KBIJX>]U.SUGQEX)O[";SK67[=L?:5
MSB/!X(!Z@U$Y\J^[\TC.I4Y$OE^:7ZF+J>K7NH?8_M<HE^S^-TM8OE VQKG
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MQG&1N5_$MXQ..ARG->DE"9;[/ 9!@_\  37+=.7N_P!77_ 1PW4IOE_JZ?\
MDA;9?WL+Y_Y=P*5?^/>#_KH/YFG0#;)&/2$"B-"]O#CL^3^M7%:?UY&T5I;^
MNA8"A<X&,G)I:**Z#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \?^+_\ R4/X8_\ 85/_ *-MZ]@K
MQ_XO_P#)0_AC_P!A4_\ HVWKV"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'_V<?^2>:A_V%9/_
M $5%7L%>/_LX_P#)/-0_["LG_HJ*@#V"BBB@ HJI?:KIVF>7]OO[6T\S.SSY
MECW8QG&3SC(_.N9O_B?X5L1*%OGNI(VVF.WB8[CG!PQPI'?.<$=*B52$/B=C
M.=:G#XFD=C17@7B3]H&XMM5O+/3+,1VP4"*26#,JDH,G_6;<@DXX(Z9K@]9^
M,OBK4?*$.JW2!-V2N(<YQ_SSQGIWS_.H]K?X4W^1'MV_ABWY]#Z9OO''AC3X
M/.FUNS92=N()!,W0GHF2!QUZ5XGXR^.=_/#JFG:3/;(HG*6\\,<T<NQ9.#NW
M#!('/U->+W>IWE[&([B;>@.X#:!S^ JI1R3E\;MZ"]G4G_$=O)&QK/BC6=?N
M!/J&H7,SB/ROFF=LKDG'S$^IK'KH_"O@7Q!XT^U_V%:)<?9-GG;ID3;OW;?O
M$9^Z:]I\'_L^64$J7?BEC<J4)^Q1SD!20,;V4 DC+<*<94<L#Q:M'1(T7+#W
M8H^=41I&"HI9CT"C)KJ] ^&GBKQ&DDUEI;K;P7GV*YDE=4,$@*A@R$[_ )=P
MSA3W]*^I]!^'GAOP_%8M;:59?:[1RZW2VRB0G!498Y;H?7J,^M=72BYRC=JP
MH.<HW:L_O/"-)^ %Q#]H2YU."U8["CP*TRO][((8J01\OY_EUWAWX-:)I,XN
M-3G;595;*(\?EQ#!!&5!.X\'.200<8KTFBI5""=WJ_,B.&IIW>K\S+LM(MX-
M,M+5+>.&.WF,JQA!A3N)X';DGI6B\22(R.H*MR>V:?15QIQBK)&D*4(1LEY"
M8&<X&3QFEHHJS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_VC
MO^2>:?\ ]A6/_P!%2U[!7C_[1W_)/-/_ .PK'_Z*EKV"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=,%@N)@S+S\K?=/7'7FG&E".R*A0IP^%?UZG@]=!_P ()XP_Z%37/_!=-_\
M$U])Z;\!O =C;M%<6-WJ#E]PENKMU8# ^4>7L&.,],\GGI7IE:&I\P:'^SQX
MDU**RN;_ %&QL+6XB65U*R//#N7(5HRJC<#@$;ACGKC!]7\*_!3PKX>@T^:Z
MMOM^KV4HF%_YDL6YU?<A\L2%1CY1WSCGK7I%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \?\ B_\ \E#^&/\ V%3_ .C;>O8*\?\ B_\ \E#^&/\
MV%3_ .C;>O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N+^)GCZ'P!X:%XL4=QJ%RYBL[=W !;&2[#.2B\9QW*
MC(W9':5XO\;OL?\ PF7PZ_M'R/L/]H/]H^T8\OR_,M]V_=QMQG.>,4 1Z?\
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M>/\ _"0_'/\ Z$S0_P#O\O\ \D4?\)#\<_\ H3-#_P"_R_\ R10![!17C_\
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M]"9H?_?Y?_DB@#V"BO'_ /A(?CG_ -"9H?\ W^7_ .2*/^$A^.?_ $)FA_\
M?Y?_ )(H ]@HKQ__ (2'XY_]"9H?_?Y?_DBC_A(?CG_T)FA_]_E_^2* /8**
M\?\ ^$A^.?\ T)FA_P#?Y?\ Y(H_X2'XY_\ 0F:'_P!_E_\ DB@#V"BO'_\
MA(?CG_T)FA_]_E_^2*R/$?Q*^+7A'3H[_7/#.AVEK)*(5?)DRY!(&$G)Z*?R
MH ]WHKQ__A(?CG_T)FA_]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(H ]@HKQ_\
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M* "BBB@ K'\3^)]+\(Z'-J^KS^5;Q\*J\O*YZ(@[L<?H22 "1L5X_P#M'?\
M)/-/_P"PK'_Z*EH CM?CK<Q/876O>"=2TG1;MU4:DSNZ ,I*LH,2AP0,\'.,
MD XP?8()X;JWBN+>6.:"5 \<D;!E=2,@@C@@CO7C?QHAT:3X*:0^G77DV$4M
MJ^FIY;MYR>4P1,MRO[LELM_<P>36P/%^L>%/AYX*_LGPE?:_]ITJ'S/LA?\
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MK9^']/LTTQ8;&*,:>7,!7K'N4J>>IR#SG.3R>17F_P#PM_QA_P!$FUS\YO\
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M* "BBB@ HHHH ***Q[?Q3HUWXHN_#4%YOU>TB$T]OY3C8A"D'<1M/WUZ'O\
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M<$BM?8@# *N&Y88ZTZBBPK(3 SG R>,TM%% PHHHH **** /'_VCO^2>:?\
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M "BBB@ HHHH **** "BBB@#D_B'XXA\ >&EU:6QDO7DN%MXH5D" L0S99L'
MVJW0'G [Y'GEM\8O%GAW7--B^(/AV#3=,U"+?'-;PN'CSCYB"[9V_P 28#C<
M#CH&S_VFO^96_P"WO_VC6W^TA!"W@73+AHHS/'J:HDA4;E5HI"P!Z@$JN1WV
MCTH ]DHHHH **** "BBB@ HHHH **** /&[OXC>/]9\8Z_I?@KP_IM]9Z1<"
MWD:[^20-RI)S,H(+(^,#H!G!KM/ NH^.;_[?_P )IHUCINSR_LGV1PWF9W;\
MXD?IA/3J>O;SB3X3?$3^UO$%_IOB2QTC^U;LWABL[N8%G\QBJ-((U8*%DDZ9
MR0N5[KU?P;\;ZOXKTO5+#Q"LAUC2K@),[P"(E6W8#*,8=61P1M' 7J<T >F4
M444 %%%% !1110 4444 9^MZWIWAS1Y]6U:X^SV,&WS)=C/MW,%'"@D\D#@5
MY_X)^*LGC;XE:MHUC% ="M[1IK6<Q,DTA5HU).6QM)9B/E!QMS@Y%>D7UA9Z
MG9R6=_:07=K)C?#/&)$;!!&5/!P0#^%>/^$+"STS]I7Q39V%I!:6L>E)LA@C
M$:+D6Q.%' R23^- '6?$OXAS>!K?3K>PTJ34=4U1Y(K2,$[0RA0,@?,QW.F%
M&,\\CC/-^'?BOX@M/',?A7Q]HL&F75WY:VDEHC%=[G"@_.X96/R[E/RL"#W*
MX'Q3_P"3A?!7_;C_ .E;UH?&**WC^*?P_N;-8)-7:[C5XWG*[D6>,Q!L [5+
M-+\P4]^NW% 'M]%%% !1110 4444 %%%% 'E?CSXV:'X>L+^TT2ZCO/$%O<?
M9_LTMM+Y<;*^)"Y.T$ !@-I/)';)KT#PUJ4VL^%=(U2X6-9[VRAN)%C!"AG0
M,0,DG&3ZFO/_ (S^&M!MOAKKVJ0:)IL6H%XG-VEJBREFG3<=X&<G)R<\Y-=9
MX3^V?\*LT/\ L[R/MW]B0?9_M&?+\SR%V[]O.W.,XYQ0!YIH?Q,^*GC"WN=1
M\-^%=&GT]+AH5\R3#(0 VTEIDW$*R\A0#[=*]/\ !5YXKOM&FE\8:9::?J N
M&6.*U8,IBVKACAWYW%AU[#BO'+7X5_$SPCX>GETKQ-!%]BE:]CL;"24_:&V?
M-D;!O;]W&JHP93D].=WI_P )_&-QXV\#0W]]S?V\K6MTX0(LCJ 0P /=67/3
MYMV !B@#N**** "BBB@ HHHH *YOQQXSL? OAJ35[Z.28EQ#;P)P9I2"0N>B
MC"DDGH <9. >DKG_ !9X7\.^)=.7_A)8?-L;/=.=]W)#&F!R[;64<#/)Z GI
MDT >86WQ<\<:'+IM[XV\*06.B7\OD"X2*6)X3N 9F4EVX4,0A52V,@X%=7\4
M/B3-X*2PT[1[.._U[47 @MVRX1=P&2BD.Q8G:H&,D-S\N#PGBG6+CXZ:Y9^&
MO"R3PZ)82F>^U"XB 3/*HP7[WW=VU206WG(4*6!XXL=+TSX^> [!HYX["UM+
M.&W2!LLI6:00@ENJA@F[OMSWH Z/PO\ %'Q''X\3PEX[T:TTN[ND4VDD!VIN
M() )+L&#8V@J?O#;@DG;ZY7A'Q6^Q_\ "]? FSS_ +=YMKYN['E^7]I^3;WW
M9\S.>,;<=Z]WH **** "BBB@ HHHH *\;U;XJ^+]4\8WWA_P/X5CO#IUQ);W
M-Q=@LI9<C)(95C&4DQN8[N.AXKV2O+]?UWP3\&?M4UK9SR:OJ_[Y[=;J2628
MKO(DD:1CM4LS#=R22<!MIP ;'PU\?2>.-.OH[ZP_L_5]-E6"\M?FX)'WL,!M
MRRR#9DE=O)YK@/#GQ*^+7B[3I+_0_#.AW=K'*86?)CPX )&'G!Z,/SK;^&'@
M[Q7I7AKQ+K5_<QVWB+Q$AGA2:, P2XD*O(,$ EI,E-OR@#(R2HYB+X?_ !+\
M"^%9[VQ\4Z;:0:0DUV+:U!VS*48RM)F,"1P%4*'#8[%=HR >U^%KC7;OPY:3
M^);*"RU=M_VB" @HF'8+@AFZKM/4]?PK8KB_A7XMF\9> [/4;R:.74(G>WO"
MD90>8IX..F2A1CMXRQQCH.TH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J>FZ3INC6[6^EZ?:6,#/O:.UA
M6)2V ,D* ,X Y]A5RB@ HHHH **** "BBB@ HHHH **** *=YI.FZA<6MQ>Z
M?:7,]H^^VDFA5VA;(.4)&5.5'(]!Z5<HHH **** "BBB@ HHHH ***IQZMIL
MVJ3:7%J%H^H0IOEM%F4RHO'+)G('S+R1W'K0!<HHHH CG@ANK>6WN(HYH)4*
M21R*&5U(P00>"".U5]-TG3=&MVM]+T^TL8&?>T=K"L2EL 9(4 9P!S["KE%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7.KP6]]81+-=+.&C2)&V $R, G)D0=?XJKZ/\1?".OZX^BZ7K<%S?KOQ&JN
M^W[VQB K^ORDY )' S7F \,:7XH_:<UZ'5X/M%O9VD5VL#?<D=8X% <?Q+\^
M<=\#.1D'J_B_I.FZ;X!DUZRT^TM]4T5[1M.N8X5#6^R9 JCC!0!C\AROMP*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=><8Z&H_%_@^V\6V]BS7,EEJ&G7 NK&]BC1VAE ^7(8'<F[:2O&=HYXKI**
M//\ ^Q/B3J7_ !+=3\2Z59::ORM?Z9;.+VY0?*0=_P D3,I+;DSM8#'%=AH>
MC6?A[0[+2+!-EK:1+$F0 6QU9L  L3DDXY))K0HH *\S^"4\UMX3U#PW=RVC
M7>@:G/9,L#$DKNW;SGG!<R ' R%Z9!KTRL^TT33K'6-1U:VM]E]J7E?:Y=['
MS/+7:G!.!@'' &>] ')W_@G5]*\0:CXB\%:G:6EYJ+J][I]_;AK6X91M!W(
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MYXKT"LN/P]ID7B6;Q"L$AU26W^RM,T\C 19!V*A;:HRH/ '.3W.=2@ HHHH
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M]62 P#%3R?NCZGN* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gjnp4w4lrub1000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Z [ # 2(  A$! Q$!_\0
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M44 %%%% !1110!!>_P#'G+_NUP.A_P#(VK_GO7?7O_'G+_NUP.A?\C:O^>]
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M:8ES YPLJ$^S5Y_K?B9XA9VDC;4FC&Y@>1Q69+?PZ8(I=/N7FED<*RLQX&:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<J#ZBEH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6?8NX'-5=1T!;V0R*X1CU-;=% &1I^@6UF,F-6?^]5>]\-K=7!E5PN>M;]%
M&*FDPZ982&"(&3V[U4T+2Y8]1>_D)!D&-I[5TM' H BN(O/A:/.,USDWA"*:
M;S'8$YSS7444 9D.CQ)9-;2 .K=C6<OA.W6?=\OE@Y">E=)10 R*)(8PB*
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MB/+<-]UR.OUKI3JMN(C(3P!F@"]16"OBS3V;;ELUMPRK-$LB_=89% #Z***
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M@!*6BB@ HQ110 4444 %%%% !1110 4F,TM% !1@444 %%%% !1110 4444
M%&!110 4A&1BEHH KI9PK)YFQ2XZ'%6*** "BBB@ HI,@]#2T 5-1L4U"T:W
MD^ZU26ELMI;)"G11BIZ* *>H:?%J%LT+@8/?%8\7A-(Y 3<,R@\*>E=)10!3
MBTVVAE61(D# =0*N444 %9^I:5%J2*'P"O0XZ5H44 <];^%HXI0TLQE7^ZU;
MT<:Q1JBC"J, "GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2K:+1[0(@&Q@10!W,4BRQJZG((S3ZP_#$[SZ?\YSMX%97]L77]O2V_F'RU;
M% '8T5QNK:Q=V_BJSM(Y"(G0$C\J@UK5;^XD\BRN!"ZGDL< T =QFJ.JWZV-
MJS$@,1Q7!:7>Z]'XDM[6XO!+$PR=O([>]:?C*>6:2T@A;D2 -CZT /T_Q1<^
M4_FQ '=Q]*Z^SG-Q:I*1C<*X/78H]-6,XP-@)_*ETC5K[5-L5G+L6'E@>XH
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MY\ W21H  /I5"'6IQHD%D$'G?=9?3-=]#86\$)BCC 0]15<:'IZS>:(!O]:
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48'I110
M4A /4"EHH 0 #H!2T44 %%%% "$ ]0#2X Z"BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[:,'!YJYX%\ 232+?ZDC!]VX \C!J;P)X!+[-0U !RXSM8<@UZY!"D$2HB@
M#% #;>WCM85CC4!1Z"IJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K$\2ZC96.F2F\8!,<\5MUQ?Q"BC.B3R.PX'W3WH X!Y
M=$GN?M$<IP3D5Z9X.O(+C3CY&-H..!7GVC^(=.M]-AB;1!(RC[^#S^M>B>%-
M0M[ZR9X++[,-WW: .DHHHH *9Y2%]^T;O7%/HH **** "BBB@ HHHH ****
M(+W_ (\Y?]VN!T/_ )&U?\]Z[Z]_X\Y?]VN!T/\ Y&U?\]Z /1:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *I:EJ4&F6KSSMM51DFF:IJMMIELTLTBK@'&37AOB?Q;>>);\VEF)!&25(7
MO0!)XP\9W/B"]-C8ONBW +@^]=-X$^'WD;;[4(R)<[ESSG-3^!/ *6L:7MZH
M=F'W6'(->GQQK&@51@ 8H 2.)8D"(  /04^BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N'^(JQ?V-.[DY [5W%<YXL
MNH[;3Y&DLQ<@#[I[T >;Z-XD\-6VFPQ7#L)5'/%>C>$]2TW4+)GT\DIN]*\V
M.O6"C+>&T'O@_P"-=_X&U"VO]/9[:R6W4-@JM '7T450U;4AIMD\^S>5_AH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@##T+PEIVBQKY,.V0=ZZ$# P*** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4456N[Z"QB,D[[5 SF@"S17,IX[T)Y_*%X,U5UGX@:5I
M\&Z*Y4N1P#0!UKRQQC+NJCW-<WK?C73](C.YUD./X6S7E&L?$;5M;D:UM$4J
MW0J<&J^D>!=8UN?S;X3+&QS]\T 7=>^)-]J4C1Z8)E!Z84FL[3_"NN^)YEDN
M96"YR=XQ7J/A_P"'.G:05DY=AV<9KM(;:&!0L<2+CT4"@#A?#_PUL-/C4W<*
M22#J17;6EC;V2;($"K5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4%V_$ZW$8P-G;\* /7E.Y01WI:BML_9DSZ5(Q('% $-Y_P ><O\ NUP.A_\
M(VK_ )[U-K.N>(XI+B.&U0PC@$GM^59?@Z>YN/$2/=(%D]!0!ZG1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/ND8_C6M8Z''& \F=W?-;*1J@PH''M0!1L]+AMT&4!8=ZO@ # I:* "BBB@
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M?\J[GPC'?)8L+V1W?=_%72^6G]Q?RI0 .@ ^E "T444 %%%% !1110 4444
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M8[@,5ROAFYCN_%"R1_=H ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKI,, &Y58CO5Y45!A1BG44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_R-J_Y[T >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSX<^&FTC2PTRD29SR.:[ZD  &!2T %%%)D>HH 6BHWF1!DL/SJE-K-M#PQ-
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MO^[7 Z%_R-J_Y[T >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_JDE'X&J4GB;6)/N></^ FK6'D/D9ZPTJIU-0/J-M']Z0"O*?[2U^X/^LE
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M^>R_D*</$&E?\]5_(5P?]G2_\\7_ "I?[/F_YXO^5=7MZ:^RQ>U1WHU_3/\
MGL/RI?[?TW_GL/RK@OL,_P#SR?\ *C[%<?\ /)_RI_6(?RL/:H[\:]I_:84O
M]MV!_P"6U<!]CN!_RR?\J7[-=?\ /-_RH^LP[,/:+L>@?VS9?\]:7^U[,_\
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M;6Y<M!A*BI1FUO<4H2L<E82.MY%M)^]ZUZ7 28ESZ5S^F^&OLTN^4AL'BND
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M^4= %+_A86@?\_?Z#_&C_A86@?\ /W^@_P :N_\ "(:-_P ^4='_  B&C?\
M/E'0!2_X6%H'_/W^@_QH_P"%A:!_S]_H/\:N_P#"(:-_SY1T?\(AHW_/E'0!
M2_X6#H'_ #]_H/\ &C_A86@?\_?Z#_&KO_"(:-_SY1T?\(AHW_/E'0!0/Q$\
M/!L&\Y/L/\:=_P +!T#_ )^_T'^-86L>#[3_ (2:U,-J!!CY@!Q74)X0T;8,
MV4= %3_A86@?\_?Z#_&C_A86@?\ /W^@_P :N_\ "(:-_P ^4='_  B&C?\
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M,H_\)_X>_P"?H?D*7_A8'A__ )^Q^0_QJ[_PB&C?\^4='_"(:-_SY1T 4O\
MA8/A_P#Y^Q^0_P :/^%@^'_^?O\ 0?XU=_X1#1O^?*.C_A$-&_Y\HZ *7_"P
MM _Y^_T'^-'_  L+0/\ G[_0?XU=_P"$0T;_ )\HZ/\ A#]&_P"?*.@"BWQ
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M?\_?Z#_&D/Q#\/J,F\_0?XU>_P"$0T;_ )\HZR?$7@_3?[(D^S6:B3L0* +
M^(?A\]+S]!_C2_\ "PM _P"?O]!_C5+0/!^G>0/M%HI..XK:_P"$0T;_ )\H
MZ *7_"PM _Y^_P!!_C1_PL+0/^?O]!_C5W_A#]&_Y\HZ/^$0T;_GRCH I?\
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MMR* /8[:<7$(D4$ ^M2TR(QF,>7C;[4^@ HHHH **** "BBB@ HHHH ****
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gjnp4w4lrub1000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J ^L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/.#_ *YK_*IJ0!1110 456N=0LK)E%W>6\!8942RJN?IDU!_;VC_ /06L?\
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M /DKP3\'-=\8VTET[C3;4#]W+<1$^8?8?UKK?^&:M3_Z&.T_\!V_QKZ+ "C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***QO%'B.Q\*Z#<:K?R!8XE^5>[MV H YKXI_$&'P1H++"RMJETI6W3^
M[VWGZ5YM\&OA]/K>I-XRU]6E0N6MUEY\Q^[GV':N?\,:+JOQE\?2ZKJI9=-B
M?=+Z!1TC7]!7U#:6L%C:16MM&L<,2A451P * )J*** "BBB@ HHHH **** "
MBBB@ HHHH **** .1^)>JW6D>";RXLV*3.1'O7JH/4U\P,[.Y=F+,3DDG))K
MW'XO^,H4M#X:LPLUQ/CSR.=@SP/J37,Z/\%M9U&RM;NXN[>V290S1MN+J#[8
MQG\:X:Z=2=HZV/J<LG3PF&YZWN\ST\SN?@QJ]WJ/A>>"Z=Y!:R!8W8Y.#GC\
M,5Z36-X8\-V?A;1H].L\L =SN1R[>M;-==-.,4F?/8NI"I7E."T;"BBBK.<*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ1_R*
MFK_]><O_ *":UJR?%'_(J:O_ -><O_H)IK<&:%I_QYP?]<U_E4U0VG_'G!_U
MS7^534@"BBB@ HHHH **0D*"20 .237"ZO\ %GPUI-\UIYLMRZ'#M"N0#Z9/
M]*F4E'=FM*A4K.U.-SNZ*R- \3:5XFL_M.F7*R@??0\,OU%:]---71$X2A+E
MDK,****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 17%Q%:6TEQ.ZQPQ*7=V.  .2:^7_%VOZI\7_'D.B:1O&G1/MB4
M=,9^:1JZ+XU?$&;4KW_A#M!=I,N$N6B/WVS]P?CUKT'X4_#R#P7H2SW"*VJW
M2AIWQ]P=E'^>] '3^$_#%CX1T"WTJQ0!8U'F28YD;NQ^IK;HHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Y#Q_XSA\(Z,S1E6OY@5@0]C_ 'C["MW7M;M/
M#^CSZC>.%CC7@9Y8]@*\)T73M2^*OC.2^ORRV,;9?T1!T0>]8U9M>['=GHX#
M"QG>M6TA'?S\C6^&'@R;7M2;Q/K0:2,/NB5_^6K_ -X^PKW+H,"H;6UALK2*
MVMXUCAB4*BJ, "IJNG!05C#&8J6)J<[VZ+L@HHHJSE"BBB@ HHHH **** "B
MBB@""[O;:Q@:>ZG2&-1DLYP!7+7?Q-\,VLI3[3)-C^*&/</YU0\0^"+[Q1XI
MDENKQXM,C5?+4-G)P,X';FM2R^'7AJS3'V!9CCDS'=_.@17@^*/AF>0)Y\\>
M?XI(L#^==18:G9:G )K*ZCGC/\2-FL.Z^'WAFZCV-IL<?O%\A_2L&P^'UWX>
M\3VE]I-X[61?$\1;!VX/YB@-3T6BBB@84444 %%%% !1110 4444 %9/BC_D
M5-7_ .O.7_T$UK5D^*/^14U?_KSE_P#0336X,T+3_CS@_P"N:_RJ:H;3_CS@
M_P"N:_RJ:D 4444 >=_$KQQK7A*\T^+2K6WF6XC=G,L;-@@C&,$>M<+_ ,+F
M\7_] VQ_\!Y/_BJ]^HK&5.;=U*QZ-'%T*=-1G14GWO\ \ ^>-1^+7BS4-.N+
M22RM8DF0HSQ0.& /7!+5YP2223U/7-?9CHLD;1NH9&!5@1P0:\SU;X*:)?WS
M7%K>3V:NV6C10P_#-8U*$WK>YZ>"S7#4[Q<.1>6IXYX5\2ZKX7U)KS2T61RI
M5XW4LI'N 179_P#"YO%__0-L?_ >3_XJO6O"?@K2O"$#K8JSS2#$DS_>;_ 5
MTE5"C-*W-8PQ.9X:I4;]ES>;T_0\%@^,?BZ2>-&TVR"LP!_T>3_XJO=H',EO
M&[##,H)_*I**VA&4=W<\W%5Z56WLZ:C8CN)#%;R2+C*J2,UB176LG3UOWFLF
MBV[S$(F4X],[OZ5L7G_'E/\ [A_E6/I6C6\VEV[RRW3JR F-IV*?]\YQ1*[=
MD>=/F<K(U1?P+8QW<SB*-T#98],BEM;^TOE8VTZ2A>NT]*H74<7]NV:3JH@2
M+]R#]T/_ (XQ27JHNO636^//.1-MZ^7CO^.*.9CYY+\BX^L:?&P5[N($G &>
M]/EU*RAF2*2YC61_NJ3UK+T2TA^Q7KE 6EE?<2.H]*@T^WC7P6QVY+PER3U)
MQD4N:1*J3M^)T$UQ#;Q&2:140=R:KQ:OI\XS'=Q-DA>#W-9<6V34M/-W@Q_9
ME,._IO[_ (]*3Q&MI]MTYFV_:OM"A<?>QGO[4.;M= ZDK.2)4N+B9IP;[R-E
M[L4LH.Y=H^6M2ZU"TL<?:;A(L]-QKGGZR_\ 85'_ *"*T=)$9U&_:;;]L\T@
MYZ[/X<>V,4HR>Q,)N]D21W_GZW%'#,'MV@9L#H3D58GU:PM9O)GNXTD_NDUC
MH+9?%DXL]OF?9F+A>F[_ !JYHD=K_9+%PA=RWVG?C);/.:<9-Z#C.3=O4U);
MJ"&-9))55&.%8G@U#!JEC<[_ ";J-]GWL'I7//"LVCPPG)MS?8B_W,''X5HZ
MK:POJFE*4&T.PP.A ' ^E'.]Q^TD]5Y?B7A?6U[:SFTNTRJG+CG9[TL-Q';:
M;'+<W:2*$RTQX#>]9FH@)K+;1C?8R[L=\;<5#:"-KC21=;?*%L#%NZ>9_CC%
M',[B]H^:Q<OM7AEMHWL;I6)F56*^A/-:-U?6MDH:YG2('IN/6L7Q(+036)8J
M+HSJ%Q]XCW]J39?'Q)=/&+1I%51$)RP(7_9P/7-+F:;0.I)2:]#>M[F&ZB$L
M$BR(>A4U'?33P6Q:W@,TI.%4=![GVK-TR.<:Q<O(]H,H/,CMRQ^;U.1UK5GN
MH;8(9GV!VV@D<9K1.ZU-(RYHW>AG17M[:WT-MJ#P2><#L:%"NW SR"3Z5&M_
MJ=Q"][;I +52=L3J=[@=3G.!^50:A:"UU>&X@D:2:XW1M'(VXA2#RN>@JQI5
MU$GAS+LJ>4&1P3C!R>*S3=[,R3?,XMV_I#CJLU\UO%IH0/+$)6>4$A![@$9/
MXT@UF2UCNHKU%-S  P\O@2 \#'I6?H -M?P"9/+-Q:[DSQWSCZXJ/6<W&H7<
MT2AX[>.,.P]=W3\*7.^7FZD^TER\U]33-]J-D89K\0-;RL%(C4AHB3@9))S^
ME;+.JH78@*!DGVK'UV>.;3(8XBKM<2((P#G.2.:T+L8TV8'M$W\JT3LVC:+L
MVMR59XF@$RN#$1N#=L4PWEN+47)F3R",A\\8K*@NX(_"*3&1=@M\9![XZ?6J
M%J$DBT-+G'V4Q$@-]TR=L_AFDYB=7:W5&]%K&G3D"*[B;+!1@]2>@J+6;J6"
M"&&W;;//*J(1V[G] :J:]':&ZTUW"?:%N4$?KC//X5,2+OQ&$ZI:1[OH[=/T
MS0Y/5"<I.\626MQ+_:UY#+*3'%&A&>W7)J['=V\L+3)*K1KG+ \#%<OJ"3-X
MBN&<.]BJ)Y\<?WCUP?<>U:.K-!+:6 C9?[/>51)M^[MQQ^&<5*F]11J-)^7]
M?<7DUO3'W;;V([>O/2K]87B:*R.AD2B/Y2##TX/M6XOW1]*M-WLS2,I<SBQ:
M***LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O,/C!\1D\):,=-L) =6NU(7!YB7IN_P^E=
M7XV\7V7@SP[/J5TX,F-L$6>9'/0?U_"O!/A[X3O_ (H>,KCQ)KH=[".7<Y;I
M(W9![ 8H ZGX(_#EE \6ZW$SW$OS6J2\D9_C.>Y[?6O=J:B)%&L<:A44850,
M "G4 %%%% !1110 4444 %%%% !1110 4444 %,FFCMX7FE<)&BEF9CP *?7
MBWQ7\;R7MQ_PB^CNSEF"7#1\EF_N#^M14FH1NSIPF%EB:BA'YOLC#\5:W?\
MQ*\7Q:1I>[[#&VV,=CZN:]M\,^';/PQHL.GVB_=&9'[NW<US_P ./!$7A72!
M/<(K:E<*#*V.4']T5W%12@U[TMV=./Q496H4?@C^+[A1116QYH4444 %%%%
M!1110 4444 %,F8I#(ZC)520*?10!Y!;7?B_5X'O;'47D^U7#6\UN$S]F4DC
M/X"M6SM+GPEXNTNR@U26\2^RMQ#(V=I&/F]J[ZRTNST^:XEM8%B:X??+MZ,W
MK7GFI^*/"OASQ9=W:64]WJ+'$DJ-PI]!GC\J8CT^BO-A\9-+)Q_9=Y_WTO\
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M$+*968CIR<8%:=E8_9)+F1GWO/(7)QC [#\*N44*"0HTXQ(EMX5FDE$8$D@
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MX.3Z%^BL[6-1DTVR2>-%=FD5,-[FH;C4[N;4&L=,CA>2( S23$[4ST''.?\
M&DH-JY4JL4[=37J&6Z@@EBBDD"O*2$4]6Q639:KJ#:]_9=[:Q)B R^;&3M?!
M XS]:11]N\4S2Y!CLH=@]G;D_IMJO9V>O:Y/M4U[O>QL07$-U'YD$@= 2N1Z
MCK4M<EHFJL+5K&QB\^Z$\F_^Y$,_Q'^E:][J5S'<PV%I%%+?.F]]Q.R-?4]_
M7\J)4FI6%"O&4.9FM16!_:NJVNL65A>VL!6Y+?OX2=HPI.,'G/%;]1*#C:YI
M":G>W0****DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(.I_OG\:]EK&G%R?M)?(]+&UH4:?U2CLOB?=A11170>0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%>/>)_$6MZ_>ZI'IDYM].TY,R%
M3@MSZT >PT5Y#I7BO4-#\*^'Y\F6"6Y=9VD)8D;CQ7KD;B2-7'1@"* '4444
M %%%% !1110 4444 %%%% !63XH_Y%35_P#KSE_]!-:U9/BC_D5-7_Z\Y?\
MT$TUN#-"T_X\X/\ KFO\JFJ&T_X\X/\ KFO\JFI %%%% !1110 444A('4B@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHS@9-(&4XPP.>G- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^*/^14U?_KSE_P#030MQLT+3_CS@_P"N:_RJ:H;3_CS@_P"N:_RJ:D 4444
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MSEB2>:ZFD"JO10/H*6G&-MQPAR[A1115%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S?C7QEI_@K0I-0O7!D(VP0YYD;TJWXG\
M3:=X3T6;5-2EVQQCY4'WI#Z >M?-]C9Z_P#&[QP;JYW0Z9"WS'/RQ)G[H]2:
M '^%O#FL_&/QA-K.L22+IL<G[QNP':-/P_G7T[86%KIEC#964*0V\*A41!@
M5!HNC66@:3;Z;I\*Q6\"[5 '7U)]S6A0 4444 %%%% !1110 4444 %%%4M5
MU>QT6R>\U"Y2"%!DECU^@[T-V'&+D[+<N,P12S$!0,DGM7E'CGXM0V7F:;X?
M99KK[K7 Y5#_ +/J:YCQ+X]UOQUJ']C^'X)H[1SMVI]Z0>K'L*[CP-\+++0!
M'?ZF%NM1^\ 1E8C[>I]ZYW4E4=H;=SV(86EA(JIBM9=(_P"9R?A#X7ZAX@NE
MUGQ1),(W.\1.3OD^OH*]LL[.VT^U2VM(4AA085$& *GZ# HK2%.,%H<.*QE3
M$RO+;HNB"BBBM#D"BBB@ HHHH **** "BBJU[?6VGVS7%S*L<:COW^E-)MV0
MI245S2=D6'=8T+NP50,DGM7!>(O&;S,;#2"26.TRKR3[+6=JFNZEXIO/L.GQ
MNMN3@*/XO=JZSP[X3MM&19I@LUV1R^.%^E>G&C3PJYZ^LNB_S/"J8JMCY.EA
M=(=9?Y&1X<\%D.M]JP+R'YEB;^9KN54*H50 !P !TI:*X:^(G7ES3/4PF#I8
M6')37SZL****Q.H**1F"J68@ <DGM7E/CSXIK:.^E>'G\VZ/R/<+R%/HOJ:B
M<XP5V9U*D::O(E^,/B334T)M$6???2.&,:'[H&?O5X/@^E>Q>!_AA/J,RZWX
MEW'>=Z6[G+.?5O\ "O43X7T(W"SG2K0RIC:_EC(Q7)*C.L^9Z'%*A4KOG>AR
M'P<T>[TWPQ-/=(R"[D#QHPQ\HSS^.:]&I  H    Z 4M=D(\L5$[J<%"*BN@
M4445184444 %%%% !1110 5YKXB\9:U?:Y)H?AB$F6+B28+N(/X\ 5Z5VKR/
MPCJ=KX9\9ZO::NWD/._R2R#W/?WS^E F6]*\8>(M UB#3O%41>.X8*DY4 C/
MN, C\*]0!#*".A&17D_Q&UBQ\076FZ5I4@N;D3 EHQG&>,9KU2U1H[2%&^\J
M '\J 1+1110,**** "BBB@ HHHH **** "LGQ1_R*FK_ /7G+_Z":UJR?%'_
M "*FK_\ 7G+_ .@FFMP9H6G_ !YP?]<U_E4U0VG_ !YP?]<U_E4U( HHHH *
M*** "BF2RI#$\LC!8T!9F/0 5YIJGQAM+:]>&QL6N(D.#(S;0WTK2G2G4^%&
M56M3I*\W8].HKF_"GC/3_%4#>0&BN8QEX7Z_4>U=)4RBXNTBX3C./-%W0444
M5)044R61(8FED8*B#+$]A6+!+JVKQ_:;>=+&V8_N\QB1W'J0>!51C=7(E-1=
MMV;M%9MG_:L-T8;LQW$!&5G0;2#Z%?\ "J&FG5]222X_M18D69E$8ME/ /KF
MJ]GUN3[796=SH:*YW5/[8M;NU6+5E"7$PCP;93M!_'FM&:TU%H(ECU01R*/G
M?[.IW_AGBAP22=]_7_(%4;;7*]/3_,T:*PM"GU"YN;MI[T7-K&_EQMY(3<1U
M/';M^!IUYKRQ>(;+2H5WM*3YK]D^4D#Z\4>RES<JU!5H\JD]+Z&W16%JVH2K
MJD-E%J4-C^[+N\BJ<^@&3]:LWES-INA2SR7:33!?EF*!1D\ XZ8Y%'LWIYA[
M57?D:E%9.DFYE_>R:Q#>IMY2.-0%/U!JQJ3WX2*.PC7?(V&E;&(AZX[_ $I.
M'O<MRE.\>:Q>HKGX]5N=/U&6RO;A+K; TXD5 I7&."!TSGBHFOM9BTK^V7DB
M:$)YQM @R(^O#>N*KV3,_;Q[>OD=+14<$RW%O',A^5U#"FVUW!=Q&6"3>@8J
M3@CD'!_6L[,VNB:BJL>HVDMM)<K.ODQDJ[G@ CKUJE_PD^D!69KHHH&=SPNH
M/T)'/X4U"3V1+J06[1KT5FZW>M9Z/-+$2)& 2,CKN8X'\ZJ027$&LV-M+<2,
MOV4M)N;@MZFFJ;:N3*JE+E]/Q-VBJT%_:W(D,,H98CAFP0H_'H?PJE_PDND[
MB#=$ =7,3A/^^L8_6DH2>R*=2"U;1K45';SQ75O'/"^^*10R-CJ#TJ2I+3OJ
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K/UK6;+0-)GU+4)EBMX5RQ)Z^P]ZGO[^UTRQFO;V=(+>%2SR.> !7S'
MXH\1ZU\8_&$.BZ.DBZ;&_P"[3L!WD?\ SWH COKS7_C?XX%M;;H=,B;"C'R0
MQ_WCZDU](>&/#.G^%-$ATS3H@D:#YG_B=O4FJG@KP9IW@K0H]/LD!D(W3S8Y
MD?N:Z2@ HHHH **** "BBB@ HHHH **1F5%+.P50,DD\"O*/'/Q9BL7?3/#Q
M$]T?E:X RJGT7U-1.<8*[.C#X:IB)\M-'6^,/'NE^$K<B9Q->L/W=NIY/N?0
M5Y!;6/BCXKZP9YY&BL%;&XC$<8] .YK7\'_#"_\ $5S_ &UXGDD$<C;Q$Y^>
M7Z^@KVRSL[?3[2.UM(4BAC&%1!@ 5BHRJZRT1Z4JU# +EH^]4ZOHO0Q_#'A'
M2_"MBL%C"#*1^\G89=S]:WZ**Z$DE9'D3J2J2<IN[84444R HHHH **** "B
MBB@ HHKE?$GC"#3 UM9D371X)'1/_KUK2HSJRY8(PQ&)IX>'/4=D:FM^(+31
M+?=,VZ4CY(@>37!1PZOXUU#S')2V4\G^!![>IJQHOAF]\071U#56=86.?F^\
M_P!/05Z+:VL-G;K!;QK'&HP% KT'.E@URT_>GW['CQI5\R?/5]VET75^I4TC
M1;/1K416T8W?QR'[S&M&BBO,G.4WS2=V>Y3IQIQ4(*R04445)85!=WEO86LE
MS=2I%#&-S.QP *I:[X@T_P .Z<]YJ$ZQJ!\J_P 3GT KP[4M:\1?%/65L+"%
MXK$/Q'GY$']YSZUE4JJ&BU9A5K*&BU?8T?&'Q$U#Q5>_V'X;206\C;2Z#YY?
M\!76> _AA;Z$J:CJRK<:@1E4/*Q?XFM[P=X%T[PE:YB59KUQB2X8<_0>@KJJ
MB%)M\]3<BG1;?/4U?Y!11170=04444 %%%% !1110 4444 %%%% &1/XFTBU
MU1M-N;V.&Z7'RR'&<C(Q577O".C>*$5[I")!TGA8!L>G<55\2> =*\27#W4Q
MDANV 'FH<]/;I7(/X3\9>%/WFB:@;FV4DB$/P!ZE3Q^5,1VOA_P-HWAR4S6L
M<DL_:6<ABOTP *Z6O*-,^+<]O-]FUO3SN4[6>+@Y]P:]4BD6:%)5^ZZAA^-(
M8^BBB@ HHHH **** "BBB@ HHHH *R?%'_(J:O\ ]><O_H)K6K)\4?\ (J:O
M_P!><O\ Z"::W!FA:?\ 'G!_US7^535#:?\ 'G!_US7^534@"BBB@#@_B#X:
MU_7KJQ?1I_+2)&$G[\QY)(QTZUQG_"N_'/\ S^C_ ,#6KV^BNB&)G"/*K')4
MP=.I)R;>IX5>> /&L%G-++<F2-$+,BW;,2._'>N!92K%6!!!P0:^LZY74OAW
MX;U2[:YFLBDC'+>4Y0'\!712QMOC7W'+7RZ]O9O[SQ#PUH6LZY>O%HY9)$7+
M/YA0 ?45U7_"N_'/_/Z/_ UJ]?TC0].T*U^SZ=;)"AY.!RWU/>M"HGC9.7NK
M0NEET5'WV[^1XI#\/?'"31LUX-H8$_Z:U>T0JR01JWW@H!^N*?17/5K2J6N=
M='#QHWY>I4U.U:]TNZM5.UIHF0'TR,53T7489+-+>0K#<P#9)$W!4BM>J=YI
M6GZB5-[907!7IYL8;'YU,9*W+(N49<W-'<$U2TEOC9Q2>9,J[F"\A?J:PM"T
M6PNK>6XFA=I?M#G(E<=#Z XKHK6SMK*+RK6".&/^[&H44^*&*!"L4:HI.2%&
M.:I3Y4U$ETW)ISL[&5K0 NM) Z"Y7^E2:]>/;V(@@_X^;IO)B ]3U/X#)K1D
MABE9&DC5RAW*6&=I]10T$3RI*\:M(GW&(Y7Z4E-:7Z#=-^]9[E1+673]&%O8
MQJ\T<>$#' 9O4GZUR20ZK87^D"YT^-KI[AGDE^T@^8Q1L_P\#KBN\J-X(I9(
MY'C5GC.48CE3C'%5"KRWNKW(J4.:UG:QF&;2+V>Z-S#%Y\(V2^<HR!UXSVY/
M-9>D75FNF)!>*S6<]TXMC(,KM#$KD^G Q6_=Z5I]]*DMW903R)]UI(PQ'TS4
M\MK!/;FWFA22$C!C9<J1]*%4BE;4'2DY7T_S]3 Q;1^+;:/3E5<0N;D1<*!D
M;<@<9ZUMW-_!:30QSL5\X[5;'RY]S2V=A9Z?&8[.VB@0G)6- H_2GW%O#=P-
M#<1)+$W#(ZY!_"IE*,FNQ4(2C%VW?W'(WUC%;ZK-#I3;_M-NYN(]V_!&-IR>
M1WXJ[)JD!\%Y5E:8VWDK$.IDQMVX^O%;MGI]GI\9CLK6&W0G)6) H/Y4T:5I
MZWIO190"Z/681C=^=:.K%VOT,E0DK\ME?\/07386@TRWB?AEC -8OAO4+2/2
MKH/.BF&XE\P$]/F)KI*Q--\-V=L/,NK6VFN1*[K+Y8) +$CD_6HC*+B^8TE&
M2E'DZ7_0YZUD^T>'[><JWV/^T&>X&/X.<9]MVVMCQ;-IS>&Y5<Q/E?W(7'7M
MBM2[TP26306;_96W;P8Q@$]]P[@UCQ>&I69HY+32[:*3B5[5#OD'H<@=:V52
M$I*3=K,YW2G&+@E>ZL6;]OMFLZ98#E4!N)1[ 8'ZD5G>)K2ZN_$%FMJ2P2%F
MDB!QYJYY7/:NC@TY(=2N+[>6>550 CA0.PJR8(C.)C&IE4;0^.0/3-9QJJ#3
M71&TJ#G%J75_D<_?SPW?A>5=.1HUC*K+"HPR*&&\$?3-6;Z?2SX;<,8C:F+"
MJ,>GIZU?N=.BE2=H?]'N)A@SQC#\=.>]8:^';H3$_9M*C=AAKN.,^<1W[8S3
MBX-;VL[DSC.+T5[JQK>'O^1=T['3[.G_ *"*TJBMK=+6UBMXAB.) BCV Q4M
M8R=Y-G3!<L4@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA674II;^?.6W':A_#K^M=XB+&BH@PJC 'H*=10,**** "BBB@ HHHH ****
M"BBB@ K)\4?\BIJ__7G+_P"@FM:LGQ1_R*FK_P#7G+_Z"::W!FA:?\><'_7-
M?Y5-4-I_QYP?]<U_E4U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"0!DG %+7B?QA^
M*O\ 9ZR>&= E+7\@VW$T9SY8/\(/K0!F?%_XGS7URWA/PS(TCNWEW$T7)8]-
MB_R-=9\)?A?#X4L%U74XQ)K$XSSR(5]![^IK,^#WPK_L6*/Q%KD.[4I5W0Q2
M#/D@]S_M?RKV:@ HHHH **** "BBB@ HHJEJNKV.BV$EYJ%PD,*#.6/)]@.Y
MH;L.,7)V6Y<9E12SL%4#))/2O*?'/Q9BLC)IGAXB>[)V-<=50_[([FN7\2^/
M=;\=:A_8OA^&:.U<XVIPT@]6/85W'@;X5V7A\1WVJ*EUJ Y (RD1]O4^]<[J
M2J/EAMW/8AA:6$BJF*UETC_F<GX/^&&H>(+L:UXGDD$3G<(F/SR?7T%>V6=E
M;:?:I;6D*0PH,*B# %3T5I"FH+0X<5C*F)E>6W1=$%%%%:'(%%%% !1110 4
M450U'6M/TM"UU<HA'\ .6_(<U48RD[15V1.I&G'FF[(OU%-<0VT9>:18U'4L
M<5PFH_$":5C#I=L03P'<9/X"J4/A[Q#XBD$U]*\<9.09CC'T7M7=' .*YJ\E
M%?B>54S>,I<F%BYO\/O.@U/Q[I]KN2S4W,G8@X7\ZYMK[Q-XG<K"KI"3T0;5
M'U-=9I?@G2[#:\R?:91WDZ?ETKHT18T"(H51T & *KZQAZ'\&-WW9'U+&8K7
M$SY5VC_G_P .<#!\.I&M7:YO<7!'RA1D ^_K5>U^'EZ;H"YGB6 'DKR2*](H
MJ/[2Q&NNYH\CP6GN[>>_J16UO':6T=O"N(XU"@5+117"VV[L]9))604452U3
M5;+1K"2]OYTAAC&26/7V'J:3=@;2U9:EEC@B:25U1%&2S' %>->./B?/J,S:
M+X8W-O/EO<(,L_LO^-9'B+QAK?Q$U,:-HD,J63-@(O!<>KGL/K7I'@?X=6/A
M6%;FX"7.I,/FE(R$]E_QKF<Y57RPV[G)*I*L^6GHNYS_ (#^%JVK)JWB$>==
M-\R6[<A?=O4UZL %4*H  X ':EHK:$(P5D=%.G&FK1"BBBK- HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *Y[0?%MMK5Y>6;0M:W-J^UDD(^8<\C\JZ'
MM7D6J?#C48KV?4[CQ';6^]R?.E=E(SVW4 >M^8G]]?SIU>0V?@+6;]/,L_&$
M-P@/+13NP_0UZU;QM%;QQLVYE4 GUH DHHHH **** "BBB@ HHHH **** "L
MGQ1_R*FK_P#7G+_Z":UJR?%'_(J:O_UYR_\ H)IK<&:%I_QYP?\ 7-?Y5-4-
MI_QYP?\ 7-?Y5-2 ***9,I>%U4X8J0#0!B7?B[3+2Y:#]_,RG#-#'N53[FM:
MWO;>ZM%NHI5,+#ACQ7(Z/KEAX?L3I^I0R072L0P\HGS/?/>H_$L_VJPTZ80/
M!IS%C)&R,H'^\%YKG55VNW\CC6(:BY-I^78ZW4=16QTV6\11,$ X#=><=:G2
MX0V\<KLL>]0?F;UKA;2,KX5U)X9MUFQ7RD"N OS#H6[5)K7V7^T;0ZR+@Z?]
MF7R]F[;O[]._2CVKM</K#MS>GI]YW2R(P)5U('7!Z4BRQN"4D5L=<'.*\ZMA
M*?#FK#3_ #PGVD=<[]F>??I4WAN*,W<TEA.%A6%A-&JR[6..Y;C-"KW:5MP6
M*;:5MSOA/"Q 65"3T 8<TK2QHP5I$5CT!;!->;6FG0V^DZ5J<9D%TUV%+;ST
MWXQCI3=44-K=T-0<K<L_^CLPE) _V=O%+V[2NT)XN2C=K\3TZBJNG),FG6ZS
MR>9($&YB""?SJU70M4=B=U<****8R&ZN8;.UDN9W"11J69CV%<JGC2]FQ<P>
M'KN33B?^/@,,X]=N/ZUOZ[I[ZKHEW91L%>6,JI/3-<W:>(]9L;6+37\.73W4
M:A!(B_NCCOGIBNFC"+C>UWZV./$5)1FE=I>2OKV-C7/$]OHNF171B:2689B@
M)PQ^O7%9FI>,[VQBL98M$>>.\12C"; W,,[>E4?$/AS7KR:XU6&ZB4M;A?LQ
MCWLOJ%Z]_2G7&GZE_8'AJ*6*26:&YC:0)&<HN.X[8K:%.BE%NS[[G/4JXARD
ME==M%W.VM)99[2*6:$PR,N6C)R5/I4U%%<#/36P4444#"BBB@ HHHH ****
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MLNR.K#Y7AJ#YK<TN[U$ "C"@ >@I:**Y#T0HHHH **** "BBD)"@DD #J30
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MP?\ 7-?Y5-2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^A:F_[X?_"NMD\)0R>,E\0M.WF*NWRMO'W=M=!Y4?\ <7\J8CS(?$[6<_\
M(M3?]\/_ (5Z9!(9;>.1EVEE!(]*7RH_[B_E3Z0PHHHH **** "BBB@ HHHH
M **** "LGQ1_R*FK_P#7G+_Z":UJR?%'_(J:O_UYR_\ H)IK<&:%I_QYP?\
M7-?Y5-4-I_QYP?\ 7-?Y5-2 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAQX4LL%-)C=AT:0DFMZWTG3[5 L%E;Q@=,1BO/<:TG>4CU52K6MS)+R/#O\
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M;5[PQP9REO'D*OX5$IQCNS6G1G4^%?HOO/3/&WQ\&]].\)1&68G9]K=,C/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML,^9JT4F/^>'[S^5<Y>_&W0X<BUM+FY]#C;_ #KS75+'P3HH:./4+S6+@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@4*,*  .P%+117FGM!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU4W]X45B\2_]EP\I><MCK$MK:,L8;6.%6.=BC@>W-2PZF- $UY#*MJ778\@
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M3W-TXZX8*I_#!_G6O<?%3PO#D)<RRL.RPM_/%95S\9-*16%O8W,C8X.0!1#
M2_E(K9_4EI[1+T.3\7?":WL[\RZ9JEK;PR=(+E]I7Z'O^5=G\-_ -KX:C;47
MNX[R\E7:'C^Z@]!7CNL:M=:UJ<U[=2,[R-D G[H[ 5K>%?&NH^%&E%NJSPR#
M_4RD[0?48KK_ ++C%<T=S@EQ+7JQ]C4^'OU^9]'T5XO_ ,+HU7_H%V?_ 'TW
M^-'_  NC5?\ H%V?_?3?XTOJ=7L8?VA0[_@>T45XROQCUAP=FD6I]P7-1_\
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MKIY8P<B/;C]:[2BLY4H2=VC&="G4ES26HV.-(HUC10J*, #L*=116AL%%%%
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MC';:K:I'%*VT2QM]TGID>E>H+>VCKN6YA(/<2"OE[3--NM6U"&SM(V>61L#
MZ>]=_P#\*I\1Q86+4DVX[.1_6KKX>BGORF>&Q5=Q?N\Q[*MQ"WW9HS]&%.$B
M,<!U)]C7B[?#/Q;%_JM1SGKB<C^M,/P\\;QC='?.6]KPC^M8>PI_SHZ?K57K
M39[;17B'_"#?$%?F%W-QS_Q_D_UI?^$9^(O_ #\7'_@11]6A_.@^MSZTV>W4
M5XC_ &7\24^427?''WL_THV?$R#Y!]N('<1AOUQ1]57\Z#ZZ^L&>W45XC]N^
M*%MPL>H'/I:JW_LM+_;WQ-@^>6"_*]/GLU _]!I?5'TDOO#Z]'K!_<>VT5XE
M_P )=\0H_G>VN-HY.;48_E2_\)]XV')LSQ_TP-'U2?=!]?I]4_N/;*1W6-"[
ML%4#)). *\5_X6AXJ'!L(<C_ *9M_C65X@^(VNZSIIT^>.*U4G]XT08,P]#D
MTU@JC8I9C22NKGMT/B#2+BY^SQ:C;M+G&T/6E7R:CO'('1BKJ<A@<$5Z3IGQ
M>OK/3H;>YLDN)(U"F4DY;'<^]74P,E\&IG1S*,OXBL>TT5Y,GQH^7Y](.[_9
M?BID^--IM^?1Y]WM*,?RK'ZK6['0L=0_F/4Z*\T7XRZ85!;3;@'N-X_PJ8?&
M'1"H)MK@'N*7U:K_ "E?7*'\QZ+17!#XN>'2!G[0/^V9J<?%;PL<?Z1<#_M@
MU+V%7^5E?6J/\R.VHKD!\3?"Q(_TYN?6,U.OQ#\,,P']IQC/K4^QJ?RL?MZ3
M^TCJ**YY?'/AEF _MBU&?605.OB_PX[;4UNP9CV$ZTO9S[%*K3?VD;5%9B>(
M]%D;:FJ6C,>PE%3IJVG2-M2]@9O0.*GE?8I3B^I<HJ*.Y@E.(YD8CL&J3</4
M?G2*N+129'J*7(H **HZKJ]EHM@][?3"*%.YZD^@]ZY.R^*WA^[O5MV,L(8X
M61UX_'TJXTIR5XHRG6IP=I.S.ZHI$97170AE89!'<4M0:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^'_^@O:?]_*/^$M\/_\ 07M/^_E%F%T;-%8W_"6^'_\ H+VG_?RC_A+?#_\
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M/^_E%F%T;-%8W_"6^'_^@O:?]_*/^$M\/_\ 07M/^_E%F%T;-%8W_"6^'_\
MH+VG_?RC_A+?#_\ T%[3_OY19A=&S16-_P );X?_ .@O:?\ ?RC_ (2WP_\
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME&&% %NBLK7_ !#8>'+#[5?.0"<(BC+,?:N'C^+,@EWW&@SQV>?]<&)./7&
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y9\4O\
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M!TZUW?A+PJGA33YK2.[:Y$LOF;F3;C@#'4^E5K'P5'8^+KC7Q?.[S,S>28P
M,^^: .3D_P"2UK^'\A7JU<NW@R-O&0\1?;7WC'[GR^/SS_2NHI @HHHH&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4UT$B,C#*L,'FG44 9VEZ#IFBF8Z?:+ 9FW2$,6+'ZDFM&BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gjnp4w4lrub1000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -7 W0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S^+M]XJT
M3PY>:SI.K16ME;QQ Q")'=G:4+GYD/&&'<=/ST/@]J-WJOPWTV[O9?-G?S=S
M[0N<32 <  = *@^.'_)(]9_WH/\ T<E,^!W_ "2K2?\ MM_Z/DH YGQSJ^KR
M_%6VT2WUM-.LWLED+.L0&XSLGWG1NW\J[/PMX;U2SU**^F\1_P!HVJYRBF$J
M<J1U2)3W!ZTWQ?\ "S2?%NJ#5)K[4;6^2+RT:UE1!@,S#)*$]6]>PK@OAWJF
ML>%_BC<>#+R_FOK2YED,+3S/*8UC67&"2 "=@S@=J -#Q-XSU7Q!\5K;P%IU
MW]EL)'"W,D42%W0Q+*<,P89 #=AU_&J>I>(M?^&GQ%TO0CJ+7NC7QBSY\,99
M0\Q3[RJG(5/<<_EC:9!)IG[4-NEW]XMM#9W<FSP/YBK7QKD6[^*'ANPA.;E_
MLNWMUFD'7ZT >Z_VSIJPPRRWUO")4#J)954X(!]?0BDBUS2)[A;>+5;&29ND
M:7"%CT[9SW'YUYWX@^&6I>([?3)8]8N;-H;:-'2.Z9!D1HIZ*>ZG\ZX73/"F
MH>&/BUIEA-JUS<XD1R7N6?(#PG'(']^@#Z-HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 5X_K_\ R7+3OP_]"MJ]@KQ_7_\ DN6G?A_Z%;4
M>P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \3^(W_(W77_ /_1:5R5?06J:%IM\SSSV-
MO+,PY=XE8GH.I'M7!KH5FWB.>#[+%Y:Q,P7RQ@?/CIB@#%\#_P#'U<_\!_DU
M>M:7T/T_K7,V6B06LI,$"1D]=B 9_(5U6GQ&,'/I_6@"_1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ KQ_7_ /DN6G?A_P"A6U>P5X_K_P#R7+3OP_\
M0K:@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>X_LSP3+:>)+AHG$$CVZ)(5.UF42%@#T) 9<CMN'K0![U1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7C^O_\ )<M._#_T*VKV"O']?_Y+
MEIWX?^A6U 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%>/Z_P#\ERT[\/\ T*VH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 5[V^L]-LY+N_NH+6UCQOFGD"(N3@98\#D@?C6/_P )WX/_ .AKT/\
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M ,)YX9W[?[53/_7)\?GMH Z.BN>_X3GPU_T%8O\ OAO\*:/'GADMM_M5,_\
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MZ.6^R1G/8QI@?I3QX7T?_GQ@_P"_2?X5UGV6+^X*/LL7]P5R&AR">%-'3/\
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MN,#)W/B3XV_X0+PD^JI:_:;F646ULC'""1E8@OWV@*3@<G@<9R #KZ*^8?\
MA=?Q)MA_;\^GP'1[G]U"LE@XM0XZ[) 0Q;Y&X+D?>XXX]_\ !?BRS\:^%[76
MK-/*\W*S0%PS0R*<,I(_,9P2I4X&<4 ;]%%% !1110!ROB'X<>$_%>HK?ZUI
M7VJZ2,1*_P!HE3"@DXPK =6/YU7T?X5>"M U6'4],T7R+R#=Y<GVJ9MN5*GA
MG(Z$]J[*B@#G?$_@C0/%\:C6;+[0R !&\V1-N-V/NL,_>-.\+>"M"\&V\T.B
MV?V<3E6E/FN^X@8!^9CCJ>E=!10!B^)/"ND>++#['J]KY\0!"CS'7&2#_"1W
M4?E5/PQX!\.^$&:31[#R)74J[^=(V0=N>&8_W17344 %>/Z__P ERT[\/_0K
M:O8*\?U__DN6G?A_Z%;4 >P4C,$4LQP!WI:KWW_'G)^'\Q0!Q7B+Q1!<0O-I
M7BJVLS'$3Y02&4R,,GJ6XSP/PJMX9\6K#$9M7\2P7.[&(2D,6WCGD'GDC\J\
M7HKE]J[W.+VSO<^I;*^@U"V2XMW5XGSM96!!P2.H^E6:\/T/QMXBTK1H;:ST
MH2PQ[MCM;R,#EB3R& ZDUMP_$KQ#Y8,NAMGN4M),?^A5LJB.A5HVU/5:Y_QM
M_P BEJ/_ %[R?^BVKBYOBCJL4>3H[HW^W;,!_P"AU5UCXBOJNA7-G+IUPDDT
M;H&6#"\J1_>/K0ZD;"E5BU8\OHIS(R_>4CZBI([??_RVB7_>;%<AQGM/@B=A
MX?M%[ O_ .AFN[@.8@:\H\,^)M+TW3[>UN+A=ZL<L'7'+9[FO0;'Q-H<T"[=
M7L-Q'W3<IGIZ9KLC)6.^$E9:FU155-2L)75([VV=G.%595)/TYJ6XN(;6!YY
MY$CB0%F=V   &3R:LNYR7Q5_Y)KJW_;'_P!')7S37N_CZXT;6-'O)+?Q%)*[
M;,64-ZAC?YE_@&<XQGZ\UY1_9-M_M_I_A7IX'&TZ--QEW_R.:I!S=T<_7KL$
M'Q$"CR=:LE_[9*?_ &E7!?V3;?[?Z?X5[K8H6 Q_GK58K'0G;D2?JATZ35[G
M.1P_%'8,:_IW_?I?_C-#P_%/ QK^G_A"I_\ :->@1VTA0''\Z?\ 99?3]#7'
M]9?\L?N1I[/S9Y;KNI_$G0=)FU&ZUVR:&+;N$4*%N6"\9B ZGUKS+4_$NK:O
M,9;Z[\UR<D^6B\\GL!ZFO;OBA Z> M09AP/+_P#1J5\]UZV 4*M/GE%7OV1S
MUKQ=DSH=,\;^(=(A,-C?^4C8)'DQMT&.ZFO3EC^*&1M\0:=C_KDO_P 9KQ$=
M:^F[!I)#@'/_ .NLL>X4.7DBM;]$51O*]V<OY/Q2_P"@_IW_ 'Z7_P",TSRO
MBGYN/^$@T_;_ -<5Q^?DUZ&MM+M!QV]Z7[++Z?H:\[ZR_P"6/W(V]GYL\9\;
MV7C:XT6%->U2SN;47"E$C0*0^UL'B->V>_>N!_L:Y_O1_F?\*]R^)4+Q^'+<
ML./M:C_QQZ\KK6&858*T4E\A.C%[F#_8US_?B_,_X5Z=9VOQ%5OW6M6(';,0
M_P#C5<?7M=C&S;<?YZ4IXZI/XTG\@5)+8Y@0_%':,:_IV,?\\E_^,TU(OBGD
MY\0:?^,*C_VC7H:VTNT<=O0TOV67T_0UG]9?\L?N0_9^;/$_B GC--!@/B+5
M+2ZL_M2[$A0 A]K8/$:\8W=^]>;5[_\ $^RW^&;<3*"OVQ2..^QZ\E_L^V_Y
MYC_OD?X5W8?,80A:2^XRG1;=TS$TT7!U6S%JX2Y,Z")B,A7W#!Z'O[5ZO8P?
M$8 >5K5BOINC7_XU7'Z38VZ:S8L$&1<1D<#^\*]IT^-FVX':L\3CHU&N6*^:
MN5"DUNSF&B^*6WC7M/\ PB7_ .,T+'\4MO.O:>?^V2__ !FO0OLTOI^AI/LL
MOI^AKE^LO^6/W(OV?FSPSQ]<>+[0:?\ V_J-O<;_ #/)\E%&W&W=GY%_V?6N
M*_M2\_YZ_P#CH_PKU#XV1-&FB%AC_7X_\AUY'7LX2G3JT5.4%=^2[G-4E*,K
M)FK8:EJ4FHVJ6TX6=ID$;%!@-D8[>M>GV:?$;RT,>L60X[QC_P"-5Y7H/_(Q
M:9_U]Q?^ABOHS3HF:-,#M7+CW&C)*$%KY(THWDM6<I+_ ,+1&W;K5EUYQ"I_
M]HT\?\+.P,ZQ8G_MFO\ \9KT#[-+CI^AH^S2^GZ&N#ZS_<C]QK[/S9X-\1O^
M$G_XEO\ PD=Y!<?ZWR/*4#;]S=GY%_V?6N$KZ&\<^"KOQ0EEY+0I]F\S/F$C
M.[;TPI_NUP<WPNO83AI+8_1C_P#$5Z-#,:<*:C):^1C.C)NZ.(\/_;?[;M_[
M/95NOFV%AD#Y3GL>V>U>J6D_C]&'EW5OU_N#_P"-5FZ)X%N-+U>"]=HBL>[(
M4G/*D?W1ZUZ58PN67Y3U]*Y\3C85))QBGZHNG2:6K.,?4_B4MTH^T1F/N! ,
M=?7R:M_VQ\0%ZK$WT7_[37>?9Y,?=_2D^SR>GZ5SO$I_87W%\C[G@GQ$U#Q%
M?36:ZZA5(R_D?)@<A=V#L7/:N(KZFU'1+34D07UA;W7EYV>?"'VYZXR..@_*
ML2;P?H^>-&L!]+5/_B:[:.90A!1Y?N,I4&W>YX/X>N9[/7;:>VMVN)DW;8DS
MELJ0>@/;GI7J]E\0]<LP W@G49,'.Y6?_P"-UT$'A;3K:99H--M8I5^Z\<"J
MP[=0*V[>T*C!4GZBL,1C*=65W"_S_P BX4Y15KG(I\7+\.5G\%ZC&!_==B?R
M*"I?^%R6:?Z_P]JL?_ !_7%=:^GV['+6<1)ZDQ#_  JN^B:8_P!_2[1O]ZW4
M_P!*R]KAWO#\65RS[G&77QUL$D46FB7,J[?F,TRQD'TP W'3FN9U'XJ)?>*K
M#6AI#(+2)H_*^T9W9##.=O'WO3M5+XK:?9Z=XEMHK*T@M8VLU8I#&$!.]^<
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MV\JA@",X8D9P3S[FJ^FZM\,M&N&N-+U#PC8SLFQI+6:VB8KD'!*D'&0./84
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M]9O_ &2O,: /H:VU;2[R58[>?>[YVC8PSCZCVK2"@=!7@?A"7R/%-G)Z;_\
MT!J]PM+KS@.1UH NTFT>E+10!X?\9=*O+OQ5:2VT.^,62*3O YWR>IKS5M'O
MUD"&##'H-Z_XU]9W;;+25]K-L4MM49)P*\;US6Y)/&MK>#2M0\NV62,C[.?F
M^\,CGWKU,-C*JCR12T7]=3"I2C>[.;\ :;=VWB)GFBVKY)&=P/\ &OO7M5C
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M2]>@#6<V9!]Y-C<<MCD@>AKGQBG4E[7==T:4K)<O4ZJBBBN$U"BBB@ HHHH
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MMG2,L=JLPD#$#H"0JY/?:/2O._B)\6-4^($,5E)9P6.F0RB9($/F.7V[<LY
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M%7<&++WXV\=> #T_QE\+O#/C=TFU"W>VO%?<UW9[8Y9!@#:Y*D,, 8R,C'!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXA^%K#Q0OAJZU3R]7:6.$6_V>4Y>0*4&X+MYW+W[\T =/1110 4444 %%%%
M!1110 4444 %%%% !1110 5X_K__ "7+3OP_]"MJ]@KQ_7_^2Y:=^'_H5M0!
M[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ] ^&7Q,_P"%BC5#_9']G_8?*_Y>?-W[]_\ L+C&SWZT =_1110 5\Q>,/\
MDZ*V_P"PIIW_ *##7T[7RC\3]+_MS]H"YTGSO)^VW5G;>;MW;-\42YQD9QGI
MD4 ?5U%> ?\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;0![_17@'_  S+_P!3
M=_Y3?_MM>H?#GP-_PK_P[/I/]H_;_-NFN?-\CRL95%QC<W]SKGO0!U]%%% !
M1110 4444 %%%% !1110 5X_K_\ R7+3OP_]"MJ]@KQ_7_\ DN6G?A_Z%;4
M>P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5RWQ L+G4O"=U;6D+RS-LPJ*6)Q(IZ >@-=312:NK":NK'S7)X4UJ+
M[]A<#ZPO_A51M-N[*YC6X@DBW="Z%1T/J/:OHR[L1,3]/05Q7CWPZ9?#DES
MO^D0.C*0 "03MQG_ (%FL94DE='/*@DKHWM-[?Y]:ZE?N+]*\]\#ZLVK:2LD
MN//3/F8SW9L=?8>M>@QG* ^U;)W5SH335T.HHHIC"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (;JUAO;66VN$WPRJ5=<D9!]QS7-/
MX#\-Q3":/3=L@Z'SY#[_ -ZNKII0-UJXU)QTB[":3W*=I$L$<<48PB*%4>@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?//Q^\5^(-(\8:=
M8:9K-]8VPL!,4M9VBW.TC@DE2">$7KTYQU.?)O\ A._&'_0UZY_X,9O_ (J@
M#ZTG^&G@RZ\02:Y<>'[2:_E<O(TFYHW8C!)B)V$GKG;UYZ\UKZ_X=TGQ1I;:
M;K5E'=VC.'V,2I5AT*LI!4]1D$<$CH37QI_PG?C#_H:]<_\ !C-_\51_PG?C
M#_H:]<_\&,W_ ,50!]"0?LZ^#8;F.5[O69T1PS127$85P#]T[8P<'IP0?<5Z
M?I6E6.B:7;Z;IMM';6=NFR*)!PH_F23DDGDDDGDU\6?\)WXP_P"AKUS_ ,&,
MW_Q5>\?L^:YX@UK3-<;6+^^OK:*:(6\UV[28<AMZAVY. (SMSQD' W<@'L]%
M%% !7RU9V5O8?M-M#KL?EQMK,DT8W$_/(2]N?D]6:(_C\W>OJ6O./'?PCL_&
M&N0:]9:M/H^KQ>6/M$,08-LR0V 5;S!\H#;N H&/0 Z3Q_;PW/P[\1QSQ)*@
MTV=PKJ& 98RRGGN" 0>Q ->.?LTV-N^H>(K]H\W4,4$,;[CPCERPQTY,:?E[
MFO?OLB2:?]CNS]LC:+RIC<(I\X8PV\ !3GG(  YZ57TS0M'T7S?[*TJQL/.Q
MYGV6W2+?C.,[0,XR>OJ: .0^-?\ R2+7?I!_Z/CKG_V<O^2>7W_85D_]%15U
M'Q)\ W/Q!TVRT]-;_LZVMY3-(GV03>:^,*<[E*X!?Z[O85L>#/"=GX*\+VNB
MV;^;Y66FG*!6FD/+,0/P SDA0HR<9H WZ*** "BBB@ HHHH **** "BBB@ K
MQ_7_ /DN6G?A_P"A6U>P5X_K_P#R7+3OP_\ 0K:@#V"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N[
M2"^M7MKF)987QN1AP<'/\Q7EW@#49;74+[0;B1F>VDD*Y/0*53'^37K%>2^-
M[!_#GBRTUZ'_ (]994$P /+%V=N3QT%9STM(RJ:-2/4[5]\?TJ>L;1-0BOK*
M&YB(*3(KX!!QD9P??FMFM#4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_B_^-5XWXI^+WB[Q'JCW$.K7>EVBNQ@M;&8Q"-3CAF7!<\#ENY.  <5A_\
M"=^,/^AKUS_P8S?_ !5 'TYH'P3\$:"ZRMI[ZG.KEEDU%_- !&-NP (1U(RI
M.3G/ QZ'7Q!_PG?C#_H:]<_\&,W_ ,57O/[/]]XDU*QUJ[URZU6ZMI#!]CFO
MI)'1L&4/Y;/P>0 <>@S0![-1110 5XK\6/A1K6N>)$\5>%'0:@$C,T(F,4K2
MH0$DC<G:"%QW7&S(R37M59'B#Q3H?A6S%UKFIP64;?<#DEY,$ [4&6;&X9P#
MC.30!X''X^^-<>ES6;:%J,D[ON6];1'\V,<?*H"A,<'JI/S'GIC=^$'PNUVR
M\1CQEXH:>WNAN>""5PTTS2(0TDIY(X<_*?FW9SC&&[J#XS?#ZYN(H$\11AY'
M"*9+:9%!)QRS( H]R0!WKM+*^L]2LX[NPNH+JVDSLF@D#HV#@X8<'D$?A0!R
M'Q8TK6=>\ 7>CZ'IOVZZO)8D9?/2+RT5@Y?YR >4"XS_ !9[57^#WA'4?!O@
M;[%JJ^5?7%U)<RP95O*R%0+N4D-D(&R/[V.U=)XO\20^$/"E_KT]O)<):("(
MD(!=F8*HR>@RPR><#/!Z5G_#WQO#X_\ #3:O%8R63QW#6\L+2!P& #95L#(P
MR]0.<CMD@'5T444 %%%% !1110 4444 %%%% !7C^O\ _)<M._#_ -"MJ]@K
MQ_7_ /DN6G?A_P"A6U 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >;?%?3Y1%9ZS;Y#VJLC
MMC(PS*!VQ_$:Z7P]JB:G86]ZA&V0GI[,1Z^U:>N:6FLZ//82 ;9=O7V8'T/I
M7FWPYU&2UDFT:[)66(KY2CD<[W/.<>E9[3]3+X9^IVVJ>,K329_*GT_4G^;8
M'CA!4G)Z$L/2M72M5BU:T6XC@GA5AD+.@5N_N?2L'Q:L3Z79-Y:[OMB9.WG[
MK5K6#*EE;A0%'E+T&.U4KW*5^8UZ*8G*T^J+"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/BE_:'_"
ML/$/]F?\?'V0[_N_ZG(\W[W'^KW^_ISBNOJIJNG0ZQH]]IEPSK!>6\EO(T9
M8*ZE21D$9P?2@#Y8^ ^FZ;J/Q,@;4&3?:V\EQ:1N5Q)," .".2%+.,<@H#V-
M5/C;_P E>UK_ +=__1$=7/#G@CQ_X.^)5F]EX>NKFXL;@GS8UQ;SQ[3N F<;
M &0D9/()Q@-Q7H7Q[^'^J:\]CXBT:UGO9K>+[+<VT(WOLW$HR(!EN68-@GJI
MQ@,: +OQPTWP[KGPWB\5!H_MBI"VGW(/EM.DC ["",L-I9P.HP3P-P.=^S;J
MM]=:5KFF3W+R6=D\+VT3'(B,GF;]O< E0<=,Y/4G/S^MQJ>I)9:4LUW=)&Y2
MTM S.%9VY$:=BQQP!R:^G/@9X%U3PCH5[?:N/(N-5\IEM&7#PHF[&_T8[_N]
ML#/)( !ZO1110 5\G>.9;[XB?&Z32,/&J7HTN'9'YAABC<AWP "1G?(<] 2,
MX&:^L:^8OB3IE_\ #[XPQ^++.RG&FRW45XLD+2*KNV?-B:0@@,Y60E1GY6Z8
MXH [:]_9N\-R6DBV&LZK!<G&R2<QRH.><J%4GC/\0_I7G$-QXT^!7B>WANF\
M_3ILR&!)6-K=J=H?:2/ED&%&<9&!D%3\WU5!,MQ;QSH'"2('421LC $9Y5@"
MI]B 1WJOJNE6.MZ7<:;J5M'<V=PFR6)QPP_F"#@@CD$ CD4 >:?$7Q-I?B[X
M"ZOJ^D3^;;R" ,K</$XGCRCCLPS^H(R""8/V<O\ DG=]_P!A23_T5%7D_P 0
MO!&N_#.2^M+.ZGF\-:OMC\W (?:P=8Y1T$BE<AAC(SC&64>L?LY?\D[OO^PI
M)_Z*BH ]>HHHH **** "BBB@ HKSCQC\58/"GB./1AIE[=SO )@+> 2<%V7^
M^#U7T[U+X4^)<OB77(=.?0-5LQ)G][<69C085FY.X_W<=.] 'H5%<9XT^(5E
MX5DAL88)K[5KDE8+6V197W?+P4W!N0P(Q6;X6^*UIK&L#1=5L+O2M28?)'>0
MB .=RJ  SEB2Q/&.Q]* /1:\?U__ )+EIWX?^A6U>P5X_K__ "7+3OP_]"MJ
M /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\H\267]B?$[3-248CO9A&/\ OA$]_P"]Z"O5
MZX?XI6L4GA26[;<);?:8R,<9D0&HFM+]C.HO=OV)?$SYTVS'8WB']#6_9 ?8
M+?\ ZY+_ "%>+OXY>31["Q:'FU,?S;?O;5QUW5NV?Q3VQPP?9?NH%SY?H/\
M?J54C<A58WN>O+]VEIB2*PX-/K4W"BBB@ HHHH **** "BBB@ HHHH ****
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MY&:6K- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\EKZ9KY#O]+O-,U233;R'R[R)PCQ[@<$]L@X[^M>W_"7PGK?AE]6.L67V87
MB\K]ZC[MN_/W2<=1UJL=1C]7A[WPK3SVV_IBIR?M9.V_X;GIM>!^(?\ DO</
M_7]:_P#H*5[Y7@?B'_DO</\ U_6O_H*5R9=_%?\ A?Z&N(_A,]GUWPYI/B6V
MCM]7M?M$,3[T7S73#8QGY2.QJ%VT3P-X:.-MGIMJ#M3<6))).!DDDDDU?U75
M+31=+N-1OI?+MX%W.>_L!ZDG@5X3(_B+XO\ B39$/LVF6[<9YCMU/<_WG/\
MG Z9X>E*JFI2M!;]O^'+G*,=>HOP]@G\2_%276HH3';QS2W<N.B;]VU<^N3^
MAKT7XG>,_P#A'-'^P64A_M6]7;$%ZQH>"_U[#W^E=)X;\-:=X6TI;#3HR%SN
MDD;EY&_O$_Y%?/>L^)+RV^(]]K$T<%Y<6UXZQ)<J2BA&*IP".F 1SUYKKARX
MNOHO=BMNYE[U.#D]V,\6>$W\+:=HPN<_;KR)YKA2?N<C"?@.ON3[5]#>&_\
MD2]*_P"O"+_T6*^<O%GC+4?&,]M-J$-K$UNI5!;HR@@G/.YCZ5ZS\*_%VH>(
M+"[TZ[AMDATZVBCA:)6#,,$?-EB#]T= *TQU.K+#)SW5VR:4HJJK;?\ #'F/
M@'Q/9>$_$\FHW\5Q)"8'BVP*"V20>Y'''K7IS_&[PTT;*+'5LD$?ZJ/_ ..5
MP7PFT^RU+QM-!?V=O=0BUD;RYX@ZYW+S@CK7M\OA+PT(G(\/:2"%/_+E'_\
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ML]UC4M5LH;<#.;8/(Y.1QA@H'&><GZ5<\1?!B]N=20Z%+806,<*1@7$CB1F
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MA2,9Y_'&*]?HK*C7G1ES0*E%25F>-7OP8U%3!?:3J=O:7X97>'<XCB?DDQR
M;L9Q@%<CU.*:_P *?&6KR1P:YXH26T4EOFN)K@J<'!". ,]NHZU[/171]?K?
MTB/8Q/(/'_A>P\)_"V/3[$,V;V-Y9G^](V&Y/]!V_6NG^$G_ "3NQ_ZZ2_\
MH9KEO$?PV\:Z[J-X6UZWDT^6X:6&WGO)BJ*2=HV[2 0#VKOO V@77AGPI;:7
M>R0R3Q,[,T+$K\S$CJ >_I6E6I'ZM9RO)N_X$\O[Q66B_P""='1117G&X4R6
M-94*L,BGT4 <3K?@NQO[GSW,X;).%;CD_2L^Y\)0S:5/9*'.]"%+,>#U'0>M
M>AM&K=0/RJ/[*F<X'Y4N5$\L3R3PIK%QH&MMH6I_+'O*PLR[2?F5%Y.,C@]J
M]<MY5DA4@@Y'!%<3X\\(MJ-L-1T]52^MOGR"%RJAFX.,YR1WJ7P3XB2^TZ.R
MF=OMUFHBN%()^8;AUR<_=J(W3Y61!N+Y6=O12*P89%+6AJ%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 5[ZRM]2T^YL+N/S+:YB:&9
M-Q&Y&!##(Y&03TKQ"^_9HLY+R1]/\3SV]J<;(Y[,2NO'.6#J#SG^$?CUKW>B
M@#PBQ_9HLX[R-]0\3SW%J,[XX+,1.W'&&+L!SC^$_AUKV^QLK?3=/MK"TC\N
MVMHEAA3<3M10 HR>3@ =:L44 %4+70M(L=0GU"TTJQM[V?=YUS#;HDDFXY.Y
M@,G) )SWJ_10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5X_K_\ R7+3OP_]"MJ]@KQ_7_\ DN6G?A_Z%;4 >P4444 %%>27/Q1UN&ZF
MB6UT\JCLHS&^>#_OU%_PM77?^?33O^_;_P#Q=).ZN#5G8]@HKRW3/BO<_: N
MJ6$+0L0-]ME2@[G!)W?F*M>)?B)?:9JPATV.RGM'A26.21&)8,,]F'\J;T ]
M(HKQ_P#X6KKO_/IIW_?M_P#XNI(?BOJZS*9[&Q>('YE0.K$>Q+''Y&@#URBN
M%N_B"LOA-]5TV*,744J1RP3Y8)NSZ$9''!]NE<S_ ,+5UW_GTT[_ +]O_P#%
MT=; >P45Y"GQ6UH2*9+.P9 1N"HX)'L=QQ^5=WX8\96'B56C13;WB#+0.P.1
MZJ>X_ 4["N='17->-?$-WX;TF&ZLXX'D>81D3*2,8)[$>E<)_P +5UW_ )]-
M._[]O_\ %U-RK'L%%>/_ /"U==_Y]-._[]O_ /%UWO@S7[KQ%HLEY>1PI(LQ
MC A4@8 ![D^M58FYT=%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O']?\ ^2Y:=^'_ *%;5[!7C^O_ /)<M._#
M_P!"MJ /8**** /GZQD2'QC;RRNJ1I?JS,QP% DY)/I7MW_"1Z%_T&M._P#
MI/\ &N)G^$_GW$LO]M;=[EL?9>F3G^_4?_"H_P#J.?\ DI_]G2C=12!_$V,^
M)?B'3+^QM=/LKB*YE67S6>)MRJ,$8R."3G]*\VKU6S^$UI'/NO=4EGB ^Y%$
M(R3[DEN/\YJQK7PT@U.^6:UOULH$C6-(%M]X4 >NX46L.]SJ/#7_ "*^E?\
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MGN:U_AU_R)=I_OR?^AFFG?F$UM_7<ZJBBBD,**** "BBB@ HHHH *\Z^,/\
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M\/\ GTK9KM/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P +-^(G_0(_\F;?_P"(KW^B@#P#_A9OQ$_Z!'_DS;__ !%'_"S?B)_T"/\
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MD.UC@*SD] ?44 <I_P +-^(G_0(_\F;?_P"(H_X6;\1/^@1_Y,V__P 17O\
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M:&19(I%#(Z'*L#R"".HI] !1110 4444 %%%% !1110 4444 %%%% !1110
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MZRD1B6??\I7;C:[+TR?[OK6%K_Q0LK'7AX>TFTN+_6"VWRUC4(#N*8+.Z?Q
M>W-4/@Y(T7P:LY%^\D5PP^HEEKA/A$HN_CGXIEF&6V7;X]#]ICH ]0\-_$FR
MU;Q!)X:U&VN+'7H3LDMWC!0L%9CAE9APJYY/>O,?BAX^TKQ)=/IR:C/;6VG'
MS8PJ.IN)&0%<X!!4?,#G:?F&,\U5\>DV7Q\%W /WS=?_  %4=_8U[9XI\'6W
MB72'L5F^RNY)\W:7_A*]-P]?TH 7P#J5KJ?@;1Y+6;S1%9PPR':1AQ&N1R.>
MO6NDJAHFEKHNAV.FI)YGV6WCA,F,;RJA<XR<9QTS5^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\7^+NM:]J^G:KX7L?"NM7,;^3LNH=.D>-L&.0X<$YZ$=.HQ7M%
M% 'F/PO\0:O-867A[4O#.K6$=G8)&9[NP>*-R@1,;F/)/)QCH#7/7]KK7PS^
M(5]JNFZ1>ZEIFL.US<"SMGF,;;I< [=JC_6#@D]Z]OIKHDB[7167T89% 'AW
M@CPSK_B?XGMXXUVQFL%A962WN(9(B3Y31\*X/0JI^]WS[5[G2  # &!2T %%
M%% !1110 4444 (QPI(!.!G KY]^+VI>)/%]L^B6GA#762SU NLZZ;)LD5!(
M@*L"<@[@0<<U]!T4 >>_"W5M2O?#=OHVJ:!J.G_V;:P0!KVS:)9<*02I8_-C
M:.PZCUKS[2]-\0?"#Q%K"6&C7NIV6H0HD#6EK)-B15!&X@*,9=NF3Q]:^@Z:
M\:28WHK8.1D9P: /&?A9X*U63Q5J?C+7K9[>6\DE:.VFC9'0NZ2@[77@#D=?
M\:]HHZ# HH **** "BBB@ HHHH *Q_$^KW.AZ%/?VFG76H31[=MO:P&61LL!
MPH()P"3] :V** /F_3=7\46/Q2U/Q<?!7B$QWELL C&E2Y&!$.F?^F?KWKT/
MXD^'[[Q]\,K9[>RD@U$/!=+!-$RNI*X92H#$$;SQVQ7IM% 'SQKOB;QMXL\'
MCPQ_PBVK0W4W_'Q/)I\RJ,2"1<-DGHN.17N'AC14\/>&]/TQ=NZWMXXY&7HS
M*BJ3T&>GI6H(XU<N$4,>I Y-/H **** "BBB@ HHHH *YOQGX@OO#VE1SV&C
MW^J222B,Q6=LTS*"K'<0",#@#/N*Z2B@#YP\&:SXH\+^)O$FJR>"O$,BZO=?
M:%5=*E)7YI#@\C'^L]37HOQ4\,7FLZ?I_B#3+=GU+19/M,4"H2\AWQG 506)
MPG8BO2J* /GCQ'?>+OB79Z3X=;P]J=A#'+"UU<7%E+$N\ H_S?-QA\\CMS7N
M?AO21H7AC2])R";.UCA8CH2J@$]!WSVK26-$)*(JDG)P,9IU !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIJD%K#/%>O;A;5&52H1&S\S,<Y8]_2@#NZ*** "BBB@ HHHH **** "BBB@
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M,K*#@@DHO4=">,]/G/Q9<:5=^+=6N-#B\K3)+J1K90,#86."HVKM4]0N/E!
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MS?<\4?6U_P#:M<?\>O#O]C?$.2_BBVVVJ1+< I#L02#Y7 /1FR Y/7]YSZD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'? SZ"O0/"GP@\(^$K@7=M9R7UXK[H[F_82M%RI&T !005R&QN&3SCBN[HH
MS-?\.Z3XHTMM-UJR2[M&8/L8E2K#H0RD%3U&01P2.A->/ZE^S5ILMPK:7XCN
M[:';ADNK99V+9/(92@ QCC'8\^GN=% 'E'ACX ^%M$EANM3DGUFZCY*S@) 6
M#9!\L<G@8(9F4Y.1Z>KT44 >>>*?@MX1\5:H^I3175C=RN7G>QE""9CCEE96
M /&<J!DDDY-</!^S/"MS&UQXKDD@#@R)'8!&9<\@,9" <=\''H:][HH X#PA
M\'?"W@W5UU6R^W75]'GR9;N<'RLJRM@(%!R&(^8'MC%=_110 5\@_&[_ )*[
MKGTM_P#T1'7U]7AGQ)^">N^+?&]YKNEZCIJPW21[H[IG1D94"8&U6!&%!SQU
M(QQD@'2?!37M'_X5SH6D?VM8_P!IXG_T/[0GG?ZV1ON9W?=YZ=.:Z#QU\.-'
M^( L!JUS?0_8O,\O[*Z+G?MSG<K?W!Z=Z\G\)_ +Q)I'BW2=4O\ 4]*%K974
M=RX@>1W;8P8* 44<D 9SQG/.,'Z'H X_P+\.-'^'_P!O_LFYOIOMWE^9]J=&
MQLW8QM5?[Y]>U7?&O@K3?'>C1:7JD]W#!%<+<*UJZJVX*RX^96&,,>WI71T4
M <'X*^$V@^ ]9FU32[O4IIY;<V[+=2(RA2RMD;44YRH[^M+XU^$^A>/-8AU/
M5+O489H;<6ZK:R(JE0S-D[D8YRQ[^E=W10!R'@;X<Z/\/Q?C2;F^F^V^7YGV
MIT;&S=C&U5_OGU[5)XX^'NB^/[:SBU9KJ)K1V:*6UD"L P&Y?F!!!PIZ9^48
M/7/5T4 >>>$O@SX9\'>((M:LI]2N+N%&6+[5,A5"PVE@%5<G!(YR.3QG!'<:
MKIT.L:/?:9<,ZP7EO);R-&0&"NI4D9!&<'TJW10!Y9I/P#\*Z-K-CJEO?ZRT
M]E<1W$:R31%2R,& .(P<9'J*]+O;ZSTVTDN[^Z@M;:/&^:>0(BY.!ECP.2!^
M-6*YCXA^'+SQ;X%U+0["6"*YNO+V/.Q"#;(KG) )Z*>U 'SY\?=6TW6?'%C<
M:7J%I?0KIJ(TEK,LJAO,D."5)&<$<>]>E_LY?\D\OO\ L*R?^BHJ\_\ ^&<?
M&'_02T/_ +_S?_&J]H^%?@F\\!^$I-+O[J"XNIKI[ES #L3*JH4$X)X0'.!U
MQVR0#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gjnp4w4lrub1000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *C!4H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO%O_(G:U_UXS?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5C>+?^1.UK_KQF_P#0#6S6-XM_Y$[6O^O&;_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSGG(-5_^%?QS-C4/$&L:A ?O074P9&^HQ0!3\)2'7/&NL:]'%BT5/LL,F/\
M6 $-D>U=[5>RLK;3K..TLX4A@B&U$08 %6* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_D4M&_Z\8?\ T 5K5D^%_P#D4M&_Z\8?_0!6M0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E:MX9T37MO\
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M\_["U[_Z.:@#M(94G@CFCSLD4,N1@X(STI]%% !1110 4444 %%%% !1110
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M1110 4444 %8WBW_ )$[6O\ KQF_] -;-8WBW_D3M:_Z\9O_ $ T /\ "_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1\+/^17O/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?"S_D5[S_L+7O\
MZ.:NMO=2L=-C#WMU%;H>\C!17$?"?4K*?P[=P1743RG4[MPBL"2IE8@_3% '
MH-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT[4'LH;*^U">(9F6SB#^4/\ :YXH Z6BJ.D:O::W8+>6;[HR<$'JI]#[U>H
M*QO%O_(G:U_UXS?^@&MFL;Q;_P B=K7_ %XS?^@&@!_A?_D4M&_Z\8?_ $ 5
MK5D^%_\ D4M&_P"O&'_T 5K4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5%/;6]RNVX@CE7TD0,/UJ6B@"E%H^F02"2'3K.-QT9(%!_05;9%=
M"CJ&4C!!&0:=10 R**.")8H8TCC48547  ]A3B 000"#P0:6B@!D4,4";(8T
MC7.=J* /TI%@A69IEBC$K##.%&X_4U)10 5'+;PS[?.ACDVG*[U!P?7FI**
M#I4<D$,VWS8DDVG<NY0<'U%244 %,EABGC,<T:2(>JNH(/X4^B@!%4*H50 H
MZ #I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4A(4$DX [UY)\2OC)9^'$ETS1V2YU'E6<'Y8C_C0!U7CGXC:1X)LF,\@EO6'
M[NW4\D]L^U?,VJZUXF^*'B18E66>21OW=O']U%_P%2>&_"GB3XFZ\TTCRNC-
MNGNI?NJ/\:^GO!G@/2/!>G""RA5[AA^\N&'S-0!XK-^SKJYTJ&6WU"'[:1F2
M.0X4>PXS3M _9XU62[1]:O88K8'E822Q_,5](T4 9^BZ-9:#I<.GV$0C@B&
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M &O_ *QKW-$6- B*%4= !0!3TG1[#0[".RT^V2"!!@*HJ]110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5XC\?[O2(;*S#J?[51]T3+V^M>W5\]?';3DC\4:7J<SJUON19$W<@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H!K9K&\6_\ (G:U_P!>,W_H!H ?X7_Y%+1O^O&'_P! %:U9/A?_ )%+1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5R'B;XC>'_  KJ LM3F*3%0P  Z&NEN-2LK1PEQ<QQL><,:XKQ
M+X5\&>*[];W4IX7F"A0=_:@#/NOCCX/2VD9)WD;:<*%'/ZUYS\)_-\0_%F\U
MNW@9+7,CG X&[.*[U?A;\.E8$M"<'IO/^-=OX;L/#>BQ?8]$%O'GG:AR30!T
M-%%% !1110 4444 %%%% !1110 4444 %8WBW_D3M:_Z\9O_ $ ULUC>+?\
MD3M:_P"O&;_T T /\+_\BEHW_7C#_P"@"M:LGPO_ ,BEHW_7C#_Z *UJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE[SX>^&[ZZDN;B
MRE:60[F(N9!D_0-0!U%%>3?#_P #Z#K'AZXN;^WGFF74+J(,;J0859651PW8
M"O3].TZVTJR2SLT*0)]U2Q;]3S0!:HHHH **** "BBB@ HHI"P'4@?C0 $@
MDG '6O(/BK\0_#HL(=+BO5GNH-0MYI%B(.T)(&8?7 JY\:O&AT+PM]CT^Y5;
MNZ8H2K?,J\9_0U\K.[2.7=BS'DDG)- 'V=X:^)?AGQ3,(+"^47!&1#)@,?PK
MJ;J[M[*W:>ZF2*)>KN< 5\&6EW<6-S'<VTK131L&5E."#776T?CGQ_*IB-[?
M+]TLO"C'KB@#Z#\0?&OPGHH=(+O[=,. +?##/OS7DOB+X_>(-2+Q:7%'81]
MR_,Q'XBM3P]^SQ?W)677+\6ZGDI#RWXY%>M>'OA;X6\.A6@T])9QUEEY)_#I
M0!\WV7A;QWXXG\XPWLL<AYEE+".O1O#G[.P&V77M0(8<F* 94_CP:][CBCA7
M;%&B+Z*N!3Z .9T'P!X;\.QA;'3(0W=G&\G\ZZ555%"JH51T &*6B@ HHHH
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M!K9K&\6_\B=K7_7C-_Z : '^%_\ D4M&_P"O&'_T 5K5D^%_^12T;_KQA_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6O\ KQF_] - #_"__(I:-_UXP_\ H K6K)\+_P#(I:-_UXP_^@"M:@ HHHH
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M_E7J%% '(6?PP\&V6"F@V;L.0SQ@D5OV>A:5I^/LEA!#CIL7&*T** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJIJ.IV6DVC75_<QP
M0KU=VP*\.\<_'T(9;'PQ&&[&ZD'0^PZ&@#UWQ+XST3PI:M/JEXB,!D1*07/T
M7K7SSXU^->L^)'?3]&5K2T<[04_UC_CU%<_HGA#Q;\1]2%RXFDB=LM<3L=@'
M?&>/PKZ \%?"#0O"BK/-&+V^QS)*N0/H.10!XUX-^#.N^*9A?:N9+2T<Y9Y<
M^8_X'FOH;POX'T/PE:)#IUH@D YF<;G/X]:Z, * %  '0"EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'P3\1ZQ?1-JMI)I]F""_G##,/:OJT@$8(S2T 4]+TVWTC3;>QM4"PPH$ '?
MZU<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O!OC[XEFWVOAVWB#-+ABV.>>@'Y5[S7SU\>;JPM_$6GSH3_ &A;E9"IZ,H/
M']: .=T3P)\2H;.*6RDN;9",JI(X%=_X \/_ !!L?%,,VO7<TEB$;<K$8SCB
MC1OC_HC:=$E]:S13(H#<C!/M74^&?BSH?BG68],LED$SJ2"W3@9H [^BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M24FFGL=.73DTT]BQ1117:>F%%%% !1110 4444 %%%% !1110 4444 %%%%
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MMM#LDE!R&$0ROTKI** $ "@ # ' %+110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BD)"@DG '4FO(/&GQ,NA?26&CL(XXSM>7')(]*UI4I57:)C7KPHQYI'
M?Z1_R-_B'_MW_P#0#70U\UV/C/7+"_DO([QFEE(,F_)#8Z9KVOP5XOB\4Z>S
M,!'=18$B9Z^XK;$8></>Z'/A<7"H^39ZG4T445R'<%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\T?'J.6;Q[810'$KQH$.<8.3BIHOA?\ $IXE
M8:O* 1P/M9_QKVS6_ NA^(-4AU'4+=GN(L;&#D8P<UTB*$0*.@&!0!\Y?\*L
M^)?_ $&)?_ L_P"-=/X!\">-]$\4PWFL:C)-9JC!D-QNR2..,U[/10 4444
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M*JP5-J^K,\%0G*JI6T1V5%%%>.?0!1110 4444 %%%% !1110 4444 %%%%
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MZU[E_P *<TO/_'_-_P!\#_&D/P<TPCC4)A[^6/\ &E[/"]V3[+'=_P 3P_\
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M%.HIC*L>G64+[X[6%6]0@JU11222V$DEL%%%%,84444 %%%% !1110 4444
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MT+1P/L]DC,.\HW_SK>1$C7:BJJCLHP*=17-*3D[MG9&$8JT58****DH0*!G
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M:IR?%G7F!VK&F>F.WZ5ZJG@;PY'C;ID8QTY/^-7(_#&C1-N33X0?I1[;#K:
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M40?8"Q9<G./>MH  8   ["EHKQY2<G=GOQBHJR"BBBD4%%%% !1110 4444
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MBN*_X0?6?^A]U[\HO_B:/^$'UG_H?=>_*+_XF@#M:*XK_A!]9_Z'W7ORB_\
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M>^ /$=G<&(:;+*N<!T'#5U/@_P"&-ZU[%>:PAACC8,(3]XD>M=?_ ,(-K/\
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M7ORB_P#B:/K%7^8/JE'^4C_X55H']UZ/^%5:!_=>I/\ A!]9_P"A]U[\HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?$GB2\M=0AT;1(%G
MU28;LO\ =B7U85U5<!X=/G_%7Q%))RT<$"J?08:@"236_%/AF:";Q&UE>6$S
MK&9;.(Q^23TW9)R*[F.198ED0AD<!E([@U@^.(EE\%ZL&Q\ML[#/J%-2>#[A
M[GPGILCC!\A%_("@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH XK4/$VK:IKD^B^&8X5FM@#/=W
M"[HT/IMR"3Q4"^)/$'AO5K:U\4&TN+:[8)'=VD915<\ $$D\DBNSMM/L[.66
M6WMHXI)CND95P6/O7G_CFY3Q-K5IX<T_]Y+;2+=W$J\K&$(8 GU.#0!J7_B+
M6M7UF72_"ZVZBWQY]Y<+OC!_NX!!SP:=IOB+6-,UR'1O$PMWEN06@N[="D;8
M_AP23GD54^%"@Z!?S'_6/J-P&/KB0U+\3?W6FZ7=*!YD6HP;?7[U '<T5' Q
M>WC<]60$_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5P&H2Q^$O'[ZK<HZV&I1K&\J@D(RC SCH"3UKOZAN;6WO(&@N88YHFZI(
MH(/X4 <3XU\06>J:1_8FDSI>7=^1%_H[!PBG@EB.F,]ZZ_2;+^SM(M+/C,,*
MH2.Y  IECH6DZ7(TEAIMK;.W5H8@I/Y5H4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!>,?&\5
MO>KX=TJ\MH]3G&'EEE54A7N<DXSC/&:N^&8/#.@V)MXM9T^>[GYGG-TA>5CU
M[YZ]!6S<^%M O)VGN=&L)IG.6>2!23^.*8G@_P -QNKIH6G*RG((MER#^5 '
M*^&;^U\(:O?Z'J+_ &>&:9KFWG<XC8.2Q&[H.H[T>(;N+Q?XCTO2-,?S[>VF
M6ZN+A#F,;""%W#@D\]Z[B]TG3M1A6*]L;>XC7[JRQA@/SI;'3+#3(C%86<%M
M&3DK"@4?I0!:4!5 '0#%+110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%96L^)M$\/>7_:^IVUEYN=GG
M/MW8]* -6BN8A^(O@ZXD$</B/3W<]%689KI(9H[B)987#QL,JRG@T /HHHH
M**** "BBB@ HHHH **** "BBB@ HK)UCQ/H>@%!JVJ6UD7^[YS[<U=L-0M-3
MM$N[&XCN+=_NR1G(- %FBLCQ)XBL_"^C3:I?K*;>(981KDUYY_PT-X._YXZE
M_P!^1_C0!ZU17!^$_BSX?\8ZJ=.TV.\68+NS+&%&/SKO* "BBB@ HHHH ***
M* "BBN&L/BKH&H>*SX=ACNQ>ABN6C&S(..N: .YHHHH **** "BBB@ HHHH
M**** "BBN&M/BKH%YXK/AR..[^VARF3&-F0<=<T =S1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.]?65?,GQ^_Y'O3O^N/_ +-0!ZMI7AWPGX"\-_\ "40:68Y8K</*\3$LPXZ
MG%4U^//A1M-^V;+L$R^6(2HWGCKC/2M+QI_R1B^_Z\E_F*\A^!W@C2O$UU?7
M>KVHN88,".-B<!LCGB@#Z)M-?L;GP]%K<CFVLY(_,S-P5'O7 ZC\>_"%A>-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!?M(G T
M4_\ 73^E>^UCZWX6T/Q)Y7]LZ9!>^5G9YH/RYZT >/Z7^T'HNG:'9V0TB_>:
M"!(R<KM)"@>OM7,:-;ZW\7OB)%JEY;/'IMLX)X^5%&/E^I KW!/A;X'1@R^&
MK$,.0=I_QKIK+3[33;=;>SMXX(EZ*@P* /(?CMX0N-0\/6>I6,32-IZ>6RJ.
M0G<_H*Q/#7[0$.F:)#8ZOI=S+=PJ$#0XP<>N37T"RA@0P!!Z@US,_P .O!]S
M>&[FT"S>X)W&0J<Y_.@#YHO/%-WXN^)]AJ5U 8 TP$<9'1:^I/$&CPZ]X5N=
M.F4%9H,<]N,U#/X&\,7-_%?3:+:O=1?<E*G*TSQOKO\ PC?A.\O(XV>58]L2
M(I))H ^3M+T;4]0\56_A)IG,0N^8_P"$'')_(5]AZ?96N@:)%:Q );6L6.!T
M KQOX%>&II[S4/$^IPO]HD;;'YJX.>#G^E>Z$ C!&0: /!O&>I?#+QC;WL]Q
M=)8:G%N"2[2'F(Z=NA-'[.MEJ,7]J7,@D&GNJK$6Z%@3G'Z5ZK?_  ^\):G=
MFZO=!M)IR<EV4Y_G6[96-KIUJEM9P)#"@PJ(, 4 6*\&^.7A2_CU:S\6:="\
MQA*^:%&=NW&VO>:;)&DJ%)%#*1@@CK0!X5IW[15C!I4<-]H]V;Y$VDQ[=I('
MN<USW@G3M5^)'Q._X2:\M6AM('#[\< K]T<^PKV^?X;>#;FZ-S-X>LWF)R7*
MG.?SKHK.RMK"W6WM($AB48"H, 4 ?.GC$8_:)T\?]-X/Y"OI%?N+]*Q;GP?X
M>O-:36;G2;>344(9;A@=P(Z5MT %?,GQ^_Y'O3O^N/\ [-7TW6%K'@SPYK]V
MEWJND6]W.@PKR Y _.@#G?&G_)&+[_KR7^8KBOV<?^09JG_77_"O:+K2K&]T
MQ]-N;9)+)TV-"WW2OI571/#.B^'(Y$T?3H;-9#EQ$#R: /*_COX*N]7M[;7+
M"W\^2V&V9 .2@_\ KFO/=%\8?#RUTZ.'7/ @>\089X<@-[\M7U60&!# $'J#
M7-ZA\/?"6JW37-]H-I/,W5V4Y/ZT >)^&]5\#^)/$J6%G\.@]M)@(RYW+ZD_
M-C%>D?%'P&-=\#1V.D0B-[ 9@A7IM&,@?@*[;2?#VD:%#Y6EZ?#:IZ1K6G0!
M\R> /B[-X$T]]$US3;B6*%SLV !U/<')QBJ7Q,^*L_C?3%M+&PFMM-1@7:0<
MD]NG%?1.K>"?#6NS^=J>C6MU(/XG4Y_2D;P/X8;2SIC:+:FR)#&':<9'2@#C
M/@)_R3J/_KL__H1KS#PK_P EZ?\ Z[O_ .A"OI+2-#TS0+(6>E6<5I;@DB.,
M<9-4+?P5X:M=7_M:#1[:._)W>> =V?SH \'_ &B/^1NTS_K@W\Q7T)I'_(N6
M?_7LG_H(JKK7@WP[XBN8[C5])M[R:,;4>4'('YUM1PQPP+#&@6-5VJHZ >E
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MEBWG@'=G\Z -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I" 1@@'ZT44    P !]*6BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gjnp4w4lrub1000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N!X@# 2(  A$! Q$!_\0
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M+N&=6Q@UM:3K-OJ=L)4=2<98#M0!J452DU>QBDV/<*&]*L?:(O*\W>-F,YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LD$_P!LL.V*UJ@^S+]H,O<T 3#I2T44 ,DD$49=N@KS
MOQ!J#WFHR1;LPCD"NYUARFE3L.RUYB)?,&]NII2=HG'BYM+E%' Q2U$TE26C
MQM./,;:HK)0;/-6X]8W89"-^5-8,IP5(^HKJXM4MD,<4$4<@(Y.*B\16\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYDC@9'&:BTC68-4@WHX)SCB@!Z:)8QNSK%AFZU8:R@: PLOR'M2R7UO&X1Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "J/V-_M[3Y&TU>J/SD\SR\_-Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7Y+_ -KL^/EQUH U**!THH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI* %HI,TA- #J*9FD+4"N/S1FH]]&X4[!<DS1FHMU&ZBP7)<T9J+
M=2[J+!<DS2U'NI<T!<?12 TM(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 QY$C^\P'U-5;K4(K> R AO8&J&O6]Q.8A"#[X-<;K5
MU?:.WF2+^Y'4DU48N3L@;.ADT^U,4^H72!MHWKGM7 D/K/B(W-O^[@ []*VM
M>\4)>:;:VEHX9YDVL!^-88FET/2S:;1Y^<\]:ZZ4&EKNR)5&^IT2ZR;_ &P(
M#_HO#'UJ6WU=KJ]:Q"L,*37$Z3J]QI\D[%5S,>]:OA[5'?Q.99E4*4Q3]DDW
M8TE2G""E+J;/@&^D36-2BE8G]Y@?I7IU>3Z'&;3Q#*_032Y%>KCH*QQ"]ZZ,
MX/06BBBN<L***S=8O7LK7?'@MG'- &CD'H<UR?C"ZCTNT^U1D"5FP2.M,;Q*
M;*W>24@'&:\Z\1>(KK7[@Q1@&(-D8-;T*3G+R(G)11WWA[[9>V[RK-Y>>>:?
MKNEW=W9>6U\GRG/)KCK36?$MM9K'!:)Y87&?\BG[_$5_%YDL&U#Z,:OV%I7N
M.%6SNB*UN=3L]4CA%WO3=CY:];TMWDL$9SEC7FWAK1W^U&:Z!&UN<UW,FI^2
M/*M<-MK.M:]D;U*WM$M#<HJAIVI)>HV&^9>#5^L3(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BD+!>M (/2@!:*** .2US_C\A_P!\5U47^I3_ '17*ZY_Q^0_[XKJ
MHO\ 4I_NB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !36"D?-3JH:K.T$*,O=L4 7^U%,A):%">XI] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A('6@!
M:*C:9%ZFF?:X?[U%A71/14'VN'^]1]KA_O4[,.9$]%5_ML']ZF'4K9>KT68N
M>/<MT53&IVI. ]6(YDE&4.:+- I1>S)****104444 <YXHU%["U#HY7YL5/I
MVHV\MJO*I(P[GK63XZC22P57) WCI67?6\5M+IGE2-\RCO0!TYF5+LFXE5D_
MNDU,UY8331JRJ3VYKC=79C=XW$9/K5Z?3D@CAF5WW;<]: .IO;NSA@*':V/X
M0>E<W!?_ &I)F1]I0X4YZ50TT"^UF=;AV"[">OUJO'#';V-^(F)Y- '96-W#
M!IR2W$BNYZL3UJU'?6=\I63:!T&3UK@TA^T^'K56=A\_8_2I]9B.GRV@@9N4
M!ZT =D+^SM)3%&%&/0U>M;N.[4M&0<>E<9#96]Q9&XEE<3$'(!K0\%9\BY&X
MD!R!D^] '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-PN[/>G5FBX?^U6B_A H TJ*
M!THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFDT +FD)II:HV>G
M8EL>6IA:HV>F%ZI(ER)=](7JN9*C:8+U-.Q+D6B])OJD;I!WI/M:?WJ?*1[1
M%[?1OJA]K3UH^V1C^*CE#VB-#?1OK--_$.K4?VE!_?HY6'M8]S4#TX-6?'>1
MR?=;-65>DXEJ:9;#4X&JRM4JM4M%IDU+3 :?4EA1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'BN@HV\#%=Z#D T2BXNS%4IN#LQ:***D@**** "BBB@ HHHH **** "BBB@
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MP<5HP6%W<V^U%^0]^]<,[MW9K=O<Z]6#J&!R#2U7LXVBMD1NH&*L5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9FL[O(CQ_>%:=130).H#=C
MF@!8/]2GTJ2D4;5 ':EH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBFNX1"S'@4 *S!1EC@5SNL:\L*F./DGC(JOK.O [HH&XKF&9I'+,<DUU4:%]
M9'F8K&\ONP'2323.6D8L3ZTREI0*[-$>1JW=B 4N*=BE"FBXTAF*,5)MI-M%
MQ\HS%)3B*2@30VBEI*9+"BBBF(*W/#MZ;>8QD_?-8=3V;F.]B;T-14CS1L;4
M*CA431Z914%I-Y\ <=ZGKRCZ5.ZN%%%% RIJ*[K8_+NQVKAI#<2ZFBP6KPJ&
MPQ ZUZ)UZTSRDSG8OY4 <=IUE<1Z]<NZL08S\V/K5"SLK@V>HPM$P\QCCBNX
MN+NWM6S)@$G'2K"!&4,JC!YZ4 >?:;$MM;16<VGE]A'S$5W]N +>/"[1M''I
M3O*3.=J_E3Z "BBB@ JG?:E;V,+/)(N1V)JMKFK1Z7:>8S8)X%>3:QKESJ4Y
M+M\H/&#6E.FY'10P[J:]#H];\=&0M#;J5(_B%<A)J^H7$N?/=B3Q5(C-=-X3
MT"34+I)V3,2GDUU<L8*YZ/)"C&YW_A)IWTJ$S%B<=ZZ*H;:W2VA6*,845-7$
MW=W/(G+FDV%%%%(D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *R1G^V6],5K5%]G3SC+_ !&@"0=*6BB@ HHHH **
M** "BBB@ HHHH **** "BBFDT !-1,U*S5"[521#8,U0.]#O63J&I);J0#\U
M:1BV85*BBKLDOM02VC)R"P[5S%Q=R7+EBQVGH*9/.]Q)OD/TJ.NRG345=GD5
M\0ZCLM@Q2XI<4N*TN<UA,48IX6EVTKE<I'BC%2%::13N%AE)3Z;0382BBBJ$
M%%%% B2WE\B82#K7:6<N^W1L]17#D9KIM%N3+&4S]T5SUXZ7._ U+2Y3H$-3
MJ:J1FK*&N)GLQ9.*6F T^H+"BBB@84444 %-)I3TIK4"8QC43-3F-59YA%$S
ML>!5I&<G8=),L8)9@/K6%>Z\L>41<GU%9NHZK)<R%$/[KM69WS773H=9'EU\
M:_A@6)KVXED),K;?2M30Y)6EZG;GFL6*-I9 B\G/-=?IEFEI",#EN3557&,;
M(RPL9SGS-FP#4H-55:I0U<31[298S2YJ$-3MU38JY)FEJ/=1NHL.Y)13,TH-
M(+CJ***!A1110 4444 %%%% !1110 A( R34?VF'IYBY^M1WOF>2=GIS7':G
MY]M827,).]3ZTTKNP&IJ$<>LSB-XQLB/)/>N-\6&V24Z18Q!9'&0R5J6'BRU
M2QG61\3A#Q[URUDUQ+?_ -NSC]U&2,_Y^E=-&FXN[)<W:R9MV6I-I5K#;.Q=
MY!M(JY'J[:5J"AHR21FN$N]1FEU5;@?<5]RU>U'7I+FX6Z;'RC%:.BN8J-.;
MI^TZ&OJ.H7,6M6<N]E6:0<5ZO;OO@0_[(KR;74$L6BSIU)!/ZUZ?I$GFV*'V
M%9UTN5,SB]2_1117*:!1110 4444 %%%% !1110 4444 %-=MJ$XS@4ZB@#B
MKV>XU'4TS ZK&V.1UKJ;&VCCA#>6 U6?*0'.T9^E/H **** "BBB@ J.8D1-
MCK@XJ2B@#B)9KJT\V>8L0K$@FN!\0^)KJ_F:!7=4SU[5Z1XRDN&M'M;507D7
MBN%OO#8MM'M9;M2LTCA6_,5UX:,4^9F=1Z&9I&G22(?*U5;?<<D9J_#H\LER
MZ2ZTK!>Y/6NB3X=6#6J3*T@RH/6N0U[2+;3GV6\C[P<'FM_:QD]'^ 4Z,I.T
M4:=MID$>J1%KE)0.O-=TNI1V]LL,*X/3(K@=!ATN&P>ZO97$B'CFMW1;F/4+
MJ3:V;=!N!KGK1<M5LBW&4'RRW.DLM2N([^.!PTBOSN]*Z<'(S6+I%QIUX"UL
MVXH=I^M;=<S36XPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%&1ZT
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M% !1110 55OKK[)&K8SDXJU6?JT+S0($'(:@"]&V^-6]1FG4R$%84!Z@4^@
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M-W=^1.JI'$=P+=*W9;&.2Y68YW+6+XKT^:XLQ]F'[PGFJBW<:2;L9.O^)XX
MMA;$'<N-ZGI7!RK-=7;APS@<[JU_^$.U=PTA3//>K\VGOHNF))=* TGRUT0L
MM$=RG3HT[HYNQTR2]U"-!(1;YPY[5JZI>>4%TO3(L2*=K21]Q3K$F*TELK<?
MOYCN6NN\,^%DM,75RG[]A\V:VG)1U9YCG*H[LE\&Z'-I5B?.D+LYW<^_-=72
M* H ':EKAE)R=V6E8****D84444 %%%% !1110 4444 %-D?8A;TIV:AN9(X
MX&:0_*!S0!S'B'Q7%I\&$P9,X*@\U7\.^*#>,5E&W<>,U3O/#EMJE_+>$$PD
M9'X5RYG":W"NG_ZF-L25O""E'0W<Z4866YZAJUPYMP8V*\]15?1A-(&EEG;:
MI[UBR:N+B,P YV#)IMIKT9T:Z6%OWP.!6:@V<]SNUD1_NL#3JX3P9KES?:E)
M:SMG:N:[NB<'!V8)W"BBBH&9EY9-O\V)B&)YQ4EKYC$;P>/6K]% $7V>'?N\
ML;O6I" 1@CBEHH Q8M$VZC)<.^Y6.0I[5L@8 'I2T4 <EKG_ !^0_P"^*ZJ+
M_4I_NBN5US_C\A_WQ751?ZE/]T4 /I" PP1D4M% $<L0D@:/LPQ6%#X4LD<L
M\2.2<\BNAJK?WB65NTK]!33:&I-;',7=G::<LRPA"T@Q@=JY>UL+RYN/LBHX
MW'/G>E=)I\4=]?RR39*,?EKK+6RAM4 C7]*UA5<43-.;NS.T70H=.B#%5:0C
MYF[FMJBBLI2;=V"5@HHHI#"D-+67K-Z]K:L8OOT :88'H:X[QI=QZ=:-<H1Y
MN<8'6HAXH-E;RO<MAL96O/=8UN[\1791&!C)XK>A2<Y>1$Y**/1M!CN+VT$S
M7#1[ES1K^F?:M.,1U#!SGK7(V]UXF@LE2!HQ&JXZTV.W\37\/F.R;#[U?L4G
M>XX5&G=%>REU"WU2.*.\DD17P0*]@TYWDM%9P<^]><>%M&N(;J26[QPV:[63
M4RK^5;GI6=9J]D;U*WM$M#=HJCI^H)>AE!^9.&J]6)D%%%% !1110 4444 %
M-;;CYL4ZL[5I7BA0KW:@#1'3BBF0DM"A/4BGT %%%% !1110 4444 %%%% !
M1110 4444 %9VK7JVEL<]6&!6C7'>)KGSF$>?NFM*4>:5CGQ-7V=-LP)9&ED
M9F.3FF445Z:5D?.-W=V%+244 *#2YJ'YP>.E+YH7K18=R;-&ZH//2CSUI6#F
M1/FFE@.IJ+>S?=I C-]ZG87,*SECM'YTJICKS3E4*,"EHL 4444Q!1110 44
M44 =)X8?_2 GM77UP&B:A%97>^4X7%;-QXSTZ/(#G->;77OGT&!=Z)TU%</)
MXXAS\CU6/C>3/#UB=AZ#6/X@GVZ?)"#\SKQ6/IGC*"9PD[\TNLW:W.K62QME
M'ZT :OA>!H=%A#CY^^:VJCAC6*,(O05)0 4444 %%%)D>M 'GGCJ+:"^.K5P
M$[;8SZUZ=X]B!T]6&/O5Y5>-A\5V4G[IZ^%=Z95)R<TY99$^ZQ%,HK4V+*ZA
M=I]V=Q4JZSJ*CB[D'XU1HHLA<J[&JOB'4U'_ !^2_G4B^)=2'6ZD_.L:BERH
M7)'L;H\4ZC_S\R?G36\3ZB?^7F0?C6)2@$G HY4+V<>QK_\ "1:FYP+N7\ZV
M_#FMWJ:K$9[EW3N&-<U#"%&3UJU"YBD##J*3BFANE%JUCWBVF$\"R#HPJ6L;
MPW=B?2H5SE@O-;-<+5F>-)<LF@HHHI$A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %-^7=VS3JS/.?^UFCS\H% &G10.E% !1110 4444 %%%%
M!1110 4AI:0T ,8\5 YJ1S5=S5(SDRO/($4L>@KCM1N&FNG&<J#Q70:Q<!+9
MU!Y(KE,EN3790CU/)QU77E04445U'FBBC-)3'W?PTAW)<TN:@#LOWJ//6E8?
M,3YHS4'GI1YH/W:+!S$Q.*C>3'3FF8D;KTIRH!3L*X@0L<D_A4G2BB@04444
MP"BBB@ J6V;%S']:BH5PDT;'H#S2EL5%VDCMHF^45:4US7_"16<"X9CD5 _B
MZV'W'->:VCZ""=CL5-/#5PC>,#_"]26_C$&51*_&:FZ-DF=SFG!JS;+4X+V,
M-$W7WJZ&]Z N3;J3=4>ZC-*P7'EJC8T$TQC32$V1N:Q]77,#'T%:SFLW4<-:
M2<CI6D-&<];6#1R.X;,UA74IED.>QK5N6\NWK$8Y8FN]G@,0<=*D$TB]'(J.
MBD*[)A>7*])F%2#4;P?\O#U5HHLBE.2ZET:K>#_EX?\ .GC6+P?\MG_.L^BE
MRH?M)]S0_MB\_P">[_G2?VM>DX$[_G5"M"SM"QW,*.5![2?<MVMQ?2,K-<R
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MRY(\R-USZBM[PZ =5^;TKO54!1@"O/Q/QGNY<[T3SR#P"T@RUP5JR?A\ O\
MQ\UWE%<YWGD.I^'KO396\I7<+_$*R[#5KB"[$DI9S&> >U>OZU-'!99?HW%<
MI9^#X+E9IF3YG.5H FL/'0D 62';[FMF+Q1:.N2Z#\:Y2Y\$7N3Y*C%9[>$-
M44XP* .ZD\4VJ='0_C5*;QK%&/E0-7)KX.U5N@%68_!&I?Q 4 :<_P 0".%M
MJSYO',LO2(K^-68O!$^/WB"K\/@>W_Y:QT <;J>LW&HQ;6W$=:Y>X.7YKV9_
M!VG16TA6,[@I_E7D.JVQMKV1,8 8XKIH/H>C@Y>ZXE&BBBND[ HHHH ****
M% JU!%CDU%#'N;FKH'%(I(44[%(*>*0'>^!=0W2O"YP%'&:[\<\UXYX>N_LE
M\F#C<P%>P0L'A0CNHKDJJTCR\7#EG?N24445D<@4444 %%%% !1110 4444
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M0 4444 4M1<B ICAAR?2LZ!$M=-WQJ)6)ZBMJ:)9HV1NA&*KV]BEO%Y2CY:
M.>CGL=#@N+GS(_-D&[9WS7"ZWJLVK@W".PW'_5"M_P 2>&;R[OX_+'RLU0VO
M@J]MKG<X41CFMX-+5O4[:'LX*[>IRCV\B1".2(J\H^4FMVT6'0M!68JKWAX*
M_P 52:S+$;RV..;<\XK0TO1'UW4A?2KFU;H*Z;I1NSAK574FROX4\.SZE>-?
MWNX -N0/7IR(L:[5&!Z"F6]NEM"L:# 48%2UQU*CF[@E8****S&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLNMG7T_TA6]JQJ]"D_=1X.)5JK"BBBM#G"BBB@ HHHH **** "BBB@ HHHH
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M*G-1LD>D\53ITTHO4[S0O!D-JJRS'<QZJPKJXK"VB4!84&/05E>&]<76+1)
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M.IV]L%+2*=QQPPJU%*DR!D((/H:+#L[7'T4A91U8#\:,@]#0(6BBB@ HHHH
M*Q=2UA[.[$*J#D5M52GTVWN)A)(F2* .:FUZ'4+F.!Y=A5L8'>J7C75UL-*>
MR@(\QER,=>E9WCG2CI3PW=GA&+9-<W#=MJ-ZFH:@XDA0;2I/)KKI44[3Z&<I
MVT+L9M]*TO[27!FN$YSV-2:1=6\VBR//<$3;N 35.#3YM>FN!&I6"'E0P[50
M:P:WD*Y 4=16LK6L]S?#4%5;;9T7AM4NX=77S"^U#C/X5J_#J4PQ&V/=S_.N
M:T20Z3+(IR!<_+73^'D%GXDBMP1AAGBBHO=9SNZE8]%HHHKSS4**** "BBB@
M KG?$&@PZ@IDDE*@GI715CZQ>HL1C[CFFFUL5&3B[HYW4M(BM_#MT$4?+'P<
M5Q>FRQMX16W.-X:NWO/$=E/I%U;$8?9MY-<%9^3':;>.OK791ORZF-1W>IGP
M+=%I%#.8\\\U;B$>! 2%/]X=:[#P=I5O?V]V)E!/\.:R_$.BKI4[2>62H]!3
ME/W['H8><)TU3DB6+12+8&VE>?<.<G[M=%X6N'LY1:3$@J.0:Q/!<T]W.P60
M+&K<J>]=CJ.A/+.UQ:D)(>IK"K4D_=9S5**ISLC:AN8I\^6^<=:FKF]-AGMI
M]ISR?FXKI*P("BBB@ K,UD$P1X_O"M.F21)* '&0* $@_P!0GTJ2D    Z"E
MH **** "BBB@ HHK.U;4H].M6=SR0<<T 0:UK<6F0M\P\S'"FO--4UJYU*<X
M9E!/ !J/4M1GU2[)9BW) XKI_#?A3>%N+I0R'D#TH YRRT.^O6!,3%3WK6;P
M9*(MP5MWI7HUO:Q6R!(EP*GH \7O--O=.<[E9 .^:Z+PSXF:)U@G;CH"37;:
MGI4.H0,KH"Q[UY7JVG2:7?DXPJMQ0![#'(LB!E.01FGURWA'5_M=ELD;+YP*
MZF@ HHHH *JW5C%=(591SWQ5JHKB400/(?X1FFG832:LSAM<TR+3%9PY..>:
MQ8[B.0<-S3?$>M2:C=LJ,?+Z$5?\/^&I[A?-<@*1D9KIAB&M&>=6R^,M8:%>
MBI/$KPZ&2S,I"C[JGFLNVU>"Y0,O&?4UV0ES*Z/+J4)TW[R-"BFK(C#(8?G2
MY]ZHR%HHHH$%%%% "BG"FBES4LM#P:":9N ZFH)KN.)<D@_0TBB9W"KDUB7=
MR99@58C:>U)<WSSC]V2!Z&JQ*Q1EW^M<>)Q"2Y(;G9A\.[\TAM]J$L$18R,0
M>.37)33R22LQ<G)]:NZE>F>0JI_=^E9IKKP.']E"\MV=UQIYZTVG&FFNT:$H
MHHH&%%%% !1110 4444 %%%% !113@CGHK'Z"@!M%2K;S,>(G_[Y-7+;1;NY
M/RQO_P!\FDY);CLROI\GEW\#>CC^=?2.A3Q7>G1NJKPH' ]J\1LO VI3R*RG
M;@YY%>Q>$--N],TPPW;AGSQBO/QDH22LS6FFCH0 .@I:**\\U"BBB@ HHHH
M**** "BBH9+F&/[TB#_@0H FHJJM_;L<"5/^^A5A9$;[KJ?H: '4444 %%%%
M !1110 4444 %%%% !62 W]LMZ8K6J/R4\WS,?-ZT /'2EHHH ***0T (33"
M:4FHF-,EL&-5;JZCMHB\C8&.*?-,L2%VZ"O/O$FN-<3M;Q,=H-5L2M0UOQ-+
M<,T4?"],@UAPVEY>L-@9\^]7=&T674)A(P^3/((KO['2[>R0"-,$4DKC<DCB
MX?"DKIEU8&J=[H%W:99(VP.]>G4R2))D*N,@T^4GG9YEI6L3Z?. 6) /.37I
M6FWZ7ULD@(W'J*XGQ+H8MW,T"[4 R:C\+:L]O<^7*WR8P!26A6ZN>D"@BF(V
MY%8=QFGYIDC"*A=:L&HGIHEHI2Q*PY -8-_IJ+NE#8[XKHWKD/$FJ&-?*B;#
M9P:T4W'4PG151V9FBYCW%=W(-3!@PR#6186DMY."O<]:W+NV%C:;W=1M&3D]
M:Z*=;FW."O@^1^X[D=%8,'BFSEE,?0@XR36O#=PS+E9%_P"^JWN<<J<H[HGH
MI-RGHP/XTM,@**** "BBBDQCQ3A3!2YI%H>6IA-123I&,EU_.L:\UM?FCBR&
MZ9J92C!79<82F[11/JM\L<9C1OWGI6&]Q-&C/O;'?FFEF8^9,<R>M8FKZFT2
M^6K_ 'N#BO(JU)8FHHQV/6P]!4UYF7J]XTUVQ60E?K6:23U-(22<FBO4A'EB
MHG9:P=Z6DI:L HHHH **** "BBB@ HHHI@%%%%( HI0K'H"?PIPBE/2-S_P$
MT ,HJW#I]S,<+$__ 'R:UK7PAJ%UC:I7/JM#:"Z/1/AG>+<6Z6Q )1<_I7IB
M(!T%>;> /"NHZ-?M//(#&RX %>G(O%<=1J^AG;4<HJ4"D5:E K%LM( *?2 4
MZD6 HHI":0 332:0FF$TQ7';J3=432HOWG4?4U ;^ -CS4_[Z%.PKES=GK0N
M!T %5UN(WZ2*?HU2!O0T6"Y.#2@U"#3@U%AIDV:6HP:<#4CN.HHHH&%(>!2T
M'D4 <C?:]/(US;QQ@XXKRW4;2ZOM<-OL(D(S@5[5'HD*RS2%!N<Y!KCCH-RG
MCD7&X>7MKHP\U!MD35S+\'^'+::Z?[3.6>(_<;FM/Q9$EI<,((E.!]T"M==+
M&DWWG@ >8V3BN5\8ZD[:PPB)QCH*J4^>>AT82+Y]3)MK:2XM[F01#*C)XZ5>
M0?:/"21'[V_I5_PW:7$UK<;@0KCG(Q3UT>9;D6\;#RP<X%:QFMFR<:KU-#T'
M1E\O1[5?2,5>S52S!BLHD/\ "N*G+5Q/<ROH/S1FHMU&ZBP7)=U&:BW4;J+"
MN2YI<U$&IP:E8=R2EJ/-.S0.XZBDS2TAA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &1J.I/#(\2*"0*XBZUW5M.N&,%J'C8Y8GM7?WFGB
MX;>@ <GDT'2;5X-DD8.1S5P:3U0F>-QZR)/$=S>3X1G0C'YU=\$7MH-0N)+B
M0 >82,U:\9>$?LTSW5L45">%!YK'\-M9P2FUN+9A+(<*Q&!7H<T)PT,;23/2
M=8TRRUBV:6W(+8)^45YYIP^R>)(4EX57Q7HEEI=S# #!,NPC& :FM?"]GYWG
M7$:O)G.<UQ*?+='=2KN,;2-J-(+FV& K(>AQ67)H$?V^.=&(VG.!6W%$D$8C
MC&%'04^L3 :B[5Q3J** "BBJFHRO%9NT>=P'&* +=8_B"8KIT@C)\S' %8G]
MNSV0WW+DJ_ SZUH6K">W:YN9%9!SUIJXT[.YYS=Q:M(X>99%B!SG=7<>$=1\
MVVV1N9%!PQ)Z&N4\1ZR^J71T_3=R[&Y(Y&*LZ/=+X<M38D[[B8[@4Y_SUKIG
M!\FNYI4Q'.N6VAU=[>R&]:/) !XYZULZ69S!F9<'M7$RZB$>%Y3\S,*TKCQ2
M+?7[33^?WB \?A6"IR9C='9T4R)]\8;UI]0,**** "HYI4@C+N<**DJIJ,!N
M;-HUZF@#CO&UQ!?6(VOG8,UYA:6-U>(TBAA$&QP:]AC\/++#.DZALJ0M<QH^
MBS6'B)+&7FW<DD=NM=F'J\L6C.<;NYTGAI;+^QS#$5,PCP_'-</X@M8$O&S(
M5?\ NUW(M$T.:9TC)67IM%</K,,E_KZJL3C(ZE:SC).;:.W!OE>I>M-.35;)
M6B.7MUSQ5GPS%<2>)8Y9E*E>*ZG1]&2PTAV10)'CY-4M(ECLKC]^A,N>#0ZS
M2<3"LHRJ<R.QHID;B2-7'0T^N<D**** "BBB@!KC*$>M<W>VEU)>E!&3&?XJ
MZ:B@#SS6? *2VLEQ'/(),9V@GK7FU[#<Z9^YE!5@>YKZ&NG$=M(Y&0!7GM[H
M\/B"^8JH#'^]751Q#CI+8SE"^QG>'KW4[6W4V=OY@8<UU-S)+J6E".\@5)CU
M&*P=,T36=&O-QGS;AON@=J['[=:R()7@;<?:IKR3>@X76ISVA>&9K.\\X;E4
MMGK7>@<8JM93^<G"D =,U:K!R;-IS<G=C=BYSM'Y4ZBBD0%%%% !5/4+IK6)
M649RV*N50U.!KB%%7LV: +D;;XU;U%/ID2[8E4]A3Z "BBB@ HHHH 9)(L2%
MV. *\P\5ZP]Y=M;*?D4\$5V'BK4Q:6,D2G#L.*\ZTVUEU2_&>3D$T ;WA+0?
MM+BYE'W3T->C1QK$@10 !56PM8;&U5%PO SS5@W$ ZS)_P!]"@"6BHA<0'I-
M'_WT*D#*WW6!^AH 6N3\9:7]IM%=%Y7DXKK*K7T2RV<JD9^4T >6>&+QK;68
MT)PH)S^=>LQ2"6-7'0UXU<(=/U,MT.XG]:]6T.X$^EPMGDK0!I4444 %87B:
M^%I8LI.-ZXK<9@BY8@#WKR_Q=K'VNX,"MQ&?6@#,T.S^WZNL3<JQ_K7;ZYX@
MM/#FD^6'42;, >IKC-(U*'2XOMC<LI['FN2UJYNM9OGDFDW1;LJI[5TT,/*;
MN]C*I6C#=E._U:YUV_-S*2!DC;GBKUE93'!^8#M@U6BMXXEPHJXEU+&  W K
MTITYJ'+3/.G64Y:FS#"T0&7;\ZLBXD0?(,UD1:F%'[S)J0:I'G@$5Y;ABXLS
M<*<C3%_<?Q1@5*M[_>P*STO4<<FG%XV_B'YU/UNK'2427AH/8TOML?=J/MT7
M]ZLW]UCEE_.C;#ZK^='U^75"^J1[E]K]!]T@U7DU24?<0&JS"(#AE_.F>;&@
M^\/SH^NS:TB6L+%$IOKB;ATVBJYC)?)<G\:@FU*./W^E4KC5U9<1@@T6Q-;I
M9&\*<([(TI)XH6.\@ 5AWVHM,2J_=]JJRW$LWWVS4!KMP^!C3?-+5FEQAIII
MQIM>@-#33:>0?0T"&5_N1NWT%*Y2(Z*M1:?=RG MY?\ O@UIV_A6_N,8C8?5
M:ESBMV59F%179V_PXU*XP0X&?45KVWPIO^"\L9_*LWB*:ZE<C/-:4 D\5[%:
M_"\)CS@C?E6[:?#_ $F(?O+92:R>,IH?LV>#QV-Q+]R,FKL7AW5)ON6Q.:]_
MA\):/#]RU J]%I%G#_JX@*R>.[(I4SP*W\$ZS,>;1@*W;/X:W$H'GHZU[6D2
M)]T8I]92QDWL5[-'EMK\*;7@R2N/SJ>[\':1HT19I\R 9 (KT:XD$4#N3T4F
MO)=;U*74KYE!)P2,5B\14?4?*BM)>PP,1'!&P'0[177>#[F*]B^>VB'S8^Z*
MK:%X1,\*SS@%&'0UV6GZ/:Z<F(8PM9N3>Y5BZ((5^[&@^@IX&.@Q2T5(!111
M0 4444 %%%% !116;K=]]@TUYL\B@#(\1>)EL$\N AG/!'I7"3ZE>ZE*=C."
M>P-12-+JFI]R':O1=$\-6]K;*9HPTG7- 'G7E:E 0[-(!_O&K]IXHO+)@,;L
M>IKTR32+.5=K1 BL74?"%K.A^SQJC>M %?2_&<=QA;DJE=1;7L%TH:)PP->7
M:EX6N]/)?.X=1M%5]/UN]TZ4!F8(.V* /8:*P=%\10:E&%SAP.<GK6\#D<4
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M0]#65#H,,%\;I7;)[=JUZ* &>6F,%0?PJ!K&)I-V /;%6J* &J@08  IU%%
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M)9K*1@R+71T %%%% $<D*2J590<^HKE->\)Q7$;30 ^9_=%=?10!XL1=:/>
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M5H&G@ 5<GM5/1+&>(%IP5(;@9K<(!ZTM !1110 4444 %%%% !1110 4444
M%%%% ".P1"S=!UKF]>\406%@TD#@R ]#713 -"RDX!%>?:GX<EU#53&D@\DC
M\*J-KZFM)0O[QL>'/%)U0L)2H(Z8K1U-FD8AB5A_O UYA-(^GZO#!:' C?$F
MWO78W&J_:L0HV3CH*TJ4[:HFI*+E[NQKZ(D=N;B4R,4'.2:V;:_M[L9A?<*X
M"QUW-O?VNTA\;1^E0>"[^>+6ELIG)[\T*B^5MF7-J>GT4E+6)04444 %%%%
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MH2N!AZ7JHBNBDC?*!6X-8M&0E9.E>::/>1W?BZXD>=4MBORJ3QWKMYK[2(4
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M4 %-9@HYIU9NL.R0(5;!W4 :7:BHX3F%"?2I* "BBB@ HHHH **** "BBB@
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M7?6[_P 2ZD0C2!"P(6O4/#/AT11)+.,D=C4SBT[&JLD+X>\.!0L\ZGGFNR1
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MK066FQ0 8"BM51Q7%)W=S.]V2+4@'O6%JFE7=WCR+MHN>U9W_".:I_T$Y/\
M/X5FS1(['\:4'WKC?^$=U3_H)R?Y_"D_X1[5/^@G)^G^%(H[/(]:7(]:XO\
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MM!'C^\*TZ:Z*XPP!H ;!Q GTJ2@# P** "BBB@ HHHH **** "BBB@ HHHH
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M:'G=@UZO)7@'Q,U#[1?O!G.QZVIK4F*]X\^)R2:**2NDV.H^'Z>9XOM5]?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !37=4&6IU9FLLRV\>TD?,* -,'(S14<'^H3/I4E !1110
M4444 %%%% !115:^NX[.W:1V XXS0!1UW5DTZS<[L28XKRZ5YM7U L.=S59U
MS5IM6O3MR ,C:.]=3X2\/B)1<RC.X< ]J -CPYHJZ=:#<N&/-;U(   !VI:
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M52G]EEX>K;W)'%T4K*4;##!I*Z3M+EM)D[3TJX*RHWVL*TXVW**DI#Z<%).
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MCVT;:DQ1BBX6&;:7%/Q1B@=AN*<!2T4@L%%%% PHHHH **** "BBB@ HHHH
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M@#MAA7,> /# !%W.F0PR,BO454*H4= ,5Y>+K\SY4==*%E=BT445PFP4444
M%96M:U!I%F\TK?=[ U+JNJ0:;:M)*X4XXSWKP[Q5XGFUB\;#%8QD8!X-=%"@
MZC\B)S445?$WB*?6;Q]SYA!^45S].HQ7L1BHJR.5R;8VC%.Q250KB8I0I)X&
M:4 D@ <FNR\(>$Y=3NXY9D*Q=SVJ)S4%=CBFV3>#/!\FH7"SS)E%.X9%>TVE
MK'9VXBB&% IFGV$-A;)%&H&T8R!UJW7C5JSJ2N=<8J*"BBBL2@HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1;J-U*P[DVZFEZBWTPO3L',2EZA9Z8S^]5YIUC&6.*I(SE.Q0\0:E_9^FR3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP%;W+&6)B&ZX%.%;I(5+%=)GDU7[23*D&MF\\%ZC"Q$,#,*K6_AK5DF"M:L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %9NL(7@C !/S5I4A /4 T ,A&($'M4E%%
M !1110 4444 %%%% !1110 4444 8^L:%#J8+%!OQ@$T_2=$M],3*1@2$<D5
MJT4 %%%% !1110 4444 %%%% %34;C[-:-)Z5X+K4[3:M<,3D%Z]TUN,RZ<Z
MKUKP;4P5U*=3V:NF@=V#2U94HHHKI.\O:1'YM\JU[UIV(M)@ST5*\3\*1>?K
M4:5Z[JU_'IF@/O;:PCXKEKZNQP8O621XU\4+_P [Q%)&K97%<%6EKFH-J6HO
M.QR2:HP0/<2K'&,LQP!5)61K!6C8GMKFX1PL9)]@*Z2UN&V#S,YQ74>#/AZ9
M$6ZO$96(Z=JS/$6C/I-XPVD*S?+50FF[%TJJ<N4KJP8<4^LV.4H<U=BF#CWK
M0Z26EHI: %HHI:0PQ72^$994O45"=I;FN>BB:5PBC))KT?PGH)M8O-E4ACR*
MSJ-*)SXB<8P:9V%%%%<AXX4454U&Y%I8R3$_=&::5W8#SGXBZOYBFR5N4:O-
MNIK7\1WIOM9FFW9#5DXKW:$.2"1Y=6?-,;BI(8FGD$:_>/2FXKJ/!NCM?:G%
M/MS&C<U=2:A%R9,(\TK'HG@G1EL=.BG*XD88)KK:CAB6"(1J, 5)7@SDYR;9
MZL596"BBBH&1S2K%"[L<!037C?C?Q(]]=&"%SY6,$5VGCCQ -/LO+B8;V^4B
MO&)9&EE9V))8DUZ.#H_;9S5ZEO=1%1BG48KTCCN-Q2A68X4$GT%/2-I'"J,D
MG KT/PAX+:9TNKM"N#P.U95*L::NRX0<W9%7PCX-DO)%GN%^3J 17K5E9PV4
M BA7:,4ZVMH[6)8XU  ]!4]>/6K2J.[.^$%%:!1116)84444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4  >@IU>/5JRJ.[/0A!15D%%%%9%!1110 4444 %%%% !1110 4444 %%%%
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M3Z"I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9Z"22L@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5/#Q@5K>QMK88BB5<>E6:**Y6[G0%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3))%C +$#/K3ZR]:/^CQ_[XH TP<C([TM1P?ZA/H*DH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "L'Q-J M+"2/.&=>*W2<#)KSKQQ?K+/$D;=.
M#0!QYD9GWN=QJ^-2NC&([8NG&#M[U'IVF3ZC.(X5S7H&D^$;>!%>9#OH X$)
MJTO)69OPIWV/5/\ GE+^5>O16,$2X5!^52^1'_<'Y4 >-^1JJ=(YA^%*L^L0
MG[\RU[";:)AR@_*JTND6LWWE_2@#R]-;U*,8:20U7GO-2O3@M(P/:O2V\+:>
MYR5-36_AZRMFW(O/TH XC0/"DEU*LMP"HZX85Z-:VD5I"L<:!<#!Q4J(J+A0
M!3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ IGFIYFS<-WI3ZR!_R&VZ]* ->BD'2E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I#2TPT -8U"QJ1C4#&K1FV5[J<0Q,YKRS5[Q[J]D#$D
M*W%=YXENU@TYN?FKSC:UQ<87DN>*4@AW);>\:%-L8(?^\*?OU*<YS(PKH=(\
M,%MKW*UU-MIEO;J B_I0HL')(\W%MJ)_Y9R?E0;;45Z1R_E7JBP)_='Y4[[.
MA'W1^5/E#G/*/^)K'T\U:FCU+4HOO225Z:]A#)]Y1^55)/#UE)]Y:5A\QY]+
MJNH3+M622BQT:ZU&<>:C $\DBN_3PU8HV0IK4@M(X%VHH_*BP7[&=I&B0Z9;
MJBJNX?Q"M4)3PM/"T[BM<8%IX6GA:7%*XTA M. I12U)5A,4M%% PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.6%9E 8 X-255OKG[-
M&K9ZG% %D#  ':EIL;;HU;U%.H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:[A$+'H* ,
MGQ!JBZ;8LX.6Z8KR6\N7NKAY'8G)R,UT7B[4S<W[P*V4S6:FB2M9/.5X S0!
MU7@E8C&AVC?CK7<5Y9X0U$6NHA7.%QBO48W$D:N.A&: '4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !47D)YOF8&X]ZEJG]K_TTPYZ4 7**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 0U&U/-1M31+&-52YF$,+.3]T9JPQKEO%6HFU@5%;[X
MP:K8C=G*>(-2:\O&VL?+]*9H(C-XF\ _-QFJ]A827]QM R#S3(MUGJ:@\;'Y
MJ?,OI8]610%  P,5*!5+3+I;NU60'-7U%:&*0X"GA:%%2 5+9:0W;2[:?MIV
M*5RK$>VE"U)BC%%QV&@4[%. H%(=@ I:**0PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L[5XFE@0*"<-6C2''>@!L((A0
M'L*?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5GZS<"#39SG!V\5H5QWC:^\B)(@?OC%
M'#1(^IZ@.I8FO44TU&T/R=HW-'BN'\%VGF:J'(XQ7J"C:H'I0!XSJ%I+I6I%
M!D;3UKT7PUK*7MJJ,P#*,?6JWBO0OMD#30K^\/6N%TZ_FTB^ )(56^:@#V6B
ML[2=4BU*U65#G-:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MEB)_[69]IVXZUJ4G&?>@!1THHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTM1P?ZA/I4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4R21(E+.V *?7'>-M2N+*.)(FP)!@T ;TFO:=&
M<&Y3-5;CQ/8Q(2DZ,?2O)78ROENIJU;Z1+<XV,H^IH Z#7?%DEZC01C:/[P-
M4M T>:_O4F93M5LDUH:5X3RRM=M&R_45W%A#9:?%LA95XY^84 7;>%8(@BC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4M%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDD:R@!AG%/HH 0#  ]*6BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "H_*7S-^!FI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I"*6B@",BFE:EQ28IW%8A*TFVIL
M4;:=R;$&VE"U+MI=M%PL1;:<%I^WFEQ2N.PP"G8IV*7% [" 4M%%(84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !28I:* $Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gjnp4w4lrub1000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +/!%8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"XO;6UQ]HGCCSTW-BGPSQ7";
MX9%=?53F@"2BBB@ HHHH **8LJ,[(K LO4 ]*5W6-2SL%4=2: '44@(900<@
M\@T$@#)X H 6BFI(DB[D8,OJ*22:.( R.JY.!D]: 'T44C,%4LQP!U)H 6BF
MHZR*&1@RGH13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT[(-3OJ***S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** $(!Z@&@  8 Q2T4 %)@>@I:* $(!Z@&C  P *6B@
MP,8Q2!0.@ ^@I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;K=MKY'>N?TO2[S6;(:G>ZC<QRSC?%'"P"HO88QS638:A=:#IVOW,[K+<12
M!P.&/.#BCE"YZ'17G2ZC;_8Q=?V]/_:9^?!_U>?3;UQ^-=MHU^=3TFWNV0HT
MBY*D=#0XV!.Y!J&OV]C=K:+%-<W)&XQ0+N91ZD4ZW\0:?/ITEZ9?*CB_UHDX
M*'T(J6ZMF@$MU86L3WKC!+'&[\:\\E=LW-OJ"LE_/=(;B,#";<\8]1UH23$W
M8[6W\56<T\*20W%NDQQ%++'M5S[&I;[Q':V=V;2.*:ZN%7<\<";BH]3BJ?BV
M&+_A%V.T+Y6TH1_"?:JG@<^<+VYD&9W<!F/4C%%E:X7=[&Y%K^G2Z6VH^>$M
MTX<MP5/H?>J]IXGM;BXAAD@N+;S^(6G3:)/I7(7JHOB>XLRO^B/>0EQGC);F
MNE\9QHNAQR* &BE0QD=CFG9!<Z6BJ%Y(Z:%+(K$.("0P['%0>&YI;C0;:69R
M\C Y8]3S4VT*-:BN$@UG4%T;RXIRUU<W;0QR/SL''^-6=:T2_L-$FO+'5[H7
M<<99C(P*GCG [4^45SL20H))P!UK(7Q)8L8@/,_>S>2AV\$_X<U0FU*6'P5!
M*SEKF>,(">K,>*Q?$LJ>'=,T65HV?R9 Q5>I).:%$&ST&BN9L$O)(WUW4+Q]
MFPO%;Q'Y%7'?U-0:=IMYKUJ=1O=1N(C-GR8X&VA%S@9ZYHL%SK:*Y+PK)J2Z
MQJUIJ%V;@P.%0]@-HKK:35AH**IZI<7-IITT]G;&YG492('&ZN1'BKQ9C_D4
MYO\ OY_]:A)L3=CNJ*X7_A*?%G_0IS?]_/\ ZU'_  E/BS_H4YO^_G_UJ?*P
MNCL[V\BL+22YG)$<8RQ]!4&FZQ8:O )K&YCF0_W3G%<'KGB/Q-<:+=17'AF6
M&)HR&D+YVCUZ5Y+9:C>:;.LMG<20R \%35QIW1+G8^I**\_\#>)O$.JA8]0T
M]F@_Y^0"OZ5Z!6;5G8I.X45P7Q%\2:WH+60TA WFYWYC+>OH:X;_ (6+XU_Y
MXI_WX;_&MX8:<X\RL<U3&0IRY6F>[5S6M>.M#T*X^SW5SNF'5(QDBO+)/B)X
MS:-@T2J".2(&X_6N'N)Y;JXDGG<O*[$L3ZUT4L%=^^_N.2MF-E^[6OF?2FA>
M+-(\0AA8W(:1>L;<-^5;E?+&EZC>:5J$=U8.5G4_+CG/X5V/_"Q?&O\ SQ3_
M +\-_C2J8)I^X]"J.8IQ]]:^1[M17A/_  L7QK_SQ3_OPW^->B_#[7=6UW3I
MY=60+(KX7"%>/Q-85,-.G'F9TTL7"I+E29V-0W5U#9VSW$[A(T&6)J4]#BN/
M\<R3#P_$'! :X4/CTKE<O>L==M+FC%XCGN81<6VF3R6QY5_4>O2B_P#%"6EQ
M9V\=G++-=C*)T(^M;-HB)9PI& $"  #IBN-\4F=/&6CFU1'E&[:K' [50CH4
MU34"C,=*E!'09Z_I6>OBR=M3;3AI<WVI5WE<]ORK9T^34W9OMT$48_AV/FN;
M@_Y*=<?]>W^% &Y)J=^BH5TN5BPY /3]*J6OB<S:XNDS6,L4Y7>23D ?E6W>
M74=E9RW,IPD:EB:Y#PIEX;_Q->#!N"63/9!TH V?$?BFT\.1QF9'EDD. B=?
MK2ZAXE@L-&@U%H7=9L!4'7)KB-0N;?5-(U'6;F=#-+\MO$3RBUTJ:5'XD\(V
M-O#=!#&%;>!G!% &Q::E?3SJDFFR1(W5R>GZ55N/$Q76I=+MK*2>:)=S%3Q_
M*J-UJ6K>']2LH[Z>*[M;E_+!5"I4_F:L7'AN\&N3:M8Z@L,DJ;2CQ[A_,4 ;
M=C<SW,1:>V:!@?NL:34;YK*%6CMY)W8X5$%9'AK7+F^N+O3[Y5^U6K89TZ,*
MW+LW"V[&UC5YA]U6.!0!DVGB1)-573;NVDM;EUW('Z-]*+KQ&JZC)8V5K)=S
M1#,FSHM8#&>+QM:76NH(G==EKY?*Y]SZ]*L^"BS:EK#2<R&?DT =!HVMV^LQ
M2&,%)8FVR1MU4UI%@" 2!GI7%>'-R^.=:51B/Y3QTSS4_BV1TUK10KLH,_(!
MZ\B@#KBP! )&3TI'D2/&]@N?4UR7B&1U\5:&H=@K/R >O2J-S-:W7B^^@UB<
MB&&(&%-V !SD_6@#NUD1SA6!QZ&N;OM;NCXHCT^S*^5#$9+C(^N!^E4_!42V
M.CWEY*KK'YC%7<\E!1X:MVN+?4]8E'SW);83_= H V/#FMMK5C)<2QB+9(5Q
MGTK8,B!-Y8!?7->2:+=2WSQZ&\AM+66=F>7.#+S]T?Y[UTFM>3#XDTS3;J4I
MIPCR$W<,>>M ';+-&YPKJ3[&GUP_A*SB7Q'J<UNKM:J0(G)R/?%=Q0 4444
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M3H;^T+&"8$H67!X)'3\*MT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]-NHM6BN$,K1QLN%_BW9ZT ?3E%1PA_(C\S_ %FT;OKCFGT +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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M?2I** &NB2(4=593U##(-0Q6-I ^^&U@C;^\D8!JQ10 4444 %%%% !1110
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M)KW_ !^Z5_U\?X5MU3V0ENPHHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!@>+_%^F^#-%;4M2<[<[8XU^](W
MH*^>[WXY7EQXQM=<BTR%4MHFB6-B<E3GOGKS6O\ M(S7/]M:3!S]E^S[AZ;]
MS9_3%>&4 ?9O@'XB:9X\L7>U!ANX1^^MW/*^X]1795\F? B>YC^)MI'"3Y<D
M4@E&>" A(S^-?6= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!F^(+6YOM!O+:T.+B2,B,YQS]:\QL?'^O\
MAA_L6O6,DZ(2 [#:Q^AZ$5[!4%Q9VMVNVXMXY01CYU!H X&/XOZ0R O9W"-W
M7.<?I5:\^,-KL9+'397E/W6=N,_3K78-X+\..Q9M*A)/N?\ &K-GX;T:P.;;
M3H$)_P!G/\Z!:G&>#6\3ZSXD_MG54>*S$;*D;?*!G'0'FO2*0  8   Z 4M
MPHHHH **** "BBB@ HHHH Q->_X_=*_Z^/\ "MNL37O^/W2O^OC_  K;JGLA
M+=A1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117E7Q=^)T?A33VTG3)5?5ITP2#GR5/&3[T 8?
MQF^*8LHY/#6ASYNG&VYGC.=@/\(]_P#&F?!KX6-:B/Q-KL.Z>0;K:&0<K_M$
M>M8GP@^&4VNWX\4>(8V>W#[X8Y>LK?WC[9_E7T<JJBA5 "@8 ':@!:XO4O\
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M  K;K$U[_C]TK_KX_P *VZI[(2W84445(PHHHH **** "BBB@ HHHH ****
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M?B-XM!R=#8CT\A_\*Z3PE\0SK>HG3=2M!:79^X!D ^W/.:8CNZ***0PHHHH
M**** "BBB@ HHHH Q->_X_=*_P"OC_"MNL37O^/W2O\ KX_PK;JGLA+=A111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOQI_R,OA+_ *_C_-:[
M2N+\:?\ (R^$O^OX_P UKLV8*I9B !U)[4 ,N+B&UMY)YY%CBC4L[L< "OE_
MXC^.]1^(WB&/P_H*2/8K)LC1/^6S9^\?;ZUJ?%_XF3>(+UO"WA]G>W#[)GBZ
MS-_='M_C7??"3X8Q>$]/75-0C5]6N%R<\^4OH/>@#8^&GP\M/ ^BKN59-2G
M,\V.G^R/:NZHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJFKV.BV?VO4)
MQ#!N"[BI/)^E6+FXAM+>2XG<)%&,LQ["N5UO5_">OV'V*]U*-H=P; )'(H E
M_P"%C>%,?\A5?^_3_P"%<&E[!XD^*MG=Z3&3!&REW"XR >36HOA_X= Y-XI'
MIYCUTGAV7P=I<PMM'F@6:9L#DLQ/IDTQ'74444AA1110 4444 %%%% !1110
M!B:]_P ?NE?]?'^%;=8FO?\ '[I7_7Q_A6W5/9"6["BBBI&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !2$@#). .YI:\K^.WBF[\/\ A&&TLI6BFU!VC\Q3
MA@HQG![=: %\<^-/#L7BCPXC:K 3:7A:?:2P097N/I7+_%SXNPRV9T'PU<&1
MIU_?W,?8'^%?>OGQF9V+,26)R23R:ZSX9/9+\0]&2^MDN(9+A8PK] Q(P??%
M 'LWP:^%O]F11^)-;BW7L@W00N,^6/[Q]Z]LI  %    ' %+0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5Y1\5_BQ#X6MGTK2)%EU:12&8<B >I]_;VH^*_Q7A\+6SZ5I$B
MRZM("&8<B$>I]_:N!^%WPMNO%5^/$GB42-:%]ZI*3NG;U/M0 ?"[X6W7BJ__
M .$D\2B1K0OO5)2=TY]3[5])0PQP0I%$BI&@PJJ, "B&&."%(HD5(T&%51@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGB02-:%]ZI*26G;U/M7TE##'!"D42*D:#"JHP *(88X(4BB14C0855& !3Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%5[Z_M=-LY+N\G2&",99W. *
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M *X'^8H E\(?\B?I'_7JG\JVJQ?"'_(GZ1_UZI_*MJ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDOB/]B_
MX1"<7ID"EP(RBY(?G'X=:ZVL?Q*VCKI6=<"&SWC[XR-W./ZT >?>$_B;IVEZ
M);V&HP3@VZA%:)0VX#UY%=/IWQ,T'5-1@L;=;SSIW")OB &3Z\UCK)\-&.,6
M@]RHK>T/1?!]U,E[H\5I+)"V0\6,J:8CK****0PHHHH **** "BBB@ HHHH
MQ->_X_=*_P"OC_"MNL37O^/W2O\ KX_PK;JGLA+=A1114C"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9NN:'9^(-/^Q7P<P[@_R-M.1_\ KK1) &20!ZFL#Q;!JU[H930K@QW?
MF [T?;\O.>1^% &/_P *H\,_W+O_ +_?_6KDK6Q'A#XH6MAI\[-;S%58$]F/
M0_E4ZZ#\2F./[5F'UN3_ (5M>$O -]9:Q_;&O7"SW:G* -NY]2:8CT2BBBD,
M**J7>IV5C+%'=7,<3S';&&/WC[59>1(XS([!4 R2>E #J*HV6LZ;J,C1VEY%
M,Z]54\T7NL:=IKJEY=Q0LWW0QZT 7J*9'+'-$LD;AD89# \&J4>N:7+>&TCO
MH6N <&,'G- &A1110!B:]_Q^Z5_U\?X5MUB:]_Q^Z5_U\?X5MU3V0ENPHHHJ
M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6D1/O.JY]3BN&^'TB"
M^\29=1G46QD]>35;XE>'+W5I[6]@N+:&WMXBLC3R[,9/TKS;PSIPU?6/+M-3
ML#);7 #JT^"^#R5XY'% 'T;7)>-_B#H_@FP:2\E$EVP_=6R'YF/]!7)_$GXR
MV7AI)=,T9DNM4/RLX.4A_P 3[5YAX.^'7B#XEZL=;UV>5+%VR\\F=TGLH]*
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"0!DG%
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M+J\YMPD[G04445YYZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN'5N>GJAT<4^;V=;27YG>4445RG:%%%% !1110 4444 %%%% !1110 4444
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M** "BBB@#$U[_C]TK_KX_P *VZQ->_X_=*_Z^/\ "MNJ>R$MV%%%%2,****
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M9\9W'BS^S=6C-E9?V3M8>;O_ 'GE^N,]?PI_@VX\6?V?I,9LK+^R?+4>;O\
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M\[47H.<U8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#^JUUM_:+?V%Q:/(\:S1E"Z'#+GN/>O+/$O@NVTS5-"MTU"_E%Y=>4S22
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M^1E9]6U-BARI:4':?;BN[HH P?#WA:'P[+/)%?7ER9E (N'W!<>G'O6]110
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M% !1110 4444 %%%% '$^._^0SX6_P"O\?S6NVKB?'?_ "&?"W_7^/YK7;4
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M>&+':9K=[MA_%*Q'\L5R'C3X23+<2W^@!/(P6:W9L;<=<$U[35;4/^0;=?\
M7%_Y&JE0IM6L<]+-L73J>TY[^NQ\]>$OAIJGB18KQRD%@S$&0L"3@X( ZU]!
MZ7IMOI&FP6-JNV*% H]_>N9^&/\ R)%M_P!=9/\ T(UV-.G1C3V)QN95\9;V
MFRZ(****U. **** "BBB@ HHHH P?&G_ ")FK?\ 7NU.\'?\B=I/_7LG\JJ>
M--1L?^$4U:W^V6_G^2R^5YJ[L^F,YS3O!VHV/_"+:3;_ &RW\_[.B^5YJ[LX
MZ8SG- '2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD:YN]^)WC&_.V/5#; _PPQ*<_F":]GM/AAX4M<$::)''\3R,?TS6W;>&]%M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!XG
M43+I]J^#%-=()%/1AD<4WQ5 D>FV]Q$%26WG0QL!@@9Z?2KFO:;+J-G']F95
MN8)5FB+="0<X-9LT>IZ^UO;76GO96T4BR2M(ZDR%3T7!/'UH Z6,EHD8]2H-
M.I  J@#H!BEH XGXB:?J=VNDW&F1EI+6X+EP =AXP<=^14>@:QX@M99CK;27
MB,H$8B@V[3WSP*[JBFFNHG<PO^$E7_H'7G_?%'_"2K_T#KS_ +XK=HIW78+,
MPO\ A)5_Z!UY_P!\4?\ "2K_ - Z\_[XK=HHNNP69A?\)*O_ $#KS_OBC_A)
M5_Z!UY_WQ6[11==@LS"_X25?^@=>?]\4?\)*O_0.O/\ OBMVBBZ[!9F%_P )
M*O\ T#KS_OBN:TRZN;7QQJVK2:==?9[J)$CPO.1C_"O0J*+KL%F87_"2K_T#
MKS_OBC_A)5_Z!UY_WQ6[11==@LS"_P"$E7_H'7G_ 'Q1_P )*O\ T#KS_OBM
MVBBZ[!9F%_PDJ_\ 0.O/^^*/^$E7_H'7G_?%;M%%UV"S,+_A)5_Z!UY_WQ1_
MPDJ_] Z\_P"^*W:*+KL%F87_  DJ_P#0.O/^^*/^$E7_ *!UY_WQ6[11==@L
MS"_X25?^@=>?]\4?\)*O_0.O/^^*W:*+KL%F87_"2K_T#KS_ +XH_P"$E7_H
M'7G_ 'Q6[11==@LS"_X25?\ H'7G_?%'_"2K_P! Z\_[XK=HHNNP69A?\)*O
M_0.O/^^*/^$E7_H'7G_?%;M%%UV"S,+_ (25?^@=>?\ ?%'_  DJ_P#0.O/^
M^*W:*+KL%F87_"2K_P! Z\_[XH_X25?^@=>?]\5NT4778+,PO^$E7_H'7G_?
M%'_"2K_T#KS_ +XK=HHNNP69A?\ "2K_ - Z\_[XH_X25?\ H'7G_?%;M%%U
MV"S,+_A)5_Z!UY_WQ1_PDJ_] Z\_[XK=HHNNP69A?\)*O_0.O/\ OBC_ (25
M?^@=>?\ ?%;M%%UV"S,+_A)5_P"@=>?]\4?\)*O_ $#KS_OBMVBBZ[!9F%_P
MDJ_] Z\_[XH_X25?^@=>?]\5NT4778+,PO\ A)5_Z!UY_P!\4?\ "2K_ - Z
M\_[XK=HHNNP69A?\)*O_ $#KS_OBC_A)5_Z!UY_WQ6[11==@LS"_X25?^@=>
M?]\4?\)*O_0.O/\ OBMVBBZ[!9F%_P )*O\ T#KS_OBC_A)5_P"@=>?]\5NT
M4778+,PO^$E7_H'7G_?%'_"2K_T#KS_OBMVBBZ[!9F%_PDJ_] Z\_P"^*/\
MA)5_Z!UY_P!\5NT4778+,PO^$E7_ *!UY_WQ1_PDJ_\ 0.O/^^*W:*+KL%F8
M7_"2K_T#KS_OBC_A)5_Z!UY_WQ6[11==@LS"_P"$E7_H'7G_ 'Q1_P )*O\
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M_?%;M%%UV"S,+_A)5_Z!UY_WQ1_PDJ_] Z\_[XK=HHNNP69A?\)*O_0.O/\
MOBC_ (25?^@=>?\ ?%;M%%UV"S,+_A)5_P"@=>?]\4?\)*O_ $#KS_OBMVBB
MZ[!9F%_PDJ_] Z\_[XH_X25?^@=>?]\5NT4778+,PO\ A)5_Z!UY_P!\4?\
M"2K_ - Z\_[XK=HHNNP69A?\)*O_ $#KS_OBC_A)5_Z!UY_WQ6[11==@LS"_
MX25?^@=>?]\4?\)*O_0.O/\ OBMVBBZ[!9F%_P )*O\ T#KS_OBC_A)5_P"@
M=>?]\5NT4778+,PO^$E7_H'7G_?%'_"2K_T#KS_OBMVBBZ[!9F%_PDJ_] Z\
M_P"^*/\ A)5_Z!UY_P!\5NT4778+,PO^$E7_ *!UY_WQ1_PDJ_\ 0.O/^^*W
M:*+KL%F87_"2K_T#KS_OBC_A)5_Z!UY_WQ6[11==@LS"_P"$E7_H'7G_ 'Q1
M_P )*O\ T#KS_OBMVBBZ[!9F%_PDJ_\ 0.O/^^*/^$E7_H'7G_?%;M%%UV"S
M,+_A)5_Z!UY_WQ1_PDJ_] Z\_P"^*W:*+KL%F87_  DJ_P#0.O/^^*/^$E7_
M *!UY_WQ6[11==@LS#7Q(K,!_9]V,G&=E;E%%)VZ @HHHI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***1V"(SL<*HR30 M%<S;3:YJUJ^HV
MUXEM&2?)MS&K!P/[QQD9]JUM&U(:KID=SMV.<JZ^A!P: -"BBB@ HHHH ***
M* "BBB@ HIDS.D$CQH7=5)5!_$?2N;N)=<M+!M4NKZ.+;\QLS&NW'INQG/\
M6@#IZ*AM)_M-G#/MV^8@?'ID9J:@ HHHH **** "BBB@ HHJM>P7%Q!LMKQK
M5\_?6-7_ $- %FBN60ZNGB*&Q36GN(T7S+@-;QJ .PR!U.:ZF@ HHHH ****
M "BBB@ HHI&!*D [21P<=* %HK%T&YNY6OH;RY^T-!.45R@4X'L*K1W&JZS<
MW3V5XMG;02&),1JYE(ZYR.!]* .CHK*T/4I;^":.Y55NK:0Q2A>A([CVK5H
M**** "BBB@ HHHH **S=?DNH=%N9[2Y,$T2%PP0-G';!JQILTEQIUO+*=SN@
M+'&,F@"U16!KOB)=,O;&RA7S)[B9%?'1%)QD_7FM\=* "BBB@ HHHH ****
M"BBL35[F]M-6T[R;HK!,Y1X?+4@\9SGK0!MT55OK>ZN(@MK>M:.#DNL:OG\&
MK"M6U7_A(Q9C67NH84W7&;=%P3T7('7H: .GHHHH **** "BBB@ HHIDTGDP
M228)V*6P.^* 'T5S*R:[=V#:FMXML "ZVIB!!4>I(R"16B+R;4/#OVNWE-M,
M\.\,%#;3C/0\4 :M%9VA74UYHUO/</OE9?F; &?P%:- !1110 4444 %%%%
M!16=K-[<65FIM8O,GED$:#' )SR?;BLZ675M'N;62ZOUO+>>41.AB5"A/<8'
M/3O0!T5%9^LZK%H^FR7<@+%1A$7J[>@I-"OI-2T.SO9@%DFC#L!VS0!HT444
M %%%% !1110 445BWUU?W.K#3;)S;*L8DDN2@;&>@ /!/% &U17-Q:M?:=/?
MV=ZXNY+> 3QR*H4N#G@@=^*K3ZAJMGI']MOJ*2Q@;S:+&NTCT#8R30!UM%,A
MD\V".3&-R@X/:GT %%%% !1110 4444 %%8EPNM7M_-'#/\ V?:Q?=EV*YE/
MT.<"GZ#J<NH1744Q5I;:7RC*@X?@'(_.@#8HK#T:ZO7U;4K2ZNO/6"0>63&J
MD @'''UK<H **** "BBB@ HHHH **9*S)"[(A=@I*J.Y]*YN:37;>P?4[F^C
M@V98V9C4KCTW8SG^M '3T5A:IJTBZ%;7$,HMIKH)L=@,)G!/7CIFK6EQ7(+2
M2ZS]OC(P (T4 _5: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *ANT:6SFC7[S(0*FHH PO#%W"/#
M4+.RIY(99 3C:03UI/"08Z0TQ3:LLK.H]LX_I4USX9TRZNFG>.52QRZ1RLJ/
M_O*#@_C6M'&D4:QQJ%11@ #@4 .HHHH **** "BBB@ HHHH 9--';PO+*VV-
M!ECCH*P/$&F66L:<+_[4RF)/,B82'RR1R,KT/XBNA90ZE6 *D8((ZUB_\(KI
M?VCS=MP5W;O*,[^5_P!\9Q^E %[2+B2ZTFVFE4+(R#( P*NTBJ%4*H 4#  [
M4M !1110 4444 %%%% !5>^NTL;*:YD.%C7/X]JL57O+*"_A\FX4M'N#8SC.
M* ,SPW:2)9O?7(_TF\;S6SU4'[J_@#6W0  , 8 HH **** "BBB@ HHHH **
M** ,+0N;O6!_T\M_6H_"TJQVU];2826&Z?>#Z>M;-M906DDSPJ0TS[WR<Y-4
MK[P]I^H7'GRK*DA&&,,K1[_][:1G\: *GAUO/O=6N4 \E[DJC#HV._ZUT%16
MUM#:6Z001K'&@PJJ.E2T %%%% !1110 4444 9OB#_D7[_\ ZX/_ "IME++#
MX=BDAA::58<K&I&6/IS5^YMX[NVDMY@3'(I5@#C(-+!"EO D,8PB# &: /-[
MF74;>&&XOM#O?MLU[&[REH\'##"+\W^<UZ1;R-+;H[Q-$S#)1L97\JBO+&"^
M6-;A2PCD61<'&&!R*LT %%%% !1110 4444 %8/B#_D(:1_UW/\ *MZJUS8P
M7<L$DRDM VY,'&#0 W4[Y-.T^:Z?^!?E'JW8?G5+P[8-:V!GFYN;IO-E)]^@
M_ 8%7[RPM[]$2X0NJ.' S@9!R*L]!@4 %%%% !1110 4444 %%%-DC$L31MD
M*PP<'!_.@#G=4O)]8NVT?37P@_X^K@=%7^Z/<_XUKO;QVFCO;Q#$<<!51[!:
MR8O!.DP;O)>_CWL68)>RKDGOP:VX;.*"R^RJ9&CVE<R.68CZGF@"AX8_Y%^U
M_P!VM>H+2TALK9+>!2L:# !.:GH **** "BBB@ HHHH 9--';PM+*X1%&2Q/
M2N<LUF\1ZE'J4FY--MVS;QD8,K?WS[>GUK8U72;76;,VMX)#"3DA)"F?RJA;
M^$]/M7C:*;4!Y?W5-[(5_+.* ,759=4EUJ>XN=$O)K2W0K;>6T>W/=SEO;C\
M:UO!5Q)/X7L@]K+"$B55+D?.,=1@]/K6_(BR1M&PRK#!J*RLX;"SBM+=2L,2
MA4!.<"@">BBB@ HHHH **** "L_5]5BTFT\UU,DC<1Q)]YV]!6A6/J?AG3M6
MO([NZ-SYT8PACN'3;],&@#+>&]TK1]0UJXVR:E/'D@\K&HS@8]!DU6N_#=I:
M:$=1AO'^T1+YREY"82W7_5_=_(5T%EX?LK%G*/=2AUVLMQ</*I'T8D5"GA32
MTG$F+AE!R(7N':/_ +X)Q^E &EI\SW&GP32+M=T!(]*LT@ 4  8 Z 4M !11
M10 4444 %%%% &=<"QUJ"XLO/?Y&VRB*1HV4]>HP:S/"R&RFOM,C99+:VD_=
M2 <\@$@GN<D\UH7_ (?L-1F\Z0312$89K>9HBWUVD9_&KEE8V^GVX@MHPB#K
MZD^I/<T 9&D?\C)K/^^O_H*UOU6@L+>WNI[F-2)9R#(<GG Q_2K- !1110 4
M444 %%%% #)94@B:61MJ(,L<=!6#KVF6.MZ:+W[4X\M-\3"0A#CD97H?Q%=
MRAE*L 01@@]ZQ3X5TLW'F[;C;NW>3Y[^5_WQG'Z4 164]CK%I8V^I1Q/="/S
M%A=/E;'&<8QCGI4-O%#8^,1;:>H2%[<M-%'PBG(P<= :U[_1K+48HTFC9?+X
M1XG*,H] 1R*73M(L]+5A;(VY_O22.7=OJQY- %ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHKQGQ)<:[?_ !!FTK3M5N+?>P"+YS*@_*@#V:BO(;K2_'_AJ WBZBUX
MB?,P$C28'N&KM/!/BY?$^GL)@L=["<2(._O0!U5%->1(EW2.J+ZL<"HUNK=P
M2EQ$P')(<'% $U%1+<0.C.DT;(O5@P(%.CFBF7=%(D@'&58&@!]%,DFBA&99
M$0'NS 4&6,1^89$"?WBPQ^= #Z*BCN8)CB*:-SZ*P-2T %%(SJB[G8*HZDG
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MU;K@]3^M,#"U6ZU?QYXNFT>VN##8Q,01NP-HZD^IJ;6?AU>^'='N+O3-5EE
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M'+WQ(+JU2_EM;(8,NSG<W88_.NM^'O\ R3[4_P#@7]:/@U_QXZG_ -=$_D:
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gjnp4w4lrub1000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 30!' # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]9/]VO(+/_DJ,?\ N_UKU^Z_X]9?]VO(+/\ Y*C'_N_UH ]CC_U:_2G4V/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK:G'I=E)<R*S*@R0HYKC+/X@7'VWRK^!84) !/K73ZY?Q1:%)=,JNA3=R.*
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M#?(DC*"?3/\ ]:NK\8Z+9OIAD\L;HU++]:Y&U2^\)ZZ$6 FV9B[.>W-:&O\
MB.\U>*.VM(0X<[7QV% #?"EU+<>"+OS3DK*0/UIO@;1[.YUB]>6/)SFMG3-"
M?2?",UN%.]VW8/XU'X$M9H-2O#(A /2@#FO&>D6G_"71KY?&S_"NQN-$L5\)
MLPBY$)Q6)XNLYYO%L<B(2NWK^5=?<Q.?"CQ@?-Y)&* .7^&;"/2F3.$\P_UJ
MQ>>(]"T^_F5+2228MAB@SS^ JIX(LKB/1Y$9"K&0_P!:PM">;1_$.IOJ$ 99
M'_=^8,^E %?4-4M;[Q,LT$$D;8ZL"*Z;Q@2=-TLGJ5_QK"U%KG4=?6:&S58,
M?>48KHO%=K-+INF*B$E5Y_6@!DO_ "(G_ JK^&Y&BT#5G7J(\C]*O26LW_"$
M^5L._=TIGAC3IGTG48'0@R)@?I0!E^ +"'4;@7MPH:0\$U9\=Z)8PW]E*D0#
M9S_.LS1KB\\+:L;>2'$"_P 1H\0:GJFO7]LR6O[I&^\/2@"]XDO9;/P%$T38
M)D _E70>#=&L_P"S%G,8+RJ&8U2U+0Y=5\&);;3O5MV!6=X?\27>D126EU"$
M$?RIGO0!6\;6<6EZI]KM5VR%P,CZU;\6C[5IVG"3G?$,U4G2^\5:\0\)%KD,
M''UK9\66$JQ6,4:DB- * +GAK0K >%PWD\[#_*N*\):19S>(+HO'G;,<5Z7X
M?B>/PT$88;8>/PKB_"-E<1:Y=L\9"F8D4 .^)FF6MG86\\,>US.HS^(K7UMR
M_@%LG_E@/Y5%\3K::YTJW6)"Q$X/ZBK&KVTK^!FB5<OY &* ,CPQ<-;^!(64
MX)1A^E1?#;3;>\^W3SH&<3'!_&M+PEI<DO@R."52&"-Q^%<_X;OK[PK=74$T
M&U))206],T 6?B9HMC9QVMU#%MF>X4$_\"%7?%%\\'A=(@3M:%<C\*P?%VH:
MIKTMN@M?]&6965QWY%=AK>BR7OA4;$+2K$H"_A0!S/AO7+.UT6-/LDQ<J02%
M//Z5'I<4T_C*TGM(GBM\Y<,IK0\.ZP-+L8[*^LXD,8ZLHS72:9K/VN_C6&SB
M$9/+JHXH S]/TO0-/NVFC\D%EQ_K!5"?PMX7FG>5HX"S')_>"N:/PZU$MQ<7
M/_?9I/\ A76H_P#/Q<_]]F@#HO\ A$?"W_/.#_OXM=7X4TC2M-BD&GJ@!/.U
M@:\R_P"%=ZC_ ,_%S_WV:[WP%X=N-%MYEGDE8L<C>Q- ';T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!#=_P#'K)_NUY!9_P#)48_]W^M>
MOW7_ !ZR?[M>06?_ "5&/_=_K0![''_JU^E.IL?^K7Z4Z@ JAJ\<TMBP@;:_
MK5^D8 J0?2FG9W \/:]U,Z[Y'F-GS,#BO7]$CGCTY%N&W2=S7+3:9;IK:2D#
M)DSTKMEDC4  @54JBDK(TFGH2T4SSD]:3SD]:BY%F1:@ADL947J1Q7BVJ:?<
M?VZ8]I)##M[U[=YL9')KE)D@;Q)(2JG\*RJ*_4Z<-4Y+Z&YHD3Q:="'Z[!6G
M4,<D8C4 @<4_SD]:T1SRU=Q]%,\Y/6CSD]:=R;',ZU_R,EE74#I7*ZS(I\1V
M9S73B9,=:B.[-:GPQ)**9YR>M'G)ZU9G9CZYKQ7_ *NV_P"N@_G71><GK7->
M*I%,=M@_\M!_.IG\)I17OHZ2W_X]XO\ <'\JDJ""5/L\?/\  /Y5)YR>M,S:
M8^D/0XIOG)ZTAFC SFG<+,\P\?W-ZFHA$+>65YP*Z/P/-=26H$Q.P+QD5D>-
MM;BCN?(5$;*]2.:Z3PMJ$$^FQ*NT,%YP*YXV]H]3NJ7]@E8Z.BF><GK2><GK
M71<X;,DKG?$EC%-&A9<UO><GK61KDJF%>:F5K%TKJ2(_#5G%%9[E7!!K?K&T
M"5!8<GO6MYR>M$;6"I=R8^BF><GK2><GK5&=C'\4.@TL@L <^M6M&DC:RC"N
MI(7L:XCQ]=2AG5"=GUIOP]N)I#-YC,5'3)K'G_>6.SV+]AS7/2Z*C\Y/6E\Y
M/6MKG)9CZHZNP&F3Y('RU;\Y/6L;Q$OG:?(58\+VI-Z%05Y(;X79?[+C 89^
MM;U<5X1A*0)(SMCZUV(E3'6I@]"ZT;39)130ZGO1O7UJS$Y?QQ<W-MI :V+!
MBV#@9KDO!=[>F^VDMM9_FXKTK4(HKBU97 (P>HKG_"-M"C71"KD.<<5C*+YT
MSLIU$J+5CK:*3(I:V.,*KWW_ !Z/5BJFHR+'92,QP *3V''<Q]#_ .0C)]*Z
M.N2T/4+;^T7_ '@Y%=8"",CH:4-C2LFI"T4451D(6"C)('UJ,7$).!*F?3<*
M9>0>? R[BO':N/L]**ZLH^T2$$GC<:ER:-(04DVV=N"",BEID4?E1A,YQWI]
M49A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5KJQM[P*)TW;3D59HH :B+&H51@"G444 4[S2[2_&+
MB/=4%MX?TZT?=# %-:=% #'B22/8PROI44%E!;,S1)M)ZU8HH K2V%O/-YLB
M9<=ZE,*-%Y1'RXQBI** *]M906B[84VBJMUH.GWKAYX0S YK2HH H1:/90IL
M2+ J>6R@F55D3(7I5BB@"N;* P^3L^3TI8+2&VSY2;<]:GHH S[S1+&_;=<0
MAC2Q:-90+MCBP*OT4 1QPI%'L086LZX\.Z;=/OE@#-ZUJT4 5+33;6Q4+;Q[
M0*DGM(;D@RKG'2IZ* (XX4BB\M!A?2H8=/MH'9XX\,QR:M44 5[JR@O$"SIN
M .12O:0O!Y++F/&,5/10!#;VL-K$(XEVJ.U5+O0["^</<0AB*T:* ,\:-8K"
ML0A^13D"KHB18]@'R@8I]% &5<^'=,NY"\UN&8]ZGM-)L['_ (]XMM7J* /*
M?#NK:Y-JLJ7#RF,(2,J>O-<SJ'B+Q2E_.L<D^P.0/D->Y21VMJC2^5&N!U"B
MO+?$/Q%M[2[:"RMK:5@<'*#K^5 '+?\ "2^*_P#GK/\ ]\&O1_AUJ.JWUM,=
M19RP/&Y2*XNV^)=S'*OVK3K5$)P3Y:_X5ZIX:UNPUBT\RT\L$#Y@B@<T ;U%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W7_'K)_NUY!9_
M\E1C_P!W^M>OW7_'K)_NUY!9_P#)48_]W^M 'L<?^K7Z4ZFQ_P"K7Z4Z@ J.
M:411%FZ 5)5>\@%Q;LF2,CM0-;GE'B'79;C5EBLW*,KX)J]#;>))HPZWG!JG
M)X;D_P"$@#$-M,G6O4;"S2UM5CP#CU%<T(.3;9Z-6K&G%**N>??8/$W_ #^?
MI1]@\3?\_GZ5Z7L3^ZOY4>6G]U?RK3V2[F'UI]D>:?8/$W_/Y^E9K6FN?VBR
MFY_>]SBO7?+3^XOY5R\B+_PDD@VCIZ5+I>9<,2W?1'-K8>)=HQ>?I2_8/$W_
M #^?I7I*1IY:_*O3TIWEI_=7\J?LEW(^M/LCS3[!XF_Y_/TH^P>)O^?S]*]+
M\M/[J_E040#.U?RI^R7<7UI]D>/WEGKBZC"DMSF4_=..E:HL/$P&/MGZ5LZW
M=VH\26?(P.O%=?$8I8PZ!2I]J+<UU<J55P2=CS?[!XF_Y_/TH^P>)O\ G\_2
MO2_+3^ZOY4>6G]U?RH]DNY/UI]D>:?8/$W_/Y^E96JQ:Q'Y8N;U6^88&>AKU
M\QKC[B_E7D'BZ*]_MISL(CWC;S[UG4ARJYT8>JZDK62-&&S\1R1*8[X%<#&/
M_P!=2?8/$W_/Y^E=/X-CG_LL_:8P&[9]*Z3RT_N+^54J=U>YE/$.,FK(\T^P
M>)O^?S]*#I_B8C!O/TKTORT_NK^5'EI_<7\JKV2[D?6GV1XQJOAW4F)GNI=[
M >E7M-T77((%>VN-BL/2NZ\2(HM'PHZ>E:.D(G]EP_*.GI4*BN8V>*ER+0X+
M[!XF_P"?S]*/L'B;_G\_2O2_+3^ZOY4>6G]U?RJ_9+N8_6GV1YI]@\3?\_GZ
M5A:O=ZW9D+<3LWX5[1Y:?W%_*N2\7VEB\<9F8)Z8%1.E9:,UHXF\[.)Q.CRZ
M[>1@6]PRJ3Z5L?8/$W_/Y^E=-X1BLQI_[DAN?2NE\M/[B_E3C2NMQ5<3:32B
MCS3[!XF_Y_/TH^P>)O\ G\_2O2]B?W%_*CRT_NK^55[)=S/ZT^R/$]?AU2(,
M+V8N._%,\/#4Y2ZV,Q3UXKT3QGI$-QI[2GAB>PIOA#P_!81-("6+C/-8^R?.
M=:Q,?8WMJ8/V#Q-_S^?I1]@\3?\ /Y^E>E^6G]U?RH\M/[J_E6WLEW.3ZT^R
M/-/L'B;_ )_/T_\ KUFZL^O64)6XN\JPY%>N^6G]Q?RKD_&>CF]M/-1?]6O:
MIE2LM&:4L3>:4DC@M$N=8NL06MUM'I6]]A\3#G[9^E2^!=#>*9;MP<$=^E>B
MB-,?=7\JFG3;C=EXC$*,[12/-A%XD08^U'\J-GB3_GZ/Y5Z3Y4?]Q?RH\J/^
MXOY5I[+S,/K/]U'F4P\1+&Q:Y8C'I5'29M7'G>1*P^;YL"O5;J*/[._R+]T]
MJYWPC&C->913^\/4>]2Z?O+4TCB$X-V.>_M/6X_E:20X_P!DTT>(]5B^\)CC
M_9->E?9X?^>2?]\BFFUMR.8(_P#OD57LWW(^L0ZQ//(_&US%_K()S_P TZ\\
M<P7%HT4EO*,CNIKNI-+M9!S#'_WR*Y_7_"UM-8R/&H# <8%2XS2W*A4HREK&
MQROAO4K63569@%7MDUZ=!=V\L:[)4/'0,*\ET;PJUW?RPL[H57(VDUI/H^L:
M.^^V6215_O,:FG*45JC6O3A.6DM3U $'H<TM<#IGC*>&00ZBJQ8XKM+._M[V
M,/"^X5O&:EL<52E*&Y/+_JF^E<W:_P#(83ZFNDD_U3?2N;M?^0PGU-*6Z"GL
MSIZ***LR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *0D 9)Q2UR/C;Q)_8MG&D1!DF.P ^] '22:C:
M1'#7$0/^^*?%>6\WW)HV^C UYAI/@JYUV(W5_<W$+,<@*YZ&M6R\)W6BWBM;
M2S3*6YWN3Q0!W4UY! V))D4^C,!4?]IVA.!<1?\ ?8KRWQHLUYXTM+ S21H\
M7.UB/2MJS^'4)6.8W]SGKC>W^- '=-?VR?>GC'U84S^U+/\ Y^8?^^Q7,7W@
M2*[QF\N%P,<.?\:\]U[PZVFZE;V\=[<%9) IS(?\: /:TU"U=MJSQ$^SBAM1
MM4.&N(A]7%<?I?@&*UFBN1>W#':#@N<?SHO?A[%=S,YOKE<G/#G_ !H Z[^U
M+/\ Y^8?^^Q4\5Q%./W<BM_NG->/^*_"4.A:6\\>H7)E7H#(?\:[#X?V5Q;Z
M>)IF=A(N06)- '9LZHN6( ]2:ACO;>5RJ31L1U 85RWC763#926=JV;D]%%<
M+X(:Z36)6FED+._(+$XH ]HEECA3?(ZJOJ3BJW]IV?\ S\Q?]]BN7^)<\D'A
M-GC9E;(Y!Q7,^'_ ZZM8QW$E_<@LN3B0_P"- 'JD5S#/_JY$;_=;-)->06Y
MEF1,]-S 5C:%X:314 6XEDP/XV)K@/B(TUQXBTNT6:1%EDVG:Q'8T >I_P!I
MV>?^/F+_ +[%6D=9%RI!!]#7GT7PUA(5_P"T+KL?]8W^-=QI]D+&V2$.S;1C
M)- %NBBB@ HHHH **** "BBB@ HHHH **** ,76KNWFTZ18[N$-M/\8]*\>\
M'Z=IEUKEY_: C8^<<%F J)_"?BPDCRIB#_TT-4E\!>)4E\Q;>16SGAB* /1O
M%>@^'(M*+1+!NYQAQ69\)(9%%\ <1B0X'MFN2N/!?BFY0*\,Q .?OFO1_AQH
MVHZ3:31WL'EDGCWH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"&[_X]9/\ =KR"S_Y*C'_N_P!:]?N_^/63_=KR"S_Y*C'_ +O]: /8
MX_\ 5K]*=38_]6OTIU !4-S(8X2P!/TJ:D8 J<C- 'GLFIN=84>6_#^E=Y:R
M^= &((^M<'XBOY-.OXVAB0DMW IH\::D!@01C\/_ *U:4Z<IJ\4:57:QZ+17
MG7_";:G_ ,\4H_X374_^>*5?U>9ES(]$9@HR2 /4UR<EQ#_PDDA\U,8Z[JP;
MOQ?J5Q:R1>4HW#&17$R75Y]JSN;?G^\:4J#5KFM)WO8]]A='C4JP/'8U)7E>
ME^*-1LH @0-D=S6BGC?4 WSQ(!3>'GT,KH]#J.;/DR8/.TUPO_"<77]Q*BE\
M<SE&#*@XI?5YA='+ZVMY_;8!<EBQVGTKU/PT)1HL(F;<_>O(+WQ!<3WPG,:9
M4\<5V&C>-XHK5!<.J-W%9PPDXMLZJ]?GA%6/1Z*Y6+QSI;??N *O1>+-)EZ7
M(JG2FNARW1N5R?BVVB(MV*\F09_.M^WU6TN?]5)NK%\6',=KC_GH/YUC45EJ
M;47[Z.@M(UCM8PHQ\@_E4]1V_P#Q[1?[@_E4E49O<***0_=- CGO$LL8M74N
MH..A-:6BR(VF0A6!..QKBO&FGW<ESYJ;O+ YP36YX/M+B"U5Y=VTKQDU*MS'
M1*/[I,ZFBBBJ.<*\[^(%M=.L10DKGH!7HE8VOJK0KN4'ZBHJ*\;&U"?+-,YO
MP%;W*6ZNY(3/0BN]K(\/*HL.% Y["M>B"M$5:?--L****LR.6\7W_DV+1^6Q
MYZ@4OA?4_M,.SRG7 QDBKGBA%.E$E0>?2K6CQHME&0BCY>PK.SYSHNO9;&E1
M116ASA7+>,M1DL[(QH&^=><"NIK)\06<=SIDQ<<JO'%3--QT-*32FFSA_ NL
M7$EXML^XH!Z<5Z:#E0:Y#P;I4$%HEPOWS[5V%3234=33$RC*I[H4445H<Y#=
M?\>[_P"Z:YSPA]Z]_P"NA_G71W7_ ![O_NFN<\(?>O/^NA_G4/XD;0_AR.IH
MHHJS$*JZ@RK9N6( QWJU6+XFCFDT:=80=Q'&*3V*@KR2,3P[<1'7Y_G7[OK]
M:[-D61<'D&O&?#MGJ']L$!6W C=R:]EA!$$8;J%&:SI.Z.C%049*S,'5_"UK
M?H62-1)US7&EM1\*WH61V>#.2%'%>IUGZII<.I6S12*/F[XYIRIWU6Y-*NU[
MLM40:9K$.IV&]6 8KR">:S[7_D+I]37'3"[\+7\C#=Y#' +&M+2/$D$^JQ;G
M'/6H]IT>YLZ#2<H;'HU%,BD66,.IR#3ZW.$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** &/-'%_K)%7ZG%1_;;7_GXB_[Z%8?B72I
M]0 \HN./X217)?\ "'ZA_?G_ .^S6T*<)*[8KL[Z_P!:M+&U><RH^T9P&KF!
M\2[ N%\A^3BL9O!M\ZE6:8@]BYK'3P?>OJ+P>4VU>AK>%*C;5B;9ZS8ZU:7L
M(D$J)D="U6?MUK_S\1?]]"O-4\&WZJ &F'T<T[_A#]0_OS_]]FLW2I_S!=GI
ML<L<HS&ZL/4'-/K \+:9-IEF\<Q<DG/S$FM^L)))V105X_X^8SZQ:QN?E6=<
M9^M>P5YA\2M'G)M;NW0MLE#M[ &I ]'L45+&W"_\\U_E5CM7':!XXTNXL42:
MX D0!"/IQ5__ (3'2I9Q##<!G)QB@#SSQ_=FQ\=VUPJLQ6/HHY[5JV'CR<F&
M+[%<X)QG8:J^*=LOQ)L<@,K19P1_NUZ996=M]EC/V>+..NP4 26%P;JV60J5
MR!P17F7C+_D/6/\ UV%>K !1@  >U>4^,O\ D/6/_784 >IV_P#Q[1?[@_E3
MG<(A8] *9;_\>T7^X/Y5D^)]333M*FRV&=#MH X#Q'<OKOC%=+0EH6'/I7HB
MF/1_#X!(7R8^F:XGX?:<U]+_ &M./W@<@9^M=AXDTV34;(Q1[N5QP: .*TA1
MX@\0_P!J2RK]G *[6-4M%,4?BBY564*)>.?I4UEX6U73H&CBB?;DG.37+Z99
MWQ\0RJ%;<)>>: /6/&FD2:[X=-K;N Q.<UR%OIGB#0[+<+HF.->5 KN;?48-
M*T]1J#[".N>:CO\ Q)H_]G2MYJD%>.!0!D>$O& U2<6,RL)\<EJH>-O"=]JV
MJ65U:2A#"V[/YUD>$XS?>-O[0MQ_HQ7J.!7H\OB+2X9?*EF <'&"* .!O=4U
MOPZHFNYGEC!QA17>^'M;CUFR61 0P7G-<SXW\0:4^D^4CHTA;IM%6/AY9S6]
MK-+("%EY6@#MZ*** "BBB@ HHHH **** "BBB@ HHHH AN9UMX'D;H 37CVL
M_$V87DL=M%+MB8@E0<5ZEKZ.^F2!.NT_RKR+PU9VMS::TK@-*'.,C/>@"NOQ
M*U%QE8YR/4*:]!\ >))M=MYFEW94XYK@]+OM'L%DL]09$D5#QM'7%;WPINS+
M)J'E &(RG:?;- 'J]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 0W?_ !ZR?[M>06?_ "5&/_=_K7K]U_QZR?[M>06?_)48_P#=_K0![''_
M *M?I3J;'_JU^E.H *0]#2TAZ&@#DKVUAN=3C$R!ANK<&A:=C_CW6LF;_D*)
M_OUU Z4H2:-:O0S?["T[_GW6C^PM._Y]UK2HJ^>7<RL9O]A:=_S[K7,2Z+8G
MQ%(GDC;Z5W-<O+_R,LGTJX-N]PV-2/0=.\M?]'7I2G0--;K;K6BGW%^E.J.:
M7<#+_P"$=TS_ )]EIC^&M*;K:K6O11SR[A8\[UGPY9Q^(+2*.)1&W45T'_"'
M:81_Q[+4&M_\C+95U0Z4HU)7>II42Y8G)S>![%ON0J*HR^ WS^Y=5KNZ*T5>
M:ZF5D>:S^%M:L3N@O, =A6-J-]JEJ8UO&DD",#TKV"1D1"S@8'M7#^+-4TR8
M10JR[E<;L*/6G*JY0::N:45[Z+6C>,[>XC2*6,QD #+<5U<%S%<(&C=6SZ&N
M#E\/Z=K%LLUC,Y<*!A>.:SK:^U3PS<[)T_<9P&8YK1THR7N[F=[/4]3HK*T?
M6[;58 \3[CT/UK4)P":YFFG9C.?\3_\ 'C)]*TM%_P"03!_NUS7BS5/+1H<C
MD5L^&[S[1IT2^BU"W-91?(C;HHHJC(*Q]>_U*UL5R_B66_"+Y,0914S>AI25
MY(TO#_\ QX?C6M7.>%I;M[/$T8 S71T1V%45I,****H@P_%$B#2V!8 Y]:M:
M-(CV485P<+V-5M9T1=4!#,P!]#2Z/HXTT$!G(/J:C7F-KQ]G:^IM44459B%9
M^LR(NESAF )7N:T*P/$]O#-9.9)&4A> #2EL735Y(C\)RH=,C4.I;TS71UQ'
M@^WMXPKK*Q?'0GBNW'2IA\)==)3=@HHHJS$YKQE>SV6E;X-VXG!P*XKP?JMV
MNI^4=Y61_FXKU#4+2.[M720 @ GI7,>$M.A6:Z8 960XXK&47SIG92J15%IH
M[&BBBMCC"JU^ ;-P?2K-5[[_ (]'I/8<=SE?#L2#7YR!_#_C795R'AW_ )#T
M_P#N_P"-=?4T]C6O\044459B8GB'1XM2LF!4$J":\NT?3OLWB..*4A?F/7ZU
M[3)_JF^E>4>*8)8M4%W"N-@[<5A6BM)'=A)MIP/4[10EL@4@@#M4]<]X5U5+
M[3XXRV9%7YA70UM%W1R3BXR:84444R HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *B$$:RF0+\QZFI:* "BBB@ HHHH *KW=G#>P
MM',@92,8-6** .&N/A_ )BUHJ1@G)%:&E>#;2RD\V6)6?KFNIHH Y^]\-0W6
MM0WY5=T:[1^G^%;L:>7&%':GT4 %8.I>'(K^ZBF95RC;N:WJ* $1=J*OH,5E
M:WHZZLL:MC"]0:UJ* *&DZ9%I5IY$2A5SGBK]%%  >1BL"W\-Q0:A)=!5R[;
MJWZ* ,G6=%CU2V,;*,GN:YO_ (061F"R.IB_N^U=U10!E:3H-GI, 2"(*1Z5
MF:OX32^E\R$*C9R37444 <3;^!(VF#7H651VKK[6UBM(5BB4*JC %3T4 %%%
M% !1110 4444 %%%% !1110 4444 4?MUE=AHA/&V0<@-7,V>F:1874S+<6Z
M^8V6&X5SGASPYJ%MJ\K2&3:4(&6/O6->^ ==EOII$$VUG)'SM0!MZ]X/TO5-
M1:YAO+9-Q_OBNN\(Z-I^E6K):/$Y/WBASS7EW_"O=?\ [LW_ 'VU=_X!\/W^
MBV\RW@?+'(W,30!W-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 0W?_ !ZR?[M>06?_ "5&/_=_K7K]U_QZR?[M>06?_)48_P#=_K0![''_
M *M?I3J;'_JU^E.H *BN QB(0X-2T4 CBWTN^;41+YIVALUUMJ'$(#G)J;:O
MH/RI:F,;&DZCD%%%%49A7+R_\C+)]*ZBN7E_Y&63Z5I3ZB9TR?ZM?I3J:G^K
M7Z4ZLQA112-G:<=<<4 <KK?_ ",ME75#I7G^M2ZG_;]N?*&X'Y?>NXL&G>U4
MW*A9.X%)1M<UJ?#$LT444S(;(@="I&0:\8\66<R:W(1&P0L .*]IKE?%L,96
MV.U<^:.<>]7"[?*NI<)*+NT)X(M&@TP^8A!)R,BMO4=)MM0A9)8PQQP35JU5
M4M8@H ^0=![5-2YG>Y+M?0\KN[:\\+:D'C+&W^\0HXKOM&U:+5+-65AN(Y&>
M:GU738M1LWA=1\W?'-><P27/A?6&!R(';:,FNC2M'S(V.A\5:5YH:7(X%;7A
MVS^S:?$WJM4=7NTO-,,B'(VC/Y5M:/\ \@N'Z5G+X+%7+U%%%8@%<WXAO)(U
M"I"[9]!724THC?>13]12:NBH247=G/>&[F0PB-XF7)[BNCIJHJ]%4?04ZA*R
ML$Y<SN%%%%,D**** "BBB@ JE?V(O4VG&*NT4/4:;3NC(T_15L9=R8 ]!6N.
ME%%)*PY2<G=A1113)&3?ZB3_ '3_ "KG?"GW[S_KH?YUT4W^ID_W37.^%/OW
MG_70_P ZA_$C6'P2.EHHHJS(*S=:NUM=/D<C.!TK2JI>V$5]$8Y"0#Z4G>VA
M46D]3@O#^LXUB23RFP_%>C(VY%;U&:Q;3PQ96<OF1DD^XK; VJ!Z5-.+2U-*
M\XS=XBT4459B,D_U3?2N/N+-;V[\EAD,:["3_5-]*YNU_P"0PGU-1(VI.UVC
ME]'G?1_$4\+$B,MM%>FQMNC5AW&:X#QIIIMIH;N(<[P6KI_#>I#4=.#YR5PM
M33T;B:UUSQ51&U1116IR!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >)>(X
M/$FG:O)/;W$S1]E44[2_B+J.GN$OK2X;'4LIKV2?[.JEI40CW45P_B2[\+M&
MZW<@C./X5% %W2OB%I^HD!]L)/\ >-=5;7MO>)N@F20=]IS7S+KXT7S2=)NY
M&?/ SC^M>F_"$7@L9_/+$9XR2: /5:*** "BBB@ HI-PI: "BBB@ HHHH **
M** "BBB@ HHHH **** (;K_CUD_W:\@L_P#DJ,?^[_6O7[K_ (]9/]VO(+/_
M )*C'_N_UH ]CC_U:_2G4V/_ %:_2G4 %%%% !1110 4444 %<O+_P C+)]*
MZ28N(6,8R^.*XRXM]=_M9KA(%(/^?2M:2W$SM4_U:_2G57LS,8%\X8;'-6*R
M8PHZ"BD8;E*GN,4 <GK5Q#_PD5H?,7 ZG/2NJC=9$#(P93W%8$_@^RN)C*\D
MFXG/6MJRM$LK98(R2J]":B*:;N:U'%Q5GL6****LR"N9\6_ZNU_ZZ#^==-7,
M^+/]7:_]=!_.M*7QH&=%;_\ 'M%_N#^525';_P#'M%_N#^525FP"N:\5:,M_
M9[T4;T&[-=+4<X4P/NZ8YJH2<7= >3Z=J<D=G)93YWEN,UZ=H_\ R"X?I7E'
MB66VMM?5X6^4 YKT/PKK$&H620QOED7D5U5XWBI(E'14445QE!1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \*\17?B2^UN2"V:XCB[$#BI-/^&^KZFRR7=ZQ!Y(:O:EM
M( ^[RTSZ[14P55Z #Z"@#B-(^'.FV*K]H@CE8=ZZVRTVTT]-EM"L8/7%6Z*
M"FR.(T+'M3J9+&)8RAZ&@#SOQ+\1O[/NI+."T>1UXRM<1<>*/$FH.6@ANHU/
M3Y:]7;P5IGV^2^<$R$9.16?-XBTK3]6ATX"/>_ &T4 >8_;_ !8OS;[H_P#
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M[>#D9HJKI]RMU:(ZG/RC-6J\UJQ84444@"BBB@ HHHH **** "BBB@ HHHH
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M/63_ ':\@L_^2HQ_[O\ 6@#V./\ U:_2G4V/_5K]*=0 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XC_X\9*O:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %%%% %6?3[6X;=+"C'U(J2"UAM_\
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M621>2IQ7;>%/%B^)(I'5 NPXXK'_ .%5:!_S[?RKH?#WA:P\/1NEG%L#G)H
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M=.S[UKUS59.4VV-;!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4V/_ %:_2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKNO OAF]T""9+IE)8Y&* .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .?\ %5@+NP9\9,:DBL?P+J'^C?97/S[NAKLKJ,36LD?]
MY<5YK 3HGBU$/$?7]:QG[LE(ZZ7OTW ]0HJ*WE$T"2#HPS4M;'(%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!FZW.T&G2,O7:?Y5X?;:)'K%OJUY/=/OA<E5)KWN\MUN;=XV&<J
M:\.U_P -:WI,]R+.=1#.Q+*O/]: -WP=Y<'AW;(^%$;8)^E.^%MQ(]YJ8WEE
M\\XR?>N#LK7Q'L6U25DCZ?,I%>O?#_PP^AV<CSE6DF.XE: .WHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"&[_ ./63_=KR"S_ .2HQ_[O
M]:]?NO\ CUD_W:\@L_\ DJ,?^[_6@#V./_5K]*=38_\ 5K]*=0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8^N@%(\BMBL?7?N1U4/B J&R%[H3PD=37,^#[LV&LWENYP-VT9_"NWT<9LL
M>]>>ZM$VE>(XY>BRRUT4_>YH,EGJ8.0#2U#;3+- K+TP*FKE*"BBB@ HHHH
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M%)VT[7!8N< DG!^M>F A@".].O&T] 6PM%%%8C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X+QSHK2
M)'<0+ROS-BO-XYI7O >20<8KWZ\MUN;:2)AG<,5Y1JFD)HNM>;+&3".N!7+6
MAK='IX2M>/*]STS0B3I-OD<[*TJS-%NX+BPB\D@ +TSTK3KICL>=/XF%%%%,
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML0?C6EVH::W ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[O\ 6@#V./\ U:_2G4V/_5K]*=0 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "J=]J=KIT1DN7VJ.IJS,_EPN_\
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MG_:MA_S]Q?\ ?5']JV'_ #]Q?]]4 7**I_VK8?\ /W%_WU1_:MA_S]Q?]]4
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MY^XO^^J1M3TYAAKJ$C_>IJM-/<+(\LTSPC*^H,+A"L78UV:> M.**3))R/\
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MH_X0?7_[DG_?1KV>B@#QC_A!]?\ [DG_ 'T:/^$'U_\ N2?]]&O9Z* /&/\
MA!]?_N2?]]&C_A!]?_N2?]]&O9Z* /&/^$'U_P#N2?\ ?1H_X0?7_P"Y)_WT
M:]GHH \8_P"$'U_^Y)_WT:/^$'U_^Y)_WT:]GHH \8_X0?7_ .Y)_P!]&C_A
M!]?_ +DG_?1KV>B@#QC_ (0?7_[DG_?1H_X0?7_[DG_?1KV>B@#QC_A!]?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?1+&,Z1;K-&&S&O7Z5#-X5LI;KSA"@YSTH UK"0R64+'^X/Y5:ID<:Q1JBC
M Q3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Q_$&EMJEBT*C.5Q6=X-\.OH%@8&7;E\UU-%
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M,RVTR'[*IR.:],T?2H=*LTAB&,+@UHT4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!P.K>#)+[64NPF0L@;-=I-91W-BMM*/EV@'\JM44 >5:C
M\/+B.^FEL$.V8_-]*Z7PCX.AT2,2R(1.#FNPHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#F_%>@MK=HT2KG*XJ7PKHK:+HL5FZXVC&*WZ* .
M&\5^"(]6N5NX$)G0?+63H?P]D^W^?J2'C!'UKT^B@!D,8BA2->BC I]%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444A(4$DX H 6BL:^\3:
M78DK+>1!AV)J&T\7:1=R!%O8MQZ &@#?HI%8.H93D$9%+0 4444 %%%% !11
M10 4444 %%%% !1137=8U+,< =30 ZBH(;N"<XBE5OI4] !1110 444A8*,D
MX% "T5 M[;O+Y:RJ7':H=2U&/3K1[B0@!1GF@"[16%H?B2WUK'E,I)&>*W:
M"BBB@ HHHH ***0D 9- "T5PFI>/?LNM'3X8!(P<*<=N:[B%S)!&Y&-R@XH
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M]*/2@#(FU&+0]+$EXP C4 \^U<I+\6-&2;8!+C/I7,_%/4)WU^+3TD94D3D
M_2MW2?!%G+X76=PAD,9.2.: .QT+Q/8:]#YEJW?&":IZEXWTS3+DP3DA@<5Y
M-X4FGTGQS#8K*QB9B=N>.HJ/QSNG\01QABOF3 4 >CWGQ2T:UG"-YF",YKJ=
M'UVUUFW6:W;*D9Y->8ZWX(@M/!TET9 \FT$,1STJ#X:WLT4&I(78B*(XY]J
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M=IJ*$4*.@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9
MUSHEC=3"66/+ YS6@BA$"CH!@4M% !1110 4444 %%%% $4]O'<QF.094C!J
MO8Z5:Z<NVW3:"<U=HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHIJNK=#TH =1129&: %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBF22K$F]S@"@!]%1QS)+]PYJ2@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *.K2M#8R.K8(4\_A7A]IX\U:SU"\5Q-,BR$#:"<5[9K<3S:=(J#)V
MG^5>*:3K.G:/)J<-^461Y#MRH- '?:'X[34-.(=&68(3ANO2O.9O%VORZA<7
M$4TWV>%SD =JIV^O646L33K+B-DP,=.]:.C>(M)@\/ZK#,Z^=,24RHYYH ]:
M\%ZX=9T2&5R?,;KFNFKSCX8*S:=%*/\ 5E>/RKT>@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Y;X@74UIX6GE@<HXZ$5U-<A\2/\ D4;C_/:@"K\/
M;VXNX',\A<[>]=S7GWPT_P"/=_\ =KT&@ HHHH **** "BBB@ HHHH ****
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD@G_ .O0!T.G>)[6^G$)*I(?X2>:Y_XAD'[&1R/_ -=<9<7>F#Q6L^FSNW'
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M/#^I^'%TM9+NZ?[0ZD,"?;ZU#H6IP0>,;:VTR5GMY&);<: .]T[P5;:?=O.
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M@ HHHH **** "BBB@ HHHH **** "HI+:&;_ %B!OK4M% 7$5%0848%+110
M4444 %>9_%A"\&G+MR#.N?SKTRLK6= M-;6(7.?W3;EQZT 4="T33_[/B<VJ
M;MB\_A6O>VZ_V7/#&N 8R !4UO;I;1+&G0# J8\C% 'C_ABZ/AW6C:7*%5>1
MFWMP.O\ ]>NC\6^)+>:R6"V*RM*-OR'.*W=9\):?K4GF3Y5L8RM4;'X?Z78S
M"5&D8@Y&XYH Q?#^ERZ=X+N4D!#/)N&1]:E\ *1JE[D8KNIK**>U^SL,)C'
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MW.1_.NRMG#V\9'0J*F+U9K53442T4459@8'B;5H]-LMS '=Q65X+U>.XCE3
M!9SC\ZL^,M%;4K$; 20<UD^!]%:'?*X(*/C]:Q;E[0[(J'L&^IZ#1116QQA1
M3)-WEML^]CBN-N=7UR'41:A5W-]T5,I)&D*;GL=K15:R:=K5#<#$F.:LU1#5
MF%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW.LQ6D>D"RGV+\F_'%=WX;\'F'PO+:2\-*V[D?7_ !KNOL<._=L7/TJ8  8
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MXWMQ70>*M+EU/3WB09S7*^$O#TD5_*67_5M6$G+G5CMI*G[%WW/3!R,TM(.
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M +Y_G4NHZS:-8[P_# XJCX2O(FBF4'DN<?G3NN8E1:ILZNBBBM# *Y;40/\
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M;Z3XBM-31?+;YNASZUO&HGHSAJ4)1U6J-FN6U'_D;+;_ '?\*ZG.>E<MJ/\
MR-EM_N_X4Y[$T=WZ'4#I2T@Z4M69!1110 4444 %%%% !1110 4444 %%%%
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M>*\I\[QM_?'Y&O0/A^VN-;S?VJP)SQ0!W=%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNFN+U6UO+O4(Y0CXB;(KM:*F4;EPGR.Y3TUI&M%,JD-Z&KE%%42W=A5/5/\
MD&S?[M7*IZI_R#9O]VD]@CNC.\.?\>,=;M87AS_CQCK=I1V+J?$PIDKF.,L!
MDCM3Z0XQS5&9Y_J.IW*ZNW^C-C</YUV]C,TULA9=IVCBL'4EC_M \C[PKHX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8P-;PA&8M@8YJU14J*1<JCDK,****H@K7W_'L_\ NFL?PM_J+C_KH?YUL7Q
MMGY_A-8_A8CR;CG_ ):'^=2_B-5_#9T-%%%49!7+:C_R-EM_N_X5U-<MJ/\
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MVU^+2[NWV,Q^\W7K5JU^(3VE[>6^H+*VT87"FL+1B_B#Q_;W\,;K$./F'N*
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MN0^)'_(HW'^>U=?7(?$C_D4;C_/:@#-^&G_'N_\ NUZ#7GWPT_X]W_W:]!H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *NH?\>K5@^'D$D]ZAZ$X_E5_7A=-:,MNV&K
M!\/VNI6UV[2/\KGGBMX+W'J+J8VM(VB^)_M2#$8_*O1M.G%S80RY^\N:YSQM
MIGVK2FD1?WF>M)X*U,W-N]L[<PC;S53]^FI=A+<ZZBD8_*37):AKT]G>K"2W
MSM@<5A&#EL4==1533I7FM5>3.X^M6Z35@"BBBD 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6*TM'POR*I)'X5PFF>+-$N=>6UAM66<N1N]\T >@1+MC I](#D9I: "BBB@
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M '3]3>HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&#XB.H/!Y5G"'#C#56\,0ZC:1K;W$.V/KFNGHJ>76YI[3W>6P44451F%%%%
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M<?N#8]3HJM8WB7MLLJ$$&K-<K5B@HHHI %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $1MH&.6@C)
M]2@I/LEM_P ^\7_? IEY>Q6<3.[#@9QFL#0O&=IK4\\:@1^4VW)/6@#HOLMM
M_P ^\7_? IZ11Q_<C5?]T8JG?:M;65N93(IP,XS67X<\66_B%IQ$FWRFV_6@
M#HZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B1_R*-Q_GM77
MUR'Q(_Y%&X_SVH S?AI_Q[O_ +M>@UY]\-/^/=_]VO0: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQI'"H08&*UFHI*PB6BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M Y#\\5V]H\;P*8ONXJ!M(M&DWF%"V<YJY'&L2[5&!6DY)I6$/HHHK,84444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>OK1O7UH =13=Z^M&]?6@!U%-WKZT;U]: '44W>OK3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N3^(A/_  B%UC_/!KK*QO$^GG5-#FM0.6H \[^'>/L-_G_GD<_E
M65X5X^(\&WID_P Q46F7>I^&KB_MOL;,LBE5)K8^'VBW<NL)JES"T9#'@_6@
M#H?%\GB573^R9@@SSP:XK4K3QMJMFUK=7"M$W48/^->X-%&_WD!^M-^S0_\
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MX_\ ^?M?R/\ C7L7V:'_ )Y+^5'V:'_GDOY4 >.^=X__ .?M?R/^-'G^/_\
MG[7\C_C7L7V:'_GDOY4?9H?^>2_E0!X[Y_C_ /Y^U_(_XT>=X_\ ^?M?R/\
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MT:YP.U 'F_G>/_\ G[7\C_C1YWC_ /Y^U_(_XU[%]FA_YY+^5'V:'_GDOY4
M>.^=X_\ ^?M?R/\ C1YWC_\ Y^U_(_XU[%]FA_YY+^5'V:'_ )Y+^5 'COG>
M/_\ G[7\C_C1Y_C_ /Y^U_(_XU[%]FA_YY+^5'V:'_GDOY4 >.^?X_\ ^?M?
MR/\ C1YWC_\ Y^U_(_XU[%]FA_YY+^5'V:'_ )Y+^5 'COG>/_\ G[7\C_C1
MYWC_ /Y^U_(_XU[%]FA_YY+^5'V:'_GDOY4 >.^=X_\ ^?M?R/\ C1YWC_\
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M]!6-J'C32K";RGND#9P<]JTM+UNRU6(/;3*^?2@#3HHK.UC58=)M#/*P4>]
M&C17-^%O$I\0?:#L 6-L CO724 %%%% !1110 4444 %%%% !112$A02>@H
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MT;746\QG*U=M[:.UB$<0PHK,U;Q'8:0H-Q<*A/K4&D^+=,U6410W*-(3PHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLI]Y\B,,PQG;0!P/PNU&!&NX5C<;GP..E>JUS'AOPK!HDMPZ<^8V[D=*Z>@
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MO"K32CYB*[HQ(QRR GW%.  & ,4 +1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1145Q<1VT322-A0
M,YH EHKS/7/B@EK=^1IS)*1QSCK4.F?$ZYENDCODCC5R , 4 >I45%!,L\*2
M*<AE!J6@ HHHH **** "BBB@ HHHH **** "BBH+N[BL[=YIFVH@R30!/16/
MI7B/3]7;;:SAR?2MB@ HHHH ***9-*L,32.<*HR30 ^BL.U\4Z;=ZBUE%<!I
M@,E:7Q'J5SI^ERSVJ!V5<@&@#;R#T-%<3X+\1ZGK.T7L"Q@C/%=M0 4444 %
M%%% !113)9%BC+L< 4 !EC4X+J#[FGUY%=>*+V^\7RV-N,QQN.A[9KUF#)MX
MB>NP9_*@"2BBB@ HK@O%GCYM EV1["<X.:L>$?'">( %D*B0G  H [6BHIYE
M@@>5C@*,UYEK?Q4_L^^,,'ELHZDXH ]1) &20*19$?[K _0US5OK+ZOX<:[3
M_6&(M@5R?@OQ9<RZVNF77#,YZGWH ]3HHZT4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1,X88KA/"<<;?$*96C4KMZ$<=Z],\;1HGA2ZV(J_N^PQ0!D?#_6K>]A#1H5
M0GGZ55\2?$79?BSLD<OG;E03S7/_  \D>/3&*=?*;^59_@R.*Z\62M<?,PG.
M W/>@#8_X3W4M,E5[U)C&6 Y4BO0(_%,5[X:FOX<@QJ":P_BK:VR^'XR(T1M
M_55 ]*YGP>\C>!M5#YP#QDT 3?\ "T)=S1)%-(^/X034>G?$:[AU6*.\64*Y
MSA@1Q5/X86,-UXGN!*BL F<,,^M6/BA:16^M6QB14PO\(Q0!['IUZFH627*?
M=?I6=XLNC9^';F8'!45!X();PK:$GG%0?$#/_"(7F/[M 'G?PX@&H^*+JY<9
M++G-=EXT\5MX>N4C&[&S/'TKE?@__P A"7/79_2G?%T;K]!_L?TH @G^(]]=
M0!K:&X 7DL%.#72^!_'0UEA;3!C*6QDU8\+Z9:_\(,)#%&6,#<E!GI7GO@5?
M*\:*JG \UN/^!4 'Q(C\W6UC_O2@?K4.E;_#7C"QCSMB9 Q'Y5<\>_\ (S6_
M_7PO\ZL^/],>**'4XU/[N%1D?04 =_XIUY+;PZ)0W^N0@<UX3<V#3:%=7THR
MX<X)_&M_5/$1UO2=)L(VW.C , ?>M+Q9I?\ 9?A22+;C<H;]* .X\!)YGAA$
M]8L5P=UG1_B7"R\#!/ZBO0/AY_R+T/\ USK@/&//Q%AV_P!S_"@#W"PE\^QB
MD_O#-6:H:+_R![;/]VK] !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6)XET1-;T]H6 ) .,UMT4
M?/K:)KGA.^86SR&,L6PBY[UJV=]XDU>ZB3S)HU5P3N4\BO:7MX9/OQ(WU4&D
M6V@3[L,8^BB@#S'QQX,NM1BCOXWS+'&![YQ7-0:OKMK8C30EQPNW.PXKW<JK
M##*"/0BH?L=MG/D19_W!0!Y=X#\&7,=\NJ79RZMGD<\FLOQ7H5U/XGAECC<J
M)P<@>]>U*BH,*H4>PI##$QRT:$^I44 <QXFLY)_!K0("7*+P![5R'P\T.X@F
MU".9&42)@9&*]8*JPP5!'H135BC0Y1%7/H,4 >&Z[X9U'P_X@_M"SW';D_(,
MUIZ5?:_K%S"C/,B*PW;EQD5Z\\,4GWXT;ZJ#2);PQ_<BC7Z*!0!Y)XV\(7B7
MXU6T)W*N,*.:IVOB35HX$M?(N-P&W=L->U-&CC#(K#W&:B^QVV<^1%_WP* .
M2TE;VZ\--]I+&0GN.:Y#P3HUU;>)=0EDC8*TN02/85["$11@(H'H!2+#$I)6
M- 3U(44 >6_$S2;B^4^2C-TZ#-=%9:5++X*^RD$.T&WD>]=@T4;_ 'XU;ZC-
M."J!@* /3% 'SWIMEJ_AK5MD2RD ]57WKLO'%E=ZKI5DX1V?R^>/K7IQM8&;
M<88R?4J*<8HV !C4@= 5H Y+X=V4MGX2C@E4JWH1[5PGC;PW>6NM0WT:M(H?
M=A1FO:514&%4*/0#%(\,<GWXT;ZKF@#PG5!J>O::L"Q3(N<X*FNU\"://!HM
MW;R@AG7'(KOQ:P*,"&,?\ %/5$3[JJOT&* /!-5TC4M"\62W5NDA!P,HN>]=
MK-]NU/PC=I,KES'P".:]#>WAD.7B1CZE0:<(HPNT1KCTQ0!Y9\.=#GM[4I/&
MPS&1R,=JY[5_#.I>'M<^VVVYE+E\(,U[HL4:?<15^@Q0\,4GWXT;ZJ#0!X3?
MOK7BO9:NLR*&!^937>V_AEM*\&W5NHR\B \5VR6MNARL,8/L@J4J",$ CTQ0
M!Y)\-='N;'Q%/)-&RJ4QDCZU-\2=(N+[587A1F 7L*]36*-#E(U4^H7%#11N
M<O&K'W&: ,7PA;O:^&[:*0$,!R#3O%=J;SP]<P@9+"MH*%&%  ] *;)&)4*-
MT- 'B?PZN!IGBJZMGXPN.:V_B9I=QJ-U&\*,P\L=!GL*K7W@_5K;Q;)?V5N3
M'(XR<]LUZM%"K6T0EC4L$ .1GG% '.>';22'P4L#*0_DD8(]J\_\(Z'=VWB]
M9GC<)YC')'O7M(557:% 'H!31#$K;EC0'U"B@#QSQIHEU<^(()8XW*B<'@>]
M=MXCT7^T?"#6X7]X44?I76M#$QRT:$^I44[:",$#'IB@#P/PCX,N1KK>=&P6
M)@02*[+XDZ3/=Z0R0HS$(!@#/:O2%AB0Y6- 3W"BE:-'&'16'N,T <9X.M9-
M/\-+YH*E8N<BO.9B=9^)4(7D8(_45[1K,4QTN>*TC!=D(  Q7 >"?!]]::N-
M1U&$I*KG'TS0!Z381>1911_W1BK-%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gjnp4w4lrub1000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -2!"<# 2(  A$! Q$!_\0
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M^E>C5YS\5O\ D W'^[_2@#,^#_\ QZK_ +G]*]9KR;X/_P#'JO\ N?TKUF@
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M*[>@:N\\"ZEKEQ>,+V"1%W?Q&@#U^BD'W1]*6@ HHHH **** "BBB@ HHHH
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M 8QCBJPTJR5]PMHL_P"[0!YYXU$M_=:),J,09 3QTZU)XLT;YUU"2,O&J $
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MXP/X?Z5Z17G/Q6_Y -Q_N_TH S/@_P#\>J_[G]*]9KR;X/\ _'JO^Y_2O6:
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M0?&-OJDAA9'20''S\9KJB<*3Z"O*?$\(TWQMI@M_D5VR0O&:]1C<O;%CW!H
MX_7O&2:=J,5HJN6?I@&FV?CF);SR+B.0'IE@0*YKQ%<I;>+;1F56 ;N*BU[4
M(M2U!(F584$@(9!C/- 'HNJZ]'8K&Q!PZ[ABJ6K^*XM.T*'4&#%9&VC'X?XU
MD>)-HM+0*<@1#G\*RO%G_(D:;_UW'\UH U8_'#"+SC#,R=<!36_H?BFVUL&.
M)623;G#<&D\.V5O+I$8>&,Y0=5KC95_L?QE/)"<*Q"[1T')H W[G6KNQ\26]
MG-(2LIXKM001D5Y[XI7&JV-YW5 ?TKM-'G-SIL<I[T 7Z*** "BBB@ HHHH
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M7+6.CL=459%RF3VKOSR,5"MO&K[P!GZ5I"M**:)E339371+$*,PBG?V+8_\
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M=H6:SB+C#%1F@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXK?\
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MA_SP6M6BM53BEL;JE!*UC*&@6 ((@7BM&&!($V1K@5)15**6Q2C%;(RO$/\
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ML[>X$4<3[9,GAA79Z/86%IIXMXVC93R0#7'Q_#B.&9Y$DFRQSG<:Z+1_#1L
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MWP?_ ./5?]S^E>LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 5HK"VAD:2.,!F.2:LT44 %%
M%% !1110 4444 %%%% #)8UFC:-QE6&"*Q9?"FF22%Q;)DUNT4 95KX>TZUC
M9$MU ?[WO5^VM8;2(10($0= *FHH **** *M[I]M?QE9XPXQWK)7PCI8P/LR
M;1T%=!10!7M;."SCV0(%'M4S*'4JPR",4ZB@"E9Z9;6+.T$00N<MCO5VBB@
MHHHH **** "BBB@ HHHH **** &31+-$8W&5/45#;6,%J<Q1A35FB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNZQJ6
M8@ =2:))%C7<QP!7E?CSXB+:*;+3Y%:5OD8'M0!;\>>/H].@DM+-MTV.&0YK
M@O#/AC4/%NIF[O2WEAMV''6I_"'@J\\1WRWVHJ_DD\G)->YZ;IEOIEI'!"@
M48SB@"/2-&M=)M5B@B"8':M*BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ ZC%<YKWA&QUB,DPIYN.&/:NCHH \4U+X=:W9.7L]0*)V
M5:R3H'BY6V#4)L?2OH JIZ@'ZBF^5'_SS3_OF@#Q"S\!^([]P;C4GVGJ&KOO
M#_@*TTPK+<(DLR\AJ[,(HZ*!]!2T (JA1A1@4M%% !1110 4444 %%%% !11
M10 4444 %%%% !7G/Q6_Y -Q_N_TKT:O.?BM_P @&X_W?Z4 9GP?_P"/5?\
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MU4]OJ5K<_P"JF1OH:X/6O NFV-A/<?:9PRKD?,?\:J^!;%OL/VM7=D&1DDT
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M>GR0H,LU9.C&QU1QE2ZNSYUN(C#.R$Y(J*O0+OX?ZA-<NXA.#4/_  KO4/\
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M2^=>6X"(.<$_X5J6$K:CH4>DQ@&YB!)4?Y]J -OP*P%G/D_Q5SWCMUN[R*"
MAI%F4G;]14.GV?C'3O-B@M5\MF[Y_P *W-"\+7+Z@;_5$(F8<CM0 [Q4"GA(
M?WQ"/Y5I^ BS>$;0MUQ_A69XRG4S0Z:#_K%P!71>&K,V.AP6Y&-M &O1110
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M,.0:M^!O ,.DP)<749\_.1D5Z&JA%"J, 4 )'&L:!5& *=110 4444 %%%%
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ML%ZXK-TJ]G\#>(KDW V)MVC]:437'C/Q3:S(-T2G!- 'L7A.-W\%11@D,8V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\^ZI8V^A^.)%T_A0P'!]Z]XTQB^F6['J8QF@"W1110 4444 %%%% !1110
M4444 %%%% !1110 5YS\5O\ D W'^[_2O1<CUKSKXK$'0;CG^'^E &9\'_\
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M*'_(J7?T_H:Y7X-?Z^7_ '/Z4 >R4444 %%%% !1110 4444 %%%% !1110
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MPOIFFZ--);Q;6"\4 6/A!_Q[+_N?TKUBO)_A!_Q[+_N?TKUB@ HHHH ****
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MZK_N?TKUFO)O@_\ \>J_[G]*]9H **** "BBB@ HHHH **** "BBB@ HHHH
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MJMT4 0Q6L$'^JB5/H*FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS,!]36-JGB:PTI&::13CT84 ;55+O4[2R4M/,J8]:\JU_P"+<)W1:;YH?H"
M37&F]\5^+)=@E.QO[RF@#U'7OB;8Z<&%M)',P["O.M4\<ZYXC8Q6=K(H)ZH:
MV] ^$LSN)=51),G)Q7I.E>#-(TD*;>WVL* /'](^'VK:TX>_GG0$]&->D:!\
M-[#2=K2;9B/[PKN$144!1P*=0!6@L+6V4"*!%QZ"K-%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '@_Q.AOI/$$WV:U)PV0X[\UG6?C#Q):6Z1"QD8*,=:]C\2SZ/I\
M375\FXGK@C->>2^/?#*SE19S8!_SVH BT/QEX@NK]8YK%U4D<YKVBT=I+2)V
M&&*@D5QGAC4_#^M;6M8BCD9^8C_"NX4!4 7H!Q0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !7G/Q6_Y -Q_N_TKT:O.?BM_P @&X_W?Z4 9GP?_P"/
M5?\ <_I7K->3?!__ (]5_P!S^E>LT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8'B]@NBOD]C6O>W265I)<2?=09->!>//B+<7E
MS+:V4I6+L* )OARRCQ#=<]9C7O\ 7Q]I'B&\TJ^^T12[26W-7J]K\88AI*I)
MYC7/<C- 'L<]W!;*6F<*!ZURNM_$#2]-C;RKF-Y!_#7D-UXI\2^([@Q6TLBQ
ML<#<AK3TGX6ZKJ,JW&H,CJ>HQ_\ 7H 75_B=JFJNT%E:D@\ J:R[#PMXA\0W
M.^[-Q'&WJU>OZ-\/=&TU%/V8"0=QCK75P6\=N@2,844 >;Z%\*;.R*RS2^8W
M4AA7?6>CV5E&%CMXP1W"U?HH 0  8 Q2T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2'@9I:.M 'A?Q N)M4\5RZ7YC+&&'0^]=)9?"FPETV-VF.YT!)Q6-\
M2=#O;/5I-8M0?F;^$9/6J5M\5;BVL1;O'<>8J[0=AH I+:R>$/&3V\$SM&"
M!GWKWJPD,NGP2'JR UX/H%KJ'B[Q0U[,&\ML'YU(KWJTB\BTBB_NJ!0!/111
M0 4444 %%!.!FN#\;>.[?PZPB#$NPXVF@#O**YGPAKYUS2(KIB3N&>:R/%WQ
M!M="E%LH=I6'&SF@#O:*\@TGXL1F[5+N.8*Q &Y2/Z5ZG#J$,UDMT"-A4'K0
M!<HKRWQ'\4(+*^DM+996D0\E 3_*I?#'Q,M]2O$M)UD61S@;@10!Z;12*P==
MP.0:6@ KSGXK?\@&X_W?Z5Z-7G/Q6_Y -Q_N_P!* ,SX/_\ 'JO^Y_2O6:\F
M^#__ !ZK_N?TKUF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BHY9XX4+.ZJ!ZG%<-XG^)&GZ0KQ)EI!W0YH T_'-\EOX<O%+X9H^*^5)
M9&D<LQ)/O7H5WK&O^,KLP0O((7; W(>E9.N?#[4]%@,TQ#*/[HH Y"NP^'NA
MC6]=$,GW ,USVGZ3<:C=BWB!W$XZ5[_\./!+Z'#'=7"CS<8)% '7Z5X;L-/@
M15@C) Z[:V514&%4 >U.HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "O.?BM_P @&X_W?Z5Z-7G/Q6_Y -Q_N_TH S/@_P#\>J_[G]*]9KR;X/\
M_'JO^Y_2O6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO-<$ CJYKV&UC,5I%&>JJ!S7A?A[QQK=YJH@FEE'3(937N=F[26<3M]XJ":
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M /"U=)_Y^4_(4G_"U=)_Y^4_(5Q'BOX<+HUD9OD^[GBL3P1X,'B!>=OWL<T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5S'BCQ*^@!6PH4C))KIZS-6T
M6UU>$I<1!^,<T >#ZE\1I+C7GN$<>63Z\=:ZN#XMVZ6Z*SQY P>!1>_"1)-7
M:2$(L'9:Z&'X8:2(4#6T98#DT >>-XSN=9\2DVS95F'"G ZU[QIS,VG6Y;[Q
M09KG-,\!:3IUQYJ6J!O45U:((T5%& !@4 .HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\Y^*W_(!N/]W^E>C5YS\5O^0#<?[O\ 2@#,^#__ !ZK_N?T
MKUFO)O@__P >J_[G]*]9H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .&^)?_('/^X:Y'X0?='^^?YUUWQ*_Y Y_W#7(_"#[H_WS
M_.@#V>BBJEYJ5M91EY9D7'JU %NL;6/$FGZ-$SW,P3%>?^*?BC%%NMK)&,GW
M0R<UPUKIGB'QE<XFED6-S_&M &[XD^)][J$K6>FA75CM!'!K,T/P#JOB"=9]
M1$RQ,>3O->D>&?AM8Z9&KW<*228SGWKNX+>*VC$<2[5':@#G/#W@O3]#A 1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"/\ <;Z5\^_$Z26+Q#:/ ,RAOE%?03?<;Z5XGXTTV>Y\8Z<1 [QA^2!Q0!@0
M>(?%RQ );KM_WC_A4G_"1^,?^?9?^^C_ (5[;IVAV'V-=]LN?>K7]AZ=_P ^
MRT >-Z#KWBJ7456XMU"9'\1_PKVZS9FLXF?[Q49J!-'L(VW);J#5T * !T%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 C<*3[5YSX@\3I9>(K.U*QDR-CD"O
M1G^XWTKPOQM_R/&F?]=* /5M5U^'1]'2\F8*I.,T_P /^((=<MY)(7#!:X_X
MBD?\(3#S_P M/\*=\*2!IESS0 FK>/;ZR\62:8@3RU(Q^=>BVDIGM(I3U=03
M7A'B7_DI$_\ O#^9KW/3?^09;?\ 7,4 6J*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG(SCZU]):;QIMN/]@5Q<[^&]-O D%O;M)D#Y3S7<VS*]K&RC"E00* ):***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=U")(V!4^E4=7UJWT>(/.ZC/3)H U**X7_A9>G>L?YUKZ+XNLM9=DB=,CT-
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M@YSR:[>9!+"Z'^)2*?10!Y5JGPKAO;QY@)/F8GK52+X11),C[9/E8'K7L%%
M%#2=.33K1(5SPH'-9?BSPW'XBL5MWW<'/!KHZ* /'3\((2Q.V3\S6_X5^'D6
MA7S7&'&1W->AT4 ,V#RPG;&*\U\0?#.'5M4EN\/ESV->FT4 >.CX00YY63\Z
M]*\/:,FC:9%;+GY!CFMBB@#'\1:*FM:;+;/GYQCBO-6^$$);A9/SKV*B@#S+
MP_\ #*'2=5BN\/E#W->E;!Y93MC%/HH \\\5?#R+7;];C#G QP:P%^$$(8';
M)P?6O8J* .>\*^'8_#]@;=-W)SS6CJ^G+J5F\+9Y4CBM"B@#Q^7X11/*[;9/
MF8GK5O2_A7#97B3$.-K ]:]5HH 9$GEPH@_A4"N'\5^!(M><.0Y.<\&N[HH
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MF&M?"^'4;^6X <EVR>:]1HH \=7X00A@=LG!]37I^B:4FE6$4"9^5<<UIT4
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MA^=<4Z,KZ(ZHU(VU9TM%<U_PEB?\\A^='_"6)_SR'YU/L9]A^UCW.EHKFO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!6-?ZM;26Q595)JX5*C9,H02.0T_3OM=PT>.AQ6O+X6G&?*%5-%NHH;R1G<
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M10 4444 %%%% !7G/Q6_Y -Q_N_TKT:O.?BM_P @&X_W?Z4 9GP?_P"/5?\
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M)5(SU6ASSH^PER-W):*0,IZ&EJB0HHHH **** "BBB@ HHHH **** "BBB@
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MG7-6J*!IM;&+/X7TR?[\6:S)_ .CR<B#FNMHJ7"+Z&BK5%LSSJ[^',)S]GB
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MQD_S^%1_\*9M_P#G^;]:/^%,VW_/\U &AIGC/PW=70C@B<.?7_\ 57HL#K)
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MX<L3_P L8_\ OFCV<^Y2KT/Y#SU?']^/O&3_ +Y-2K\0KKN9/R-=T?#%B?\
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M A&:;Y2>E/HH 9Y2>E*(U4Y IU% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5YS\5O\ D W'^[_2O1J\Y^*W_(!N/]W^E &9
M\'_^/5?]S^E>LUY-\'_^/5?]S^E>LT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:F/\6+V,9=9U'J5(KUO_ (0W3?\ GDG_ 'P*\]^*N@6FG:%')"BAC)CA<>E
M&,GQ7O9!E$G;Z*33_P#A:>H?\\KG_OAJV?A?X?L]0TV9IHU)'JN:[_\ X0W3
M?^>2?]\"@#R?_A:>H?\ /*Y_[X:C_A:>H?\ /*Y_[X:O6/\ A#=-_P">2?\
M? H_X0W3?^>2?]\"@#R?_A:>H?\ /*Y_[X:C_A:>H?\ /*Y_[X:O6/\ A#=-
M_P">2?\ ? H_X0W3?^>2?]\"@#R?_A:>H?\ /*Y_[X:HV^+=VAP_G*?0J:]<
M_P"$-TW_ )Y1_P#? KQ'X@:9!9>(!%$JA?.4<#_:H U1\5+\C(BN2/9#2_\
M"T]0_P">5S_WPU>B:#X3T^;2X':),F-3]T>E:G_"&Z;_ ,\D_P"^!0!Y/_PM
M/4/^>5S_ -\-1_PM/4/^>5S_ -\-7K'_  ANF_\ /)/^^!1_PANF_P#/)/\
MO@4 >3_\+3U#_GE<_P#?#4?\+3U#_GE<_P#?#5ZQ_P (;IO_ #R3_O@4?\(;
MIO\ SR3_ +X% 'DQ^*FH 9,5R/\ @!I@^+=VS;1YQ;T"FO3=9\):=#I<KK$F
M0/[HKQ[P[IL$WC2Y@904!'&* -C_ (6GJ'_/*Y_[X:C_ (6GJ'_/*Y_[X:O5
M8O!VFF%#Y2<J/X!3_P#A#=-_YY)_WP* /)_^%IZA_P \KG_OAJ/^%IZA_P \
MKG_OAJ]8_P"$-TW_ )Y)_P!\"C_A#=-_YY)_WP* /)_^%IZA_P \KG_OAJ/^
M%IZA_P \KG_OAJ]8_P"$-TW_ )Y)_P!\"C_A#=-_YY1_]\"@#R5OBO?(,NEP
MH]2AI$^+%Y)]Q9V^BDUT_P 1O#EE8>';B2*- P'&%]JP_A9HEKJ)<3(IPO=<
MT 5_^%IZA_SRN?\ OAJ/^%IZA_SRN?\ OAJ]8_X0W3?^>2?]\"C_ (0W3?\
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MOB;H%GI]FAAC4$KV7% '9>!?$K^(--CG8D[O6NRKRSX0?\@.'ZUZG0 4444
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M:#;R^5)> ,.U '1@ # I:H:?K%EJ:;[67>M7Z "BBB@ HHHH **** "BBB@
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MB&%3T\\?SH CE\&7L?AF;53,/,7!'KSDUUGPK\03W4LEE<2%O*7O6[=JO_"
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M7 )\(='1@1-/Q[G_ !KOM/LDT^RBMHR2L:X&: +5%%% !1110 4444 %%%%
M!1110!XS\8 ?+;C^*NN\#QM+X9$:G#-$ *U/$7@^R\1*1<EADYXK3TC1X-(M
M5@@)*@8YH \DU_X;ZI?:T]Y#=;2:X[Q7X9U?2?)6\NS*#]WVKZ<VKW _*N?\
M0^$[+Q"8S<9&SIM% 'G'PJT34HR+Q[DFW9" GOBBO5-$T2WT2Q6UM\E%[FB@
M#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gjnp4w4lrub1000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )T!AL# 2(  A$! Q$!_\0
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M?%WCRYM;PV6FR%9E;::S-(\>:S9ZO%;ZQ,61AGH>E8D $WCZZ$@W 2C@U?\
MBA'':WD<D2!"(AR!["@#VBSN4O+2.=/NN,BIZXSP_K36WA&UE(R5CSS64WQ,
M8,P\E>#B@#TBBN0\,^,UU^XEB"J"G7%=?0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QGC+Q@NB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#/UFT-Y8/&.N#7B,6J:CX7NKR$),1*YQM0FO>Y'
M6-"S] .:\[\0^+M#M[G8/(=P<'*"@#S./6+J#59M3F@G)E4KG8??_&G:+X@E
MT&*[#P3 W+%AA#75W'C72)X@ACMP <_<%:NERZ5XK*H%B79\ORJ* &_#KS;S
M5FU%U8+(G<?6O4ZS]+TFWTJV6&%1A>^*T* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I&Z4M(>E 'DW@W_ )'C6/\ KI_05ZR/NCZ5Y-X-_P"1YUC_
M *Z?T%>LC[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[#P7J>NW4A&H6X0;O6@#T>BBB@ JAJ&JP:<,S,!]35^O./B@L?V-G,SHX3@
MXH [ZRO([ZW6:(@JW3!JS7C'@WX@VNF:5#:W4X&P=3R:Z@?%#2"<?:5_(4 =
M_15+2]1BU2QCN86W(_0U=H **** "BBB@ HHHH **** "D/2EI#TH \F\&_\
MCSK'_73^@KUD?='TKR;P;_R/.L?]=/Z"O61]T?2@!:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ ILF?+;'7!IU(WW3]* /!/&<%S?>*+:VN&/EN^!NZ
M8KI[7X96+P*286/J&%9WQ$M=6NM2A>UM0=AZCBL>TU;Q=9P+"MIN [EO_K4
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M7T"R1-NR,FE.'+Z 6:***S **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH X;2/B!:ZP[1BW887/-<_=?$C1X;N6-K!BRM@FNLTSP%IN
ME.SPNY)7'-<[J7P_\,Q7$DUS=2JSG)_SF@"A_P +,T7_ *![5TWA7Q=8:RY%
MM:F/G%<M_P (AX,_Y_I?R_\ KUU'A+0]!L"QTVX>3GG=_P#KH [FBBB@ KG/
M$_AZ/6H2'95XQEJZ.N%^(6O7&E6C1P8RR^M ',M\-;!3AKRV!]V%(OPXTX'/
MVVV_[[%<E;Z3XLUV(74$3F-^00YJ=/!OC(,,P2_]_&H ]R\/V$>G:3#;QLK*
MHX*GBM6L+PG:W=GH-O#>*1,H^8$YK=H **** "BBB@ HHHH **** "D/2EI#
MTH \F\&_\CSK'_73^@KUD?='TKR?PL5M?&VJF0XWR<?I7K"\J/I3::W 6BBB
MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"C_CU?\ ZZG^9KU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:L.A%.I&SN@'T445F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51FU:QBF,$ES&L
MG=2>:NL-RD5Y=X@\&:M>^)Y+VW5C"W3D^M &MXBT71K^9)+FY@4GD;C6)_PB
MWAS_ )^[7_OJJ_B?P)K.I"V\A6^1<-\QKGO^%8^(?[K?]]&@#M-,\-Z!#J$4
MD5U;&13P >:](A54C 4\5XGHGP[UVRU>WN)0VQ&R?F->U6R-' JMU% $U8WB
M/3IM2TXPPR&-N>16S10!X7/\,M5DFD;[<^"Q/2JX^%&HA]XO&W'OBO>]H]!^
M5&U?0?E0!X3_ ,*PU;_G^>NN\">#K_0]2>:XNFD4KC!KTC"^@H  Z 4 *.E%
M%% !1110 4444 %%%% !1110 5C^)?\ D!7?_7(UL5C^)O\ D!7?_7(T <%\
M*/\ CU?_ *ZG^9KU6O*OA1_QZO\ ]=3_ #->JT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6!XHTB/4=.D;:/, X;TK?J"\1I+
M9U4<FG%V=P/&3KITZ2/3Y06$+#DUZKH.K6^I6:M&5!4 8!KQ/Q9:S0ZY.SC&
M378_#.*X,#.,F,-SDUUU8)PYA'J=%%%<8PHHHH **** "BBB@ HHHH ****
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MEQX7M9EO0%+/N% '=V=I%96ZPPH%1>@%6*9%*LR!T.0:?0 4444 %%%8&O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)-<1P+ND; J&#4K6Y;;%*&-)J42264I89PM9/A^VB"!POS>M0DK7 Z*BBBI
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MC0![#12 Y4'VI: "BBB@ HHHH **** "BBB@ K'\2_\ ("N_^N1K8K'\2_\
M("N_^N1H X+X4?\ 'J__ %U/\S7JM>5?"C_CU?\ ZZG^9KU6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY;QKI@NM(FE4?O .,5U-0W4"W,#1,,@U479W Y#P/J1DA^Q.?FB7D5VM>56S
MOH'BB8G(CE<**]2A<20HP.<J#5U5K==0'T445D 4444 %%%% !1110 4444
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M8LD"N5\ )J!U4&1G$6.A%.,/<; ]9HI!T&:6L "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Z\;^#)-;N'FB#
MEF/8UZ+10!X/_P *QU$C&9\>F\T@^%U^O*B8?1C7O-% 'B^C?#O4+/58+AVG
MVHV3ES7L5M&8X%4]JFHH **** *6JVGV[3I;<_QC%>'ZFVK^%M5N5A@S RE
M6]\BO=+ZZ6SLY)VZ(,UP=AKFG>)]>FL9;,L$&<D<4 >6:-X@U/3;>YMX(5)G
M<L?SKOOAOH=Z=8EU2\B*>:G7\Z[#4O#FBZ?ITEVMBNY!GBJ/@_Q3:ZE?OIT,
M)C\M<\T =N!@8I:** "BBB@ HHHH **** "BBB@ K'\2_P#("N_^N1K8K'\2
M_P#("N_^N1H X+X4?\>K_P#74_S->JUY5\*/^/5_^NI_F:]5H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#SSQ[:KFWFB^\KAFQ70>%-7CO]/ +Y9<+BN'\>ZJR3O$K=#BJ/P_U*1=
M7BMR^%8Y(_&NKDO3$>TT4@.1Q2URC"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"(W,0.
M"U)]JB_O5\\Z[KFO0ZY);+<RKCM35N/%C*&$UR0>GRT ?0D][''!(X;E5)%<
M7X;\:W>KZG<6\BH%CD*C%>7/-XL\MMTMSMQS\M;?PO,AOY?-SO\ ,^;/K0![
MI1110 5B>(](M=4L)$N"0",9 K;KS[XC:E<VD7E02E-R]10!PM_\.[Z6<K8+
M)) #E<L:GTWP#<KJ$(U/S47TW$\5Z1X%FW^'+:2:X5Y".>:P?B3>S6N)[>YV
M%5Z T =YI-E#I^G1V\',:C@U>KEO NI2ZAX=MGE)9R.2:ZF@ HHHH **** "
MBBB@ HHHH *0]*6D/2@#R;P;_P CSK'_ %T_H*]9'W1]*\F\&_\ (\ZQ_P!=
M/Z"O61]T?2@!:*** "BBB@ HHHH *YSQ=I/]I:6RHN7!SQ71TUU#H5/<4XNS
MN!YUX:U@"TO+*Z(S&-B@\^E=1X?C185*HH/L*X3Q98RZ+J<<\*G9(VYMHKK_
M  EJ*WEJC*N,UO->[S+J(ZNBBBN<9G7VH&U8#CFIK.Z-Q&&/>HK^%'*[ES4]
MG&J6Z[1BJTL!9HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKP_"IY/FCU7</;_]5 'J%E>PW]LMQ V8VZ&K-9FAZ6VD:9%:-)YA0?>]:TZ
M"BBB@ KE?&VD7FL:/-:VJ[BXZ5U5<AXXEOK;3I;BS,F5'W5H X&#X;WUG8--
M(K*\:EN":F\#^)+N.]_LNX;JY'7T-6;;X@7(T=K6XLW,I0KENN:H> M$NKO6
M5U"6)XP')Y'J: ,^S.?']U_UU%:7Q7QYJ$?>\H?R%9^LVMUH7BN:]^SO(CR9
MSBFZ]>W'B_688HK5U4H%)'X4 =_H0U!O!UL+-<R>5QFN8>W\>[VQ N,G')KT
M_P .V7V+0K6!A\R+@UIE%Q]T4 >,?#070\2:D+P8GW?./?BO:1]T?2O)O!H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7AOQ49HM7DD Z-G]:]RKB/%E_I$$S)>VT,C9Y+T >7O\ $F^;
M13IY(V;-E9?A_P 9W6B3^9$0#C'->P:;I'AC4HU:.&U+$=!FM7_A"=&QG[%#
M^5 'GVC?%+4+_58+9RNUVP:]BMI#+"'/>N!NXM$T36[6W6PA\R0\-Z5WT#*T
M0*C H EJ&[#FUD\O[VPX_*IJCG<1P2.>BJ30!X5J5GXL-_,43Y-YV\GI53[#
MXN_YY_J:Z]/%:ZEXE2UBMOE#E6(KTJ&RM_+&Z%<T >!RZ;XMEC*/'\I]S75?
M#+0-2T_6YKB\CVADQG\Z]"\01PV>C3SQP LHXQ7+^!O%":GJ4EFT/ENBY)-
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MS+Q78/I>J0WD.0'D!;%=YHM^NH6"RJ0< #BM:BNE) :5%%%8@%%%% !1110
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MK7JGL@"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB:79?8+!+?<6V]S3J*-E8"[11160!1110 4444 %%%% !1110 4444 %%%%
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M 5W_ -<C0!P7PH_X]7_ZZG^9KU6O*OA1_P >K_\ 74_S->JT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.>+=(74M)E55S(>E='2,H<889%.+L[@>:>&O%,6E/+9W
MA.(A@"NMLO%MA?L%A#9->6>-;7[#J,DD9QO;M3/!>KO!JD<13>/>NJ5)2CS(
M1[FCAT##H:=45L_F6R/C&1TJ6N084444 %%%% !1110 4444 %%%% !1110
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M8(_W:CL.*Z:<[KE$>FVQ4VZ%!A<<5+65H-^E[ID+*1NV\CTK5KG:LQA1112
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M&_\ (\ZQ_P!=/Z"O61]T?2O)O!O_ "/.L?\ 73^@KUD?='TH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO>6L=W;M'(N00<58HH \EO+*;PQK2R8/
MD.VY@HKTK1]0AU&Q2:$_*W;-5]?T>/5+&1"/G(P#CFN&T34IO#FJ&QN,B%>
M6-;O]Y'S$>HT5%;SK<0K(AR&&:EK 84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME'/$%)?UH ZBBO%Q\6]68G;;Q$9]!_A7H?A7Q!<:W!OG15.,\4 =+6/XE_Y
M5W_UR-;%8_B7_D!7?_7(T <%\*/^/5_^NI_F:]5KRKX4?\>K_P#74_S->JT
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MP_TVUTJXF21RRQDC- &=\)FW63-ZR$_J:]6KRGX3#;9LH[2D?J:]6H ****
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M6E364.,&FG9W \PT+PD(]4,LR@KO)P?K6CX@\)2(YO+!O*;.3M]J[E;6-6W
M<_2IBH92I (-:.K*]P.!\->*WC?['?!@^=H9^.E=W%,DR!D8,#Z&N2\1^$8[
MP-<VP83J/E"\5AZ-X@O-#N?LFIX2-> <TW%35X@>FT55L=0@U"$20-N6K58[
M %%%-W#- #J*0'-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !37&48>HQ3J#P,T >*^,+&YT
M3Q#;Z@D;R(K[R%%8%WXW6;7I+\VSC=VQ7K?B+7-&\]-/NW4/-\H&!6:GPUT*
M\C^T[G]>!0!Y_P#VG=>+M?L"L,BQQG!R.*]TTRU%G8I /X:X?39O#_A[4H[%
M)!YKMA00*]"1PZ[EZ4 .HHI&8(I9N@&30 M9NMNT>FS,AP=C?RJC-XST:"1H
MWN,,IP>E5;KQAH%U T3W/RL".U '(_#6\N;J>]6=RRB=AS]:]42&.,Y5<&O/
M]#OO"VAO*UO=-F1RQSC_ !KK]-\0Z=JTICM)=[ 9H U:*** "BBB@#"\5V4^
MHZ+-:V[E'<<&O'U^&>KI.9DNB'/?%>^$ ]11L7^Z/RH \DT#PKX@M-6AEGU!
MGB7JM;WBWP5-K5M$T$HCEC.XM7>[5S]T?E2T >+-X(\0WD1LYM18PG@@]*]'
M\+>&TT&S1.#)MPS#O70[5_NC\J6@ K'\2_\ ("N_^N1K8K'\2_\ ("N_^N1H
M X+X4?\ 'J__ %U/\S7JM>5?"C_CU?\ ZZG^9KU6@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *9+$DR%'&0:?10!Y=XR\&'YKJVPO\3 =ZX70[
M%Y-66%CY; ]Z]N\1#4WA"6$*R;AALUYQ<>%O$$=Z;T6H##T__5792J7C9L3/
M6=,3R].@3.<)BK=<!X>\7&!_L>IL$D!VJ!7=PS)/&'0Y4US3BXO49)1114 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'B-9&TMQ'G.#
MT^E>4^!M5L]-U:\2\54=I3AFXKV6]EBBMV,WW"#FO'=9\-:;KE[(VDL[3!CN
MP<<T >@:UXITE=.DW30RY4@#=[5Y_P##AGDU>[DB4B-IB>/K5&W^%^LO,!<(
M_EY_O&O4_"WA2V\/VVV-2&;EL^M '2T444 <#\5HY)/#\.Q2V),G'ID5B> [
M_1(["07"PI(#SN->EZKIT.IVC0S#((.*\AU3X77@NG:R5MK,3]XT 96J36US
MXUD^RJK1EU^[]:ZGQ[HEK'HT=Y&JI(D(/OTJ7PG\.3I]W]HO5._W-=;XB\.I
MK%NL!Y0+MX- %3X=3R2^&+7?D_+U-=C65H&DQZ/I<5K&,!!BM6@ HHHH ***
M* "BBB@ HHHH *1NE+2'I0!Y-X-_Y'C6/^NG]!7K(^Z/I7DW@W_D>=8_ZZ?T
M%>LC[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7/^(-%L;V F3RXWZ[FKH*\_^(,VH1VJ>2/EW<8-733<M ,5+B_\
M.77[J1[F ')V=*[G1/$]MJ42B0K$^.0QYKGO L$^H:3*EV@*EN213=8\'7%K
M,;K3%8MG)YK:7*WRO<#T($.N5.:Y#7WFM[F(I>[=S@;<UD:=XPN=.D%MJ9"L
M.*Y;7-8N-0UI6B;,9D&WFE"DU+41[18JRVR[GWD@'-6:R/#S7#::IN!\V!BM
M>L);C"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %-D_U38]#3J0\ DT >#^)S+:^,K2:Y!,:R9^
M;IBO5+/Q1I1L<BXA7@_+NKGO&4&B:K,L$KD7)X0#UKBF^&FL.V;=7,7;YC0
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M3+06-BD & M %RBBB@!-J^E&Q?2EHH 38OI0% Z"EHH **** "BBB@ HHHH
M**** "BBB@ K'\2_\@*[_P"N1K8K'\2_\@*[_P"N1H X+X4?\>K_ /74_P S
M7JM>5?"C_CU?_KJ?YFO5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "D/2EI#TH \F\&_\ (\ZQ_P!=/Z"O61]T?2O)O!O_ "/.L?\
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MT_YYT?V39_\ /.@#Q70=4\1MK%LDUO,(RW))KW*U+- I88-0II=JCAE3D5;
M &!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0%=_\
M7(UL5C^)?^0%=_\ 7(T <%\*/^/5_P#KJ?YFO5:\J^%'_'J__74_S->JT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 45Q/B3X@6>BR&'8[R X^3FJ
M.A?$RTO[Y+.6*5)'Z%P1_,4 >B4AZ4V*19HU=>AZ4X]* /)O!O\ R/.L?]=/
MZ"O61]T?2O)O!O\ R/.L?]=/Z"O61]T?2@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH Z7_A//#_\ S_)1_P )YX?_ .?Y*YK_ (5=;_W$_2C_ (5=;_W$_2@#I?\
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MB?I0!TO_  GGA_\ Y_DH_P"$\\/_ //\E<W_ ,*NM_[B?I2?\*NM_P"XGZ4
M=+_PGGA__G^2C_A//#__ #_)7-?\*NM_[B?I2_\ "KK?^XGZ4 =)_P )WX?_
M .?Y*/\ A._#_P#S_)7E7C7PBFAPLR!1A<\5I^%/ <6KZ)!=.JDN,\T >A?\
M)YX?_P"?Y*/^$\\/_P#/\E<U_P *NM_[B?I1_P *NM_[B?I0!TO_  GGA_\
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MPJZW_N)^E '2_P#">>'_ /G^2C_A//#_ /S_ "5S7_"KK?\ N)^E'_"KK?\
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MC]Z?YFO5* /*_P#A4D?_ $$KG_OLT?\ "I(_^@E<_P#?9KU2B@#RO_A4D?\
MT$KG_OLT?\*DC_Z"5S_WV:]4HH \K_X5)'_T$KG_ +[-'_"I(_\ H)7/_?9K
MU2B@#RO_ (5)'_T$KG_OLT?\*DC_ .@E<_\ ?9KU2B@#RO\ X5)'_P!!*Y_[
M[-'_  J2/_H)7/\ WV:]4HH ^?SX.8>,)-'^WW'EJ,[MYS75K\)8V4'^TKGG
M_;-2LI_X6M<'!QMZ_B:]-B_U2_2@#R[_ (5)'_T$KG_OLT?\*DC_ .@E<_\
M?9KU2B@#RO\ X5)'_P!!*Y_[[-'_  J2/_H)7/\ WV:]4HH \K_X5)'_ -!*
MY_[[-'_"I(_^@E<_]]FO5** /*_^%21_]!*Y_P"^S1_PJ2/_ *"5S_WV:]4H
MH \K_P"%21_]!*Y_[[-'_"I(_P#H)7/_ 'V:]4HH ^?_ !EX.;PW!!)%?W#>
M9(%.7/K6UHOPV&IV2S-J-R"0#PYK5^+:DV=E@$_OUZ?45U_@\$:0F1_"* .-
M_P"%21_]!*Y_[[-'_"I(_P#H)7/_ 'V:]4HH \K_ .%21_\ 02N?^^S1_P *
MDC_Z"5S_ -]FO5** /*_^%21_P#02N?^^S1_PJ2/_H)7/_?9KU2B@#RO_A4D
M?_02N?\ OLT?\*DC_P"@E<_]]FO5** /*_\ A4D?_02N?^^S1_PJ2/\ Z"5S
M_P!]FO5** /&M9^&@TVPEN%U&Y)12W+FL;P=X,;Q%:--+?W"D/MX<UZ_XN!.
MB7&/^>9KD?A.I72GR"/WI_F: (/^%21_]!*Y_P"^S1_PJ2/_ *"5S_WV:]4H
MH \K_P"%21_]!*Y_[[-'_"I(_P#H)7/_ 'V:]4HH \K_ .%21_\ 02N?^^S1
M_P *DC_Z"5S_ -]FO5** /*_^%21_P#02N?^^S1_PJ2/_H)7/_?9KU2B@#RO
M_A4D?_02N?\ OLT?\*DC_P"@E<_]]FO5** /)[CX4)# \@U*Y^4?WS7&:=X8
MDO/%LFDM?3B-1G.\^]?05_\ \>4OTKR/0%;_ (6A.2IQLZX]S0!H#X2QD _V
ME<_]]FE_X5)'_P!!*Y_[[->II]P?2EH \K_X5)'_ -!*Y_[[-'_"I(_^@E<_
M]]FO5** /*_^%21_]!*Y_P"^S1_PJ2/_ *"5S_WV:]4HH \K_P"%21_]!*Y_
M[[-'_"I(_P#H)7/_ 'V:]4HH \K_ .%21_\ 02N?^^S1_P *DC_Z"5S_ -]F
MO5** /*_^%21_P#02N?^^S7+^)?"C>&+BREBO9WW3J"&<^HKWRO+OBBI/]GX
M!/\ I"_^A"@#TFP.=.MB?^>2_P JL57L/^0=;?\ 7)?Y"K% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2,H88-+10!Y%XK\$7D>IMJ&
MFQO)*[;B,U5TKPEJ^L:S#=:M T80;>O:O9B,TTO''U8#ZF@"*RMEL[..!?NH
M,"ISTH!!&0<BD9T3[S ?4T <7H/AB33_ !%?WK*P$S9&:[8=*8LL;_==3]#3
MZ "BD9@JDDX [U1?6+-)-AGC_P"^A0!?HIJ.LB!T((/0BG4 %%%% !112%@H
MRQ 'O0 M!Z4U75_NL#]*4D*,DXH XGQ#X7DU+Q!87BJQ$#Y.*[5!M7%-$\1.
M!(N?3-24 %%%4[C4[6V;;),@8=BU %RBJUM>P70)BE1L>AS5F@ HHHH ****
M "BF"5"<!P3]:?0!Q_C3PZ^N0LJ G*XXK3\*Z6VD:)!:L""@QS6R9X@<&11^
M-/#!AE2"/:@!:**:[JBEF( 'K0 ZBJD.H6]P^V.5&.<<&K= !1110 4444 %
M%(2 ,DXI%=&^ZP/T- %;4+<W-HT8[USOA7P^^DZE>3L"!*>,UUA( R3BF>?%
MG'F+GTS0!)11UJK<ZA;6N/-F1<^K4 6J*@MKN&Z3=%(K#V.:GH **** "BBB
M@ HHIGFQYQO7/IF@!S#*,/45Y[=^#Y)O$EO?!6PDFZO0Z89HE.#(H^IH ?12
M*RN,J01[4,RHNYB !ZT +156+4+>:X,,<J,X[ U:H **** "BBB@ HHIK2(A
M^9@/J: '5Q_B[PZ^L3JRJ3A<<5UX(89!R*1I$3[S ?4T 9^@V1T_2(;9@<H.
M]:5,66-^%=3]#3F=47<Q  [F@!:*SVUFR6389X\Y_O"KL<J2KN1@P]0: 'T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4C*K##*"/<4M% $2VT"MN6&,'U
M"BI:*I3:I:P2"-YHPQ.,%J +M07=JEY;/ _W7&#4RL&4$'@U4N=3M+4XEN(U
M/H6% %'1/#=MHB%8&)!;=S6U52UU&UNQ^ZFC;V#9JW0 456OKQ+*V:9_NBN-
M3XDVIU(6C6DBY?:&(.#0!W=%103K<1"1"""*EH **** "BBJ]S>P6@S-(B9_
MO'% %BBH;:YCNHA)$P93W!S1/=06R[I943_>.* ,P^';8ZTVI[CYK#!%;"C:
M /2J$.LV,[[4N8B?]\5?!##(.10 M%(QVJ6]!FN)U?XB6VF7!B^RR28."5!.
M* .WHK'T'Q!!KEFD\2[=W\)ZUL4 %%%% !113)94A0N[!5'4DT /HJI;:C;7
M4ICBE1F'8-FK+NL:EG8*!W)H R-<\.VVNQQI.Q 1@PQ5^PL8[" 11G( Q4!U
MNP$OEFYBS_OBKT4T<R[HW5AZ@YH ?115'4]4@TRU>:9U^7^'/- %ZBL#0_$\
M&MSO%"A&T9S6_0 4444 %%%% !14-Q=16R[I751[G%-M+R&\CWPNKJ#C*G-
M#;ZR2^MWAD.%88-4=$\/V^AP&*!B06SS6I-/% NZ615'N<52CUNPDDV"YBS_
M +XH T:*:'4IO!!7U%<AKWCZVT6^-J;=Y6Q_!S0!V-%8^A>((-;AWQ#:0,E3
MU%;% !1110 4444 %%-=UC0LQ  ZDU5@U.VN)O*CE1F] V: +,B"6-D/0UAV
MWA6TM=8;4D8^:PQBMYF"KEB !W-9\NMV,4FQKF+/^^* - # Q2U%#<13INBD
M5Q['-1W=[#9PM)*ZJ ">30!9HKG/#_BRWU^6X2!"/)?:3ZUT= !1110 4444
M %%%4KC4[6V<)),@8G&"U %VL;6?#MMK7E>>Q'EN&&/8UKHX=0RD$$56N=3M
M+3_6SQJ?0MB@"Q$@BB2,=%4*/PI]5+;4K2[_ -5/&Q] V:?>7:6=NTK]%!-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%<G>6FHW]Q%:R+(2AVER.#0!Z)X<>%]+4P.77U-;%9'AW3'TK3%@=MQZUKT
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MAZ=-:Z):02 [DCP<FO,]+TV^L[QKFXADDE#DJVWH,UZYI\TCV$+,K!BO((H
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MM.B@"C:Z7;V9_=*!^%7J** "BBB@ JGJ?_(/G_ZYM_*KE17$7GP/'_>4C\Z
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M\3^*T\3VB65NP=MX.!7K/@O36T_1XMRX+H*6S\%:1:3^:MG'D5T:(L:!$&%
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MWX>:/<7>ISW[I\IDW@U[152QTZVT^(1V\2H,=JMT ($5>B@?04M%% !1110
M4444 %>%>/\ _D9%_P"NR_\ H5>ZUC7OARQOKCSIH$9LYR: (8[4WGAE8%&2
MT2\?A7C]K=MX/\67DUS^[C88!KWN&)88U11@ 8 K(U3PQINJ'=-;(SDY)- '
MCMQ>GQAXOLYK?#HHVDC\*]OTRT%MIT4#J/E'0BJ6E^%]-TL[H;9%<'((K;H
M9Y,7_/)/^^13@H P !^%+10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1T55O+Z&RLS<S.JQ@9R>E8G_  FND_\ /Y#^= '2T5B6/B?3[^Y6"&YC=VZ
M&KVH:G;Z=&'GD5 >FZ@"[17-?\)KI.?^/R'\ZT-,UZRU5F6VG1RO7:: -6BB
MJ>IWJ6%A-.Q'R+F@"YFBO//#?C.;6M<6!8&$1.-_:O0ATH 6BBB@ HK'U#Q'
MI^G3F*>XC1QV)J33=>L=4W"WGC?;UVF@#4HH)P,UB7OBC3;*39+=1*V<8)H
MVZ*S++6K34(&>WF1SM)&TUP]IX]D_P"$A-A-"4!EV@DT >ET4BL&&5.12T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYU=T_P 1V&HS+%!/&['H%- &Q167J6NV>E[?M$R)GIN-9W_";:3_ ,_</YT
M=+16=INL6NJ;OL\J/MZ[36C0 49K,US58]*T^69R,A<@'O7+>$/%D^O78S R
MQDXW=J .\HHHH **0G R>U8=[XITZQN3!-<Q*X[$T ;M%9^FZQ::HK&VF1]O
M7::OLP522< 4 +16!<>+M+MI6C>[B# X()JXFJQ7>FFZMF$BX)!7Z4 :=%><
M:#X]:[UF6RGBV$2%5R>M>CT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)1I\,LB[SG9]: /8-.^&^EV3N8E/S+@\UA>(OAOIMAI-Q>1HP=><YJ_X!O\
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MAY1_%CF@#TO3M<M=:L&EMFR-N:\+\96;W_CF:$$_=SUKJOA)<2O#J,;N2J#
MS^%8^K#=\291ZK_6@!?ASK$FDZK)92,1YC[0#7KWB?5%TO2'G9L9!%>*ZW;-
MHFOZ=<@;0[[C^M;7C?Q1_:>C);1-R7'0T <%=P2ZA<7MV2<!BPYKVGX8?/X*
MA!YRI_E7"ZMI0T_P[')MP98LFN\^%G_(FV_T_I0!YYJR?V9XXM73Y0TQ)KW;
M3[@75HLH.0:\5^)86#Q#9.@P=V>*]3\%3&?PU [=30!T-%%% !1110 4444
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M(+B[52$+[N17=+\+[8/EKDL/0UUVE:+:Z5"$AC0$#!('6@#10811Z"O+_C!
MTEM9NH^[S_.O4JY7QSIG]H:/*P7)1"10!E?"N8OX7 )_BKBO&X/_  E=A@'_
M %WI]:UOA=J+6TBZ9+\K%CP:[;5/!MOJ=_#=-( T;;@,4 5M=S_PB)X[?TKS
MWX;@_P!M7V0?]9Z?2O9+C2X[BP^RL?EK'T3P=;Z-=33HX8RMG&* /,?&BG_A
M/"<'H.WO78^*]#74_"5O.5RT$&16[J?@ZWU+4_MK. WTK;:P1],^Q'E=FW-
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MB\/>&8- BD2)@V]LT ;:1(ARHQ6'XS_Y%BZ^E;]5-1LEU"RDMG.%>@#R/X4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3)HDFB:-QE6&"*** ,2S\*:39:B+V"WVSC^+-;U%% !111
M0 4444 %%%% ",H92IZ$8-8%MX1T>VOFNXK;$S-N+9[T44 =!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!#=6\5U \,JY1Q@BLG3/"VE:5<^?:6^R3UHHH W**** "BBB@ H
MHHH *BG@CN(S'(,J1S110!CZ?X5TG3;EY[:WV2.VXGWK=HHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gjnp4w4lrub1000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\!H0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I
M:QJ']DZ)?ZEY7F_9+:2?R]VW?L4MC.#C..N*\S_X79_U+W_D[_\ :Z[_ ,8?
M\B1K_P#V#;C_ -%M7BOPVUO3] \5RWNIW'D6[6,D0?8S?,7C(&%!/13^5:12
MY;VN2V[V.K_X79_U+W_D[_\ :Z;%\<H)8YD&@3"YBF"E3<CRRA7.[=MSNSQM
MVXQSN[5UW_"S/"'_ $%__):7_P"(KY[N-7FUV_N=1O)_/O9647$FP+EE4+T
M Z*!P*J,4WJK$MM=3UA/C? )"D^@RJ6C8Q>7<ALN.@;*C:I[L,D<<&D_X79_
MU+W_ ).__:ZX#7O[<_LKPY_;'_'G]D/]D_<_U.V//W>>GE_>Y_6IM(\0^)O#
MF@-<Z3=?9]-EU#R7;RXWS.8@Q&&!;[BCVX]:.6-@NSV+P/X[_P"$RN-1B_LW
M[']B6%L^?YF_>7_V1C&SWZUV->.^%?B9J,6F^(+_ %ZZ^V_9$MEM( L<1>20
MR@J" ,_<!/4A58@'&#FV7CCQ_P"(;J[;2I-WD1":6&UM4*1J!CC<&8EB"0N2
MQ^;' XCD;*YCW2BO+/AW\1=0UG6$T;6'AF::-FM[E4VN[C+%6"C;C9G!PN-F
M#N+5TGC_ ,6WWA33()K#3FN))6^:XD0F"W4%1\Y!'S,6"J,C/)SQ@KE=[#NK
M7.OHKPF/Q?\ $)_#TFNB]?\ LR)Q$UR]O H+;@O *@M\Q R!C.1V..T^''CV
MY\2S7&EZIY/V^"%98I(U(,T8PKEA]T$,5/!&=_"C::'%I7!.YZ%17+^.?%Z>
M$=&6:-(YK^Y8QVT+L,9 R789!*KQG'=E&1G(\Q@\;>/]2L=1U2SN'-C:-NG:
M.UB*0@\[1E22%!!/4JN"QYR10;5Q.21[M17GWPW\=W?B62XTW51$;V")9(I8
MT*F9!A7+#[H8,5/& =_"C::X[6_'7BWPSXJO-.GU7[;%8W*DQ^5$IFB.'568
M1C#%& ) X)..U"B]?(=T>Y45QOQ!\42Z-X,CO](NL3WDT26MS"J2I@_.6YR"
MI1& (!Y8?49GPOUSQ#XC.I7NK7KS6D!6"$!(E5I#\SY"J&RHV8YQ\YZD<*VE
MPOK8]%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Y#QOXY_P"$-FT^/^SOMGVQ96SY_E[-FS_9.<[_
M -*Y7_A=G_4O?^3O_P!KKUFO!_C#_P E B_[!</_ *-FK2"B]&B)76IO?\+L
M_P"I>_\ )W_[77IFBZC_ &QH.G:GY7D_;+:.X\O=NV;U#8S@9QGKBO)- \?1
M^$?AIH=I;VR76H7)O'"M( L*BXE =P/F.6X XSM?YACF >*_B-=Z-=:_!*ZZ
M7&S%I$MXMJ 'G:""Q5<X+<XVG)X-'+S*ZT'>VA[A7F_B+XK_ -@>)M0T?^Q?
M/^QLB^;]JV[]T:OTV'&-V.O:CX=_$2YU^\.C:P(?MGE;K>X3">?M W*RY^_U
M;Y1@C=PNWGS?XB?\E+\0_P#72#_TGBI1CJTPD]+H^@=$U+^V= T[5/*\G[;:
MQ7'E[MVS>H;&<#.,]<"K]>,7'Q*DT/P?H.C:.JF^BTJU^TW$J96'= I4(#P6
MPRMDY4<#!).VE>^./'_AV[LSJLFTSQ&:*&ZM4"2+C'.T @J2"5R&'&1@\B@V
MAN23/=**QO"_B*V\4Z##J=NOE,Q*30%PQBD'521^!&<$JRG SBO+O'7CKQ/I
M7C#5=.T[5/L]O"8Q$OV>)MF8D8\LI)Y)/-*,7+8&['M5%>#6OC_QW;V<>K22
M276G(<---9*('.=G+HJ\[N."/F&/:GQ^+_B$_AZ371>O_9D3B)KE[>!06W!>
M 5!;YB!D#&<CL</V;%S'NU<=XX\>?\(9<Z;#_9OVS[:LS9\_R]GE[/\ 9.<[
M_;I6=\./'MSXEFN-+U3R?M\$*RQ21J09HQA7+#[H(8J>",[^%&TUSWQQ_P"0
MEX:_ZYW?\X:(Q]ZS!O2Z.^\%>+/^$PTJZOOL7V3R+HV^SS?,W81&SG _OXQ[
M5TM?.OA'5?%UO:7MCX9\QHXF>]N!%;J[<JB@'<#D_NSM5>3\W#8XZSP-\4;J
MXU./3O$$YN5O952VNDC4;';"JA" 94G&#C()YX.5'!K4%(Z'QC\2?^$3\0II
M7]D_:MUHESYOVG9C<[KMQM/]S.<]ZH7GQ;^R:'H>I?V)O_M3[5^[^UX\KR9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8Q6\\J*3%<M'$%&[H>J@!\9V\$' QA2_"?Q3>_9(;[6+.6WM\1QAYY9/)C.
MP12N.@'&0#@#(I\R=F#6K.[^'_AB\\*:'<V5]);R2RW;3@P,Q&"B+SD#GY37
MCOQ/8IX^UYAU'E$?]^(Z]W\-:$OAO0K?35NY[HQ* TLSD\@ 8122$0  !1P
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M::\DCA$1;N,EF)P !GDDD "KUW>6MA;-<WMS#;6Z$!I9G"*,D 9)XY) ^II
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M..N.:LV6H66I1-+8WEO=1JVQG@E5P&P#@D'K@C\Z +-%0W=Y:V%LUS>7,-M
MA :69PBC) &2>.20/QJM9ZWI.HSF"QU2RNI@I<QP7".P4$ G .<9(Y]Q0!?H
MJE?ZQIFE&,:CJ-I9F0,4^T3K'N"XR1N(SC(S]145IXBT2_FCALM9T^YEESY:
M0W2.SX&> #SP"?PH TJ*S;3Q%HFH31PV6L:?<RR?<2&Z1V;C/ !YX!-:5 !1
M6.?%GAQ4+GQ!I04#))O(\8_.MB@ HJ.>>&UMY+BXE2*&)"\DDC!510,DDG@
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M4UOPPFIC6++[-YT5LL?[U'R4\S=]TGIN'YU'X5\&ZK:?$77M0U734.E7R7J
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M@1R12^&O"FMZ?\+O$VC75EY>H7J7(MX?-0[]]NJ+R#@98$<D4W+\Q);$GP5
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MMQ&OFH_W/,R/E)Z;A536/#/B2T^*S>*=/TE-1ME(EC1;I(MQ-N82I+<@@\\
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M1@XC (X!/H?Q!TF^USP3?:=IT'GW4KP%(]ZKD+,C'EB!T!-.ZYD'1E3X5_\
M).=,_P!^X_\ 1\E5/%7@K1?%6O+)9:M!I^O0%9)S 0TI50-C,H8,K+E,/UQ@
M<_+C8\ :5>Z)X*L=/U&'R;J)IB\>]6QNE=ARI(Z$&N:\5>"M<C\9)XO\-RQS
MW@97:UF*@A@HB.W. 5*9R"01R022 LQ&RKKVH_$'PWX=F?5YK"\LY?DN+NUD
M,<UN'*H C )AB6^5@C8/)X %<]X>NO"R:%?0Z;X/U?6;YT03Q2JLH@!&-J21
MC*#ARK! S$=L#;UWB:'QKXOT[^Q?^$=M--LYR#/-/>K+@HRNF"G(Y3!^5LY'
M3!-5],L?'6E^$Y?"\&C0J2TD$.II>JGE(['+X!W9&YB",$?+\I(P;Z$F?\#)
MY'.NQ&9WA"6LBKDA=S>:"P7L2%7/^Z/05G:CIUOJWQ_ELKH$P/=Q.ZX!W;+1
M) I!!!4E ".X)KI_A1X6UGPX^K2:O8_9/M,=N(U\U'^YYF1\I/3<*8/"FM_\
M+K;Q#]B_XE1EW>?YJ=/LGE_=SN^_QT]^E3?5V';1'-Z'HFC>(/C%J,$%G%#I
MMA)*QMC  )6B8(RG:>5\UF89S\H"8"X [O2_A\FB^.)?$&G7Z6]K*'5K!+8$
M;&494.6.!Y@#\ 8QM'%9VO>&/$.G_$&/Q7X?B6\678MS:M<B,M\A1ASM&S:J
M$9+$/@X(%1^'?".N77Q%N?%^N6L5AEG:.VCG#L6\M8DSC(*[-V3D'<N< '%#
M8(R?%%S-XM^+EKX5N)7BTRSE0-%G*RGRO.=N,$$J?+!R=O)'4BIOBCH\/AM=
M)\0Z"(M,NHIS;_Z-$$#$JS*V!\O&U@1@[@^#P,5L^-?!NH3Z[:>*?#8']K6[
MQ^;;AA&)PIX8ME<G!VL"?F08!&,-2UWP_P")_'VKV%MJVG-HFCVZN\A2\29G
M8X' !QNQPI*_+ESDY"EW^X+',_%G5/[6TKP=JQA\K[7IT]SY6[=MWK;MMS@9
MQG&<"J_Q3\-:7X730+;3H#A[6X69Y&+-,4,9#-VSF1^@'! Z*H'5_%/P9JVN
MIHD/A_34D@LK>XA,<;QQ+$&\H(H!(XPAZ=,5+\6/"FM^)I]';2++[2+>*Y67
M]ZB;2_E;?O$9SM;IZ4)[ T<E\5_#VF^'+7P[INGP!8V@NQ-(X!DF(\KYG;')
M^9O89P !@5Z=\0X='F\+,=<O;NWLXY5D$=I(%>X< [8\$$-S\V#P"H8D!<US
MWQ7\*:WXENM%?2++[2MM'<K*?-1-I?RMOWB,YVMT]*T?B9X*NO%EE93Z>5-Y
M9>:!&\FT/&Z@L!Q]_<B 9('+9/2DGL'<\]U^[T%_ ]K#H?A?4!;HX_XG5S#@
MAPX4[G3(?<2ZD$A5.,#@ >F_"V62;X<Z6TLCR,IG0%V)(59G51SV   '8 "N
M;\6VOCSQ7H4%@_A^.T$3++/Y=\F+E@0-H&[ 4;B^UB?N#G(&[K_ &DWFA^"K
M'3M0A\FZB:8NFX-C=*[#D$CHPHEL@6Y:\9X_X0;Q!N^[_9MSG_OTU<A\$]W_
M  BNJ9_Z";8^GDPUZ57EEEX;\8^"-=N/^$<@M]1T6YF+BU:;;Y: J0#O8$/M
MR@8%LA<L/N@):JP^MSTVZN[:QMFN+NXBMX$QNEE<(JY.!DGCJ0/QKDOB7-%<
M?#34)X)$EAD^SNDB,&5E,T9!!'4$5SOB31/''CN[@LKS3[31],AD\Y&>592K
M8"DDJ268!I"  BX)!.<&NK\8:!-=?#Z?0]&MM[(D$5O#Y@&$21#C<Q[*O<]J
M<;*2$]4S1\)?\B9H7_8/M_\ T6M>9^/_ /DM/AW=]W;88^OVJ2NLTC4?%^EZ
M+8Z=_P (9YOV6WC@\S^U(EW;5"YQ@XSCI6-I7@[Q)=:[-XN\2QQ76H6Z/+9Z
M6)%PTJ[A&A)RL:#@K@DY8,Q# [DE9:C>I1^-#:9<7FF6,5HTNN-@EDA+%K=M
MRB/C[Q:3[H )&&Z;OFU_@U/I,GAVYAM(MNI)(&O9-A_>*Q;RB&YRH4$8XP0Q
MQ\V2G@?P9JR>)[[Q/XHA\O4&E+VZ+<;@&<$,< GY0I"("QP >.%-5-4\'^(M
M!^(+>)?#-HE]!.[RR6QN/*Y;_61L6;D,Q+J>0K8^7"C+=FK=A+>YZK7CGP2E
M;4-1U_4;P1RWTD<$CS^6H8M*TK28P. S*"0..!Z"O8Z\8^&Y_P"$2^)6K>%9
M?DCE#0PF3YY'\K+PY9?E&Z%W8Y Y '!X*7PL?4Z_XI>&H-<\*3WQ'^E:9%)/
M&6<A6CP#*I&"#E5X]P.0"<\U\'M&2_N+_P 37MW<7E[#,UHIN3YC;MB$R%VR
MQ;:P0=,#<.<\>D^)+2>_\+:O96J>9<7%E-%$F0-S,A &3P.3WKF_A=X?U3PY
MH&H6VJVOV>:6_:9%\Q7RABC7.5)'56_*B_NV"VIS-[_PA5C\1+EI8=9U_5))
M)&:W54N(A(<Y0*<%C&H("_,%'NORX7A&Y?\ X7):&+3IM&$TLJRZ>2X\L&W9
MRIR%)4L X& !\N!P*Z;PQX9\3_#[4[^'3-(BU;3;A0(V^V)&ZJC-Y>XL!\VT
M_, N,D8/!%5?#?A#Q9'\2[;7]9LP(S-)/-,+A7"F2%@% W%L*6" <@!>"1@U
M3:LR5N4/B=9QZA\6=)L9F=8[JULX'9,;E#W$JDC((R,\9!JCXW\-:7:?$O2M
M#LX#;65U#9JX1BQ!:5HBP+9^;:J\]R,G)))Z_P 8>$];U3XH:-K%E9>;86RV
M8EE\U%V^7<.[\$@G"D'@4OB[PIK>J?%'1]9L[+S=/MUM!+-YJ+MV7#NW!.3A
M2#P*.;\AV_,YOQ7I=CI/Q<\-:=86L=O:QI8,$0=6%RXW$]6;"KDDDG'6NS^*
M$'A^33;*77[_ %&)8W806UC(FZ5C@%]K@@[!GYCC 8CJP!H>+?"FMZG\4]&U
MFSLO,T^VCM1+-YJ#:4G=VX)R<*0>!5CQ[X-U74?$>F^)=#2*>]LTC5K>:3:&
M\N7?'M' ZL^[+#@#'-*^J] Z,X#QM=:1=:3I0TCPI=:;9;5$5_-"5%PI0_(2
M,A\@*P=F+'#>I)]D\-Q1ZOX"T1=3C6^$^GVSS"Z'F^8VQ6W-NSDYYR>_-<%X
MVTCQOXQ-H?[ %I;VK<6POXW+LP.9#R%.T*%'&1YAQD$X](\,V4^F^%='L;E-
MD]M8PPR+D'#*@!&1P>1VHD]@74\:^%5S!IVG^*=<GLX[N;2M/BNH=^-P(2<L
M%8@E=P&"1^M;_P +M'A\1IJOB'7A%J=W+.(/])B#@$*K,V#\O.Y0!@;0F!P<
M4_X=^$M?\-:AJ%AJVB0W&GZA&MO<3FXC:,)&)>=AR75]X&"!@'D=15G0O#_B
M?P#JU_;:3I[:WH]PJO$7O$A9&&1R"<;L<,0OS80Y&"H;W=@70S?"US-X2^+=
MWX4MY7ETR[E<)%G"Q'RO.1N<DD*/+)R-W!/0"NQ3XG^#I(U==8RK#(/V:;I_
MWQ6;X)\&ZA!KEWXI\2 ?VM</)Y=N6$@@#'[P;+8.T;5 /RH<'.<+Z#4MJXU>
MQYWKOA;P[X[U"UU'2-9@L]5,<=RTD S*\>U6C=DW*RL,QD/P0, _PXI:QJ?C
MOPQHC3:]#HVL::[!;PD=$8JGED80$-N(!V-U.>,"I_%7@K7(_&2>+_#<L<]X
M&5VM9BH(8*(CMS@%2F<@D$<D$D@*_P 30>-?%^G?V*?#MKIMG.09YI[U9<%&
M5TP4Y RF#\K9W#I@FJ7GL(Q?#'A75I-.7Q'X+U,:8NH91[*[&X1*I8$;\,),
M.IVDJ#M;DYR#=OO&&L_VQ)X.\6:9!''JR"T6;3I,.D<Q>(2#<6!!.,9VE0"2
M"?EJ3PUHOC'P)=7ME:Z9;ZSIMPWG*T=RD)#_ '<_-R"45<K@@<8;[V<CQ1HG
MB&\GO/&FO&WT633H-EDD!$TAD5RUN#]Y2/,D 9CC.W[J@Y!N&Q<^!M_++::U
M8%(Q%&T%T& .XO(K*V>V,1+CCN?P];KS[X/Z.^G>$7O)K=(Y+^8R1ML(D,*@
M*F[('&0[+U&'!'4UZ#42U;L-;!1112&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!RNN> K#Q%J#7.HZEJTD!E27[$+D"!2JA<*N,KD9R00?F;!&:Z:""&VMX[>
MWB2*&) D<<:A510,  #@ #M4E%%[@%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MD^(_#MEXHT=]-O\ >L;.KK)&%WHRG.5+ @$C*GCHQ'>KFFV;:?IT-HUY<WAB
M7:)[I@TC#MN( R0.,XR<<DG)-JB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *6L:9'K.CW>F332PPW49BD:+;NV'AA\P(Y&1TZ'C!P:AT'0=/
M\-Z6FGZ;#Y<2G<['EY7/5V/<G ^@  P  -.B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@""\MOMEC<6OGS0>=$T?FP-MDCR,;E/9AG(/K7/Z+X$T
MO1M;DUDSWE_J#J%6XOI1(T?&TE3@<E<+DY.!@8!.>GHIWZ %%%%( HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Y_7/"-IKFK6.J_;+RQO[(,(KBS**Y!((#%E;<!\V
M>/G8$')KH** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO$O
MA6Q\5Q6<&I2W'V:VF\[R(F55D;&/F.-PX+#Y2/O'O@C=HH C@@AMK>.WMXDB
MAB0)''&H544#   X  [5)110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M>:>,_B[%X:\3MX>TS19-6OX+=[B[!N!;K"JQ^:<$J=Q\L%CCV R20,P_'S2[
MNRT:+1='GO\ 6]1E6%].>;R1 Y.T RE2K98C&!TY;:>* /7J*XSX=?$6Q^(6
MEW$\%K)9WEHX6YMF;>$#9V,'P P(4]@00>,8)[.@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHJGJFJ6.B:7<:EJ5REM9VZ;Y97/"C^9).
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y_\ !+_DD.A?]O'_ */DKT"O/_@E_P DAT+_
M +>/_1\E 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>?\ QM_Y)#KO_;O_ .CXZ] KS_XV_P#)(==_[=__ $?'0!Z!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Y_\$O^20Z%_P!O'_H^2O0*\_\ @E_R2'0O^WC_ -'R4 >@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%_,B%Q"LFQO[R[@<'W%)<Z3IM[>V][=:?:3W5L<P3RPJSQ'_ &6(ROX5<HH
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M\/:/97ME8:1:0VE](TES!LW)(3P05.1MQ_".!V%;5% '/_\ ""^$/^A4T/\
M\%T7_P 35GQ/9:CJ'A?4K#2&MX[ZXMVAB>=BJ)N&"20"> 3CCK6O12:NK,:=
MG<P_!_AV+PIX3T[18BK&VB D=>CR'EV_%B:W***IMMW9*5E8****0PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW]K]NTZYL_M$]OY\
M31>=;OLDCW C<C=F&<@]C7#_  2_Y)#H7_;Q_P"CY*] KS_X)?\ )(="_P"W
MC_T?)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445X9I_P"T'J6KW+VV
ME^ ;N^F12[1VMXTK!00,D+"3C)'/O0![G17C_P#PM_QA_P!$FUS\YO\ XQ7J
MNE7<VH:/8WMQ:/9S7%O'+);29W0LR@E#D Y!..@Z=* +=%%% !1110 4444
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M]*O:-K%OKEC]KMDE2,.4Q* #D8]"?6A:AL:%%97B35#I&A7%TAQ+C9'Q_$>
M?PZ_A6+K#WNG_#Z-_MEQ]K"QLTWFMORS GGKWQ2N.QU]%>?3:1K%MX?&K_\
M"47?$*S"-W8#D [<[C].G-)#X@UCQ)]ATNQF%M,\6^ZN ,'@XXQTXP>.Y["G
M;H+I<]"HK@M0@U_PDD>HKJ\NHVV\+-'/G@=NI./J,=NM=Q;7"7=K#<1_ZN5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>?_  2_Y)#H7_;Q_P"CY*] KS_X)?\ )(="_P"WC_T?)0!Z!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7G_ (2_Y*]\1?\ N&_^B&KT"O/_  E_R5[XB_\ <-_]$-0!Z!1110 4444
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MD(>:(++L(W%U+EW 8#:0G!Q0!\_'5+XZ&FD&Y?\ L]+IKD6X.%,I4*6/J<*
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MN^;8G(KL_BCH]GX>^ NH:18)MM;2*VB3( +8GCRS8 !8G))QR230!Z?1110
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M"Y[KRP/.> /AII6D_%O7UL[_ %)#X=>T:U8O&3()H6,BR93!!&1QM(!ZYP:
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MF:=XKU+7+^ZGM[2_*1K)(9&ZG"(&/?TX%=S_ ,)/8Q>&!X@OH[BPLRGF;;E
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MA1116AJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'D_QU\4Z-:>"=2\-3WFS5[N*":"W\ISO03J2=P&T?<;J
M>WTKT#PYXIT;Q;ITE_H=Y]KM8Y3"S^4\>' !(PX!Z,/SKYP^/=];ZS\0V.FR
M?:UTS3TAO6A4LL#B5\ACTX,B ^C-MZ\5ZG\ ])U+1O M];ZII]W8SMJ<CK'=
M0M$Q7RHAD!@#C(//L: /5**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3
M7_B7X/\ "^IG3=8UJ."\5 [1+#)*5!Z;MBG!QS@\X(/0BNKKXG\6:-J/AG5-
M3TOQ#922:Q+<).E^TS,)(_GW,N?OAR5.X\@H0<$L  ?6OAOQYX8\77,]OH>J
MQW4\"AY(S&\;!2<9 < D9ZD9QD9ZBNCKYJ^"NFZGK/Q"A\1Z=8_8-&LK1+6[
M96VI.X@5"!@#<S.!*1VZDYVY^E: "BBB@#RWX]:3J.L>!+.WTO3[J^G748W,
M5K"TK!?+D&<*"<9(Y]Q7&>)O"OB"SU'X;^)X]&OKRVTW3]/AN[:T@9[F)XCO
M8&/J."1[$$'&1GZ%HH \5^"'@34;#PUXA_X2/3I+>UUI5@^RS[HY6C42*^Y>
M"H._ Y!X)X&">J^"7_)(="_[>/\ T?)7H%>?_!+_ ))#H7_;Q_Z/DH ] HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKA_$OQ
M2T+0[QM*L%GUS73N5--TQ#*^Y0V0Y&0N"A##EAUVD5EOIWQ(\:7!34[F/P=H
MZN UO83B>]F *'_7+P@.'PRX(Z,K#F@#J/%?CSPYX,MR^LZC''.4W1VD?SSR
M<-C"#D E2-QPN>"17+OXA\?^,;@V_AS19/#&FJX634]:A_T@X*$^7 <C."_7
M*L/XD(KH/"_PV\*>$'2?2M*C^V*BK]LG8RRY"E2P+<(2&.=@4'/3&!764 >?
MZ3\(]"M[R+4=?NK[Q-J21+&)M8F,R+@-NVH>-I+$[6W8XP<\GT"BB@ KS_PE
M_P E>^(O_<-_]$-7<7U_9Z99R7E_=P6EK'C?-/((T7) &6/ R2!^->7^&/%G
MANW^*7CV\F\0:5':W7]G_9YGO8PDNV!@VUB<-@\''2@#UBBBB@ HHHH ****
M "O$?C9X0U@Z/KGB4>++X:8!!_Q)</Y/WHT_YZ;?O?/]WK^=>W44 ?./P0\(
M:QJVG1:W:>++[3[&TU0>=ID0?R[C8(V;=B0#Y@0IRIX'?I7T=110 4444 %%
M%% !1110 5Y_\;?^20Z[_P!N_P#Z/CKT"O/_ (V_\DAUW_MW_P#1\= 'H%%%
M% !1110 5FZEX>T36I4EU71]/OI(UVHUU:I*5'H"P.!6E10!#:VEM8VL=K9V
M\5O;Q#;'%"@1$'H .!45CI6G:89CI]A:VAG?S)C;PK'YC?WFP.3[FK=%  0"
M,$9!JC#HVE6]E+90Z99Q6DQ)E@2!0CYZY4#!Z#K5ZBE9!8J6&E:=I:.FGV%K
M9JYRZV\*QACZG:!FH[S1-)U&X2>^TNRNID&%DGMT=E&<X!(R.:OT460N56M;
M0:Z))&T<BJZ,"K*PR"#U!JI8:/I>E%SIVFV=F9,!S;P+'NQTSM S5VBG97N%
MDR.>"&Z@D@N(DEAD4J\<BAE8'J"#P16/K?A^&_\ #,NBV5K8PPR (BO"/+A!
M/+*H&-P!)'3GO6Y14RBI*S!JY%;0):VL-O'G9$@1<]< 8I;BW@N[=[>YACFA
MD&UXY%#*P]"#P:DHJGKN"22LB&VM+:SMDMK6WB@MT&%BB0*JCV XIEEI]EIL
M)AL+.WM8BVXI!$J*3ZX ZU9HH\PLBLNG6*Z@U^MG;B]9=C7 B7S"OH6QG' I
ML&F:?:O</;V-M"UR<SF.%5,IYY; ^;J>OK5NBE9!9%2WTVTL+)[73;>"QC;)
M MXE0*Q'WMH&,]/RKSJX\%>,IX]0M9+CPU+]N+1RZE]D,5VT3$9^XH'('0D_
M6O4**B5.,MR94U))=C(TOP[8Z=X?L='>&*ZAM%7:9HP07'._!S@YR?:M>BBM
M!QBHI)="I;:9I]FLZVMC;0"<EIA%"J^83U+8')^M9VJ:'*/#L^G^''M=)E;)
M39:H8B>ZLF,8/0G'Y]*W**EQ35AV1YA'\/M>U%]-M=8_X1^TTRSG%Q(FE0,C
MW#@ ?,,!>1GD>O2O3Z**(Q45H1"E&&QS.M>&[B[\6:-X@T]X4N+,M%<+*2/,
MA8$'! /S#)P/?J*W&TVP?4$U![*V:]1=JW)B4R*.> V,@<G\ZM44U%+8KE5V
M^X5G7N@:-J5Q]HOM(L+J; 7S)[9'; [9(S6C10TGN-I/<:B)'&L<:JJ* %51
M@ #L*=113&4;_1=*U1T?4=,L[QD&$-Q LA4>VX'%51X4T!+^TOH](M(KFTSY
M#Q1A-F?9< ^V>G:MBBERK>Q+C%[HR[KPWH5[<O<W>BZ=<3N<O++:HS-VY)&3
M5JQTVQTR%H=/LK:TB9MQ2WB6-2?7 '7@5:HH22V'RJ]['+Z3X:NH/&NL>(M0
M>!WN%6"T6)B3'$.N[(')P.F>_-=1111&*BK(2BE>W4****904444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y?\4O'5
MQ;;?!?A4SW'BK4=L:BT8!K5#R26_A8KGTVJ2Y*X7.Q\1/B);^"K.*TM(?M_B
M&^PEC8("Q8D[0[ <[<\ #ECP.Y6O\,/ MQX9L[S6->$$WB;5I6GO)T49B#$-
MY0(^7[V6.T $G'(530!R_C/P+I?@/X":W86 \VXD^S-=W;KA[AQ/'R?11DX7
MMGN22?:*\_\ C;_R2'7?^W?_ -'QUZ!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\Z^&->^+OC#6M6T_2/%>FNFF/LENVA@\ESN(785B)8-M8@XQ@<
MXR,_15?/NH^$;OP%XPU$^"OB#X?T2&X5?-L=4OD$D6?F"E&5PP .58@-AB.>
M2P!AZK\1?BAX7US4++5/$%B]UI4L9EM'@AQ<1M@@J0BEE(*Y (<!\X&UBOO_
M ()\1_\ "6^#-+UPQ^7)=1?O4"X D4E'VC)^7<IQDYQC/-?/LWPSOO%M]-._
MCSPSJOB2^G+,(]3WYC"Y.%5"6/L H14XSGY/HKPMX?M_"OAC3]$M6W1VD00O
M@CS'/+O@DXW,6.,\9P.* ->BBB@ HHHH *\_^"7_ "2'0O\ MX_]'R5Z!7G_
M ,$O^20Z%_V\?^CY* /0**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\1Z!
M_P )'IT=G_:^JZ7LE$OG:9<^1(V 1M+8.5YSCU ]*\W^'GAJ\U34=8O+SQCX
MKE_L;Q!-9PPMJ9:.:.$H5$JD'=G)#8P".PKV"O/_ (6?\SK_ -C7??\ LE '
MH%%%9^LZYI?A[3GO]7OX+*U7(WS/C<0"=JCJS8!PHR3C@4 :%1SSPVMO+<7$
ML<,$2%Y))&"JB@9))/  '>O-Q\1?$?B@NO@3PI)<V>]436-4?R+<_O"K,J<-
M(@"G[IW GE<C!+7X2+K3K?\ Q UF[\1W^S @$C06MN2J9\M4VG.4^\-H8')7
M/- %BZ^*T-_JC:7X*T2[\47<3[9Y8'$-K%]_K,P(R=G'&U@>&)XJG'X$\4^-
M-EQ\0=;\JQ;:W]@Z23'#_P LVQ*^27Y4Y&6P>5<=*](L;"STRSCL["T@M+6/
M.R&",1HN22<*.!DDG\:L4 8_A[PKH7A2S:UT/3(+*-OOE 2\F"2-SG+-C<<9
M)QG XK8HHH **** "BBB@"O?6%GJ=G)9W]I!=VLF-\,\8D1L$$94\'! /X5C
M_P#"">#_ /H5-#_\%T/_ ,37044 %%%% !1110 4444 5[V^L],LY+R_NX+2
MUCQOFGD"(N2 ,L>!R0/QKPVXTH>+[F23QM\7='6RD<J=+TC4(UA:/.Y.6(&0
MQ_B1SA1\V>FY\?/#.O\ B#0M+FT>WGO+>SF=KFT@W,[EMH1Q&/O;?F'J-_IN
M(XSQ?\.-(\(_#W6]?CL[J=]6>W^PP2VA5](C:3S"LA+M@X"QENN>/XC0!V7_
M  SOX;M_W^G:WKMK?1_/;S^=&?*D'*MA44\'!X(/'4=:ZCP3X?\ &GAS4+FS
MUOQ'!K>BB+_19IE872R9!.[.<KRPY=CPN,#(JGX"\5:-I'@31].USQ;X?;4+
M:W$<@34H"$4$[$R#@E4VJ2,Y(/)ZGOX)X;JWCN+>5)H94#QR1L&5U(R"".""
M.] $E%%% !1110 4444 %>;_ !UOK>T^%&I0SR;)+N6"& ;2=[B19"..GRHQ
MY]/7%>D5Y_\ &W_DD.N_]N__ */CH ] HHHH **** "BH+V[BT^PN+V<D0V\
M32R$=E49/Z"O'=&LO&OQ1@FU\^*[C0-.:5DL[:R#9V@X.[:RYZ=222<\ 8K:
ME1YTY-V2ZBD[(]IHKB_ -CXTTQ+ZQ\4W<-[;0N%LKKS-TLBXY)XR1[L=V0>H
MP:\ITHZAX@U?7#??%&YT 6U])'%#/>L-Z[C]T&5< =.!6L,,I2DN96775DN5
ME>Q]%45X_;?#GQ!?6(O+'XM:G=6[ E98'D=&QP<,)R.HQ7F5IJ7BN?2;'4I/
M&6LQ07&IG3Y&:\EVQ?*C;R=_HQX_V>M:4\%&HVHSV\F)S:5VCZMHKRCP]>:G
MX=^+DWA5=;O]8TR6S\]S?S>=);L%SRW;MQP,.._-85OK-[XZ&M:M<>-I/#P2
M=K;1[9;X6L3E0#\_=_O+DCD9],"LUA&WOI9._KIL/G_KY7_(]THKD[ZR\:7'
M@..QM]0TZ+Q&RA)KP%A'C/++\GWB,?P@ DXQQ7%:5=:EH/Q3T[P_I/B74?$%
MO+ ?[52\N/M MF7<"0W_ "SP<<=<X!SD5$,/SWM)75_PZ^G8'*T>:Q[#17GG
MQ7\5W>C:(VE:.[C5;N&24O&Q5K>! 2\F1T/&![].16Q\-+NYO_AUHUU>7$UQ
M<21,7EF<N['>PY)Y-2Z$E2]J]KV_/_(;DE+E.KHHKPKQ=XJMY_BU>:?J?BO5
M]%T6SMQ&3I\\BEI< XP@;G+')(_AQ10HNM+E7:XY/E5SW6BN#FUFU\*_"N[U
MK2=9NM:C6,R6UW?7'G.S,0H!.!P"?ND9&"#7$W-[X@\&Z%X9\8S^)-2OFU&5
M/[0L[N8M!LE&_")C"$ $<=^F!P=(85S;2?6WS)<[*_K^![E17*>(OB#H_AC7
M++2;^&]>>\C\R%K>'S >2 N =Q8D8  /)'2LJ#XO:'/)<6HTO75U2%@HTPV)
M-S)QD[5!(X')R1Q6<</5DN91T*<DMST"BL#PKXPTKQ?I<M]IQEC$,ACGAN%"
M21,/[PR1TYR"?S! YY_C!X<5;V=+75I;"U+(=0CM,V\C@ [%?/WCGC=@>_(I
M*A4<G'EU0<RM<] HK)T7Q#9Z[X;@UVW66*SFC:4"< ,JJ2#G!(['O6-\-;F]
MU#P@NJ7]Q<32:A<S7*":0MY<9<A57T7 & /6DZ4DI-Z6T^?])BYDTFNIU]%>
M0^"/&ATG3?&6J^(-1N[BVLM1*1+)*9&'+ )&&/?TX'X"O0/^$MT^'PD/$FH1
M7.G61C$FR[0"3!.%^52>3Q@9SS5U*$X.V^WXJXU*^GK^!O45YU)\9=!@M+6>
MYTO7+8W;J+>.>T"&5".)%);:R=!D'/(XKT6HJ4IT_C5A*2>P45Y[XAUF]U'X
MJZ#X7L;N>WM[=3?WQA<H9  =J$CJO'(Z'=[5SGCA=<UGXQ6'AW3O$FHZ1!<6
M(<FWF?:"/,).Q64$G:!G-:T\,Y-7=KIOY+_A@E)*_E;\3V6BO"KZ]\0?"SQG
MH\=_XON=<L;T?Z3!<%BT:9QNVL[8]001G:1VJUHMEXV^*,<^OGQ3<^']-,K1
MV=O9[N5!P<[67/U)))SP!BM/J?N\_,N7OK^6XN>VC6I[717E/@SQ#XAT#QY)
MX%\3WO\ :&^(R6-ZWWW !(R3R<@-UR001DBO3[V[BT^PN+V<D0V\32R$=E49
M/Z"N>M2=-I7NGJBHOF=NI/17BFBV?C?XHQS:\?%-QX?TPRLEG;V>[) .#G:R
MYZ=6).<X &*UO!^N>(_#GCP^!O$U\-226%IK&]8DR.!DX)/)R W7)!'4C%;2
MPC2:YES+5K^M">?KT/5:*\<\:Q:YK?QAL_#VG>)=1TB";3Q*3;ROM!&\D[%9
M02< 9S5349/%GPGUK3+V_P#$USKNB7LHAN1=%LH>>@9F(XR00><$$=*<<)S*
M-I+FDKI?\'8'.U]-O^'/;J*\VT'7;W2_C'K?A>^O9[FSOX5U#3_.D+^5D?.B
MYZ+][ ' V^]>DUQ]$^Y?5H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *YOQQXSL? OAJ35[Z.28EQ#;P)P9I2"0N>
MBC"DDGH <9. =C5=5L=$TNXU/4[F.VL[=-\LKGA1_,DG  ')) ')KR/P7H^J
M?%#Q#:_$'Q,_DZ7:2DZ+ID,N50H_WV(]&7GH79>0$"J0#8^'?A/7;S7)?'OC
M1\ZU=Q&.SL3& +&$^@.2C8R H.0&;<2S-CU"BB@#S_QMX"\1>,?MUE_PF?V/
M1+KR_P#B7_V7')MV[3_K-P8Y==WXXZ5T'AG2?$6E_:O[>\4?VYYFSR?] CMO
M)QG=]PG=G(Z]-OO7044 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*W
MP[T7P7J7BOQ%#X\U>TN9X7/D32W[1PW+;V$DHERI<YVD9;D,3@XR/JFOE77-
M8^&^GZKJ$.G?#F34=/M+C[/]O&LSJDC<XQMW##;7*_-R%SZ@ 'L?A;PU\*=/
M\1VMUX:GTI]73?Y M]6:9^4(;"&0Y^4MV]Z]'KYU^%[:?J/Q2@_L;P-:Z*NG
M)(+SS]1FEN8&*NA(1W7(R50CRVVYY(R,?15 !1110 4444 %>?\ P2_Y)#H7
M_;Q_Z/DKT"O/_@E_R2'0O^WC_P!'R4 >@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y/J/B3XIZ9XCT70YH
M_!K76K^?]G=%NBB^4@=MQ)R,@\8!_"O2-$_MC^QX/[>^P_VG\WG?8-_D_>.W
M;O\ F^[C.>^: -"BBB@ HHHH ***Y/4OB=X(TJW6>X\3Z:Z,^P"UF%PV<$\K
M'N(''7&.GJ* .LHKS_\ X6;<:C^[\/>"?$>HR2\VL\]L+6TG3KO$SGY5*\KE
M>>!@$T>=\5=6^>.U\.:#:S_(4GDDNKNU'0N"N(G;JRCIR >] 'H%>+^#_B'X
M6\+:=XQO-1U:!O.\2WLUO#;L)9)U(4JR*O\ "VT@.<+GN*N>+? _CAO#\MU:
M>,?$&K>(-ZQVZ6,L6G6ZQYR3(@8 G&[Y@V22HQ@$UQGP+\-Z]IGC2\N;G0H)
M;&WEFL+FZ=X2]E<QCG:>7/!*'9P=^23MH ]#.N?$CQ<4BT70H_"NGN[$ZCJA
M$EQL$@ VP8^1RH8[7!!!X8<$W-&^#_AJRG2_UE9_$.KG!EO=5D:7>=@3&PG:
M5&. VXCCDX&/0** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O&?VC=-N+CPCINH)>;+>TNRLML9 HE+K\K %AN9=I  !.'8\ &O9J\)
M_:5^Q_V9X>\SS_MOG3>5MQY?EX3?N[[L^7C'&-V>U %*"3]GN6WCD>%X'= S
M12&^+(2/NG:2,CIP2/0FO=-#_L__ (1_3?[)_P"0;]EB^R?>_P!3L&S[WS?=
MQUY]:\+@^*OPF:WC:X^'Z1S% 9$CTJU=5;'(#%@2,]\#/H*]TT.ZM+[P_IMW
MI\'V>RGM8I;>'8$\N-D!5=HX& 0,#@4 7Z*** "BBB@ HHHH *\_^-O_ "2'
M7?\ MW_]'QUZ!7G_ ,;?^20Z[_V[_P#H^.@#T"BBB@ HHHH I:S8'5-#U#3P
MX0W5M)"&/;<I&?UKR/X>?$#2/!F@R>%_%3S:9?Z;,ZX>!W#AF+<; 3W[\$$$
M$]O::S]1T'1]7D234])L+UT&U&N;9)"H] 6!Q6]*K&,7":NG]^@I*]K=#G_!
M?C^W\;7>I+9:;=Q6=I)MCNY,;)A_,-WQSQ@DC.*\[^'G@CP[XKU'Q3-K>G?:
MI(-3=(SYTB;02Q/W6%>WVMK;V5M';6D$5O;QC"11($51Z #@5#9:9I^G&8V-
MC;6IG??*8(53S&]6P.3[FK6(C#F]DFKVMK_6Y/*VE?O_ )D&F:-I_A_0UTS2
M[?[/9PJ^R/>S8R23RQ)ZD]Z^:-*NI5\!V6GW3/#H%YX@*ZE.BYVJ%A(&>W&X
M_P# ?:OJD@$8(R#6?!H6CVUA-86^E6,5G.29;>.W18Y"1@[E P> .OI3P^*]
MDY.2NW9_<.4;JRTW_%6/)/#J:5I'QDATOP1-'-HMW8DZ@L$WGQH0&P0Y)[[.
M_5L5S?AS3?"VC^'O&FF>*([2/6K<NL/VD 2$!3L,.><EN?EZ@C/%?06G:/IF
MD(Z:9IUI9)(<NMM L88^IV@9J.^T#1M4N4N=0TFPNYXP%26XMDD90#D $@D<
MFM/KBNUK9I*]]='>_P"@E'KYW\NQP'A/Q1)X0^#>CZKKMK?W$0^0>2BL\<19
MO+)W$?+C: ?=:Q-?N](O_B3X2NO TUJ=0N96DOWL" 'B+*Q\W;WQOR&Y]>U>
MTNB2QM'(BNC@JRL,@@]015+3M#TC1VD;3-+L;(R !S;6Z1[L=,[0,]:B.)@J
MDJG+JV_37HQ<CY.5'C>OVGC"T_X3+5]3\*BX^W6TENE]_:$2BUM0#@+'DD\
M$]"2*Z/X<>)H]"^%5G>Z_;_V=IMM^[@NM_G>>&=N=B LO/&#]:],N+>"[MY+
M>YACF@E4K)'(H97!Z@@\$5B:_P"&H-1\)S:#8VEA!!*HC1'@'EP GEU0#&X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?-TOP5\3P)XIT6UMHWTQW2\TRY:Y3=-)$Q"1MT()CFE
M!RJC>J_,%Z_2-?,WA7P$WQ$^(/BA?&]Y=V&K6[B1[.%U$AW$\J7W?ND 4#&1
MATPV,9 .G^'WP_\ &C?$F+Q;XLBCLWM+=8AF99GNF$'D DJ[8.!N9B>2>!R=
MON5><>%O@KX<\(^([77+"]U62ZMM^Q+B6,H=R%#D",'HQ[UZ/0 4444 %%%%
M !7G_P $O^20Z%_V\?\ H^2O0*\_^"7_ "2'0O\ MX_]'R4 >@4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%>?_$KQOJ.@_8?#_AJU^V>)M7W+:HI5O(4=9&4GZX+
M?+\K$G"D$ Q_B1XKU36]8E^&WA&V\[5+N+;J5U*N([6!U&1DCNK#+<X# +ER
M-O>>$?"]CX/\-6FCV$<8$2 S2JFTSRX&Z1N2<DCIDX& . *Q_ASX"7P1I=P]
MU=R7VM:BXFU&[9V8._) 7/) +-\QY8DDXX [2@ HHHH **** "BBB@ HHHH
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M*B_VM\0'Q\WVAQGVS+7/[*DH<S7V4]^[L)1CU\OQ/0]#UVP\0:-#JEC(3;R
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M:&&2<8J]8@P?'O4O.&//TX&'/?B/I_WRU8_C'0K7Q+\9+'2KR2:.":Q!9H2
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MM=S7FNJ#S?CMH:P\F#3V,OTQ+_B*]*KBKI6@^Z_S7Z&,]_D@HHHKG)"BBB@
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M /H:]#_\&,/_ ,55>Q^''@K3[..UA\+Z4\:9P9[99G.23R[@L>O<\=.E6/\
MA!/!_P#T*FA_^"Z'_P")H /^$[\'_P#0UZ'_ .#&'_XJL>^^,'@'3[R2UF\1
MP/(F,F"*29#D \.BE3U['CIUK8_X03P?_P!"IH?_ (+H?_B:V+&PL],LX[.P
MM(+2UCSLA@C$:+DDG"C@9))_&@#A_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0
MP_\ DE<?_&Z] HH \_\ ^%K6\G[RS\'>,KVU;F&ZM]))CF0_=="6!*D8(R!P
M>E'_  M/_J0O'/\ X)__ +.O0*BN$EDM98X)O)F9"$EVAMC$<-@]<'G% 'SK
M??%JXG^+\FH:)X=G:^ET\:';6M_((7$YF#!I%[8<[2NX=,[EZ#T-_A[XK\2H
M_P#PF/C>[6"5)5;3M#46\2AV^Z7(S*FT8PZD\]3SNX#_ (4UI/\ PM'_ (1G
M[3_H_P#8O]H;_+?[WG>7C&_/3W_"OH:W26.UBCGF\Z94 >7:%WL!RV!TR><4
M 9&@>#O#GA9%71='M+1PA3SE3=*REMQ#2-EV&<<$GH/05N45!=7MK8Q"6[N8
M;>,MM#S2! 3Z9/?@T 3T5C77BS0+.(22ZM:LI;;B%_-/Y+DX]ZI_\)SH\WRZ
M>+S49AR8;2U=G5?[QR!QG _$4 =+17-?\)/?7/R:?X8U1YAR1=JMLFWV8DY.
M<<?7TH_M#Q;=_NX-#L[!AR9;N[\U"/[H$8SGOGIP: .EHKFOLOC&[_=SZCI=
M@HY$MI TKD_W2).,=\]>!1_PC6IW7_(1\4:A)M_U?V-5ML>N[;G=VQZ<^M '
M2U6N]1L;#9]LO+>VWYV>=*J;L=<9//45A_\ "$:9/_R$;C4-3Q_J_METS>7Z
M[=N.O&?H*M6G@_P]9;_*TFW;?C/G R]/3?G'7M0 7?C#P]9;/-U:W;?G'DDR
M]/79G'7O57_A-],G_P"0=;ZAJ>/]9]CM6;R_3=NQUYQ]#6Y::=8V&_['9V]M
MOQO\F)4W8Z9P.>IJS0!XMKWBO6G\2_:29+1[1W^RQ2P!7B5P!\P(/)7!.<]>
M*[ZR\4ZO]AM[N^\-71@FB5EELG68N2,@^7U52,GD\<"L^^\->(M1U2WU"YM?
M#;S0[MP,<A6;*A?GR/FP!QZ5V6G_ &[[%'_:/V?[7SYGV;=Y?4XQNYZ8_&@#
M#_X3#_J7/$'_ ( __94?\)A_U+GB#_P!_P#LJZ6B@#FO^$P_ZESQ!_X _P#V
M5'_"8?\ 4N>(/_ '_P"RKI:* .:_X3&)?FGT/7((1R\TMD0D:]V;!Z <FC_A
M/O#'_03_ /($G_Q-=+10!S7_  GWAC_H)_\ D"3_ .)H_P"$^\,?]!/_ ,@2
M?_$UTM% '*7GQ$\/P6<LMO=-<S*OR0K$ZESZ9*X ]_Y]*YCPCXZM;&>\AU2/
MREN[F2Z:XCR51F ^7;@G'!YR>H^M>CZIIMOJ^FSV%T&,,RX;:<$8.01[@@&N
M/\"^'+&TU#4[U3(\UI>36<7F;2 HV_-T^]C(R.Q/% &M_P )]X8_Z"?_ ) D
M_P#B:/\ A/O#'_03_P#($G_Q-=+10!S7_";Z9/\ \@ZWU#4\?ZS[':LWE^F[
M=CKSCZ&C_A,/^I<\0?\ @#_]E72T4 <U_P )A_U+GB#_ , ?_LJ/^$P_ZESQ
M!_X _P#V5=+10!S7_"2ZG=?\@[POJ$FW_6?;&6VQZ;=V=W?/IQZT?VUXG_Z%
M+_RI1_X5TM% '-?VUXG_ .A2_P#*E'_A1_;7B?\ Z%+_ ,J4?^%=+10!S7]H
M>+;O]W!H=G8,.3+=W?FH1_= C&<]\].#1_Q6_P#U+_\ Y&KI:* .1U'_ (3?
M^S+O_D#_ .I?_CV\[S?NG[G^UZ>^*\[\(V^H+XQLDMH9!/!-^_!7F-,[9-V>
MG!(]<GCG%>TZA]N^Q2?V=]G^U\>7]IW>7U&<[>>F?QKEK72_&%IJE_J$;Z&9
MKWR_,#&;:-B[1CCT^M '94444 %%%% !1110 5XK^T<-)/AG23<NZZLMPQL@
MJ%@R8'FACD #_5G/)R  ,%B/:J\I^-_A3Q%XMTW2+/0-(@O3%-)+-,SQI)%P
M JJSL/E;)) SRB],<@%*#XO>-5MXUN/A3K,DP0"1XUF16;')"F$D#/;)QZFO
M6-*NYM0T>QO;BT>SFN+>.62VDSNA9E!*'(!R"<=!TZ5Y/!KOQUBMXXW\):-.
MZ(%:626,,Y ^\=LX&3UX 'H!7K&E27TNCV,FIPI!J#V\;7,49RJ2E1O4<G@'
M(ZGZF@"W1110 4444 %%%% !7G_QM_Y)#KO_ &[_ /H^.O0*\_\ C;_R2'7?
M^W?_ -'QT >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_;Q_Z/DKS/X?_%'Q/#X0U!;F[AO397L*+<Z@'D9(Y$G=MS;@2 8A@D\;B.F
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MQ8J!)S\A+ C!QR,41^)=!F>9(M;TUWAM_M4JK=(2D.T-YC<\)M93N/&"#WH
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MNQ8J!)S\A+ C!QR,5(FNZ/)>6MG'JMB]U=Q">VA6X0O-&02'1<Y9< G(XX-
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MU_X*^:&^9*[7W:_\$RK/Q1XHTF6T%S\.;RYU/3HS;1WO]AAWC4;ALCDBVKL
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M0 ETP "IX.!Z4]?AOI&^R,MYJ4R6*&.WCDG7;%&5"LBX4%5*C:0I''%=C12
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MB@8  '  ':@"2BBB@ HHHH **** "O/_ (V_\DAUW_MW_P#1\=>@5Y_\;?\
MDD.N_P#;O_Z/CH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_QI\3[A=1NO"G@>QG
MU7Q*,1O+#&'AL\G:Q8]-RDJ#GY%+?,?E*UGZSXTUWX@>*'\*_#^[^S:?;Y&I
MZZJAE52"N(C^>TJ0S,,J552Q[CP+X%TOP'H8L+ >;<28:[NW7#W#CN?11DX7
MMGN220#F_#7P_;P%X?GU>'3(_$WC&1Q-+-+.J,SL<.(Y9 =H"LY+'E^<]0!E
MZ3/\0]+\7^(]?_X5WYO]L_9OW']M6Z^3Y,93[W.[.<]!CWKV"B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^6?$WP^\/^#KU[W3?'^ARW$5VT/V+4+5;DQ A@1(B++N88QS&!GGY3
M@5]35YYH/P3\$:%()FTY]3G5V99-1?S0 1C;L "$=2,J3D]>!@ X_P"$7Q1\
M3>)-;L]!N=%M'TN"W\E[NRMGC%N50E"^,HH;85"@*,GCIBO<ZC@@AM;>*WMX
MDA@B0)''&H544#   X  [5)0 4444 %%%% !7G_P2_Y)#H7_ &\?^CY*] KS
M_P""7_)(="_[>/\ T?)0!Z!1110 5@>)?!>@^+("FJV*/,%VQW*?+-'P<88<
MD L3M.5SU!K?HJHRE%WB[,:;6J/)M;^'WB*%0XEL_%MFOR&UU-!%>+%YH8!+
MH$,6 +<E@H&?E.<#*\-ZM>VE[;Z=H?B.YT_4$6.*70?%@;;]W"^5( ,#+J%0
M!6;&2,8%>W5E:YX;T;Q+:BVUC3X;N-?N%QATY!.UQAESM&<$9Q@U;E3J?Q%K
MW6C_ ,F#49:R6O='+1_$2\T5X8?&OA^YT<.J@7L)^T6[/AL@E,[22O"@L>>>
M!D]=I.NZ3KL'G:7J-M=J%5F$4@+(&&1N7JIX/! /!]*XIO!WBOPI&LOA#Q#-
M?P11!3I>LMYB,%5@!&XQLZJ HVCCEL#%<_YG@R^UB&WU?3[SP'XA@SL>WD%L
MCK^\!V2@;"I /SD+G@ L*ET)VO3?,OQ)Y)KX7=?B>RU\P_$4V_\ PD_$@W?V
M]\X_MNR; WOGY FZ'_>D)"]&R:]=M4\>Z%':S65]9^,-,DB3:&9+>8#:V&63
M)5E/R$LQ8GT'+5Y#XN\3+?ZWFY\$Z-IL\-XEW)'/8_OY6QN*S,0I=7+;B,#.
M1SW//*KR+70RG445K='K_P *%?\ L:_=)M]J;@!%_M*VO<.%&X[H(U"Y!3@D
MGCHO\7H%>5?##QAH#Z7?37EKX=\/W)F"D6HBM5G0+D94MN)!+<D8^;C)W8[O
M_A,/#'_0QZ1_X'1?_%5:FFKW+C.+6YM45B_\)AX8_P"ACTC_ ,#HO_BJ/^$P
M\,?]#'I'_@=%_P#%4^9=RN9=RGK'P\\(:[O.H>'[)I'E,SRQ)Y,CN<Y+.F&;
M.23D\GFLC_A6UQI_[SP_XS\1:?)%Q:P37 NK6!.FP0N/F4+PN3QP><5T?_"8
M>&/^ACTC_P #HO\ XJM>&:*X@CG@D26&10Z2(P964C(((Z@CO6L<1-*RE^HM
M'L<+_P 7-T3_ * GB6TA_P!ZSO+C/YQ+M)_%5]31_P +$U#3/E\3>"M;TW'S
MO/:*M[;PP]Y))$^[C#$K@D  \YKO:*KVL7\45^7_  /P'8Y73OB5X+U2W:>W
M\2Z<B*^PBYE^SMG /"R;21SUQCKZ&NJK,U'PYH>KW"W&IZ-IU[,J;%DN;5)&
M"Y)P"P)QDGCW-<K_ ,*D\/VG_("O=;T#=_KO[+U&1//Q]W?OW9V\XQC[QHM2
M>S:_'_+\@U.]HK@O[$^)6F_OK3Q?I>L2-\IM]2TT6\:CKO#0G<6X P>,$^@H
M_P"$S\5Z1QK_ ($O9(E_=?:M%F6[\Z0?Q"'ATC(#$%CD< \FCV+?PM/^O.P7
M.]HKBK+XJ^%)[M+&^NY]'U%L[[/5;=K=XN,C>Q&Q<K@CYN<CN<5YU\5=/\#W
MDEYKL&KM<ZW?1Q2V\<)66WE56$1(94(X$;_Q]5_"LZD725YIHF<^57/>J*\X
M^%^D>"[&?4YO"6IWMXQ6-;@3AD51EBOR[$!/#<D$CG&,G/37?COPI96KW$OB
M'3F1,9$-PLK\G'"IECU["L^:-KW!35KLZ&BN+_X6CX=N?DTA=1UFX'+6^GV,
MC2*O=R&"C:#@=>I%'_"8^(KW]YI'@349;<?*S:A<QV<F[OA&R2N"/F]<CM2]
MI'H'M(]#M**XO_BY%[_T+FG0S_\ 76:>V5O_ !QW4'_=)'I1_P (=XBO?W>K
M^.]1EMQ\RKI]M'9R;NV77)*X)^7UP>U',^B#F?1':5EW?B30K"Z>UO-:TZVN
M$QOBFND1UR,C()R."#^-<_\ \*PT.Y_Y#-WJ^M[?]5_:-^[^3Z[=NW&>,YS]
MT5IVG@7PI96J6\7A[3F1,X,UNLK\G/+/ECU[FB\^P7GV,S_A:GA:?]WIMQ>:
MG=G_ %=I9V4K2R>NT,H' R3ST!H_X3G5;W]WI'@C79;@?,RZ@BV<>WOAV)!;
M)'R^F3VKM*J:I'%+I%['/>26<+P.KW4<HC:%2IRX<_=('.>V,T6D]V%I=6?'
M-?3O]A^/;S]_/XQL]/E?[UK9Z8DL28X^5I#N.>ISW)'2O)I/!7@*+QM%HS>*
MKDZ5+8^<MXM[$V+C<1Y9D";5&P$X..<<\@'Z"TN.*+2+*."\DO(4@14NI)1(
MTRA1ARX^\2.<]\YK.G1C&]I7_ PH4[7NSEO^$#OKK]]J7C7Q')=M_K&L[A;6
M(]AMC4$+QC//)R>]'_"J_"T_[S4K>\U.[/\ K+N\O96ED]-Q5@.!@#CH!74Z
MCJNG:1;K<:G?VME"S[%DN9EC4M@G +$#. >/8UB7OQ$\&V%H]S-XFTMHTQD0
M7*S/R<<(A+'KV'O6\:'-M&_XF_)#JB6T\"^%+*U2WB\/:<R)G!FMUE?DYY9\
ML>O<UM6EG:V%JEK9VT-M;IG9%"@1%R<G ' Y)/XUQ/\ PN?X?_\ 0?\ _).?
M_P"(H_X6?_U(WC;_ ,%/_P!G6JPU1?9M^ URK8[VBN"_X33QA>?O]+^'%[)9
M-_JWOM0AM)CC@[HFR5YSCGD8/>C^T/BAJ7[ZTT/P[H\:_*;?4KN2XD8]=X:$
M;0O(&#SD'U%/V$NK2^:'<[VBN"_L_P"*&I?N;O7/#NCQK\PN--M)+B1CTV%9
MCM"\DY'.0/4T?\(AXXF_=7?Q)G:V?Y9EM](AAD*'[P20$E&QG# <'FCV4>LU
M^/\ D%SO:*X+_A6'_4\^-O\ P;?_ &%'_"F/A_\ ] #_ ,G)_P#XNCEI+>3^
M[_@H-3IKWQ5X=TV[>TOM>TNUN8\;X9[R-'7(R,J3D<$'\:Q=1^*W@;2[A8+C
MQ':N[)O!ME>X7&2.6C# 'CIG/3U%6[+X=^#;"T2VA\,Z6T:9P9[99G.3GEW!
M8]>Y]JV].TK3M(MVM],L+6RA9][1VT*QJ6P!DA0!G '/L*/W*[O[E_F&I\U^
M*_C'?WWCVSU?2[6R:VT:6X73S(DA\Y)%"%WY4\@;@ %QG!SBO6['XV^!Y]/M
MIKO5OLMS)$K36_V:9_*<@%DW"/#8.1D=<5B>-/ GAF[^*WA5)=*39K+WKWZI
M(Z"9DA#*?E(VG/)*XR22<YKUN""&UMX[>WB2*&) D<<:A510,  #@ #M757J
M8=PA:+V[^;]>MQ).YR6G?%;P-JEPT%OXCM4=4WDW*O;KC('#2!03STSGKZ&M
M/_A./"7_ $-.B?\ @PB_^*K3U'2M.U>W6WU.PM;V%7WK'<PK(H;!&0&!&<$\
M^YK,_P"$'\)?]"MHG_@OB_\ B:Y;T>S_  _X ]2_INN:1K/F_P!EZI97WE8\
MS[+<)+LSG&=I.,X/Y&K]<EJ7PO\ !&J^5]H\-V2>5G;]E4V^<XZ^65W=.^<<
MXZFL_P#X4Q\/_P#H ?\ DY/_ /%T6H]W]R_S#4[VBN"_X5)X?M/^0%>ZWH&[
M_7?V7J,B>?C[N_?NSMYQC'WC1_PK#_J>?&W_ (-O_L*.2ETE^ :G>U!=V=K?
MVKVMY;0W-N^-\4R!T;!R,@\'D _A7$_\(/XHL/W6B?$35(;8_,RZE:Q7TA?N
M1(V"%P!\N.N3WH_X13X@?]%+_P#*%!_C1[*#^VOQ_P @,3XL^'?#EKX=LX[=
M=%T6YDNPPD-L4:1 C;@/*1F(R5SQCIDYQGS#P?H6BZEXGL[;5M7MS:M=^3Y$
M2S![GLFT^7@*S$ Y*L!GH<&O2/'>D?$NW\%:E8IJ]KKUK.BB62&R>&^(+J#'
M&D659,=<\D,X/&*\P^#]WXKL?$TUQX;TR?4[=(O].M%G6&.12"$W._RA@QR/
MXL!@.-U-98JD754UI_76WY'/.DG.Y]#Z?\.O"&F>9Y&@6;^9C=]I4SXQGIYA
M;'7MC/X5=_X0_P ,?]"YI'_@#%_\37.?\+;\/VG_ "';+6] W?ZG^U-.D3S\
M?>V;-V=O&<X^\*ZK3O$>AZO<-;Z9K.G7LRIO:.VNDD8+D#)"DG&2.?<5E+#R
M@M8Z>ANHQZ(CA\*^';>>.>#0-+BFC8.DB6<:LK Y!! X(/>M>BBH22V&DEL%
M%%%,84444 %%%% !1110!2U;4?[)TR:^^QWEYY6W]Q9Q>9*^6 ^5<C.,Y/L#
M7F^D>)[JP\8>)-7E\(^*3;ZG]F\E4TT[U\N,JVX9P.3Q@FO5:*B46VG<B46V
MG<****LL**** "BBB@ KB/B1\0-(\#Z=##JNFSZA_:,4R1P(B&.3:%!63<>%
M.\#@-QGCL>WJGJ6K:;H]NMQJFH6EC SA%DNIEB4L03@%B!G /'L: /G"S^&/
MBGQAKT&JV?AJT\%VGVA[A)UEE65/W@P!&7RKK@E<+$IQV&VOI#2K2;3]'L;*
MXNWO)K>WCBDN9,[IF50"YR2<DC/4]>M3P3PW5O'<6\J30RH'CDC8,KJ1D$$<
M$$=ZDH **** "BBB@ HHHH *\_\ C;_R2'7?^W?_ -'QUZ!7G_QM_P"20Z[_
M -N__H^.@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHK'\3^)]+\(Z'-J^KS^5;Q\*J\O*YZ(@[L
M<?H22 "0 7-5U6QT32[C4]3N8[:SMTWRRN>%'\R2<  <DD <FO'+JZUWXXZC
M!965O?:-X%BVRW%S,@62]8'[J]5.&4@ $JI&YLG:H?8:!XF^,=QIVM>+5CTW
MPG&[36NE0NPDN1GY'<^A4XW\$@':JA]U>T000VMO%;V\4<,$2!(XXU"JB@8
M '  ':@#/T#PYI'A;2UTW1;&.TM Y?8I+%F/4LS$ECT&23P .@%:E%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7:VL333/M)VHH)8X')P >E</\$O^20Z%_P!O'_H^2@#T"BBB@ HHHH ****
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M<62 "H.22<8.#G=M/=UXK^T<-)/AG23<NZZLMPQL@J%@R8'FACD #_5G/)R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKS_XT167_  K.^O;W3H+_ .PRPS0PSO(J;RXCR?+=6/RR-WKYH\+:
M./&OB.T\.VMI8V$U]=O*+L&9C#$$9FC4%R"H"DC(W$X!?% 'O?C/X@WWB/5$
M\%?#J>.ZU&Y3-WJD$F8K2(XR5D&1G!&7&=N0%RY&WK/!'P[TOP5]INHYI]0U
M>\YN]1NSNDD)P6 _NJ6RV,DDXR6P,:GA?PCHO@_2TL-'LHX0$599RH,LY&?F
MD;&6.6;V&<  <5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '&^-K">TTN^UJVU?5(9E\O;!'<E8AEE7A1[<]>M=!I.C_V3YW_
M !,=0O/-V_\ 'Y/YFS&?N\#&<\_05F>/O^1)U#_MG_Z,6NEH **** "BBB@
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M"_[>/_1\E 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQV-Q=>1-/Y,32>5 FZ23 SM4=V., >M"KROLON7^0^=_TD?*?_"<Z[_PF/\
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MIVGFN8,GQ#^,82(0R>$_"TB,QE!8R7*M&,*>5,J-N)& J$$Y+%17I?@[X?\
MA_P/9^5I-KNN&W"2]G"M/("0=I< 87A?E  XSC.20#R36_AKXX\46_\ ;_BJ
M*[U._EN'6+0[*_BMULXR/OK(^] /D V*"3E6+$AA4?P]^'/B/PMXTL=6N/!U
M\/+NV"3-K5J4@@<%"70+ND959CE2N<#@=_H>B@ HHHH **** "BBB@ HHHH
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M_'W_ ").H?\ ;/\ ]&+72T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P""7_)(="_[>/\ T?)0!Z!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5Y#\?/".J>(M"TO4-)MI[R;3IG62U@BWNR2;?F !R<%%&
M#][/ !KUZO*?CEXYU3PEH5C8Z0WD7&JF5&NPV'A1-N=GHQW_ 'NV#CD@@ \A
MUSP;XT>\O-/L_",\5GKEW!J<26\#%+7(DV1%L*L>SSF5@P7&T'A>3]2Z':W=
MCX?TVTU"?[1>P6L45Q-O+^9(J ,VX\G)!.3R:^2G\5>+-*%]<KX\OI[G3=1C
M@CC2_>:.Y'[PF1=S8>,&->JD$2#..A^M=#U+^V?#^FZKY/D_;;6*Y\K=NV;T
M#8S@9QG&<"@"_1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#H^.O0*\_^-O\
MR2'7?^W?_P!'QT >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?.&N_'OQAHGB'4]
M)^QZ'-]ANY;;S?LTR[]CE=V/-.,XSC)H ^CZ\S\;?&32/#UQ/HNBQR:QXBWF
M".VAC+1QS94!7(Y8Y;[J9.5*G:>:XS3;GXD_&C3H8[B:#0/#K>:);NS1U^T\
M;=FTR;I%Y(ZA/O9)*@5ZOX.^'_A_P/9^5I-KNN&W"2]G"M/("0=I< 87A?E
M XSC.20#S^Q^&'B7QWJT>L_$Z^VPPY^RZ39R*!'F0DJQ7("D #*L7(*Y<%:]
M<TK2K'1-+M],TRVCMK.W39%$@X4?S))R23R223R:N44 %%%% !1110 4444
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M>?\ P2_Y)#H7_;Q_Z/DH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>[L%JCW=CS3_ (2'XH:U\VF^&+/3+2X^2.2\?][!_"78,P/!R1^[Z8X;N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC.T#.,G\ZNT45IL:;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>?_  2_Y)#H7_;Q_P"CY*]
MKS_X)?\ )(="_P"WC_T?)0!Z!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYAMK=,;Y9G"(N3@9)X') _&@!MIIUC8;_L=G;VV_&_R8E3=CIG YZFK-8O\
MPF'AC_H8](_\#HO_ (JL7_A;/@C_ *#?_DI-_P#$5+G%;LESBMV=I7D^H>(/
M DUXZW?CC5Y9(IRXVL[(L@)^9-L6WCG!7CTXK3OOC5X2M)UC@-_>J5W&2WM\
M*#D\?O"IS^&.>M>:>,/B'J7B;Q#:C1+B\-I'<PW%G:2VD?F1W"\#;MW%\DY
M)ZMC' K*I627NLRJ5DE[K/=/"=]IVH:&L^EZO/JEKYC*)KALR*>ZME01Z_,,
MX([8K<KRJS\>^/+JQM["W\#7AU/RU4W=X&CB=E'S,P*HJYP<#<.2.O0S_P!J
M?%ZY_P!'_L#2+3S?D^T^8I\G/&_'FMG'7[IZ=#TJE55MG]Q2JJVS^X].HKS'
M_A'?BO<_N+KQ;IT=O+\DKP1CS%4\$KB)3N Z88<]QUH_X5CXG_Z*3J_Y2_\
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M:#0;9V9=I%P6G7&0?NR$@'CKC/YUKVGAO0K"Z2ZL]%TZVN$SLEAM41UR,'!
MR."1^-:E%)1BMD:*,5L@HJIJ.JZ=I%NMQJ=_:V4+/L62YF6-2V"< L0,X!X]
MC69_PG'A+_H:=$_\&$7_ ,56BA)ZI%&]17):E\4/!&E>5]H\263^;G;]E8W&
M,8Z^6&V]>^,\XZ&J(^,G@(C(UQB/465Q_P#&ZM4*K5U%_<"UV.[HKS._^.O@
M^TN5BMUU*_4IN,MO;;5!R?E_>,ASWZ8YZ]:K?\+^\+_] O6_^_,/_P =JUA*
M[^RRE&3V1W7BZ:PM_"]Y+J>J7FF6:[/,N[-F66/YUQM*@GDX!XZ$UY1%??#N
M&ZGNHOB+XICN+C;YTJ2S!Y-HPNX^3DX' STIGB#XZ66H07=A!X5BO;.10(SJ
M4JE6; (+PA2" PSC?S@<@]//O"^LS#Q.DLGARRUP3Y\S3DTZ'][M1@-@6([,
M?>.P#.WFNFGEJE%RJIW7FBEA^;62/K:BO%KWXE?$M[MVL? TD%L<;(Y].N97
M''.6!4'G/\(_K19>/?BU>W:6\?@ZW5WS@S:?/"O SR[R!1T[GVK'ZE4M=M?>
MA>SE_5CVFBO'=2O?C;?>5]GTNTT[9G=]E:W;S,XZ^8[],=L=3G/&*&SX[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7G_P $O^20Z%_V\?\ H^2NXOYKBWTZYFL[7[7=1Q,\-OY@C\UP"53<
M>%R<#)Z9KA_@E_R2'0O^WC_T?)0!Z!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7G_P ;?^20Z[_V[_\ H^.O0*\W^.MC
M;W?PHU*:>/?):2P30'<1L<R+&3QU^5V'/KZXH ](HHHH **** "BBJ>I:MIN
MC6ZW&J:A:6,#/L62ZF6)2V"< L0,X!X]C0!<HKD]2^)W@C2K=9[CQ/IKHS[
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MHO\ XJL7_A;/@C_H-_\ DI-_\17BM[XM^'<5VZ6?@626W&-KSZM+$YXYRH+
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MYV*K<=>".E:O_"H? O\ T __ ";G_P#BZ''#+JW\D%H=QG_"XO ?_0<;_P
M;C_XW534/C;X*LX%DM[J\OW+[3%;6CJP&#\Q,FP8XQUSR.*O?\*A\"_] /\
M\FY__BZGL_A9X)L;I+F+0(6D3.!-+)*G(QRCL5/7N/>JOA%_-^ O<\SFO^%_
M>%_^@7K?_?F'_P".UGZE^T)IT7E?V7X>O;K.?,^U3)!MZ8QMWY[^F,#KGCTG
M_A#/"W_0M:-_X 1?_$T?\(9X6_Z%K1O_   B_P#B::J85/X']X>YYGE _:(E
M)P?"('N=2_\ M595[\?O$SW;M8Z3I,%L<;(Y_,E<<<Y8,H/.?X1_6O<[/PSH
M&GW275EH>FVUPF=DL-I&CKD8."!D<$C\:U:?M\,G[M+\0]SLSYP_X7WXQ_Y\
M-"_[\S?_ !RLR'XI?$O5M3,-AJ1:69V:.UM+".0@<G:H*%B /4DX')-?45%4
ML716U)?U\@O#M^)\K^*/$7Q(NM#DLO%#WZ:7<NJ.MQIB0*[ [U ;8#G*YP#V
M-<MHS:K%JUM#H=[=6E_=,MK&UM<&%I-S !-P(X)QU..!7UCXOAEFTF%8?"UK
MXC83@_9+F2-%3Y6_> R C(Z>OS5P/A+P]K&E:M(U]\--/*W&JFZCNVNK8M81
MLRX5  20F"1MQ[ 5U4L9'V3M%+RNE^!I%QY7HOO.&O?A_P#%C4K1[2^DU>ZM
MI,;X9]81T;!R,J9,'D _A19? 'Q1<6B2S/IMK(V<PSW#%UY[[%9??@GK7TO1
M7+_:-5*T4E\C/F79'SWIW[/&JM<,-1U;3[>'9PUNKSL6R.-K! !C/.?PYK3_
M .&=8_\ H95_\%W_ -LKW&BH>88A_:_!![1]/R/+/^%">%O^?_6?^_T7_P ;
MK5L_@SX)MK5(9=.FNY%SF::ZD#MSGG857CIP!TKOJ*R>*KO[3!U)]SDK#X8^
M"]-G::#P_;.S+L(N&:=<9!^[(6 /'7&?SK1_X0SPM_T+6C?^ $7_ ,36Y16;
MJU'JY/[Q<TGU,+QB-?/A2]'AAMNL_)]G.(S_ !KN_P!9\OW=W7^=>#Z7X ^*
M.BZN=6TW3(;>^._]ZOV,A=W78I.U/3Y0."1T.*^E:*UHXJ5&+BDG?N$965@H
MHHKF)"BBB@ HHHH **** "BBB@ HHHH RKSPSH&H73W5[H>FW-P^-\LUI&[M
M@8&21D\ #\*GT[1M*TCS/[,TRSLO-QYGV:!8]^,XSM SC)_,U>HJN>5K7'=A
M1114B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/
M_@E_R2'0O^WC_P!'R5Z!7G_P2_Y)#H7_ &\?^CY* /0**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O/_ ()?\DAT+_MX_P#1\E>@5Y_\$O\ DD.A?]O'_H^2@#T"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/\ XV_\DAUW
M_MW_ /1\=>@5Y_\ &W_DD.N_]N__ */CH ] HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_^"7_ "2'0O\
MMX_]'R5Z!7G_ ,$O^20Z%_V\?^CY* /0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;NW*N\XQU9%/% 'J]%>?_P#"K/\ J??'/_@X_P#L*/\ A5G_ %/OCG_P<?\
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MXR^W>4OVC[/K!\OS,#=LW)G;G.,\XJQ_PJS_ *GWQS_X./\ ["@#T"BO/_\
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M >@45Y?=_"S6/[8T[[%X]\5_V9^]^W^=K#^=]W]WY6$V_>SNW=NE:'_"K/\
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MU/OCG_P<?_85G_\ "K-8_P"$A_Y'WQ7_ &)]D_Z##_:?M&__ '-OE[/QS[4
M>H45Y_\ \*L_ZGWQS_X./_L*/^%6?]3[XY_\''_V% 'H%%>7ZW\+-8_L>?\
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M[_\ U(W_ )-UGZKJOQ?TO[%_H'A6\^U7<=K_ *)#=R>3NS^\DY&V,8Y;MD4
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MS/E@ORKD9QG)]@: /4**\_\ ^+O_ /4C?^3='_%W_P#J1O\ R;H ] HKS_\
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M'V#PK?\ D[?]&L(;N69\L%^5<C.,Y/L#0!ZA17G_ /Q=_P#ZD;_R;H_XN_\
M]2-_Y-T >@45Y_\ \7?_ .I&_P#)NM#P;JOC"[UC7-/\5V%C#]A\C[-<V$,R
MPW&]69MK2'YMOR@XQ@YH ["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^=M9\0>+?&_P 2?$NDZ;J^I6%GH=O>20VFGSF.21HE$:@%%RY:4(=K
M9P&8 YZ_1-?,U_?:C\,?BUXLU&\AD@75;>^%A?>6QC\Q\31E<H0Y#;$8= 6Y
M.!R >C? [QQ?>+?#5U9:K*]Q?Z6Z(;AAS+$P.S<<Y9P58$X&1M)R237J=>._
ML]^&+[1_#6H:Q?1R0C5GC-O$Z8)B0-B3KG#%S@$#A0>0PKV*@ HHHH ****
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M+/;RN86=RHP^T@N^<ER>C8X^;.;^T9_R4/3?^P7'_P"C9: /IRBBB@ HHHH
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MS!6(]0#CI0![[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<9XC^(L/AJ_N[>X\+^)[J"U0227MIIX>WV[0Q(<L!@ \GL0:
M[.O$OC]K%Y>2:'X*TM]USJ4RR30J2A?+!(5+$A2I?<2#T**>.X!Z=X.\6V?C
M70O[7L+.^MK4RM$GVR((9-N,LN"05R2,YZJ1VK?JAHFCV?A_0[+2+!-EK:1+
M$G !;'5FP "Q.23CDDFK] !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV5C9Z;9QVEA:P6MM'G9#!&$1<G)PHX'))_&K% !1110 4444 %%%% !1110
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M(*[".-I4C<&Y&%QD[EP#D9P[?XS?#^YN8H(_$48>5PBF2VF102<<LR */<D
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MMSY?F><=F[MNQYF,\XW8[T ?1.@?$OP?XHU0:;H^M1SWC(76)H9(BP'7;O4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?E73T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gjnp4w4lrub1000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,'" 8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ IDO^J?_=-/HH BM_\ CWC^E2T44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37)6-F'4 FG4
MV0$Q.!U*D"@!L+EX48]2.:DJ.!2D"*PP0.14E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHKS#W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYC'%K%TXTZLZ?*J=M;G??$;_ )%A?^OA/Y-61\+O]9JGTB_]FK; _P"$M\"
M#!G>/U_Y:+_CC]:X7PMK;>&=9D%U&XBD'ES+CE2#P<>W/YUA1@Y8:=%?$F=>
M)JQACZ6*E\$EO\G_ )GLE%<S=^/-"@M6DANC/)CY8T0@D_B!7!>'H[_7?$L>
M)9-GF>=,0QP%SG_ZU<E/!3E%RG[J7<]&OFE.%2-.E[[EV9['1117&>F%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %(Z[T9?48I:0D*I8\ #)H ;$GE1*F<[1C-/I$
M=70,IRIZ&EH **** "BBB@ HHHH **** "BBB@ HHHH *K:C_P @N[_ZXO\
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MK"/+&6AC5P.'K2YYP396L-/M=,M5MK2)8XE[#O63K?A*PUZ\2YNGF5U0( C
M#&2?ZUOT5$:LXRYT]36>'I3A[.4?=[''#X;Z.",RW)]MX_PK>TOP_IFC9-G;
M*CG@N>6/XFM.BJGB*LU:4F9TL%AZ4N:$$F4M5TV/5M/DLYI)$CDQN*'!(':L
MW1/"6GZ%=M=6S2M(R;,R'.!_D5OT5*JSC%P3T9I+#TI5%4E&\EU"LC7/#MEK
M\<*W9=3$259#@\UKT5,)R@^:+LRZE.%2+A-73,O0]"MM!MY(+625HW;>1(<X
M.,57UCPGI>M.99XBDYZRQG!/U]:W**I5JBGSIZF;PU%T_9.*Y>QQ$7PTTU9
M9+NY=?[O _I75:9I-EI%MY%E"(UZD]23[FKM%54Q%6HK3E<BC@L/0=Z<4F%%
M%%8G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,F_P!1)_NG^5/I" RE3T(P: (;
M/_CTB_W:GI$540*HPHZ"EH **** "BBB@ HHHH **** "BBB@ HHHH *9-$L
M\$D+9VR*5./0C%/HH:NK,'J<I_PK_2O^>MQ_WT/\*!X TD,"7N" >A<<_I75
MT5Q_V?A?Y$<WU.A_(BCINCV.DQE;.!4SU;J3^-0ZUH-KKB0I=-(HB)*[#CKC
M_"M2BMW0IN'LW'W>QJZ4'#DMIV,[1]&M]$M7M[9G9'?>=YR<X _I63<^!M,N
MKF6=Y+@-(Q8X88R?PKIZ*B6%HR@H2BK+8F6'I2BHN.B.6B\!:.CAF,\@'\+/
MQ^E=#9V-MI\ AM85BC'91UJQ13I8:C2=Z<4ATZ%.F[PC8QM8\-6FMSI+=2S#
M8NU51@ *N:7IEOI%BMI;;MBDG+'DDU=HJHT*<:CJ)>\^HU2@I\Z6H5SM_P"#
M--U"^ENY&F620[F", ,UT5%%6C3K*U1705*4*BM-7(H85BMD@R755"Y;J?K7
M/7_@?2KR0R1A[=CU$9X_*NFHI5</2JQY9QNA5*-.HK35SD[7P!I<+[II)I\'
M[K' _2NIAACMXEBB14C48"J, 4^BE1PU*C_#C8*="G2^!6"BBBMS4**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5R[>/-+\N22.WOIDC8AVBAR%QW)SP*EG\;:3%$LL0N;F(J&=X(BRQ@_WCVH
MZ.BLJ]\0V%CHL>K.[/:R;=I0<G/3BJEMXQTVXOH;4QW4/G\12S0E$D/H": -
M\LJD L 3TR>M+7,:RQN?&>AV@)VQ+).XSCM@?K5O4?%5AIUT]MY=S=31C,BV
MT6_9]?2@#<HK)D\16*Z$-8C\R:T[F-<LO.#D'T-/N]<M+6:R@&^::\/[J.(
MDC&=QR>!0!IU%/<V]L 9YXH@> 9'"Y_.GN_EQLY!.T$X R37GMI>V?B3Q?</
M?Z=>30#$$"/"=D1 RV_G@T >B45@7GB[3;*ZDMECN;EH3B4VT6]8_J:T(M8L
MI]';5(I=]JL9D)'!P.HY[T 7Z*YRW\::==0R3Q07A@CB,KRF'"#'\.<]:B_X
M3O2OW+M#>)!*0!.T/[M2>Q;/;VS0!U%%<[)XTTJ.Z2(BY\EWV+=>4?))Z?>K
M3U36+/2+=9KIV_>';&B*69SZ 4 7Z*Q]*\266K7+VJ1W%O<HN[RKF/8Q7U%;
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %-D;9&S?W033J9,"8) !DE3_*@!
M()/.@20C&X9Q4E068*V<0(((7D&IZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ@$8<Y9LDEOJ3S5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC/<GUH [:BO.)];NK.T34U\31W-TI5I+( !".ZCW]Z]%C<21*XZ, >1B@!V
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M8 +'/O0!U]% X&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDJEX74=64@4^@D 9
M)P!0!%;1M%;1QMC<JX.*EI 0P!4@@]"*6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH *YWQO.T/A:Y1#AYV6)><<D_\ UJZ*L_5]'M=;M%MKO?Y:N'&QL'(Z?SH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG65U]I:VS/<-*JVS$HN<<#/O6_0 4444 %%%% !1110 4444 %%%% !1110
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M44 <0;W66T1-"M]#FBN/*$#3%QY:KC!8'OQVJU<Z/+%>>&]/B1VM[0EY9 .
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)=IJ$?DQG:Q.00?IUJWIFKV&L0M+87"S(IPV 00?H:YS2M.M+GQYK%WY";8
MBJ,<!R/F.*KQ2&VU#Q=>VBK&$144+_> .3^M '0W?BK1+&[-K<7\:S X( )P
M?<BK=]=P+I$UU]J$<)B)$Z<[01PPK&T73],M?!ZR31QM'-!YMP[8)8D9.36
MSS#X9PV[D@W4PBBSUV%^/KQ0!V%M>V^EZ#;SWVH^9'L'^D2C!?/MUJ33M>TS
M5DD:RNTE\L9< $$#Z&N4UA+Z;Q;8V=E;VLPM+4.D-P2$R>,X'>K^FZ;J\GB<
M:A?6UC;J+<QR+;L27YXR#_.@!;/QK9W?B9K%+A#:LH$3!&RS]Q716>HVFH6I
MN;:4/""06P1@CKUK \+1)/J>MW^T?/=&-#C/"],5ABXDM4U7P];\75W?%(\'
MD1L 2V/3% '>6&H6VIVPN+23S(B2 VTC./K5FJ]A9Q:?8PVD*XCB0**L4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '+WFHZMJNMSZ9HTT=K%:8\^Y=
M _S'^$"L_2Y+I?&.I7.J312-IUF$:6/@$'YLX[' Y'K4EM>7/AS7-5CGTR[N
M([RX,\,EO'N!SV/I1HNGWVI:?XBDNH&MKF^E=%5QP %P/PYZTP(/[=UG4;.3
M4[;5=/M(QEHK)]I9U'9B3P3BM"Y\3W-QI>EKIL2-J.I+\@8_+'C[Q/TYK"LK
M>RALX[&;PC/+J<:["?*_=N1_%OZ<]:V-6MY=&U32-3MM.>2UMX6AE@MUW&,'
MI@=Z &7=UXDTN_TRSGU&WN1>7 !D$(1E4?>&.1T[U8U._P!:N?%?]E:5<10Q
MI;!Y7D0-M)/7'KC'%4H=0EUWQWI[-:36\%K;O*BS+ASGC)';_P"M6IH4$TGB
M;7;^6*1%:588RZXW!!C(]1[T 0WK^((Y8[4ZK96<4:#=>2JNZ9N^%)P!4N@Z
M_--IVHMJ,D4C:>[*\\1^60 9R.U<^MLL>LZ@NMZ)>:A>33DV[JFZ+9_",DX6
MKVAZ3<2^"-3MEMFM[BZDE*PL-H4] !GMQ0!-;WGB6^LGUM;FVM;0*98[1XPV
M] ,\MU&15+2-4?0? ]K. C7M_.WE^8^%W,Q^8D]@,43ZY?OX3DTR+1;Y;M+?
MR9"T1V 8VD@]_P *LZWH<PT+0V6S-VFG@":V/WG7: ?Q&* %CUG5-.U*R^UZ
MM8ZA;W4HB=(0H,)/3&#DBI9K[7M3\3ZAI^F7<-M:VRH&D>,.58C/ _/K4>D6
M^F7FJ0M9>&)+>.,[GN+B/RRC#I@=ZO\ A.";=JM[/%)$UU>.RJZ[3M' XH Z
M"(-';H)I [*OSN1C)[GVKE+2^U_Q"\M[IUU#8V".5A#Q!S-CJ3Z"NJN(S-;2
MQ X+H5!^HKB=*U?4-'T)M(.C7C7]NKJC+'F,\DYW?TI 1:3J%Q9^&/$&N,4%
MU-<N4*MD \ 8SZ$FM(7.OV&@W.K:E?P';:Y2!(@-KG&"6[GVZ<UG-IUTO@72
M-,%O-YES<H9ALY12Q8Y].HZUT7BVRN;WPQ<V]HF^3"DQ_P!]002/TI@,N]3N
M[#P0=1EE!O!;*Q=DQ\[8'3ZFJMYJ^J;--TFR*'5+F 2332*,1+W;;ZY[5E:Q
MJUSKNG6FFV^CW\44D\23O-$0%&>F.X]_:M+56N-%\5Q:J+*>ZM9+7R&^SIN9
M"#GI0 T7?B"R\1:9I5U?07$<^Z1Y5B",R@?=Q_45U]<7I-W-K/CZ>ZEMI+=+
M6T")'(/F 8Y!;T)Y-=I2 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J.X4O;2JHR2A 'X5)10!7L8VBL84<895 (JQ110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!GZ;I$&F2WDL3N[W<QF<OC@GL/:C2M(AT
MK[5Y4CR-<3&9R^,Y/;@=*T** ,VPT2VL+6YMP6F2YD9Y?,QSNZCZ5DKX&L 1
M&]W>R6:G*VC2_NQ^'6NHHH SKW1K>]DL6=G1+.3S$C3 !.,#/T]J@U?P[;:M
M/%<F:>VNHAA9[=MKX]*V** ,S2=$M])$C))-//+_ *R:9]S-5&WL=-\(1W-W
M)>SQVLK<12'<B,<GY0!WKH:;)&DJ[9$5UZX89H Y;PS9+>:M?^(GMS%]I;;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO_H9H V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K&O_\ D:='_P"N-Q_[3K9K&O\ _D:='_ZXW'_M
M.@#9HHHH **** "BBB@ HHHH **B>Y@C^_-&OU857?5K)/\ EN"?1036-3$T
M:?QS2]6BE"3V1=HK,;7;4'A)F]PH_P :3^WK;_GE/_WR/\:Y'FV!3M[5?>7[
M"I_*:E%4(]8LI#@R%"?[XQ5Y75UW(P93T(.:ZZ.(HUE>E)/T9$H2CNA:***V
M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *AN_^/*?_KFW\JFHH IZ5D:7; _W
M!5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH QM(_Y#>O?]?4?_HF.MFL;2/^0WKW_7U'_P"B8ZV: "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAR[H">*LU6TZ)X-/@BD&'5 "*LT %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17RM7"QG"5"HK1:LUV7_ -SE9I_R,^TI5G=58.[W]?\ ]I:/^\CT7%)MK/\
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MK:L0ETHC8]''W?\ ZU:P((R#D&OI,+C:&+AST971R3IR@[20M%%%=1 4444
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M,Y$443=@2#UX'/:L'XC^#;+PFNGFSN;F;[07W>>P.,;>F![T >M^-)#+\/\
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M0I+&<HXR#4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+[_CPN?\
MKDW\C4](ZJZ,C#*L,$>HH I:-_R![7_KF*O4R*)(8UCC4*BC  [4^@ HHHH
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MPUW3TO=/G$L+<>ZGT([&@"_1110 4444 %%%% !1110 4444 %%%% !1110
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M::93C3:^<F]3E04$X&313&^9@G8<FH0Q #(=S?=[#UJ2BBFV 4444@"BBB@
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MEI %%%+BFD E+BEQ2XJU$5QN*,4_%&*?(*Y'BBGXI,4G$=QM%+25#0PHHHI
M.21X94EC/SH<CW]JZJVN$NK=)D/##IZ&N3JUI]Z;&?)R87^^!V]Z^BX?S582
MK[*J_<E^#[_YG)BJ'M%S+='444U)$E0.C!E/0@TZOT1--71Y04444P"BBB@
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M5+B.XE%%%0,**** +^D7@MK@PN<1RG@^C5T=<81D5NZ5J7FJMO.W[T#Y6/\
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MEBOX #^E>=F/\+YGDYM_N_S1W5%%%>&?+A1110 4444 %%%% !1110 4444
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M-M-(J7(Q3&K:<4D2F,21X)5EB.'4_G[5U=M.MS;I,O1AGZ5R9K?T/_D'_P#
MVQ^=?1\+8F:KRH?9:O\ ,Y,;!<JEU-*BBBON3S0HHHH **** "BBB@ HHHH
M**** "BBB@ JOJ'_ "#;K_KB_P#(U8IDL:S0O$_W74J?H: *6A_\@2S_ .N0
MK0J*VMTM+:."+.R,;5R:EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8S8_;Q3&%.W4TFMIN-M"%<C-1FI":C-<%0U0PTPT\TPUQ3-$)1116)04444
M%%%% "@4\"FBI%KHIQ3);$*TPBI2149IU(I"3+ND79M[@6[']U(>/]DUT5<>
MF?.CQG.]<8^M=>.E?<<,8F=7#2ISUY7IZ'G8R"C--=1:***^F.,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI8EHEW4%JCW4;JU]MH3RCB:8329I,UC.I<I(#3#2DTVN:4BT%%%%9C"BBB@
MHHHH *<#3:*I2L _=2$TVBJ<V*P'<<!1EB< >IKJ[.W^S6D<7=1S]>]9&BV?
MF2?:W'RKQ&#W/<UO5]WPUE[HTGB)[RV]/^">9C*O-+D70****^H.,**** "B
MBB@ HHHH **** "BBB@ HHHH *9-*L,$DK9VHI8X] *?5;4/^0;=?]<7_D:
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M'U+"J$OB>K]3Q\15]I._0****]4P"BBB@ HHHH **** "BBB@ HHHH ****
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MM^77\JY\34C"FW+4YL16C2IN<CT+3[:6"RBFO[:-)YXU:<QCD-CU]JW+566
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M\MN(QCH*+(0[>S?<'XFE4,N?G;D8.#@&G4549-.\= MW$V@=J6EQ1BE9L!N
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MJQ_E6Y7/ZW<":X6W'*Q\M]:\7B"=.. FJG6UO4Z,*FZJL9(!DY;A>PJ0  8
MHHK\S;/8"FNVT<<D]!3J8OS.6[#@4(!47:.>2>IIU%. II7$&*7%*!3@*VC
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M_M"R25(MY3$H .1]#6,='30OA7=:>J@-'ITADQW<H2Q_/-9_P>_Y$G_MY?\
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M;0KO9P,-DG&,$^E.F\7Z?!XNA\--'.;R5=RL%&S[I;KG/0>E>>_!$ 7FN@=
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M9Z9%LMX@&/WG/+-]35VBOLZ=",;2EK)*U^I]'"E&-F]6E:X4445N:A2$ C!
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MV6FPB&RMHH$'9%Q7%5S**TIH\ROF]..E-7/)M(^%VJWH$FH2I9QG^'[S_P"
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M ''X UV]II]M8V?V2VC$<//R@^IR?YU3N;?^R=%:'3-/6=5/_'N6QN!/S=:
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M%)*>K8^]]?6@"OX5L8[33I98[\7HN93*957:"3UP*W:9%%'!$L<2*B*,*JC
M%/H **** "BBB@ HHHH **** "BBB@ HHHH **** $9@B,QZ 9KCBQD=I&^\
M[%C75WO_ !XW'_7-OY5R8Z"OB^+:CO2I]-7^1Z&!6[%HHHKXP] :YVH32H-J
M@4U^2H]33Z?0!13A313Q6L$2QP%/ IHJ05V4XF;8H6G;:<M/QQ7="DFC-R("
MM,(J=A41K&I!(I,B(IAJ0TPUP31JAAI*4TE<TBD:6D7WD2"VE;]VY^0G^$^E
M=!7&$9%=%I-]]I@\J0_OH^#[CUK[?AO-?:+ZI5>JV].QYV+H6]^)HT445]<<
M(4444 %%%% !1110 4444 %%%% !1110!Y=\;?\ D":9_P!?#?\ H->CVD$/
MV.']TGW%_A'I7/\ CCP>WC"QM;9;T6OD2%]QCWYR,>HKIX4\J%(\YVJ!F@!5
M1$^ZJK]!BL'QQ93:AX*U6V@7=*T.Y5'?:0V/TKH*",C!H X+X2:I#>>#8[)2
M!/92,CKWP26!_7]*V/'NJ0Z5X+U*21E#30M!&I_B+C;Q^!)_"L+5_AHPU1]4
M\-ZG)I=RYW-&N=A/MCI5>W^&=]J5]'=>*=<EU!8R"L*YP<>I/;Z4 7_A1936
MG@1'F7;]HD>5 ?[IX!_'&:YCX)_\A#7/]V+^;UZ]'#'#;K!"BQQHNU548 %<
MAX'\"OX/N+^5K];K[4$  BV;<$^YSUH S_B]I!N_#,6IQ ^?82AMPZA&X/Z[
M:Y33]0;X@^/M"+(3!86R239'\2\G_P >P*];\0FU7PYJ1O<?9OLS^9GTP?UK
M@?@QH_D:3>ZLZX:YD\N,G^XO_P!<G\J .Z\5#_BD=8 '_+E+_P"@&N3^#<T;
M^#I(E<&2.Y?>O<9 Q7H+HLD;1NH9&!#*1P0:\S?X9:KI.H37'AC7GLH9B=T3
M9X'89!YH G^,\\2^$;:!G42O=JRIGD@*V3^H_.M[_FEK_P#8';_T2:YF]^%%
MUJUHTFIZ_+<:DSJ?.="RHN#E0,^N.?:NZ_L<_P#"*'1?.&39&U\W;ZIMW8_I
M0!Q7P8NX'\,7-JLB^?'<L[)GD @8/Z5N?$K48[#P-?AI-DEPHAC /+$D9_3-
M<]9_"6;2[/S=/UV:#5%8E9XU*JR\84C/MZTJ?#+5=6OX9_$^O/>PPGB)<_-[
M9)XH L^"[*6R^$-R905:>VN)0I&, JV/S'/XU1^"7_((U3_KX'_H->CW6GI-
MHT^G0XB22W:!,#A 5P./:L#P/X.;P?9W4#7HNO/D#Y$>S'&/4T <7X*N!H?Q
M5UO3+PJC7;OY9/<[MR_F":]:NI8X+2:65U2-$)9F. !BN3\8^ ;?Q//%?6]R
MUEJ40 6=1G<!TR/;UK$3X?\ B.]A^S:[XGFGT]!EH8R<OCL2?PH RO@E_P ?
MNN_2+^;U-J\T=O\ 'K3I)G"(4503TR8V _4@5!\$1MO-< [+"/U>NS\9^!+?
MQ6T%U'<M::A;\).HSD9S@CZ]* .N9E12S$*H&22> *\F^$\J3>*O$LL;!D=P
MRL.X+M6A'X \37ZK:ZUXIFEL 1OBC)RX],D_XUL^#/ @\(ZAJ%PEX)H[K 2/
MR]NP D]<G/6@#C/%W_):M(_WX/YUW/Q*R?A[JV/[B?\ HQ:K:QX$?5?&]GXB
M&H+&MN8SY'E9+;??/]*ZK4K"'5-,N;"X!,,\91L'UH Y#X2_\B%;?]=9/_0C
M7*_%7_D?- _W8_\ T::WO#?@+7O#>JQ+;Z_G25E,CP;2-XQTQG%:7BSP*_B;
M7]/U-;];<6@4&,Q;MV&W=<C% #?BG_R3Z\_WH_\ T(5I> ?^1%T?_KW6K'BO
M0#XE\.S:4MP+<R%3YA3=C!STR*L^']*.B:#9Z:91,;>,)Y@7&['M0!YW\8/^
M0IX:_P"NS_\ H25ZJGW%^E<GXR\&-XKNM,F6]%M]B<L08]V_)4^HQ]VNL PH
M'H* !E5AA@"/0BF>1#_SRC_[Y%244 1^1#_SRC_[Y%'D0_\ /*/_ +Y%244
M1^1#_P \H_\ OD4>1#_SRC_[Y%244 1^1#_SRC_[Y%'D0_\ /*/_ +Y%244
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MO%UVQJ *MT4 4M0TC3M5$8U"QM[H1Y*":,-MSUQGZ"KBJJ($0!548 ':EHH
MQM3\*:%K$WG7VF6\TO=RF&/U-<#\5])T_1_!]G!I]I%;1_:AD1J!GY3R?6O5
MZS-;T#3?$-JEMJ<'G1(^]5W%<'\* (/"/_(G:-_UYQ?^@BG:GX5T/69O.O\
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MW\C4]% %'1E*Z/:@@@B,9!J]110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !3)BX@D,:[I IVCU..*?10!@>'
M-(EM/#!LKM2D\PD,O()!8G^AK+LU\4:58?V1;Z?#*J92*\,@"A>Q*]<UV=%
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M<%B68?C73ZQI)U>&.$WMS;1@G>(&V^8#V-6[.S@L+2.UMD"11C"@4 3T444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 (0&4A@"#U!K$U#2/+5IK13QRT7^'^%;
ME%<>-P-'&4_9U5\^J-*=25-WB<8"",BEK1UBT$$ZSH,)*<,!V;_Z]9U?E^.P
M<\'7E1GT_%'L4ZBJ1YD%%%%<AH%%%% !1111< HHHHN 4444 %%%% !1110
M4444 ;FA3EH)+=C_ *LY7Z'_ ":UJY_0_P#C_?\ ZY_UKH*_3\AK2JX"#ENM
M/N/'Q,5&J[!1117L'.%173M%:32(<,L;,#[@5+45Q&9;6:-<;G0J,^XH BTV
M:2XTZ":4Y=T!8X[U:JM80/:V$,$F-R* <=*LT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %-DD2&-I)&"(HRS,< "G5S?CAV
M7P\%W%8I+B-)2/[A/- #XO&FD2W*1!IUC=MJ3M$1$Q]-U7]5URQT=(S=2,7D
M_P!7%&NYW^@J'45T9=*AL[XQ+:S%8XU&?F/;&.?QK*TZ."3Q[J(GP7MX(EM5
M?J%(YQ0!LZ3X@L-9:1+9I%FC^_%*FUE_"J$WC;287G0+=2M Y1Q%#NQCOUZ?
M6JC3Q2>/);FUP8[2R(N70\$YR!]:/"44=MX2GOY55I)S+-(Q/WASC)^E %R7
MQKHZ6T<\;3SJZ[R(8RQ0?[7I6D=:LO[%.K+(7M F_<!SC_&L#PM!#I_@>2[,
M:!I$DF<D=>N,_A@5ES9MOAC9V[''VR5$Y&,!VW?ATZTP-^/QQH\CPC-PL4I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&:6@#GT\%Z(ESYPMF(SN\HN2F?\ =Z5?U71+'6+>.&[C)6(Y0JQ4K]"*T:*
M&1QB*)8USM48&33Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH YS65"ZB2/XD!-4*GO)Q<WLLHY7.%^@J"OR?-*D:F,J3ALVSVZ*:II,****
MX#4**** "BBB@ HHHH **** "BBB@ HHHH *0G )I:M:=:F[NU!'[N/YF/\
M(5OA<//$UHT8;LF<U"+DS?T^(PV$*$<A1GZU9HHK]=I4U3@H+9*QX3=W<***
M*L04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3JV,W$D8U$QH+4PFHJU+CBAK5&:>33#7!49J@C=X7WQ.48=Q6H->;[.4>/\
MTC&%(Z'WK)8A5)/:FHIY9OO']*ZL'F>*PD6J4M'T(J483?O(?R69V8L[')8]
MZ***\^4G)W>YJE8****0!32#O4CMUIU% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !6-J>IDEK>V;'9W';V%/U;4?*!MH"/,8?.?[H_QK#4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%-*L3PY'X4FU_[Y_(4[ /HIG[P=U-'F8X8%??M18!]%%%(
MHHI"0HR: +%C#]HOXH\9 .]OH/\ Z^*ZNLW2+(V\)ED&)9/T'85I5^F9!@7A
M,(N=>]+5_HCQ\34YYZ;(****]LYPHHHH ***CG)6WD(."$)!_"@"2BH+)F>S
MB9B2Q4$DU/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M62X4Q+EK.-OG_D5]=A;8Y^VM9[QL0K\O=R.!71V5E%91;4&6/+,>I-6  HP
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M0 4444 %1S_\>\O^X?Y5)2,H92IZ$8- $%E_QY1?[HJQ38T6.-44?*!@4Z@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$?B4Z39V;B+RS(MPS]<8X*XXZ^M ';45@>*/%VF^%+-9;QB\TG^J@3[S_P"
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MUNUW<K"O0\N?05%R2%4%F8X '<UTNFV0L[?#<RMRY_I7M9)ECQM>\E[D=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %9'B3P_;^)M'?3;F66*-F#%HL9X^HK7HH \U'P9TE1A=6U,
M=@Z?_$TO_"F]*_Z#&J?]]K_\37I-% &?#HUHFA1Z/,IN+5(1"1+R7 &.?>N'
MG^$=K'<M)I6L7EC&_6-3D#Z'K^=>D44 <=X;^'.E>'[P7[O+>WXY$TYSM/?
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M",BEK<OM&60M+;81SR4_A;_"L21)(7V3(4;T/?Z5^;YAE.(P,O?5X]UM_P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!'/"EQ"T4@RK#FN6NK:2SG,<@.T_<?LP_QKK:CG@CN(C'*@93V->/FV4PQ
M]/M-;/\ 1^1O0KND_(Y&BK]WI,]L2T0,L7_CP_QK/SGCN.H]*_.L7@J^$GR5
MHV_(]:%2,U>+%HHHKE+"BBB@ I<TE%.X"YHS244^8!<TE%%*X!1112 ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &O&DB%'4,IZ@BL.]T9HLR6GS)WC/7\*WJ*XL;E]#&PY*J]'U1I3JRIN\3C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPHHHK004444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4C<*3[4M(1E2/:@!$)* GN*=2*-J@
M>E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%(WW3]* %HIJ?<'TIU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4'D8HHH 0# Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gfvy2su3zcnu000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gfvy2su3zcnu000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+  D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#VP\:Y$/6,
M_P JTJS7_P"0[#_US/\ *M.@#,?_ )#L/_7,_P JTZRV/_$]A_ZYG^5:>: ,
MMO\ D.P_]<S_ "K4K+;_ )#L/_7,_P JU* ,QA_Q/8?^N9_E6G6:_P#R'8?^
MN9_E6G0!E-_R'8?^N9_E6I68P_XGL7M&?Y5IT 9K_P#(>C_ZYG^5:59;?\AZ
M/_KF?Y5I4 9S#_B>Q_\ 7,_RK2VUG-_R'8_^N9_E6G0!E-_R'8?^N9_E6I6:
MZ_\ $\B.>D9_E6E0!F,V=>C'_3,_RK3K*_YC\?\ US/\JU: ,K_F/Q_]<S_*
MM6LK_F/Q_P#7,_RK5H S6_Y#L/\ US/\JTZS'_Y#L/\ US/\JTZ ,Q_^0[#_
M -<S_*M.LJ3_ )#\/_7,_P JU: ,MQ_Q/H3_ -,S_*M2J+*O]JQMCY@AYJ]0
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gjnp4w4lrub1000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /["#0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45%<7-O:1^9<3QPI_>D<*/UK(?QCX?C;;_:<3G&<QJSC\
MU!IJ+>R)E.,?B=C<HK*M/$FBWK*EOJ=LSMT0OM;KCH<&M7J,BAIK<:DI:IA1
M112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAD_\=8#\*\]66NN^'DP.HZO$!U2&0D'_ 'QC]*4(N*:.[ SM62[G?5R/Q/\
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MK!HYB=D8$;O-!(R/]X5DVTB^*/$&N_VYXAN-/CL+AH8;2*?R $!/SG/7./\
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M_.@#RW38=,U/PPNO:YXNO?M,JLTD<=T$V')^0)U_SZ5?T%&D^ DBHI9C:77
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MO7?U6O=/L]1B2*]M8;F-'$BK*@8!AT(SWY-6: "BBB@ HHHH **** "BBB@
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M1XAUS2M99K6*[NVN[6X<$I(K=LCN*]'"@9P ,]<"HY[6WNDV7$,<JYSAU!%
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MXY__ %^E=U?:;8ZG$(K^S@N8P<A9HPXS^-+9:=9:;#Y-C:0VT?\ <A0*/R%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VO_\
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M3LP/./H>2/Q%2^)F5/'/APNFX;B,>Y( /X$@_A5'QA>VEPNB>(;)PR1W.SS
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MK$8;D]Z&QJ4445],<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSR64\>&EB)PPV^ORU4MY_#-_=6UMIO@=I+AW'F":S$2Q+W)8^E>D9QTH&!T
MI7"QYWXGC%C\0H=5U?2[C4=(-ILB\N,RK#)GJ5_SU]J;I+/>_$;3]0M?#]QI
MVF_998TD:WV;SR<MC[OMFO1L@]12YIW%8X/4M:$&I7MAXMT%KRU$FZRG@M/-
M5T]#Z$<53\,^';G4M \2VHMI[#2]0)%A:W.<QG!^;'4#.W\J])X/4 TH-%Q6
M//M(\93Z%HEOI&I:%J7]I6<2VZ)# 62;;\JD-Z'%16GA[4;3X::^UU;LVJ:H
M9;EX8URP+8PN!WZGCUKT?@G.!FEI@<Y=V\[?#6>U$,AN#H[1B(*=Q;R<;<>N
M>,4O@:VGM/ NF6]Q#)%,D)#1NI# [CU!KHJ* /,+3PI?:M\&;/2VMWBU"!WG
MCAF4J2PE<X(/JI/7U%0QWWAMK5(#X"E.KD!?LIL0%WX_O8X'?/I7JU)@9S@9
M]:!$%A"MOI]O"ELELJ1@"!,8CX^Z,=A5BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "L[7_ /D7-4_Z])?_ $ UHUG:_P#\BYJG_7I+_P"@&@"KX/\
M^1.TC_KU3^5;=8G@_P#Y$[2/^O5/Y5MT %%%% !1110 4444 %%%% !1110
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M-RFT\*!Z=#^==AXKN5M?"NI.Q'S0-$,^K_*/YUS$^GZMX-U6XOM)MOM>FW+
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M&A0/F.VQ-<8/60CY1^ .?^!"N2+^LXG75?H.I+V5)L\_EE>YFEGF;?-+R[X
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MCK;SZM=6<BS!6EME&R6 'TY.[&>^.E<EI>M:;J.NQZ9H"/>Z@['%[<H$B@C
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MLUS&%+Q@$!NG6K$3%XD<]64$U3UN*2?1[F*)"[LHPH[\BKD(*P1@C!"@'\J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%8_B339]3TT1V['<CARF<;^O'UJH)2DDW8RK3E3IN<
M8\S73N<#XBU>\O-6,LMN'M5W1"/;R@S_ !>]:GA+^RK*\E2XU")!%,6MHVEP
MA8KM+C('/)7UZT^ZL_/C@BU18]/  5[J278\@'7 !P6/K66--L[[1KB-8W:W
MM97<7*CYY(P1MQGH3R.G]:ZL3BJ5*FH/KII9_P!=_0^=PV&K*L\3+6[ZW3?R
M\ON.]U/7+>TM2T$L4LK [0K@A<#))QV%<'I NK[6$%M-B:3)60$@@8Y)].*S
M;N-H-+571%!7<A;C;M'3ZGZ5T.VXO+RS_L%HHI[BRC^UK'\OV<#!P&'W2<XQ
MUXKYJ$/[0J<\G:,=N_W_ *_=W/1E3GC)*6R3+]UI.FVVHZ;:7%TKDR.]P';
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MH **** "BBB@ HHHH **2B@!:*2B@8M%)10 M%)10 M%)10(6BDI: "BBB@
MHHHH **** "BBB@ HHHH *KWTS6]A<3IC='&S#/3(%6*K:A$\^G7,,8R[Q,J
MCW(H =93-<6%O,^-TD2N<>I&:GJO81/!IUM%(,.D2JP]P!5B@ HHHH ****
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MHK1[-+>0@B.5$"I(PY(&.AP<X^M='7H4JD:L%..S.J$U.*DNH4445904444
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M,S1FBX6'YI<U'FES1<+#Z*9FES0%AU%-S2YIB%HHHH 6BDHH$+1110 4444
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M0L.HD4C\Z93X5+7$*CJ9%'ZUMAK^VA;>Z_,F?PLZ^BBBOV$\$**** "BBB@
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M,K#&0?\ Z_%:J+D[(QO8W]#TZ'Q=JM]K>I(9;99C%:PL?D '?'Y?CFN[ "@
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MF'AZ#'SW=V['OYN/T&!3AX>L /F$['N3.^3^M5R5.Q'M:*ZO[BOYE.\VI/\
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M*ZM_2M9Q5"]@%Q:S0GI(A0_B,5SU%=.QVT6E)-G1452TFZ-YI-K.Q^=HQO\
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M)<^'M9,0AFGMB"F[<5*D-C/0XWU[)I]R+W3;6Z4DB>%) 2,=0#_6O*/%,O\
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M:)F+1*#2TP4X51#%I:2BF(6H;N?[-9S3[=WEH7QGK@9J:JFJ*6TF[502QA<
M =>#0(EM9OM-G#/MV^;&KX],C-355TT%=*LU8$$0("#V^45:H **** "BBB@
M HHHH **** "BBB@ HHHH **** (KFWCN[66VF4-%*A1P>X(P:XOP'<2:?=Z
MCX=NF_>6\I>//&X=#C]#^-=S7)^)_#=W<W\6LZ-((M1A'S#./, Z?CVYZB@#
MK**X:/QQJMLGDWWAZY-PO#&/< ??[I_G3AK_ (POMWV30T@4]&E!!'YD?RH
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M>PD>;3K660Y=XE9CZD@58H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)FWFBS]Q\@>@(_QS6M67HENT5O),X(,I& ?[HZ?UK4K].RA5(X&FJF]O^&_
M\:O;VCL%%%%>D9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4=1@T44 <1>^$=1TO47U#PS<K#OY>V<X7Z#L
M1['I33=>/;@^0MI;6Y7@S?+S[]3_ "KN:* .0T_2/%AU&"XU'5T,*R R11GA
ME';@ 5U]%% !115#4-32S/E(-\Y&0O8>YK'$8BGAZ;J579(J,7)VB7Z0.I.
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MMH_,UK&G+L<\ZT+VNC745**@MKBWNH_,MYXYD_O1N&'Z58%6D9MW'"EHHJB
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MD5<A):",DY)4$G\*KZG:O>Z;-;(P5I  ">G6K$:E(D0]54"@!]%%% !1110
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MW?#>@B8K>7:_(.40CK71##/>I]W];BJ5Z6&C>.K[_P"78U_!FH>(+"VDCBD
MM''R"8%MASU4?G[5T$JR7D@DO9I+EP<C>?E'T7H*8N%  & .@%2 UO&E&]TC
MP:^,G4W9(B(@PJJ /04_"GJ ?PJ(&G;JZ(Q."=0:+:-'\R M;RCI)"Q1A^(K
M:T_Q9J&G,J7X-[:CK*HQ*@]QT;]#]:Q]U(6IRI1FK21,,34I.\&>H65];:C:
M)<VDRRPN.&4_H?0^U6*\IL-2N=!O&O;)"Z.?](M\X$H]1Z,.QKT^RO(-0LHK
MNUD$D,J[D8=Q7GUJ+I/R/=PF+CB(]FBQ1116!UA1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M844458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%&!45W<QV=K)<2YV(,G YJ56#HK#HPR* %HHHH **** "BBB@ HHHH ****
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M3")4#E;G,J,.W^T"<]C2A7C.I*FMX_J*-12DX=4;U!JK87;W-E;2W$7V>>5
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M@00"#P0:SAK^C?\ 07L/_ E/\:BN_$FDPV<TD6JV#2(A95^T(<D#CO5F9KJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"&ZM8KN$QRCCL1U!]17+SP/:W#02?>'(/]X>M==6=J]G]
MIM?,4?O8LLON.XKP,]RJ.+HNI!>_'\5V_P CJPU9PE9[,YZG@U&"" 1T-+7Y
MS&5F>J3AJ7?4 -+NKIC7=B>4>33":0FDK&<[C2&J"-V>YS3J*0D*,DX%9;E"
MDX&34>3)]TD+Z^M S(<L,)V'K4E/8! H48 Q2T44@"BBB@ I@QYK8]!FGT@
M&<#KUH 6BBB@ HHHH 4&EW4VBK4V*PXFFT45+DV,U-!7-U.V?NHH_,G_  K>
MK(T!/W,\G]Z3;T]!_P#7K7K].R&GR9?33ZW?WMGC8EWJL****]@P"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH S/$'_ " KK_='\Q5^W_X]HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!" 001D'K5:STVSL-WV6W2,MU('-6J*=W:Q+A%M2:U1R$MVFE^+[CSU
M9HITQ@+DG<!C ^HQ5'0X;G1?$LFESQ-]FN"T:.XXD4 D8/3..WO73ZSHZ7MM
M++;11+J"E7BF(P=RD$ GKCC%5C#J>L75HUY9I96]K,)\&4.[L,XQC@#FO.I8
M)QFY2?VFU\]T<L,,U)MOK=?,J>'M(U#3]5G\Q=EM&616)SYB]L?I75445U4*
M$:$>2.QT4J:IQY4%%%%;&@4444 %87BKPQ;^*--6UFD,4D;[XY0,E?4?0BMV
MBFFT[HJ,G%W1S$_@#P])IL-C#9"V2%MZ20G#Y/4D]\X[YKG/%\,<NA0^'O#W
MDM:PDRWLBN,1JO=FZ=<D\Y^6NP\374\6E_9;,K]KO'%O'GMNSD_D#67HOAS0
M]1T:$M:2?*3'-$\K8+J?FR,X/-:PK2BT[[:BJ3G4I^SDW8X_1]+U#QO%96,L
M367A[3P-H52IGZ@,">I/.3VS[UZO9V=O86L=K:PI%#&NU448 %3*JHH50 HZ
M "EHK5G4=MEV,J=-0\V%%%%8F@4'@9HHH Y.+^TIM+CU\ZC,))"LJVR\Q"-B
M,*5[D ]>M/O9XM>TF0,JK=1 GRP<[D[X]>.?P%4M4_M'P_?166D7(^SSY:*T
MP'93GYMHV\+^/K3)='UV5EO?+6.?&2L9 .>>>,<GVKR<P=9_#%N+5FK?BGW7
MW'FXFK)S<(IONK?C?N-FCU*Y\-?:/[2^TPP<O$T2[DV]26SZ?H:U-$B;6?"I
MMII-I23;&RCE"I#*3Z\X/TQ7*17NJ:5<,C9B5Y )!*N48?[8].3^=:6A:I::
M)>PV<.J17,5Q-MFB"%5B8]"A/\(P <FJP+C6E[>3]]*S7IU'A)JK/VDKJ25G
M_F49Y-1FU-9]W^GQS%W;>,*%)!4C^$<'J>F/6N^T?4DUC2+>_1=HE!X]""0?
MU!K"\2^%H=6N8[RV9-Y/[Z,2;!,.QR,\CZ56O+/4=,T5&$JV$%NR1PV]K(VU
M-SC+R-_%U/MS7N5:L)Q5MR<%AJM&K-M^Z_Q??\[Z_D=D:B:I>",@Y!Z$4QJY
MSUD57%8/B"YDM;6$I,(!),L;RD9V*0<G]*Z!Q6=J-E#?VDEM<+NC<8-2S>#/
M//$%GJ.L:)+.S%[6V'GPR2H [XZ].V,UK?"*XB-O>P1C:V%9_<Y/(_ BNBEL
MH#9?8WC#P!!&4;D%<8P:P_"FDQ>'/&;00,?L][ PC5N2I')&?PJ7-*'*^_\
MP#=PO&7I^6OZ'H]%%%:'G!1110 4444 %%%% !1110!RWB[PM_;,8N[0 7L:
MXQT$@]/KZ5YC<6UQ9S&*YADBD'\+J0:]WKC_ (AV GT:*\ ^>VD )Q_"W'\]
MM<&+PT))U%N>=C<)&2=5;GFB*TCJB*6=C@*HR3^%=WX1\(3)<QZCJ49C\L[H
MH6ZD^I],>E:W@*UA3PVDX1?,ED<LQ'/!P/Y5U53AL'"RJ/4G"X*"2J2UZA11
M17HGIA1110 4444 %%%% !6-XG59=*2W?!CFN(T=2/O#=G'Z5LUAZ\^Z\TVW
M_P"FCS'CLJE?_9Q659^XS?"J]5>6OW:F4GAO1CUTRU_[]BK*>%]#/72K0_\
M;(5=C%6DK.)O4,Y?"F@'KI%G_P!^A4@\)>'_ /H#V7_?D5JK4HK9'-(QQX1\
M/?\ 0&LO^_(J"^\(:$;"X\C1K/S?+;9MB&<XXKH12U9F<]9>$-"^P6_G:-9^
M;Y2[]T0SNP,U/_PB'AW_ * UE_WY%;=% C$_X1#P[_T!K+_OR*/^$0\._P#0
M&LO^_(K;HH Q/^$0\._] :R_[\BC_A$/#O\ T!K+_OR*VZ* ,3_A$/#O_0&L
MO^_(H_X1#P[_ - :R_[\BMNB@#$_X1#P[_T!K+_OR*/^$0\._P#0&LO^_(K;
MHH Q/^$0\._] :R_[\BC_A$/#O\ T!K+_OR*VZ* ,3_A$/#O_0&LO^_(H_X1
M#P[_ - :R_[\BMNB@#$_X1#P[_T!K+_OR*/^$0\._P#0&LO^_(K;HH \(^)&
MGVFF^*1!96T=O#]G1MD:X&23S57PYX(U;Q%MEBC^SVA_Y;R@@'_='>O9+SPE
MI6H:^-7O83<3+&J)&_*#&><=SSWK<5510J@!1P !TH YWPYX+TGPV!);QF6Z
MQ@W$O+?AZ?A71T44 %%%% !61KT&88K@#E&VGZ'_ .OBM>JVHQ>=IUPF,G82
M/J.1^HKBS'#K$82I3?5/[^GXFE*7+-,Y:BD!R ?6EK\E/<"BBB@ IK.%XZGT
M%(S'.U?O']*54"^Y/4GJ:?J G[QO1?U-*J!3GJ3W-.HHN 4444@"BBB@ HHH
MH **** "BBB@ HHHH **** "K6FQ^;J< QPI+G\!_B156M;08LRSS$= $'\S
M_2O4R6A[?'4X]G?[M3'$2Y:;9N4445^IGBA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**^</H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MII:H]U5[J1F7R(S\\G&1_".YIV%>XZT;?YLQ_P"6C\?0<"K.ZH$ 1%11A5&
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MHI,T +56YL;:[YEC&[LPX/YU8S32:RJ4X58\E1)KS*BVG=&4VA1Y&RXE [Y
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M@"G"K1DV%%%%,0M5-4!;2;P $DPO@#Z&K=% BKI@*Z59@@@B! 0?]T5:HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ***QO$WB&W\-:5]MG7>6D5$C!Y8D\_D,F@#9HJ*U
MN8;VUBN;>020RH'1AW!J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:VVR+=.K)\[5K+1'GF@2:\FHR:[!I1O9)]V)'Z9)Y(Y]L5=\(7,T'Q N8[J
M6\]TL@:+GY2</_(5Z18V<6GV,%I""(X4"+GKQ65-X6M9O$J:YY\R3H0=BXVG
M QZ9Z5*P\H\K3OK_ ,.2L+.'*T[V=W^IR<!$7Q?<R'8&=L;N,YBX_.NSUWQ#
M9>'[>.6[WL9&VJD>"Q]3SV_QJMX@\)V>O2).SO!=H,+-'UQ[^M9]EX LH[I;
MC4+J>_=3\JR'"_CZU:C4A=16[W*C"M3YHP6[O<ZBSN1>64-RJ.BRH'"OU (R
M,U/2    # '04M=*.Q;!1110,**** "BBB@ HHHH **** "BBB@ HHHH *2B
MB@84F:"::32 4FFDTA-,+4FRTAQ:F%J:6J)GJ&RU$YV_=H?B'I3JQQ/:2QLO
M;"_,#]<UTA>N5UA_+\:Z#,P.UDFC!'J5KH3)4N1HH$Y>FEZKF2HI+F.,9DD5
M!ZL<5#F:*FV7/,I-]9;:M9+G_2HS@XPIR?TI?[2@_P"FO_?E_P#"I]K'N:>P
MGV-/S*<)*R?[5M </.$/I("I_6IHKR";_5S1O_NL#351/J)T9+=&B'IP>J8D
MIXDJE(S<"X'IX:J8DJ17JU(S<"T&IX-5@]2!JI,S<2;-.!J(-3P:I,AH?12
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M<^N%%6Z^RC=I7/06P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\]:RM>ANM>TNPU2SM96:,F*1>K.,#YA[ @C\:^=Q5YXBHE\2Y6OE?_,Y:O\
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M0,U8JO8Q-!I]M"_WXXE5L>H %6* "BBB@ HHHH **** "BBB@ HHHH ****
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M\M?TY_6KD&B:9;X,=E#N'1F7<WIU/-7Z*T5*"Z&$L15EHY?H,6*-%"K&H Z
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MHX(PD4:H@Z*HP!7!BN)*:5J$;ONQ&)H7AJVT9!(V);LCF0CI[ 5IR_NYEE'
M/RO_ $-6":AF7S(F3U%?)U\14KU'4JN[8A3138VWQ*_J :=7,2%.B@-W<0VJ
M_>GD$?'N>?TS3:Z3P=IWGW;ZC(O[N+*0Y[MW(^G3\ZWPM%U:JB5"/-*QV@
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M4+ZDJ>* (O#\C3>&]+ED.7>SB9CZDH*T:Y[P+*LW@G2F0Y BV_B&(/ZBNAH
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M[URZL)O[8CD"H5$+RKM=O7/J.G-4!&EW\6)1.@<6]N#&"/NG:IS_ ./&NYH
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M)_W];_&N@W4;JZH8[$05HU&OFP,JV\+Z+:D%+")F&,%_FZ?6M956-0J*%4=
M!BDW4FZLJE>I4UG)OU8#\TTFFYI":R; AC.VYF7UP_Y\?TJ4FH,_Z8W_ %S'
M\S4A-2V("::3033":S;$!-,H-(S!49CT S4"&6_^H6I*@BE1(47.YL<A>:?L
MED^]^[7T'4_X4[,!DKNY,4/WOXF[+_\ 7KTSP_=6MUHT!M(_*2,;&CSRA'4?
M_7KSE45%VJ, 5L^%[\V.M+$QQ#=_NVS_ '_X3_3\:[\NKJG5Y7LS2E*TK'H-
M%%%?1G6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M T 5?!__ ")VD?\ 7JG\JVZQ/!__ ")VD?\ 7JG\JVZ "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8=EXQ\/ZC>6MI9ZE'-<7:EH8U5LL!G.>./NGKBFZEXT\.:1>&SOM5ABN <%
M&8J?? ..O>@#>HK-N=?TJTT;^UYKV,:>0")URR\G Z9/6N5\!>.X_$#W-G?7
MD;:@;F3[/&L17=" "#G&/[W7F@#O**PM4\9>'M%NQ:W^J0Q3]T +E?KM!Q^-
M/URXL[OPI=7']J-:V<D0;[;;G)1<CD8H VJ*QCJ^F:#H^FF^U%C%,L<,5Q*&
M+2L5X)P.IZ\U#;^-O#5UJ(L(=8MWN2<!>0"?0-C!/XT ;]%4M4U?3]$LS=ZE
M=1VT(.-S]SZ #DGZ55T?Q/HNOEUTO48KAT^\@RK8]<$ X]Z ->BBB@ HHHH
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MMW=S%V7/C74(]-MYG31K!51Y ,>80,9'N<<>@YKT>*)((4AB4+'&H55'0 <
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M4/WHTQG/_ OZ5YWX>\.F[=;N\0K;@Y5"/O\ _P!:O2/#=[_9?B:T92%@NO\
M1I0!QS]P_@W'_ JY,7>5)QB<_P!<IPKQIKYGJE%%%>">N%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5C>+?^10U?\ Z])/_036S6-XM_Y%#5_^O23_ -!- $WA
MS_D6-)_Z\H?_ $ 5IUF>'/\ D6-)_P"O*'_T 5IT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ3H,]\L6J:5(8=8LP6@<?
M\M!W1O4'WJUX<\10:]9D[3#>P_)<VS<-&W?CTK:KC_%FDRV5POB?2G2*^M%S
M.C'"W"?W3[^G_P"JAM)78F[:LZYI$5U1G4,^=JD\G'I2E5+!BH)'0XZ5QOA2
M[7Q5?2:[/( T)\N&T#9,'')/N>:[.LJ<Y33<E;70BG)R3;5@HHHK4T"BBB@
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MKC$SE,55J512**D K1(PDQ13A2 4ZK,V%%%+3$%%%% @HHHH **** "BBB@
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MM4.I-[:&D:%*.^OX?U]Y5E;4+\G[5<>5"?\ EA!Q^;=3^E2P6L<"!(HU11V
MJR(ZD5*E0UNRW4TLM$1JE3*E/5*D"UJHF$IB*M2!:4+3P*M(R<@ IP% %.JT
M9MA1113$%+110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>"
M.Y@:&9=T;<$>M/50JA0, # JO?W8L;*6Y*%Q&,[0<9YJ=&WQJ^,;@#0 ZBBB
M@ HHHH **** "BBB@ HHHH *YGQMH4FL:0LUJFZ]M"9(AW<?Q+^/\P*Z:BJA
M-PDI+H9U:4:L'"6S/!$D#J&'_P"JG[J[OQ?X-=Y)-4TB'=*QS/;+QO/]Y?\
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MI6K117!*3D[L]J$(PCRQ5D%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L;Q;_R*&K_ /7I)_Z":V:QO%O_ "*&K_\ 7I)_Z": )O#G_(L:
M3_UY0_\ H K3K,\.?\BQI/\ UY0_^@"M.@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6-XM_Y%#5_^O23_ -!-;-8WBW_D4-7_ .O23_T$T 3>
M'/\ D6-)_P"O*'_T 5IUF>'/^18TG_KRA_\ 0!6G0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 54U16;2KM5!+&%P !R>#5NB@"KIJE=*LU8$,($!!'(^45:HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!Y^E?2\)UG:I1?D_\_T./'1VD34445]B< 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MINDZS=:AJ/A_6;[0KQ9W6[@9PJF3NS(3^N<=:['3?#&BZ1)%+8Z?##+$A19
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M<$_6F!QMAX(T9OA1+K+PNVH&TDN1-O(*D9P .F./U-8FG_\ )$-6_P"PJO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5KZPMM1B2*ZCWHD@D49_B'2K-9]CJ?VW4=0M1'A;1U029^\2,G\JSF
MX:0EU_X<B;CI&74T****T+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;&REN64L(QD@'KS4R-OC5P,;@#6?X@_Y 5U_NC^8J]!_Q[Q?[@_E0!)1110
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M4445ZQ@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXA2O-\/O!TDC%W:#+,3R3L2M#4O#'C[Q-H,&FZC'9006A5HTR 9"!M!)7.,
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ME&DHKJ*4&.E15:Q5>5=K^QKYM4[Z'@6&YI<D$,K,CJ<JRG!4^HIN:*7LVG=
MKIW1Z]X4UMM<T999L?:8F\J;'0D=#^(P:W*\[^&TC"_U*,'Y&CC8CW!85Z)7
MV&#JNK0C.6Y]3AJCJ4HR84445TFX4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R::.")I97"(O5CVIP(900<@C(K-\0?\
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M#I&78Q_]\YQ70*H50J@!0, #M2Q&(52-D>WF.90Q,%""?S%HHHKD/&"BBB@
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M_((LO^N"?^@BK=-C18HUC10J* J@=@*=0 4444 %%%% !1110 4444 %%%%
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M:;I5G*)S;I()'F<=,GICD_K0 :]_R6+PM_U[S_\ H#T?$/\ Y&'P9_V%4_\
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M7L7Q,O=>;R_L4U@+=<-\V[*'IZ?*:-2T"]NOB-HVN1^7]CM+>2.7+?-EE<#
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M_P#7I)_Z": )O#G_ "+&D_\ 7E#_ .@"M.LSPY_R+&D_]>4/_H K3H ****
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MQW4+,?0!QFO<ZY\ K<S>[9SY>^:,I=V%%%%>@>@%%%% !1110 4444 %%%%
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M%4HM)L8=5FU2.W1;V=!'),.K*,8'Z"KM5K^_M=+L9;V]E$5M"-SN03@=.W-
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M)J.3PGHLFOIKALP-04[O-5V7)QC) .#QZBMJB@ HHHH **** "BBB@ HHHH
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M0+V/XF7.O-Y?V*2P%NOS?-NRIZ>G!H Q_$T,.F?$SPG=VD21RW3303%1@.N
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M5M*WL]OOF$<D6>2#G@C.?_K5L1:/J^M>&-2LO$T\ >]R42 ?+;K@8&>^",T
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MD9)[!B!73UB>$-+N=%\*:?IUWL^T0(5?8<C[Q/7\:VZ "BBB@ HHHH ****
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M4_"L:W]M%I&(7%U:I&"LQ$@7J>5Z9K,T&3P6^@K/K,4][KSNWGP/YC2O)D\
M"M'2(GNO@+=0PKND6.8E!U&)2Q_3F@#9TL:MHOPLFOWU1IW_ +,2:U'E!?LX
M\L$+_M8XY/I5K5/$]_8^$]!^R*L^L:M'#'"7^Z'9 6<CVS^M4HM5L=3^#MS%
M9W"RR6ND+#.H!RCB+!!_(U5URUF@\-^"_$$=O).FD)#)/&GWA&R)N;'MM% %
MK4W\8^%+'^VKC5X=5MH2&N[4P"/"DX.PCTS3O%?B'6!KWAFWT&YC1-31VQ*H
M*MD @GOP#GBH/%OC/2]>\-RZ1H<K7VHZB!%%"D;97)&2V<8P,U%JM@=,\7^
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MMNK!FC3.<DCN3C\J]7$3I>STMY'KYE4PT\,U&WE:QY#'(]O^[<%)8V*N#U#
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M<TS0X%GU.]BMHV.%WGEOH!R:9I'B'2->1GTN^BN=GW@N0R_4'!H TF954LQ
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M><1_$_3G\:M;G4HO[$-L"DGDMDS9''3/K7<:KK6FZ';"XU.\BMHV.%+GEC[
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MR.OKF@#F'^&NGLGV8:KJZZ=G_CQ%T?*QZ>OZUU]I:6]A:16MK$L4$2A411@
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MM% "%0W4 XZ9%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRTT4]N2T,\$A1XR?0C^M4-)\#V.G:HNIW-Y>ZG>Q@B*:^E\PQ_3C]?>NGHH
M**** "BBB@#+M]#M[?Q%>:TLDIGNHDB="1M 7ICC.?QK4HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *QO%O\ R*&K_P#7I)_Z":V:QO%O_(H:O_UZ2?\ H)H F\.?
M\BQI/_7E#_Z *TZS/#G_ "+&D_\ 7E#_ .@"M.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "L;Q;_R*&K_]>DG_ *":V:QO%O\ R*&K
M_P#7I)_Z": )O#G_ "+&D_\ 7E#_ .@"M.LSPY_R+&D_]>4/_H K3H ****
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M+,::J[Y(HI6\^-?4YXXK5UOQC%8VFF?V;;-?7NJJ&LX =NY2 =S'L,$5;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %8WBW_D4-7_Z])/\ T$ULUC>+
M?^10U?\ Z])/_030!-X<_P"18TG_ *\H?_0!6G69X<_Y%C2?^O*'_P! %:=
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M'CO_ )\]#_[^24?:/'?_ #YZ'_W\DKJZ* .4^T>._P#GST/_ +^24?:/'?\
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MDKJZ* .4^T>._P#GST/_ +^24?:/'?\ SYZ'_P!_)*ZNB@#E/M'CO_GST/\
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MR3PC ?Y@ X^O-<UH^D^$M#-QI7C"TEM[Z"5MEPS2[)XR?E(VG'Z5N7%IH_\
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M/B<-,,Y%C_8_V@Q<8W^;MW?E71P7$%RF^":.5 <;HV##/X4 .1$C4*BA5'0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ@< "G5G02ZL=>NHYH+==+6)3!*K'S&?^($=,=?TK1H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=
MLO"4,&OMK-Y?75_<H7^SB=\K;ANH4?3BNBHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N=M/"4,7B%M9O;ZZOKA&<VR3OE+<,>0H^G%=%10 4444
M%%%% !1110 4444 %%%% !1110!GZSITVJ:<UK!?W%B[,#YT!PP'I^--T/0[
M3P_IPLK,.5+%Y))#EY'/5F/<UI44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gjnp4w4lrub1000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ #\# 2(  A$! Q$!_\0
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MC1= &N:^H??@QQ..#GH .Y->]%TL-33M=LUEA[[G!AI3R$D(['!I<S?W)/\
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5>.,1K@5ZD6^6S,\RS&.(BH4]C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gjnp4w4lrub1000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .7!TD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:>JS-9Z6SHFXJ.E<#=M'<.'W!78\K0!V$WB2W6T,RYP*K)XK@&S?N^?I7-P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)&BW2J=WO0!=FUGRTCCR?,<8!JI+JMR7^QK+MN.NX]*KZ=8SW>HS&="JQ/\
M+[U%J>FS?VZTV&6/'WA0!KZ3?W'F-'<OO).!BM/4IGBMMT;!6]ZR=#L65W9\
M]>":?XACFEA*ID+GJ* ,]=4O8+^*.:8,LC< 5UZG<N:X!+*<ZC:-AB%;FN_
MP* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  #8JWJ5[+;(AA7=NH N"WC'1:5X(WV[AG;TJK9WIDBS-\K>E6DFCD)"MG%
M#RH(P>E-$2#.!UZTR2YCC.&;!K!M->FN;B[C5 ?*^[[T = L**NT#BE\I-I&
M.#69I>HRW,!>X4(0<5HI<1N<*V: (_L4*KA5Q64NDW4MYYEPX:-&R@]*VGF2
M/[S8I$N(G/RMF@"0#  J.2".3[RYJ.[NX[2$R2, !4=GJ,5V&*,"!0!8BMXX
M1\BXHEMXYB"ZYQTH6>-FVJV34A( R>@H 1$6-<+P*1XTE&&&17-:IX@EBOS:
MVZAS6[;W0^SQM-\K,.E $D=I#$<HN#2R6L4K NN2.E2*ZLNX'BF"XC+;0W-
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M9W'4#BH-,U 7=LK.0'/44 :%%,\Q,XSS1YB;]F?F]* 'T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI;::T.FW$F1\ZYJG:-)I^C"Z!YSCBNCE@F_LZ.%4Y*X-5)-*=]%%N5^8'.*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***"<#/I0 A95&6( ]Z175ONL#]#7*>(]=6&
M86R/\K#DU;TN\MK.PCGFF.UNY- '1450M]7L[I28I=P%12>(-/BE\MYP&]*
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M* "BBB@ HHHH *K7[%;-R.M6:CGB$T31GH: (-/8M:(3UJW44$(@B"#H*EH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.6&*Q]+T1KQ[DDL%=N<&@"J;DVT2A#^Z)P,5->3R6D2!<[)1D@=ZW)?"T?\
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M#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTKJ#X1L2 -SX!SBK-QX>M+E(U?(\L8&*8'%Z/:NFNR1E]^$ZBI]/2,75P\@
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MLI;>PL@@(9OO$5'8Z8\EVFR89([5WMWI\-W$(Y!P.G%4K+P[:V4XFC9BP]:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^\^W:+/W%KN:\6I'EDT;+8****@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R20
M1QEST%/JKJ/_ !Y24 3Q2"5 P[T^J>F_\>:5<H **** "BBB@ HHHH ****
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M"@!20 2>U</XJU(SW"VT#9##! K0UOQ-%"C0P-^\Z&L70=*FU"]^URC*ALT
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M** "BBB@ HHHH **** "BBB@ HHHH *1E#KM89!I:ANI3# SCM0!(B*B[5&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVQB=5!SFNVQ1@>@H Y6ZM9K>"%#&TPQT]*FL-+>1?-(,:D?ZNND('<"@8[4
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M>&0$A>U1Z!*\VF([DECZUS>G2/'%- Y^_P 5U.D0^18(F.E %^BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_&$$2:?&5C4'?U KJ:YOQD"=.CQ_?\ \* '>$_^/)_K715SWA,?Z$_UKH:
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M4X:!]I)P:]I\%3O<:<S2-DUP8FCROF-8NYTSHKJ58 @C'-<%XJ\+@[KFW4G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR3LV*S4VBDI(S;N)24M%,D;@DX'4UT>@^'OM6)I@0,U@1<SQCU:O2]%B,-B
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57
MO9#%:NZ]15BH+N(S6S(.IH ;8RM+;*[=35FJ]G$8;=4)Y%6* "BBB@ HHHH
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M1W86.3Y6]6K>5@PR""*YFK'>FFKH6BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1
M3PK/&4<9!'I7+GPC"+X3+NQNR:ZVB@"*V@6WA$:]!4M%% !1110 50U'2K?4
M(&CD0<CKMJ_133:V \=\3^#)+!S/;(2F>]=/\.KE!82Q,?G#8Q797MM'=6SH
MZY^4XKSRS1M&UQ4'RHSDD5M*LY0Y6*VIZ9145O*)H5D7H:EK 84444 <SX@\
M/_;!YD()DSGBN=_L36/N;'V_[QKTBDP* .,TSPF3()+K?D<\G-=?! D$81%
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M_P!EKGUKC]3N6U/64B7)5),5WVGV_P!FM53VH M4444 %%%% !1110 4444
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MWMG()[5:KLI4K:L\K$XGF]V.P8HHHKH.$**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JKJ )LI,5:I&4,N&&10!5TX$6:9JW2*JH,*,"EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LG5>AK6K)U
M7H: -"U_X]H_I4U0VO\ Q[1_2IJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBHIKB.%278#ZT 2'CFLN^U>*#*(W[P=JHWNJR3DQQ
MKVR*SV4(A:9@6 ZGO0!%J%[+*K2S'!'3!K&C4SR&5NAZ4LTKWMP&!*HIP1ZU
M8 "C &!751I_:9YV+Q'V(B]****ZCS0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *EME
MWW"+ZFHJNZ9'OO(SZ&ID[(N"O)([&QB\JV5?2K-(!@8%+7G-W/?2LK!1112&
M5KVS2[A*L.G(K#M+J73+O[/<?*'/R_2NEK.U6P6Z@9E&) /E;TH T%8,,BEK
M!T:_:)A8SG,B#ECWK>ZCB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %07DK0VS.O45/4%Y&9;5T'4T )9RM-;J[=35BJUE&8K9
M5/:K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M10Q[%S_>YJ6N^G'EB>)7J.I.X4445H8!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[4 8T*R:MK8;JB25Z)#;I%$$51@>U<]X6TS[/ TKC)?D9KIZ $  Z"EHH[4
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MK3?*SWX'(!]:6H;:3S(%;V%35U'H!1110 4444 %%%% !1110 4444 %%%%
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M''IWKI@<C- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJAKEL;FT4#^$YI-$N/.@9?[AQ0!JT444 %%%% !1110 4444 %%%% !1110
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M4N75CJ***U-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6H+1M]NK>M3T@"BBB@ HHHH ***:[K&I9C@"@!U%5+?4K:YG:&*4,Z]0*MT
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M0H&YE!/%;?45Y->KSR-XJR/*/%D1BOA[FH=$T&75)"!C&,C-;GCJS/G)(HX
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M0+#6K7GC"BBB@ HHHH 1@2I'J*R(]&7[<MU( 74\&MBJ<FHV\5XELS@2-T%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=XR1OLY?MFNQK,UO3AJ%BT9'OQ0!YKK%LM[IB
MR*.8DYKF+(9@!-=/=M+IT5S;.ORMP,URPD$:>6IYKTL&[Q:.;$:V2-C3-,DU
M.;9&P'.*BU_1)='F;S'!QZ4FBZXVD2%@ <G/-5_$7B&76+EBP 4^E:MU/:>0
MH0BHF*TS$$ \&HJ*4<G K8L6.-I'"J"2?05Z+X-\'F79=W290]%(YK)\&:?8
MS7BO=/B0-\J^M>S0QQQQA8U 7V%<6)K->ZBXI;A#"D$2H@P ,5)117GF@444
M4 %<;X]S_9J_[U=E7+>-X#+I:X'1JJ'Q(UH/]XCS$9[4V3S>R,/?%:NC6)N]
M2CC(^7.#7HI\+6DD 1N,=\5TSJ*+L=]6LJ;L>/E6[@_E0(W/1&/T%>HS^#]-
MB!>24@50,&B6#928,P[$5/M5T(5?FV1RND>'[G4)E^0JN?XA7J6BZ/%I=NH"
MCS ,$BN=_P"$IBMQB&.+CN%%(/&DVX#:N,U$N:1E4C5F=Q5:^M8[NV>-US\I
MQ5?2M3348-ZD$CKBM&LM4SDE%IV9XIK^D2:9>LI'#$G@5E(2CJPZ@YKUSQ7I
M"WMA)*BYE X&*\GEB:"4Q.,,O45ZV'J\\;,X:T.5W1Z'X5U--1L#:71W%C@
MUS'B?1&T^\>5%_=L> !6?I-^^GWT<RG[O;->FW%O'KVB+*X&[:2,"L)_N:EU
MLS2+]K"S/)H8_,D"^M>S>'81%H\''.VO*8;1[?5A%*N/F./SKU_21MTV(#TI
M8R5TK!0C:]R[1117 =(4444 %%%% !31&H)(')IU% "$9&*A^QP;BVSDU/10
M P1(IX%*J*I) ZTZB@#G-?LM1F9GMIMJ>E<X=&U.]FC7S<*I^?(ZUZ*0".0*
M0(@Y"@?A0!3TNP73[,0J /I4[V<$C;F3)J>B@!JHJ+A1@5&]M%(P9ER1TJ:J
ME_<2V]L\D2Y8#(% %H  8IK1(W450T6]N+ZR$MP@5\]!6E0! EI"C[U3#>M3
M%0PP11G S52+4[669HDD!93@B@"SY2%=N.*<% & .*6B@!@C53D#FFR6\4Q!
M=<XJ6L+7/$$>F%8T8&9_NJ>YH V%@C085<4XQ(2"1R.E<./%^IV[![Z!(X2<
M;J[*RNTO+=)4;.X9H G,:DY(YI2H88(XI:* *&I6T\EGY=J^QAWKBY]/U8EX
MS*2['@XZ5Z'3?+3.=B_E0!SOAO0Y;!5GN6#3D89JZ2CITHH **** "BBB@ H
MHHH *ANHC/;M&.IJ:FNZQJ68X H BM(3! J'J*GIJ.LBAE.0:=0 4444 %%%
M% !1110 4444 %%%% !1110 TU&U2&F&FB60MTKQSXC1O/KFR-2Q*] ,UZWJ
M%TEK Q8X8CBN6T_2!J6IKJ5PN2IQ@C(K2$N5B7<XSPSX#FN"L]R 4/."*]0L
M=-M]/@$4"!5':KRQ+&N$4 >PH(JG-LAZGFGQ.OQ#;0HIZ\&N4^&T6_Q-$];/
MQ#TK4KZ=-D)*AN*3X=Z'?66KQ2W$)51WJ[KE+2M$]9VXI"*D/6FFLS&Q&15:
MYG6",NQ%67( )/05R.NWKR7!A3[OK515V8U9**N23W4DSL>2M5PR-QD5<T[R
MVMF1C\Q&*Q;Z)K:Y*@G%;QET.*<';FN:<4TMNX:)L+W'K70Z?JR3X5C@^]<C
M:W.X;6_"K+?)\P8C'I4SIJ6J-*.)<7:6QW>X$9SQ5*XF._ -<U8>+H"YM99
M&'RCWK;5O-&Y3D&N5IK<]6.JN*23UJW;+\@--CMLC+<5810BX%(=PJ-Y O%$
MTH4>]46<LV:!E_.1D4E00.2,5/2 ;3:=3:!C33:>:90!@>(DW1;O05R*\K7<
MZU%OL)#Z"N%7Y4YI .HJ%[J&/[S8JO)JUF@_UHS3LP+U'2L2;Q!$G^K8&J,G
MB:;HJK5JG)@=<EU)%]U\59CU^[@Z70'XUY[+K]Q)V ^E4I+Z:7JS#\:M47U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<SIIL'EJ0;@=7%<_+*TKEF.231)*TK;F)-,KNITU!>904445J 4444 %%%%
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MAFYV\5Z"F?+7/7 H$.HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^Z-P!]YJ]*KG/&%E]LTK:!DC)IQ=G<#PH\'%%2W"&.XD4]F(J*NY .HHHH
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MYK)EN))F+,QY[9K>%&3\D58T+S5-Y*VX*)Z5ELQ8Y)Y-)175"$8*R&%%%%6
M4444 %%%% !1110 4444 %%%% !1110!;TZ W%Y&H&?F'\Z^C?#=F+33(P!C
M<@->)>!=.-[K&W;D#!KZ"MH_+MHT]% KDK.\K%$M%%%8@%%%% !1110 'I7-
MZSI%]/>K/;7&Q%'*UTE% '%V7A>Z-W)/<3!]W3-:5OH$D5\DQ<%5[5T5% ''
MP>';JVUVXO%E^24]*DU/P]=/>I<VLPC"CD>]=9@>E'% '-:5I>I17#27%UO0
M]!72#@ 4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0W,
MZ6T#2N<*O6@"AK.LQ:3 LCX;)QBJ=IXJMKD@$!<^IK@/$^LO?W[QJV8@<@YJ
MA&[;1AB/QK>-*ZU.ZGAHN.NY[-'?VT@XF3\ZG5T;[K _2O'8+Z:$Y5V_.MJP
M\474,JJ^-G<YJ72:)EA&MF>E455L+H7EHDP.=U6JR.1JSL%%%% @JM>W:6=L
MTS]%JS7+^+Y76SD0="* ,+4-6N]5N3%;;PN<<5I:9X2/RRW!#YY(-6?"EE M
MNLHY=ASD5U0&.E &?'I-E!'_ *E1BN<U[5+2W<VT4.YB."M=1J4WDV4I_P!D
MUP>AVIU+5/-FR0&(_6@"C'IEQ?R@B-E!/<5W^@:>^GV/E.V23FM&*WBA0*J+
MQ[5+0 4444 %%%% !1110 4444 %%%% !1110 5F:Y ;C3V05ITUU#H0>XH
M\^\,W(M-1FA8XW/BNH\0:H+&R+*?F]JY#5[1]*U9)P"%9\U%K&I&_(.<J2*
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M3PM8-W%N %*\2R)M89%/5:>!4-E)&'=:?+ QEB;Y1R5'>FPW0E4%AL/H:W\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445-%:R3'"#-
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M*UK?P_96^-D8X]14NNN@6/GF#P[J,W_+K*/^ UKVG@.^N<;@Z9]17OR6L*#
MC3_OD5((T'1%_*H==A8\;M/A3</@M=8^M;EK\+DBQYDJM7I. .U+4.K)C.0M
M? 6GPX\R&-_PK5A\,:3 ,_8X^.];59VJWHMK=E!_>$?+4N38&%<VEK=7YLH(
M%3RR&W#_ #[5U-O$(H$0#H,5DZ):947D@_>N,&MNI **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *JW=I;31DS1J?<U:K'\0:@MI8R+G#D<4#3:V. UBQ2XU:2"W4!0>,5&W@^
MYWH 6PPSG%;OA>S>[OVNIAE6'!KO BA0,#CVJU-HVCB)I6.2T#PA%9[9;C;(
M?0CI76HBQJ%48 IU%2VWN92DY.[&R,%C9CT )KQ;QYJ$5WJ:B(  #!Q7IGBK
M5UTO368MC>"M>%7<[7%S(['.6)KLPE.[YF9RE;0@J2"+SI0G3-1UL:1I[31F
MY ^5#UKMJ2Y8W,TKL]>\'000:3"J,ID"\XZUTM<5X+7$C'/\-=K7C2=W<V"N
M%\92;KY8AW6NWE;9$[>@S7G=Y+_:GB*-1SU%(#?W?9_#<0Z90BLWP?#OD:7T
M<_SK7U>W,6CI&!]U:SO!LBB-T/7>?YT =FPRI'K7FGBB867BJ$YP-N?Y5Z6Q
MVJ3Z"O&OB'>%M>0H>B_X5M0ASRL)NQZSI4HFTZ%P>HJ[7!^"/$R7-NMI(_*#
M KNP<C([U$X.$K,:=P(R,5Y)\1[,C4_. X"UZY7#?$*SWZ7-/CD"M,/*U1"E
ML>.T^-VC;<IP:;@@TM>L8'O/A.]%SI$"9R53FN@KSOX<7OFB6,G[HKT2O'K1
MY9M&Z=T%%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDR!XF4C/
M!I]% 'FDR-INO1MR%9\UZ+:SK<P"1>AKD_&%B25F0?=&:O\ A.\$NF1Q$_,*
M .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CO&%O<ROF
M)69=O(%8.AZ!-=7 ,J,BJ<\CK7ICQK(N& -"1+&,* /PH CM;:.UA"1J%&.<
M5/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1SR^3$SGM4E5
M=0!-DX% $L$PFB#@=:EJIIP(LTS5N@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IM.I* (I7$<;.>@&:YJ\\4Q0L45 372S1B6)D;HPP
M:YNX\)VS2ET!S3$5-$>)KF:XFF5=QR >U3Z_?17-J;> "1L]5IP\,(1@@@>U
M7[#P_;6CB0 EAZT!H6=+C9+&+=UV]/2KX%"J ,"G8H%8!3@* *6D,****!A1
M110 4444 %%%% !1110 4444 %1RP1S)MD4,/>I** .;O=/EMG\R,EEZ[15=
M)0X^;Y6[K75LH88(K&O](!8S0#]X>M &!J]BE]8R1LH+$<&O%=<TU]/OI$*G
M:.]>Y[VB?RYOO'I7*^+] 6]M3+$N9,Y-:4Y\K \B[T5)/"T$S(PQ@XJ.NP I
M:2EH$%%%% !2TE+0,****!!2TE+0 M%)2T % HHH 6BBC!]* "BEP?2GK$[=
M!0!'15M-.G?HM;]CX"UB\172(%3R*GF2 Y6BO0[;X8ZB<>;#6Q;?"U#CSXS2
M]K%!8\E )Z5(MM._W8V/T%>VV_POTE<%T;-;%MX$TBVQM0\>U2ZT0L> II5^
M_P!VUD/X5<@\-ZE*?^/24?A7T/!H5E!]R,?E5U+6&,?+&OY5#K]@L?/]MX%O
MY\;DD3/J*V[3X6W$N"UP5^HKVG8G]U?RI< =A4NM(9YE:_"I8\%[@-]:VK7X
M?64.-Z(_X5VE%0ZDF!A0>$])BZV41_"KT>B:;%]RTC7Z"K]%3=@0I:PQ_<C
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M:#Y10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNXV!(&[FJ='2@#V'3[M;RU612#5NN)\'ZE]VU9NIKMJ "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#+@C(I:ANY#%;LXZB@"5
M5"C &!2U7M)3-;JY/)JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'+!',/G0'ZBL6X
MT1ED,T4S#N%%;U% '.Q:K=V\HCE@(C'5C6M!J5M, !*-WI4T]M%<*5D7(-9-
MSH:QC=9*$?U- &V"",BEKFHY=4L.;J3>@[**MP^([=VV%'#>I% &U144=S%*
MN0Z_G4@(/0@T +1110 4444 %(RAU*GH:6B@#SKQ9IWDWAF480"N8KU'Q)8?
M:]-<*/G->8RQF*9HSU4XH 96CHUX;6^CP<!FYK.I58HX8=10![-;S+-"KJ<C
M%2USGA2^\_3U5CELUT= !1132Z#JP'XT .HJC=:I!:@EOFQ_=-9KZ\+GY+97
M5NF2* -V2:.(9=@!6;=:S&BD6Y$C>@K/CL=5NI/](D5H3VK3MM%M("'$?S]S
M0!F*+W5AB57@![BM.RTF.V'SXD;U:M$  8%+0 @4*, 8I:** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,!Q74Z+X)1'6:Y#!AV-=TL2)]T8I]9.HV<<\1*1#;VT=M$$C4#'<"IJ**S,
MK$\5,5T24BMNLW7+4W>FO$.IH \_L;S['#+C[T@Q6QX6THS3"\E!//?FN6DC
M>*_\I\X5L5Z9X>5%T\!<4 :P4*  , 4M%% !1110 4444 %%%% !2,<*3Z"E
MJCJMPUM9,ZJ6/3 H X'Q#J-M>:]:F:7"P2<_K3-2U+3[;6OM]K*"QP*N>'O#
MXO[R\FO(MVYLKN'2KVO>$K8V&8(@'!SQ0!8UK4FDT:)4/^NCY(H\+Z/"VAKO
M^9CW89-95G!/>Z5<1LC!K=<+D4[1O$CZ7IRVDMK*SCOM- &BOAQ-/MKUPS,)
M.<,>E9'ABTC.L-P/N^E;.F75YJ=I>&0.JG[H85BZ3<R:=X@>-X)" .N.* $\
M0$KXITU03C?TJ]J^[2=?DU$DA6XZ\54UR*6?Q+ILJQ/MW9)QTKH/&&G->Z7B
M,?-G- &#J%TVK:SI[Q,2@/S8-9NM7)/BN:S9B(TY S[UL>"M-ES*URIRC?+D
M55\1Z:UGKTFIM"TJ.<;5&: *VI3^?%&8% =%P-HQFNV\+-,VA0F<$2=\US*:
MK8OY<:Z;(&(Z[379Z7C[ F%*CT- %T]*\W;_ )'VY^@_F:](/2O.S;S?\)S<
MOY;;2!SCCJ: .MU>*&71W6>1HXRG+ ]*X^*[L+:P-O;N)0JG#,,GI73>)(9I
M=$D$>3\G0"N0TV[L[;21#+ITC3[2"VT^E $G@^9C:7OS$@R'J?>IO#MHD_BZ
MY,A+#;G!Y'>HO"D<BV]WF%T#.2 1[UH^&H)4\4W+M&P4KU(^M %;Q22WBFQL
M5)6.08('%;6K:+;QZ0(U^7:"<CK5'Q;8R+J]OJ:*6$(Z <FJM_XK-SIBI]FE
M5CU)4T 9MK<O!X8U! Q^\<'/UI=$O432AO"N[*1EAD]*ETFQ:_\ #-\%'S,Q
MQ^M)I%W;:=;"TN=/D=T'+;3S0 _P['/YKQ,"8G<DY/O4GA^SB;QE>(0,*,CC
MZUN:%/#>*S1VKQ8/\0K"LKF32_&-U(\$C+(< @4 >CJ,* .PI:9$_F1JV,9&
M:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5KY&DM'51DFK-(<8YH K6$;1VJ*PP15JD&,<4M !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/Q*-1\V*<@2IP0/6JL-]$?%[0@C>%SBLF:-+36L6X WR?-BFVO\ R4-_^N=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<],?Y-=YM&<XH90PPPS0!YU(GB#6KB.*Y@ @/#D?_JK2\0:!.=!M+.S3<8Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '!>*[+[/<+= 8RX_G74:#>"[L@0<[0!4/B6Q^V6.!U7FL+PC?>2S
MVS'DN0/SH [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
M*JW50?PH  Z "EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M, ]10 !T I:* "BBB@ HHHH **** "BBB@ HHHH **** $P/04M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K
MY2]HZKU-6:0X(YZ4 5K!"EHBMU%6J1< 8'2EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@".9!)"Z^JD5YS=1OH>M+(WRJ26KTJLC6M'CU
M&!A@!\<&@"QIFHQW]NKJV215^O-(_M^AW14"1XUZ>E;<'C0;0LD&"/6@#L**
MY&7QJBCY8-WTJG)XNN)?N6K_ (4 =U17"6VO7TMP@-O( 2*[B(DQ*3U(!H ?
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5!=EQ;,4^]VJ>D(!&#0!!9ES;J7^]WJQ2  # %+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!7N+*&Z7;(H_*LB7PEI\C9*
MGFBB@!L?A#3D.=IJ[%H-G$/E7]*** +26$"'A1Q[59 P,444 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gjnp4w4lrub1000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,!!X@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME%I-Y%]BN6G\QPI#'-:.H,7\>:<QZF('^5 '>T4#I10 4444 %%%% !1110
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M:] C;=&K>HH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:J>"])4W4T_F/\DIXS[T =W<3/;6VYLLP]*Y6Z\9BUNA \,NX]/E-=KM!&"
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M0!P>F732Z/J4'DN& QR#S566UF_X0RUC\MMPD&1CZ5Z&EG#'NVQJ-W7Y:?\
M9XM@38NT=L4 <_=Q.?"C(%.[RAQBI?!L;1>&X$=2&'8BMXQJ4VE1M],4T>7
MFT *OH!0!Q_BJPE&K6NH*"R0<D =:S];UEO$%I#;06\J,L@)+*?45Z RQS*0
M5##W%11V,$;;A$G_ 'R* .1OK*2.6R^4G"#.!776 (LT!%3-$C$$J#CIQ3@
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M10 4444 %%%% !1110!%<,5M96'4(2/RKSK1!K6N27;Q7NU8Y"H!^M>B7?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^X/Y4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG"KU- $M-+J.K 5QVI>-(XV*6CAC[UE'6M=O>8H5(^O_ -:@#T7S8_[X_.G
M@]#7FPN?$B?,8!@>Y_PJ[IWBVYBN%AOMJ GF@#O:*AMKA+J%98SE6Z&IJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>S'_ !-,1GOB@#IJ*S['6K+4!_H\FZM"@ HHHH **** "BBB@ HHHH ****
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MQ%./PJYS<>AWK_,;DX/:KT6B*!^^P];%%6J,492Q-21GC1K$=8%S4@TJR7I
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M "BBB@ HHHH ***0G S0!FZXI:P;'H:Y3P0P$EP#U\P_SJ;7O&5I:7,UG+(
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MQ!0'2HSCG=7E9ZFO6_'2;]+3ZUY*X^<_6GA_@*I['HG@.&-V)9 ?EKT!5"C
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MTEN2J'YLUSV:,BW+KDMI"T>XLS\YJM#XBN]R+YKA00<5EW231E!,,9'%,$3
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M-<\H.+LSMA4C-7B.HHHJ2PHHHH 0]#7F7CW0KNZD6:,NX49P*].IDD22H5<
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M067AZ2(L#L;( [U%E@,Q]NM*)F8?-TI]+(F;E+=EEBI&.#59X27RHR3VI/-
M_P!7UIT5PR2JQZ@C-3'GZD-,O;);6#$EL3N'#$=*C1QLR37076LV%YIXBS^\
M"XKFMAW;1THIN^Y$&*H,K[NF*L=.E0+O1L=JGS\N>U66&,]\>];$$'F6L:QK
MYCY[5DP()90#]SO7IGA[3]+M[*.<_?QSFN3$23T,*K3)O"5C=01YDW*,YP:[
M.L0>(;%2(H\[N@XK5MY?.B#]C7(9$U%%% !1110 4444 %%%(3@9]* ,K6YY
M;:U>6,,<=A7#W>MW,L;*79>.17H4TMO<(8G/!KSC7(HK>YF"=#TH*BFV<E=2
M&28\_,>]9A4B?+>M774FZ^7[W:B=%9>/OCK51:6Y]3&FE%=S8LDBFM\E :9>
M6L"Q$[%SCBLK3[Z1&\H'O4VH7S[5&>14WL>-/#5/;63T9DF,F7!&VGB+:P^>
MF23/(^[O2J0 2_7M7I47[@Z\>6=B62%9.<C-5'1T;@'%*9V7D4@NW;@UIS:&
M-KL>H+-GH:NH#LP?SJFC;N!UK2BF@\O:_7%<]2K*GTNC2<+1YDAMLXCDVY_&
MM*.XDB/R.1GTK'D"B7*=*LPSG'S]NE<U:E&<>=(Y)1=[Q-=99IVQ)*0/>M2T
MT-9L/YH/>N<\]R,]JOVVL75O@*?E[UY6(H8F4/W#2/3I9:YP4[ZG7VUC%; 8
M49'>K58EAKT4Y$<C?/6TI#*&'0U\?BJ5:G.U;<3INF^5H6BG 4N*YR1N*,4Z
MC%%@N,HIV*0B@8E%%%(!\4ACD##UKJ;299H1@YP*Y.KVGWIMW"D_*3S7LY3C
M50GR2V9SUZ?,KHZ:BHXY5E0,IX-25]>FFKHX HHHI@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ,F!,+A>N.*\J\47>H6M\R>=($KT*X\
M0V5M(R2,<CK7'>+M1TS4;.1XB3-VH6C.W 55"JDU>YY_>2/)ABQ)/4U5A.Z3
M:>15B5PB$'OTJ/3H_-N I[U3UU/<=;>4U9(AF4(V14#RDKCO6Y-I$CG*BLRZ
MT^6VRSC@5O1FHN[.*OB*==<L&5HCV)QFK/D(Z8!&?6JN :FC^[\GWJ[KW5T<
M%K.S%V;.,;JC=?FP!2-+-&3FEC<N<]Z+VU8F30QY4GN*43E."*;#*$8AN]2E
M%9MYZ4I2LKB;T+6FQF\N5W#:H/->B:?;P0P+Y84^XK@[0F%#MZ&NCL-8AM[,
M1ECY@KY'.Z5?$:PV[!2J1OJ=(2 ,DU$)HS)PXS7,3ZU<R-M4_*:($OI7#Q]3
M7CK*)PAS59)&GMTW9(ZVBJMD+@1_Z1C/:K5>3./++EO<W3NKA12@4NVI&)BC
M%.HHL*XRBGD"FXH&)12XI*0!6EIEUY<NUCQ6;2J2K CM73A<0Z%531,XJ2L=
MD#D TM96G:@)%".?F[5JU]U0KPK04XL\R47%V84445L2%%%% !1110 4444
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M4@E0,*?7T"::NCE"BBBF 4444 %%%% !1110 4444 %%%% !1110 4AI:0T
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M_P!Y?SH Y)_!;%\B\(7TK?TK2TTRW\I2&YZU?R#T(I: "BBB@ HHHH ****
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M6J/%QO+S<R=V1I%O7.^HI8MHXDR:4OY>0O JNTA[]:Z=3C&#=G')J];RM&H
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MC/+U5CEGR$8_2B5'67YR"*XJE&4M6RX59QZA)+F4+C@GK5E(T:3:,&J)90X
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MK5U*Q$;;XQ@=ZRJ^5Q6&EAZG)([834U=!13=V>E'S5SV+'49%-)8"D SR:+
M/60HV0,U<&H2; HR,53 I<5M3Q%2DK0=B7!/<L?;)<_?-2)J,B'/)JIBDQ5Q
MQE>+NI"]G'L;=MJ^_ <8K3BN(Y1\K FN1(J:"ZDMVRAQZUZV$SJ<7RUM483P
MZ>L3K:*H66H). "?FJ_7TM*K"K'F@[HXY1<79A1116@@HHHH **** "BBB@
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MR<5K>'=7N]1.9&)4'!S6!B=0.12T44 %%%% !1110 4U^5IU-?[M T<G9_\
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MQRPJ5 ''WL5UNIZ3;000OY1*@9?%<M>>4TY-JA6/T-"FYKL"DV6[+1[B\.8
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MN.,$4YO!MH'#1Q 8-<;W,C>T]$?3[<E0?D%7,8Z5%;Q>1 D8_A&*EI %%%%
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M<%H;57JR9*G%1(*E'2MD<LAXI:04M40%%%% !1110 4444 %(WW3]*6D/0T
M<)XA8M<C/8UDJ:V?$\9BN4_VJPP:^?Q5U69S3^(F!I=B-U4&F T\&LXR)%\N
M)5)$:_E3#;1W"'<HP1TQ2NW&*DB.$ K13:UN.YQ.L^%WC=I( 6SS@5S$UI/
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MCJ*[,%B70K*70BI#FC8[&BJ]G-YL"G/.*L5]W"2G%274\QJSL%%%%4(****
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M0 4444 (5##! -*!@8%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 130K,NT@5A7NFM"2R D=ZZ*FN@=2I'!KCQ>"IXF-I+4TIU'!Z'&XQUH
MJ[J-OY,[%1A>U4J^(Q%&5&HX2Z'HQDI*X4445B4%+FDHH 7-)FBBF 4444@"
MBBB@ HHHH V-(N/G*$\"MRN6T\D3<>M=0OW1]*^SR>JZF'L^AY^(C:0M%%%>
ML8!1110 57N[I+6 R.< 5++((HV=N@&:X/Q!K37,S11L1'W%8UZRIQN9U*B@
MB'4M9EN+O*,0J-D8/6M2RU*'48/(N0JD]\<UR0J:-RC94X->.L3*,KLY8R=[
MFIJFBM;GS8060\YK)''%='IVKAAY%WEU/ ]J34]&!!N+;'E^@YJZE*-2//2&
MXK=&$M7K*Q>]E"A?E-0VMK)-<"/:>N#Q7=Z7IJ6<(R!N]:C"X5U)7ELC2$>8
M=!ID*V0B9%Y7!XKC/$7A,INGME+'T%>ATUT5UVL,BO=2LK(Z5H>4>%].QJ7S
MK\R/S7K ^Z/I6?!H]K;SM+'& S')-:-4W< HHHI %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5"\T]+@$]#5^BLZM*%6/+-70XR<7=')7%N\#X88J"N
MHO[99H6./F[5S,B&-RIZBOCLRP/U:=X[,]"C5YUJ-HHHKRS8*,FBB@!<T9I*
M* #-%%% !1110 4444 *KE&W#K7564OF6Z^N*Y2N@TDDH1[5[V1U6JKAT.;$
MQ]VYJ4445]6<(4444 %%%% !1110 TU&XJ4BF&DRD5G%5I!5QA5=UK.2-HLQ
M-0#6Q\^,9;.*Z2QG$UK&<_-MYK+N(ED0AAFJ^CW9MYY(I3]XX6LX/EGZF]2/
MM*>FZ.EHHHKI. **** "BBFNXC4LQX% "LVU2:X7Q/<7+3 %2JU8UKQ!(MP8
MH'(P:EM[RVU:#RYES+C )-<56K&K>FGJ<U22G[J..4U(M:6IZ/)9R%UY3MMY
MK- KR:D)0=F8)-.S)HV*G()%;VG:MQY$X!4]2:P%JS;PM/*L: Y/>II59PG[
MIJC=N-#CN)!-;DL&/:NBTZP2SA"@<FFZ3:O;6B*_45H5[U*C&/OVU9O""6H4
M445N:"$ ]12T44 %%%% !1110 4444 %%%% !1110 4456O;I;2W:5N@I-V5
MQI-NR,37KEI)88XCG#8;%2V\81  *H6BM-=23/RK'*UKQK7*O>?,>A-*$5!=
M"5!5A142"IU%;Q1R29(M/%-%.%6C)BT444Q!1110 4444 %%%% !112-]T_2
M@#D_%=VR21QH>".:Y< 5L>(F+W(SV-8XKP,9-RJLYIOWA/)[@T;7':I%-2 U
M@K,D@"R'^&F%61LXY]*N%MJDTD:B3YSWJU%#( ^:=NITMNP.Y>E0$D'&#4.+
M0K$VZC=4631N/H:5V(DW5%))Q@5(D+R]./K5L6D8CY'S>M7&#>K'8HJ,"BGB
MW<D\CK3OLDGJ*3IL+$)(% 5G/3BK(MU'WAFG8"C@4*%MPL5@ODL%'(-2$T3?
M=)[TQ3\@HDP$-*@RZCU--JS8VSW-T@3LPS4PBY220+<[;P]&8K$@]S6O4-M$
M(854#' J:OI81Y8I'4E9!1115#"BBB@ HHHH **** "D) &32UA>)-833;*0
M;L2$<4TFW9 E<YWQIXC\M&M87^<'G%><.Q=RQZDYJ:]NWO;IIW.6:K.CZ<^H
MWT<04E6."<<5Z,(JG$ZHI11/IVF7P"W44)9.H-=IIOC!X5$5V%CV\5U.FZ5%
M::<ENR@X&#7,^,-'L8-.FG1%5P,]:XIR=29SM\S/.O$U^+[7)Y$;,9/!K)'(
MI"<MFGQYW# )^E>G%<L;&ZT1[/X+BVZ'$3W6L+70(O%5N8_3M^%4]*\0SVFF
M1P)%+D#'"FK>D:?>:IJT=Y<9VJ>C#%>5-WDV<[W.?\62%VYZYKES]VNE\8,J
MZG+$/X6KFNM>E2^!&\=CVOP8/^)- ?\ 9KIJY[P@N-"MS_LUT->;4^)F#W"L
M[7"!I4I/2M&N;\87HATB:,'#&H$87@T'^U;PCICBH-:RWBV$/TV_X5L>#+,Q
MQ&X8?ZQ:R_%2^5X@CD'&%_PH [NQ %G&!TQ5FJ6E-NTV%O5:NT %%%% !111
M0 4444 %%%% !1110 56GO[:V.)9 M6:YSQ3I\EQ8L\/$GK0!!K>M6\X6WBE
MRDG#$=JS_L^E6NE>4LX=Q_$1S7$R23I*R$DLIQTIW^E.F2& ]2*KFTL.YF:M
M$KS2%#P#Q4=H76T7"\9ZU/-&Q# @C/J*?;)BW$>"2/2KYWR<H^;W;$Z7/EPF
M-8U;<.2173^%[=I%42VJ&+'WBHKE[>(B\BWHVS/.17KFA6]LVF1F-,+6=V3<
MS9O!]A?@MD+]!63XIT*'3_#T-M"H;#XW8Y[5WR1K&/E&*Y[7KB&=Q;-RRL#C
M-:0G*Z*3=SF+;X<V]W9+(\TB,RYP":S;OX=R6Q/V?>]>KV@"VL0'3:*FI^WF
MGN/G9XS#X/G1_P#2%:,>M=SX6M(K*3REG9\#H3742VT4PQ(N:BAT^VMWWQQX
M:B59R5F)RN60%'0"EHHK$D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDR!U(HW+_>'
MYTKH!:*3(]12TP"BBB@ HHIKN(U+$]*3=E=@8^M%2F.^:Q:N:A/YUPV#\M4Z
M^'S.JJN(;B>E1CRP"BBBO/-0HHHH **** "BBB@ HHHH ***<B%VVCJ:<8N3
ML@9?TJ$M*21Q71#H*J6%N(H%./FQS5RONLOP_L*"CU/,JSYI7"BBBNXS"D+!
M1DGB@G R:YWQ!K2V\;01GYR."*BI-0CS,F4E%79;N;ZUN_,M_.PPXP*XO5-)
MEM)2X!:/KDU56YD$YE#?,3G-='I^J0WD0MKL;B>YKS'5A7]V6C.5M5-SE!4J
MUL:GHC0GS8L%&Y '-8X!!P017%6IR@[,A)IV9*G%;>D:A*DJPD;Q[UBQJ68*
M.IKK-!T@KMGD%5@X5)5/=V-HJ[T-BTL(D/G;1N?GITJ_2 !0 *6OH$DEH="5
M@HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBDW+_>'YT7 6BDW+_>'Y
MT9'8T7 6BBB@ HHHH 9)@(<URMYS=N1TK?U&Y6*!ESR:YIFWMN)ZU\WGM:+2
MIK<Z\-%[B4445\T=@4444 %%%% !1110 4444 %%%% !R>E=/IT6R!6]16+I
MUMYTZDC*UTJ*$0*.@KZ?(\*TG6?4X\3/[(ZBBBOHCD"BBB@ HHHH **** $I
MII]-(H!$3BH'6K1'%0L*AHTBRFZUE7L&V5+A>/+YXK:=:JS1AU*D9!K&<;HZ
MJ4[,N:7?"\ME<GYCVJ_7)13-IEYOY\GH%%=3!*LT2NIZC-:4I\RL]S'$4N1\
MRV9)1116ISB$X&?2N5\1:V(U,$+ Y&#[5TMRCO"RH<'%><:O8W%O<LTN6R<@
M@5R8N<HP]TPKR:6AGERYRQR:FAD:-@RDC'H:KBI5KQ&W>YS1.GT_54N8Q;W(
M4+CAC534]&,1\VW!9#R362G!R*W--U4C]Q<9=6[5U4Z\:JY*GWFV^YB1QLSA
M .<UV6A:2(8Q)(/FZC-2VNCV[S_:!& AZ"MM5"J .@KLPV#5-\TC2$.K%Z=*
M***] V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"0H)/05S.K7;7=U]
MD3_5L.2*T=7U%;:,1KRS\<=JS+&V(&^7ER<@USU97?*CMP\.5>TE\BU;0B.-
M5':KB+3$6K"+3BB9R'J*F44U14@K5'.V**6BEJB HHHH **** "BBB@ HHHH
M *0]#2T4 <-XGC,5RG'WJPJ[?Q'IYN8O. ^X*XCGN,5X6-IN-2_<YIJS' U(
M#4-/4UR)DCW/&/6I(N$ J!C4B'*UHF!9!S055AT%1 TX-5IC$^SKGK4B1*O;
M-)NI=U.XQ^0.@H)IFZDW4<P$;G$P%2%J@D;]\M/)I-BN*33":":C+5#8ALI^
M0U&I^6DN) D3,>U9$VL(J[5!S6M'#5:^E-7)<DMS4FG2)22:U_!VJ0/?R)*5
M''%<!/?22YRW%&G7LEM?PLC8RXS7T6#R=4H<T_B,XU_?78^@A@@$=,4M4M+N
MUO+*-U[* ?RJ[4M6=CT0HHHI %%%% !1110 4444 1S2K#$SL<8!->/>*]9;
M4[X@-PA*\&O1/%]ZUEI6]3C<2*\:E;?,[?WCFNO#0^T;4H]1%&YU4=SBO5O!
M>A_8K0R2I\S<@D5P'AJP_M'4Q'C.W#5[7;1B*WC0#HH%/$S^R%670D)VJ3Z"
MO*?B'K)>[6")LJ1@\UZ9J-RMM9R.Q_@/\J\!UF]:]U"1B<X<@5.%A>5R::NR
MB.E;/ART-WK$,9&5)YK&'I7I/P[T@2H;ME^9&XKLK2Y8-FDG9'>6FDV\-NJ&
M),C_ &:ME(K:,L$50/05/67X@N/LVCS2YQ@5Y2U9SGC7BF?S?$-SCINK(7K4
M^H3?:+Z27^\:;:IYDRJ.]>LM(G2MCV_PH,:!;?[M;E9/AN/R]#MU]!6M7E3^
M)G.]PK@O'$A,_E=BM=[7$>-K21B;A02%7L*D1T7AZ,)HUOC^[7)^,2#K"@==
MM:.C>)K>+2TA<89%YS6#<7)U[Q%&T:MLQCI]* ._T;_D%0?[M7ZKV47DV<<?
M]T58H **** "BBB@ HHHH **** "BBB@ IKH'4JPR#3J* .9_P"$.M#=M.7.
M6;.*=JNDH;+[/!&I(/4"NDII12<XH \H\3V2V?V< 8)'-4=%56O0& (->E:[
MH":I'\H <#@FN=T_P5=VMR)&E4@4 :\_ANWEL!*HP^W(P*N>'V\BU2U;[Z]J
MUX8]END;<X&#65' \6N/(/\ 5D<"@#8D;:A/I7!O8ZA=^+)93$?LYZ'/UKO2
M RX/>FK&J?=&*J,N4:=@A79"BGL*?114B"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHIDCB-"Q/2DVDKL!7=47+' K-N=5"'$6&JE?:@TK%4.!5$=<FOG\;F]I>SH_
M>=5.AI>1?-]+*>1BCS7]3^=5E-2;N*\]8JI+64C7D2V1*+Z2/IS4D>L29PR@
M"J+'-0FI_M"O3?NR'[*+Z'1Q:E"X^9P#5M)%<94YKC^AR*LV^H20'YF)'I7H
M8;/+OEJHRGAOY3I)ITA7+'%8-[J3S91>E075Z]RQ()V^E5:Y\PS:51N%+8NE
M02UD-V^I-+MI:*\*[.D;G!P>E.I",TM !1112 **** "BBB@ HHHH *T-+@W
MSJ^.!6?6SHI&S!ZYKT<KIQGB4I&59M0-H  8%+117W!YH4444 96M:A]AMLC
M&6%>=7-T]U,7<]Z].O[".^A*NH)QQ7!ZKHDMC(2!E>O KSL;";U6QRUXRO?H
M92U,A(Y!(/M4(R."*E6O)D91.@TW5L+Y,P!4\9-/U'2(YD-Q:9;Z5@K72^'Q
M<22*"3Y7<5UX>K[;]U-7-EKHR/1-$=Y=\ZE=IR*[!$"*% QBA$5.@IU>M1HQ
MI1LC:$5%!1116Q84444 %%%% !1110 4444 %%%% !1110 5!/=1P@[FP:BO
M;Q;=",\GI7/37#SN2QXKR\?F4<,N6.LC:E2<]6:,NJR,Q"@8J+SY'Y)/YU34
MU,K5X7UZM5=Y2.GV<5LB?SW7N?SH&IS1]!FH6:H&-3+&58?#(%"+W1KPZON_
MUF!5Z.]AD^Z^37+&A9'C/RG%=%#.ZL':HKDRPZ>QV&>,U1O-02 $*06]*REU
M5UB*$DL>AJE)(TCEF.2:[,7G,537L=V1##N_O#[FX:Y?<QQ4&WWI:*^9J59U
M)<TGJ=BBDK(;C%*#2T@&&S47ON,6BBBD 4444 %%%% !1110 4H&6 ]:2G1_
MZU?K505Y)">QT6EP".#)'-:%06I!A&*GK]!P\(PI1C$\N;O*X4445L2%%%%
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MKAE&3CUKU;X=66S3FD(YW5>(E: YO0[VBBBO,, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)
M &34-Q<I A)Y]JQYK^24_(2!7'B<;3H;[FD*;D:[WL$9PSXJNVJ0@_*U8S;F
MY8YJ%E KQ:V<U;^ZC>-"/4WUU6#^)\4_^U+;_GI7-$"FD5BL]KKHB_JT3H9-
M6C ^1@:S+C4I9LCH/:J-%<M?-<165KV+C0C$,D]:***\UNYL%%%%( I<TE%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BGE$49
M8^E2UDZQ-M50.]<^*K*C2<RH1YI6,V>X:XE+$TJ8JNIYI^_ KXMUG.3G+<]#
MELK(E<C%0,:5GS49-9U*EQQ04TT$TE<YH%%+B@KF@!**-I]:-A]:+ %%)DB@
M&BP"T444@"@]**1ONF@ '/-+34^[3J; ****0!1110 4444 %%%% !115RPM
M#/*"1\O>MJ%&5::A$F4E%79'#933#*KD5*^EW&.$KHXH5B4!1BI*^GIY'14+
M2>IQO$ROH<F-/NNGEU9@TJ5F_>*0*Z+:/2EJZ>24(RNW<3Q,F5[:U2W0!:L4
M45Z\(1@N6.Q@VWJPHHHJA!1110 4444 %9.H_P"N_"M:LK4?]=^% &A;_P#'
MNGTJ6HK?_4)]*EH **** "BBB@ HHI&.%)H SM2O!$NQ3UK%7).2:?=R&2X8
M'L:C5J^-QV+=:L^R.^G#EB6!@"HG-(7J-FS7).JK6+2$/6FFES32:Y7J:(2B
MBEQ2&)12[:38?6BP!12%2.])N[8HL ZBBBD 4444 (>M+VII^\*=38!1112
M**** "BBB@ HHHH ***4#) ]::5W8 56=MJCDU<33+AESLK0TVQ"IO<<UK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU-*C"E'E@K'#*3D[L****U$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 UD5NHI!$J]!3Z*7*@"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !@5&8D)Z5)12:3W :%"]!3J**8!1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%MM;P7(9)59CSBI/#FFP7T)(E D*'Y?PJ-&KL]^NHRP_/;4=<>*6GNB"WR
MXKLM'N(KO3U*_P 0(->;3^'+Y+UE2)RI8\UV4"2Z1H4?!+XP13Q,:4(<T3P,
M(Z]2?)+8AU3P=;7-QYD*KR<GFK,?AE+?3]D:XDVG-8$.H78N-YD<C/3-=:-9
MCMM+2:9@">QKCI8R5;W3TIY?]7FIQU9Y]+X>NENRA7EF..*U9=8DTBQ2UC.)
M%X:MZR\165Y<A&2,,3@&LSQ7H:2I]JCD^\>U=D&G)*8LQKUW3Y;69!HFJ1W5
M\B3G+L>*WO$VIR:;8(;<XSQ7)^&-/A_M".5[@!D.-M=[JFEQ:G:;&8 #G-35
MA3A/W4<N!K2DTZSN>=V'B#4#?*6?Y<\U8U;2+FY/VPC(D.:LQZ386-^#)>)P
M>AKL5>U?3<1;9 %.,4I34=4>S4K*$E*FCD_"^DR17B3D@*IYYKO99TAC+L1@
M#/6O-FN9_M3>6S1J&/ J[JL][<:9&D6\D#DBN.GB56GRV%B,+*<E*3.IA\26
M,]P(5;YB<=:UU8,N1T->+VL5U]J&QGWYKUO2 XTR$29W8YS75.*CL<N*P\:5
MG%EZBBBLSC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9J
MEIYD9=1\U<^P*L0>U=D0",$5DWNF!\NG7TKP<TRUU?WM/<ZJ-;ET9A45,UI,
MGWDQ3?)?/W:^9="I%V<6=G,B.BIOLLW]RHV1D^\,4G2G%7:#F3&T445F,***
M* "BBB@ HHHH **** "C%%% !1110 4444 %/'2F4X4P'K4RBH5J93732L9L
MDV\5&PJ7/%,:NB:5B$5V%--/>F5PSW-4(OWQ]:Z733FVYKFE^^/K73::I6VY
MKW,AO[21SXG8N4445]2<04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 A&:@:R@9]Y3YJL44#3:V&-&K1["/EZ55_LJT#;O*YJ[12<4]QJ<
MELSD_$OA=M3VO!M4J,<UF:#X/N[2Z\RX=64=J[^DP!T%;JO-1Y4<\J$'/G>Y
M#);K+:^2PR,8KG)?#$IN-T94)GI7545RSI1G\1V4J\Z7PE2PLULX=@'7K5I@
M"I'J,4M%6DDK(RE)R=V<5X@\'RW]QYML54=\U9\,^&)=)F,LY5LC'%=916WM
MI\O+T,%0@I\]M0[8I, 4M%9&P4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% #&A1_O#-1_9(<YV5/14N$7NAW9'Y$>/NU#-80R*?D
MYJU14RI0DK- I-'+WMB]NQ./E]JIUU\T*S)M85SUY8/"Y*CY:^7S+*W3?M*2
MT.VC6OHRC1117A'2%%%% !1110 4444 %%%% !1110 4444 %*#24HH <.M2
MJ:BH!Q6D)6):+&ZD8U%NH)K5U-"; 33312&L).Y:%A4M,N/6NL@39$![5@Z5
M!YLI)'2NB' Q7U>24.2DZCZG%B97E86BBBO<.8**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IDD:R+AAFGT4FDU9@8UWI.<M'@"LB2!XVP5/Y5V%120)(,%1^5>
M1BLGI5?>AHSHAB)1T9R%%;\VCQ-\RDYK/ETR=3\J9%>#7RK$4NET=,:\)%"B
MGR0O%]\8IE>=*$HNTE8U33V$S2TC=*6D,****0!1110 4444 %%%% "@T[-,
MHH ?13<T9IBL*30B&1MHZFF]:V-*LLD2L.E=>"PLL1545L14FH1N:%A;B&%3
MCDCFKE &!BBONJ=-4XJ*Z'FMW=PHHHJQ!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4=:** ();2*4?,H-8=_IYA.Y?NUT=5KY0;5\^E<&-P=*M3
M;:U-:=1Q9R3=*=VI),;L"EKX>2MH>B@HHHJ1A1110 4444 %%%% !1110 44
M5:L[-[AQQ\G<UK1HSK34((4I**NR33[-IY,D8 ]:Z..-8T"J,4V"%88PH'2I
M:^VP.#CAJ=NIYM6HYL****[C,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^>E'/'N',B_15#^V+3_ )Z4?VQ9_P#/2CFCW'S(OT50_MBS_P">E']L6?\
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M69I45F_V[8_\]*/[<L?^>E%T%F:5%9O]NV/_ #TH_MVQ_P">E%T%F:5%9O\
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MWK#_ )ZT?V[8_P#/2BP<DNQIT5F?V]8_\]*/[>L?^>E%A\DNQIT5F?V]8_\
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MYZT<K U**R_^$@T__GK1_P )!I__ #UI\K U**R_^$@T_P#YZTG_  D&G_\
M/6CE8&K165_PD&G_ //6C_A(-/\ ^>M'*P-6BLO_ (2#3_\ GK2?\)!I_P#S
MUHY6!JT5E?\ "0:?_P ]:7_A(-/_ .>M'*P-2BLO_A(-/_YZT?\ "0:?_P ]
M:.5@:E%9?_"0:?\ \]:/^$@T_P#YZT<K[!<U**R_^$@T_P#YZT?\)!I__/6C
ME?85S4HK+_X2#3_^>M'_  D&G_\ /6CE?8+HU**R_P#A(-/_ .>M'_"0:?\
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M]VJG2TQ\L>Q;_M2\_P">[4O]IWO_ #W:J= IV'RQ[%S^U+S_ )[M2_VG>?\
M/=JITO:BP^6/8N?VG>?\]VH_M.\_Y[M5.EIV'RQ[%O\ M.\_Y[M2_P!IWG_/
M=JITM%@Y8]BW_:=Y_P ]VH_M.\_Y[M52BG8.6/8M_P!IWG_/=J/[3O/^>[54
M-%%@Y8]BW_:=Y_SW:D_M.\_Y[M56DII"Y8]BW_:=Y_SW:C^T[S_GNU5**=A.
M,>Q:_M.\_P">[4?VG>?\]VJH:*+$\J[%K^T[S_GNU']IWG_/=JJ44[(7*NQ:
M_M.\_P">[4?VG>?\]VJI119"Y5V+7]IWO_/=J/[3O?\ GNU5#13LA<J[%O\
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M*F/VD.YA45NCP?J__/(4O_"'ZO\ \\A3*]K#N8--KH/^$.U?_GC3?^$.U?\
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M (0O6/\ GC3YX]Q.I'N<]170_P#"%ZQ_SQH_X0O6/^>-'/'N+GCW.>HKH?\
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M119 1^1%_<%'D1?W!4E%%D!'Y$7]P4>1%_<%24460$?D1?W!1Y$7]P5)119
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M^RP?\\UJ6B@"+[+!_P \UH^RP?\ /-:EHHN!#]E@_P">:T?98/\ GFM3447
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7(^/\ _D#K]:ZZLO6M*35;=8G&5!JX.TDR9J\6CY]M],NKVY*Q
M0NP+'D"O0O#GP[)"7%R_7G8PKN]+\-V.EK^X3D\G(K8  Z"MZF);TB84\.EK
M(I6.E6MC&%BA12!U%7J**YFVSI2L%%%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gjnp4w4lrub1000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +5!D # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;VKFM0M+BY@,SR.&8?=S5J-E=@:4WB^"X<Q6S%7SCDU"UQJ\@#"Y38QX&?\
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M%MOO7<>%-?2[S;EAA!P:[Z4_:0N]T>5BZ*ISTV.OHH'(S15'*%%%% !1110
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M\=Z9+,\*9100.IJD;]2N\-\_]VM.916IER.3-O[.ODL3C '-5(UD?(C<*F.
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MJ#BMZIDK.QSA1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNTTO2(;"$ *"Q'.17;5J0Y?,XJ5.?-Y%%KNZF/R;U_"H6MM3D.5N"*Z78O\
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MX)]#5;YLY\Q_S-+FB<[Q"Z'HBRQM]UP?H:?7!0ZG<VN/+Y^IKHM+UQ;G$<[
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MCAE"*P89S3X6DF?RAD(*IFXVLQ3G/6G0:D\4G(&* +TA\DA2>3WJ-8BTN\R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&* %HHHH **** "BBB@ I" >M+10 FT#M2T44 (!BD,:MU%.HH ,8I,"EHH
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M Q8-'D1LR2[L=*U88C&,9J6BDVV 4444@"BBB@ HHHH **** "BBB@ HHHH
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M,C#!KA2"*ZJSL(;*/9&OZ5E5KQM:)I3PSO>0S3[%;.U6/ R!@FH[[2H[I"4
M23LU:-%<3=SM2L<Q'<W.D2A)0TJDXSZ5T%O=1W"!D8'V%+/;1W"%7'45S\UI
M<Z3/OM@3;]230!TU%4-/U.*]&P-^\4?-5^@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*[SU-6J** "BBB@ HHHH **** (9[:&Y7;-&''O4,&EV=N^^.W17'0@5<HH
M**** ()[6&X*F6,-MZ9J95"C &!2T4 %17%O%<Q[)4#*>QJ6B@"*&WB@7;$@
M4>U2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C,%4L3@"
MEK&UK41 JPJ>9/EXH J:E=2:A<_8H"0C?\M%[5JVVFPQV@C906(P6]:AT?3O
MLT.Z0?.3FM6@"C9Z;':'* #GM5ZBBFVWN))+8****0PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!" 1@BH)+&VE^_"I^HJQ11=H32
M9R]S%+HUVLD2EXY&Y Z**Z*VN$N8@Z,".^*+J 3P,A&<C KG[&232[\6;'$9
M.:!G344BL&4,.AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F"J6/04 5K^[6SMFE/:L
M;2K5KN[DN)P64G*9[4V]F?4=26T',##D5T%M"MO L:C 48H D P,4M%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !67K-A]JM6\OY9>S#K6I10!BZ+?%PUM)]Z+C)[UM5S>I6TEC=I/;<;V
MR];MI<+<PAU- $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5EZQ?"UA$8ZR<"M-F"C)Z5S*?\
M$WU-TDY6%LK0!H:'9>3;EY!ER<@GK6O2*-J@>@Q2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!!=PB>W=2.2.*PM*F>QO18ODY.<FNDK!UZ P(;Z(?OEX!H WJ*IZ;<_:+.,L
M<OCFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%(2!U- "T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_>
M'YT +12;E_O#\Z-R_P!X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^=
M"T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_ 'A^= "T4FY?[P_.ER#T- !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *R+[G4D!Z8Z5KUD7O_(3C^E- .,:9^Z/RI-B_W13SUHJR!NQ?[HI-BY^Z
M*?24 )L7^Z*-B?W13J* &[$_NBH+M5%NQ  -6*@O/^/=J'L,U+/_ (]8_I4]
M06?_ !Z1_2IZS*"LJ\_X^JU:RKW_ (^J +X9EMP5&3BJIO)8UW2)@5:5]D"G
MVK.OY_,MRN#0-;FG'(7C# =13@Q/:H;4_P"BH/:I5/% F&=W44S:I."@_*G@
M\FDS\U #/)BS_JE_*E,4>,>6N/I3\\T$T -V)@#RUQ]*;Y48.?*7/TJ0GI03
MQ0 B@*/E4#Z4H8D=*,\4 \4  8GM4,T\BG"+DT_S0IJ!I<2EL&@!K32R6TOF
M)MP.*K:6?GJV\_F6TG!&!532OOB@#8HHHH **** "BBB@ HHHH ***0D#J0*
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9@JY-<UII-WK%R'
M'RJ>*U]8F,&G22 \BJ^C6P6/[1CF09)H UQP,4444 %%%% !1110 4444 %%
M%0W<WV>TEEP3L7/% $U%>2ZI\29K:\:-(;C ]$/^%4O^%HW &3%<?]\-_A0!
M[/17BG_"V&!P?-SZ8-/'Q2N#R(K@C_<;_"@#VBBO(+/XFSRW"JT-Q@G^XW^%
M>JZ?<_:[&&;!&]<\T 620HR:R[K6(X7VJ0?6K=^S+;$KUKB9R3,Y/7-:TX*6
MYR8FLZ>B.QL]3CN<#<-WI5XL NXGBN(TYF2Y!7K76W#-_9K-WVT3@DRJ%9SB
MV^A5N]9C@<JI!-26>J1W/!8 UQDK,TA9NM3Z>[+>1[?6NEX>/*<\<5+G.ZEE
M2%"SG KG;GQ5%#-L0J0#S4OB::6/2-R9W9KSAR2[$]2>:SH45)79O6K.+LCU
M;3M6AOU&UQO/85:N;F.UA:21L #->>>%)9%U+"YQBMSQE-*EAM4G!7GBIG12
MJ<J-*-1SC=D=SXXABN2D95DSUKH-+UBWU*+='(">X%>$=Z[+P//*MR$4G:6Y
MXK>KAHJ-T6I:GJ]%%%<!84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6+XCA+:<S(/GSVK:J&XA$T)1
MAD4 5]*EWV,2D_,J\U>K T.8_;;J(GA3@5OT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 4EU6T<964$4O]IVO_/05F:)IUO+IJ,Z9)JW/9V5NN6C
MH L?VE:_\]11_:5K_P ]!67OL/\ G@U&^P_YX-0!J?VE:_\ /04?VE:_\]!6
M7OL/^>#4;[#_ )X-0!J?VG:_\]11_:=K_P ]167OL/\ G@:-]A_SP- &I_:=
MK_SU%']IVO\ ST%9>^P_YX&C?8?\\&H U/[2M?\ GH*/[2M?^>@K+WV'_/!J
M-]A_SP:@#4_M*U_YZ"C^TK7_ )Z"LO?8?\\&HWV'_/!J -3^TK7_ )Z"@ZG:
MC_EJ*R]]A_SP-.5;";Y1%@GUH V(;J&X_P!6X-35BZ8@BOI$484"MJ@ HHHH
M *R+W_D)Q_2M>LB]_P"0G']*: D/6DI3UHJR [4E%+0 4E+10 E07G_'NU3U
M!>?\>[4,9J6?_'I']*GJ"S_X](_I4]9E!65>?\?5:M9=[_Q]4 7=S+ NU<\5
MG7DDKQ$-$ /6M)7"0*2,\50NKI9(RH1A]10-;EFT)\@#'0584G'2JMG(-F/:
MK:MQ20/<1<Y/%)D[^E.#<FFAOFIB%R<]*"3Z4N[F@M0 A)P.*"3MZ4I:D+#;
M0 9(7)%5WN#C;&,FDDF:0[4R/6I8(E09(^;UH BC@).XYSZ42EEE)5<GTJTK
M<FJTLH28D@F@!ADD>VEWQA>*JZ5_K*M-<K-;2X4C [BJVE??H V*1SM1F]!F
MEIDO^J?_ '30!Y]JGC758=0^SV5H)?FQ3?\ A,/$-LZM=Z<(XR<;C6>EW':^
M(LOT\PUO^*-?LI-/"&-G); "\T =1INIQ7]LLBL"V/F'I5L3QEL;N:\PMI[[
M3=&N98W*%QN3(Z5>\+Q:W<V U*YN@T14G'?@?6@#T)Y4C&6.*$D61<J<BO,6
MU34?$-T\=E>I L+;6#MC/ZU/H^LWVF:Q+:WUTLR(O\)SZT >CO*D8RQQ7*>*
M=<>PBA:'D-(%_45AZAJ>IZ_?I'ID_EH#ALUCZ_I^K6)@6^N!(@E7 'U% '=W
MFK:E%<62V]OOBD0%V].*Z&"1F@#R#:W<5PFL:I=6FI:5!%)M1XER/PJ37M<N
MWMH[:SD*3[L$T =PMQ$[85LFJ>J:M;Z7&CS.%#-@9KACIOB73PM[)=AX@-Q5
M1R?UK+\8QZG>:/:W+RX1Y!M4]1R* /2;K4W;2I+BS ED RH]:AT74;RZB5KR
M'RB17*:;'J>F^$IYI9P6 !4CM3+?4-4O-*ADBFPR_,Q]J /2,C&:0.I. >E<
MC;^(6;PY<W1?YX3@FLRV\074%I]LGD)CF7">QH [YKB-6VEN34@((R*\K":[
M>0R7::G"H!X!89Q^==5X3UB6[)LYY/,FC'S,.AH ZNBBB@ HHHH **** ,77
M9@\#6H/S,.E7]-0QV$2GJ!6'?9D\4P1_PE>?TKI44(H4=J '4444 %%%% !1
M110 4444 %(RAU*L,@]12T4 9$_AZPGDWM;Q9_W15'4O#6GIIT[""+(7^[72
MU3U7_D%W'^Y0!\U:E;HGB'RPH"YZ8]Z]VT3PY82Z-:NT$9+1Y/RUX=JO_(S?
MC_6OHGP__P @*S_ZYB@"*/PWI\;;A;Q9_P!P5JQQK&@10 !P *?2$X&2>* &
MR()%VFN>N]#_ 'I9,G)J;6?%5CHP/G,&([!JYE_BOIP; MYC] ?\*J,G'8SJ
M4HU%J=1IVCB%Q(V<^E;+QAXC&>A&*X>R^)VF74@0Q.A/][BNQLKZ&^A$D+JP
M(SP<T.3;N.%.,%9&)>Z%F4M'DU-IVB")Q(^01S6_5+4M2BTVU>>7[JC)K1UY
M\MC-8>"ES$EY:)=P&)NE<7=^$W%P3&&()H_X6EI><"*0_2G#XH:83_J)!^!_
MPJ8590V+G2C/<VM"\/I8$3'._'0UI:IIL>H6CPOW&,UDZ;XUT[4G"(P0G^\V
M*Z*.1)%#(P8'T.:3G)RYBHQ459'E]SX$D2Y*QAF3UKKO#GAF+28\Y)8\\UTM
M4=3U*+3+1[B7E4&35RKSDK,=B]17GQ^*NE[L"&0_3/\ A3A\4]-)_P"/>7\C
M_A6(SOZ*Y33?'>FZC($7Y"?[QQ7412I,@9&5@1V.: 'T4$X&:Y?7/&UCH<ZQ
M3J68^AH ZBBN"'Q1TP]()/R/^%+_ ,+0TW_GA+^1_P * .\HK&T7Q#;ZV@:%
M&7(SS6M+((HR[=!0 ^BN,U#XC:;87;V[HQ9?0U6_X6AIO_/"7\C_ (4 =Y17
M&VGQ%TRZD";2A)_B.*ZFUO8+N,/%(C9]&!H LT44A(').* %HKG=9\7V&C_Z
MU@Q]%:N<;XKZ<&XMIC] ?\* /1:*X:Q^)FF7DHC\MT)./FXKLK6[BNXA)$ZL
M#Z'- $V11FN4UU]3M+F-HYP(W; %4I-9O-/UF&.XE+1%<G]* .YHKD-&UR:^
MU6="Q\H'Y177#H* %HHHH **** "BBB@ I#TI:* .80&PU-B>/->NF'05SWB
M!=MY9E?[W-=!&<QK]* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
ME>'_ /D%1TW5%WW4*Y(!IWA__D%1T:C_ ,?D/UH F33H]M._LZ*K:?=IU %+
M^SHJ/[.BJ[10!2_LZ*C^SHJNT4 4O[.BH_LZ*KM% %+^SHJ/[.BJ[10!2_LZ
M*C^SHJNT4 4O[.BK+N[<0ZK"%)QBNAK$U'_D*P_2@!]A_P A&3Z5L5CV'_(1
MD^E;% !1110 5D7O_(3C^E:]9%[_ ,A./Z4T!(>M%!ZT59!'+*D*[G.!54ZK
M:K"TK2@(.IINIVTEQ$-AP%Y-<[<Z3<7ULZ6YV)G!!I-C1T?]JVN$/F##]/>K
MJD,H([USZ:*5M;9&P6C/)KH$7:BCT%- +4%Y_P >S58JO>?\>S4,$:EG_P >
MD?TJ>H+/_CTC^E3UF4%95Y_Q]5JUE7O_ !]4 7T8+"N?2J=U(C1D #\JL^;&
ML"YP>.E49IHG7"QD'UH&MR6V^4#WJ^I^6J$1X6KRL-O2DAL4'DTF?FI 1D\4
M;ANZ4R1V>:":;D9Z4I8>E  2,56GE+?(G-.N)@ %4<FB&/8F6&6]: 'PQA$R
M>IJ4'BDW#'2@,,=* %!ZU7=@)R2!4ZL.>*JS.JRDE210 LLBM;2;0!QV%5-*
M^_4YFC>VEVH5P.]5]).7&* -FF2_ZE_]TT^D894CU&* /(Y-,34?$.UI&7]X
M1P:[:W\&6L,@9I6DQV;FKL6@01WGV@(-V[.:VJ ..\80I!IC(B@ )C@5)X70
MR>"HU7^XW\JWM2TV/4(BDB@@C%/TVP2PL%M4 "CM0!XYHVD6QU"\%]>26[-*
M=H5B,\UT-CX=T<7LWE:A)+-L/!)]ZZ?5?"5O>3>; BJ_7)J32/"\-A-YTJJT
MI&"10!R7AZ>'0]1>&[;:7<E<^E2>-=5LKPP1P2AG$RY'XBNIUGPM;ZC(LJ(H
MD4<$U3C\%6^U&F16E4@DT 8'B+_D-Z1_UR7^5-O?^)?J NKCB)F !/UKMKO0
M(+JYMYF0$PK@4_4M M=1M%AEC#;3D9]: *K^)-,6R0>:C-M&%(KG_&TZW/A^
MRF0 *90>!QU%:%MX+1+A6F"L@/ ]JW+W0[6ZL%M#&-B_='I0!S$MW!/X+N!&
M^2% -'A",3:2RD9S$0/RK6LO"XM[&:U<*4D/2M33-)BTZ+8B@#&.* /+C))9
MRSZ(V<W3D@=^O_UZVO$.BRIX5LK=%/[MOF([#BNLN?#=I<:O%?M$#)'T-:UQ
M:17$!B=<J1C% 'E&FZ-I,]JQ?5)5QPP#'K^==?X2TG3[&Y>6TN6F9ASDU'+X
M(03$P!5C8Y(KHM*TF'38@$0!\8)% &C1110 44C.J#+$ >YK"OO$4-NYC523
MTR*!.26YO4V0[8V/H*X]];N&.5<@4PZQ<F-@9"<BE==S+V\#4A3[3K*7 _AX
MKH:Y#0M4CCD\J8'>QSN-=:DBR+E2#]#3-5)/8=1110,**** "BBB@ HHHH *
M*** "J>J_P#(+N?]RKE4]5_Y!=Q_N4 ?.&J_\C,?K_6OHCP__P @*S_ZYBOG
M?5?^1F/U_K7T1X?_ .0%9_\ 7,4 :=9NNW?V/2+F4'YE3(K2KGO&)_XD-U_U
MSH \*1KGQ7XC,3228;L&/K7J^F_#:PCLT+R,69><UYI\-@#XP&?2OH>/_5K]
M* /'_&W@.'3-.:\M97W@] <57^&6O3PW,MI,Y;+;1N.:]%\< '0'S[UX]X)X
M\2D#_GK0!]#UQ7Q#9ET>7!(^3L:[4=*XGXB?\@>7_<H \K^'^A1:[J BGD8#
M;GK7IK_##3V0CSW_ %KB?A'_ ,A@?[M>YT ?/_C'PI-X8?[3;3S>6&X.XUW/
MPT\1R:G9O',<E.!DT[XM*#X<!_V_\*Y;X2DAYA_MT >W5Q_Q )&@7."1\E=A
M7'?$'_D 7/\ N4 >0_#_ $>/6]5,,[L!MS7JI^&FGNG^N89%>>_"7_D/-_N?
MXU[VOW10!X/XT\&OX;07EK-*1NX^8UU7PP\0S7UH\4YRRG:,FM;XH*&\.KG^
M\?Z5Q/PLXN9!_P!-/ZT >VR?ZI_]TU\_?$4L^OQ*7;!]Z^@9/]4_^Z:^?OB'
M_P C'#0!V'AGP!9:EH<%S),X9QS6Q_PK+3_^>[UL>!_^17M?I71T 8^C:!!H
MR!8G+8&.:L:T2-+F(..*T*S];_Y!4WTH ^<[^,W7BMXG=L,X'7WKUNU^&MA+
M:1.9WRR _I7E$W_(Y'_KHO\ .OI"P_X\+?\ ZYK_ "H \K\2?#6.TM6GM)Y2
MR@DX)K ^'_B&ZM-=CTZ5V92Y!+-GH:]NU4 Z;<9_YYM_*OG?0?E\=IC_ )ZM
M_.@#Z31@R@CO6-XJU$Z9H4]ROWE%:EF<VJ5R_P 1?^14N_I_0T >,6<5SXK\
M0/NEDVE@2 QXKUNS^&VGQVR@R,20"<UYO\+0#KDV:^@4_P!6OT% 'B_C?P-'
MI%NMS:2R;B<G!(JW\+M=G8BRE<ME\?,<]Z[#Q^,Z0?\ =->9_#3_ )&!/^NA
M_G0![1JVG"_\G)/R-GBLW5O#::BRDLP(7&172]J* ,#2M 33\;22?4UOCI11
M0 4444 %%%% !1110 45')*D2%F8#'J:P;SQ)$CF)%;=ZB@F4E'<NZQ#O5)/
M[G-3Z5/Y]H&SGG%<M<ZI<3QLN\X(J/3M2FL8=C,2N>@HNNYG[>!W=%8EAXAA
MNCL*E2.,FMI6##((/THL:II["TR258D+.< 4^N9\;WLEEH321MABV*!D=WXO
MB\YH[-ED*'##TJQIGBFWNY_LTLBK/C.VJ'A;P_:&U^U2Q!FF&XFG7WA#.I&\
MLML;8ZT /U+Q/+::M:VJ*"LKX)KJQR :\C\5/-;:OIT0),V[&X>O-:MQJ^JZ
M,ZW-W,SPD@;<4 >D45S&H^)XK72X7.1),F5KF&UO588%OVNLPL<;.] 'IU%<
M;-XIW:7YT9.Y4R:QH]3UJ_L%OX)V6,\[<4 >ETA.%)]J\TLO$FHZX'AM'=)(
M?E8D=36AH6OW2:Q)I=Z[/*BY+=N] '1C59_MJP[!M)QFMFN%35U.MI'@\OBF
M:SXAN9];ETNTE\F1.=QZ4 =[5.?4[2WD\N24!LXQ7%V.MZA:7<=I=,\S2GAE
M!(%<[XH;41KS;9B%WCC\: /858.H9>01D4M<'=ZS>:5ID1D<DE 1BH]+N]8O
M+<ZAYY\AE)"D4 >@45R7AKQ']OMKIIB<PL5YI-'UN>_\33V^6\E5R...] '7
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 97A_P#Y!4=&H_\ '[#]
M:BT>X2WT>-G( )QS3[YP]S RG@T 37=\UN@$8!;/(JQ:W:W"9SSWK,B0S:PZ
MN,IBI+DBRNHQ&I"MUQ6G*MA&Q13(I!*@8=#3ZS&%%%% !1110 4444 %%%%
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MBI=PN<*V34]>=C0M>&GI<QWPR4#<?2M+PIKLUQ>/IMTQ::(?,Q[T =E1110
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M#XL7T+:'Y22*S;^@-8_PDM)-LTA4@;L\B@#V:N.^(/\ R +G_<KL:X[X@_\
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M)O#C-K\NH[AAUQB@#D(2!XAB)Z;ZNZSI-E>:_--:SL;S&2@K<3PLPU!;@LN
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MRIUB+<!E/%>E_#[PLVBV3--@L_S4 =U)_JG_ -TU\]?$@L->B*C+=J^A9/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEKMOIEQ'#,0"_3)J_;7"74"RQD%3W% #HH(X<[%5<]<#%252U'48=.MVEE8
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M_#N\F#7EO(Q8)(5&3GO7HM>;>!(I$O[\LA&9CU'O7I- !1110 4444 %%%%
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M:ZX;!K4\";;#0HP['"*3DGVKFX5?6].O[V4$^43M)K1TV21?#<90G)!SCZ4
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M.U:W0P9"*,<\"M2JNH+NM)/930!2\/N'LVQV:M>L+PL<V,O^^?ZUNT %%%%
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M% %6VL(+4YC10?85:HHH **** "J=UIMO=L#)&I(]5JY10!E?V!8_P#/)?\
MOD4?V!8_\\E_[Y%:M% %>VLH;48B0#Z"IR 1@TM% &?-H]I.Y=XUR?\ 9%1?
MV!8_\\E_[Y%:M% %.+3+6'[L2?\ ?(JTJ*@PJ@?04ZB@ HHHH KW%E!<KB2-
M3G_9%93^%-.=MQ0?]\BMVB@#-M=#L[0_)&OXJ*T555&%  ]A2T4 %%%% !11
M10 4444 %%%% !1110 4444 5=1_Y!T_^Y67X5!_LS)_O5=U:7;!Y?\ ?&*;
MH<'V>QV>^: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,.WM;RTB
M$4:_**EVZA_=%:]% &1MU#^Z*,7_ /=%:]<CXLO[NSO(/LX<CN%[T :^+_\
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MO6B[ R(/#EH9(IQNRO(K= P,4  # ' I:+@0W7_'L_TK-TO_ %E:5U_Q[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JAJW_'C)_NFK]4]2C:2U=5&25Q51W)EL>3
ML[1SLRGG<:[#PWJ%],=C'Y!6>?#SP6LEV^20WW#WKL=&CM_L491%#XYQ776K
M1:Y4<E&C).[-(=!2T45Q':%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C,%&2<4 <#XQ7$D9
M]ZQM.TNZO'!A!KK#;C6M1=7&%A;\ZZ.VL8+9 $C4$=Q76L0HPLCD>'<IW94T
M>TGM8 LW7%:E%%<K=W<ZDK*P4444AA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D>M "T4W>OK2
M>8F<;AF@!](3@4A=0.6 I!+&W 84 4[C5K>WDV.3FF)K5J[!03DU4UJP\Q3.
MG4#H*YWE3UPP[5I:-C&=1Q9WJL'&1TIU<]HNI<"&0\D]ZZ '(R*AJQI&2DKH
M"<#)KS_Q5JAFE\E&^Z:[JZ8K Q%><_89-1UF48. W-<]9O9!(RK6RFO) D8Y
M-=;I7A,8#7*5T.FZ/!9QK\BEO7%:8 '2B%%;L2CW*-OI%M; ;%JZL:J. *=1
M6R26Q8F!Z4M%%,"":TBG.7%0_P!EVW]VKM%.[%9%+^R[?^[1_9=M_=J[11S,
M+(I?V7;?W:L10)",(*EHHNPL@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH BG@6>$QL.#6!IDCV>HS)*<1DX2NDK#URS9_*FB^78<G'>@#;!R,
MTM4-+O!>6V[N.*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MSNJV<MK.MQ:?+DYD]ZZ*HYHA+&R$=1B@"OI]ZEY '4\C@YJY7,$2:/J SG[/
MU+=JZ*"99XE=3D$4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3DFMFH+6=)X5=",$=JGKD.L**** "BBB@ HHHH **** "BBB@ HHHH ****
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MN@Y)'-7[.VP^4].A;?$K>H%/K 'BW2 ,"[3BE_X2[2/^?M*T*-ZFO(L:EG8
M#U-8?_"7:1_S]I7#>/?'42V8CL9@Q/!*F@#K]:\6Z5:*T-P=X/7:U>4:QKNG
MO>,]NI"L>.:X2>_N;B1FDG<Y/<U7,CGJQ-7";@[H+'HEI>QW"_*>?K5P5YS8
MWLEM.K[B0.V:[VQG^T6R/W(KMI5><EJQ:HHHK81/92_9[M91U%>NZ7+YVG0O
MZK7C3'"\5ZYX>).DP?[M<F)6S*1K4A /6EHKD&(%"C ICCBI*JWTAC@9AV%
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M:6N=LM2ELY1;W0VK_>-= CK(@=3D'I6)L.HHHH **** "BBB@ HHHH ****
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:K<</M4ZPU.L5-(B4R...K*+2JE2!<521BY7% I:**9(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% #719%VL,BL.]T=XW\VQ(C/
M5O>MZC&: .?M-9:"06URK%_[V.*V&NXE@,N]2 ,XS45YIL5VA4_*?4#FN3U5
M)-,98HW9E?@Y-!,I<JN2:EJ\MU*1$Q$?I664#')'-*!M%.12[!5Y)Z5E*39Y
M\YN3$Q3=BYSBKO\ 9EW_ ,\S59T:-MKC!I6:)::W+%GJ4UE,"6)B]!79V5XE
MW"&7TYK@>*U]!OOLTQB8_?/&:TC*^C.BC5=[,[&BBBJ.P**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J&YN%MH6D;H*EKF/$=\1*+=3\K#F@F<N
M57,_4=5FNI6$;D)Z5G;%)R1S2@;1BC(K)R;/.E-R>HN*;L7.<<U8BM9YE)C3
M( S4)^4X/44M1:K4N6&J3VDP#.3&3@"NRMKN.XA$@88[\UP'!%6=/NKD2"QC
M!*2').>:TC*^C.FA5=^5G57^L16HVJ"['@;>:SX[.[U.822O_H_=#5ZQT6.!
MO-=BS'LW-:RJ%&% 'TJCK(+6SBM4 C7%6*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0@$<]*10H&%Z4RX.V!R.PJ&Q
M<O I- %NBBB@ HHHH **** "BBB@ HHHH 0J#UJ*6!&B<8ZJ:FHH \FUVS-G
M>D$?>)-95>D>*-&%Y"9T7YU' %>=21/"Y2088=17J4:BE$Y9QLQA&141A!;-
M2T5L0-"!>E.HHH 9(NY#7:^!+EVF:$GY57BN,;D8%=OX(L)89&G=2%9>#6&(
M:Y#2G\1W%%%-=@B,S'  R:\PZ3-U?6(=,B8ORP&<#K7'S:OJ5](9+:X\M#T!
MIGBFZ%_?B2R8R%1C;VS5"&&\,8W1[3Z"@"\+C6QS]L!JAJ5U]J01S F5>K'O
M3Y#?P#,<6XCUJJTSZJWE,@62/E@M.,G%W0&:Z.AP$9OH*$CFD; AD_[Y->A^
M'-*@N+ LZ@D''(K?BTJVB.1&A_X#75]9TV%8\\TKPK<WKJ[\1]P17H&F:1;Z
M=$!&@#XY(J^L:(,*H'T%.K"=24]QV"D(R,&EHK,"![2%XRC)E3VIGV" 1E%3
M (Q5JB@#(M]!MH+L7 C&\=ZOK8VZ,S*F"W6K%% #4C6-<*,"G444 ,*TTI4M
M&*!W(/+H\NIL48I6"Y$$IX6GT4PN)BEHHH$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH:'<@-.I%&U<4M0>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111VH **K
M&_MUG$)?YST%6: "BH)[N&V&96Q4D4B31AT.5/0T /HHHH ***9+*D,;2.<*
MHR30 ^BJECJ-MJ$1DMGW*#@FK= !1110 4444 %%07-W#:1EYFVJ.]212I-&
MLB'*L,@T /HHHH **1F"#)Z5!;WL%R[I$VXIUH L5@>)-.-W )%',8S6_370
M.I4C@TT[.XI14E9GD3DHQ# @^AJ'S"&R#S7;:]X:,S--;*2_I7&75A=6I(E3
M&*[Z3A)'FU*,HL?_ &C<!=GFG;Z5"9"QR3R:IF3!Q5FVMI[DXB7)K;EBB.5L
ME5B3@<UTVC:'<SH95;8PY!-&B>&)7D5[I"HKN8(4@B5$ P!CI7%6FMHG70HM
M/F9@"/4+'YI9C(!V%*GB7#A&M9/3.#70E0>H!^HJ)[:)Q@HH_"N8ZRO;ZG%,
M,DA/J:LBY@/25/SK.GT&"<Y,CK]#55_#J0@F*61F]R: -6YU&"V0L9%..V:P
M&\5QS7\=O&I&3C-<YKEI>P3,TFX1_4UGZ<)OMT;Q+N<'C-=L*$>7F>IQ3KRY
MN5:'K41)C!/6GUST=_JB#]Y"HJ9=7E'^L %<1VFW161_;<(^\X%']O6O_/2@
M#7HK(_MRW/1Q33K!/W,&@#9I"0!DG K";4[]O]5&IJM<7.N31E%MUP?3_P#5
M32NQ-V1-KGB".RC*(<MTX-9WAS5FF=O.DZMQDUS]_I>I>8TL\9 /O4>CPB6_
M2W=BNX\X-=OLHJF['%[63J*YZ;)>P(,B13]#67<>(UA; MW;W IT?ANW0[O.
MD/U)K2AL885QM#?45PG<8GVVZU$8A#Q9]169JNA7ODM<S2^85'2NU"(O15'T
M%#HLB%6 P::=F3**DK,\A<E3A@0?0U$7KL==\,L[--:J68]17(7-E<VQ(E3;
MBN^DXR1YLZ4HL$N9(L[&QGK3?,).2:IF3G%6[:TN+HXB3<36S42>5LD1BQ '
M4UW'A;3BD/G2+A@>,U0T/PNY=9+I2N.17;1QK$@50  ,<"N&M-;1.NA1:]Z0
M^BBJ6IZE#IEF]Q,VU5ZFN<ZR[17GTOB;Q!<R&33K9)+?J&/I^5:VA^*6N;A;
M/4-L=VW1!0!U=%)D49Q0 M%':F>8N[;GF@!]%%-9U49)H =13&D58R^> ,UE
MPZ]:S:B+-9 9#VH UZ*YS4[[6(;Z%;:!6A9L,3V'Y5<NM<MK.X6"60*Y'(H
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M*+$6 [BL?Q5<7']I0V[Y6-QS@UC.ZV[%$.X#UH Z^/Q?$[@&!A[FMRTOX;M
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M5-275;(VZZ/*LQ/^L*FNK&FW"^%N<DB'A,<UV M8 V1$G_?(J7:NW;M&/3%
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MC=6U55K^W2Z^SEOWA[4 9@\.Q-9""8!RJX4GM69'X+3.V5E>+^[77@Y&12T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH4?W!]*:\*.P9E!(Z<5)0 4444 -D?8A;TID$PFC# 8S2SJ6@8#J14-E&T<
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M;L_93Y><;^U6M0\5I9I 5A\PS#@"N,L8[FZT0(ZCRMW7O6A>0^7>Z6IZ!O\
M&@#6_P"$W;[3Y#6+!\=*N6/BL7-P(9K<PECA=W>LBZC4^,B-HQM]*C\0#9K>
ME!1CY^WT- 'H%%(/NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M5VP0QP* .0\+Z&\UK+]JB*@MRK#K6T/"ZB4_O!Y79.PKH5*;05P 1FER/44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBV,.9E/F&HM \-KI5S=/MP)#E: ,Z"WA/C-H_+79MZ58U5O[.U>SCA&U97Y
MK1329(_$#7Q'R;>M4KF+^U]6B= 3]G?F@#JAT%+2#I2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %)@>E%% "TF!Z444 +28'I1
M10!1U: SV4B+*T9*XW+U%<[X9T&.TN1/)<23R@_><<T44 =C28'I110 M%%%
M !1110 4444 %%%% !1C'2BB@ HHHH **** "BBB@"/[/%NW>6-P[U)110!&
M;>)G#F,%AT-$L,<P D0, <C-%% #P H  P!2T44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "8S4:6\,;ETC56;J1WHHH EHHHH **** "BBB@ HHHH
E **** "BBB@ HHHH **** #%1I!%&Q9$"D]2*** )**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gjnp4w4lrub1000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -'!M8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *YOQKXRL/!>B/?WK9<Y$48ZNW^<5TE> ?M +(-<T%
M[DG["9.0>G;=0!0'Q.^)FL1R7^FZ8JV8/R 0-T_/FNL\!?&=M4U)=&\36_V*
M_8[4<J44GT(/2O4/#_V3_A'[#[#Y?V?R$V[.GW17/>(/AGH'B+7;75KF I/"
MV6\L[?,^M '9 @C(Y!I::B"-%1>BC I)98X(FDE=411EF8X % #Z*X#5_C-X
M,T:Z-O/?R3..";>/S!^8-+I'QD\&:U<B""_DA8G -Q'Y8_,F@#OJQO%=]/IO
MA?4+RV;;-%"S(?0@&M:*6.>)98G5XV&593D$5@>._P#D2=6_Z]G_ /030!SG
MP=\3:GXI\*R7NJS>;,)2H;VR:]%KR+]GO_D1I?\ KNW\S7H&H>+]&TO6(=*O
M+H17<Y_=JW&: -VBD!! (Z&EH **PKWQ?HMAKL6BSW8%_*5"Q#D\]*W: "BL
M+Q!XPT/PQ%OU2^CB8C(CR"Y^@KCE^/?@9G"_:+T9.,FV./YT >G45CZ%XHT;
MQ)!YNEWT4_JH8;A]16Q0 45B:OXLT?0]0M['4+H17%P,QJ>_.*3Q#XOT3PO!
MYNJWT<1QD1@@N?H* -RBO-K7XZ>"+NY6!+NZ1F/WI("JC\<UZ#8W]KJ5HEU9
MSQSP.,J\;9!H L5Y;!\0M9D^-'_")LMM_9WS\B,[^%)'.?;TKNM?\3Z3X8@B
MFU6Y$$<K;$)[G&:^?;;Q=HR?'S^WFN@-._>?O?JI _G0!]-45A>'_&&B^)VF
M72KL3F'&_';-;M '(?$?Q5=>$/##ZG:1H\JMC#C(KR*#XW^-KF)98- ,L;<A
MX[1V!_$5WWQU_P"2?2_[]:OPA_Y)II'_ %Q% 'F'_"Z/'G_0M2_^ 4E>N_#W
MQ#J?B;PTE_JUFUK<ERIC,93@$]C75U7OKV#3;&:]NGV00H7=O0"@"Q17/0>.
M/#]QHTVK)J$8LX6VM(Q Y]*RM ^*WA?Q-K TO39KE[DYP&A(!Q[T =M13)9H
MX(FEF=4C499F. !7!:M\9O!>CW1MYK^29QU-O'Y@_,&@#T"BN!T?XQ^#-:N1
M!!?O"Y. ;B/RQ^9-=W%+'-$LL3J\;#*LIR"* 'T5%<3QVMM+<3-MCB0NY] !
MDUEZ/XJT?7;.>[L+Q'@@.)')P%_SB@#9HKS[5OC1X+T>\:VFOI97'5K>+S%_
M,&M?PU\1/#7BMA'IE\#*>D4HV.?H* .JKE/B+XCO?"O@ZYU73Q$;B-@%$JY7
MOV_"NJ) !)Z"O&?BWX\\/:GX-O\ 2;6^#WBR[3'[C(- 'H'P]U^\\3^"-.UB
M_$8N;A6+B)<+PQ' _"NGKQKX7?$3PUH_P_TG3;V_6.ZC#!D/8ER1_.O8XY%E
MC61#E6&0: '4444 <II/C.WU#QKJWAQMJS6>UHS_ 'E*@G]375U\AW?BRYTC
MXM7'B"'<8X[K;)Z,!Q@_E7UEIM_#J>FV][;N'BF0.K#O0!:HHJIJ>HP:3IEQ
M?W+!88$+L?84 8%_XSM[3QQ8^&TVM+<(6<_W3G@?K755\E:%XIN-5^-5AK=P
M2$FO !Z%!P/Y"OK13N4$=QF@!:*PY_%VC6^OKHDMT!?L,B.MR@ HHK"M/&&B
MWNN2Z-!=AKZ(X>/TH W:\KT#XAZSJ7Q?N?"TZVPT^*.5E*QD/E>G.:[KQ!XK
MT?PPD+ZK="!9B0F>Y%?/WAKQ;HUG\<KO7)[H+8/',%E]2>E 'TW16+X?\5Z1
MXGCF?2KH3K"0KD=B:VJ "BN4\1?$?PQX88IJ&H*90<-'#\[#Z@5@VGQT\$7E
MRL"7=TC-_%+ 54?CF@#TFBLF?Q+I$&B-K!O8GL5&3*C BI])UBRUO3H[^PE$
MMO(,JP[T 9_C36;G0/"E[J5F$,\*@J)!D=:ROA;XJU#QCX+CU;4UA%RT\D9$
M*[5PI&.,US_Q-\>>'G\-:MHHO1]N7]V8_<&N=^#GC[P[X>\ 16&I7RPW N97
M*'T)&* /1/B?JNM:/X+GN]"C=[P.!\BDLJX.2 /PK/\ A%K?B+7/#4\WB*.1
M9DEVQ-(I5F7'?/O787>MZ?::(=6N)@+'RQ(7/3:1FET76=/US3TO--E$ENWW
M6% &C11T&37'^(?B=X5\,RF*_P!0#2@X9(!YC#Z@&@#L**\VM/CIX(O+E8$N
M[I&;^*6 JH_'-=_I^I66JVJW-C<QW$+='C8$?I0!:HHK$L_%NC7^N3:-;W0>
M^A)#Q^F.M &W17'>(OBAX5\,2^3?ZAOE!P4MQYC+]0.E5-$^,'@[7KH6]M?O
M%(3@?:4\L'\S0!WE%("& (.0>A%+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 07E[;:?:O<W4R10H,LSM@
M5XUXC^/<2W,EEX9TZ6]F4X$Q4LI_X#C-8'Q'\1ZG\0/&D?@_1"PM8I-DC*>'
M/<GVYKUCP7\-]$\(6")%;)-=D9DGD4$D^WI0!Y9#XW^+NIIY\.EQ1KC[ODLG
MZ$T1?&/QOX>GV>(]$\R%>2T<++_X\<BOH:JU]IUGJ4!@O;:*XB/59$##]: .
M7\'?$K0?&406TG$-T!\T$AP0?;U_"NQKQK5_@=&GBBUU3P[>O81^9NF56Y4>
MJ\_I7L4,?E0I&6+;1C)ZF@!]%(S!5+,0 !DDUQ.O?%GPAX>G,-WJ)ED!P1;+
MYF#[X- ';T5Y[IGQJ\%:K=+;Q7TT3,<!IXMB_F375:IXHTC1].BU"[O$6UE.
M$D4@AJ -BN(^*OBS4?!G@TZMIBPFX%S'%B9=RX.<\9'I776]_;W6FIJ$3[K9
MX_-5_5<9S7B7QJ\<Z!KO@>33-/O1+=K>1L4'HN[- 'K7A#5KC7/"UCJ5V$$\
MZ;GV# SGM6Y7E7@#XC>&;/PII>FS:@JW2IM*>^37JBD,H8=",B@!:*I:IJ]A
MHUH;K4;J*WA'\4C 9K@;CX[^![:=HFNKMRIQE+<L#^.: /2Z*Y3P[\1O#'B=
M@FG:@OFM]V*7".?H*ZN@#@?B[XCU'PQX,:_TN;RK@2JN[V)%;O@C4KG5_"-A
M?7C[YY8PSMZG%<9\?O\ DG3_ /79/_0A74?#7_D0=+_ZY#^0H ZRBJFI:G9Z
M18R7E].D$$8RSN<"LW0?%VC^)7D72IS.(_O,%X'XT ;M%(S!5+,0 !DD]JXC
M7?BUX0\/SF&ZU RR X(MU\S!]\&@#N**\[T[XV^"=2N5@COIHF/\4\6Q?S)K
MOK6ZM[VW2XMIDEA<95T;(- $U%%0W5W;V-L]Q=3)#"@RSNV * )J*\ZU#XW>
M"=.NF@DO9Y6'\4,.]?S!J]H7Q9\(>()Q#::B8I"< 7"^7GZ9- ';T4@(8 @Y
M!Z$5G:YKVG>';#[=J<XAMPP7<?4]* -*BLN7Q%I4&D+JLUY%%9LNY9'8 &N(
MN/CMX'MKAX6NKMBIP62W+*?H<T >ET5S'AWQ_P"&_%  TW4$,AZ1285_RKIZ
M "BBN>\0^-M \+H3JE^D;XSY2D%_RH Z&BO,D^/7@:20(+F]!)QDVQ _G7<:
M+XCTGQ#;>?IE[%<+W"L"5^H[4 :M%-DD6*-I'.%49)K T[QMH&J1W<EM?QF.
MTSYS,0 N* .AHK@K7XP^$;W65TJVNKB2Y=]BE825)^M=[0 5RTGC*VA\=Q^&
MY2JM) 71B>K9''Y5U-?*/Q,UZZM?C#=7]DS;M/D4JR]AM&?YT ?5U%9'AC7+
M?Q'X>L]4MV!6>,,1GD'T-:] !7*>)?&=OH&OZ+I)VM-J$X5AG[J8//Y@5U$T
MT<$+RRL$C099B> *^1_%7C*;7/B='K"[OLMK<B.$]E X_GS0!]=@Y&?6BH[=
MM]M$WJ@/Z5D:MXLT?1-0MK&_NA%<7+!(E/<DX% &W1110 45AS>+M&@U^/0Y
M+H"_D.%B]:GUWQ%IOANS6ZU2X$,+':&/K0!P6K_$+6;'XR0>%(EMO[/=(F):
M,[_F SSG^E>I5\RZYXNT:Z^.]OKL5T&T]4A!E^@&:]ZT'QKH7B6X>#2[P3R(
MNY@.PH Z"BBN<\1>.O#WA=3_ &GJ$:2#K$A#/_WSUH Z.BO,X?CSX'FE6,7-
MXI8XRUL0/SS7;VOB32+[29-3M;V*:UC7<[HP.T>] &K5/5KF2RT:^NXL>9!;
MR2)D<9521_*J^A^(=-\1VLESIDXFBC?8Q'8USGC'Q[X>TRQU32KJ^"7AM9$$
M?N5('ZT 9_PC\<ZKXWTJ[N=56W62)PJ^2A4=_<UU/C.]U+3O"6HW>DQ&2^CA
M+1*!DY^G>O$?@CXTT/PUHU[#JEX('D<%0>_6O>K?7=/N]$_M>&<-9;2WF>PZ
MT >=?!KQ'XJUU-0'B&.<QQG]W),A4YXX&>U>KUC^'_$.D^(K6:;2)EEBAD\M
MRHZ-C-;% !17,^(O'_ASPOD:EJ"+(.L4>&<?A7,P_'CP//,L:W5XI8XR]N0/
MSS0!Z916?I.N:;KEJ+C3;R*XC/78P./K5]B%4L>@&30 M%8FE^+=&UC4+FQL
MKH27%L2)5_NX_P#U5B:_\6/"/ARY-O>:@9) <%;=?,P??!H [:BN)T#XL>$?
M$=S]GL[\QRDX5;A?+W'VR>:[:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Y7Q[X*M?&^@/8S'9.GS0R8^ZW^!XKJJ* /F[PWXS\0?";5AX?\
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M *]G_P#037D?QPMELO&_A_4X,+.SI&0O4_,>:]9\;.7\"ZHQ4J3:N2#V^4T
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M]]5[Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDE6=Y-R],,: (?BW_P DTUG_ *X-_(UE_ W_ ))W:_4_S-=5XVT*;Q+X2O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG)_6H=)^#.L:UJ<>H^-M4>X*G=]G63</IG/2O:;.S@L+2*UM8ECAB4*B*,
M4 >5?'CPO<:MX=AU>T!:;3\E@!SLZD_H*ZGX<>,[+Q7X:M665%O(D$<T);Y@
M1QT_*NPFACN(7AF17C<896&017B_B#X,:A8ZO)JW@S4GLYG.3!OVC\\]* /:
MZ\^^(_Q+MO!U@L=DT5SJDKA4@!W8]<@5Q1\,_&:ZB%M<:A;11=#)'<#=6[X/
M^#-OIVH#5_$=TVI:CNW+O.0I]\YS0!W.FZA>:KX-2]OK;[-<30;FCSTR*\D_
M9_\ ^0SX@_ZZM_,5[I<P>;920)A=R;1[5Y[\,OA[?>"[_4Y[N=)%NG+*%[9-
M 'I-%%% '(?$^]^P_#G67!PSV[1@^Y!KG_@39&W^'\=P1_Q\N7SZX)%='\1?
M#5YXL\)2Z38RK'+)(I+-TVC.?YU=\%Z"_ACPE8:1(P9[="&8=\DG^M %OQ'H
MT'B#0+S3+A R31D 'U[?KBOF2'QAK'@K0=:\#L'-P9O*A8>C'#?F.E?5]>=^
M(OA;9:[X]L/$+$*D6#-'C[Q7E3^= %GX3^$AX5\'0+*H^UW8$TS=SGD#\ :V
M?'EG]O\  NL6N,^9;D8_$5T( 50JC  P *BN[=;JSF@89$B%: /)OV?+SS?!
M][:L?F@NB /; JE\?K%[=="UV)"PM+G=*0.P*XKI?A?X!U'P1)J"W=PDD5PV
MY O8YKM]:T:RU_2IM.OXA+;RC!![>_UH K>%M=L_$.@6E[:3))OB7> >5;'(
M/XUJ7%Q#:P/-/(L<:#)9C@"O!YOA%XT\,7KOX/UC=;,Q(B>7RP![\\TR;X=?
M%'Q$PMM<U9(+0\/Y5QN!'N,\T )X7G'C#X]7.L6@+V=BQ9),<8QC^9KZ!KEO
M _@?3O!&D?9+3]Y,_,TQ'+G_  KJ: / ?$G_ "<Q:_\ 7.#^0KWZO--5^'=_
M??%N'Q8DZ"U1(U*'K\H%>ET >/\ QS\.7MU8V/B&P4M)ISAI O7:#V_$UV/@
M#QO8^,= @N$F07BJ!/"6^8-WX]*ZNX@BNK>2"9 \<B[64C@BO%M=^"VHZ=JL
MFJ^"M3>SE<Y-OOVCZ9ST]J /;:\K^,GCJTTCPS<:/:3++J%XICVQG)1>Y.*P
M/^$>^-%U$MK/?6D4)X,D<XWBMK1_@Q!9:;?7&HW;:AK5S$56>7D(3]<\^] $
M'[.Y)\&7Y/4WG/\ WR*].\0_\BSJO_7G-_Z :YGX8>#+OP5H=U8W<J2/-<&4
M%>PP!76ZI:M>Z1>VB'#3P/$">Q92/ZT >/?LY_\ (OZC_P!=!_6O3_&7_(FZ
MM_U[M7-_"OP+>^!M,NK:\F21IG# K^-=AKU@^J:#>V,9"O/$44GMF@#RK]G3
M_D6-;_["'_L@J/XX:#>PW6G>+;%2YLG42A1R%!X_G76_"SP1>>!](U"TO)4D
M:YNO.4KV&T#^E=M>6D%_:2VMS&LD,JE65AD$4 87@SQ=8^+M"M[VVF0S%1YL
M6[YE;OQ729P,FO#M7^#.M:-J4FH>"=5>WWG/V<R%!],YZ54?PC\9+U/L]SJ,
M$,+\,\=U\P% &I\:_&L3Z<OA32I!<7EZ0DPC.["YZ<=\@5W?@/09/#G@"ST^
M< 3K!F4#^]BN>\"_""R\-WG]JZK.=0U0_-O<9"G]<GWKTN1=\3H.ZD4 >"_!
M]0?BCXF8CD3/C\VKWVO-? OP]OO#'B_5]7N)T>*]D9D5>HR3_C7I5 &9XA_Y
M%Z__ .N+5Y+^SM_R"-3_ .NQ_I7L6J6K7NEW-JA :6,J":XGX6^!+WP18WD%
MY,DC32%AM_"@#T&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ]C?6VI6<=W:3)-!(,JZ'((JQ0 445YCXB^-FA^'/$%YH]S!,TUJ^QRJG!.
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MP?I_C+6KQ=7G:.VMXP[MGJ3GO^%?0GQ@O);7X<:DD ;S9E"KM&3]X5\T>$_
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M#!C]/Z5],ZK?#3-*N;TKO\E"^WUKPZ[_ &AK"ZC>WN-!,L9/*M@@X_&@#8^
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M+_:"_P"2??\ ;Q'_ #KPOP5\0-;\&6MW!I,2NEPZN^03R!@4 >Z?\,_>%/\
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MQD=:^D/%.G27'@S4-/LX\NUMY<2?3&!7C7P@\">(/#WC&2\U*R,4#)@-GWH
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M,LDVPPJ /4GU/O0!\_?M'_\ (R:5_P!<'_FM>O\ PEADM_AAHD4J[7$39'_
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MK''D_7=7T77D/[/VA_8?!\VI/%LENY",D<E5Z?SKUZ@ HHHH **** "BBB@
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MA$5<_P!T8IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'SS\2/".I^'?B39^*-&M))8KB8/(8QG8_0\>FVO?[.Y6\LX;
ME 0LJA@".14KQI(,.BL!ZC-* %    '0"@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "O ?BW8:QXS\>Z?H=E9RM9PD;Y"#M!R=W/TKWZF>5'OW^6N[
M^]MYH I:)I,&AZ+::;;C]U;QA ?7 QFM"BB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKR_XF?%B'P@\%CIGDW6H._P"\
M1F.$7\.] 'J%%9GAW49-6\.V&H3*%DN(@[!>@)KS+Q%\2_$J_$&7PSX<TR"\
M9(]PW$YX^]0![!17!^$-6\<WNM&+Q#HT-I8^4Q$B$D[N,#^=97C+XGW]CXF7
MPUX7TU=1U,'$RDGY#UQQWZ4 >HT5YCX)^)M[JGB.3PUXDTY=.U5<^6@)P^.O
M7OP:].H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YGQMXSL/!VA37MQ*AG
MVD0Q$\NW;\*R?A9XVO/'&BW5]>P1PM%*%58R2,<^OTH [RBO.?BIX_OO!4&G
MKIUO%/<W4NW;(3TY]/<5GV7B'XH2W5N+CPY;I [J)&W'*J3R?RH ]6HKC/B'
MX]@\#Z9$XA%Q?7+;;>#^\?\ )%<1;_%OQ-HFHV7_  EV@)8Z=>8*SJ3E0>_7
MI0![513(94GA26,Y1U#*?8T^@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN4D=.* /&_\ AI31O^@!?_\ ?U*/^&E-&_Z %_\ ]_4KTK_A7O@__H6],_\
M =:\I^//A?0M$\)6$^EZ3:6<SW@5GAB"DC:>.* /9_#>MQ>)/#ECK,,+PQWD
M0D6-R"5'H<5J5R'PL_Y)?X>_Z]%_F:Z^@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_7C-_P"@&O)?V:?^0/X@_P"OB+_T%J /=**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\;_:._Y$K3O^OX?^@-7LE>-_M'?\B5IW_7\/\
MT!J .U^%G_)+_#W_ %Z+_,UU]<A\+/\ DE_A[_KT7^9KKZ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Q?%_\ R)FM_P#7C-_Z :\E_9I_Y _B
M#_KXB_\ 06KUKQ?_ ,B9K?\ UXS?^@&O)?V:?^0/X@_Z^(O_ $%J /=****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\;_:._Y$K3O^OX?^
M@-7LE>-_M'?\B5IW_7\/_0&H [7X6?\ )+_#W_7HO\S77UR'PL_Y)?X>_P"O
M1?YFNOH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\7_\B9K?
M_7C-_P"@&O)?V:?^0/X@_P"OB+_T%J]:\7_\B9K?_7C-_P"@&O)?V:?^0/X@
M_P"OB+_T%J /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZW_X$_\ V->!F$8/$2NS6%['<>;'_P ]%_.CS8_^>B_G7#_\(U:?\]];_P#
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M)E-U_O&NK#Y?*NFX27XB<K'UU_PD^F_\]OTK6BE2:)9$.589!KXO'C#7L_\
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MD^U6_P#SWB_[[%'VJW_Y[Q?]]BN;_P"$!T;UN?\ OY_]:C_A =&];G_OY_\
M6HY:7=_<&ITGVJW_ .>\7_?8KP/]H2>.2[TQ4=6PN<J<^M>L?\(#HWK<_P#?
MS_ZU>/?&GPO%IUS8+8!BK+EO,D&<\UV9?[..(33)E>QXS7H/P:E6+X@VQ<@
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M0KM_A9XAO]3\8I!<2 Q^2S8QWXK..)A)V1VU<GKTH.<FK(]XHHHK8\H****
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (Q 4EB
M.<UYWJ'AGX>^.]3O8&2"6ZM_GN7M7"$9/4D?2M3XI:K/H_P\U6YMF*S>4 K#
MME@*\3\(VEUX0^&.M>+)+K+ZG&MND8/)!/7/K\U '9:9;_"#PSK?V:%U>X1\
M%KAQ(BD'U->S6\D,MM&]NRM"R@H4Z8[8KY \.?#JZ\1>#=5\2/=>6EHK.H//
MF;02V?RKW#X"ZI/?^!#!.[/]EDV*S')P<F@#U2BBB@ HHHH **** "BBB@ H
MHHH Q?%__(F:W_UXS?\ H!KR7]FG_D#^(/\ KXB_]!:O6O%__(F:W_UXS?\
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M(:O//B%_96CWUL;T-*KQX7SOWF#D^M==]C\5_P#/_;_D/\*\I^+T&K1RV/\
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M_H*/^*R7D1Z:Q'8RM@_I4<_D8^P_O+[S5_L.W_Y[W?\ X$-1_8=O_P ][O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P")KJJ*OD1S_6:GE]R_R.5_X1+4_P#H<-8_\A__ !-'_"):G_T.&L?^0_\
MXFNJHHY$'UFIY?<O\CY;^(=G+9>+;B":\GO'"KF6;&X_D *Y3!]*^L-1\%Z!
MJMZUW>:=%).X 9BHR<54_P"%<^%O^@5#_P!\BN26&DVVF>_1SNE"G&,HNZ7D
M>4_"'2;K4Y[\6^KWFG[$!)M]OS<CKN!KU;_A$M3_ .APUC_R'_\ $UJZ/X;T
MG03(=-LXX#)PQ48S6K6].ERQLSR<7CG5K.<-%YI'*_\ "):G_P!#AK'_ )#_
M /B:/^$2U/\ Z'#6/_(?_P 37545IR(YOK-3R^Y?Y'*_\(EJ?_0X:Q_Y#_\
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M!=!T"_\ MNGVOESA2N[CH:PAAI*2;/5Q&=49TI1BG=HA_P"$2U/_ *'#6/\
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M?V:?^0/X@_Z^(O\ T%J]:\7_ /(F:W_UXS?^@&O)?V:?^0/X@_Z^(O\ T%J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQPKN?RH#CZ2$FO8_B+:^([WPC-#X5EDBU0RH4:.0(=N?FY/M0!U=>-_M'?\
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M&4@]",4M% &;I!*QS0'JDK8^A/%:59L/[G6IT'250P_ <UI4 %%%% !1110
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M]:\7_P#(F:W_ ->,W_H!KR7]FG_D#^(/^OB+_P!!:@#W2BBB@ HHHH ****
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MA60Z\]PUUYO!G^]C%>@T %%%% !1110 4444 %%%% &+XO\ ^1,UO_KQF_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M._Y$K3O^OX?^@-0!VOPL_P"27^'O^O1?YFNOKD/A9_R2_P /?]>B_P S77T
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MV&98R1]1ZBO2M/O[75+&*\LYEE@E7<CJ<YKY4\*?#FSUGX<:MXDN[AXW@5S
M ."5!R/QXKUK]G^]FN? \L$C$K;R[4R>QR: /6J*** "BBB@ HHHH **** "
MBBB@#%\7_P#(F:W_ ->,W_H!KR7]FG_D#^(/^OB+_P!!:O6O%_\ R)FM_P#7
MC-_Z :\E_9I_Y _B#_KXB_\ 06H ]THHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_T!J .U^%G_ "2_P]_UZ+_,UU]<A\+/^27^'O\ KT7^9KKZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $(RI'J*YGP@YMY-4TH\+97&R/W4@'^9-=/7,KC3_'C _+%>
MVW'O)N_P%3+=,WI:QE'RO]QTU%%%48!1110 4444 %%%% !1110 4444 %%%
M% !1110!5U"#[19NH^\/F'X<TR+R]2TLQS+E94*2+]1@BKM9MO\ Z)J4MOTC
ME_>)_O=Z ,CP3--%;7NDW+$SV,Y !ZB-B2@_[YQ74UR.H;](\>V5Z/EM+^,P
MSGUEX$?Z9KKJUK:OF[B04445D,**** "BBB@ HHHH **** "BBB@ HHHH **
M** ,+QCH(\3>$]0TG<%:XCPK'L00?Z5\KS?#_P =&XCT!K"Z>".4E!D; 3@%
MNO3C]*^O;Z]@TZRFO+F01PPKN=CV%?/GB7]H+47OI8_#MG"+9&($LR%BP]1@
MC% %[QK\.=?A\)>&_#^AJ[JNXW:QG W-MR3[#FO4_A]X27P;X5M]-+AYOO2N
M.Y//Z9K@[GXKZII?P]TK7YX89I[B8K*@4X*@C..>M>F>%?$MGXKT&WU6R/[N
M4<J>JD=1^= &U1110 4444 %%%% !1110 4444 8OB__ )$S6_\ KQF_] ->
M2_LT_P#('\0?]?$7_H+5ZUXO_P"1,UO_ *\9O_0#7DO[-/\ R!_$'_7Q%_Z"
MU 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'SC\:O#FL:CXZ>YL]/FFA:% '0<$A1FO-)O"^MV[1+-ILZ&5]B C[S>E?;!
M /4"N6\>P;= &H(F7L)1<+@=^G]:]C#9G**C2Y?(S<.IX;\+]&UCP]XC_M:^
MLYK>UA #EQ@-N.T#]:^G*Q-;MDU3PM,J ,&C608[[<-_2K/A^^.I:#9W;'+R
M1 MGJ#CFO,Q%=UJSFU:YTV_<I]M/U_S-*BBBLC(**** "LT?NM>V_P#/6(M^
M1 K2K-N_EU>T?U!3]: -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\$_:&5EU#P_+<H[6*L_F;?3*YKWNL7Q1X7T[Q9H\FFZC'E&Y5P.4
M/8B@#P'QKJ?@^;1_#[: MM$T;IYH50KCUS2_&/7_  SK,>CPZ08I=461#--&
MHY7&,;AU.<5<U']G*^2X;^S]322'/!E&TC^==!X4^!>F>';I-7UZ^$_V?YO+
M( 13ZDT >I>%(IX/"FF17((F2!0^>N:V:BM9X;JUCGMG5X77*,O0BI: "BBB
M@ HHHH *\<\5>./$6M>.SX2\)/'$T'%Q,ZYQWX/XBO8Z^>?A?*\_QJUV27[Y
M0Y_[Z% '3>#_ !QX@TSQR_A#Q6\<DS@_9YD7&<9ZG\*]@KYX^($TD'QYTJ2+
M[VQ!^;&O7?B'XME\$^$IM:AM$NGCE2/RG<J#N..HH ZJO&_VCO\ D2M._P"O
MX?\ H#5S'_#2VI?]"W:?^!+?X5R/Q ^+=WX^T>WTZ?28;-89O.#QREB>",<C
MWH ^BOA9_P DO\/?]>B_S-=?7S5X4^.P\.^&=-T8Z2LHM(A$9-YR>>N*^@?#
MNM1^(="M=4CB>);A P5Q@C(H U**\L\?_&*/P5KW]E+IK3R*@9F<E1R >*K>
M"OC;'XK\10:2^EM"TQPKH2P'U]J /7**I:OJ*:3I5Q?/&[K"A8J@R37B$G[2
M"B1@FBJ5!X)D(- 'OE%<SX&\7Q>-?#ZZI';/!EBI5AQD'M6+\1_B;%X!DM8C
M8M<R7"E@3PH ..OK0!Z!17B.B?M!1ZIJ]M92Z.4$SA-T;%B,^U>US2"&"24@
MD(I8@=3@4 /HKPS4_P!H>.RU*XM8M&WK%(4R[D'@XZ5W7PZ^(L?CVUN)%LFM
MW@;#=U_.@#N:*Y'X@>.(O NC17TEJ]PTK[$4= <9Y/:O-+?]HY9;F.-]% 5F
M )5R3SZ4 >\T57L;I;ZPM[M595FC60*PY&1GFO)/%?QVB\.Z_<:9'I)E,)PS
M2,5.: /8Z*\T^'GQ:C\<ZG-8G3FMY(TWAE)88]Z[#Q;XCB\*^';C5Y87F6'
MV(,DDG H VZ*\"_X:1&[_D")C/\ ST/^%>S>&==C\2>'[758X7B6=<['&".U
M &O17E_C_P",$7@K6%TY=-:>0KN+.2H_#UJCX-^.$?BCQ##I4FE&$RYVM&Q;
MIZT >O454U2_72]+NKYT9TMXFD*J,D@#->'S?M'JDSJFBJ5#$ M(0: />Z*Y
M;P'XSB\;Z$=1CMGM]K[&5AP3C/'J*R_B+\2HO 26X-BUQ).>,\+^= '>T5XA
MHW[0<>IZO:V4NC[%GD";D<L02<=*]L60-$L@!P5W8QS0 ^BO#=5_:&CL=3N+
M6+1MZ1.4S(Y4G'M7;?#GXD1^/8[K;9-;26X!/=3GT/K0!WE%<IX]\:Q>"-$&
MH26SSEF"JHZ9]S7E\7[2"M*JR:*H0GDK(2: />Z*K:?>+J&G07B(R+,@<*PP
M17E'C#XY1>&/$=UI,>E&9K=MC/(Q7)]O:@#V"BO,?A]\78_'&LMIITYK>0(7
M#*2R\>IKM?%.OQ^&/#UUJTL+RK N=J"@#9HKP+_AI$;L?V(F,_\ /0_X5[)X
M5\01^)_#UKJL4+Q+.N[:XH V:*\Q^(7Q=B\#ZPFFC3FN)2@<LQ*K@^AK,\(_
M'./Q-XBM=)?2C$;AMJNC%L'W]J /8:*K:A>+I^GSW;HSK"A8JHR37AT_[1RQ
MW$B1Z*I56P"TA!H ]ZHKD_ /C6/QQH9U!+5[<JY5E/3(]#5#XC?$>+P#%:[K
M)[F2XR5[* /4_C0!W=%>&:7^T/'?:E!:RZ-M65PN8V+'\J]O\T?9_.P<;-V.
M_3- $E%>(ZW^T%'I>L7-C%H^]8'*;I&*G(]JZ_X<_$N/QZ+E18M;R0$9QRO.
M>] '?T5R_COQC%X)T#^TY+9Y\OL55Z9P3SZ#BO+(OVCU>9$;15"LP!(D)- '
MO=%4M)U!-6TFUU"-&1+B,2!7&",^M>7^,_C?%X6\02Z5'I33-$/F:0E?RH ]
M=HKRWP#\88_&NM-IK::T$FW<&0EAVZUWOB36X_#GA^[U:6)Y4MTW%$&2><?U
MH U:*\"_X:1&[_D")C/_ #T/^%>P^$?$D?BOP[!JT4#PK*2-CCH1_2@#<KE_
M%Z&WFTG5>B65SOD/^R5*_P VKG/B'\68O VI0V(T]KB1UW98E5Q[&N1A^-<7
MC#=H<NDF+[2/E:-BQ!4[OZ5,E=&M"7+45_ZN>\T5C:9JXF\)0ZLX+ VWG,%Y
M)P,UX_<_M')%<R1QZ*"BL0"[D'\133NKD2BXR<7T/>:*Y#X?>.8_'6CRWR6K
MVYB<(RGH<^AJM\1?B)%X"M+>1K-KAYVPO9>_?\*9)W%%>%Z;^T0EYJ-O;2:,
M%660)E')(R<=*]PBE$T"2A6 90V".: )**\2US]H&+2M8N;&+1RZP.4+2,5)
M(..E=9\./B='X^ENH18M;20+N)!RI''?UYH ]!HKFO&_BZ+P9H#ZG+;O/@[0
MJCC/O7E"?M( R*&T10I/)$AS0![Y15'2-235])MK](WC6= X5Q@C(KS+QM\;
M(O"?B&;24TMIGA.'=R5!.,\>O6@#UNBO*O ?QDC\9Z\NE-IC0.ZDJZ$L!@9Y
M]*]"\0:Q'H&B7.I21/*L"%BJ#)- &G17@3?M(@,0NB(1GC,A_P *]>\'^)H_
M%OAZ#58H'A$H^ZP_E0!OUEZ]%(=,EGA.V:%2ZL.N!UKB_B)\5HO E_!9?V>U
MQ+(F_+'"XY[^O%<MI7QZBUV[_LV72#&)U*!HV+$$C'Y4UN!Y3K7C/Q#/J4R2
M:K=,D5P7C4R'Y""<$>F*B'C_ ,5#C^W;[_O\W^-9.LX_MJ]QT\]__0C5&OLH
MT:?*O=1SW9]>_"[4+O4_ ]G<WL[SS,.7<Y)KLZX+X/\ _)/[+Z5WM?)XE)5I
M)=S=;!1116 PHHHH **** "BBB@ HHHH **** "BBB@#A_B['<R?#+6!;@D^
M4-P7KC<*\9\,:AX+7X67MM+%;KK6P[FF0;B<?PDU],W%O%=V\EO.@>*1=K*1
MP17AWB7]GF&YO9+G1+XQ)(V1!(.%_&@#(M?$OA2+X(_V?J;Q3WY618(PH9D<
MC@^W-=C^SY#/'X(FDE!\J2;,>?09S^M<OHW[.<IN4;5]3"Q*<E(1NW#T[8KV
MWP]!I-AIPTS2&C,-IB-E0_=/O[T :]%%% !1110 4444 >=_%/QY=>$[.TLM
M+57U2_?9#N&0.G7\ZXN]\5^._ %UIVH>(KB&ZTR[P9E1>4SV')JG\8)I&^*_
MA^%O]6DL)7\2,UO?M _\B'9?]=X_Y&@#V"TN4O+.&YC.4E0./QJ:N7\$W4G_
M  KS3;F09=;4M@]\9_PKQU_VE-25V7_A'+3@X_X^6_PH ]P\7_\ (F:W_P!>
M,W_H!KR7]FG_ ) _B#_KXB_]!:N<U7]H;4-5TB\T]_#]K&MU"\)<7#$KN!&>
MGO7._#/XG_\ "O[/4(/L"W/VN1'R6(V[01_6@#ZYHKCOA[X\B\>:5->):/;M
M#)L8'H3C/!J/XB_$"/P%IUO<M:-</.Y11T7@9Y- ':T5X5I_[1*7>H06\FC!
M5E<)E')/)QTKW&"43V\4P! D0, >HR,T 245XIX@^/\ %H^M7-A%I!D$#[2T
MC%2?PKJ/AS\48_'MS=6XL&MY($#D@Y4@G'6@#T.BN<\;>+(O!OAV359;=YPK
M!0JCN3@9KR5/VD5+C?HJA<\D2&@#WVBJ.CZDFKZ3;7Z(R+.@8*PY%>:>-_C5
M'X1\02Z4FEF=HOO.Y*@_3VH ]9HKROP#\9(_&GB!=);33;R.C.K*2PX&3FO0
MM?U=-!T*[U.2-Y$MHRY51DG H TJ*\"/[2(#D#1$VYXS(?\ "O7O!WB>+Q;X
M>@U6*%X5D'W6'\J -^BO-_B)\5HO M_#9_V>UQ)(N\ECA<>QK!\+_'B/7_$%
MKI<FDF+[0X16C8L02?Y4 >S45%<SBVM9)V5F"+N( Y->&7?[1B07<L4>C!D1
MBH+.030![Q17'_#[QW'XZTF2\2T>W:-MK#JOX&H?B)\08O 5E;S/9O<O.2%'
M11CU/XT =M17A-C^T7'<WL4,NB[4=@"4<D_@*]QCF$ELLVT@,F[&.>F: ):*
M\4\0_'Z/1M=N].CTCS!;R%"TC%22/:NI^'/Q/C\>2W,/V$V\D(!.#E>_>@#T
M*BN;\;^+(_!GAV359+=I]K! B^ISU]N*\GC_ &D%:55;15"DX)$AS0![Y15#
M1=336=%M-2C1D2YC$BJPP1GUKS3QQ\:H_"/B&324TLS-&H+,Y*]?2@#UJBO*
M_ 7QCC\9Z[_9;::T#E2RLA+#MU_.O0?$&L)H&@7FJR1M(EM'O**,D\X_K0!I
MT5X$?VD1NP-$3&?^>A_PKU_P?XEC\6^'(-6C@>%9"04<=Q_2@#>HKS;XB?%>
M+P+J$-E_9[7$DB[LL<+CV/XUA>&/CS'K_B"UTR323%]H;:K1L6(/TH ]FHJ&
MZN!:V4URREEBC+D <G S7AEU^T:D5U)'%HH**Q +N0?Q% 'O-%<A\/O',?CK
M1Y;Y+5K=HGV,IZ'KT/X57^(OQ"C\!65O,UFUP\[84=%'7O\ A0!V]%>%Z=^T
M1'>:C;VTNC!$E<(61R2,G'2O<8I!+"L@! 89P1S0 ^BO$M>_: CTG6KJPBT<
MR+!(8RTC%22#@\5UGPY^)\7CV6YA%BUM) NXX.5(X[_C0!Z#17->-_%T?@S0
M'U.2W>?!P%'3\:\HC_:0#2*&T10I(R1(<XH ]\JKJ-LEYIUQ;R#*R(013=*U
M!-5TJVOD1T6>-9 KC!&1FO,/&_QKB\)>(Y]'32S.T. [NQ4'(!X_.FG9W [;
MP1.UUX1MH)SFXA4Q3#T;)_H11X5?[+<:EI+??@N&D7_KFQ^7^1KSKX5?$B/7
M/$VI6/V)HQ?SFX3;R(S@#'TXKK_$VK1^#O$3:P\3RQWELR,B#/,8+?UJL0K5
M.9=?U-J/O1E#R_+_ (%SNZ*\";]I$;CMT1",\9D/^%>O^$/$L?BSP[;ZM% \
M*R@_*P]#CBH,3>HKS;XB_%>/P)J5O8C3VN))4\PEB57&2.#^%8?A;X[Q^(=?
MM],ETDQ><=H:-BQ!H ]EK.U7Y3:2_P!R8$_3!JU>7*V5E-<NK,L2%R%&2<>E
M>)'XZ)J^KC24TH(&E**[.<\9[4 >Y@Y /K2UR7@'QK'XUTJ>Y2U:!K>7RG4]
M"0.QJM\1OB#'X!L+6=K-KE[ARJCHHQC.3^- ';45X9I?[0Z7VIV]K)HVU97"
M91R3R>PKV^*42VZ3 $!D#8/7D9H DHKQ+7?V@(])UJZL(M(\Q8'V;I&*D_A7
M6?#CXG1>/I+J$6+6TENH8D<J0?>@#T&BN9\<^+XO!?A]]4EMWGPP154<9/J:
M\I3]I!3(H?15"D\D2&@#WRBJ6DZ@NK:3;7Z(T:SH'"N,$5YAXU^-L7A/Q%-I
M*:69FAX9W)7)]O:@#URBO+OA_P#&&/QMKW]E-IQMY"A=64EAQUS7>>)-;C\.
M>'[S5I8GE2VC+E5')Q0!JT5X$?VD1NQ_8B;<_P#/0_X5[#X2\21>*_#UOJT4
M+1+,,[6% &Y17FOQ$^+$?@74HK$:>UQ(Z[BS$A<>QK&\)_'6/Q'XCL])DTHP
MFZD$:NC%L$T >QT5!>7(L[*:Y9698T+$ <FO#+C]HY([B1(]%#(K8!9R": /
M>J*Y+P!XWC\<Z,U\EJ]N48JP/3\#53XB_$2+P%:V\C6;7,D^=HZ*,>IH [BB
MO"]-_:(CO-0@MY=&VK(X4E'+'\J]R1M\:O@C<,X- #J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH X7XI>.F\#>'$N;=$>\N7,<*OG'&,G\
MC7SV?B5\0G<ZHNH7?V??GB-=H]NG2O0OVDF/V;15SP)7./\ @(KU#PQI]H_P
MTTV!K>,QRZ>A==OWLH,T <3X;^-UG+X&N=4UA56_M6$1B0\RL02,?E7E&L>,
M_%_Q.UF.UM8IO)W_ "6MN?E'U/\ ]>J/A+P4WC+Q]=:1')Y%M'-(\A Z(K8P
M/?FOJ?POX-T;PC8BWTNT2-B/WDN/F<^I- %OPS8S:;X:T^RN!B:&%4?ZUJT4
M4 %%%% !1110 5\^7+R_#7XQ7>K7MK*^F7XPLL:YVCC^HKZ#J"YL[>]B,=S"
MDJ'LPS0!X-I(D^(OQE37+6VDCTRR7!D=<;NN,?B:]]EABGC\N:-)$/\ "Z@C
M]:CMK2WLHA%;0I$@_A48J>@"I_9>G_\ /A:_]^5_PKQ_]HBSM;?P9IS06T,3
M&] )2,*?N-Z5[77C?[1W_(E:=_U_#_T!J .L^&&GV4OPS\/O)9V[NUHI+-$I
M)Y/M7;(B1H$1551T"C %<E\+/^27^'O^O1?YFNOH @ELK2X??-:P2-_>>,$_
MK21V%G"X>*T@C8=&6, U8HH 1E5U*LH93U!%5?[+T_\ Y\+7_ORO^%6Z* &1
M0Q0)LAB2-?[J* /TIDUI;7)!GMXI<=-Z!L?G4U% %5=-L48,ME;*PZ$1*"/T
MJUU&#110!5.F6#,6:QMB3R28E_PJ6&VM[8$0011 ]=B!<_E4M% $<UO#<+MG
MACE4= Z@C]:@_LO3P<BQMO\ ORO^%6Z* $ "@   #H!5>33[*5R\EG;NQZLT
M2DG]*LT4 00V=K;L6@MH8F/4I&%_E4DD4<R%)45T/56&13Z* *G]EZ?_ ,^%
MK_WY7_"K*1I$@2-%11T51@"G44 02V5I<-NFM89&]7C!/ZTD=A9PN'BM($<=
M&6, U8HH 1E#*58 J>"".M5?[+T__GPM?^_*_P"%6Z* (XH(H$V0Q)&OHB@#
M]*2:UM[G'GP12XZ;T#8_.I:* *JZ;8(P9;*V5AR"(E!'Z5:HHH JMIE@S%FL
M;8D]28E_PJ6&UM[;/D0119Z[$"Y_*I:* (YH(;A-DT22+Z.H(_6H/[+T_P#Y
M\+7_ +\K_A5NB@!  H 4  = *KR:?93.7EM+=W/5FB!)_2K-% $$-E:V[;H;
M:&)O5(P#^E2R1I*A21%=3U5AD&G44 5/[+T__GPM?^_*_P"%68XTB0)&BHHZ
M*HP!3J* ()K*UN&W36T,K>KQ@G]:;'I]E$X>.SMT<=&6( C]*LT4 (0&!# $
M'J#57^R]/_Y\+7_ORO\ A5NB@".*"&W39#$D:^B* /TI)K6WN<>?!%+CIO0-
MC\ZEHH JKIE@K!EL;8$="(E_PJUVQ110!5;3;!V+-96S,>I,2DG]*EAM;>VS
MY$$46>NQ N?RJ6B@".6"*=-DT22+_==01^M0?V7I_P#SX6O_ 'Y7_"K=% "*
MJHH50%4= !P*@DL+.9R\MI ['JS1@FK%% $$5E:6[[X;6&-O5(P#^E2NB2H4
MD174]589!IU% %3^R]/_ .?"U_[\K_A5B.*.% D2*BCHJC I]% $$UG:W#!I
M[:&5AT+QAOYU$=+L=C!+.W1BI&5B4$9'TJY10!S7@_$5C>Z<P&VSNG@53_<&
M,5M?V7IY.38VO_?E?\*P;/-GX_OX>D-S;)(H]7RV[],5U-3#:QOB/CYN^I'#
M;PVZ[8(8XE/9% 'Z4DUM;W( G@CE Z;T#8_.I:*HP*HTRP4@BQM@1T(B7_"K
M73I110!5;3;%V+/96S,>I,2DG]*DAM+:V),%O%%GKL0+G\JFHH 9+#%.FR:)
M)%_NNH(_6J_]EZ?_ ,^%K_WY7_"K=% "*JHH55"J.@ P!4$MA9S.7EM()'/5
MGC!-6** ((K&T@??#:P1MZI& ?TJ5T21"KJK*>H89!IU% %3^R]/_P"?"U_[
M\K_A5B.*.% D4:HHZ*JX%/HH AFL[6X8-/;0RD="Z!OYU6N-+L/LTP6SMT)0
MC<L2@CCZ5?IDW^HD_P!TT ?-U_\ "_3Y=0N)#J%T"\K-C"\9/TJO_P *LT[_
M *"%U^2_X5Z'=?\ 'U+_ +Y_G4-=JQ^(7VB>5';?#_2(M$\*6]G#(\BK_$_4
MUU-8_AG_ ) L5;%<DI.3<GN4%%%%2 4444 %%%% !1110 4444 %%%% !6?K
MFK0:%HEYJER<0VT9D;Z"M"N)^+;$?#/6L'&8"#0!X%JGQ6\<^(]2DDTRXF@A
M0DB*V0%0/7D5VWPO^,5]<7[Z3XHE!"Q,ZW,@VL-H)((_"M+]G&WA;PIJDS1J
M9/MFW<1SC8O%>>?&+2ED^+'V.RC$;W8C!VC^)F(S0!H^._C-JWB2ZETGP\K0
M6;-L62/_ %DO;\J]1^"FAZMHOA29M7BDBGN9!(%D.6QSR:L^ OA/HWA&"*YF
MB6YU/;\TSC.T]]M>AT %%%% !1110 4444 >+?&[0[Q+_1_$UI;M.EC,&F5!
MDX!&/Y&N=\?>+%^)5GI'AW0[.=KB1D:1F7 1AQ@_G7T4Z*ZE74,IZ@BJEKI5
MA92-);6D43MR65>30 S1=/&F:)9V/411!3_6I/[+T_\ Y\+7_ORO^%6Z* .;
M\6Z;8)X.UIELK96%E,01$H(^0^U>4_LX6EM<Z1KQGMXI2L\6#(@;'RMZU[!X
MO_Y$S6_^O&;_ - ->2_LT_\ ('\0?]?$7_H+4 >X0V\%NI6"&.)3R0BA1^E)
M-;07( GACE Z!T#8_.I:* *HTRP4@BQM@1T(B7_"K0X&!110!6?3K&1BSV5N
MS'J3$I)_2GPVEM;$F"WBB)ZE$"Y_*IJ* &2PQ3ILFC21#_"Z@BJ_]EZ?_P ^
M%K_WY7_"K=% "*JHH55"J.@ P!4$MA9SOOEM()&/\3Q@FK%% $$5C:0/OAM8
M(W_O)& ?TJ5T61"CJ&4\$,,@TZB@"I_9>G_\^%K_ -^5_P *L1Q1PH$BC2-1
MT55P*?10!#-9VMPVZ>VAE(Z%T#?SIB:=91.'CL[=&'1EB4$?I5FB@ (!&",B
MJATO3R<FQMB?^N*_X5;HH CAMX;==L$,<2^B*%'Z4DUM!< ">".4#H'0-_.I
M:* *HTS3P<BQM@1W$*_X5:QQCM110!6?3K&1R[V5NS'DEHE)/Z4^&TMK<DP6
M\41/78@7/Y5-10 R6&*=-DT:2+_==015?^R]/_Y\+7_ORO\ A5NB@!%544*B
MA5'  & *@EL+.=]\MI!(Y_B>,$U8HH @BL;2!]\-K!&W]Y(P#^E2NB2(4=59
M3U5AD&G44 5/[+T__GPM?^_*_P"%6(XHX4"11JB#HJC I]% $$UG:W#!I[:&
M4CH70-_.FIIUE$X>.SMT8=&6)01^E6:* $(!&",@]154Z7IY.38VQ_[8K_A5
MNB@".&WAMUVP0QQ*>H10H_2DFMH+D 3P1R@= Z!L?G4M% %4:98*018VP(Z$
M1+_A5JBB@"JVFV+L6>RMF8\DF)23^E20VEM;$F"WBB)Z[$"Y_*IJ* &2PQ3I
MLFB21?[KJ"/UJO\ V7I__/A:_P#?E?\ "K=% "*JHH50 HX  X%02V%G,Y>6
MT@D<]6>,$U8HH XO4[>WT;QWH]W!!%$M\#:N50 #:&;M5SQO ?[.M;Q4#FWN
M8\@C/R%@&_2CQY [>'_M<(_?VLJ21GN,L ?TS6O>I'K&@S"([EN(&\L^Y!P:
MTJKFII_(NC+DJ)CXM/TV:%)4L;4JZA@?)7H?PJW'%'"@2*-40=%48 K'\)WO
MVWP]!_>MR;9OJGRG^5;=9)W5PG'DDX]B":SM;A@T]M#*PX!= W\Z:FGV43AX
M[.W1AT*Q*"/TJS13($(!&" 0>H-9NH:79&QG*6=N)"O#")0<_E6G37 9&!Z$
M4 5M,CA2QC,,21JPR=B@9_*IIK:"Y $\$<H'0.@;'YU4T8G^S8T/\&1^M:%
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M#M?A9_R2_P /?]>B_P S77UR'PL_Y)?X>_Z]%_F:Z^@ HHHH **** "BBB@
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M4 %%%% !1110!B^+_P#D3-;_ .O&;_T UY+^S3_R!_$'_7Q%_P"@M7K7B_\
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M .E:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_H#5[)7C?[1W_(E:=_U_#_T!J .U^%G_ "2_P]_UZ+_,UU]<A\+/^27^'O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB^+_ /D3-;_Z\9O_ $ UY+^S3_R!_$'_ %\1?^@M7K7B_P#Y$S6_^O&;_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>#]0^V>"M-O96/-OEB?09']*PC\9? :L0=<3(.#^Y?\ PH Z+Q?_ ,B9K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;_T UY+^S3_R!_$'_7Q%_P"@M0![I1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@^(M,DE$6J60_T^T.Y
M!_?7NI_ FLJ\OTF6R\2V*$.C"*ZC_B"G PW^[DFNSKE-8TZ72;NXU2TA,]I<
M)MO+4$#CG+CWY)/TK2WM(\CWZ%TY\DK].IU$4J3PI+&P9'4,I'<&GUYEX?\
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M._Z_A_Z U ':_"S_ ))?X>_Z]%_F:Z^N0^%G_)+_  ]_UZ+_ #-=?0 4444
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MCD5K0J.:U.+-<'##5%R=0HHHK<\H**** "BBB@ HHHH **** "BBB@ HHHH
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQO]H[_D2M._Z_A_Z U>R5XW^T=_R)6G?]?P_P#0&H [
M7X6?\DO\/?\ 7HO\S77UR'PL_P"27^'O^O1?YFNOH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#R_XV(S>&[?:I/[X=!]:\#,4@ZQN,_[)K[*>-)!AT5AZ
M,,UR?B^WA6[T+$,8S>\X4?W&KEK4>9\USW<NS/V,%1Y;[]3YW\-V,MSK]I"8
MW&]\9VGCWKZ7\/7LD6[2+TD75L,*3_&G8_D*VEMX%P1#&#ZA16=K&EO=-%>6
MK!+VWR8V_O#NI]CBKITO9K0Y\9CUC&E)6_S-:BLW2=7CU.%@5,5Q&=LD3=0?
M\*TJV3N>9*+B[,****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &+XO\ ^1,UO_KQF_\ 0#7DO[-/_('\0?\ 7Q%_Z"U>M>+_ /D3-;_Z
M\9O_ $ UY+^S3_R!_$'_ %\1?^@M0![I1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4CJ'1D895A@TM%
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M"NJ+NKGAUJ?LZCAV"BBBF9A1110 4444 %%%% !1110 4444 %%%% !1110
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M/P%\<$8.KVA'O<R?X4S_ (4!XU_Z"EE_W_?_  KZ;HJK&/,^Y\R?\* \:_\
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M!KY6^'_@/Q)XPM;Z;0M22T2W=5E#3O'N)!(^[UZ5]4^+_P#D3-;_ .O&;_T
MUY+^S3_R!_$'_7Q%_P"@M0!@_P#"D?B'_P!##%_X&2_X4?\ "D?B'_T,,7_@
M9+_A7TE10!\V_P#"D?B'_P!##%_X&2_X4?\ "D?B'_T,,7_@9+_A7TE10!\V
M_P#"D?B'_P!##%_X&2_X4?\ "D?B'_T,,7_@9+_A7TE10!\V_P#"D?B'_P!#
M#%_X&2_X4?\ "D?B'_T,,7_@9+_A7TE10!\V_P#"D?B'_P!##%_X&2_X4?\
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M[?6NA_X4C\0_^AAB_P# R7_"NW_9X_Y)Y/\ ]?S_ /H*UZW0!\V_\*1^(?\
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M[9074?B",)/&LB@WDN<$9';WKTCX_?\ )+YO^ON'^9KO] _Y%O2_^O2+_P!
M% 'S]_PI'XA_]##%_P"!DO\ A1_PI'XA_P#0PQ?^!DO^%?25% 'S;_PI'XA_
M]##%_P"!DO\ A1_PI'XA_P#0PQ?^!DO^%?25% 'S;_PI'XA_]##%_P"!DO\
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M]%95CXET34[@V]CJMI<S+U2*4,1^ K5H **** "BBB@ HHHH **** "BBB@
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MT.*]-H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \K\?_  ]U>]\36OBKPQ+&FJ0#!C?@/U[Y'K69H?P^\5>(?&MO
MXD\<&WC^S8\NVB((W#[I&"<<U[/10!YY\4--\;ZA%9CP=<S0LN?.\N<1YYXZ
MU<\=>!W\:>$+>QEE$>HP*KI*W.) ,'/KWKMZ* /!+CP/\2_$=G:>'M:EM8M(
MMF \]6!:51ZC=7MNCZ7!HNCVNFVP/DVT8C7/4@"KU% 'CWQ8\!^(/%/BC1[W
M2;5)H+8$2LTJKCD>OTKUNSC:*RMXW&&2-5(]P*FHH **** "BBB@ HHHH **
M** *.L:9#K.D76GW S'/&5/]*\1MO WQ+\+Z;=>'-":TN-(NF;=*S!64-PQ
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M10!Y[\'?"VK>$O!\NGZQ L-RUTT@57#?*0.X^E>A444 %%%% !1110 4444
M%%%% !1110 4444 >,>&OA_XBT[XPW7B"YM$73I/,VR"52>2".,YKOO'_@^/
MQKX8ETTNL<X.^"1AD(_K_.NIHH \"D\$_$[5-(@\*:@UJFBQ$*;@,"[J#GD;
MLU[3X=T2#P[H%GI5N<QV\83<?XL#K6I10 4444 %%%% !1110 4444 %%%%
M'D/Q>\"Z_P"*];TBYTBU2:*VV^86E5<88GO7J2V8ET@V4Z_+)"8G'L1@U<HH
M \(A\"?$+P3>ZA;>$FM;C3KUB0'(7RASC&6'/-=Q\,? ,G@[3[J:_E6;4;V3
MS)F'12<\#\Z[^B@#Q;4_A_XN\+^,+[7_  0;:47HP\$I "CTY(SR,UL?#?X?
M:II.MWWB;Q)(C:M>G<R(<A">O.3FO4:* "BBB@ HHHH **** "BBB@#G?'.E
M7>M>$+ZPL8Q)<2H0BE@,G'J:Y_X0>%]6\)^%'L=7@6&X,I8*KAN,GN*]"HH
M\J^(/P[U:_\ $UGXJ\,21)JEKR8WXWMZYR.U9V@^ /%7B#QK!XE\;?9XI+4;
M8X(2""!G'0G')KV:B@#@?B=X!E\9Z?:RV,RP:E9R>9"Y'!Z<?I7#S> _B#XT
MNK"Q\6/;6^E69 /E,"95'<X)YKW:B@#C_&W@:#Q3X-&BQLL4D"@VTC#(1@,
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MC=&'0T^@ HHJ.:>*VB,LTBQQCJS' % $E%9R:]I,CA$U"W9B< !QS6CU&10
M451GUG3;64Q3WT$<@ZJS@$5-#?VEQ;M<0W$;PKG+JV0,4 6**@MKRVO4+VT\
M<J@X)1LXJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX[^ D>3(,-Z&OMS1=6BO_"UKJB,#&]OYF<\<#_ZU?*7@[1%U3P9XFFV%Y;:
MNB@9YQ7H_A'QH+7X#ZD W[_3U^SHA."<D?\ Q1H \@\;ZI+K?BS4M5W,T$]P
MWEG/ 'H*]^^!-M'??#*:UF&Z.665&'J":\<N]&6V^#MEJ$L0$T]](48CG;A,
M?UKVG]G[_DGW_;Q)_.@#D/AKK-QX,^*&H>%+N4"SNYCY:XZ.3\OX8)KZ'KY?
M^,6= ^+,&KVXQ*VR4#/=0!7TQ8R^?I]O+D'?$K9'TH L4444 %%%% !1110
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M=1\0O!;^-/#JZ7#<);[7#;F'';_"E^'7@V3P/X<_LN6Y2X/F,^]>G)H \/\
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M8ZS+X?\ "&IZK F^:V@:1 >F0.]?/_P[TB]^*6N7UWKFM7:QQ'<88Y" W3C
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MD1'E#Z9R,UZKJ6G+>:+/I\.V)9(O+7T6@#YV_9[_ .1VU3_KA_[-70_M+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\2^.>H7MEJNCK:WEQ &@D+"*5ES\PZX-
M>VUX5\??^0OHW_7"3_T(5UX%7KH:W/+_ .W=8_Z"M]_X$/\ XT?V[K'_ $%;
M[_P(?_&L^BO>Y8]BS0_MW6/^@K??^!#_ .-']NZQ_P!!6^_\"'_QK/HHY8]@
M-#^W=8_Z"M]_X$/_ (UV/PMU;4KGXA:=%/J%W+&V_*23,P/RGL37GU=M\)O^
M2CZ9_P #_P#0#65>*]E+3HP>Q]/T445\V9A17E^M?$+Q5#XNOM$T+P]!J'V7
M!)W$-C Y/(]:B'C_ ,=V*F?5O!?E6B#+O$V2!_WU6WL)VZ?>1[1'JM%9'AOQ
M%9>)]'BU&R8[&X9#U1NX-:]9--.S+3OJ%%%%( HHJCK-\^FZ-=WL:*[P1,X5
MNAQ32N[ 7J*QO"VLRZ_X?MM1FB2*27.43.!@D=_I6S0TT[,2=U<****0PHHH
MH **Y/0?%ESJWC'6=%DMHDBL,;)%)W-DD<_E6;XH\>:GH7BRSTBVT8W$$Q7=
M,0>^.F#V]ZT5*3ERD\ZM<[ZBFQL7B1R,%E!(]*=690445P/BGQYJ>@^*[/2;
M;1C<03E=TQ![XZ8/;WJH0<W9"<DE=G?45S'B_P 3W'AS2+.\@MHY'GF2-DD)
M^4$$]OI721.9(4<C!90:'%I7"^MA]%%%2,**** "BBB@ HHHH **** "N(\;
M7$\.H6PBFD0&+)"L1WKMZX3QW_R$;7_KE_4T <Y]NN_^?J?_ +^&C[==_P#/
MU/\ ]_#5>B@"Q]NN_P#GZG_[^&C[==_\_4__ '\-5Z* +'VZ[_Y^I_\ OX:Z
MWP1/--)>>;+))@+C<Q..M<578^ _]9>_1?ZT =K1139'6*-G<X51DF@!U%<>
M_BS5+N5WTG2?M%JAP9&/_P!>MG0M=CUF)P8S%<1'$D9'2@#7HHHH ***R7U:
M1/$<>F"-/+:/?OYSTH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BJ
M>J7C6&FSW2*&:-<@'H:CTW4)+W1(KYHP'>+?L7UQTH T**YW0/$-WJUY/#/9
M>0L9X;G]:Z*@ HHIDKF.%W"EBJD@#O0 ^BN=T'Q#=ZM>SP3V7D+&>&Y_6K<&
MKRR^(Y],,:".- P?G)X% &O1110 4444 %%%% !1110 4444 9WB!V3PYJ;H
MQ5EM)2&!P0=IKY._MW6/^@K??^!#_P"-?5_B+_D6=5_Z])?_ $ U\@5QXINZ
M/H\BBG"=UU1H?V[K'_05OO\ P(?_ !H_MW6/^@K??^!#_P"-9]%<MV>]R1[&
MA_;NL?\ 05OO_ A_\:/[=UC_ *"M]_X$/_C6?11=AR1[&A_;NL?]!6^_\"'_
M ,:^G/A[-+/X!T:6:1Y)&@RSNQ)/)ZDU\IU]4_#C_DGFB?\ 7O\ U-=.&;YF
M>+GD4J,;+K^C.IHHHKM/F HKDO$WC,Z7=)IVEVWV[4GZ1#HOUK'_ ++^(=^/
MM UB"R#<^01G;^AK&59)VBF_0Z(X=M<TFDGW/1:*\Z7Q!XH\+2(NO6XO;,D!
MKJ(=/Y5UNI:F)/"UUJ-C+C_1VDC<#H<9%.-6,D^Z)G0E%KJGU-BBO+=)L/'^
ML:=%?0>)(DCER0KKR.?]VNBT;1_%]L+K^T];BN"\6V':/N-GKTJ8UG+[++GA
MU"_OK\?\CL**\GUR#Q[H5DMU/XCCD1I%C 11G)(']WWKH?#^D^,HKZ"YU/78
MKBS*Y:(+R<_\!I1KMRY>5CEAE&/-SK\?\CMZ**Y7Q]J-_INA))IUP8)VD"AP
M >OUK:<E"+DS"G!SDHKJ=517G*:!\0RJO_PDUN1UQM_^QK1\/^(=7@US^PM>
MB3SRI:*=>DF*S5;6TDT:RP^C<9)V[':T5P'C2_U[_A)=-TO1M1^R&Y4Y) (S
MD>QJ'_A'?B)_T,]O_P!\_P#V-)UGS-*+=AK#KE4I22OZGHM%<>FC^+QX>:V;
M6XCJ1DR)\<!>..GUKE;V/QY8ZS::;)XBC:6Y!*L%&!C'7Y?>B5=QU<6$,,IM
MI37X_P"1ZU17-^&--\26+3'7=4CO0WW @QM_05TE:QDY*[5C"<5%V3N%%>>>
M++WQ#-XRMM(T;4_L@DA#?, 1GGV/I2?V%\0X?G/B&WEQ_!MZ_P#CM9.OJTHM
MV-UAO=3<DKGHE%>>67C/6-%O([/Q/8>7$QVK=KT/N:]!CD66-9$(96&01WJX
M5(SV,ZE*5/<=1116AD%%%% !1110 4444 %%%% !1110 445R>B:K>W/C;6;
M&:=GMH$4QQD#"Y+?X5,I*+2[EQ@Y)M=#K****H@**** "BBB@ HHHH ****
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M+5F4^Q6KFU9][&=-/F3Z7."\._$3^RM#M[/^P;^?R\CS(Q\IY^E=AX9\9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CGQI\/:QK6IZ4^F:
M;<W:QPN',*%MI+#K7L=%:T:KI3YT-.Q\F?\ "!^+/^A?U#_OR:/^$#\6?]"_
MJ'_?DU]9T5V_VE/^5#YCY,_X0/Q9_P!"_J'_ 'Y-'_"!^+/^A?U#_OR:^LZ*
M/[2G_*@YCY,_X0/Q9_T+^H?]^376_#3PEXATSQYI]W?:/>6]NF_=))&0HRI[
MU]#45,\PG.+BTM0Y@HHHKSR3S_0=)U"W^*FNW\UI,EI-&!',R_*W"]#^%>@4
M454Y<SN)*Q5U)&ETN[C12SM"X4#J3@UR?PPTV]TOPS)!?VLMO*;F5@DBX."Y
M(-=M10I6BXA;6YSGC/PI#XLT;[(TABGC;S()5ZJU<3%XB^(_AN);&Y\-?VOY
M?RK/"QP1^"UZS15QJ67*U=$N-W=:'AGBC2_'OC729+K4+%K2VC(:*PB!,C'W
MX!]*],>RN3\.?L0@?[3]@6/RL?-NV 8QZUT]%.59M)6V!0MJ<;X;M-9T[X=Q
M6]K;"/5$1MD=Q\H!W'KQ7+W/BWXB7$$FEGP>1+(#&;O+%.>_W<5ZU12517;:
MN#AI9,Y#PAX2;2O!1TC4=KRW =IP.0"PP<5R<,7C?X>M+9Z;IO\ ;FEEB8%#
M'>@/8X!KUNBA57=W5[@X+H>2OJ_Q'\6#[%'HG]AP,<2RRDY*^Q(ZUZ?IEFVG
MZ;!:M,\S1I@R.<EC5NBE.?,K)6'&-NIY_P"%-)U"T^(_B6]N+.:*UN OE2LN
M%?YFZ'\:=X^TJ_U#Q!X<FM+26:."Z5I61<A!N')KOJ*?M7S<PN32QQ'Q)TR]
MU/1K"*RM9;ATNT=EC7) P>:[. %;>,$8(4 C\*DHJ'*\5'L4EK<X;5=,OI?B
MCI-_':RM:1PN'F"_*I*GJ:A^(&E7^H:[X=EL[26>."Z5I61<A!N')KOZ*I56
MFGV$XZ,X+XJZ+>Z[X8MK.RMY99#<H6\I=Q48/-<_:WOQ#\%0+8C1_P"W;-0!
M R$AU'^U@?6O7:*J-6T>5JZ$X7=TSR&<^/?'Q%C>:8=#TQB//#$[V'H"0*]/
MT;2;;0]*@T^T7$,*@#W]ZOT5,ZG,K)60XQMJ%%%%9E!1110 4444 %%%% !7
M,>)]!O-6NX);;R]J1[3O;'.:Z>B@#SO_ (0O5O\ IA_WW_\ 6H_X0O5O^F'_
M 'W_ /6KT2B@#SO_ (0O5O\ IA_WW_\ 6H_X0O5O^F'_ 'W_ /6KT2B@#SO_
M (0O5O\ IA_WW_\ 6KH?"^B7>D/<&Y\O]X %V-GIFNCHH *J:E9+J-A+;,S+
MO& RG!%6Z* .)BOO$VC)]B_LPWJKPDRD\#WXK3\.Z5>1W,^IZE@74_&P?PC_
M ":Z.B@#F=9TB_AU(:MI##SL8DB/ <?XU3/B'Q,_[I?#[(QX\PDX'OTKLJ*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gjnp4w4lrub1000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +\" (# 2(  A$! Q$!_\0
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ME)''CZLZ=!RB[,U_^%H:W_SS@_[YH_X6AK?_ #S@_P"^:XBBO4^J4/Y4?/\
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M_P"%H:W_ ,\X/^^:XBBCZI0_E0?7L3_.SM_^%H:W_P \X/\ OFC_ (6AK?\
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M_P#(2C_W*Y^N@\6_\A*/_<KGZZ8?"C&6X44450@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** -J7_D58/^NIK%K:E_Y%6#_KJ:Q:F(V%%%%4
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KF/%/^O@_P!T_P ZZ>N8\4_Z^#_=/\ZZ<'_&1P9E_NS^7YG/T445
M[)\R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ;/A/_D;=*_Z^4_G2^+?^1MU3_KY?^9I/"?\
MR-NE?]?*?SI?%O\ R-NJ?]?+_P S6'_+_P"7ZG3_ ,PW_;WZ&+1116YS!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9L<,-5FN:*T.0HJUJ&GW6EW;VMY$T4R]0?Z5LZ9X/N[ZQ%_=7$.GV9^[-<'
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M%MH1C'G:.U1QWMCJ%M'#J):*6,8691GCWI):(?4=!'HUO,LL>J3JRG((B/\
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M3_KX/]T_SKIZYCQ3_KX/]T_SKIP?\9'!F7^[/Y?F<_1117LGS(4444 %%%%
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M^1MU3_KY?^9K#_E_\OU.G_F&_P"WOT,6BBBMSF"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#L+/_ ))EJ/\
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M45=_LG4?^?*X_P"_9H_LG4?^?*X_[]FBZ"S*5%7?[)U'_GRN/^_9H_LG4?\
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M.=L+'%=.$DE53;.+,8REAVDNQQM%:_\ PBVO_P#0&OO^_#?X4?\ "+:__P!
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M:_\ PBVO_P#0&OO^_#?X4?\ "+:__P! :^_[\-_A1[6'=![&I_*_N,BBM?\
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M_P (MK__ $!K[_OPW^%'M8=T'L:G\K^XR**U_P#A%M?_ .@-??\ ?AO\*/\
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MVO\ _0&OO^_#?X4>UAW0>QJ?RO[C(HK7_P"$6U__ * U]_WX;_"C_A%M?_Z
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MX%:' ,B%03D>M;4(R51:'1A(25:+:.^HHHKU#WPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH JJ['5)(]QV")2!VSDU:JFG_(
M7E_ZXK_,U<IL HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 55@=VO[I"Q*KMVCTXJU5.W_ .0C>?5/_0::
M N4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL37_%6D^&X=
M]_< 2$?+"G+M^'^-><:A\9+R20KIVG(B#HTK9)_ 5M3P]2IK%'/5Q5*EI)ZG
ML5%>(1?%[74?,MI;NO<!2OZUU^@?%?2=3D6"_C:QF;@,QW(3]?\ ZU7/"58J
M[1%/'4)NR9Z!12(ZR('1@RL,@@Y!%+7,=84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5+S4(+$#S22QZ*
MO6@"W15.WU.UN(7E#[50;GW<8%88\>Z,;S[/NF"YQYQ7Y/\ ']*F4XQW9G.K
M"'Q.QU%%8^K>)M-T>*-IY"[2#<B1C)(]:-*\2Z;J]O)+!*4\H9D208*CUI>T
MC?EOJ'MJ?-RWU-BBN7'CW13>_9]TNW./.V?)_C^E=.K*ZAE(*D9!'>G&<9?"
MPA5A/X7<6BBBJ- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK$\6ZQ<:
M#X<N=1MDC>6+&%D!*\G'8BJ5KXDNY_ ']O-'"+KR3)L .S(..F<_K3L[7%<Z
MBBN-T;QMYW@Q]=U58HV5F4)$" Q'0#)-+X*\1:[XE2:\O+:U@L02(]B-O<_4
MG&/PI\K"Z.QHKS:^\5>/+66X9?#T'V:,DB1HF^Z._P!^M/P'XJUGQ0]U+?6]
MK%:PC:#$K E_Q)XQFAP:5PYE>QVU%>6?\)]XLO-6N[/2])M;K[.Y!VQL2!GO
M\U=GX=U+6[O1I[G6M.^SW:.0D,:D%EP,=2>^:'%H%),Z"BO,/^$_\2P>)+;3
MK_2K>UCN)0%61&W["< _>QFO3Z3BT"=PHK,\0:LFAZ'=:@P!,2?(I[L> /SQ
M7.ZMXVFT+P[97%[;QOJEVN4@CR%']?2A1;!M([6BO-;#XB:Q:ZE;P>(M)2VA
MNL")XU*GZ\DYZBO200R@CD$9%#BT"=Q:*QO%&O1^'-#FOV :0#$:'^)NU5?!
M^K:MK.C#4=5BMX%DYB6)2OR^IR319VN%];'1T5Y]JGQ'DDOVT_PYIS7\ZG'F
M')7/T'^-4SX_\4:2PEUWP\$MSQF-64C\235<C%S(]-HKC]9\:>3X-&NZ4B.2
MX39.IP/7H16#8^+_ !Y?)#-%X?MWMY2")%B;!'K]^DH,?,CTZBO./%7C+Q5H
M%[.R:5;_ -G*P5)Y(VYS[AJDT7Q5XQU2RGNFT6#RS 9+9DC;$C=A]ZGR.UQ<
MR/0Z*\PG\7_$"V@>>;P[;I$@W,S1-@#_ +[K<\!^*-7\3Q75Q?6UO%!&0J-$
MK#<>_4FDX-*X*2.SHKF/&GBZ/POIH:/RY+V7B*-^GN3CM2^!_$5WXET1KV\C
MACD$I3$0(&!CU)I<KM<=U>QTU%><ZUXX\0)XINM)T+38+P0 9#(Q;IST8=ZW
M?"FK>)=1GG77M+2RC5<QE4(W'/N33<6E<+G4T5YYXA\;:[;>*9-'T/3X+MD0
M$AD8MGOT85J>&=8\6:C=SQZSI,5E&(B8W$;#+=L_,:.5VN',KG7T5PFC^,]2
M_P"$OET#7+>VB?I#)"K#=Z=2>M=W2::!.X4444AA1110 4444 %%%% !1110
M!33_ )"\O_7%?YFKE4T_Y"\O_7%?YFKE-@%%!X&:Y'P7XDGUEKZ"[8F2.9C$
MQ &Y <?IQ^=%M+BN==137=8T9V.%49)]!7)^&/$EQK7B+5H9,K;1[3;(1U7D
M$^^2*$KA<ZZBFJZL2%8$KP0#TH+JK!68 MT!/6D,=16#!?W3>-KJQ:4FV2T$
MBQX'#9'/K4*ZP_\ PG#V)O$^R"TWA,KC?N Z^M.PKG245SV@QZ]%J>HMJU[!
M-:E@;=$QE!SUQT[=:W&N(%4,TT84]"6&#0T,EHIJ2)(NY'5E]5.:P] O[J\U
M+68IY2Z6]T4B! ^5?2BP&]143W$$;;7FC5O1F -2 @C(((/<4@%HK+\1WTFF
M^';Z\B8K)%&64@=#4'A75WUG0;>XFXN0H692,'=CK^(P?QIVTN%S;HJEJVHQ
MZ5ID]Y(,B-20HZL>P'UK)\&:Q<ZMX>^U7[CSUE=9-P VX/2BVEQ7.CHI 0P!
M!!!Z$4@=2Y0,-PY(SR*0QU%1O<0Q'$DT:'T9@*5G!A9T8'C((H ?16#X0O[K
M4M CN+N4RS&1P6( X#''2MDW-N'V&>(-_=WC--JS EHI"0!DD #N:C:Y@3&Z
M>-<\C+@9I 2T4QI8T3>[JJ_WB<"E21)%W1NK+ZJ<B@!U%,DECB&9)$0>K,!2
M">%DW"5"I.,AAB@"2BBN;O[V[O/$_P#8\-Z]E'';B<R1JI=R21@;@1@8].]-
M*X'245A^&=3FU&TN5GD69K:X>$3*,>8!W^O^%;E#5@"BL2]O;F+Q9IMFDI%O
M-%(SI@?,0#BMHD*I9B !U)HL M%(K!E#*00>A!I/,3<5WKN R1GD"D ZBHFN
M8$ +3QJ&Y&7'-.:6-4WLZA/[Q/% #Z*:DB2KNC=7'JIS2&:(!B9$&W[V6''U
MH ?14<<\4O\ JY4?'7:P-8FJ7]U;^*-(M(I2L$XD,B8'S8QBFE<#?HJ-;B%G
MV+-&7_NAAFI*0!142W,#/L6>,MZ!QFI&947<S!1ZDXH 6BHC<P*^PS1AO[I<
M9ITDT<0!DD1 >FY@* 'T4BLK*&4@@]"#3))X8CB25$S_ 'F H DHI@EC.W$B
M'=]WYNOTI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5.W_ .0C>?5/_0:N5G)<PP:E=B614SLQG_=IH3-&BJW]H6G_ #\)^=']H6G_
M #\)^=%F.Y9HJM_:%I_S\)^=)_:-G_S\)^=%F%RU157^T;/_ )^$_.C^T;/_
M )^$_.BS"Y:HJK_:-G_S\)^=']I6?_/PGYT687+5%5?[2L_^?A/SH_M*S_Y^
M$_.BS"Y:HJI_:5E_S\)^=']IV7_/RGYT6871;HJI_:=E_P _*?G1_:=E_P _
M*?G19A=%NBJG]J6/_/S'^=']J6/_ #\Q_G19BNBW15/^U;'_ )^H_P Z/[5L
M/^?J/\Z+,+HN453_ +6L/^?J/\Z3^UK#_GZC_.BS"Z+M%4O[7T__ )^X_P Z
M/[8T_P#Y^X_SHLPNB[15'^V-._Y^X_SH_MG3O^?R+\Z+,+HO450_MK3?^?R+
M\Z/[:TW_ )_(OSHLPNB_15#^V],_Y_8OSI/[<TS_ )_8OSHLPNC0HK._MW2_
M^?V+\Z/[>TK_ )_HOSHLPNC1HK._M_2O^?Z'\Z3_ (2#2?\ G_A_.CE?8+HT
MJ*S/^$ATC_G_ (?SH_X2+2/^@A#^='*^P71IT5E_\)'H_P#T$(?SH_X231O^
M@A#^='*^P<R-2BLK_A)=&_Z",'YT?\)-HO\ T$8/SHY9=@YEW-6BLG_A)M$_
MZ"4'YTG_  E&B?\ 02@_.GRR[!S+N:]%9'_"4Z'_ -!.#\Z3_A*M"_Z"=O\
MG1RR[!S+N;%%8_\ PE>A?]!2W_[ZI/\ A+-!_P"@I;_]]4<DNPN:/<V:*QO^
M$LT#_H*V_P#WU2?\);H'_05M_P#OJCDEV#FCW-JBL7_A+O#_ /T%;?\ [ZI/
M^$O\/?\ 06MO^^J.278.>/<VZ*Q/^$P\/?\ 06MO^^J3_A,?#O\ T%[;_OJC
MDEV#GCW-RBL/_A,O#O\ T%[;_OJD_P"$S\.?]!>V_P"^J.278.>/<W:*PO\
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MM#4[5B*;@YWT1LT5CZ%KG]NZ&-1AMRA8D",MW'O6>/$FJG53IW]BCSQ&)/\
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M*P90RD$'H10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 (6 ZD?G1N7^\/SICP1N067./>F_98/[GZF@"7<O\
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M 'A^=1?98/[GZFC[+!_<_4T: 2[E_O#\Z-R_WA^=1?98/[GZFC[+!_<_4T:
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M?98/[GZFG)#'&247&>#S2 DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+J%LER%(^X#T7\!BNQUG4XM'TBYOY>5A0L!ZGL*;5G8$RW'/%*SK'(K%#M8
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MWB&R710-=TX""2)U^TH@PLR$@'([D9SGVK8OM:M+"U@FE+,UQ@0Q(-SR$C.
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MN4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRT_OR?G1_P (W:?WY/SH]T/>+']NZ;_S\C_OAO\ "C^W=-_Y^1_WPW^%5O\
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MFLW_ (5EH_\ SWN?^^A3?^%8:/\ \][G_OH4[4>["];LC3_X3WPS_P!!,?\
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M.I"/18-,C^::YD!VCK@5UWAJQ;3?#EA:.,/'"H8>^*E_ /[1JT445!04444
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M6-DN6W2JPR&/K61L<A?VEY<ZGIIDFTNVFCDWH;<'>Z[3E?IBJ$5G!'X&$PB
M#WW^DNH^8IN.>?3I7<V6@:7ITIEM;-$D(V[R2Q ] 3TJS!I]I;VC6D4""!LY
MC(R#GKUH Y;Q@NB_\(DVP6XP%\CR\9SVQBJVBC3SXQN?M8C\[[';^5YG3[@S
MCWKHH_"FAQAPNGQX<8()) 'MSQ^%9T/A^WN?$>I_:[,-:E(A"3D?=4#@]>U
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M+%$@PJJ, 4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 V2-)8VCD4,C@JRD<$&N;\/>#+?PW
MJ%Q<V=[<&*?[T# ;/;\JZ:BG=A8****0!1110 4444 %%%% !1110 4444 %
M%%% '+3^"+6\\3IKEY>SW$D;;DA<#8N.@_"NIHHIMMA8****0!1110 4444
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M="<=<4)]PL;=%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG;_ /(1
MO/JG_H-7*IV__(1O/JG_ *#30BY1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX/\ WS0!/14'DS?\_!_[YH\F;_GX/_?- $]%0>3-_P _!_[YH\F;_GX/_?-
M$]%0>3-_S\'_ +YH\F;_ )^#_P!\T 3T5!Y,W_/P?^^:/)F_Y^#_ -\T 3T5
M!Y,W_/P?^^:/)F_Y^#_WS0!/14'DS?\ /P?^^:/)F_Y^#_WS0!/14'DS?\_!
M_P"^:/)F_P"?@_\ ?- $]%0>3-_S\'_OFCR9O^?@_P#?- $]%0>3-_S\'_OF
MCR9O^?@_]\T 3T5!Y,W_ #\'_OFCR9O^?@_]\T 3T5!Y,W_/P?\ OFCR9O\
MGX/_ 'S0!/14'DS?\_!_[YH\F;_GX/\ WS0!/14'DS?\_!_[YH\F;_GX/_?-
M $]%0>3-_P _!_[YH\F;_GX/_?- $2?\A>7_ *XK_,U<K-6*3^U)%\XY\I3G
M'N:M^3-_S\'_ +YH8B>BH/)F_P"?@_\ ?-'DS?\ /P?^^:!D]%0>3-_S\'_O
MFCR9O^?@_P#?- $]%0>3-_S\'_OFCR9O^?@_]\T 3T5!Y,W_ #\'_OFCR9O^
M?@_]\T 3T5!Y,W_/P?\ OFCR9O\ GX/_ 'S0!/14'DS?\_!_[YH\F;_GX/\
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M-_S\'_OFCR9O^?@_]\T 3T5!Y,W_ #\'_OFCR9O^?@_]\T 3T5!Y,W_/P?\
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M9DB5F" N<9). *0R:BHYIX;>%III%CC49+,< 52M]?TF[+BWU"WDV*6;:XX
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M1&I&3LF$*U.;:B[EBBBBK-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM\ECJ-QO5FW[2-OTIH3-:BLK^W8/^>4GZ4?V[!_SRD_2CE871JT5E?V];_\
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M!S_*O*S&BN7G1[F4XB7-[-]3TVBBBO'/H HHHH **** "BBB@ HHHH ****
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M9QVML@2-!@#U]ZLUS5ZBJ3<DCJP])TJ:BW_78****R-@HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P?$4<K")UR8P,$#UK>I" PPP!![
M&@#C=/AN)9V^SY#;&&[T.#BO.KJ":"ZDBG1A*&.X$<DU[K'%'$,1QJ@]%&*C
MEL;2:99I;6%Y%Z.T8)'XUSUJ'M+:G)BL+[>UG:QY1JFGZE%X:TR2=7,"ER%_
MN9QC/ZU!X7M;RXUJ,V88%02SCH!7L;QI)&4=%9",%6&0:C@M;>U4K;P10J>H
MC0*/TJ/JOO)W,?[/]]2YM%;\#PRX@GM[F2*X1EF#$,&')->L^#(+BW\-6Z7
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MJ+ 6**K^;<?\\!_WU1YMQ_SP'_?5%@+%%5_-N/\ G@/^^J/-N/\ G@/^^J+
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M-/\ D+R_]<5_F:N533_D+R_]<5_F:N4V 4444@"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD4[!<Z[SXL ^:F#T.X4">$G EC)/8,*HMX>T5X$A;2;%HD)*H8%P,^@Q7/\
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ML*R_NM_WT:3^P++^ZW_?1I^Z'O"?\)#8?WI/^^*3_A(M/_O2?]\4O_"/V/\
M=;_OHTG_  CMA_=?_OHT>Z'O"?\ "2:=_>D_[XI/^$FTT?Q2?]\4O_"-Z?\
MW7_[Z--_X1G3C_ __?1H]P/>$/BG3!_%+_WQ2'Q7I8_CE_[XI3X7TT_P/_WV
M:;_PBFF'^!_^^S1[@O>$/B[2A_'+_P!^Z:?&.DC^.;_OW3CX2TL_P/\ ]]FF
MGP?I1_@D_P"^S3]P/?&GQIHX_CF_[]TT^-]&'\<W_?NG'P9I!_Y9R?\ ?9II
M\$Z.?^6<G_?9I_NQ>^-/CK11_'/_ -^C33X]T,?\M)_^_1IQ\#:,?^6<G_?P
MTT^ ]%/_ "SD_P"_AH_=>8OW@T_$#0A_RTG_ ._1I#\0] '_ "TN/^_1I3X
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M "UN?^_!I/\ A:WA@?\ +6Z_[\&E/PL\-G_EC-_W];_&F_\ "JO#1_Y8S?\
M?UO\:?\ L_F2_K72QX_K^J#7_%-U?@DQR-E 1T4=*CHU;3_[&\37=CM*K%(5
M4'TZBBO=H6Y%8^6Q3E[1\VX4445L<Y%<('A;V&17J_P<OWGT*]LV.5MI5*^V
MX'_XFO*9VVPN3Z8KU#X,6CQZ5J5VR_+-*BJ?]T'/\Q7GYC;V1ZV4M^VT/3Z*
M**\(^F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVYW9&.M6+^PM]3LI+2Y3=%(,''4>A'N*+[!8DE/^B.?^F9_E7 ^3N^%DB/\
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M44 %4[?_ )"-Y]4_]!JY5.W_ .0C>?5/_0::$7****0PHHHH **** "BBB@
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M8\&Z;X7@/V9?-N&'SSN.3]/05T5>/BL3[9V6Q]!@<']7C=[A1117&=X4444
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MA;:9:+:VL8CB7H!Z^M6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"FG_(7E_ZXK_,U<JFG_(7E_ZXK_,U<IL HHHI %%%% !1110 UXTE
M0I(BNIZAAD5'%9VL#;H;:&-O5$ /Z5-10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5.W_P"0C>?5/_0:N53M_P#D(WGU3_T&FA%R
MBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HYH(ITVRH'7T-244 1Q010)LBC55]!5(:%I8N_M0L8?/SG?BM
M&BDTGN2XQENBM>:?:7\/E7=NDJ#H&'2EM+"UL(?*M8$BC]%%6**+*]PY8WO;
M4SAH6EB[^U"QA\_.=V.]:-%%"26PU%1V04444QA1110 4444 %%%% !1110
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M?;(O5ORH^V1>K?E4]% $'VR+U;\J/MD7JWY5/10!!]LB]6_*C[9%ZM^53T4
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M/MD7JWY4?;(O5ORJ>B@"#[9%ZM^5'VR+U;\JGHH @^V1>K?E1]LB]6_*IZ*
M(/MD7JWY4?;(O5ORJ>B@"#[9%ZM^5'VR+U;\JGHH @^V1>K?E1]LB]6_*IZ*
M (/MD7JWY4?;(O5ORJ>B@"#[9%ZM^5'VR+U;\JGHH @^V1>K?E1]LB]6_*IZ
M* (/MD7JWY4Z.=)"0N>!GD5+12 **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"FG_(7E_P"N*_S-7*II_P A>7_KBO\
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MJ***S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXYKF+2-(OB%=)&BHBV,855& !D]*=XW!.EV8 R3>P?\ H8HMK8+G3,RHI9F
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MA+FTCD25),J-Q5@><>U*U[:I)Y;7,(?^Z9!G\JYS6IAI/AZSMM.CCM9+Z6.
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M^^!_A1RBYCHJ*YS[1K'_ $T_[X'^%-^TZSZR?]\#_"CE#F.EHKF3<ZUZR?\
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MYF;L2/05[!7B8[$*H^6)]+EF%=*//+J%%%%>>>J%%%% !1110 4444 %%%%
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MG0 ZBF[T_O+^=&]/[R_G0 ZBF[T_O+^=&]/[R_G0 ZBF[T_O+^=&]/[R_G0
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M\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z
M'44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44
MW>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G
M]Y?SHWI_>7\Z '53M_\ D(WGU3_T&K6]/[R_G52W9?[1O#N')3O_ +--"+M%
M-WI_>7\Z-Z?WE_.D,=13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z
M?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE
M_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C
M>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]
MY?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =6;JN@Z7K46S4+.*;
M'0LO(^AK0WI_>7\Z-Z?WE_.FFT[H32DK,XA_A/X8>3<([E1W FXK9TGP5H&B
MNLEK8(95Z22?,P_&M[>G]Y?SHWI_>7\ZMUJC5FV91H4HNZBAW3I13=Z?WE_.
MC>G]Y?SK,V'44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHW
MI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>
M7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z
M '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '4
M4W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>
MG]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y
M?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SH
MWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_
M>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\Z '44W>G]Y?SHWI_>7\
MZ '44W>G]Y?SHWI_>7\Z '57NK*"\7;,F<=#W%3;T_O+^=&]/[R_G0!#;V-O
M;1-''&-K##9YS60/!NB"]^U?9?FSG9GY<_2MW>G]Y?SHWI_>7\ZEPC+=$2IP
MG\2N4-3T+3]7A6.[@#!/NLO!7Z&C3=#T_2H&AM8 JO\ ?)Y+?6K^]/[R_G1O
M3^\OYT<D;WMJ'LX<W-;4PAX-T07OVK[+\V=VS/RY^E;P  P!@"DWI_>7\Z-Z
M?WE_.B,5'9!&G"'PJPZBF[T_O+^=&]/[R_G5%CJ*;O3^\OYT;T_O+^= #J*;
MO3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^
M\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OY
MT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T
M_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+
M^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYTH93T(/XT +1110!&T,;G+*#BD^S
M0_\ /,5+10!%]FA_YYBC[-#_ ,\Q4M%%P(OLT/\ SS%'V:'_ )YBI:*+@1?9
MH?\ GF*/LT/_ #S%2T47 B^S0_\ /,4?9H?^>8J6BBX$7V:'_GF*/LT/_/,5
M+11<"+[-#_SS%'V:'_GF*EHHN!%]FA_YYBC[-#_SS%2T47 B^S0_\\Q1]FA_
MYYBI:*+@1?9H?^>8H^S0_P#/,5+11<"+[-#_ ,\Q1]FA_P">8J6BBX$7V:'_
M )YBC[-#_P \Q4M%%P(OLT/_ #S%'V:'_GF*EHHN!%]FA_YYBC[-#_SS%2T4
M7 B^S0_\\Q1]FA_YYBI:*+@1?9H?^>8H^S0_\\Q4M%%P(OLT/_/,4?9H?^>8
MJ6BBX$7V:'_GF*/LT/\ SS%2T47 B^S0_P#/,4?9H?\ GF*EHHN!%]FA_P">
M8H^S0_\ /,5+11<"+[-#_P \Q1]FA_YYBI:*+@1?9H?^>8H^S0_\\Q4M%%P,
M]((O[5D78-HA4X_$U;^S0_\ /,5 G_(7E_ZXK_,U<IL1%]FA_P">8H^S0_\
M/,5+12N,B^S0_P#/,4?9H?\ GF*EHHN!%]FA_P">8H^S0_\ /,5+11<"+[-#
M_P \Q1]FA_YYBI:*+@1?9H?^>8H^S0_\\Q4M%%P(OLT/_/,4?9H?^>8J6BBX
M$7V:'_GF*/LT/_/,5+11<"+[-#_SS%'V:'_GF*EHHN!%]FA_YYBC[-#_ ,\Q
M4M%%P(OLT/\ SS%'V:'_ )YBI:*+@1?9H?\ GF*/LT/_ #S%2T47 B^S0_\
M/,4?9H?^>8J6BBX$7V:'_GF*/LT/_/,5+11<"+[-#_SS%'V:'_GF*EHHN!%]
MFA_YYBC[-#_SS%2T47 B^S0_\\Q1]FA_YYBI:*+@1?9H?^>8H^S0_P#/,5+1
M1<"+[-#_ ,\Q1]FA_P">8J6BBX$7V:'_ )YBC[-#_P \Q4M%%P(OLT/_ #S%
M'V:'_GF*EHHN!%]FA_YYBC[-#_SS%2T47 B^S0_\\Q1]FA_YYBI:*+@1?9H?
M^>8H^S0_\\Q4M%%P(OLT/_/,4?9H?^>8J6BBX$7V:'_GF*/LT/\ SS%2T47
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M"#D'H:6O%/HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M77;:/[/=>&I7NEX+J6 S]-I_G6CX9;Q9J]]<7.KA+?3YHRGD,O//]WT_&@#
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MSS4>BZ3<:?J>K7$QC*7<XDCVG)QM Y_*G<5BIJ$26'B[2I;9!']I#QRA1@,
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MPZ%'1+V_L=4DT'5)?M$B1^9;W.,&5!Z^]1^%K=-6CFUJ]42W,TC*H?D1H#P
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M% !1110 4444 %%%% !6--?_ &+4KH>7NW;>_P#LULU0BB234KS>@;&SJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY7D73,8]CY/+$\C\:[6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ/0"BBB@ HHHH **** "FB-%=G"*&;JP')IU% !1110 4444 %%%% !1110
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M0!!]J3_GG-_WZ;_"C[4G_/.;_OTW^%3T4 0?:D_YYS?]^F_PH^U)_P \YO\
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M +]-_A4]% $'VI/^><W_ 'Z;_"C[4G_/.;_OTW^%3T4 0?:D_P"><W_?IO\
M"C[4G_/.;_OTW^%3T4 0?:D_YYS?]^F_PH^U)_SSF_[]-_A4]% $'VI/^><W
M_?IO\*/M2?\ /.;_ +]-_A4]% $'VI/^><W_ 'Z;_"C[4G_/.;_OTW^%3T4
M0?:D_P"><W_?IO\ "C[4G_/.;_OTW^%3T4 0?:D_YYS?]^F_PH^U)_SSF_[]
M-_A4]% $'VI/^><W_?IO\*/M2?\ /.;_ +]-_A4]% $'VI/^><W_ 'Z;_"C[
M4G_/.;_OTW^%3T4 0?:D_P"><W_?IO\ "C[4G_/.;_OTW^%3T4 0?:D_YYS?
M]^F_PH^U)_SSF_[]-_A4]% $'VI/^><W_?IO\*/M2?\ /.;_ +]-_A4]% $'
MVI/^><W_ 'Z;_"C[4G_/.;_OTW^%3T4 0?:D_P"><W_?IO\ "C[4G_/.;_OT
MW^%3T4 0?:D_YYS?]^F_PH^U)_SSF_[]-_A4]% $'VI/^><W_?IO\*/M2?\
M/.;_ +]-_A4]% $'VI/^><W_ 'Z;_"C[4G_/.;_OTW^%3T4 0?:D_P"><W_?
MIO\ "C[4G_/.;_OTW^%3T4 0?:D_YYS?]^F_PH^U)_SSF_[]-_A4]% $'VI/
M^><W_?IO\*/M2?\ /.;_ +]-_A4]% $'VI/^><W_ 'Z;_"C[4G_/.;_OTW^%
M3T4 0?:D_P"><W_?IO\ "C[4G_/.;_OTW^%3T4 0?:D_YYS?]^F_PH^U)_SS
MF_[]-_A4]% $'VI/^><W_?IO\*/M2?\ /.;_ +]-_A4]% $'VI/^><W_ 'Z;
M_"C[4G_/.;_OTW^%3T4 0?:D_P"><W_?IO\ "C[4G_/.;_OTW^%3T4 0?:D_
MYYS?]^F_PH^U)_SSF_[]-_A4]% $'VI/^><W_?IO\*/M2?\ /.;_ +]-_A4]
M% $'VI/^><W_ 'Z;_"C[4G_/.;_OTW^%3T4 0?:D_P"><W_?IO\ "JL%PHO[
MIMDOS;>!&<]*T:IV_P#R$;SZI_Z#0A$OVI/^><W_ 'Z;_"C[4G_/.;_OTW^%
M3T4#(/M2?\\YO^_3?X4?:D_YYS?]^F_PJ>B@"#[4G_/.;_OTW^%'VI/^><W_
M 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?IO\ "IZ* (/M2?\ /.;_ +]-
M_A1]J3_GG-_WZ;_"IZ* (/M2?\\YO^_3?X4?:D_YYS?]^F_PJ>B@"#[4G_/.
M;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?IO\ "IZ*
M (/M2?\ /.;_ +]-_A1]J3_GG-_WZ;_"IZ* (/M2?\\YO^_3?X4?:D_YYS?]
M^F_PJ>B@"#[4G_/.;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D
M_P"><W_?IO\ "IZ* (/M2?\ /.;_ +]-_A1]J3_GG-_WZ;_"IZ* (/M2?\\Y
MO^_3?X4?:D_YYS?]^F_PJ>B@"#[4G_/.;_OTW^%'VI/^><W_ 'Z;_"IZ* (/
MM2?\\YO^_3?X4?:D_P"><W_?IO\ "IZ* (/M2?\ /.;_ +]-_A1]J3_GG-_W
MZ;_"IZ* (/M2?\\YO^_3?X4?:D_YYS?]^F_PJ>B@"#[4G_/.;_OTW^%'VI/^
M><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?IO\ "IZ* (/M2?\ /.;_
M +]-_A1]J3_GG-_WZ;_"IZ* (/M2?\\YO^_3?X4?:D_YYS?]^F_PJ>B@"#[4
MG_/.;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?IO\
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MVI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?IO\ "IZ* (/M2?\
M/.;_ +]-_A1]J3_GG-_WZ;_"IZ* (/M2?\\YO^_3?X4?:D_YYS?]^F_PJ>B@
M"#[4G_/.;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4?:D_P"><W_?
MIO\ "IZ* (/M2?\ /.;_ +]-_A1]J3_GG-_WZ;_"IZ* (/M2?\\YO^_3?X4?
M:D_YYS?]^F_PJ>B@"#[4G_/.;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^
M_3?X4?:D_P"><W_?IO\ "IZ* (/M2?\ /.;_ +]-_A1]J3_GG-_WZ;_"IZ*
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M;_OTW^%'VI/^><W_ 'Z;_"IZ* (/M2?\\YO^_3?X4^.99"0$D&!GYD(J2BD
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M)\3;.6[\(R-$&/DRK(P'IR/ZU=\"ZI;:AX6M%A=?,A79(@/*F@#F;OX9W6F
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKU#Q JO=H&A)[KS5BH;HXMV]^*4MBH?$CVKX5:B]_X.2*0Y-K*T()]/O?\
MLU=O7GWP@M7@\*32L"!/<LZ^X  _F#7H-?,XA)596/LL*VZ,;]@HHHK$Z HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW4VAQV;'O0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)HV*NGT8<BK]%%P,.7PEI5Q&ZW2SW+.NWS)YF=U'LQY%7KO2+.]M;>VG1C'
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M?2I)*R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKTC_ %HL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/\
M6C-UZ1_K18"Q15?-UZ1_K1FZ](_UHL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?
MZT9NO2/]:+ 6**KYNO2/]:,W7I'^M%@+%%5\W7I'^M&;KTC_ %HL!8HJOFZ]
M(_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/\ 6C-UZ1_K18"Q15?-
MUZ1_K1FZ](_UHL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KY
MNO2/]:,W7I'^M%@+%%5\W7I'^M&;KTC_ %HL!8HJOFZ](_UHS=>D?ZT6 L45
M7S=>D?ZT9NO2/]:+ 6**KYNO2/\ 6C-UZ1_K18"Q15?-UZ1_K1FZ](_UHL!8
MHJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/]:,W7I'^M%@+
M%%5\W7I'^M&;KTC_ %HL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+
M 6**KYNO2/\ 6C-UZ1_K18"Q15?-UZ1_K1FZ](_UHL!8HJOFZ](_UHS=>D?Z
MT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/]:,W7I'^M%@+%%5\W7I'^M&;KTC_
M %HL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/\ 6C-U
MZ1_K18"Q15?-UZ1_K1FZ](_UHL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9N
MO2/]:+ 6**KYNO2/]:,W7I'^M%@+%%5\W7I'^M&;KTC_ %HL!8HJOFZ](_UH
MS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/\ 6C-UZ1_K18"Q15?-UZ1_
MK1FZ](_UHL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/
M]:,W7I'^M%@+%%5\W7I'^M&;KTC_ %HL!8HJOFZ](_UHS=>D?ZT6 L457S=>
MD?ZT9NO2/]:+ 6**KYNO2/\ 6C-UZ1_K18"Q15?-UZ1_K1FZ](_UHL!8HJOF
MZ](_UHS=>D?ZT6 L457S=>D?ZT9NO2/]:+ 6**KYNO2/]:,W7I'^M%@+%%5\
MW7I'^M&;KTC_ %HL!8HJOFZ](_UHS=>D?ZT6 L457S=>D?ZT^/SLGS F,<8I
M 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%8VFW^K730R7-A!':S)O5XIBS*.VX$#]":V:0PHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '_UZS_A["H\6:Y:IE8B&7 [#<17=>$O#K>&=':P>Y%P3(7WA-O7';)]*S]
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M_D-Z!_NK_.K$OPJ,C6\QUB1[E'W2R2H6W], <\=_6M[Q)X/?7K[3[A;U81:
M J8]V[GZ\4 =77E#7">&OBQ+<7V4M[HL1(>@W X_7%>KUD:_X;T[Q':B&^B.
MY?N2(<,OT- &HDT<L0DCD5HR,A@<BLR77+"9KNSM+R*2]BB+>6IR<X./K7&-
M\,-01C';>);B.V[1D-P/P8#]*Z+PWX'TWPZYN%+W%VPP9I3T]<"@#D?AI;6-
M_J.IW&H*DVH"3[LHS@=R ??^5-^(,%KIWB72Y]*"QZ@6&Y(A[\' [UOZY\.8
M+_4&O]+OI-.N)/O[,[3[\$$?G4OA_P"'UOI5^-0O[R34+Q?NO)T'OSDY_&@#
MG/']LM[XZT6VF7*3;$<>H+ &K7Q3TVSM/#]B]O;1Q,LP0%% XVFNCUSP@^K^
M)M.U=;Q8EM&4F(QY+8.>N>*F\8>&'\4Z;#:)=+;F.7S-Q3=G@C'4>M '+>,T
M1_AM83,BF7]V-Y'.,'O6-XNMXO\ A&O"RK&B^8&W%5QG[O6N^UKPF^K>%;?1
MEO%C:$K^],>0< ]L^]4]8\#2:IINCV@OUC.GYRQBSOZ>_'2@"/QA$=+^'K)I
M\:Q HBN47!*XY)I_@'3-';PG;R1PP32."9F=03NSR/:NLDLX9['[)<(LL138
MP(X/%<#/\+I([A_[+URXM+9SDQ<G]010!0\.K'9?%6ZM=).;%M_F*O*C@\?@
M:L?#S_D<-=^A_P#0A76^&?"5CX9A?R2TUQ)_K)GZGZ>U5O#?A%]!UJ_OVO%F
M%UG""/;MY!ZYYH ZFBBB@"FG_(7E_P"N*_S-7*II_P A>7_KBO\ ,U<IL"MJ
M,+7&F7<*?>DA=%^I!%9OA6XCE\.VB!@)(4V2(3RI'K6W69<^'],NYVFEMR)&
M^\8Y7CW?7:1FCI81F:>1>>.-0NX3NAAMHX"XZ%\L2,^W'YU%X65?^$@\1O@;
MC=J,^VQ:Z6UM(+*$0VT2QQCLHIEMI]K9S7$UO"$DN'WRL"?F.,9_("G<+&+K
M?_(T:#_OR?R%0Z ZV/B/6;.Z8+<3W!GB+?QH>F#[5T,UE;7%S!<2Q!I8"3&V
M3\N>M,O=,L]151=0!ROW6!*L/HPP11?2P6,'Q_?V=MX4O(;@JTDJ[8X^I)SU
MQ[=:K^)?^1=T7_KZ@_E6U_PC&C^3)$UF)%D&UC)([G'H"22/PJY<:99W=O#!
M/ 'BA97C4D_*1T-":06*&LZ';ZM+%+'<M:ZA N8IHR-R@^H[CBN:O+S4=8\(
MW:3H)9K&["2/$.)T7DD#\>GM787NBV&H2B6YA9I -H9)70X]/E(JQ:VEO96Z
MV]O$L<2]%'^>:$PL)97MM?6D=Q;2*\3*""#T^OI1#?6MS-+#!.DDD7WPISMJ
ME-X;TF>0NULR$]1%,\8/X*0*N6=A::?%Y=K D2GK@<GZGJ:6@:GGL$,C>%;:
MX",\-MJIEF5?[@.,_@2#^%>C17,$UNL\<J&$C(<-QBH[33[2QMVM[:!4A9BS
M)DD$GKUJBWAG2&D+_96&3DHLSJG_ 'R#C]*;:8)6,G1X8;_6]>O"H_LV?9%N
M8_+(5!W$>W('X5''#=>%=5L+2TNFN=-O)/+6WDY:'W4]Q75&RMFLS:>2@MRN
MWRU&!C\*JVF@Z;8SB>"W(E PK/*[[?IN)Q^%%PL<QI.F,/$.LP3ZG>VEQ)<&
M6-8G51(AZ$94YQTJWK6F6*116>H:UJLWVF142 2(68YZXV]!US717NF6>H@"
MZ@#E>C!BK#Z,,$5'9Z)I]A+YMO;XDZ!Y':1A]"Q)%',%C"?9I?CF&:Z8BWN+
M3R()'Z*X()!/8D#]*WM6O+6RTNXFNG41>61@G[W'0>M6+JTM[V$PW,*2QGG#
M#]?:L^/PUI,3;A:E_02RO(!] Q(%%T!2\",K^#[-D7:I,A"^@WM1XC_Y"^@?
M]??^%;=E96^GVJVUI$(H4)*J"3C)R>ON:BU#2;+55C6\A,GE-N0AV4J?7*D&
MB^MPMH7:\^N+6>\M?%T-L"9//5MHZL <D?B :ZZVT#3K.X6>&.82+T+7,C#\
MBQ%6K>PM;2:XF@B"27#;Y6!/S'UH3L#5R'1[VVO=*MY;9U,80 C^Z0.A':N:
M^V6UU\485M\,T=BZO(.A.X<?A_6N@F\.Z5/,96MBKDY/E2O&"?<*0#69_9+V
M_C:SGMK3991V;H74?*&+#CZT*P.XWPX!:>(=>M96"RR7(F13QN4HHR/7D'\J
M?JNVY\9Z/%&=SP!Y) /X1CC-;-]I%CJ3*UU!N=.%=79& ],J0<4ZRTNSTX-]
MEAV%OO,6+,?J22:+]0L<+<VL]YIWBR*V!9Q=[RHZL <D?B!7<:5>VU]ID,]L
MZF/8.!_#['TJ2VL+6TEGE@B"/</OE()^9O6J<WAS2IY3*UL59CD^5*\8/U"D
M"AM,+6,&*]M+SXHJML0[16#K(Z]"=R\9]OZUV=4+?1--M+M+JWM(XYDC,:LN
M1\I()_D.:OTF[@CFO#?_ "'O$/\ U]+_ .BTI)-MK\0%EF8*EQ:;(R> 6!Z?
M6MZWL;:UGN)H(@DEPV^5@3\QP!G\@*2]T^UU&'RKN%9%!R,D@@^H(Y'X4[ZA
M8P?&I6>RLK)3NGFO(=J#J0'!)^@ -%ZB_P#">:3N )6TEQ['*UKV>B:?82^;
M;P$28P'DD:0CZ%B<58>QMI+Z.]>(&XC4HCY/ .,C]!1<+&)XU57T6%6 (^UQ
M<'ZUJZKQHMT!_P \6_E4UW96]_$L5U$)$5@X!)'(Z'BI98DFA:*1=R.-K#U%
M*X'!1J8_#/A6^D5FMK9D:;'\(P,$^PKO!<0F'SA+'Y6,[]PVX^M1P6-M;626
M44*BV1=BQGD8].:H?\(QH^_=]D./[@F?9_WSG&/PIMIA:QQ]ZOG:-X@OHU(M
M+F]A\K/1L2#)'L:[R2&WN-+\BY"F!XPKAC@8(IUQIUI=67V.:!6M^,1CY0,'
M(Z>X%/GM8;FV:VFC#0L,%<]J&[@D<M EWX8UFPT^&[:[TZ\8JD4GWX,<Y![K
MS77UG6>AZ=83^?;VY$N,!GD9R![;B<?A6C2;N""BBBD,**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6)R[#Y5VAP/X@.V:U9K:"XQYT,<F.F] <?G4BJ%4*H  Z "@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#*T_PYI>E7]Q>V=L8[BX),K>8QW9.>A.*U:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"FG_(7E_ZXK_,U<JFG_(7E_P"N*_S-7*; ****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[?_D(W
MGU3_ -!JY5.W_P"0C>?5/_0::$7****0PHHHH **** "BBB@ JA<:)I5VS-<
M:;9RLW5G@4G\\5?HIIM;":3W*EMI>GV3;K6PM8&]8H54_H*MT44-M[@DEL%%
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<WKUG+]J^T*"T9 SCM7244
M <8ND75_I=XL>4\R(JF?XCUQ7GXTJ_:\^Q"UE\_.-FVO<Z*YZN'51IW.3$82
M->2DW8\G\2^';^P%K.5>6(0*C,.=A&>/UH\/>'-0O[:]F5'B1H2B%N-Y/]*]
M8HJ?JL>:]S/^SX<_-?0\,&E7YO/L8M)?M&=NS;7LVD6CV.DVMK(VYXHU4GW
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MS+C_ )XC_OJCS+C_ )XC_OJIZ* (/,N/^>(_[ZH\RX_YXC_OJIZ* (/,N/\
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MSQ'_ 'U4]% $'F7'_/$?]]4>9<?\\1_WU4]% $'F7'_/$?\ ?5'F7'_/$?\
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MU+*57(P/4U;W#.,C/IF@!:*0D#J0/K2T %%%% !1110 4444 %%%% !1110
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M [DD[^O;M69-\2M5L+R)M2T)K:QE/R,P8.1Z\\&H?&<:S?$S1(W *L8P0?\
M>JY\70/["LCCGS_Z&@#JM<\3V.A:.NH3G>L@'E(IY<FN0@^(?B"2/[:_AQCI
MO7S41NGUZ5G^.K>;_A&_#]YY9>VA51(,9'/K_*NSM_&'AXZ"DYO[8((L&$N
M_3IMZT 9_A/QI<>*)=2BEMHHHX(\H4SD@YZY^E<WX&9$L_$[21)*@W$QOT;D
M\&G?#26.;5=?EB7;&Z;E'H"6Q4?@O_D'>*OHW\S0!K>$M9BL? FI:E9:=;V[
M0%F\M69@Q [DG-06OQ*UK4+ O8Z#Y\T>3,R*Q15_#FJ'AK_DE6N?1_\ T&NF
M^%\2KX.# #+RONXZ\T :'@_Q<GB>TF:2$07%N1YB \?45AZE\1KJ35GT_P /
MZ9]O>,D,2"<XZX K)^'L;R7_ (BBBX=HG5<>I)Q2_#G6=.T:[U*QU*6.UN6D
MR'F^4'&<@D].OZT 6;OXGZE:S6]K+HZV]T6Q,DX88SC!'_UZ]-C;?$C'^( U
MY!\1=:TS5=8TV*PFCG>%OWDD9R.2,#/>O78/^/>/_<'\J )**** "BBB@ HH
MHH **** "BBB@"FG_(7E_P"N*_S-7*II_P A>7_KBO\ ,U<IL"EK/_(#O_\
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M.!S5C4O[:L+"34QJ(;RE\Q[4Q+LV]P#C=G'O3?&'^KTK_L(0_P#H0K0\2?\
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M;+4[H-&6W;3P?:MBLY;:&?4KLRQJV-F,C_9IKS$RN?$$0_Y8/^8J-O$T*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME(' X/>K^D:5!H]@+6 LPW%V9CRS'J: +]%%% !1110 4444 %%%% !1110
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MQ7^9JY5-/^0O+_UQ7^9JY38!3&BC<Y>-&/J5!I]%(!  !@# ]J JJ20H!/7
MZTM% "%02"0"1T..E#*KC#*&'H1FEHH 8(8E4J(T /4!1S3BJD %00.@(I:*
M &/%')]]%;'J,TX  8   ["EHH 8T,3G+1HQ]2H-. "C   ]!2T4 (JJHPH
M'L*:88BVXQ(6]=HS3Z* $(!&" 1Z4U8HT.4C52?08I]% ",BN,,H8>A&:1(T
MC^XBK]!BG44 (0",$9%-6&)#E8T4^RBGT4 (JA1A0 /0"AE5QAE##T(S2T4
M(J*@PBA1Z 8I'C208=%8>XS3J* &JBH,(H4>@&*7:N[=M&[IG'-+10 @55SM
M4#)R<"FM#$S;FB0GU*BGT4 (%4-N"@'&,XI:** $"A<X &>3@4,JN,,H8>A&
M:6B@!J1I']Q%7Z#%+M&[=@;NF<4M% "%5;&X XY&100",$ @]C2T4 (  ,
M#TIODQ!MPB3=Z[1FGT4 (5### $>XH(### $>AI:* &I&D?W$5<^@Q3J** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J=O_ ,A&\^J?^@U<JG;_ /(1O/JG_H--"+E%%%(8
M4444 %%%% !7FWQ0\'2ZI"NLV";KB!=LJ*.77L1]/ZUZ30>1@UI3J.G+F1E6
MI1JP<)'RU#<C[DORL..:M @]#FO9?$GPSTC7)'N(";*Z;DLBY5C[BN%G^$'B
M".0B"[LGCS@%I&4_EMKVJ6/IR6NA\[6RNK&7NJYR+R)&,LP%2Z/I%[XGU:*R
MLXVVD_,^.$7N37<Z7\&[EI VK:C&J@\I "V?Q.,?E7INB>'].\/VGV?3X!&O
M\3'EF^IK*OCXVM#4VPN5SYKU-$3:1ID&CZ7;V%NN(X5"_4^M7:**\=MMW9]
MDDK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSNW[N<U[7HT\USH]I/< B9XE9P?7%9@\%:(+W[3]G;.=WE[ODS]*Z  *  ,
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M9(?1O^^S_C1]DA]&_P"^S_C0!-D>HHR/45#]DA]&_P"^S_C1]DA]&_[[/^-
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MR/45#]DA]&_[[/\ C1]DA]&_[[/^- $V1ZBC(]14/V2'T;_OL_XT?9(?1O\
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M4/V2'T;_ +[/^-'V2'T;_OL_XT 39'J*,CU%0_9(?1O^^S_C1]DA]&_[[/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gjnp4w4lrub1000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -6!NL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO>0L&29 P(Z<B@"U1110 45C:WXJT/P['NU748+;/02-@FN93XR^"WG\O\
MM1%&?OL1B@#OZ*R]'\1Z/X@A,NE:A!=H.IB;.*U* .:\>:]<^&O"5UJEHJM-
M%]T-TZ&JWPV\37?BWP=;ZK>JJS2,P(7IP2*Y3XJ>-O#-[X,U+3;;6[.6]#%#
M LF6W#((Q]:H?"#QQX8T7X?VEEJ>N6=K<HSEHI9,,,L: /5]?N;RST&]N+"/
MS;N.(M$F.K5Y5\(O&'B[Q!XAU*VUM2]K$I.XQA=C9'' ]*]@CN8)[5;B.57@
M9=P<'@CUK+T/7?#NKRSIHEY97#QG$HM\9!]\4 ;5%9>K^)-&T#RO[6U*WL_-
M.V/SFQN/M6C#-'<0I-"X>-QE67H10 ^BBLW6/$&D>'X$FU?4(+.-SA6F; )H
M TJ*BMKJ"]MH[FVE66&50R.IR&!Z$47%S#:0//<2+'$@RS,< "@"6BN$O?C!
MX,LK@P_VM%,1P3$016OH/CSPWXCD$6FZI!+.?^66[YORH Z2BLF]\3Z'IVI0
MZ;>:I;07LW^KA=\,WT%7;_4;/2["6_OKB.WM8EW22R'"J/4T ><_$[X@:GX0
MU?2[6QCC9+J15?=[GZ5Z9"YDA1SU(S7S?\9?%&AZYKVBS:7JEM=QPRH9&B?(
M49[U[9I'CSPKJ4L%E9:]93W3C"Q))EC0!P'Q?\8>+_#VM6<&B(4M'VG>(PV]
MO[O(_P YKU70+F[O- L+B_CV74D"-*N.C$#-5]<UOP_I+VZZW>6<#3-B$7&/
MF/MG\*TS<VZ69NC(BVZIOWY^4+C.?IB@":BLO2/$>C:\DSZ5J-O>+"<2&)L[
M3[_E6%J_Q1\(Z-<-!<:M"TRG#(C E3[T =C17-:!X]\-^)9/*TW4X9)_^>6[
MYORKI: "BBL+7?&7A_PYQJFIP6\AZ([88T ;M%<':?&'P7=3B+^UHXL\!I"
M*Z_^V-.&F'4OMD7V(+N\_=\N/7- %VBL_2-<TO7K7[5I5]#>09*^9"V1FM"@
M KEM:\96VB^,=)T.X"@:A&2CD]&W8 KJ:^8?COJDP\?VIMW99;*/Y6'5<X-
M'T]U&117->!/$D/BGPG97\;#S#&%E7/*L..?RKI: "L+Q9XEM_"NAOJ-Q@X9
M55<_>)(']:W:^9/CSXQ;4O$*:':R9M[!LR8/_+3H0?R% 'TAI=Y_:&EVMX!C
MSHP^![U;KEOAQ>B^^'^C29R5MD1C[@"MO5M9TW0K(WFJWL-I; A3)*V!D]*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1@RL,\$=.]=+0!X)^T#_ ,ASPW_UT;^:U[=I'_(%L/\ KWC_ /017B/[0/\
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MVKGOC&BM\+-:) )6-2/;YUJK\$I&D^&]GG^%BH_(4 >BT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?.'CNZ?XD?%>S\/V3E[*U.URO0#(WG\#7L
M?Q%\3Q>%?!]Y>LP$KJ8HAGG<PP#7S=X \:2>$M4O-6DT>:\N[@DK($)V@]:
M/?OB%X'AUGX>-IEK$//LX@UO@<EE&,?C7._ CQ2;W1I_#UV_^E6#$(I/)7//
MZFL?_AH*\_Z%N?\ [X/^->=:#XP.B?$M-=BM)+*SN)?WL3*1\IZ_K0!]?5P'
MQ2\?#P;HJQVHWZE=?)"H_A]Z[JWG2YMHYXR"DBA@1[U\_>,0?$'Q^TK3+EMT
M$;[ K=. 30!:\'_"2]\4JNO^,;R:5K@>8MN3Z^OI^%>@?\*;\"^1Y?\ 8<6[
M&-^]L_7K7=JH1 J@  8 %+0!X%XF^%&K^$+J+6?!=S<2%)%S: ^_8>E>U>'K
MF_N]#M9M3MC;WC(/-C/8XYK3ZT4 >*_$_P"&GAO3/"^I:S;686\9S(7R>IR3
MW]:S_A7\,O#7B7P/:ZEJ5F);EV8,V3V8CUKT#XO_ /).=0^G]#5#X&?\DRLO
M]]__ $(T =VUK%8Z,UM NV**+:H]!BO$OV??^0MK_P#UU;^8KW.^_P"/&?\
MW#7AG[/O_(6U_P#ZZM_,4 >@_%?PJOB?P;<!$W7=J/.@P.=W?],UE?!+Q2=;
M\(KIUQ)F[L/W94]2HQ@_G7IKJ'1D895A@BOGN7?\,OC27 *Z9JC9P.@!)P/S
MH ^AJ^?/&MQ-\1/BU9^';5B]C8.&DQTR#\X/Y5ZYX\\2Q>&?!][J+$%BA2,
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M1110 4444 %%%% !1110!X!\>_\ D9M!_P"NJ?SKV2ZT6RU_PRNGW\*R0RQ
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MA\Z[G11&FX#.&!ZGZ54^%>@ZCX<\$P:?JD'DW*N24W ]AZ4 =M1110 4444
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M/,L+49N)RZ@LV3R>YKWI 1&H/4 4 >"?'O\ Y&3P_P#]=D_G7O%M_P >T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]\3ZFJ.TGF 2=9G]#_GM7UU+/!:VYEED5(5'+$\ 4 2U@>-O^1,U;_KVD_\
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MN@Q;OLBQ>4/7&,5\[VWQV\5RW4,;01[7<*>#W-?2VEW#W>EVUQ)]^2,,WUH
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MOKWQ 73KO/DRS,&Q7TI\/=,_LOX26J%-DDMDTKJ>H8IS7RW;ZO<Z%XK?4+0
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M70KW^T=#LKP_\MH@_P"= &A1110 4444 %%%% !1110 4444 %%%% !1110
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M.K87^[RI8U+8^E>>ZI\#/"UII5U<1B7?'&6')Z_G7KR;0BA?NXXQZ5GZ]_R
M+[_KBW\J /CKP!H5IXB\>:?I%YG[//(RMCKPI/\ 2OH:#X%>%;>XBG02[HW#
MKR>H.?6O#?A#_P E:T?_ *[/_P"@M7V%0 R-!%&J+T48%/HJMJ$_V73;FX_Y
MY1,_Y#- 'S/\8=9E\5?$>WT*"4_9HF2%-I_B; /'UKZ(T_3X]+\*064:[1%;
M*I^NT9KY9\$1+K7Q?CEF^;-Z\XR>X?(KZWO?^/&;_<- 'QCX?TJWUSXEVNEW
M6?(NM0,;X]"QKZ"_X4)X3])?S/\ C7S?!JMQH?C,ZI:@&>UO&DC!]0QKOO\
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M<8R&!_I5O3?#.L:O\=9M8O;*1+"*=F1FZ%<'% 'M=Q;)9^'I[>,82.V=5'_
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MRMX$MK>.&,81!@"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/M,_ZYC^0KR+]HV[N#K6FVI8BW6-BH[$\5[)\.;.XL/ ^GVUU$T4R( R-U'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U[3#K.AW>GAPAN(FCW'M
MD8K1HH X?X;^ 7\!Z?<VK7:W'G,&RH/&,_XT>._AKIWC0Q7)D:VOX?N3IU_&
MNXHH \DT[X+M+JMO>^(]:EU-;;_51L>,>AXKOO$WA33_ !1X??1[Q2L)7",G
M5". 16[10!XRGP+FF,%E?^(;B;2;=]T-N#ROZ5Z]8V4&FV,-G:QB."%=J*.P
MJQ10 4444 ?-?P\_Y.-U'_KK=_UKZ4KYK^'G_)QNH_\ 76[_ *U]*4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\U_#S_DXW4?^NMW_ %KZ4KYK^'G_ "<;
MJ/\ UUN_ZU]*4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\V
M> /^3D-1_P"NUW_(U])U\V> /^3D-1_Z[7?\C0!])T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S7\//^3C=1_ZZW?]:^E*
M^:_AY_R<;J/_ %UN_P"M?2E !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?-G@#_DY#4?^NUW_ "-?2=?-G@#_ ).0U'_KM=_R- 'TG1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 449HH **,T4 %%&110 4444 ?-?P\_
MY.-U'_KK=_UKZ4KYK^'G_)QNH_\ 76[_ *U]*4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXIR=D!J45\_G]HF]!(_L6V_[[;_&@?M$WN?^0+;?]]M_C7=_9F)_E_$GG1]
M450T741J^CVM^$V>>@;;Z5?KA::=F4%%%%( HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<]Q%:P/-/(L<:#+,QP *DKRCX^ZG<V/@-8(&*K<SK'(1W4@Y% #-:^/_AO
M3;@Q6=M/J&&VDQML'ZBNCO/B?HVFZ;I%]J"26\.I#*$G.SKUQ]*\2O\ X::+
MIWPM3Q"+M[C4&7=F.0;![8KI_&GARPU+X*Z9JT]T8[JQM-T49? ?YCQCN>:
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M1D>H84X2QL<!U)] :X8^&M*4\-J\*]ECF./_ $&D/A_25'_'_K\1[-',V?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[7?\C7TG7S9X _Y.0U'_ *[7?\C0!])T444 %%%% !7/^.++^T?!FI6G[O\
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MH ^)]3TC4?[4NR;.8?O6/W3ZU233+V4$I:RL <'"FOLZ?P[IKK(Y@Y()KEO
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M=8Y#DGZ&LFFG9C-*BJMM?1W!*$&.0=4;^GK5JD 4444 %%%% !1110 4444
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M ,W]X^M;=9GA_7+3Q'H=KJMD28+A ZAA@CZUIT %%%% !1110 4444 %%%%
M!1110!\U_#S_ ).-U'_KK=_UKZ4KYK^'G_)QNH_]=;O^M?2E !1110 4444
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MQH_X1[7/^AA/_@./\:.9]@]E#^=?C_D=++_J7_W37CDM_9QRNCW4"L"05:0
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MO^/C1+D =?+4MS^5.3QM9#Y9[#4HF']ZU;'YT<\0^K5>B-+Q+;I=>&]0ADR
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MM9U\/[)73O\ (:=S0HHHKG&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%]1T69VN!.!(<.(]GIVKO*\7^%.O'3- EB%A=3YD)W11%AV]*[_ /X3%O\
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MLQEZBHX)TN($FC.589%25(!1110 4444 %%%% !1110 4444 %%%% !1110
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M_(U])U\V> /^3D-1_P"NUW_(T ?2=%%% !1110 4444 %%%% !1110 4444
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M<'BM!&#H&4Y!&0:Q&+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.V*YG_A3_B>^AMM)U+Q%YFCVS95 IRP]#S7L>E:;;Z/I=OI]H@2"! B*.PH
M\8\5? .^\1>*M3UB/7K>%+R=I1&UNQ*Y[9S6/_PS3J/_ $,EK_X#-_\ %5]%
MT4 ?+7P>TUM'^-S::\@E:U6YA+@8#;01G%?4M?-?P\_Y.-U'_KK=_P!:^E*
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M2FT#^=92A%6=CNI8JO)2CSO:^_;_ (!T\4:PQ)$@PB*%4>@%/HHK4X HHHH
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M891:=[A&5R[1117GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXKU7F\VK<J(]F>HVF190 C!\M>/PJ:F1?ZI/]T4^O&- HHHH **** "BBB@
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M_P!Y<G^==14P^$UQ"_>M]]?OU"BBBJ,0K \6HS:3\H)PW:M^D95888 CT(H
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M *U]*4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&SC)],5[);S+<6T4Z9VR('&1@X(S68OA;P^CJZ:)IRLIR"+9 0?RK6 "J%4
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MM':46 .D3 $\GS/_ *U>O:)J\&N:1;ZC;JZQ3*& =2"*K_\ "*>'?^@%IO\
MX"I_A6K%#%;Q+%#&L<:C"J@P!^% 'G/C;XPZ9X,UHZ7+933S*H+$94#//!QS
M5+PO\<=+\2Z];:4NGS0R7#A$;)89]^*]&O-"TC4)O.O=,L[B7IOE@5C^9%,M
MO#NBV<ZSVVD6,,RG*O';JK#Z$"@"Y>7265G+=2!BD2[B%&37C<_[1>DQ3R1I
MI4S*K$!M^,_I7M3*KJ590RG@@C@UDGPIX>)).AZ:2>I-JG^% &3X%\>67CK3
MY;JT@DA,3;65O\:?XZ\<V?@72X;R[@DF\YRB*@/4>I[=:Z"RTVQTV,I8V<%L
MA.2L,80'\J6]TZRU&,1WUI!<Q@Y"S1AP/SH \<A_:,TF29$?2IE5B 2'SC\,
M5[)87D>H:?;WD0(CGC61<C!P1FJ \*>'@01H6F@CH?LJ?X5JHB11K'&H5%&%
M51@ 4 >7^+?C9I?A;79=+:PFGDB W-DKU_"IO!?QDTSQAK0TN.QF@F92RGE@
M?TXZUW5UX?T:^G,]WI-E/,>KRP*S'\2*=::#I%A-YUGI=G;RXQOB@53^8% #
MM9U2'1='N]3N QAMHS(X49.!Z"O('_:-TI9&4:3,0#@'?C^E>U2PQSQ-%-&L
MD;C#(XR"/<5E?\(IX=)R="TW_P !4_PH I^"O&-GXUT8ZC9Q21*K[&5P>#C/
M'K6=X]^(]AX$C@^U6TL\DQ^55! _/%=;:6-II\/DV=M#;QYSLB0*/R%,O=*T
M_4@HOK&VN@OW?.B#X_.@#R.Q_:'TF[OH;=]+GC$CA-P;=C)QTQ7L<,RSP),F
M=KKN&1@UFIX6\/QN'31-.5E.01;("#^5:H  P!@#L* /(]?^/6DZ)K-SIPTZ
M>9K=RC,25Y!P>,5N>!/BOIWCC49+&"TEMYE4L-V2"![XKK9O#6A7,S33Z-82
MR,<L[VZ$D_7%366BZ7ITADL=.M+9R,%H850G\A0!6\2Z_;^&="N-5ND=XH1D
MJ@R37DY_:.TK/&D38_ZZ?_6KVJXMH+N!H+F&.:)AADD4,I^H-9G_  B?AW_H
M!:;_ . J?X4 )X7\1VWBK0H-5M$=(IAD*XP17->/OBEI_@2[M[6XM);B:9-X
M"Y  R1UQ[5W%M:V]E L%K!'!$OW4C4*H_ 5!>Z/IFI.KWVGVMTRC"F:%7('X
MB@#RS1OC]I.JZK!9-IL\7G,%#!BW/TQ7KLL@BB>1L[44L<>U9L7AG08)5DBT
M73XY%.59;9 1^E:A (((R#UH \<U/]H+2=/U*>T73)I/)<H6+;<X]L5UG@'X
MEV'CPW"6UK+!+!@LK9(P??'M712>%] ED:231-/=V.69K9"2?RJU9:3IVF;O
ML%A;6N_[WDQ*F?K@4 9GC'Q5:^#= DU:\C>2-7"!4'4GI7F _:.THL =(F ]
M?,_^M7L]W9VM_ 8+RWBN(2<E)4#+^1K._P"$3\._] +3?_ 5/\* #3M1MO%/
MAE+R!76"ZC.%=<']:\O/QFT[PGI-E8SV4T]P ^[JH&'(].:]DB@BMX5BAC2.
M-1A41< ?A7&>&-%TF].HP7NF6=PUK<;%,T*L0"-W4CWJ7\2-XZT9+LT_S1SW
MAGXZ:5XBUVVTO^SYX7N&VHV2W/Y5ZE=7*6MI+<N"4C0N<#)P!5*W\.:):3K/
M;:18PRH<J\=NJL/H0*TF574JP!4C!!'6J,#Q6?\ :,TB.=TCTJ=T!P&+XS^&
M*[WP)X^LO'5C+/:P20M$<,K9Q^=:Y\*>'B<G0M-)/_3JG^%7;+3+#34*6-G;
MVRMU$,80'\J ,#QSXXL_ ^E)>W<,DWF-M54!_4]J\[C^/.F:U<0V(TR6)GD&
M&+YYS]*]DO-/LM1B$5[:07,8.0LT8<?D:S)_"V@I;R-%HNGI(%)5EMD!!]0<
M4 :MG.MQ9PRJ" R \CVKQWXD_%#3](\3VEC':2M>:?<)*[\KD8SMZ=#FO7=+
M;=I\?M\OY54U7PQHVKQS?:]-M))I5VF9H5+_ )XS5TY<LDP9Q/@SXRZ;XNUI
M-+2QF@F<?*>6!/OQQ7H.JZC%I&E7.H3AC% F]@HR:Y?P!8Z;'IS(NG6D5_9R
M&*62.%5;J2,D#/3%=C+%'-&T<J*\;##*PR#1./+)H$>*O^T;I2R,JZ3,0#@'
MS/\ ZU>D>"?&5IXVT7^TK2&2)0Y1E<'@C'?OUJ[_ ,(IX=_Z 6F_^ J?X5H6
M=C::?#Y-E:PV\6<[(D"C/T%0!RGCWXB6/@.WMWNK>6>2=B%500./?%<59?M#
MZ3=7D,#Z7.@D<+N#9QD^F*]=O=+T_4U5;^RM[H(<J)H@^/IFJ:^%O#Z.KIH>
MG*RG((MDR#^5 &G;S+<VT4Z9VR('&1@X(S7E'B#X\:3H>LSZ>-.GF,+;68DK
MS],5ZT %4*H  & !VK,G\-Z'<S--/H]A+(WWG>W0D_B10!R'@3XLZ=XXU233
MX+.6WG1#(,Y((&.^/>NN\1Z];^&M"NM5NE=HK=-Q"#)-366B:5ITIEL=-M+:
M0C!:&%4)'U JU<6\%W T%Q"DT3C#)(H92/<&@#Q7_AH[2MV/[(FQGKYG_P!:
MO5/"OB6U\6:'#JEHCI'(/NN,8I__  BGAW_H!:;_ . J?X5I6MI;64"P6L$4
M$2]$C0*H_ 4 <1X]^*&G^!;F&VN+26>:5=V%R !]<5S6D_M Z1J6J6]D^FSQ
M><X0,&+<DX'&*]5O='TS4F5K[3[6Y9>AFB5\?F*KQ^&- AD62+1=/1U.59;9
M 0?RH TW<)$TASA1D\5X]JG[06DZ=J=Q9KIDTODN4+%MN2#@\8KV/J,&LF3P
MOH$LC22:+I[NQRS-;(23^5 '.> OB;8>.WGBMK66"6+J&R1^>*V_%_BFU\(:
M#)JMW&\D:':%0=3_ $Z5I66D:;II8V-A;6N[[WDQ*F?R%2W5G;7T!@N[>*>(
M]4E0,I_ T >,#]H[2BV#I$P&>OF?_6KUS0-9@\0Z'::K;*ZPW*;U#C!'./Z5
M#_PBGAW_ * 6F_\ @*G^%:D$$5M"L,$211(,*B+@#Z"@"2BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /(OVA78> XD!^4W49(_.KOP:T+2
MIOAE83S:?;2R3[_,:2)6+88CN*H?M#?\B-#_ -?*?UKRWPI\:M6\*>';;1K;
M3K>6*#=M=W()R2?3WH Q_$V@2R_%&^\/Z,IC-Q<"*.,,0#D X/M7O_@+X/Z/
MX42.\ND%YJ)49:095?H.GXU\[0>.[N#QVWBL6D37)D$GE$_*#C'6N\_X:,UW
M_H$VO_?P_P"% 'TL  , 8 I:X_X;^+;GQEX9_M.Z@2&3S-NU#D=!784 %%%%
M !1110 4R6*.:-HY8UD1A@JPR#^%/HH PH/!OAZVOC>1:5:B8G.?+& ?88K=
M P,"BB@ HHHH ^:_AY_R<;J/_76[_K7TI7S7\//^3C=1_P"NMW_6OI2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#CO&]CA(=05&8(=LJ*/OCT-/\ :G]JTB2P=]\E@_E;\_?'7/ZXKI;^U6
M\LI8&'WEQ7ENA7+^%O'"VTORVMX/+4'HG.<D^O%:4]4X=_S7_ -?BAYK\CUN
MBBBLS(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_VA78> HT!
M^4W49(_.O7*\A_:%_P"1%B_Z^4_K0!=^#&AZ7-\,K&>:PMI99R_F-)$K%L,1
MW%>$>*- ED^*-[H&BKY9N)Q%'&&(!R <'VK6\)_&G5O"?AVVT:VT^WEB@W8=
MW()R<^GO7/0^.[N'QX?%?V2)KDR"3RB?E! QUH ^B/ 7P?T?PJD=Y=H+S42H
MRT@RJ>P'3\:]*  & , =A7S3_P -&:[_ - FU_[^'_"O9OAMXMN?&?AK^T[N
M!(9/,V[4.1TH [&BBB@ HHHH **** &211S1M'*BNC#!5AD'\*Q8/!OAZWOC
M>1:5:B8G.?+7 /TQ6[10   # &!1110 5\V> /\ DY#4?^NUW_(U])U\V> /
M^3D-1_Z[7?\ (T ?2=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>>^/O#YNX)9;<$7"?OXB.K,.J_EFO0JHZI:_:;-L#YTY7^OZ
M4T[.Z*C+E=REX2UH:_X:LK_@221CS%'\+>E;=>=>%[A?#_BVYTIB$L-2'VBT
M'8.>J?@%S7HM7424KK9B:L%%%%9B"BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(1D8/>EHH \_P#&FE3?93/9[A>6#_:;4KU]&'_?.:ZKPWK<7B'0K;48L RH
M"ZC^%NXJ75[;S8!*HRT>>/4'@_I7 ^';T>%?%]QI+$)IEZ?.M_1,]!^@K3XH
M>GY%P7,N7J>GT445F0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %137,%
MOM\Z5(]QP-QQDU+7*>/O"#^,="^Q0W9M;B.02Q2]E8=* .K!!&0<@UYE\;/$
M&HZ-X4A@TR0Q37DPA,@.,*0?\*Y2+Q3\0/AM*MOX@LY-7TM/E6=.7;\<\#ZB
MN@UG4O#7QA\*OI]GJ,5M?H0\:S\&.3'Z]>U '%I\ ]2DTQ;L^([<7#)YF2S;
M<]:[GX+:UJ5WI=_I6I3FXDL)O+67.05P./UKA_\ A7'Q07%BFN3&SQLW"3Y=
MOTS7J_PW\"KX%T%K5YQ/=3/YDT@'&?0>W% ':4444 %%%% !1110 4444 %%
M%% !7S9X _Y.0U'_ *[7?\C7TG7S9X _Y.0U'_KM=_R- 'TG1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XK
MMOMGA;4(,9WQ?U%;-17,8EM98V&0RD4FKJQ=.7+-2[%71+G[7HMI/G.Z/^7%
M7ZYSP1*3X9M[=S^\M\QO]<D_UKHZ(NZ0ZT>6I)>84444S,**** ,_6!_H.__
M )YN'_*KL1W1(WJH-0:E'YNFW$8ZLA%+82>98Q'T7'Y4 6:Y;QQ:.=,@U6$$
MW&F2B>,#J3]W^1-=345S"MQ;2PN 5=2I!JZ<N628,;9W*7=G%<1L&210P(J>
MN4\#3-#8W6C2DF33)C "?XE !S].:ZNBI'EDT""BBBH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,OQ#K]CX9T:;5-0?9!$/Q)[ 5XW=?M#6EQO5O#-Q+9'(;=(,,OY
M5T_QXLI[OP!OC1I(H;A))44_PC.37+:?\3_AI#HD%M-HL7F+$%>,VF03CGG%
M $L'@7PM\1M._M[PC*VDZC&W*K]V-^O0 <^]0P>+O'_PWN%MO$EE)JNFCA9H
M_F<CU+<XK2^!"-<RZ[J5M;/;:?-<?NHR,#H.1ZU[)<6\-U"T-Q$DD;##*XR#
M0!@^$?&ND^,[!KG2Y&/EG$B,I!4^GO71UCZ-X7TGP_/<2Z9;"W^T'+HG"_@*
MV* "BBB@ HHJAJ^M:?H5G]JU&X2"'<%W,>YH OT5R7_"RO"?_06A_P"^A74-
M<P);?:7E1(=N[>S8 'KF@"6BN>M_''ANZOOL<6K6IFS@#S%P3['-=""",@Y%
M !1110!\U_#S_DXW4?\ KK=_UKZ4KYK^'G_)QNH_]=;O^M?2E !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!NTNK#XU?9+Y]]U"EPDK;MV6"D'GO7U/0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *" 1@C(-%% $/V2VSG[/%_WP*\R^
M)/P_UK6-4M=>\-WS0ZA;D'RF<A#CH<>V/2O4Z* /"KKP-XZ\>ZC9Q^*GBM].
MML!U0\O[XP*[_P <^ (/%/A"/28"(IK4 V['@!@,<UVU% '@=SX-^).N:5:^
M&=1>W33H&P\P;[Z_E7M/A[1;?P]H-GI5L/W5M&$!]:TZ* "BBB@#YK^'G_)Q
MNH_]=;O^M?2E?-?P\_Y.-U'_ *ZW?]:^E* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \B^/Y(
M\*V@SP93G]*^;*^M_B<;)-%@DOT#0*YR#^%>3?;O"?\ S[Q_E7J83,Z>&I^S
MDC18.M57-"+:/+=*8IJMJRC)$@('XU]H>'M1M]2T2UFMY P$:JWL0,&O!(;K
MPS+,B6\2),3A& Z&O2M+U&?3+A93&(YM@,UNOW94 ^^ON!U]S6.-QD<7:4%M
MN6L+.FN6HK-['HM%0VMU%>6R3P.&1AD$5-7"8M-.S"BBB@04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ! (P1D&H?LEMG/V>+/\ N"IJ* /+?B5\
M/]9UG4[77?#=\T.H6Y4^4SD(<=#CVQZ5SEWX&\=>/=0LHO%+Q6^G6V-X0\O[
MXP*]UHH XGQQX M_%'@^/2("(Y;8 V['@!@,#-><W/@WXDZWI-KX9U![=-.A
M;:\P;[Z_E7OE% &7X=T2W\.Z#9Z5;#]U;1A ?6M2BB@ KYL\ ?\ )R&H_P#7
M:[_D:^DZ^;/ '_)R&H_]=KO^1H ^DZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT5.4=?4QFW&5DSZ3TGX]Z7JNK6M@NBW<37$BQAVE4@$G%>NU\1>'O-/B+3A
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MBB@ HHHH *^;/ '_ "<AJ/\ UVN_Y&OI.OFSP!_R<AJ/_7:[_D: /I.BBB@
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M5.WX@8'O6S_>+FZK^KBV.FHHHK$84444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-X-_YY:E_P!^!_\ %4?\-#>#?^>6I?\ ?@?_ !5 'K-%>3?\-#>#?^>6I?\
M?@?_ !5'_#0W@W_GEJ7_ 'X'_P 50!ZS17DW_#0W@W_GEJ7_ 'X'_P 51_PT
M-X-_YY:E_P!^!_\ %4 >LT5Y-_PT-X-_YY:E_P!^!_\ %4?\-#>#?^>6I?\
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M_P!^!_\ %4 >LT5Y-_PT-X-_YY:E_P!^!_\ %4?\-#>#?^>6I?\ ?@?_ !5
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MBD[[(,K^>:%^-?A=I5C$5^'8X"F$9)_.O%=*:Z&B39Z/17#?\+3T?_GPU/\
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M\:[JB@#A?^%.> _^@!%_W\?_ !H_X4YX#_Z $7_?Q_\ &NZHH X7_A3G@/\
MZ $7_?Q_\:/^%.> _P#H 1?]_'_QKNJ* .%_X4YX#_Z $7_?Q_\ &N ^,7P\
M\+>&O 3ZAI&E);70N8T$BNQX.<CDU[S7EWQ__P"282?]?D/]: +6C_"/P/<Z
M)83S:%$TLMM&[MYC\DJ"3UJ[_P *<\!_] "+_OX_^-=3H'_(N:7_ ->D7_H
MK1H X7_A3G@/_H 1?]_'_P :/^%.> _^@!%_W\?_ !KNJ* .%_X4YX#_ .@!
M%_W\?_&C_A3G@/\ Z $7_?Q_\:[JB@#A?^%.> _^@!%_W\?_ !H_X4YX#_Z
M$7_?Q_\ &NZHH X7_A3G@/\ Z $7_?Q_\:/^%.> _P#H 1?]_'_QKNJ* .%_
MX4YX#_Z $7_?Q_\ &C_A3G@/_H 1?]_'_P :[JB@#A?^%.> _P#H 1?]_'_Q
MH_X4YX#_ .@!%_W\?_&NZHH X7_A3G@/_H 1?]_'_P :\R^+/@/PUX>O_"T>
MEZ8ENMY?>5. ['>N5XY/N:^AZ\<^.?\ R$_!7_83'_H24 =3_P *<\!_] "+
M_OX_^-'_  ISP'_T (O^_C_XUW7:B@#A?^%.> _^@!%_W\?_ !H_X4YX#_Z
M$7_?Q_\ &NZHH X7_A3G@/\ Z $7_?Q_\:/^%.> _P#H 1?]_'_QKNJ* .%_
MX4YX#_Z $7_?Q_\ &C_A3G@/_H 1?]_'_P :[JB@#A?^%.> _P#H 1?]_'_Q
MH_X4YX#_ .@!%_W\?_&NZHH X7_A3G@/_H 1?]_'_P :/^%.> _^@!%_W\?_
M !KNJ* .%_X4YX#_ .@!%_W\?_&C_A3G@/\ Z $7_?Q_\:[JB@#A?^%.> _^
M@!%_W\?_ !KQ?0-,M-'_ &D4TZPA$-K;WKI%&"3M&P\<U]15\T6?_)T<O_7_
M "?^BS0!]+T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7RWX<T+3?$?Q]U33M5MA<VCW%TS1DD9(R1T
MKZDKYL\ ?\G(:C_UVN_Y&@#UG_A3G@/_ * $7_?Q_P#&C_A3G@/_ * $7_?Q
M_P#&NZHH X7_ (4YX#_Z $7_ '\?_&C_ (4YX#_Z $7_ '\?_&NZHH X7_A3
MG@/_ * $7_?Q_P#&C_A3G@/_ * $7_?Q_P#&NZHH X7_ (4YX#_Z $7_ '\?
M_&C_ (4YX#_Z $7_ '\?_&NZHH X7_A3G@/_ * $7_?Q_P#&C_A3G@/_ * $
M7_?Q_P#&NZHH X7_ (4YX#_Z $7_ '\?_&C_ (4YX#_Z $7_ '\?_&NZHH X
M7_A3G@/_ * $7_?Q_P#&C_A3G@/_ * $7_?Q_P#&NZHH \^O?A!X%BL+B1-!
MB#)$S*?,?@@'WKQCX(>$]$\5:]J]OK5BMU%! KQJS$;3NQV-?3^H_P#(+N_^
MN+_^@FOGK]F__D9]>_Z]5_\ 0Z /5/\ A3G@/_H 1?\ ?Q_\:/\ A3G@/_H
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M!%_W\?\ QKNJ* .%_P"%.> _^@!%_P!_'_QH_P"%.> _^@!%_P!_'_QKNJ*
M/!OC%\//"WAKP%)J&DZ4EM="YC02!V/!)R.378Z-\(_ ]SH>GW$VA1-++;1N
M[>8_)*@D]:K?'_\ Y)?+_P!?</\ ,UW_ (>_Y%K2O^O.'_T 4 <O_P *<\!_
M] "+_OX_^-'_  ISP'_T (O^_C_XUW5% '"_\*<\!_\ 0 B_[^/_ (T?\*<\
M!_\ 0 B_[^/_ (UW5% '"_\ "G/ ?_0 B_[^/_C0/@]X$!R-!C'TE?\ QKNJ
M* .'_P"%0^!O^@&G_?Y_\:/^%0>!C_S T_[^O_C7<44K(KFEW.%_X4YX#_Z
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1W$#AXI%W*P/!% &3HGA#P_X;GFFT;2K>RDF4+(T0.6 .<&MNBN>\8>,-/\
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MNZ1X8U1M,BM+C4[Y,%X;;JN?PK5\%_$/2O&D<BVJO;W4?W[:7[ZT ==1110
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MXQTW[9ISG*G$D3?>0^AH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHJIJ>I6ND:=-?WLHCMX5W.Q]* +=%>1+\?=(.H"(Z-?
MBQ+[?MQ_U>/7I7J>GZA;:I80WMG*);>9=R,.XH M5AV?@[P]I^MOK5II-O%J
M3EBUPH.XEOO?G6Y7G/BKXP:3X;U1M-M[&YU2Z3_6):_P?7B@#T:BN4\&>/\
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MOEGX@Z+XOU?3+GQ/XAG\NUAD"P6Y'J<<#/'6OJ*TU"SU",R65W!<H#@M#('
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M[_UQ;^5 'A7[/$1@U;6(2<F-MN?7'%?0E> ? +_D8=>_Z[-_,U[_ $ %%%%
M!1110 4444 %%%% 'B'[1.HNFE:;IP;"RRB0CUQD5J>/M(L8_@B%2W0"VM@\
M6!]T^OZFLG]HJQ9].TR_"DK'((R>PSDUM>/]0M'^"+,LZ$36P6/##YCZ#\J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHBMR376$X&30 45QU[\4/"&GWLMI<ZQ;I-$VUU+=#6U:^)=*O=#;6+>Z22Q
MW&4'C% &O167H7B+2_$ED;O2;N.YA#%"R'."*U* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HK,UCQ%I&@0>=JNH06D9Z-(V*Y^'XK>"IY
MQ$NOV@9C@$MU- '9T5'!/%<PK-#(LD;C*LIX(J2@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **9)(D49>1@JJ,DD]*ALK^UU& SV<R31!BNY3QD=:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9NYQG%?-F@WFH_"[XI_V2;AWL_."2KGAU(!S]:]#_:+<2>"-)<=&O 1_WP:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[B+>K@_*OH.1Z5Q_P1O)M-^(TE@L[")]T17/#8;_ .M0!]3U7OKI+&QGNI"
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MOAYJEQ9ZE;2O:2D*\?0QMGKS7UI7GWC#X0^'O%ER]XT;6UZW)DB. Q]2,<T
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M60X*F@#BO@KKNF#P':69O(Q<>:P\LGYNW:O(O&W_ "6Z+_K[B_\ 0J]3\,?
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M)O\ KM_05TOQ$\#KX\T:WT]KH6XAG\W<1G/!&/UJ?P'X/'@K0CIJW G!?=N
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MKZ;J&\(3E60X*FO/O#/P,M?#VOQ:F-2:3R6RB@$?G0!Y;XY_Y+;%_P!?</\
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MVQ\#6DZPOY]U.W[R<C!(["NRHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$U?X;6U]XW
MM_%%I=&UNX_O@#A^N?Q.:[NBB@ HHHH **** "BBB@"IJ=I)?:;<6L4WDO*A
M4/C.,US'@+X>V/@:UG$+^?=3M\\Y&"1V%=E10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445#=W"VEG/<N"5AC:0@=2 ,T 345Y3_PO
MC0?^@9?_ /CG^-'_  OC0?\ H&7_ /XY_C73]4K_ ,H[,]6HKRG_ (7QH/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\3:18R^7/>(K>@!/\JECU_3)K1KI+I#$O4]Q^% &E5:#4+2ZN)8(9@\L7WU
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MM3Q#</=_#:XFD^\]KD_E4JI-74EJE<IT82<7!NS=BU_PL+PK_P!!B'_OEO\
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M.Z ^.****^J- HHHH **** /H+X$_P#(IWW_ %]G_P!!%>IUY9\"?^13OO\
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M@HLWS*B=A@]^M.\8Z'IWA#6-%U;1+9+*62Y6&181M5E8@=/Q-=YX1 7PCI0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD<L<XQWK9HHK&4G)W8B.X@2ZMI8)03'*A1L''!&#5#0M!L?#FG"PTY'6 ,6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gjnp4w4lrub1000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ #\# 2(  A$! Q$!_\0
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M_P#(-M?^N*?R%99A44(QND_4URRFYSG:37H?/VN1ZQ>>)I+?4PQU"20)L+#
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GANT\,:>UK:N\A=M\DC]6/T[<5R5JV'5!TZ75G;AZ&*>(56OT1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gjnp4w4lrub1000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *1!/4# 2(  A$! Q$!_\0
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M,:D^)#[_ !=8/_>B!_04 >N>%R6\/VQ/I6Q6-X6_Y%ZV^E;- !1110 4444
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M@_\ [:#^=='\.?\ D#C_ '!5KQ=X0C\2VWEO*4^;/%:7AW0UT.S$"N7XQDT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLS 9/N: /6-'\26>L_Z@X.,X)K9KP?3Y)?#GCBXMDE9H]P4 FO=+=M]M$_\
M>0']* )***1F"C)Z4 +147GQ_P!ZI%8,,@T +1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1TZT5#=[S;/L&6QQ0!P7Q8D0Z!" ZD^;TS[BG?#1T_LF8;UR3TS7.^*M"UO
M5[EHA!(8@<CFI/"6AZUI6H1(\$@A)^8DT <WXCLVN?']TC$!20.?J:M>)M!&
MAQPW5JZ*P0-P0>U=9XT\&S74YO[,,T[-DA?K6#'X8UK6;R%+Z&2.)!M)SVH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZE_R#+G_KDW\JX7
MX:?\>MW_ -?#?^A&NZU+_D&7/_7)OY5POPT_X];O_KX;_P!"- 'HE%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !136=4&6.*%<,.#F@!U%%,\U-VW/- #Z*3/&:B^
MTQ;]N[F@":BD!R,BF23QQ_>;% $E%,219%RIR*?0 4444 5=2_Y!ES_UR;^5
M<+\-/^/6[_Z^&_\ 0C7=:E_R#+G_ *YM_*N&^&G_ !ZW?_7PW_H1H ]#HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*LT %,DB25"KC(-/HH R=1TRT&FW)$0R(V_E7(?#-0MI=@=//;_T(UW>I?\
M(,N?^N3?RKA?AI_QZW?_ %\-_P"A&@#T2BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"C+$ #UI:XGXA^))="
ML%6+&95[T =;]OM-VW[3%GTWBK"L&&5((/<5\GGQ3J!O?M'FOG/3><5[Q\.O
M$LVO6+)+C,2XXH [FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \F@\=Z6DIDCTV15(X?!Q6AHOCSSM22VDMY5$K80L#3[;P6S^&;>RE
MAVR(V20.>U3ZEH;IJ6EM'"H2  ,0,4 =Z0'7D9%4Y=(LII!))""PZ&I4NX N
M-]3JX<9!H 2*)(4"(,*.U/HHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *NI?\@RY_ZY-_*N%^&G_'K=_]?#?^A&NZU+_D&7/_ %R;^5<+\-/^/6[_
M .OAO_0C0!Z)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 445#=745I TLK;549)H ?+,D*%Y&"J.Y->,_$G6HM<GBM+6
M)I&C.TE1FKOB?QA=ZU>-I>D8D5NX.#70>$/!$-@GVNY#--*-S!^<'\: /#X_
M"&HR7 C\F09[[:]V^'OAJ30;%FD(S*M=@+2W!R((O^^!4H  P  /:@!:***
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M?RKA?AI_QZW?_7PW_H1H ]$HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHK/U;5[;2;5I9WVX&10!+?:A!80-+*ZJ!ZFO)]>\
M2WWBC4!8::)(T5MCL!P14.I:IJ7C343;68W6;<;U.#^E>A^&/"EKHELK;=TK
M#YMPSS0!4\)^#(-'MTDN$62YZ[Z[  *,#H*6B@ HHHH **** "BBB@ HHHH
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M_N/LXV*9 ,#ZU[I:G=:0L>Z _I7AO&O>/KAK7YT#AL_C7N=LNRUA4]0@'Z4
M2U%<7"6\1DD8!1ZU+5/4M.CU.T>WE9E5NI6@#,U#7[)M.N%$T>3&P^][5S'P
MQ</9W; Y!G;_ -"-6[[X=:;'93R"XGRJ$_>/I]:H_"V%8+&ZC4D@3L.?J: /
M2:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 0W?\ Q[2<9^4\?A7@$NIZAI&O7$EMI\X3S23M7K7H4GQ*L;*^:VOI@N.H
MXJPGC'PI<?.94)/^R* .13XBZH74?V7<\G^Z:]0\.ZE+J-F))8FC..C"N<E\
M7^$XER9$X_V152+XCZ=-?16NGRJ0QQC H ]'HJO93-/;*[]35B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH JZE_P @RY_ZY-_*N%^&G_'K=_\ 7PW_
M *$:[K4O^09<_P#7)OY5POPT_P"/6[_Z^&_]"- 'HE%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGC9O136A7A&C2R>%_&EQ9QNWE A1N->YP/OMXW_O*#0!)1110!5U+_D&7/\
MUR;^5<+\-/\ CUN_^OAO_0C7=:D?^)9<_P#7)OY5POPT_P"/6[_Z^&_]"- '
MHE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZGILX%O'-,@'"J*[?_A.=:_Z!MS_ -\UV'A#P-;:%$DCQ_O@,$,*Z_[';_\
M/%/^^10!Y%'XXUHRJ#IMS@L!]VO1)0^K^''62,J[Q]#6S]CM_P#GDG_?(J78
MNW:  * /.M$U1='C;2F(!1#_ "I?#44EO::G>2@DARRD_6J7B7POJ<OB1[VS
MCRC,/RS7=VVE@:)]G9<.Z -]: /.EO[J\U"69XWE1EX7T-6M)N;]-/O$FCD"
M,>,CH*N)8:MI6I.L<*_90,*2*VX(K^[TRX26) QZ8% '+Z)HDMY=32-/\FPD
M+Z<&KOAV2XM8;R*28O\ .0/;FMOP_I=S:>9YJXRA'Z56LM&NXGN-R?><D4 9
M-CJDT.LW0+DCRSCVX-2>'=*GUA+J66X+,'.TGMS5JQ\.W)U6YDE3"LA"_7!J
MEIL7B#16N(HHE^=R5S0-B>/K)['0M/B>3?MN%Y_$5'XBUF>VFTZSCW%9(5R!
M]!5_Q-INKZUHEDLL0,RS*S ?44_6_#MU*]E>01[I8(P.?7% CF]0GU"$6YM+
M>5',B[BH[9%>KZ<[O8PF0'=L&<_2N0M)=7D**\$>X$9XKM8=WDKN&#@9H \[
MOOW_ (IEC<_*K C/UI_B;/\ PDNGQM_JC&,^G04WQ$ATW6A=-P)9  ?QK:\0
MZ+-J5C%=6B[KA8QL_*@#H;)8UT]53&S':N"OP$\?V0@^X1\V/PJ6VO/$MK8?
M9FB7>%(K)TJYGL-;2371LN"Q*8]* -#1/^1^U#_/K6]X[CB/AJX<X\T+QZ]*
MYF.TU6+Q%<ZG91@PS?=)J]<6/B#7+A8KN(?92,,10!TO@S/_  C-IG^[7,>/
M+@VNII,J%RJ_=%=UI=DNGZ?%;(.$&*YKQ-I%U>ZM'+$FY N#0!R[W5YXEMK2
MV%I)"L3 [B.M.U2U>S\765NYS$8QN].U>DZ7:B"QC1HU# <\5A>*]!FO0;RS
M3==(,)0!OVRH--"KC9MKSP@+\1[00_ZO:<X^HJ[!>^)(K(6K1+OVXJ[X9\/7
M2W(O]23;<JWR_2@#/\2L;;5[=H^"\HSBO08#FWC/^R/Y5P%VO]K^(#"O/D2
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M8?6@"IX=\-7WB2^74=1=_+#']U(.HKU>QT^WL(%B@C5 !CBIK>WCMXECC4
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M/QH 6BD!!Z$&EH **** *NI?\@RY_P"N3?RKA?AI_P >MW_U\-_Z$:[K4O\
MD&7/_7)OY5POPT_X];O_ *^&_P#0C0!Z)1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 456OKZ&PMFGF.$
M7K7$3_%/18;EHC*>#0!WDT\<$9>5PJCJ37F7BSQI-<S'3]-1I&)VEH^U9^O>
M,KKQ'<+8:,^Z.0<_6NG\(^"8=/1;RY3_ $EQ\V?6@"AX/\$L"+W4F\Z0G<!(
M.>:]&CB2% D:A5'0"G*H50 , 4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (2!U-)O7U%8VK?VEO/V7&.U9/_%0?[-0Y
MV>QE*I9VL=:\R1J6+#BN=NO%B03%%C#8.,UG7*ZX8CYF-M<O*'\UM^=V>:PJ
M5FMC"I7DMM#TS3=8BU! >%8]JT=Z^HKS32%OO.S:?>QWK<_XJ#T6KA5;6J+A
M7;6J.OWKZBJ&LZ@-.TR:XZE%R!6 O]O[ATQFE\5K<'P_*TO41_-6L97-H3YN
MA@6.FZIXJ_XF,6H2V\4@X0=!^E:J:5J&B:1=&6^DG;&03VJ[\/)$/A.V (_R
M!6OXA*G0[GD?=JBS@=+T;4=9VW']KR1!OX<__6K?F\)ZA)!A=7D! ZC_ /56
M#X>M]8DC0V@'E]J]"L$NDMB+G[V* /*+'3-6N/%L^E?VO*!$,[L]>OM[5VW_
M  B6HFW*?VM)DCK_ )%8FD?\E/OO]P?^S5Z2[B.+>W0"@#R3Q)HNJ:'##(NL
M2RLT@4J#[CVKO-+FET[0OM%S(7.P'YJYIY#X@\6S6+_-#%AU_7_"K7B_5TTX
MP:>^?)= &P/:@#F-9UG4)-62ZBGD2"210 .G6NO\2W$_]D1".=HF:($L/I7"
M:UK.F"QL[:WW9253R/<5Z0+2T\0:/$.3B,#]* .;T/P_>74,,YUYF.02F?\
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MK30]9\977VC40&M\X_#M5O\ X5%"+K(A_=@T 1_""S26P,TL 9P_#D=.:]B
M & ,"L;P]X>M= LO(MDV@\GZUM4 %%%% !1110 4444 %%%% !1110 4444
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M:VJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MREO\B%P J].M>Z6QW6L+'N@/Z5X;*G]J?$*Y\D;@K@Y_&O<K8;;6%3V0#]*
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M.UTZWLSF%,4 &F6_V;3X(CU5 #^56Z** "BBB@ HHHH **** "BBB@ HHHH
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MZL:\DN[#Q7X4V74EROEE@.!_]>O7/#>J_P!J:=&Y)+A1N/O0!M4444 %%%%
M!1110!QGBOP1#KH\Q)/*DSG<O6L#3OADXO(YKJ^DE5#PKG->I44 <]J?A6VU
M#2$L#M54Y'%<*OPMF$[)_:$WDL>5R<5ZW10!@:1X8MM,TS[( K':5+8]17%:
MG\,&-VTEK>R1*Y+$(<5ZI10!QOA7P1%H<IN9)?.E88);K79 8&!110 4444
M5=2_Y!ES_P!<F_E7"_#3_CUN_P#KX;_T(UW6I?\ (,N?^N3?RKA?AI_QZW?_
M %\-_P"A&@#T2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'<)G#C/-7LB@ HI-P]12T %%8VM:S'IDMO&Q.93@8IM_XBM])M//N0Q &>*
M-NBN4MO'NG73JJQ2C)ZD<?RKI+>ZBN8O,1@5^M $]%8=_P"*;'3[J*WER7D;
M:,&MF.02H'7H: 'T5C:[K":8(T)P\GW:SQXLAL-/\V]#LV>U '4T5RUIXZTZ
M[E5%BE7)QEAQ_*NEAF2= Z,"#Z&@"2BLG5O$%II#QK/DE^F#4<VM)+I0O+?.
MTF@#:HK/TO4H]0C.P_,O6M"@ HHHH **** "BBB@""[C\VUD4=U/\J\2M;Z\
M\'ZU=,]IE)I2VYJ]R=@B,QZ 9KRWQ7XK\-R7)@O+669E./EY_I0!B^(_&]QX
M@MDLX+17.\'BO1_!EA)9Z8#*I4NH.#7F5CXD\*65PKP:;<JY(&=I_P *]?T+
M5(M3LE>%&50O 84 :M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M5U+_ )!ES_UR;^5<+\-/^/6[_P"OAO\ T(UW6I?\@RY_ZY-_*N%^&G_'K=_]
M?#?^A&@#T2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "@G S4$UW! I9Y4&/5A7)ZYX_T[38W3:\C8Q\G- %;Q?\0(
M] (CAVR,>HK T/XMK=W'EW:)$F.IKR[Q1?3:M?-/Y4NPMD94UE:?IT]]=I$D
M;<D9^4T >[:A\29'4QZ="L['TKGBOB7Q')^]@GMD;NIKN?#'@?2++3[>?[-B
M8H"3[UV$<:Q+M08% 'F^D?#;:1+=WDDA/)5SFNVL?#^GV2!5MHB1WVUJT4 -
M6-$&%4 >U.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *%YK%C8L5N)U0CUJI_P )7H__ #^I4>L^&K75G+2QAB:QO^%?
M:?\ \\!6B4+:B=S5O/%^EQ0,T5TC-CI7F&I^,+N>]<QLP4-Q@]:[.[^'UIY#
M&*$!@*\WU#1;FTNWC\MB V!A36U)0Z$2N=[X3\:QD+!>R!% ^\QKK_\ A*]'
M_P"?V.O-_"_@UK\K+=1YC(Z$5U?_  K[3_\ G@*F:IW&KV-T>*M') ^V)S5;
MQ-J:IH,[P/G*9!%9B_#_ $]6!\@<'-7?$>DA/#LR0+@K'@"LI*/0I7ZF?X*T
MJ*_T2&]N@))''.X9K6UC2XK31KIH<+\N<"L7P/K45GHD-C<!A*@R<\5L:OK$
M-WHUTD:L3MQ4#.9\-WVBQPHM[)$)>^X<UVL5OIM[ 6A2-UQV%<9X:\*:7J,"
M3W5L6D/)-=Y::=;Z? 8[=-J^E SS?2K*!OB/>0F-3&$&%QQWKT<:5:%-ODI@
M^U<%I"M_PLZ^.TXV#G'UKT*]N!:63S'.%% CS[QG:6TODVMG"GG+*"P4<XR*
MZ.:1=(\/!4/[XQ@A:P= AEU/Q=<7<H)MV7*@CZU>\6:/JM[?0-8R*L2C!!%
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M'M8]\@Z"M&B@#S2\U3Q$;.8-8,%*')I?A6SMI]R9!AO.;(_$UZ!J7_(,N?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***3<O\ >'YT +1110 4444 %%&0** "BBB@ HHHH **0D#J: 0>A!H
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MQ'<CFHYO$\:S%0&P#6QIVIQWT89>,^M90KPF[)FL\/4A'F:-"BBBMC$****
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M96,!O6LF33;^R.^.7Y1V%1S5:?Q*Z+Y*-3X79G2&WA;K&GY5#)IT#@CRU'_
M:Q;?7GA;9/&Y/3.#6U;:A#<*"& SV)K6%6$]C&IAY1W1R.N:!*L@:VC+ ]:S
MK'0+N>;;)&57UKT9WB(^9EQ]:;&8<X1E_ U+HQ<KG&\,F[G*G0[FU4&%I&/I
MDTT7>LVA_P"/?('J:[*F/&KC##-7[/LQ^QM\+L<U%XBN5(%Q&J5HP^(;)^&F
M -6I-+M)?OQ UGW'ANV8DPQA32M-!:I'S-2/4+:7[DF:L!@W2N4D\/ZA'S#.
M%Q40_M6S_P!9*S@>@HYVMT'M)+XD=C17)1^)GA;;+#*??::TH/$D$V,QLOUJ
ME4BRE5@^IMT56BO8)1D2*/QJ<2(>CJ?QJ[EW0ZBBB@84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )M&<X%+110 C(K?>
M4'ZBD$:+]U0/H*=10 4444 %(5##! /UI:* &B-!T11]!3J** $(!ZBEZ=**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" >HS2T4 %%%% !1110
M 4444 %%%% !1110 4A.!FEH(R,4 >+_ !)\73_:VTU&VJC\D'!QFE\':UH.
MC19>Y5I7.XEAD@UZ)J'@W2=1NFN)[56D;J355?A]H:MD6:4 <E\2(#K.@VE_
M9CS%\T-D>@(-4T\:VA\*36#2K]HVA0OTKU4:+9#3ULC"/)4<+6%_PK[1OM/F
M_9$ZY- 'G?AWPY<WEG+>-&</$Q!_"E\$>)HO"J7=K>L(RTK$9^IKV:UTZVL[
M;[/#&%CQC%8-_P"!M(OIO->U0L>N: /-M)MY/$?C>YNXUW0DAE85[= NR"-/
M[J@5FZ3X?L-(7_18 C8QD5K4 %13P)<1E' (/J*EHH \P\5>')8G::WB^7.3
MBN8TW3)]1FV1(6&<&O:=5C233;C<,XC8C\JX;X;QK)#=.PRPG8 _\"-<\L.I
M2N=4,5*,;$T'@"%[96D=P^.1DU7F\ @?<+G\37I%%7[&)'UB?<\HE\#7*_<1
MS^)JJW@W4D.5A8_B:]AHI\EMF'MGU1X^-!UB'I:9^M.6SU:(_-9+^7_UJ]<,
M:GJ*C:UA;JF:.6?20>UCUBCS&.2[C^_:1C_@(_PJ[#J")_K;>(?\!%=XVF6K
M?>B!J%M$L&ZP"BU3^8.>F_LG*)J^FK_K$A'_   5:CUS0A]XP_\ ? K:D\-:
M:_\ R[K563PCIS?=@44KU>X?N61Q:YH![P_]\"K::MH;?=\G_O@5GMX-M_X$
M45 W@Z3_ )9NHHYJ@^6D^INK?:2WW5B_[X%3I+8/]U(_^^!7*OX1U$?<N5%0
MGPOKB?<O0*.>?8/9T_YCME6V/W8X_P#OD5'>06K6S>:B!/7:*XO^R/$$)_X_
M<U2U4ZU;6;>;.SCV%)U6N@*@F[*1GZCI&@MJ+-]J(RW(';]:Z_1=$TF;3Q';
ML)%_O$<UY9(S-*S/]XGFNF\-:^^ELH>-WC'H*B.,G)VD;5,)%1O'<ZB^\!6L
MV6CGE4^BDBL67P]JVEMFS\V4#IN8UUMIXJM;G&5V9_O5K1W]K*O$T?\ WT*Z
MXUO,XI4VMT>?P>(_$%@VVXM%5!W/_P"JMRS\;V;86[E5&[BNAFM+*[&'"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74O^09<_\ 7)OY5POP
MT_X];O\ Z^&_]"-=UJ7_ "#+G_KDW\JX7X:?\>MW_P!?#?\ H1H ]$HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 3:OH/RJO=645W"8G48/M5FBBPT['
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MOP-/VJZA[9=3L**Y>/Q4,X:VD_(U>B\10R=8ROUIJI%E*K!]3:HJC'JMN_\
M&H^IJ=;N!NDJ?G571:DF3T57FO(88RY=2![UC'Q3;B?R]O?&:3DEN)SBMSH:
M*AMKE+F,.A!%35104444 %%%(2 ,DT +14?GQ9QYBY^M/!!&0<T7"S%HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPYO8(;:[WMC,[?\ H1JW>^$-32RG<WV0$)(_"N6\%>'KZ^@N##=;-LK _F:
M/7?[5M/^>E']JVG_ #TKDO\ A#M4_P"?^C_A#M4_Y_Z .M_M6T_YZ4?VK:?\
M]*Y+_A#M4_Y_Z/\ A#M4_P"?^@#K?[5M/^>E']J6G_/2N2_X0[5/^?\ JM?>
M%-5M[5I/M_2@#MO[5M/^>E']JVG_ #TKRWP_I.K:CJ%Q";X_N_6NE_X0[5/^
M?^@#K?[5M/\ GI1_:MI_STKDO^$.U3_G_H_X0[5/^?\ H ZW^U;3_GI1_:MI
M_P ]*Y+_ (0[5/\ G_H_X0[5/^?^@#K?[5M/^>E']JVG_/2N)O\ PIJMO83S
M?;_N*36%X6TK5M6MRYOCPQ'- 'J?]JVG_/2C^U+3_GI7)?\ "':I_P _]'_"
M':I_S_T =;_:MI_STH_M6T_YZ5R7_"':I_S_ -'_  AVJ?\ /_0!UO\ :MI_
MSTH_M6T_YZ5R7_"':I_S_P!5;[PKJMO;-)]OZ4 =O_:MI_STH_M6T_YZ5Y7X
M8TK5M5O+R,WQ_=-CG\*Z?_A#M4_Y_P"@#K?[5M/^>E']JVG_ #TKDO\ A#M4
M_P"?^C_A#M4_Y_Z .M_M6T_YZ4?VI:?\]*Y+_A#M4_Y_Z/\ A#M4_P"?^@#K
M?[5M/^>E']JVG_/2N&U3PMJMIID\XO\ [BYK*\,:-JVJV*2F^//K0!Z=_:MI
M_P ]*/[5M/\ GI7)?\(=JG_/_1_PAVJ?\_\ 0!UO]JVG_/2C^U;3_GI7)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM8M;GPQ"(ID=C)C /TH T?AC>276F2JYSLX%=[7 _#"TDMM-F9U(W\C-=]0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12,
MP498X%0_;+;_ )[+^= $]%-21''RL#]*=0 4444 %%%% !1110 4444 %%%5
M[B]MK1=UQ,D8]6- %BBJUKJ%I>@FVG27'7::F>:./[[A?K0 ^BH/MMM_SV7\
MZ<ES#(<)(K'VH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3/A[86]OIY> L2X!;)JQXOL]>N(F_LH G.>:M>"]%?2=*1FG,GFH"/:NE?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H[444 5O^6GXU9HHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gjnp4w4lrub1000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ #\# 2(  A$! Q$!_\0
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$V1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gjnp4w4lrub1000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1^ R<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !7(_$7_D4;SZ5UU<C\1O\
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ME/8BMFRMHK>!1'&J\=AB@"U1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQOQ':3O\0DD6&0KMZA3CJ*]FJ)K:!GWM#&6_O%1F@"'3 1IL (P=M6Z0  8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !29&<9%4-4U>UTNV:6XDV@
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MDM6 P_K6GX>T9-*M$10!@8XK-U/4(],L9+J5MJIU)K3\/ZU!JUHC0N&R,\4
M;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI6CZ!<7<$CET'&: .(^&QSK;'W%?2T/^HC_W1_*OFKX<#&NL/<5]*P_ZB/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!F:\5&FR;HO,X/'X5X-8Z_J>A:I=^393[&D)P%KZ%NFC6!FE^Z 2:\P
MU/QEX9MKN2,R)O#8;Y10!D)\2=4+J/[.N.2!]VO5/#VHR:C9++)$R'&<-7FR
M>.?#;2*!(F2?[HKTS0KVWO;-9+<@KCL* -:BBB@ HHHH **** "BBB@ HHHH
M **** (Y9XH%W2R*@]2:XSX@ZC9R^%+M([F-F(Z U'\39KB'1XS;D[MW8UX-
M?7NIR12+,6V$\_,: -SX<_\ (=;ZBOI6'_41_P"Z/Y5\T?#;_D-G\*^EX?\
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MYU>> (GU+]R7\@,".?>O6-!TV'3K"..+^Z : -:BBB@ HHHH **** "BBB@
MHHHH **** *]U96]ZFRXB611V-</X^T'3+7PM=RPVD:.!P17H%<C\1?^11O/
MI0!XK\.?^0ZWU%?2L/\ J(_]T?RKYJ^'/_(>;ZBOI6'_ %$?^Z/Y4 /HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***.U '.ZYK\-A<Q6SXW2\#FFQN'7<.E)KOABRU*ZBNYBWF1<KBB*-8H
MPB]!0 ^BBB@ HHHH *1B IR<4M86MW\L";4]: ,_6;7]^&\S-:NAP[(%;>#Q
MTKF)KV68?/6SX<>4S$'[F.* .FKD=9:Y^VN!NV9XKK00>E136L<_WQ0!E>'V
MF,#>;NZ\9K;ID<2Q+A13Z "BBB@ HHHH **** *][>)86K7+XVK6KHNJ1:C:
MJT>.1GBLC4-/AU2T>UG)\M^N*U="T2VTBU5+<L0!CF@#7HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH R]?O'LM->5 2<'I7AENNO^)-1N?(OYXU20C K5U'XEW5S$T+L-
MI'I7-Z#XRN]%N9WB VRODY% '2)X*\2"12=5GP"/3_"O6/#EE<V5BJ7,K2-C
MJ:\M3XJW;2*OR\D#I7JGA[4VU.R69NI&: -BBBB@ HHHH **** "BBB@ HHH
MH **** "N1^(O_(HWGTKKJY'XC?\BC>?2@#Q7X<_\AYOJ*^E8?\ 41_[H_E7
MS5\.?^0\WU%?2L/^HC_W1_*@!]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1VHHH Y'Q'XF;3K^"U%LS^:<;
MAVJQ#)YL8;&,]JNZMI-M=R)/(/GCY%554*N!0 M%%% !1110!D:OJGV)@@7.
M15&&\AU)1'(H4^IJ[K.FF[&]1EE%85IIMS]I QR#DT =%;Z1!&GS*K9Z55U@
M?8K4?9TV'/45MQ@K$@/4"H[FVCNH]DG2@#F-(O+A[I59F8$\UUA;:I)[#-4K
M;2X+5LH.<U<D7=&P]10!CS:^D<^S9GGK6K;S">%9!WKEY]"N6N257Y2<UOVV
MW3[)%E."* +U%10W$<ZYC.0*EH **** "BBB@"CJVH'3-/DNA&9-G\(K3\.:
MTVK6B.8#'D9YJK<6T=W"T,H^1NM;&F6,-G;(L0X H OT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >9?VEH<OB>328M#ADVC.\ _XUV47AC0WB5CID()&<8->3Z-J$6B?
M$28WIQ\N/U->R0:K:S0K(CC:1GK0!QGBM]%\-1++_8D4BEPN<'U^M=;H-U;7
M>GQR6T2QJ5!VKVKS_P"*>NV<^EQVD;9E$H_F*Z;P!'(FD@OW48H Z^BBB@ H
MHHH **** "BBB@ HHHH **** "N1^(W_ "*-Y]*ZZN1^(W_(HWGTH \5^'/_
M "'F^HKZ5A_U$?\ NC^5?-7PY_Y#S?45]*P_ZB/_ '1_*@!]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E
M%% '#>*M?O++5;6WALY)(Y#AF7H*TK>0RPAV7:3VK8U"")P&8+D=,UF#&* "
MBBB@ I"0HR3BEJ"[5F@(3KB@"+^T(#)LWK^=642/.]0.>]<2MM/]N.,YW5V-
MDK):JK_>H L4444 %%%% !7-Z\+C^#<1GM725'+"DPPPH Y[0A<9R^X#/>NE
MJ.*%(AA14E !1110 4444 9NNWLMAI4L\,32NO15ZFM#PGJUQJ5DAGMGB.W^
M*G;%?Y6 P?6MJTC2.!0H ^E %BBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SOQGX!_M>
M9[RUE\F9CG*CFO/I/#/B>V?RH[VZ*C@8Q_A7T)E?44W$?HM 'B.B?#K4=1NU
MFU"[D89!P_\ ^JO9["SCL;..! !L4#([U8&P=-HIU !1110 4444 %%%% ",
MP522< #-84OBFR34H[)949W..M8WC?6]1L;0IIY^<G:?I7D>D?V@/'5DU\?G
M=LCF@#Z0\Q1&7)P ,YKG;WQGIEI<>4;F(^O/2H_%FJOI6A;T."X*UY5X>\+0
M>(],OKZZW&59#M(/N: /<-/U6UU*(/;S(^>RFKU>+_#N^DL/%-SII8^5&N "
M?K7INK^*=/T1E6[<@L,T ;=<C\1O^11O/I4?_"R] _YZFN=\:>.]'U/PY<VU
MO(3(PXH \[^'/_(>;ZBOI6'_ %$?^Z/Y5\U?#@YUUC[BOI6'_41_[H_E0 ^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ H/2BB@#@?%TFI+K%F+99?*S\^WI6O;%C"-V<UM7\D:KAMN3TS650
M 4444 %!HHH C^SP[MWEC/K4G2BB@ HHHH **** "BBLZ]U6"U.UFY!YH T:
M*J65]%>QEHSG%6Z "BBB@ HHHH R_$+7"Z-,;8,9>VWK5[P>]X]BGVL.&V_Q
M5,"%.6QCWK;M61H5VX_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Q/AS(B^&K[)'#G^9KT'6-)75-*:!QDA3CZXKQU=(\3:"+FRM0!%,Y8#GUH
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M;93@X%7[>3S8@WK0!+1110 4444 %(5!ZC-+5:ZOHK1=TG2@"KJUXEO;M&"
MQ'%<G$9I[A=FXG(S6OJ:_P!K.)+?HO7-6-%TN2WE\V0#!% &S:JRP(&ZXK&U
M^8(F/+'7K7054O;&*\3;(N: ,70[URVS;D$]:Z6J%GIL-F"5&.:N[T_O#\Z
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MB5..PKE=>GN[?299;)MLP^Z:O^$[K4;FR1KY]S%?2@#I:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,7Q-#)-I3+%G(R>*\:CU#3[?3M4@N4B6=B0NX<U[U/L\IA)C:1S
M7FVK>!]%U>2:>"%=RDEB2.M ''P^([5/ UG8HZM,'Y3OVKU'P+!+'II>12-X
M!&:\[L/#WARRU007,2LRD<AAUKV?3T@CLHE@QY848Y[4 6J*** "BBB@ HHH
MH **** "BBB@ HHHH *Y'XB_\BC>?2NNKD?B+_R*-Y]* /%?AS_R'F^HKZ5A
M_P!1'_NC^5?-7PY_Y#K?45]*P_ZB/_='\J 'T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!Z4 9VHBWX\Q
M5+]LBLT8QQ61XJL]=FU6U>RF58%/S@CK^M:=NLBP@2G+=Z ):*** "N?UR]D
MBRJY !ZBN@JG>:?#=KAUR: ,?1;^1@=Y)&>2:O2ZTD<_EC!'K4L.E0P0.D:X
M+5@76D3_ &LD8P#F@#;U&1IK)FA).1VKG=/^T_:0,L3WYJ_)J26T'DC.[&#6
M;;WTJ78=#U(% '<1Y\M<]<52U:!KFUV+G(]*MPMOA1CU(J2@#C['3;A;Y69&
M !ZUOZAIWVNV$9;ISFDU34/L2[1D,1Q5/2]7:YF*2,3Q0 NG:*+>82%CE36[
M0.1FB@ HHHH **** $8(5_> %>^:VK(1"W7R@ ,=JY378KR;294L'"SG[I-7
M_"=MJL%D@U&4.=O:@#I:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3Q.91I3&+.[GI7D
ML'BA;+3=3M?/S/(2%!/.:]ON8HYH&67&T@YKR+5]'\,6.J^=+ &)?+884 <O
M%X;N)=!M]8GNY4D=QD$_2O8/ \\LNF[9"3L  )[US[:CHFKZ;%IEJH2-&R S
M"NZT>P@L;-%@  *]C0!HT444 %%%% !1110 4444 %%%% !1110 5R/Q%_Y%
M&\^E==7(_$7_ )%&\^E 'BWPY_Y#S?45]*0_ZB/_ '1_*OFKX<_\AYOJ*^E8
M?]1'_NC^5 #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBCM0!EZG>VD++'+(H=ON@U0!##(.:SO$^@WM_J
M5M<PNHCB.6S5V!&CB"MUH EHHHH **** "LS4=1CM0PPI8\5IU@:QI<MPY=,
M<F@# F5KAVD49YJ[H]A)+<YD3"CG-:6E:6;>)OM&,$UL0"%.(R/SH F4;4 ]
M!6?=:K%;R;-PW \BM&N.URSDCNGG/W6/% &U<01:O"9$?D#'%0:?I<=A+YDC
MXSZUF:)>R0W"P@G:QYJUK=S<!RJD[0>.* .DC='7Y#D"GUS^@3SO&0Y.,^E=
M!0 4444 %%%% #))8X$,DS!4'4FMJPN8+BW4PN&&.U<QK5E-J&F2VT! =NF:
MT?"^E7.FV:)<,"0,<4 =#1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^))I8=+=H02V#
MTKQ?P_X4?Q3J-X]Q>RH4D/&XTZ\\0^+)@T;S2%3_ +!K'TZY\1Z5-)):R.AD
M;+?(>: -SQ9X(/A>WCO(+Z4GS ,9/K7J/@B[GN=)3S@?E48)[UXSJ5]XEUKR
MX;V1Y(@X.-A]:]L\'Q&+2HU*D$(,Y% '1T444 %%%% !1110 4444 %%%,,L
M8.#(H/N: 'T4@(/((/TI: "N1^(O_(HWGT_I775R/Q&_Y%&\^E 'BOPY_P"0
M\WU%?2L/^HC_ -T?RKYJ^'/_ "'F^HKZ5A_U$?\ NC^5 #Z*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M##U?7+"RE2">=4DDX4'O5='61=RG(JMXB\+P:E?V]VZ F(YS5B&)8HPBC %
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M-CG6R3ZBOI:'_41_[H_E0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-;7";HVZBM;1M(M-+ME6VCV#&* -2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO7%U#
MP?XPFU&V@+PG@$].M;MO\6D\@>;Y:N!TKT;4M%L=5C*7<0<&N9E^&>AO)N%F
MO)]10!YQXF\8WWB[R["WA#() <K]:]<\(:8=.TF(,"&9 3FF:9X(T;37$D-J
M%<=ZZ15"*%48 &!0 M%%% !1110 4444 %%%% '$_$J"YGT1!;!B0V3@]JXC
MPIK6DV6@7D-\8A/O. R@GJ:]GN;:*ZB,<J[E(QBN/NOAQH\\Y=;5<$Y/2@#B
M/A^LMSXRN[B'/V=E^7'3O7J^HZ%;:IM:=5) QR,TW1O#EAHJ#[+"$;&"16Q0
M!R__  @^F_\ /-/^^:YKQQX4L;'PU=3QHH91QA:]-KD?B+_R*-Y]* /%?AP,
M:ZWU%?2L/^HC_P!T?RKYJ^'/_(=;ZBOI6'_41_[H_E0 ^BBB@ HHHH ****
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MT444 %%%% !1110 4444 %%%% !1110 5R/Q%_Y%&\^E==7(_$7_ )%&\^E
M'BOPY_Y#S?45]*P_ZB/_ '1_*OFKX<_\AYOJ*^E8?]1'_NC^5 #Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4'I110!P7BP:P=7M#:0EH0?G(-:ML7,(\P8:MF_GA0;7E16/0$UE@@C(.:
M%HHHH **** ,S5=0:R7"@9(JAIFM2W4S1N .*U-0L!>)CC=C@U3L-'^Q2>9(
M5Z4 9>KP7#3 @'!]Z9I=E<^?N*D+ZYKI7DMG&7*G;[TVWN[8R;$(7'O0!9:1
M8(-SG  YK#OM:1E*(016M?1?:;1UC8'([5R9TF<RLG/'?% !9QVSW&Z23&3F
MNQM=@MU$9RO8UPLMK)!(%/6NPT@$6,>6SQ0!H4444 %%%% !1110!E^(/M1T
MB86:;IOX0*O^$/[1%D@OHBAV]S4N]$^9V"J.Y-;5I+') NQU;CL<T 6****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (YH5GB:-AD$8KRK7_AEONVGLI9@7.XA6(KUFHVGB
M0X:11]30!XYIGPOGN+I3?2W&P$'YG)KUS3K&/3[2.",<(H'2K EC*[@Z[3WS
M3P0>E !1110 4444 %%%% !1110 4444 %%%% !7(_$7_D4;SZ5T]S=PVB;I
MG5 >['%<1X_UFRN/"UW''<1,Q'0,* /)OAS_ ,AUOJ*^E(?]1'_NC^5?-7PY
M_P"0ZWU%?2L/^HC_ -T?RH ?1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4=J** .$\5Z'=7FJVD\32;$.6VL
M0*U+:,QPA23^-:.J:C;V[K%)(H9^@)JDI##(.10 M%%% !1110 5GZOYGV3]
MUUK0IDRAHF!'8T >?L\OF%=S9SZT;I8CN+,/QJ2XBE6Y?"-]XXXKI+&PMYK"
M,S*-_?- $6A73M;L9#\H/)-6Y]7M8RP4KN ]*F>RCBLI(X !GTKDY;&8W14J
M>O7% !=ZB]S(25 P>,"MOP_<22-L8?*!Q44?A_<%.]3D>M;5E9):1@ #=W-
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MM'05Y%XU\<0^(;*.SM[9RWF Y SW%>A^!K66WTE3+D;E! - '5T444 %%%%
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M]17TK#_J(_\ ='\J 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\BC>?2@#Q7X<_P#(>;ZBOI6'_41_[H_E7S7\.?\ D/-]17TI#_J(_P#='\J
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M!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#E[;QMI-_*\"%B0I)KB-1U?P1-?L\Z2>:C<X]:Z2P\,Z;::HZ+>QM,5
MP4[UDZMX TVU:2YN+V--QW?-_P#JH Q7OO <T^[9)N;BNBT3P+H%S<QW]I$W
MRG<,US=CX>T"XNE0:G!P01U_PKUO1K".PLU2)PZE>"* +T,2P1A$& *DHHH
M**** "BBB@ HHHH **** "BBB@ KD?B+_P BC>?2NNKD?B+_ ,BC>?3^E 'B
MWPY_Y#S?45]*0_ZB/_='\J^:_AS_ ,AYOJ*^E(?]1'_NC^5 #Z*** "BBB@
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M<U?\)V^J06:#42-VWM2O-' OF2L%0=2:V;&Y@N+=3#(KC':@"W1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!XYX=O?/\ 'EQ+=/CY,\GZUG>.M>EUK5X--LWRK'816GXN
M\"7O]KRW^GS2(7XVI3_!_P /IXKU;R^D9G1MPWT <MJG@B?P_I$%^!ME,@!/
MY5[!X*U"2^TE!(<E$ K*^(5C=:CID=I;0,0) ?E^HK=\*Z6VF::BMG<RC(-
M&_1110 4444 %%%% !1110 4444 %%%% !7(_$7_ )%&\^E==7(_$7_D4;SZ
M?TH \5^'/_(=;ZBOI6'_ %$?^Z/Y5\U?#G_D/-]17TK#_J(_]T?RH ?1110
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MOK-9+92$QGFO#K>PTIO"EJ\D\:7(<$KW[5[!X*N1/I@54"JB@ CO0!U%%%%
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M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%(JAAUYIT48,P5SCF@#>T+3PQ$Y'*FNEJGIMNEO;@(V<C-7* "BBB@ HHHH
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MOH%G\DR(']-PJ?>NW.1CZUY[>:)-<^(A?"XE5<?=#'%='YK_ &3R=Q^[C.:
M-A;Z!KCR1(A?TW"IV=40L2 !UYKSRTT2:W\1B_\ M$K+C[I8XKI+R62XL98
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MBB@ QFN0^(H \(WGTKKZY'XC?\BC>?2@#P[P'_R&6_"O>HO]4G^Z*\%\!_\
M(9>O>HO]4G^Z* 'T444 %%%% !1110 4444 %%%% !1110 4444 %5KXN+9C
M&<-5FD(!&",T <,K3_VAT;.[KBNTM2YA&\Y-)]DBW[MBY^E3CCI0 4444 %%
M%% !1110 4444 %%%% !1110 4444 <[XA:8,H3.TCG K,T^_ELVW2!MF..*
M["9(V0F0#'J169=6EK>P>5$1N'/ H HPZ\6G 8G:3536+K[0YP#MSQ4<VG-9
MMN(/'2JT]V9H@FT#'>@"K1110!(NX(< XJ,\FKUK.B6KQL!DU2;&[B@"Y;7S
M6]NT:D@FJ[2M)(&<YYYJ*B@#K](2SEC#QIAQ6S7*:3NM[=IR2-IZ5;B\1-)/
ML95"DX!H Z"BD1MR!AW&:23/E/CKCB@"-[F-'VEE_.I58,,@Y%</>K<_:2"6
M!R<<UU6DB06:"3.<=Z +]%%% !1110 4444 %96I:3]LP8\ ]\UJT4 9FFZ7
M]B7Y\%O45IT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5[3^]4:O:?WH U**** .>UWPIIVKAY9X5,AZL37#6OAWPYI,LRWJ
M0R$M\N''%>@^)KE[72F>/J017AO_  CDVJ6^I:A)=3@PDL '.* ._AA\'1R*
M5M4#9X^85W^FRV\ELOV< (!Q@U\]0>&"WAVVU1;N8R.XRNXX[5[7X+9#I:JK
MEBJ@')H Z>BBB@ HHHH **** "BBB@ HHHH **** "N1^(W_ "*-Y]*ZZN1^
M(W_(HWGTH \.\!_\AEZ]ZB_U2?[HKP7P'_R&7KWJ+_5)_NB@!]%%% !1110
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M/[N,+C/4"@"GJ$L<AC\L8P.:I4XJPZU>M+**Y3[QW 9Q0!GT4^50CE1V-,H
MLPV;S0M*& "U78;3BIH[EXX6B'1J@H **** )K:802J_I5N1GU!CLSQS6=6U
MX>D5;I@V.1WH S8TGBE 56!^E=MIY<V:%_O8YI_V6)G#[5_*I@ !@#% %/5)
MW@LG9,AAT-<S;:O=";+N2OI777$"W$)C;H:RQX?@3<RL22* $_X2*#>JE3TY
MK7AE$T2R+T-<B^BW'VC 4[<]:ZFRA,%JB'J!0!8HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%(>E  2!U(% (/0YKG-9U*6*556K.BWTEP C#C%
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MWJ+_ %2?[HH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9]]IB7; X&14ME8I:1@ #<.]6Z1ON-]*
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M7'&:1)#R0?0&@#O#<0$8,B_G7/:S8QMFX21>?0U@F9_[[?G4CS2O %).WZT
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M"=_+A9_05QU]J4KW+8/'UH K7MJ+:7:'#9]*K9.,=J&8N<DYI* "BE..U)0
M4444 %%%% !1110 M36\'VA]H.VH*?'(T;96@#I-,T4(PD9@V*Z!5"K@=*YC
M1]6E:986Q@FNHH **** "L[4M46Q4$KG-:-8NL::]TH,8).: )M.U9;SC;@D
MUJ5A:1I<ELP>52"#6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %7M/[U1J]I_>@#4HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'-:]=SQR((V91[5)H-U-+(%D+$8ZFM:[T^&\QYG:FQV]OIL.1P!0!=IK.J+E
MF ^M8Z:Y$USY>[OBJFMW[$%$/RYH J:_.LTZ[2#CTJSX?LP7$S<@CI7/LQ8Y
M)KI]$N[:*U16;YZ )->N)8-JQ$@8[5RS,\S[G;+'O75:Y)%Y/)Y(XKD@<4 .
M9=M-I22:2@ HHHH **** "BBB@ HHHH 4*6'%;&G:A!;@(\0)Z9JM8I&\9#]
M<U5N%"W#*M '479MIM-DDBC7/M7*%69CA372:'$&M&CD_B-,U6T@T]1+']YC
MWH H:.98[V/<2L??-;>K6\%W&H$RC'?-<RU_*5*\ >U1//(Z@%CQ[T =/I.F
MI"WF"0-@]JW*YWP]YOE>JYYKHJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]I_>J-7M.[T :E%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<C\1?^11O/I775R/Q%_Y
M%&\^G]* /#O ?_(9;\*]ZB_U2?[HKP7P'_R&F_"O>HO]4G^Z* 'T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !4,US'"/G8 ^AJ:N7\01S&Y++G9
M0!T<4\<PRC _2I:YSPY',OF%LX-='0 4444 %%%% !1110!6N[U+--S8^E8]
MSK,=[!LVA*FUN'[2%"_>%<W-9SVZ;G&!0!&6\NXWCG!J:3SKL[E5CGL*BMH3
M/,J#N:['3M.6TB&Y?F% '(?8KC./*;\J417$,@ 1A@^E=C-J%I;N%? )]J9/
M):M 9SC##B@#G;V7S8DW/R!TK+%27# S/@\9XJ*@ HHHH **** "BBB@ HHH
MH ***51EU'J<4 *LC)]TXIY7<-Q;FKEUIQAB$BCC&:SQDG% %JRNY(+A3O.T
M=JV-6O4EL8R5R363!I=Q/@JO%;<^CDZ>HQ\ZC)H S-)CAE?;)MY/>J^I0>3<
M-M7"YX-5_GMY>."#5_4+F.>PA /[P=: +6A:@L)%N1]X]:ZE2&&17":;&TEZ
M@7K7<0J4A53U% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5[3^]4:O:?WH U**** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "KVG]ZHU>T_O0!J4444 %%%%
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MG\S0![5_PD6E_P#/Y%^='_"1:7_S^1?G7BO_  A/B'^Z?S-'_"$^(?[I_,T
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MC)J@LL3-^ZD#@>E<1_PA'B#^Z?UKI?#OAO5[9@LZ< 4 ;<]SYRJ-N-HQ5>M
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MI_,T >U?\)#I?_/Y%^='_"1:7_S^1?G7BO\ PA/B'^Z?S-'_  A/B'^Z?S-
M'M7_  D6E_\ /Y%^='_"1:7_ ,_D7YUX=<^$M=M8C)("%'N:QH(;RXN_LR,W
MF;MN,F@#Z*_X2+2_^?R+\Z/^$BTO_G\B_.O%/^$*\0D9VG\S2_\ "$^(?[I_
M,T >U?\ "1:7_P _D7YT?\)%I?\ S^1?G7BO_"$^(?[I_,T?\(3XA_NG\S0!
M[5_PD6E_\_D7YT?\)%I?_/Y%^=>*_P#"$^(?[I_,T?\ "$^(?[I_,T >U?\
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MT- 'RU>*!X\=0/E^T=/PKZ/T"SMVTQ"8E/ KYUO(9/\ A/7.QL?:?3VKZ2T
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MF;LYQS6Q%$L*!%  'I45U>0VD9>5@ !GK6?;>);"ZF\N.0;O<T ;%%(K!E#
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M5*Q\/V.GN7@@C0G^Z*MWNH06,1DF< #WJI9^(;&]<I$XR/4T :U%("",BEH
M**** "BBB@ HHHH BN($N(C'(H93V-94/AG3H;CSTMH@^<Y K4N+F.VCWR,
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MU?##_6+VK-^$UU=3ZU=?:)'+;>0QKO/$NBV<6D3W"I^\'>N'^&/_ "-%]]*
M/9!THH'2B@ HHHH **** "FR$K&Q R0*=10!Y#XHT[6M<\5K;QF>&U9>6'2L
M#Q'H]WX4N+"2/4I':1QN7->Q^(-;M=#LGN9R!M].M>1 7WCO75=3NMX)-PSZ
M4 >M>%+V2_T=)900W YK=JCI5BFGV20H,  9J]0 4444 %%%% !1110!YYX[
ML]4OV:"T,J*3]Y*X36]'FT+['-'JKO,W+)GG//M7O$SH%*EE#8[FO&/&F@:C
M!J*W\Q4P(V\8]* /1_ ]Y<7OAZ.6X#!S_>KIJY'P#JL&H:#&8L]:ZZ@ HHHH
M **** "BBB@".>9((F=V  !/->$?$/Q3=ZA=%+,N(XR0Q0UW/Q(\3-ING^3
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M0 4444 %%%% ',>(?!\.O,3)(%R<UP'BKX>265BQMG:4A> *]FIDD22C##-
M'FGPO\,3:?8QWD^Y)&7!0]N**]+BB6) JC %% #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **,@49STH **** "BBB@ HHHH **** "BBB@ HHHH ***
M,@=: "BC.:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBDR/44 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<KXG\7)X?W JI('
M>NJKQCXN >>^?2@#<3XGN0K-;J$/>NNT'Q-::W$#'*I<]A7FL=MX>_X0]&EB
M!N##Q\PZU5^%D4RZJKHI6 ,>H]Z /<:*\S\3^/)(+T65A(5EW;3]:RH/'&JZ
M5?*NJ7&^/OB@#M?&OB&70;>-XTW;A4W@G7)->T1;J1-I)QBN4^(=XE_H=G<I
MTDCR/UJ7P#>FQ\$><N<ANU 'IE%>0WWB;Q&9)I8;@K$AS@@]*T_"?CB?5'^R
M7$C-/CK0!VU]K]C87$4,TZJ\AP >]6+J],=D9X1OXXKY[\::C?3>)(3(QS'+
M^[XKT3PWK&HR::/M3$IM]#Z4 :WA[QA?ZKJ5S;S61C6)]H;UKM^U>0^&]>,E
MUJQB)WQL<?I6IX;\:7-YXC_LZZE)P,X- 'I5%<#XT\7RZ/?6<%M(09CCC\:B
MU+QNVF^'UFE<_:"<4 >AT5XR?&.OQK]K>Y_T?[V.>E>A>$O$L6OZ9',"2S>M
M '25S7B'Q?9Z&K*TJ&4'[IK:U.<VVG33 X*KFO!O*?Q=XYE@F^>/ .#]30!V
ML?Q2E:7YK91'G[U:6O\ C;[/X;AU&V ?>^,#\*T(_ &B-8+$UMSMP>E<K\0]
M&MM$\(0V]JFR-).!^5 '8>#==DURR>61-I%=/7SUX?\ %6H65A(MB74 <_*:
M[GP1XZFU6^-E>.S2JN3F@#TRBO/_ !3XCU&WNHX;!F4MWP:Y8>.]9TN]1-0N
M"R%@O /K0![317(:YXE>T\/_ &V%R&\L-FN$B^(VIZA8J+5Y/.'+-@XQ0![5
M17E_@SQ[/J-W]EO79I2V!FK?BWQM)9W;6-BY6=6P: /1:*\1O/&_B'3KB.&>
MY.Z097@UV?\ PE[V'AJ&]O7)>08!'K0!W=%>,'QGKUS%+>07.+=#R#G-=GX+
M\7KKO^CR,3.JY8F@#M*PM>\2VFB0;Y95#=@:VI9!'&7/:OG_ ,57,VO^+7L6
M;=$DHX_&@#L_^%IRF4[;93&#]ZNWT'7HM9MU=2-Q&2!618> =$73HT:V^\@)
MZ>E6Q8Z=X4M9)H4V*%..: .EHKQF3QWK&J7+_P!FRN(U8KT-:/ASX@W!U(V6
MI.S.#M[CF@#U6BO.O&/C2;0M2B1'(B9 V!]!7+W7Q"UD!+B.1Q"3G[IZ4 >V
MT5XTOQ*O+^V,=FTGG=,X)J]X2\?75UJ<EIJ$C,P.!0!ZO17FOC#QQ/H.MQ0J
M[")DW$#\*YVZ\?:V MQ'(X@//W3TH ]LHKB_"OBY=8T9KAF+2!L5SFI^)]?D
MO)ELYBB1GN#0!ZO17E7A;QY=W&N1Z;?REI&J[XU\;3Z')!Y4A"NW04#2N>D4
M5Y5X>\9ZIJ^LQX=_LI'((-2^(O'LR7*VEA(5F#;6/O0(]0HKR"U\<:KIFH*F
MJ3[XSR<5VFM^+8-/T2*[#'=-'N3!H Z:XE\J%G'.!7G6@>.+C4/$5Y9-#A8I
M=H/Y5S,?CO6KB-KEI':VY& IK/\ A].;KQ+>3G.7ER<_A0![^#\H/M65?>(+
M&PN(X9IT5Y#@ ]ZT)6*V^5Z[:^=/&U_?2>)8C(QS'+^[XH ^CHI5E0.AR#3Z
M\[\&:UJ#P+]L<F,#N,5CZO\ $"]NM1DM=+D<-&VUN": /7**\<LO'^I:;J0@
MU65F'?@BO6[&Z6\LHKA#Q(N10!8HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O%_BZ,S./]FO:*\X\?^$+_ %^5FM64 CO0!P5QX-N8/#]K
MJ,5S+(I3>R9X%=E\.-6MY]+\D1HLX..!S7766AR)X373YL&00[/QKB_#'@C5
M=%\2K-O06N22H'O0!P,[3-XRO!M+MYWR@UT6J^'=2U2,>9;.F<<UM^)? &I'
M4/M^E,D<I;>Q-1VNG^/9G5)+^/8.V#_C0 WQA:/9>&;"%R<K%CGZFK/A#5(M
M)\ ?:955E#]&K;\4>&]1UC1[6'>IG1,.3Z\U4T[P3<_\(6=*N-ID+9H YK_A
M(;W6HKLPZ:HB0?>4=JSO 99O&8#)M^7I6C9^%/%VG2SVUK=(D$AVXQV_.M;P
MMX(U;3/$JWMVZ,N.<#_Z] &%\088D\2Z6=B@&7GCKP:]%"6X\.9B10=O8>U8
M?C_P9>ZS):W%@562'G)_&F^'="\1I9>3?7".F,8Q_P#7H Y?X?QB77=5C/1I
M<?RJ'Q"#X?\ '<MRHVQA<9KK/!W@W4-(UB]N)V4I+)N7 ^E7/B!X,FUZV9[0
M*)R>IH X#[0_B?Q%ISJ2ZQ2<_K3_ (B1O;:T\(SY0(P.W6NL^'O@2[T1Y9+_
M &LV<KBMGQOX-;78&DM0HN<YW&@#AX]/U"^T58EM&V-'C<*ZWX>:#/I,,8D+
M  =#7.6^D^/+1/LT-\@0?*HP?\:]$\*VFK6VG1C59EDF'WB* -+7(S+HURB]
M2M>&>&;E-%\?RFZ(0;0/F_&OH%T$B%6&0>M>9>,OAU+J5T][IH1)R<[C0!Z'
M'J-L;59C* FW.:X'XIW4-UX:B>%PZF3J/PKG(/#GCD@6IO8_)'RXP>GYUT.J
M^"]3N_"-O8,Z&X1\L>W:@"+P%I]K)H%RSP(QQU(KE]%"VWQ)O!& JJF<#\:]
M(\)^'KK2=)FMYRI=QQBN=L_!&HQ>-+K469/)D3 'Y_XT 1:_XQ*ZA!9VUE'-
M(W&<<UQ/BY[MY(3<6ODGS5_F*[#Q%X%U=-4AOM+=(V3DDCO^=4-1\%>*M:6&
M2\N(WPX8\>X]Z -77R3X'.?^> _E3_AK86TGAT2/"C,8FY(]JV-6\+WMSX8-
MDC+YGEA:L>"?#EWHNB+;7!4OL*\?2@#SK3$6'QS$$ 5?-/ ^M1>+)FM_&-Q+
M;KY\FX93\:ZJ+P7J%OXF34'93"KEB*Y#78Y;WQS=II[K#/D99SQU- %L0ZEX
MHUFS>?3S!'& I(%:'Q*MGT_PY9VZYPLH_F*S=1NO%'AQHW;4(F3;G"'/]:[7
M^S9/&WA"V>8;I_O98=^* .+T6TOKS26CAM2R$<D5T_P_\.7.FZW-<2AEW+C!
MK(M?#_C;1]]O9WD:1D\#'_UZ[GPA8^(;>=I=8N%E5EXP._YT =5=(7MF4=<5
M\^W[G2_'LTDPPK2 9/UKZ)KSWQMX!_MK_2+)56XW;BQH [.RU&UDL(I%E&T(
MN3^%<3\2K]9=)C6UDW'/S;?2N5A\-^.8!]FBO8Q'TQ@_XUV=AX0NIM*,>I%9
M)BA&1ZT 9'PJBLI-)F,B(S^:>H]S7)^*%C3QBHM< ^>N0OUK07P=XLT.>1-,
MN8XXF8MC'O\ 6MGPUX!U!]2:_P!:9)78[@1ZT 8GQ$7?JUF&'_+!>OT%=+>V
M%J/ L#B!-WE'G%/\9^#K[6-6AFMF41I&%Y_"MNYT"ZE\*QV"D>:L94T <;\)
M[&VGL)GEA1R)B 2/<UA-&L/CR<1@*/.' KT#X?>%[W0+&6.Z92S2EACZFL>3
MP1J3>*I;\,GE-(&% &!\1=G_  E%KYF-ODC.?H*Z^\CTT>"8VV1;C"<'%<=\
M3;=I?$]O".OE ?RID7A?Q;?6,$8ND^R$85<=OSH F^'5X;&REG<9B64\'IU-
M76\4W.KWUU!:::C+&>64"NIT#P-]A\./93JIE=MV17(Q^#?%&CZI</IUPD<<
MQQC';\Z ,#23+_PL6W,D?EMCI^(K7^(JA[W2U;D&09_6M'2_ NNQ^+(=2O94
M<*.2!_\ 7K3\7>"]1U:[L)(&4"%P6S0!T>A:?;P:"KQ0('P.0.>E>,;ICXMO
M%"%V\W@5] Z19/:Z<L$V"0!TKSGQ+X"U,:B;[1V2*1GW,30!AZKX=U'4U!>W
M=,]Q3O'%O-9:7HT#EMJK@Y^IK6M-/\>3RJDE^A0=L'_&NJ\1>%9=;T."*?:U
MU%'C=[T 9WA>+2_^$2W2I$1ZD>U<1X)V?\)AJ'EXV>=QCZ"K>G^#?%T -B+J
M,6Q/W<?_ %ZU_"/@34](U2:XN&0[GR<4 >K8S'SZ5X=\1(HT\3Z80B@&;GCK
MUKW(#Y0/:O.O'_@R[UJ6WN+ JLD1W9/XT :-V(D\+[K=5#XZJ/:N'^&JVTFM
M:E]I"LWF<;A]*Z?PIH6O+$(=5F62#&-H'_UZY[4? GB#3-3ENM(F2(2/N/'_
M ->@"O\ %1+:.Z/D!5DW#[H]Z]/\'^9_PC]IOS_JAUKSJP\"Z]J^I+<ZW*DR
M=QC_ .O7KEC:K9V4-NHP(UVT 6:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I"H/44M% !VQ2;5SG S2T4 (0#U&:01HO10/PIU% "8!ZB@
M #H*6B@!OEIG.T9I<#.<<TM% "$ ]1F@*JC  %+10 @4#H*" >HS2T4 (% Z
M#%+110 SRDSG8,_2G#CH*6B@ H(!ZT44 -\M <A1FE(!ZBEHH 3 '04;1G..
M:6B@!"JMU -)L4#&T8IU% "8&,8H  X Q2TUF4=6 ^IH 1XU=2"!S7G.O_#9
M+[4Y-0AN7CD<\[3BO2>#R** /*X?AF]Q<H]S>3,J\88DUZ/I6G1Z781VL?W4
M%7:* &&-"<E0?PIP '08I:* "BBB@!OEIG.T9IU%% #2B-U4&E  ' Q2T4 (
M5!ZBC QC%+10 @ '08HVCT%+2%E7J0/J: .'\2^"EUK74OC(PVKC _"NLTZR
M2SL(H, [!C)JX&#="#]*6@ IIC0G)44ZB@!-JYS@4%0>HI:* "D(!ZC-+G'6
MFAU/1@<>AH !&B]% _"G4W>F<;ESZ9IU #0B Y"C-+M'I2T4 %(0#U&:6B@!
M JKT %!56Z@&EHH 0*J_= %+110 4444 %%%% !1110 4444 %%%% !1110
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M6YEB<, <<5I;AZUXC\-DU[[5&5N!]CW?.N.M2^)?&NJZ=KD]K'.V"VU0 >*
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M(K<+M- %'XFS+=Z[YT;DP[>3VJY8Z"+[1HQ]HDVLG//2NRUSP;:7NBLF%67
M^<CVKC(_#.NVS>5!K$2Q#@+L/2@#7TGPW#I&@.8IF<!L\UB?#S_D,ZY]?Z"N
M^TC1[A?#S6]Q<+(Y/W@*R_"OA-M,U#493.C^<>@'3I0!QUK_ ,E0C_W?ZUTG
MBKPK9:FJ7$4Y$T7S87UJS#X19/&::CYZ8 ^[@YIGB+0M4:7-EJ"09/.5- '-
M^%O$5]I?B%--F0D#NQR:]LMI/.MTD_O#->7^%_!LHUE+W4+I+B0=PI%>IQHL
J<:HHPH&!0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gjnp4w4lrub1000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,I [T# 2(  A$! Q$!_\0
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MI;6"0W+WZC]XK;@:V[#PY>7U_->2PM K(<1]@>:H6FEZLVHFV>T<0LQ&[VH
MCAN'\2WDUK>G?'&I90?7_(K<\&W?]E1SH<^6'/ ^M5KSP_>Z)(]S9PM,T@VD
M"MGP5H]P(I9+V$HS-G:U %BZ^(FGVL[1-%-E?13_ (58TKQYI^J7B6T2R*['
M W5MS:-8.KLUK$6P>=M>>-;Q6WC>S6)%1<]%% 'JM%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 F*" :6B@!  !@4;1FEHH
M0@'K0!BEHH ;)_JW_P!TUYA<_P#(]6?UKT^3_5/_ +IKS"Y_Y'JS^IH ]1HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** &R?ZI_\ =->87/\ R/5G]:] UC45TZT,CD 'CFO,K>_6_P#&
MEHZD'#=J /7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1CA2?05QFM>,1IEQY
M9CE/T!KM*P-?M+=XR6A0G'4B@"EX=\4C6+@H$D  SE@:ZP=*R]$M8(K"-HX4
M5B.H%:E !1110 4444 %%%% !1110 4444 %%%% %/4=/M]0MFCN$W* 2!7F
M2V,%CXVLTMTVJ6->KR?ZI_\ =->87/\ R/5G]30!ZC1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5C:[_J3]*V:QM=_P!2?I0!;TC_ )!L7TJ]5'2/^0;%]*O4 %%%% !1110
M57OI&BLY'3.X#C%6*0@$8(R* /(_MVIMXGD:68^2<84CW-2>-=<N8;ZQAC9O
M+=!N4#KQ6OJNE7+^)))8X?W9(P1]:SO%^C7G]I6-U!!YBQJ-V?I0!7T[5;JW
M1BLVV,J0$[BL^V?48[MKPSY56)J;3] U*^U6>ZDA98RF5 /&>:AM;36'O6M'
MM<1,Q&: +0U6]U^YEMA,?D7<,UM>#M3N+2*9+IS)AR!BL>31=1T&XDN;> N9
M!MYK;\%Z3=31327L1C)?(% &M=^.K2!WB-O(2!UP:XVTU2/5/&=I+&C* W>N
M_N?"MI*7D)Y(/:N%BL8[#QK9QQ]"U 'K=%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8VN_P"I/TK9K&UW_4M]* +>D?\ (-B^
ME7JHZ1_R#8OI5Z@"IJ%S]EM&EQG )KR2Z^*IBOI8?+D^1B*]?NK9;J!HGZ$$
M5Y7K?PULX9Y;N,N6)W'- %-?BA.Y^2VF;Z*:W_#OC2ZU.]CB>TG0,<9937G5
MWJ4_A^3$<$;!3_$HKLO!?C.35+J.*2"%3G'RJ/\ "@#UNBBB@ HHHH ****
M"BBB@"AJVF6^IVICN(PZ@$@&O,H=.M].\:VD=O&$4MT%>M2?ZI_H:\PN?^1Z
ML_K0!ZC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM/J5[J6ERR'!E!POTH ](M;V.YMEE4C)&<5"FI%KQ8/+//>N(CO=1TFSM7;
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M"CC6*-448"C H <JA1A1@4M%% !1110 5FZI]P_2M*LW5/N'Z4X[C6Y9T_\
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M2QW,.Z)PRL, BO/M6\*1MK5N50[6;)KN].LDL;58$&%6@#B?$>DW<%QN2_D
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M!B0<<58T[5X-2CWQ!@,XYH MQP1Q'**!]*6:%)XC'(H93U!I^Y?4?G1D#J:
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MG)J\;2$EB8U^;KQ4VY>F1^=!('4@4 <[KV@QW-BZPH!G^$"L*#P[+<RVXV&
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M];V@S-($^M6:R-9T=-44AE!XQ3C:^HUYD=SXGTZ*%F2Y1B!TKEXOB"6O=C1
M)DC-277@1!"QCC (%<O%X2O6O/+(&,GM73"%*VYK&,#TZW\2Z=+"K-<HK'M6
ME;7D%Y'O@D#KZBN)MO D8A7S(P6[UU.BZ4NE6QB48!.:RFH):,SDH]#A;VXE
MC\17 $/G#=]T]JZ4Z@]KX>ENA:B)UZ*.]8]]9W-IK4UR!\KMQ@5J7#S:CH$T
M0!W'CD5D29#:[?JMO.8FVR,*T-0\1S2WD6GQ)\TB Y'X5+/ID[:19Q#[R=:R
M[G2KRTU>+4E^Y&N#@<]O\* -,:O=:=$5GC;YAA2>]4?[6OK>%K^2-PBGH>E3
MW,-]K,8=CD1_,N151_MU_8OIKDDL>..* +6I>)+G[+:O#$6,QP<=JLR7DT&G
ME9V9"W.XGI43://'#9Q]XR,TOB.SNI+E&?YK0( R@4 4=.UZ2\BOH 2VQ" <
MUF^'I6M"U],F[:Y^9OK5O0=$D@>\=%VK(OR\5J66A33:/);.!EFS0!G'Q(TU
MV6#X"G( /6KDOB:YFXBB);'05EV^BP6MXR7$1/.!@5LPZ2T>H(\2X3% %2'7
M[JTW_:(CB3H&JGK.H?:-$?$87)[5IZ]I-Q<>3L['TJC=Z)=OI31K][Z4 )8W
MU_;VUNWE/Y8'7VKN=+OA?V@E ]JXJ,ZAY$-HQ.W&T\5JZ?<2:9=+IRY!//%
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MLE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX>N])B>Y2'S3U)<5UVBZ'H-K=H]HD0<'C:X- '<T444 %%%% !1110 4444
M9.OZ>VH67EJ[+CG*G%>96%BUAXRM$9V;+?Q&O89/]4_^Z:\PN?\ D>K/ZF@#
MU&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU$.G<&@#T2QUZPU&X,-M,'<#.*TZP= \.0Z0BN5!GQ@L*WJ "BBB@ HHHR*
M"BDSBEH ;)_JG_W37F%S_P CU9_4UZ?)_JG_ -TUYA<_\CU9_4T >HT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS^IH ]1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MJU[<&VMGD"EMHS@4 6:*\VG^)7DWAMS92[\\#!S78Z'J[:K%O,+Q\9^84 ;%
M%%% !1110 4R:5(8FD<X51DFFSSQV\9>5U51W)KSW6M=NM:O196(=4#;68#@
MT 2Z_P"(KC5KAM.TO$F[T.#6WX;\,Q:=']HE!:>098/S@U+X?\-PZ9$LDBAK
MCKOKHJ  # XHHHH **** $/0UQFH2K%JL;L<*KY-=!KM^+"P:7=@UX]?:M<W
M-ZY\PX+<5T4:;EJ:4XMG;:]K\U_,;"Q.[Z'FM7PWX=6T0SS F1_F.[FJO@W2
MHY+)+R9 9#W-=F %&!T%3.7+[L12=M$   P!BEHHK$@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N3\=3Q1:-.&QO*?+765R7CE
M5.DS'RC(P3C H \PT+7?%%KIT<=C9Q/".A/_ .JNO\-ZYXFNKZ-+VSB2,MR1
M_P#JKF] \91Z7IL=M+I$KLO?::Z[0/&4&HWJ1+IDD18XR0: /0Z*** "BBB@
M HHHH **** &R?ZI_P#=->87/_(]6?U->FS,JQ,6('!ZUYC<,K>.K,J0>30!
MZE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#ET0BJ%&  !2T45D0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9&O:0FJV3QMG)7 P:UZP/$
M[W0LG2U#[RO!7M0!Y7J5AJ_A20O: &-3QN-=#X,\>W6IW"VMTPW9V\52L? V
MKZP1->:C*JMU1\?X5W.A>#[/1P&V(T@_BQS0!TU%%% !7.>(/"UMK,JSN#YB
M#C%='10!R>F^";*UW2NI\UE(.:I6_P /[.'41< -][-=S10!RFJ^#+2[7,:G
M<3SBKWA[PY;Z' R1 _,<G-;M% #)%'E/P/NGM7F-R,>.K/'J:]/D_P!4_P#N
MFO,+G_D>K/ZF@#U&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.@H *9+
M*D,9=S@ 9-9VIZY::=$Q:5#(.B9Y-<-/J&I^*+MH(4EM8E/WQT84 ;&M>,TW
M-::<^;D_=!K/TWPQ>ZS/]IU@$+G<N#70:'X3@T] ]P%GFZ[SUKI%547:HP!V
MH JV.GP6$(CB48'M5NBB@#B]5_Y'*#_=_P *["'_ %2UQ^J_\CG!_N_X5TTU
M_!9VF^2100. >]:S6B*>R+<DBQ)N8X KC]<\5*&^S63YD)VFLW4]=N]9G-M:
M1NJMQO6MG0O"RVX$]T1*[<_-VIJ"@KR*22U9E:3X;N=1N%N=04X/I7<VMI%:
M1+'&H  QTJ9$6-=JC IU1.;D2Y-A1114$A1110 4444 %%%% !1110 4444
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M ;E%4[#48;^,O"ZL!Z5<H **** "BBLK4]=M-/C;=*AD X7/>@#2DE2)"SD
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M249B;Z&O,;G_ )'JS^IH ]1HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY\? _P ]Z?X7.K6>LI#?RJQ+X&*B/C7Q(P(_L:3D8[5)X;L-5U76HKVZMY(
MCYP>] 'L5%%% "$9&#WK!U;PEINJ@M-#ND[&M^B@#BK#P%8V;NPA )4@51MO
M T\>I"1U7R=V2/:O0Z* .*U3P:#E]/0+(W#$^E:/ACPZ-&A<.HWL<G%=)10
MV3_5/_NFO,+G_D>K/ZUZ?)_JG_W37F%S_P CU9_4T >HT444 %%%% !1110
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MX4445(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.X_[Z-;7A[P-<Z7>QS/?32!6SAF- 'H]%%% !1110 4444 %%%% #9/]4_\
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M'P:J$/-.SGT:NCM],M;=0%A3COBE:3%:<M]#B8-"UC4GWWDBLA[5O67A#3X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU,FT\.Z=: >7#@BM1$5%PHXIU%4DD:));!1113&%%%% !1110 4444 %%%%
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MC6%-6NR**".!=J+@5+115FH4444 %%%% !1110 4444 %%%% !1110 4444
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M)2[A=G0'Q%:#N/SIA\2VG^36,O@6+'-S+_WT:>/ T&/^/B7\S1RTNX>\:O\
MPD]I_DTG_"46GI^M9P\#6_\ S\2_F:</ ]M_S\2?F:+4>X>\&L>*8O[-E\@E
M9,<&O/SXHU7/_'P:[35O!D4.G2O#*[N!P"37"-H6H9_U!KIH*E;0B5S?T3Q=
M<Q2@W3M(N>0*Z5_'EJO_ "[RG\#7,>'/#D\LZBXC*C-=POA:T4^OX5G5]DI:
MC7-8QV\?08XMIO\ OD_X57;QSD_+;3_]\&NG7P_:+_ OY5832+5!_JD/_ 16
M7/270JS.*?QG</PD,X_X :C_ .$GU!^B3#_@!KOET^U4_P"HC_[Y%2?9+?\
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M=7Z"X%96L>';^SC:2:4/@=!7K>X>@K/O]+BOVS(<>U"YHN\6#I::'BBVTI8
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M0] GTDX\P;<Y(%='FDHII6*BDE9!1113&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 '>I^U0=ZG[4#"BBB@ H
MHHH **** "BBB@ HHHH **** &R?ZI_H:\PN_P#D>+/ZFO3Y/]4_^Z:\PN_^
M1XL_J: /2N]%!ZT4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M =]17 _\)CJ7]Q*K7'C^ZM<>:$&3@4 >CT5P"^,]190P1,$9%+_PF.I?W$H
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MHHH **** //=?\-W4>JS:A;.09OEPO\ GWK0\'>'9-/MYC=-O+MNYKL2H/4
M_44  = !0!0FTBQ=79K=2V#7F]QID'_":6B" >63SQ7JY&01ZUF-H5JU\EV<
M^8G2@"7^Q=/_ .?9:3^Q=/\ ^?9:T** ,_\ L73_ /GV6C^Q=/\ ^?9:T**
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MZ?\ \^RT?V+I_P#S[+6A10!G_P!BZ?\ \^RT?V+I_P#S[+6A10!G_P!BZ?\
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M%T__ )]EJ]&@CC5!T48%.H S_P"Q=/\ ^?9:/[%T_P#Y]EK0HH S_P"Q=/\
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MT9>E>?:CIEN/$-LJP#:9>:]2K,ET2VEN5G;.Y3D4 /&BZ?M'^C+TH_L73_\
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M5<\=L6N1%-Q:E?G8=17-^$1!;ZLW]G,7R>=WI0![&IRH/J*6FQY\M<]<"G4
M%%%% !574+@VUC-*!G:I-6JK7Z(]C,)/NE#F@#RJ?Q#>M%+JXO&2*)BIASU_
MSBO2?#^I?VEI<,W=ER:\?UZ'3A:3VEI(Q=F)Q7J/@VU>VT.WW#^"@#I****
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MB]LM8BM9KAKCSFSG^[6W'J4>F>%('FP$8[3G\*Y*">T;Q/:MI;&17;+[NQH
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MO:EC'&J[CDXJY10!5NM/M[M0)8U;!SS3[>UBMH]D:!1Z"IZ* "BBB@ HHHH
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gjnp4w4lrub1000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +L!GP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQU3@WL/F/5O%OB#_ (1?PU<ZQ]E^T^0T2^5YFS=OD5.N#TW9Z=JY[P=\2/\
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M$G&YBQQGC.!Q5U--$*&NIJ4445D6%%%% !1110 4444 %%%% !1110 4444
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M X; ).2IQD, <@ [:FT?X=^+=0\2OJFK74NG2-+YDUVEP#.^001&4) X 7G
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M[MGDYV_OM_\ #][?NSWW9[UXW\,#_P 5]H7F??/F_GY$E;<'A?XDVV@R:''
MZZ?,H,D*7,)'S ,R!B=P&<A@, G=U!R>K^'OPZGT"].L:NT+7GE[+>W3#B#<
M!N8MC[_5?E. "W+;N%I&-KCU<KGF_P 1?^2D^(/^ND/_ *3Q5@WW_'VG_7AI
M_P#Z105Z%XT\!>)M6\;ZQJ-CIOFVEP\1BD\^-=P$,:G@L".5(Y]*R;OX:^+I
M+E732<J+.SB)^TQ?>2UBC<?>[,C#\/2K37X$M.S,KQ5][PO_ -BO8?\ M2C5
M_P#D1O!/_<5_]*5KIO$'P_\ %%\V@_9],W_9=!L[.;_2(AMF3?N7EN<9'(X]
MZO7'PVUF]^'NAV_E+%J^F27A:WDF7:\<LC/@$9!<[8\98 9;)]$FO=&T]2[\
M)K"/5? /B'3IGD2*[O9H':,@,JM;Q*2,@C//I7G?AO7[OP3XB-[<6SM-;K-:
MW5I&4)=L$>7NY  E5"6&>%.,]#W?@O0/'_AW4;:UBM8;?2Y;L37BS/$ZD;0K
M'*DONVJ N.-P&>,USGQ2TVVTSQY/]EC*+>6Z7DB@ *)&9U;  '7R]QSDEF8]
MZ45=N+![)C/A3H8O_&-H6CW6VFPFX8M#O0N/EC!/16R=X/7]V<>H^A*\_P#A
M'H*Z;X7?5)$=;K4WWD.C*5B0E8Q@G!!^9PP R)!U !KT"HD[NY25E8****D8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !14%Y=P:?8W%[=/LM[>)I97VEMJJ,DX')X':N(TOXAZGXBDNGT#PI/>6L#
M*IEFO$A.XJ"5((*Y'H&/!4G&X4TFQ7.^HKD/"/CZT\4WD^G26-Q8:G;HSR02
M#<N%?:0&P#D97(8*06P,X)KKZ6PPHHHH **** "BBB@ HK&U#4M;M]:M[6RT
M#[982>7YM[]L2/RLN0WR$9;:N&XZYQ6S0 445QGB#Q[_ &%XTT[P]_9OG_;!
M;GS_ #]NSS96C^[M.<;<]><XXHL!V=%%<+=?$?S?$SZ!H.BW&J7D+R),3*(5
M4I@,02#\H.5);:,@ ;MPII-A<[JBN%MOB,8/$T>@Z_H=QI=U.\:0LLHG4E\@
M$D <$X4%=PR3G;M-=U0U8 HHHI %%%% !1110 4444 %%%% !1110 450US4
MO[&T#4M4\KSOL5K+<>5NV[]BEL9P<9QC.#7'Z+X^UWQ%9R76E^$/M$,<AB9O
M[21,-@'&&4'HP_.FDWJ*YW]<?XWT#Q)K<^G-H&K?8$A647 ^TR1>86V;?N Y
MQM;KTS[FH/#WQ#&J^*9_#NI:3+IE^A*(C2&3<Z@LRGY1CY0&4\AAW^[NKZ'X
M_P!=\1V+7FE^$//A5_+9O[21<-@''S*#T84TFG<&TS(\)_"6?3=;AOM:N+>2
M*T9);:&T=OFD4Y!8E5P%(! '4]> 0WJU<%'\3(K'7CI'B729=&F.PK*TZRQ@
M,#\S,  %R -PW#.[.W::DUOXC)X?\9Q:%J&F>7:R&-A>FZ4 1OQYA4CA0X8'
M+# 4MSP".[=V"LD=S17+^-?&UGX,L8)9X'N+BX+>5"#M7:N-[,^"  "/4DD<
M8R1O:=->7&GPS7]HEG=.N9+=)O-$?H-V "<8SCC.<$CDS89:HKG/&?C"S\':
M0+N81S7,C 06K2[#+@C><@' 53DG&.@SEA1J?BM/#OANWU7Q!9O:S3.L?V2V
M<3LK')"[L*N0H)/;@@%N,NS"YT=%>>CX@Z^?#?\ ;X\&.=/\KS1+]O'W/[VW
M9NV]]VW&WYNG-:J?$'2KCP5?^);:.;RK-FB,$ZE&,W 1"5W#YBZ?,,@;N<8(
M!RL5SK:*XGP3\18/&&H75B;(6<T40EC F,GF*&VOSM &TE._.[V-=M2>@PHK
MA/''Q,MO!]VMK#9)J,ZQ-)<(+CRS#P"@/RL,L,G'4  X^85TOB/Q#9>&-(;4
MK[>T8=8UCC*[Y&8XPH8@$@98C/12>U.S%<UJ*\W;XIW5G8Z?J.J^%KJVTV^#
M>5/'<"0M@$@ %5Z]1N*Y7+#(%>@V5Y!J%C;WMJ^^WN(EEB?:5W*PR#@\C@]#
M0U8=R>BN!U+XGV]GXTC\/6VG?:5-U#:270N0 LCN%;  .=NX Y(.X,,#&3VN
MH:A::5837U].L%M"NZ21NP_F23P .22 *+/8+EFBN-\">/&\:2ZA&^F"Q:S2
M%CBX\W=YF_C[JXQL_'-1WWQ!<^*)/#^A:++JUY 6$S+<)&B[0I.&Y'!)4[MN
M&&.2:+,5SMJ*X[P]X]35O$$^@:CIDNEZI$7Q%)*K*VT*< \$L02P !!5=V<5
M8\.>,UUK7-1T*]L'L-4L68M%N9TD12 75BJG&64C(&592,Y."S0[G4T444@"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X6Z^(_F
M^)GT#0=%N-4O(7D28F40JI3 8@D'Y0<J2VT9  W;A32;"YW5%<+;?$8P>)H]
M!U_0[C2[J=XTA991.I+Y )( X)PH*[ADG.W::[JAJP!1112 **** "BBB@ H
MK,UN]U2QM8I-*TC^TYFE"O%]I6'8FTG=EN#R ,?[6>U7+*6>>QMY;JW^S7#Q
M*TL&\/Y3$9*[AP<'C(ZXH GHHKFO&WBW_A#]*M;W[%]K\^Z%OL\WR]N4=LYP
M<_<QCWII7=D#=CI:*HZ-J']KZ'I^I>5Y7VRVCN/+W;MF]0V,X&<9ZXKGO%_C
M^S\*W4-@MG<7VI3HKQ6\0(!#/M W8)+$AL!0Q)7!QD&DM=@>AU]%<#JOQ"U3
MPZUM)KWA*XM;29F7S8;Q)CD*2   !D^A8<;B,X(KM[*\@U"PM[VU??;W$2RQ
M.5*[E89!P>1P>AIM6"Y/1112 **** "BBB@ HHHH **** "BBB@ HHKS?PY\
M3-7\50O)I/A+SS$B/*O]I(NS?G'WD&?NGIZ4TFQ7/2**X*U^(\L7BV'P_KFA
M2Z7--M5'\_SLLY 3HH!4G(W G!&#T8J^V\=ZOJ6KZK8:3X7^V'3;AH)7_M!(
M^C,H.&7OL/ SBGRL+H[JBN N_B5/H6J06GB;P[<:9'.F])8YUN/X@"<*!D '
M)P2P^7Y3N%:'C'QP?"^FZ?J-KI\>I6=Z2J3I=JB;BNY,'#;@RACD<?+[BERN
M]@NC5\5Z?JFJ^&[FST:\^QW\C1F.?S6CV@2*S?,H)&5##\<5YHGPCU^_U9)]
M8U:VDBE<&YG29Y)RH&.-RX)P ,D\#G!Q@^D2>+M+B\'+XG9I#8-"LFU 'D#,
M0HC(4D;]QVGG .<D $U%X.\1W?BG23J<NF1V5J[%8"+GS6DVDJY(VC: PP.Y
M(/ &"6I-+0&DV;=E9P:=86]C:IY=O;1+#$FXMM10 !D\G@=ZGJKJ6I6>CZ=/
MJ&H7"6]K NZ21^@[ 8ZDDX  Y)( Y-<_X9\7S:UX9N/$&HZ='INGQ([JRW)G
M9E3=YC8" @ J0.I)!X'&9L,ZJBN!TOXAZGXBDNGT#PI/>6L#*IEFO$A.XJ"5
M((*Y'H&/!4G&X58\/?$O3=734$OK6XTRZT^WDN;J.12ZK'&Q#X(&=R_+E2H.
M3@;L$TW%BN=M17GGA'XJ0^)]>ATJ?3!8R31L487!ES( &V8"#'R[CDD?=QU(
MKT.AJSLQIW"BN2\:^.K;P@EJ@@2\O)VR;;SO+9(\'YR=I_B  !QG)Q]TUHQ^
M)[9?!,'B>\C\B"2QCO&B#@D%T#"-2=H+$D*.F21ZT687-RBO-_\ A:=T--&L
MMX7N1HANO(^V?:!G&[&[;M_#KMW?+NS7<:'K-IX@T:VU2Q\S[/<*2!(NUE()
M5E(]001QD<<$CFAIH2=S0HK@?&OQ/M_"6J'3X=.^WS1P>;.1<B,1D_=3@,=Q
M R<@8!4\YX[ZAIH845PEE\3+;4?'D7AVSLDGM997CCOTN.&VQ,Y(7;R-RE0<
MX/4'%:'B_P <VWA6:ULTLY;_ %&Z&8K:)P#]X*-W5ANR=N%.XJ1Q19WL*ZW.
MKHK@Y_B+<Z/K%K8^)/#TNEQW0'EW NTE098*2QX4*N26.20,<<BM/4?&:Z/X
MSM-"U&P>.WOE46MZC,ZN[$*$9=HP=W!P6QN0G 8[2S"YU-%%%(84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9'BC0(O$_AR[T>:=X%G"D2H 2K(X=3@]1N49'&1GD=:\
M_P##=[XN\"6RZ/J'ARYU&P,[F"2R_>&)-V7/R@Y!+;E#[3R1G'"]WXQM-5OO
M"E];Z'*T6HD(T+)*8F.UU9E##H2H(&2!SR0,FN.\(?$:WL=).F>+9[JUU.T(
M4O<PN7E1OF7< NY6"D [ADC#9))Q:O;N2]S@;WQ=I=M\28O%.CV%PMHK+<3)
M+%'\S,"DQC"-C)0[@6/+L2>*[+Q[J^IZUX]T[PKH&HW=E/&/+N)K>=H\-( Y
M)7*AO+C7>.3G>0,&N.\16.J>+M2USQ=IFGW":2$2X9KO$?[M(UC<+R58C8[$
M GA3W(!Z/X+:")KV\UJY#S_8U6UM99&5]K%?F SE@5C\M0>!M<CGLY6W$K[$
M/B.;7]6^+MYX?T[7KZR26XB$86ZD6.,"V21CM4C/ 8[> 3U(R35Z\O\ 4_!?
MQ3TO3EUG4]2L;L0HT-W<%L+,YBYSD$JR[\@ X^7N285_Y./;_KO_ .V%'Q"_
MY+)X<^NG_P#I6]#ZKR&OU-+4=>U/QG\0QX:TB^N+'3-/E?[5<VDACD<H-KYS
M@X#GRP!D9._Y@!B'5=7U/X:^,+8W>IWNH:!?1KO>_F,C1!6PY7&3E-P;A0&#
M;>2 1!<6TOPY^)TFM7",VB:M+*&N""[(93YCKQC!$@R!@Y0'&Y@<1>),?%;Q
M?9Z9I.9-'L8O])NPIC*K(P\P@MGDJ@" KG<&ZJ,@?X?U^H&G\1+_ %3PKXMT
MC7;:_P!2_LV9P+JUC9GBRA&X ,VP,\9("X7E"P.<D'Q!US4-2\1>'] \/ZG=
MVXO469KFR^9725MJ2 H<LJJLCD9"X(.>,CI?B1H4FO>"[J.WA\V\M66ZMU!;
M)9/O !?O,4+J!@Y+#IU'G'P?TU]3\77&J7+QS?V;:HJ')5E9E\J+ 48($4;J
M<^H/)Y"Z7#K8V/&.HZCIGQ3\.Z99ZE?Q61CL$:$74A#@W+J=V3\Q*@ DY)[Y
MJ=X-275+Z?QCX^@L_L\.?L>CWIC=3R^-F,X"G@;6=@1SP-V)\58[Z7XH:5'I
MDR0Z@]M9K;2R#*I*;F38QX/ .#T/T-0^#[[PQH\.I3>,=/G;6E8OLOH'=I%=
M5;!5^!)N!.YP#\X^;!.*M^@C;^%WB35+GQ7J.BW&J2ZE8^3+/%/<;BY*2(@9
M=Q)565LE3G!QT.[-7X@?\EG\._2P_P#2MZH_"(.?B'?M);16T@L[D2V\49C2
M%S/%N15/*@'( [8J]\0/^2S^'?I8?^E;TGO(:V1[+7D&G>'?$OPQUFZFT>QE
MUC0WC1&1<&5QDA!A06#J6Y*J5*DD@?P>OUY!X7\4:SX*UFXTCQO->-!+_J;N
M4M*@=!\Q1B"SHP9.GW3@%06;$QV&S/\ '&M:)XO\BQNM/&C:TH2*XN-31T6)
M&P3'N3)Y+ AI$"A2Y^4D4FOR?V/X6MVC^(-_>ZX^#)#:7[R0L,@,%93E"H8$
M,Q^;:<*,_*SXCZY#XRNK:30K>]N;?2HYC<3K WEXD",&]5 \MP2P7H<9'-1>
M+M4\'2>$+>R\-:7#YID2:XEEM6:6U3>#@RMD[C(R)G++@E<C*UHEL0WN>J^
M]9O-?\%Z?J-^R-=2>8DCHNT-LD9 V.F2%!.,#). !Q7DW@ :UXHAU">^\7:I
M9VME8+(]PU_)A';)5F!."@".6Y4].>N/2OA4I7X<:8#_ '[@_P#D>2N$^"=E
M;ZEIGB*QNX_,MKFSMH94W$;D83!AD<C@GI6:TB6]RQX(M/$?C:VO+NY\2:Q:
M6MM$+:T9;@%B_+#S-NW>4!7<Q4%]P^88Q7;> /\ A+(M.N+7Q5 X>,H;>:2>
M.1F4K@H=F22I7.YB2V_VKA_!'B0?#_\ M?0O$<,L)C8W$!C@;,[C,;;2V,JW
MEKL; !PV2.*ZOX8:CXHU;2[J]\17#2Q-Y2VI>W$1?Y=S. % 9&#)@@GHW3NY
M7%$PM*U?4_B7XPN3::G>Z?H%C&VQ["8QM*&;"%LX.7VEN5(4+MX)),VG:]J?
M@SXAMX:U>^N+W3;^5#:W-W(9)%WC:F,9."X\L@X&1O\ E!.<WPUCX4^+KS2]
M6W1Z/>Q'[-=E3(66-CY9)7'(5R& 7.XKT4Y,MM;2_$;XGIK5NI71-)EB5;@#
M8SF(^8J\YR3(V2,#"$9VL1EOKV!$7Q-O]:/Q#LM(TS5KRS%W9VR(D5W)"GF/
M-*H)V],_*"0,X%9_B(^*/#OBZW\.6?BJ_N)+^U@02SRL &E<QGJ6*_,A(9?F
M4-@$D9-[X@?\EK\/?[NG_P#I7)3O'O\ R6SP]_N6'_I5)1?\@_S"_N]<\)_$
M;0]$A\0ZC=I<QVAN6NI/,63?.4<*K9V@A..2PR?FKN?':Z^VEH='UC3M*MP&
M%U<7DIB/S85%5\';DL>>&SMP>N>&\>?\EO\ #W_7*Q_]*I*N?%B+4!KVD75X
MEQ<>&8@CSP0JV%<28<L1@ LCJJ9;KNQC))-VO0.AC>*[\Z##I_\ 8WCS4M1U
M!2K7"K<M)$>"0X()4#<F#&Q8D,,\=?8/#VH3:MX:TK4KA46:[LX9Y%C!"AG0
M,<9).,GUKQ'Q[J'ABXM=+L_#%A;"VMF FO%M65]Y5A''YC?,<JLC'=G)53DD
M&O9?!@*^!O#ZGJ--M@?^_2TI] CU&>-_^1 \1_\ 8+N?_135YW\,/%VA>'O#
MMW:ZI??9YI+UI57RG?*F.,9RJD=5/Y5Z)XW_ .1 \1_]@NY_]%-7+?!;_D4K
M_P#["+?^BHJ-.77N/J8#B;XA_%*QU33K2XCTG3Y(E-XR91A YESSC!8LJA<E
M@"&(Z@;WP4_Y$V[_ .O]O_145>D5XY\+O%^A>'O#$]KJE]]GFDNS*J^2[Y4Q
MQC.54CJI_*C62T\OU%LS6^-L<7_"-Z5*8D,O]H"(.5&X(T4A90>N"44D=]H]
M*/$VDV^M?!W2]2O[LK>6.G0W27,I#/,YB&8V9N3YA('7);8><8./XSUNY^(U
M_;:!X7LS=6UO*LSWCHRJLA1P"W'R(%+\D98C"C@;JNO"7Q7K^E^ =#G<:;I"
MB!IY[<LPDA4H\C$=0J_*.$#.Q&<%2&M+>0=Q/AI:-XG\8OJ>M:E)=76FPQM!
M%<%7:4#*J>><1\'(&=[JQ.<[O<*\8\=>'9? VLZ7XD\,6:06\"A''EETBD V
M@OEB<2*Q4D8Y&=VYP:]7T/6;3Q#HUMJMCYGV>X4E1(NUE()5E(]001QD<<$C
MFIEW&NQYAK<_]O?'G3=-G,\4&GO&L867(9UC-SN (PNX[%;N0@YZ8Z?XE>"9
M?%NFP7%G(?MUBLOE0$@+,K[=RY/1OD7!SCJ#UR.1U@_V'^T!9WEU\\=Y+"\2
MP\L!+$;5=V<?Q@DXS\OOQ74?$V#Q3Y&FW_AJ:[7[,[B>.T9BY+%-C&,<2*"I
MR"#][IC<0^N@NA2C\;ZKI>FRV/C7PQ>20Q0^3=7D<*O%.6P &'$>&#8.&(W<
M8&<#A_$-]X8NK&TT?P1:3QW6H2PM>1/-*I+*"(86WG8V7E8Y#$ H.O!'HL/Q
M=\-MH<5],TZW3*I>SB0NRG.#ASA"!USD9';/%>8?#+PU#XB\00VUZK3V-K;&
M6X(#;9#C:BEP1M))+#GGRR/7%)65WH)ZZ&QJ^D1_#;QYX<OE*&U$,1FN&C 5
MF5?)N'6-/F!V,'YSEG/+<BO;KZU^W:?<VGGSV_GQ-%YUN^R2/<"-R-V89R#Z
MUYMXZ^'FB6'A"]O]'T]XKJT G.VX8AHP?WF=Y(P$W-Q@Y48]#O?"_6/[6\$6
ML9B\M]./V$X7"L$5=A')S\A3/3Y@W&,5$MDT4NQY;\5?".E>$K#2X-,6;,UM
M="6263)?;Y>W@848W$< <=<U[W>Z?9:E"L5_9V]U&K;U2>)7 ;!&0".N"?S-
M>0_'S_5Z/_U[WG_M&O1?&>J:[H^BQW>@:<M_<?:%26,QM(5C(/S!5()^;8.,
MX!)Z D-W=A+2YPOQ$O=?71%TV30AI/AR*Z$#S6[1S;XE<"(A!CRU^4$*<<[%
MW#H;U[XUCTCX9:%%H4T\^IWMLEI9,;0[MT>V.1BF2 P/  +98KC<N35#7?B-
MI^O_  [2Q2%+C6]02.WDM/LS,BR%@"Z<G/(S'@LVXID=<:6C_"NWGTC29M9N
M+NUU2TBVXLYEQ'^^DE3DJ?G!DZ@XR./4O32X>AYX?#+^%/''A6RE9_/F;3[B
M:)MN(7:X(*+M)& % SDY.3T( ]IU[P-I/B76;?4=4DO)E@A,*VHFVPX))+8
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M#/0X/RG!]!7(:E'XF\.>#-!\0MXJU*::_N%(A-S)(JH\9DC)+'YCA#N!&#O
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M2YD99" 1$!A&7^(%I%;D\%!^'::KX1MM3\#CPO\ :IXX$@AACG.&<&(J4+<
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MD]2:]<O/#.C:AK=MK-W8I-?VRJL,KLQ"[22ORYVY!8D'&0<'L*\N;_DY!/\
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MARV\+:##IEN_FLI+S3E IED/5B!^ &<D*JC)QFMFBG< HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% ''_$+P2GC+1XTA*+J%N2+=Y)&6/:Y42*V <@@9'&<J.0"<
M]-IIOSIT/]J);)?;<3"U=FC)]5W '!ZX/3.,G&3:HHN 4444 %%%% !1110
M4444 %%%% !1110 5Q/ASP7=VWB[4?%.NS6\VH7#L((H0'2!2  =Q126" ("
M /EW9R6X[:BBX!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*QO .B:QX;\/+I&J"P*0,S026DKL3O9G8,&4=&)P1U!Q@8R>JHHOI8 HHHH
M**** "BBB@ HHHH **** "BBB@ KB?$/@N[\4^,K&]U*:W&AV" QVP =YFR&
M8."F K84$9;A.,%CCMJ*+@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445RGB_XA:+X,N+
M&TO$N[S4+UPL%C81B6=@3@-M)'!/RCG)/0'!P =717G'_"\/!?\ PB_]M_:I
M]WG>3_9VQ?M>[/\ <W8VXYW;MO;.[Y:DMOC1X1ETK5+RZDN]/N--<I+I][$(
M[IVZ81-QW'.01GY2/FVCF@#T.BO/-'^-'A'4WNTNY+O1WM[=;G;JD0B,L97<
M#'M9MQ*E2!U8,"H/.#PY\9?#/B/6;/3%@U+3Y;U"UI)?PK''.=Q7:C!CDDA@
M.Q*D9S@$ ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,I!63/'M7JE>/^'O^3H?%G_8*3_T&UH ]@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5X_P"'O^3H?%G_ &"D_P#0;6O8*\?\/?\ )T/B
MS_L%)_Z#:T >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >?_P#-PO\ W*G_ +=UZ!7G_P#S<+_W*G_MW7H%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/^
M'O\ DZ'Q9_V"D_\ 0;6O8*\?\/?\G0^+/^P4G_H-K0![!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116?K>J_P!B
M://J'V"^O_)V_P"C6$/FS/E@ORKD9QG)]@: ./\ ^;A?^Y4_]NZ] KR?PYK_
M /PD?QUDO/[(U72]GAHQ>3J=MY$C8N0=P7)RO.,^H/I7K% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/^'O^3H?%G_8*3_T
M&UKV"O'_  ]_R=#XL_[!2?\ H-K0![!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &/?>+/#>F7DEG?^(-*M+J/&^&>]CC=<@$94G(R
M"#^-2:;XET'6;AK?2];TV^G5-[1VMTDK!<@9(4DXR1S[BN?^(/AK0;GPAXDU
M2?1--EU :9<.+M[5&E#+"=IWD9R,#!SQ@4?#[PUH-MX0\-ZI!HFFQ:@=,MW-
MVEJBREFA&X[P,Y.3DYYR: .THHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_\ YN%_[E3_ -NZ] KS_P#Y
MN%_[E3_V[KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O'_  ]_R=#XL_[!2?\ H-K7L%>/^'O^3H?%G_8*3_T&UH ]@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_'?_)//$W_
M &"KK_T4U'@3_DGGAG_L%6O_ **6CQW_ ,D\\3?]@JZ_]%-1X$_Y)YX9_P"P
M5:_^BEH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** //_ /FX7_N5/_;NO0*\_P#^;A?^Y4_]NZ] H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***Y#XC>.?^%?^'8-6_L[[?YMTMOY7G^5C
M*NV<[6_N=,=Z .OHKQBR^-WB34[..\L/AAJMW:R9V30322(V"0<,(,'!!'X5
M8'Q?\7D@?\*FUP?C+_\ &* /7Z*** "BBB@ HHHH *\?\/?\G0^+/^P4G_H-
MK7L%>/\ A[_DZ'Q9_P!@I/\ T&UH ]@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O$/'WPM\&Z)_PB_P#9VC>3]N\06EE<?Z5,V^%]VY?F
M<XS@<C!]Z]OKS_XI_P#,E?\ 8UV/_L] !JG@GP[X.^'GC#^P-/\ L?VK2I_.
M_?22;ML4FW[['&-QZ>M=!X$_Y)YX9_[!5K_Z*6CQW_R3SQ-_V"KK_P!%-1X$
M_P"2>>&?^P5:_P#HI: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \X\5^$/&_B;QG;R0^*/[(\,PX'EZ=<217+C +E
ML#:6+# ).%&#@G(/B6D_%?QGH.CZU:PZK/J<)E1(-3FW3>1)NR"K2J<JZ(^$
M8 ]Q@A@>V^/'Q'N[:[D\&Z3-Y*&)3J,RY#G<,B(<<*5*DD9SNV\88'$U72?"
M>I_#$^'? %V^L:Q:3Q:A?%;*83W2C,1*@IT4S#"9X7<>3DD CB\4^*_AWJWA
M'5M2UK5=2T_5K".YNX[F=[B)D=R2L>_ $BQ^4>O#'J5;!^G:^3II[WXJ7O@?
MPUI@D$>GZ;'!=!8]PM"K[))6)"Y!C2)L9QDA0=QY^@=;\ _VWK$^H_\ "6^*
M[#SMO^C6&I>5"F%"_*NTXSC)]R: ,_\ YN%_[E3_ -NZ] KR?PYH'_".?'62
MS_M?5=4W^&C+YVIW/GR+FY VAL#"\9QZD^M>L4 %%%% !1110 4444 %%%%
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M2)3P?;T]:@\1?#3X3>$=1BL=;\3:Y:W4D8F1,"3*$D Y2 CJI_*@#Z&HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'G__ #<+_P!RI_[=UZ!7G_\ S<+_ -RI_P"W=>@4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_A<_!#Q1KL.DP>';ZRN9^(6O;F5$D?L@*S-\Q[9QGIU(! /H>BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >?_\ -PO_ '*G_MW7H%>?_P#-PO\ W*G_
M +=UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!Y!\1?BSK'A_Q=_PCOAFPL;NXM[1[F\:Z#_+MC,I
M&Y1Q&N[.3G< .1@\9+\7?B'JJ:-')+HWAZUU5V:VU-H&\IPK,C*S,9 HW#!^
M4$?*20IR>I^)_A73-.\=Z?XQNM;T[3K.X3R-3M[IY/-N8L"*3RE4,S$Q/L.T
M+MP&SDDCS/PWX/TKQ%KMEX?/CS2I-'CNY)HD6*6">3?L0A!+&%\Q]D8V[VQR
M0&P<@'UK1110 4444 %%%% !7C_A[_DZ'Q9_V"D_]!M:]@KQ_P /?\G0^+/^
MP4G_ *#:T >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 8?B4>*OL\#>%I-&$X<B9-42
M4J5QP5:,Y!![$'.>HQSP>@>)/BGXC_M3[''X-3^S=0ET^;SENANDCQN*X)RO
M(P3@^U>L5Y_\+/\ F=?^QKOO_9* /0*KW]];Z9IUS?WDGEVMK$TTS[2=J*"6
M.!R< 'I5BN+U: ^,?%G]A2Q1OH.CO%<:BLBR8N[AE+1P=D9$!25@2P),8QUH
M L>#M*N97N/%6M6T<6M:JB%8L.6L;;:-EM\_((.6? 4%V/' KK*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP=-I.I67A*QU*+[.\;W=QJ*Q^;.7W[>4)&%"D 8 &<]22?4Z "BBB@ HHHH
M\_\ ^;A?^Y4_]NZ] KS_ /YN%_[E3_V[KT"@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KE/B'J'A73?"TDOC"VCN-.=S''$T!D9I2C8"8^ZY 8!LKCU%=77.>-?
M!>F^.]&BTO5)[J&"*X6X5K5U5MP5EQ\RL,88]O2@#Y[UG2?".N6=C>>$?AOX
MR>V;?OF@=U23D 88K.&P0PXVX]^UW2?"'QD6ZL7TR76=/TX/&;:.\U=66WBR
M-HDCW<A5QE?+[$;>U=U_PSCX/_Z"6N?]_P"'_P"-4H_9R\( @_VEKG'_ $WB
M_P#C5 'K]%%% !1110 4444 %>/^'O\ DZ'Q9_V"D_\ 0;6O8*\?\/?\G0^+
M/^P4G_H-K0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!E^(]?L?"WA^\UK4FD%I:H&
M?RTW,Q)"JH'J6('.!SR0.:\$\)>-=+\1WFH>$1)/9P^)/$LUY/+-\@:T<!O(
MW+("))"BQD#(Q(<9.!7J_P 7M-M]3^%^M)<WGV18(A<(YD*JSH050C< VX_*
M <_,RD D"O(/ /P2\76_BW3M3UB&#3+73[N*Y(>9)7EV-NVJ$)'50"6(QNR-
MV,4 ?2<$$-K;Q6]O%'#!$@2..-0JHH&  !P !VJ2BB@ HHHH **** "BBB@
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M3FO3Z "BBB@ HHK/UO6].\.://JVK7'V>Q@V^9+L9]NY@HX4$GD@<"@#C_\
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M_ACP];^&=#AT^%O-F_UEU=,#ONIV_P!9,Y))+,>>2<<#H!6Q0 4444 %%%%
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M))Y- %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>I_=9VO]WIO]A4D>E:X/%DVHR^))&T<IB+25LXE"MM RTO+L,[FP,<D<X&"
M;E%8^CZ=K-EJ.J3:GKW]HVMQ+OL[?[&D/V1,L=FY3F3@J,G^[[UL4 %%%% !
M1110 445SGC>^\2Z9X;DO?"MC:WU_ X=[>X5F+Q '=L"D$OG! SR <9.!0!X
MK\3XK/6/CC9:1XIU_P G0#"HC\B8 V>Z,\/E2$9I "20?D922 !B\/A9\( 0
M1X\YS_T&+3_XBJ\GBSX4>*M<NKOQMX;OM*ULY6[,\D[('3"!/W;!MVT#.8UQ
M@CKUCU&]^ %C;K+;:9=Z@Y<+Y5JUVK 8/S?O'08XQUSR..M 'T76!XU\-?\
M"8>$;[0?M?V3[5L_?^7YFW:ZO]W(SG;CKWK'\$^(/&?B/4+F\UOPY!HFB&+_
M $6&9F-TTF0#N!QA>&/**?F7&1DUV] 'EE_\%+'4?AYI'AF?59!>:4\K6VH+
M!@8DD+N&BW8((P/O9RH.<9!J+\ ]+N[+69=:UB>_UO496F744A\D0.3N)$08
MJV6)SD].%VGFO7J* /(=-^ >F-/=3^)-8GUB22TCM;=HH?LOD*B!%;Y6.Y@J
MJ!GC@Y#$\/\ #/P/BT?7M)U'5=?DU2+2$Q96ZVH@",)&D4LP<E@'=FQZD9.!
MM/K=% !7C_A[_DZ'Q9_V"D_]!M:]@KQ_P]_R=#XL_P"P4G_H-K0![!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17
MD_Q%'COPMH.L>);/QUFUAE#PV']D0?(CRJJIYAR3M##DCG'O7:>&M$\2:9<3
MRZ]XNDUM&0+%$-/AMEC.>6.W)8] .0!SP>, '2445Y7JNJWWQ4U2X\.>'+F2
MV\*V[^7J^LQ'FZ/>W@/0@C[S="#_ '2!( 2:CXG\0?$#4;[1/ <\%II%O^XO
MO$,FX_.2-RVV/O,%S\WOD%?D9N@T[X6^"M.TZQLQX>L;G['RLUS"LDDK8()D
M;'SYW$X/R@XP!M7'2:5I5CHFEV^F:9;1VUG;ILBB0<*/YDDY))Y)))Y-7* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** *FJVDVH:/>V5O=O:37%O)%'<QYW0LRD!Q
M@@Y!.>HZ=:^27\'^+M#DL+27P)=7-WI]\UU)*+-KF*Y5EB*Q.4!#(-C9 8_Z
MQAP<Y]^^(&@WT^L66N1_$9_"MK"J0K%(V()90S."0TBHQ(XVD'(7G(KRM_BU
MXO\ #LMU)+XU\-Z])%F(6BVDQ#-N +(Z0QJ<<\[]I&<9.* /0?@5X1USPOX=
MU"76DGM?MTR206,A'[M0GW\ G:S;@"I 8>6,]L>K5PGPQ\9Z]XQTJ>;7?#\F
MF/$L;Q7 C=(KM7W$-&''0 +R&;.[/&<5W= !1110!EZ;X;T+1[AKC2]$TVQG
M9-C26MJD3%<@X)4 XR!Q["M2BHYYX;:%IKB6.*)?O/(P51VZF@#RCXK6\9\0
MV-[<0RRV5K!&;X12;6-L\C1R*.1G<&"X!_B],UXY<^/]7\-^*K*"R?[7;>&;
MN\@TO^THG\P0N/+V2#Y6^55X! *DXZ  >[>,IM+U2?6$-S;SQ-H3B/9,#NF5
M]Z*"#RVX*<=Z^;-2LGU+4IKV2%A)*V^0^:6,C?Q.Q8D[F.6/.,DXP.*]7"8.
MIC:7)"27*^KMOV_&YJU*5-<J;:OLKGHVL>/OBC%#8ZT-5BTO3-:N3_9\%PEJ
M"D;$D<NH8HH*_O& &"ISAAG%\<>-?'MMHTWAOQ1=VE[!JUM#=12JD1Q$)-RM
M&\)"D,4[YX QC->?:GILUC/'F"5(ID#Q,Z8#CE3CKD;E89]NW2O0-)\+>%+C
MX*ZGJLDT4_B>*4/L\UTEMH_.C3&S=AU(.=^W'[S'5:CZI5G5="%-7NE=<UM[
M7NWL_-?<8RER[Z%G6/C7XIUKP"EDIGM;^.[1+G4[(&(&/9E%)&<2.RR,=NP8
M3 !!8!GP3FLY_%<<_B2Z4Z5H]N[V+7TY%O:W+NI&W<=H<@2,!W*%ARN1[QH7
MPK\&^'X'BM='CG,L @G:[=IA. 5;+(Q*9+(K<*,$<8KE?!_AIKOX7:$NDZ%X
M;N9?,G>5]6@+@?O"N0%4DL0J@L3T0#GC'-2I4Y-.3?+I?YWV^[_@%Q@Y1;7]
M?U8[+_A+O VBV]S/;ZSHL*RS&:9;.6-GED8@%RL>69CQDX)XYZ50O?BKX5^P
M7'V#6H?MGE-Y'GVL_E^9@[=V$SMSC..<5P?A+PQK=ZOB#[)H?@J=H-9N(7^W
MVCL(W7;E(\#B(9^4?6M70Y/B"WCOQ6EI_P (S_:"_8_MOF^?Y7,1V>7CG[N<
MY[]*]:>68>,I<DK\FKNTNWD]-11E!+WU?M;_ (89#<^/+CXFQM#)X6EU&30A
M(DB&<VS6QFX((Y+%OPQ7JNC_ -J_V5#_ &W]B_M'YO.^Q;O*^\=NW=S]W&<]
M\UR,)E;XWQF=$28^%P9$C<NJM]IY 8@$C/? ^@JAX@B\:Z%_97_%:^?]OU&&
MQ_Y!4*^7OS\W?.,=./K6.-M5Y()1C[J>S\^JOH.E!U'9R^__ (8\>^/#O??$
MB22"]^W0Q6\< 6.( 6S G,61]X[B6SV+[?X:L_#7[$/".KVE_P"!K#6GB\VZ
MFGN)XHIXH-@!V[EWX&UCE3D%AT)&?7_'-EJEA\*-9BU;5_[4N#)$RS?9E@VK
MYL>%VKP>03GW]JN?$73=?N-#U2]T_P 2?8=/ATV4SV/V&.7S\*Y;]X3E=RX7
MCIC-<V'H4ISBFUJ[:WM?3LKZW_S9J_9P7-:_]+T[AX"ENXK&TMK'P5:Z'HDL
M*SI/'?(YDRB[255=S.1MR6(.!R<\'A_#,T/ACX;^%?&B>0LEE]JM;R(RQ1/=
MVKS2,R(7'S2(R"14W+G#@<M7<?#K3=?M]#TN]U#Q)]NT^;38C!8_88XO(RJ%
M?W@.6VKE>>N<UQEII=YJ_P"S&EOIM@E[?A)7@C,*R,/](<.4# _/Y9?&/FY^
M7G%=%6E3IT*L;II3A\-^U3^;7]#GE)2FG%6_I>IK>%O%'A^'XI^/;N77=,2V
MN?[.\B9KN,)+M@8-M;.&P>#CI6K_ ,W"_P#<J?\ MW7RSX4NUL/%6G7DMD;V
MWMY?-N;<6ZS[X%!,OR,,']V'.3C&,Y&,CV.?XS>&8?BY+XC2#4I]/31SIJM'
M"H9W$^_> S#Y"OK@^H%>5+DY5RWO_5AZG3_$'QAH&C?%OP:]_J4<8TM+Q[W:
MC2& 2PA8]P4$Y)'3J 03@$&M"P\#Z1\1D_X2SQ99273WZ Z=;%S"+6S#,8@?
M*?YG=6WL2QP6P ,5\X>(K._U7Q#)JS0VD7]MW<ES%$M_#)Y7F/NVR$-^[QO
MRX7H>F#CZP^&\<%M\/\ 1[*'4EOY+6W2.=UNDN/+EP&:/>A(PN[:!GA0O7K5
M3H58*\HM+T%=&'XI.I>'O!^KZ!HO@^-=!M].EBCNDOXU"(8B7;RR-Q()8G)R
MQ!.<FL'3?!EQ\0=#T.V\0V6JV&DVVE0"W>WU.)H9F50%?R=A*N5=N>P&*])\
M:?\ (B>(?^P9<_\ HIJ/!?\ R(GA[_L&6W_HI:]&GB'3P5X))\UOP\]!MQ;M
MR]//_,\=\%?!S1?%7PVM[Q]2U*UN+W>Y2-T,(DC>1(V*%<M@9_BS\S $9JFG
M[/-YING:K=3W$>KW:I)%I]G;MY(<MA4F=V(P5RS^6."5 W$$@]Y\/O$FD^%_
M@[H5]K-W]FMY)9H5?RW?+F64@84$]%/Y5J_\+@\!_P#0=_\ )2?_ .(K7&X7
M%5<9.5.DY0C)I6B[63>GNV_!W,HRBHJ[/G31?AEXS/BF:T@TJ;[5I,T,ET+>
M_ABDBW?.A20L0&(&00#@XR.U?1'B&1I?B9\/9'A>%G6_9HI""R$P+P=I(R.G
M!(]S3-#^T_\ "Q_B+]B\G[7Y=CY/G9V;_L[;=V.<9QG'.*P-?_X3C_A8/@_[
M5_PCWV__ $W['Y7G>5_JAO\ ,SSTZ8[]:="A"G7<(V_AMZ[^]2O;T3?KW;+2
MYHWOU_4Z7XE?\RA_V,UE_P"SUE?%31[O3M U;Q18^)-?MKB/R=EK!?%+=<LD
M9P@&1P2>O4YJSXU_M/\ LWP5_;'V3[?_ ,)-:>;]CW>5UDQMW<],9SWS5SXP
M?\DKUG_MA_Z/CK3!3E"IA8KK*S\TY(F:^(9J?A5?#_@OQ/,=<US4VDTJX0#4
MKXS+&/+8G:N ,GCD@GCC&3E^F^&O^$A\">%?^)WK.F>1ID/_ "#+KR?,W1)]
M_@YQCCTR:D^(GBK1=*\/:OH][>^5?W>F3>3%Y3MNW(ZKR 0,D$<FH? /C7P]
M>:'X?T*WU#?J2V$41A\F0?,D0W#<5V\;3W[5A[7$O"^WUOS;VZ<OW%^RE?;2
MQB^!/#UWJ5_JMU=>*_$TG]DZY-:Q0MJ),<L<14@2 CYLYP<8!'I6MHEY!IWQ
M%^(U]=2>7;VT5C-*^"=J+;L2<#D\#M4WPU_YF_\ [&:]_P#9*/"__)5/'O\
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M*4:=HJ^RTL@BU;<U:***X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,_4]"TC6_*_M72K&_\ )SY?VJW279G&<;@<9P/R
M%5['PGX<TR\2[L/#^E6ES'G9-;V<<;KD8.& R,@D?C7CWQ9\=>(I_&5QX0\.
MZB^FQ6=D]Q=RI\DDC)$;@A9!E@-B@#&W)+ Y%>>:'\0/&GAX:9XAEU^^OK*>
M[DMI+2YNFE\Q8_*=Q\X8+D2* P^8?-^(!]>4444 %%%% !1110 5X_X>_P"3
MH?%G_8*3_P!!M:]@KQ_P]_R=#XL_[!2?^@VM 'L%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRP-Y;EBRA"VU5/&"G3H,8('6ZQ;W-K\1/AW#=WKWMPBZ@)+AXU0R-Y(R=J@
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MA\6?]@I/_0;6O8*\?\/?\G0^+/\ L%)_Z#:T >P4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO-/$'AB+0GM_%:>-M.U'5?MT=S=K9+"[1.S;FD13(!)A\87:N<Y.T X[C6?
MWA)?'7@NUL;%&T[4UO'E\NYD=9E6$,A#;CQSG(/-=<Z5*E*G.A4;7LYQ=D]X
MPE?>W>Z&ENJBL[K\S>^*.F:?I/PDUN#3;&VLX6:%VCMH5C4MYT8SA0!G '/M
M4_CGPO*VGZWX@@\3>([2:&SDGCM;6_,<"M'%P H&0"5R>>I-4/B+X?TOPW\'
MM<L])M?L]N\D,K)YC/EC-$"<L2>@%:?Q!\2-9:#K>EMH6LS"73IE6\@M@]N
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MCP7_ ,B)X>_[!EM_Z*6CQI_R(GB'_L&7/_HIJ/!?_(B>'O\ L&6W_HI:\_\
MY@?^W_T+^T87P?\ ^25Z-_VW_P#1\E4?!NL6&@:5XUU/4Y_(LX/$UWYDFQFV
M[FC4<*">I':KWP?_ .25Z-_VW_\ 1\E'PU_YF_\ [&:]_P#9*]#%.*K8OF5U
MS^GVWZ_DR([1#_A<'@/_ *#O_DI/_P#$5V5E>0:C86]]:R>9;W,2S1/@C<C
M$'!Y'![UQO\ S7;_ +EG_P!N:[FN#&T\/34/8IJZ3U:>_32*+BV]PHHHK@*"
MBBB@ HHHH ^9OB-J^@Z'^T"=1O\ 3)-2M8DB&H6MPB.CLT.T%%/! 0QMANK
M\@8(VA\4_A 2 / ?.?\ H#VG_P 77<>*=&^*UWXCNI_#7B;2K+2&V>1!<1J7
M7" -DF%NK;CU/7\*\\\4:]\7?!^M:3I^K^*]-2/4WV17:PP>2AW -O+1 J%W
M*2<8P>,X. #Z*HHHH **** "BBB@ KQ_P]_R=#XL_P"P4G_H-K7L%>/^'O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <AXR\ ^'?$WFZKJ.@
M_P!JZE;VI2WB^V20>9MW,L>58*,L2-Q'&?:OG#P+_P *T_X1_5_^$S%\-4R?
MLOD[_N[3CR]OR^9NS_K/E^Y_M5];7U[;Z;I]S?W<GEVUM$TTS[2=J*"6.!R<
M 'I7S[-XKU_QW?ZOK?AWX9^']3T^W?:;G4+!9;APJ\ G>-[X ^10Q *CG@D
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M$+V\*;KY=-B.=TB^0H5SG PK?NS@'J.>@)\[\9Z@/!GC6:PNEN7L7U^T\0P
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M8+G<2=H88( 7:4VD\UA6P,J.77G)<RE=QNKI-65U^AGS>_8F^#__ "2O1O\
MMO\ ^CY*A\ 7=M86WC*YO+B&WMT\37FZ69PBKDH!DG@<D"IO@_\ \DKT;_MO
M_P"CY*A\ 6EM?VWC*VO+>&XMW\37FZ*9 ZM@H1D'@\@&GB[>UQE_Y_\ VYA"
MWNW*?_"1:'_PNG[;_;.G?9/^$=\KS_M2;-_VC.W=G&<<XZXKTB&:*X@CFAD2
M6*10Z.C JRGD$$=017F__".Z'_PNG[%_8VG?9/\ A'?-\C[*FS?]HQNVXQG'
M&>N*](AABMX(X88TBBC4(B(H"JHX  '0 5QYAR?N^7^5&BY=;=Q]%%%>< 44
M44 %4]2U;3='MUN-4U"UL8&<(LMU,L2EB"<98@9P#Q[&KE9'B/POHWBW3DT_
M7+/[7:QRB94\UX\. 0#E"#T8_G0!Y?XIL[/7_$=UJ=A\;8-(M9MFRRM]0&R/
M"!3C$ZCD@GH.M8:>!?#.H:K8S^*/C#:Z[9VSEOLL]\H+ XRH=IV*@D+G R0.
MH."-CQEX8^#/@6-!J^CNUU*F^*SM[JX>5UR!G'F *.O+$9VG&2,5C^%D^!WB
MG54TZ#0[NPNY75($OKB9!,QSPK+*P!X PQ&20!DT ?0=%%% !1110 4444 %
M>/\ A[_DZ'Q9_P!@I/\ T&UKV"O'_#W_ "=#XL_[!2?^@VM 'L%%%% !1110
M 4444 %%%% !1110 4444 >"?%_XHZ;'X@TO1K*TDNY]"UB&^N9/-41NT0SY
M2D;CG+E6) VE<8/;JX_BCJGBW9;_  _\.3WK-M$VHZFODVEL3Y993@Y=E#D%
M5((QE0XKRCQQ\-M1U;XS:II'A^2"[DN_^)C+ON%!M5D8;_,X&,,^0H#-L93R
M:][^'/@Q? O@ZWTAI(Y;MG:>[ECW;7E;&<9[!0J]!G;G )- &'IWPK_M&\@U
M;Q[K$_B34H\,EN_[NS@;"9"Q# /*8)("L#\R9KT2""&UMXK>WBCA@B0)''&H
M544#   X  [5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]ZW\SD2C5?L^G3^O/\S(T+3=4^&WA[3?$>DM=:GH%W:Q7&KZ>Q!D@9D!,\6
M!@#@CT')(^9.?\->)O$LGPO73M!M9;33]-C<:EJBQEY5WSEB+< @%EC;<22,
M#/*84MT,_AJ_\7?#[3M+\.>(H)F>UM_[1@NK[>D("JRH$5&*G<O4D$;,<Y.,
M7X:Z9JWA?1)=<F33[_2=;3[&NFF8++//O:.,8=-I&=X(W8VL6(.W%>]3KTZF
M$G5K.+K<R:3ZVO:_2]G*U^RO<Y72DJUDGRWM]YA?#2SCM_&ML--U?48KN:22
M!%CLX\/ 5.68M+@, "VTJX!13A^E=-_PIWP]_P +!_L#[9JGV3^ROMN_S8]^
M_P W9C.S&,>V<]ZU/AOH<O@WX@7FC:NEN;ZXL!):W$<YVNF[YE52!DDC/(!'
ME''!S77?\UH_[E[_ -N*X\1G&+]M*4)_9W5M>VRZ7?XG55P]&,FH+2USQW4?
M%$_@KXAZ9IIOO[5TSPW<R1V\K -*L,J*LD60P!9!E1G&&&#@ */3?&FLZ;KM
MAX.OM*O8;NW;Q-9?/$V=IPQVL.JM@C(.",\BG^)?#NAO\2/"BMHVGLMXU\]T
M#:H?/81!@7X^8Y).3WKS/XK:(VG^-;<^&_#=UIZQM$JW=I;R(LUR0"HB*G;D
M +C: =V_.>#7?AZF&S"M1LG&<8O72SU=[[;MMZ=]CBG3E3C?>_\ PWZ'J_Q@
M_P"25ZS_ -L/_1\=:7B;QK%X7G*3Z%KEY"L'GR75C:"2&-<G(9BP ("Y/H"#
M7G'B^^UKQ1\(KCQ.=;\O3;F*'S=+%B@ D65(WQ)N+;?,4L,\XP#6UXI^'\\V
MEZUKOB/6O[9N+;2)UMQ]E%OY;*K.K?(V#@[N".<^U>7##TX4J=+$:VG--:[V
M@OP-5&+N^;HOU.FT#Q]%XAO;6"#PWXCMX;I2\=Y=6(2#;M+ EPQ&"!P>Y(JC
M\+YHKF#Q7/!*DL,OB.[>.2-@RNI"$$$<$$=ZX_4M(TGPC\)M/\3Z3I<RZW/8
M0H+R.:4^0TT6'D/S@+PS $#AF7BO,_"/B:_\+B]C1IDL-0B"7#V[%98R,[)4
M(8'<I).W(##(.,Y';2RRG7P]9X=\NJBDWNT[OKVM8FS<E:[75VV_,]GDUQ?#
M?BCXH:N60-;06#1>8I96D,!" @<X+E1VZ]1UJI\.M"?0O&UHMR9FU"]\/?;;
MUYPPD::2X!;<&)(8#"GIDKG&2:\P\'65QXY\?6]AJ%_+/:SRI<WAGG),RQ(<
M#E@6."5&,E0Q(X!KWG_FM'_<O?\ MQ6>:0^JP5"_O2C%R](Q44OOYG]QI1BN
M:5G>U_S/'?C'+I-CX]>WTVV^8^7<:G;EW6">;DKE!CYMC<LK<^8<8;<3ZHL6
MG?%.9;B3SFT"TBB,<:R;3)<N%D8-L<CY$(0C&09) #D9K@/B;<MI?BW[+-X?
MT':MRFH17"V($ETI)RLIW'<"VX-G&XKGC->Q>#='?0?!^EZ9+%'%-#"#*B=%
M=B68?>;)R3D@X)R0 , 99AC(2P5!1OSQ5DV^]KO\$EV6G0N-&=!>UO\ %L><
M^,X=9^'FBWECI<D-QX9U/? D5SEGLF=6W(AR#@C)!.>1R,Y+8=AXDU7Q?X0E
M\,2:$]\+>&""R:RMCF*0$*KRRLQ"#:I!^4;@6&5&37MGB'18/$.@7NDW!VI<
MQ[0^"=C#E6P",X8 XSSC%'A[18/#V@66DVYW);1[2^"-['EFP2<98DXSQG%>
M9'%P5.[C>=_Z9T1Q,53U5Y7_ *9XOX*\)ZY8Z'J>LS2V.EV,L$T%U/=V[3S1
M0QDF4"'[I!*%6#C/RG ]>(^&^NSZ!XP2ZL]&_M2XDB>..W4$R#(R2A )! ')
MP?EW#OFOJN\LK34;5[6^M8;FWDQOAGC#HV#D9!X/(!_"LV'PCX:MIXYX/#VD
MQ31,'CDCLHU9&!R""%R"#WKT,-G%*%&M3JQ;Y^VRMMYOS_X+.:M5E5JJ;2T_
MK<\BM/B?/?\ Q!@U:VT'?<7%FNF16OVP#<S2[@V\I@<G&"/?-=QX@U;39/B)
MX-F34+1HHOMOF.LRE4S$ ,G/&:H>(OA[J8\8S^*/#KV2R>3YAM)U!6>4_*Z8
MP %="<DG)8GIG<.6U/QSX;D\4:#=R^'IK1=.^T+J%H;6/)=D"A0,C=M8'[P4
M^V>*Y'&-5J5%?9=_N=D=KC&HTZ2Z/\F,^/TVDW3:%/;7$$MZ5E!\D(VZ'(P6
M8'. P8*,$$E^00<]GKW@KP?>>#;O7;+3]Y72?-M)O.F'R)!^Z.TMV55ZCMSW
MKR;XDIH.J>(8=3T:ZW175M&TEJHQ]F;:#MP!M'!&0&;#;\XKU3PWHLFA_ R\
MBDN9)C<:;<70#/N6-9(RP5>!@8P2/[Q;GFO2Q52$<OP].,WS1>JVWU?W=#CI
MT:U&?M'HF;/@'PKHNE:+IFL65EY5_=Z=%YTOFNV[<JLW!) R0#P*SO!6GZ?J
MGP5@LM59$L98+@32.5 C7S9#ORP(!7&X$]" >U:VA^(M*TCPGH%O?77E2MIE
MNX7RV;C8!G@'T-<SX);2?$/PQL_"D^HW-O<72RI(+7*2;?-=R Q4K@J,$=P2
M*\>-1\SE*35I1UZK?\BZC<H3OKJOU.<^#OB-;7P?J>C65YIUMK;7R26JZE+L
MBF\P(NU0#N9OD;@#JR^M:NC0^,[CQWXTA2/PW+=2+9I?I<+,8&4PD*$'4@KG
M=NK,\+_"WPU+'K^H7\.J:A'I.H75LEG%(,SI&HVC"@,7.>,, 3BN'\*CQCH7
MBZ:YT31[JSN RQW4!L)I4AB=@X5UVM($PHY'SD#@DU]5.CAL;4Q%7#SLY)?$
MK*]XO>]_L]NJU.-2G1M&4=OZ_4]>U[P]I$?Q$\"V[:'ID*W"WQN8(8$,;LL*
MD _*-P!S@D#UP*O^/[2VL+;P;;6=O#;VZ>)K/;%"@15R7)P!P.237G]Y\3)S
M\3?#\OB:PAL%T3S8;K[+*+C$LL>QVRI("@[?E&YEPPRQXK4\=:MX<GM/#^H6
MWC">\C.L6UQ,HO%=X(L,S2")1N0KZ;>,XQVK@^I8JG6PRE%OW7JM5JYM:K39
MH3J<REKU.D^-NK6EC\/+BPF?_2-0ECC@0$9^5U=F(SG: N,C/++ZU6\":MI$
M-K)XKUN^MI-<UW]\\L-M(!#"I\M85XZ*8R">Y R6P&/E>KDZW?W6LZ]::Q<V
M9"BP+WB0RI;EB4WAD<G<&!XP.21D$8Z?PU9ZU:^']?M]%O+G2-)MK.2[FM[D
M17;3R;"" XC78"J@<\\9 /.(K4Z-'+_JL:EJE]>VMKQ[Z6C?S1K"A.<E-V2?
MG^FYZ3KW_"-_$&RCT!]7O8UEE$A6T#1F3:"=K%D(*_Q8/=1Z5Q'P_P#!NFZ1
MX/C\:1:QJ=C?&VN$>2-1-%&-SH&:)4W.JX5\$XRN3P*ZG0;O4O#WAW3-=U_Q
M1YVCRVD6;;^R\^3O0%?GCR1@X&6&#G'4BL'PAX\T#2OAQ:Z1*KW^I[98AIB0
M.QG9Y6VIG:5((89Z\9X)XK@H5\52H2HTY-QNKI;=;[KTOT.CZJFF[7=UM\[G
M >&?#OA^'Q@ GB"&^2":$6<,^EEDU(L/FB(?(CY.W<P.,[ATJ6+P+XUL_'Y_
MLZ*ST_6 C:E&EK*$CB0N5PHY&W)*[3GC@Y%=5X-^'OBS1=8FU*&WTZ.^M-B0
MB^,AB/F1Y<J4.25#!>A4EFP<K7-77_"1:5XT4:U>:Y8!-@N+C[6TLL-FT@Y\
MU<A@">H&-W&,\5["S;$SJ2Y:BE[MM4G^"2^?Z&CP%"4K4WLN_4WM<^(%]I?C
M?PW-XOT:6TOM'-VTZV8#1SQS1A8WBW-Z@@\]NN<J,3X@6'CW6[276=2TR\LM
M"5EG2UGODD\DO@ E<@YRV -H*@X]2>8\8W!\0>,=6U3[7YT<]RWDOY>W,0.V
M/CC^ *.1GUYKJ/$WB;Q%)X=T[3[KQ!:7]E>643310&-VC9,861CF3?\ *C,2
M1EF8#@5U>THX?V%7#QBYI6=U+2]Y/E^;>YST\OK3GRU-$_3_ ()Z]\,M$U'0
MO"4-IJMO/:W<>8VMVE1X@ 20T>PD#<&^;/)8$XQC-G4D_L#QE9ZU&F+/5MFG
MZAL3[LN3]GE.U">I:(DL!\\?I61X=U#QQ_PB"ZQJ%QIMP)(C=KYZ8D$6W(&(
MP%Y W>OS8/M0\:>)F@\"WZ^(CICQZCIY^R6T",TID<#RV(;@!2=V<Y^0D9(K
MY>G*5;&N+5^=V:6VKZ7[/5>:,JD.2\;[&O\ !_\ Y)7HW_;?_P!'R4?#7_F;
M_P#L9KW_ -DKQ+2/%EU<>!6T.[AT%]/T@FXBBO1<B:9F9S\IB8 \N1SM'S+G
MU%7X=:IX9L?$+_\ "66RRV3KOCF97812J<C<JG#*PR""K<[>@S7T>)R6O+ZW
M-:WE>R5WOS??9[&4)T_=N_P_X)[O_P UV_[EG_VYKN:X.&:*Y^-\<\$J2PR^
M%P\<D;!E=3<Y!!'!!'>N\KYG'*SII_RHTCU"BBBN H**** "BBB@#YN^*H30
M/C?8ZYXEL)-4T&5(WB@+,5V*NUD&[Y25?]X4S@[AG&XUG_$#6M,^(GQ-T6+P
M/!(-2+HC:HBR1&5\@J^ -RB, DOC. >R*3Z=X[TSXF2ZU<3:/'HVM^'9615T
M6]BB8$!!EGWA<@2#<,29SMXQD# \(_%WP[H&H2Z7KO@]/"5ZRQBXDM;/8KL%
M)R\84.HY&T8?[_4#D@'N5%%% !1110 4444 %>/^'O\ DZ'Q9_V"D_\ 0;6O
M8*\?\/?\G0^+/^P4G_H-K0![!1110 4444 %%%% !1110 4444 %1SSPVMO+
M<7$L<,$2%Y))&"JB@9))/  '>I*\_P#C!K,MEX+;1K!\ZOKTJ:=9P@IE]Y ?
M.\\*5)4MV+KTSD %?X1I<:Q9ZSXXO7Q<>([O>D(8$0P0EHXT.%7YA\P)[@*>
M#FO2*IZ3IL.C:-8Z7;M(T%E;QV\;2$%BJ*%!. !G ]!5R@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,N;Q)H5MJ@TN?6M
M.BU!G5!:/=(LI9L;1L)SDY&!CG(JY>WUGIMG)>7]U!:6L>-\T\@1%R<#+'@<
MD#\:\)_:0\.<:3XHCDZ$6$J,W^](A48_ZZ9R?[N!UJI\7?B NO\ PS\+V]M.
MAGU=1=7BP2,@4Q_*R&,\E#+NP2<9BXSU ![[IVK:=K%NUQI>H6M] K[&EM9E
ME4-@'&5)&<$<>XJY7BOB;QN?@UX4\/\ A32[&UN=6%D))2\DABC8M\SXP"X=
M_-P-R[<#C&!6AX:^*>M1_$>?P7XSLM-M;MF$=O<6+$1[RNY0=['(<%=O0Y(!
M7)^4 ]*_MW2/[7_LC^U;'^T_^?/[0GG?=W?<SN^[STZ<U<GGAM;>2XN)4AAB
M0O))(P544#)))X  [U\V^)[K6+/]IV270;>"?4VDABA2X1VC&^U5&9PGS;55
MBQ(Z 9[5TNB_%#7?$4'C;P_XET;34N-.TB[D>. NJEHP4>-\.202W56&,''4
M$ 'L.F:[I&M>;_96JV-_Y./,^RW"2[,YQG:3C.#U]#6A7R]X$^)VG^#_  QX
MBO;70=.M=0EDMX;6WMYIB)6(E.]Q+*YV)C^''+ '&01W>E?$;XCKJ.@S:MX4
M@N-'U**.XDFTNSN)&AA<D!BREQN  ?: 3M('!/ !ZG-XDT*WU0:7/K6G1:@6
M5!:/=(LI9L;1L)SDY&!CG(K3KYB\8_\ )T-K_P!A33O_ $&&NGN/C7XDUO5M
M:C\(:7I4EAI-K+=L]X9&>>*-P#(O*;?E8-L(SP>2<"@#W:HYYX;6WDN+B5(8
M8D+R22,%5% R22>  .]<A\-/'L/C_P -?;6B2WU"V?RKNW5P0&QD.HSD(W.,
M]PPR<9/,?M!Z^NF^ H])1D\_5;A5*LK$^5&0[,I' (;RQSV8X'< 'HT?B30I
MM+EU2+6M.?3X7V2W:W2&)&XX9\X!^9>">X]:I_\ "=^#_P#H:]#_ /!C#_\
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MI?VL%U:R8WPSQAT;!R,J>#R ?PJ/3M)T[1[=K?2]/M;&!GWM%:PK$I; &<*
M,X Y]A0!\M>(]2E^("?#SPSHRQR/#IL<&""7CFSY<ADVEL(!"K],A3N/7 ^@
M=;\.^,K[6)[G2?'?]EV+[?+L_P"R(9_+PH!^=CDY()YZ9QVK<TWPWH6CW#7&
MEZ)IMC.R;&DM;5(F*Y!P2H!QD#CV%:E 'D_AS3M9TSXZR0ZYKW]M73>&BZW'
MV-+;:GVD )M0X.""<^_M7K%>?_\ -PO_ '*G_MW7H% !1110 4444 %%%% !
M1110 4444 %<_P"-O^10OO\ MG_Z,6N@J.>"&YA:&XBCEB;[R2*&4]^AH \4
MT+_D8=,_Z^XO_0Q4?_"HK_\ X3_SO^$K_P")CC^U/M?]G+_K?-S]S?C[W/IV
MQ7JNK:%81Z>]S9V5G;W5J1<Q2"-4&Y#NPQ!'!Q@Y.!G/:N6UKQ/;MJ4NH:?/
MAY]*$,><AD<R\@X^ZP7)_ =<C/9A,PQ&#YO82MS;Z)_FF3*"EN&A^#M-U>;4
M9/M$_P!CAN#! T<JLS[>K$[<$'((Q[_6L'Q) ^EZG-H\5U<R65N5:..63(!*
MAB<<#JQ[=Z]7T>R@T_1[2UMG62)(QB13D/GDL.3U))Z]ZJWOA;1M1O)+N[L_
M,GDQN;S7&<  < XZ 5QE&3\.I'?PY*K.S!+EE4$YVC:IP/3DD_C7753TW2[+
M2+=K>QA\J)GWE=Q;G &>2?05<H AN;2VO(Q'=6\4Z [@LJ!@#ZX/UK+U+P_I
MTFE7B6NE68N&@<1%8$4[BIQ@XXY[UM44 >0?\(3XB_Z!_P#Y&C_^*KU^BB@#
M#G\(:%<W$MQ-8[I97+NWG.,DG)/#5S&J?#RYEU*5]->TALSCRXY)'+#@9['O
MGO7H=% '+^#_  Y>>'_MOVN2!_/V;?*8G&W=G.0/45H>(]"_X2#3H[3[3]GV
M2B3=LW9P",8R/6MBB@#SP^')/!MY;:WY_P!MMH'(G54\ME##:",DY^]TX[>Y
M#;7QCI4>LZQ=3VUS);WPB58_+4\*A5@P+8YS[UUOBFRN-1\.7=I:1^9/)LVK
MN SAU)Y/'0&O+M0\,ZQI=J;F\LFCA! +AU;&>F<$X^M '7R^%-%F^)T,[Z=:
ME(M,\P0B%0AD\S <@<$@$CG/;T%7=5T?3%\5>'XETVS$;FX+((%PQ$?&1CG&
M3^=6XY$E\?+)&ZNCZ0&5E.009>"#3M6_Y&_P[_V\_P#HL54IRE:[V*<I.UWL
M0^+;2VL_!E_':V\4"$QL5B0*"=Z\X'TJC\3_  XGB#P=<2(J_;+ &YA;') '
MSKG!/*YX&,L%STJYXVO[/_A'+ZS^UP?:OW?[GS!O^^I^[UZ<UI:I=VUYX:U2
M2UN(IT%M*I:)PP!V'C(^M.G-TYJ<>@0FX24ET/$X_"WBW0O!ZWFFP3P>9&-0
MGO[/43%B#R\^5)&=I++@MD9^\0,U8^&&@ZWJICUB"Z4PZ5*8K.&YE?R@S@F3
M:%.5ZKD8PV[GH17M6A?\B]IG_7I%_P"@"LOP#;Q6O@G3X85VQKYF!DG_ ):,
M>]=D\=*=.46M7U.J6+<H.+6K.,\4S^(KNS3Q$D-D9O#=\V?LYE#LH*B08!(*
M$8SG'R@]LYGM+O7;_P")4%Y;/I3S7'A]98GQ*(VA:;(.#\P;)[]JZ?1X(KK2
M_$MO-;O<Q2W]TCP(P5I%*@%021@D<9R.O45Y+X#\8II_B^U%REW?(MG_ &58
M^6JB5PTX:/=N?:O7;PV  H[9HP\74I2MO&_W,*,74INVZ_4]-USSO^%@^!/M
M'E^?LO?,\O.W=Y*YQGG&:S?'5AK"2>'VGUI9!)KMLL2+:*HA8[L,.23CT)YI
M->U_S?'WA*X_LC54\C[9^[>VP\FZ(#Y1GG'>N$^)VLW%QK\-W9ZAJ4,)<.+.
M>5E-M/'@;E4<+P1@@[MV_IQET(<\Z:OT?YL=&'/."OT?YLV?B MQX9\)>(M!
MO[W[3%JFS4+*9P$S+]HC^T1!2Y[LL@"J!\\GI76?%S5M7TCP=.]A;V\ME<QR
MVMZ9$=GC61<*RX( '49/<KZUY!XO\6R3^"=.T+^U(M4>=A=W,TPE>>)P/N$R
M9"X)*@H1D(3T<YT$\<ZOXW\(3^&[F[M+<6FFR7%Q+(&::[\A=RJ"S'<QVJS'
M@\,>@(/T$<!6EAZ%=QT4W?T]U<UO^W?F]>IPKEA6E!]._P#7W%:'Q5XE\:Z)
MH_@&TBLHXIDBAW*I5FCB4'YF8G  4,=HR=N!UP>L\-_#"XL-*U74]1TK^T=4
MMY'BTZQ<A8970X$K;F7<A8=&QE03AMRTGP2T6UO;ZY\0+ YALK>*QM'E2($2
ME-TY^4;LAFPK'G8^WG&![)>PW$]G)':77V6=L;9O+#[>1GY3P>,C\:XLVQ?U
M>M]6I)66K\V]7^%D_1FL*[2E[/1.WX'S3IOPH\:VVI137GAQI[?.)D%]"K%3
MP2I\S[PSD9R,@9!&09[RR\:V?C2/2WO=4.LS(L,4HN7WO$3NX<'[@.2>< J?
M0U[/:)XBNM7U&P_X2+;]B\KY_L49W[UST[8_&I_L44GQ*M[JX2*2Y@T@A9!&
M!@F3!(SDC@L.O1B.]88C/*N*GSUHK16T3^6[96%J^P36Z?YG!Q>"-4TJZTG5
MM4^SWFJ/J,>)[N>5Y"V"(PVUL;055NI/ '3BNYU34O%6D:;+?7"Z,T46-PC$
MI;D@=R/6KGBG_F"_]A6#_P!FH\;?\BA??]L__1BUX]2K.H[S=R)U)3=Y,T-,
M_MC][_:OV'MY?V7?[YSN_#I[UH5@^)-.>6SNM0CU+4+9[>V=ECMY]B$J"P)&
M*IZ;X>>\TJSNI-=UH/- DC!;O@$J"<<>]9D&]J6EV6KVZV]]#YL2OO"[BO."
M,\$>IKDM$\*:/J$>K+/;-F*_F@B=9&!11C&.<'&>X-.T.)5\/6NOZEKFJJJ/
MND7[0S1G$A4 K@D@X&?K3_#/B+2H[B_MVNL2WFIR/ OEM\X<@*>G&?>@ _L>
M;_A*?[+_ +<UGR/L7VC=]K.[=OVXZ8QCVK(\5>!-.U7QQX<:X,CQ31/%>9?#
MSB) 4)(&2QZ,<YP!C&*ZO_FH7_<*_P#:M&K?\C?X=_[>?_18K2G5E3?-!V9<
M*DH.\223PAH+Z-%I*:;;QV44T<XC6)3ET(Y;(.XD+M8GD@D9YKS3QH-7^'6E
MW.F:8Z7'AS5EEBCCN%=VLF93N16R."&)7.>AXR"6[O7/[=L+BW>'7<17EZMN
MD?V1/W0<G')^]C'XUD^+_#OB'4O#>I6EY?6%[:JGGQRRQ;)8V0;LJ%7 )Y7J
M>">F36V'KN,USZQOK_F:T:W+-<^J..TGXEZ]8>"(YH'T$BQ:*SCM)-WVAXU3
M'F8\P9&=H^4'.6/ 6M_X,:MJ][I4FGR6]NND6"E(Y@CB1Y7<OC.=I !.>A&4
M]:V/#O@VSN-'MHM2T/09+.2R55EBM\7#9489GP/FQDD@YSR*Y71]/\2^"_"2
M:YX;FBOK26*22_L[S[L3(6S,F"O\*X(SGI][C;TNK1JQE""LV]+_ -?U<Z'4
MI5(RA%6;?4[3X??\S3_V,-W_ .R5'H?G?\+!\=_9_+\_99>7YF=N[R6QG'.,
MUYQX*^(6I6^IWL$D^E6-K>W4U_<W-Q$[^6[XX51(I89"C R1DGH#4?A[XEW]
MMXTO+^^_LVWBU.6$7TACD98TB4K^[VDG)&?49(Z"JGA*G-4\TOS7^0Y8:?-/
MT_5?Y$&K_".XA\5:587.HM/<:NUP[3/.6)9%WDLQ3.3GKSFLGQIX#\1V^HV$
M:Z#:VUJ##I=K+;O$OVN3G:[X;)=N3N(7@#(%3:]=:Z?%X"7>O6:JSS69U S+
M-:PL#O.,LVU5# L,Y"$GTK2\4?$.ZFO+&PL;BWU#3]*NH+JTO)8I%EF:->/-
MW-\QR2&.%R1D8SBO;P^8X^E.$N;GTZWLONMKT^\REEL9<J7;4[_QA+JTWP2N
M&UVV^SZJ(H5N4WH^7$R#=E/E^;&[ Z;L=JZ[Q=_R)>N_]@ZX_P#1;5RGC2XU
M.[^"UU<ZQ###?S1PR2Q1*RA,S(0N&Y! P"#WS3/C/I=I=>$(]0EE2*ZLI@(-
MQYD#D!D SUP W0G"'WKY])5)QOI>3VV6VWD33A\$&^K_ $*VOR74GPP\-Z78
MGS[K4K&&VCL1$CF8F)3O);[H3&=PZ$KDCJ,WX=>"=5LM,37+2>Q%Y).P1+B#
M=MC0LA(<KN7<=P(7&5(Y[5H_"'P;!8Z3'XBO;?-_<Y^S%P?W4/3(! P6Y.><
MJ1C&3GL?!/\ R*%C_P!M/_1C5%>K[/FHP>C>K'6J<G-2@^NIGC6/$OVG4H7_
M +&3^ST5YW99=N&4MD8Y. /2JO\ PDFA_P#";?VI]I7R?[.^S^=Y+YW>9NV]
M,XQSZ5<>-Y=2\9QQHSN]M$JJHR23"V !7G7]DZELW_V?=[-^S=Y+8W;MN.G7
M=QCUXKBN<AO:_I_@G6?$VEZLES;PK#,TE]$MJX^U#EE+#:03OX;(RP8\\"K_
M (IT?PQJ_@*^DTBSM8(X[B)C);6_DG>K <C S\LC 9R!NK82-XM2\&1R(R.E
MM*K*PP01"N016-XV\1WGVR^T/RX/LO[OY]IW]%?KG'7VK;ZQ5TUV-?;5--=A
M+KQS=0^'=1TW5-!UJ:_M()+6\N[:TW6Y<)S)N^7"L"'^Z,!O3!JI EWX\L-+
MT^W34--M;>R20G4]#AN+69E 56C9\_,0QQZCICG-.]\1,;+6=0OA8P+K6GW%
MD1&H1O.AB+1L=SY;<LC)P#@K&.XKO?!&HV-[X1TF&UO;>>6WL+=)TBE5FB;R
MP,, ?E.0>OH:Z;JG!5J<;/\ K]3:2BH>T4=SS[X?Z1>Z?H>E^)8;@F&=GCEM
M-.T: S,H=OE:7&[82@)_ #'!&IX2UVS@M/%*ZAIEZUC/K-W)<.]MNBBC8+N$
MOI@9W#!XK=^%7_)-=)_[;?\ HYZRM%UA?#_AGQUJA*!K?6[QH]ZEE,AV! 0.
M<%BH_'J*NK.=2I-/5W27WA-7<XQ76VWF?/NG3:1'XOMVD\X:%]M 83Y\P6WF
M<[MG?;UV]^E?9-<OX!T!=#\,V\DR.=3OE%S?33*1*\C?-A]Q)RN['UR< DUU
M%=&=9E#'5(N,+<NF][^>R_X)R<KA>'-=(****\4 HHHH **** /-/%OA'XA>
M(_$TJ6/C%-(\.%E>);7<+B,B/!^ZJE@7SP9,8.>P%2>&/@CX.\/QPR75E_:]
M\G+3WOS(25P0(ON;<Y(#!B,]3@4OB+XMVGAKXB6OA>_TJ>*UF\L/J4LHC1=_
M1@",-&#@,VX8P_!V\^C4 %%%% !1110 4444 %>/^'O^3H?%G_8*3_T&UKV"
MO'_#W_)T/BS_ +!2?^@VM 'L%%%% !1110 4444 %%%% !1110 5YO\ O?$?
MQY_Y;BQ\*Z?_ + 7[5<K^+,IB/MAH^V?F[S5M2AT;1K[5+A9&@LK>2XD6, L
M512Q R0,X'J*XOX1Z3<6_A>XU_488(]2\17;ZI*(HP-J2'*+NR25P2X!/'F$
M=<Y /0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YSQ]H#>)_ FL:1&KM-/;EH51E4M*A#HN6X +*H.>Q/(ZUX)\+/
M!/B34/'NB2>(-'OK;3M$A:2(WEM) .'9T56VC<PEDWX)Z ]ABOIZB@#PWXY^
M!M:U?7=,\2:7ICZM!;P""YLT4DX63<.%8.P;S"#L&0%)R,\4_ O@]-3^(@O(
M?AW_ &'H6GRB>&?47NTN2R\Q[0TFUFW@,1M*@9!)."??J* /$?["UC_AJ3^U
M_P"RK[^S,?\ 'Y]G?R?^/+;]_&W[W'7KQ6)I/AO78_'OQ.N9-%U%(+S3=42U
ME:U<+.SR H$.,,6'0#.>U?1-% 'Q]I7PJ\3:GX7UB\_L74;>_L9(7BM[B!HC
M<1$2>9L#+EW!"' /3(Y) KU/1?&GQ#-AX:\.:%X'GM)(+5+6ZNM8M9EA!0;0
MP8;=J[5W'.22VT X!;VZB@#YV\5^&]=N/VC;;5(-%U&73QJ-@YNTM7:(*JQ;
MCO Q@8.3GC!KFO\ A7VI>$M7UFSU;P+?>(XVB;^S+BW2;86#[5=S"_RJ5W,4
M.6X4?*"37U=10!YY\(?"\N@^&I;V\T&TT:_U%U=[:WDF8B)1\F\2NY5\LYP#
MT(!P00.8_:/T6:[\,:5K$6]DL+AXI46,D!90/G+?P@&-5Y')<<^OM59GB+0;
M'Q1H%YHNI*[6ET@5_+;:RD$,K ^H(!YR..01Q0!YSK\$VN?LTVMOI,4E_.^F
M6*+':*969D>(. %R<J5;([8.>E4O@MX$LO\ A#+K_A)_"D'V[[>^S^T].'F>
M7Y<>,>8N=N=WMG->E^$_#%MX/\/PZ+97=W<6D+,T1NBA9 QW%<JJY&23SD\]
M<8 VZ /GWQG\//$?@KQY'XS\"Z:EQ:HWF_8[>+>8&(".GEYRR-N)^3[H)X4*
M#5;Q?<?$/XN7%EHL7@^[T33X7$TGVU65=^=N]I'1>%#GY%!/WCAN,?1=% &1
MX6\/V_A7PQI^B6K;H[2((7P1YCGEWP2<;F+'&>,X'%>4?%SX<Z[/XHMO&_A*
M+SKZ#9)<0I@R"2+E)55B0_"JNP#.5& VXX]NHH ^2?%FI?$S7/[5N-0TOQ'!
MIEU"INK::VE-M$J;6)4% J*&3(/W@.&9LL3VNCZ?::C^S#J-GX<@N[Z^DG3[
M7%' YD:X\Z(L H+9 39RO! R0#N ^@:* /G3P[XR\?>%_A[#X:TWX?:RMY D
MBQ:@]K*P4O(S[O*\O!(#$#+8R 2".*M>#O $W@WX7^*_$7B#9:W^H:1-!##*
MQ5H(V0X5\G&]VV?+C(P!U8J/H&L3Q9X8MO&'A^;1;V[N[>UF96E-J4#.%.X+
MEE; R >,'CKC((!Y9^S9IGD^'-;U7S<_:;M+?RMOW?+3=G.><^;C&.-O?/'M
MU9GAW0+'POH%GHNFJXM+5"J>8VYF))9F)]223Q@<\ #BM.@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/%O
M@)]?U_3?$6DZQ)HVO6"-%'=BW6X5HF# J8V(&?G;!]SG/&#P'X"?P;<:U>W6
ML2:IJ.KW GN9S;K"N06/" G!)=B><=, 8Y[.B@"O%8V=O=W%W#:P1W-SM\^9
M(P'EVC"[F'+8' STJQ110 4444 %%%% 'G__ #<+_P!RI_[=UZ!7G_\ S<+_
M -RI_P"W=>@4 %%%% !1110 4444 %%%% !1110 4444 9^N_P#(O:G_ ->D
MO_H!KQ"O?9(TEC:.1%='!5E89!!Z@BJ/]A:/_P! JQ_\!T_PH -"_P"1>TS_
M *](O_0!6A38XTBC6.-%1$ 5548  Z "G4 %%%% !1110 4444 %%%% !111
M0 4V2-)8VCD171P596&00>H(IU% 'A$%_>6S*UO=SQ,J;%,<A4A<YQQVSSCU
MJ\WB76'N+2=[UFEM PA=D4E=PP<\<Y'<YKTG_A"?#O\ T#__ "-)_P#%5B3_
M  UCDN)7AU+RHF<E(_(W;!G@9+<X]: .#O;VXU&\DN[N3S)Y,;FV@9P !P..
M@%=1H&MZ=9>#=4L+BXV74_F^6FQCNW1@#D#'45V>E^%M-L--BMKBUM+N5,[I
MY+9=S9)/?/3..O:N0\:Z%-_;,/\ 9>E2>1]G7=]EMSMW;FZ[1C.,?I0!KV?C
MC1].T;3[<M//*ENB2+%']PA0"#NQG\,]*@\(>*]-MM-L])N#)%*N_=-)M6(<
MLW4G\.G6N3M?"NNW>[R],G7;C/F@1]?3=C/X47OA;6=.LY+N[L_+@CQN;S4.
M,D < YZD4 =[X7U*P6358VO;8/-JDS1*95S(#MP5&><]L5QFJ^#=2LOB=>:M
MX;FA2\6W_M&&"9,K*[,4DC)+<;LL<\??P-N,CG:*UI5I4F^7J:4ZLJ;?+U-7
M5OB?IEQXN\.ZC<:=J-L^E?:5O+=D7<KO&$VKEAG# YSM/MVK 8KK-[<:S=6Z
MI+>3FX1"V[R5W;E4']3TSGI5;7K*XUWQ$FI73^89L?:6P!G: !P,=0 .!VS7
MN'@>-$\)6;*BJ7,C,0,;CO(R?7@ ?A737JTU3C[+1VU\M=OO_0WK5(*$?9[V
M_7;[SR34O!EI?^!;W7[9734+6ZPRIR)D.P8QV(+$Y'7D$'((E^)6GZ%X3^&V
ME>')K:&?7"PF6900R,>99 P4;E.T(%.#C:>=@KJ?'?\ Q+];EAM/W,5];H]R
MB_=D8.3DCU^4<CW]3G0T/6]1UCP]XB^WW'G>5:'9\BKC*/GH!Z"M,'F,\/5I
MSE>2@[VO;T5]=/TT.>I5G4I>S;T.)^#FK:-K>D_\(GJEG$L]O(UQ;&,R*;G=
MDLS[>"R@  D_=( '!SZ#X9\.Z5)<7]PUKF6SU.1(&\QOD"$%1UYQ[UTFA?\
M(O:9_P!>D7_H K#TK4H=(TWQ!?7"R-%%JLVX1@%N2H[D>M8YABH8K$2KPCR\
MVMKWUZ]$90BXJQ<TG_D;_$7_ &[?^BS1_P U"_[A7_M6N<L?&NFVVNZM?/!=
MF*\\GRPJ+N&Q2#GYJX.N,H]"\2^++"6\M;58;G?8:BDDI*K@A"0=O/Y9Q6#X
MB\6W>KS7,%O-(NFR[=L,D:!N,'J,G[PSUJO!X0UVYMXKB&QW12H'1O.09!&0
M>6KJ-+^'EM+IL3ZD]W#>'/F1QR(5')QV/;'>@"KI/B:XU#0M=CU;4(B_V8K
MK[$+$J^0  ,]JZWP[?V<^C6%O#=P23QVD>^-) 67"@'('(YKS;Q9HMMH.JQ6
MMJ\KH\ D)E()R68=@/2J>BZW<Z#>/=6J1.[QF,B4$C!(/8CTH Z[_FD/^?\
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MXBU".!L0-(T<",'DE ! ^0A"<G[I;T)'HD$$-K;Q6]O%'#!$@2..-0JHH&
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M+^'7A>6Z39]OO+V[A4@AA&5MT4D$#KL+#&05*G/-?6/A7[7_ ,(?HG]H>?\
M;?L$'VC[1GS/,\M=V_/.[.<YYS7G5$HS:CM<T6QKT445 PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***S];UO3O#FCSZMJUQ]GL8-OF2[&?;N8
M*.%!)Y(' H X_P#YN%_[E3_V[KT"O)_#GBG1O%OQUDO]#O/M=K'X:,+/Y3QX
M<7()&' /1A^=>L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V2-)8VCD171P5
M96&00>H(JC_86C_] JQ_\!T_PK0HH X__A7&C_\ /S??]]I_\372:7IL.D:;
M%8V[2-%%G:9""W))[ >M7** ,'6O"=AKUXEU=37*.D8C B90, D]P?6N&\8>
M'+/P_P#8OLDD[^?OW>:P.-NW&, >IKU>J]U86=[M^UVD%QLSM\V,-MSUQGZ"
M@#PBK%E97&HWD=I:1^9/)G:NX#. 2>3QT!KV?^PM'_Z!5C_X#I_A4D&DZ;;3
M+-;Z?:12K]UXX55AVZ@4 >6?\(3XB_Z!_P#Y&C_^*KT_^PM'_P"@58_^ Z?X
M5H44 -CC2*-8XT5$0!551@ #H *=110 5@^+-%N=>TJ*UM7B1TG$A,I(& K#
ML#ZUO44 <)X=\%:EI&NVU]<3VC11;MPC=BW*D=U'K7=T44 %%%% 'G'BGPMK
M.H^([N[M+/S()-FUO-09PB@\$YZ@UR>I:7>Z1<+;WT/E2LF\+N#<9(SP3Z&O
M<ZR]2\.Z5J]PMQ?6OFRJFP-YC+QDG'!'J: .4^&7_,4_[9?^SUM^-;]M,TFV
MNHTW3I=H8FWD!2 Q.<=05#*1Z-6IIFB:=HWF_8+?R?-QO^=FSC..I/J:H^+-
M%N=>TJ*UM7B1TG$A,I(& K#L#ZT <1:^-'M+/5(([-E>^GEF659\&(N,#''.
M.N>*P4U;4HYI)DU"[667'F.LS!GQP,G/.*ZJT^'6HI>0-=36;VZR*9461\LN
M>0/E';WKJ?\ A"?#O_0/_P#(TG_Q5 &!_P *R_ZB_P#Y+?\ V==O86WV+3K:
MTW[_ "(ECW8QNV@#./PJQ10 4444 8/BS1;G7M*BM;5XD=)Q(3*2!@*P[ ^M
M<]HG@.\LM7@N+\V-Q:INWQY+;LJ0."N.I%=_10!1CT72HI%DCTRS1T(966!0
M01T(.*O444 <1?\ P\^VZC<W?]J;//E:3;]GSMW$G&=WO73Z)IG]C:1!8>=Y
MWE;OGV[<Y8GID^M:%% '&^+/"=_KVJQ75K-;(B0",B5F!R&8]@?6N*UWPY>>
M'_L_VN2!_/W;?*8G&W&<Y ]17L]% '@D$\UM,LUO+)%*OW7C8JP[=14PU*_6
M.:-;VY"3$M*HE;$A/4L,\Y[YKV/6M%MM>LTM;IY41)!(#$0#D CN#ZUAQ_#K
M1DD5FFO'"D$HTBX;V.%!_(T >75[_7/_ /"$^'?^@?\ ^1I/_BJZ"@ HHHH
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MT@N[63&^&>,.C8((RIX/(!_"J]KH6D6&G3:?9Z58V]C/N\ZVAMT2.3<-K;E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @O+*TU&T>TOK6&ZMI,;X9XPZ-@Y&0>#R ?PKD(?A%X$@GCF30$+1N'4
M/<3.I(.>59R"/8@@]ZZ;6M<TSP]I_P!NU6[2VM]X0,P)+,>@"@$D]3P.@)Z
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M@V.T.HI<R/=LPBCMXPQPH&YB20 !E1US\W ZXVM-OXM4TJSU"!76&Z@2=%<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M..$1JH;(!<%SC.P<9.3ZY0 4444 %%%% !1110 4444 %%%% !1110 4444
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M%B!DMM!(]3C/>O'M*CL]0EU)]<U26&]E2&07;P&42N6_>$A1U"H% R H?@<
M!]!'N=8O_"'^& NT>'-(VXQC[#'C_P!!KDK?Q5%X0TC0["U=-8LKR.X>UG5F
MA,4<93]V5;<<@NRX^7:%"[>*D;XGR06\<EUHHA9[<W !NC@J=X5LE =I9#\V
M/N_, 1C+4FEH/9Z'H=%<9HOCXZKKUOI<VCW%H\Q=3YI97C<)O 9'52 5!YZ\
MKP0<B;4O'=O!K::5IEH=2N/,,#^5)@++G[@X.<<[CP%P<GAMJ$=;4%Y96NH6
MKVM[;0W-N^-T4T8=&P01D'@X(!_"N:\,^,I=?U)[&?2_L<J1/(X,Q<J595VD
M%%(/S<YZ8Q6 /^*@^,;'_09K?3N/[VY(D_$;TGF]L;/4<E[?(#N+7PYH=C=)
M<VFBZ=;W$>=DL-JB.N00<$#(X)'XUIUY?XVFBM_B-IL\\B10QI9.\CL%55%P
MY))/0 5T>A>-)=;,UPVE"RTVW5GN+NYN0HB4 D C&-V,%ANPHSEON[G)N^H7
MOJ;^H:-I>K^7_:6FV=[Y8(3[3 LFT'&<;@<9P,_05>K@Y?B.\WVU]+T26\M[
M9!+YK2-&/+R!N8;#LR<D \X4D@8;;T?AK7_^$BL)KK[-]G\J<Q;?,WYPJMG.
M!_>_2DWW#<V:*XSXE:@D'AQ--$@$FH2B,JLVQ_*7YG..K*<*C#IB3GK@XU[8
MQV7P81T*,UW):W;R+&$+>9<1LN?4JI5<]PHZ= [:I=Q7T;/3**\-M+:TF\*Z
MS?7%UY&HVMQLLX,9\]=D9'R_>^9F9=X.%QD\*:2P_M/5;RST--3F$5U)Y<4,
M\K-#$%3<?E[@+%E5Z9'&W<QI=+CMK8]SHKRKQ1H4OA">SO\ 2]0FBCG?[.&+
M8E63!D'089"$Y4CJHSN#<=]X7UAM?\-V>HNFR60,DH"[1YB,4?:,GY=RDC)S
MC&:.H=#7HKG]:\(:?KNH"]NIKE)!$L6(F4# +$=5//S&O#[6_EG-AN5!]HM6
MF? /!&SI[?,:8'T'_8VE_P!I_P!I_P!FV?\ :!.?M7D+YOW=OW\9^[QUZ<5=
MKQ.1!J&I^%(Y<JMSHFF(^SL'=P<?G6KXJ\//X3O-.U+3KMQ&TOEQL^/-BFVN
MV0<8*E0P((]OF#':.[#U/5Z*\7UC5!/>Z#XKA0)=7$;22P1+Y)>>UD\N4[P2
M2KAMG.3L !SG ]D@GBN;>.XMY4EAE4/')&P974C(((X(([T@)**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?8)[W:)(_--MN9\E@S=2>0"3Z=:\[(>WTW6[&ZA-OJC+:Q@,!F QSK)*A;J
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MO.Z/<" WSX)PH!( S\PP Q6NB\/:%!X>TS[)"[2.[>9-*<CS), $@9.T84
M>G<Y)'V0(XWXIV<AN=#U#>@AC,]J5).XO($=<<8QB%L\]Q3]6C,/P1TR)OO)
M:Z:I_!X:['Q#HXU_0KG33</;F7:RRH =K*P9<@]1E1D<9&1D=:B\-:(WA[1U
MTTW"3QQRN\;+$4(#L7(/S')W,W(QP0,<9+OJF*VC1Q'P]T33M<T[5)=2M_/>
M#4##&=[+M3RHFQ\I'=F/XUG:AH5WX(\2QZA9VKSZ?;SFXM9)G:10'&QXW?JI
MS(RJ3G@J?G(85[!126UF-O70\K\4:[)XOFL[#2]/FE2!_M 4KF5I,&,=#A4
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M1>K&F\7>&K:>2"?Q#I,4T3%)(Y+V-61@<$$$Y!![4S_A-/"O_0S:-_X'Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >?_ /-PO_<J?^W=>@5Y_P#\W"_]RI_[=UZ!0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@#. .?85Z90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*@NAR%;CYEYP<BG_ /%U/^I-_P#)JI9OA-X'GGDF?0D#2,78)<2HH).>%5P
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M<;_Q=3_J3?\ R:H_XNI_U)O_ )-5S+ J^M2/_@7_  "N;R#_ (7!X#_Z#O\
MY*3_ /Q%=/H>O:=XCTU=1TJ9Y[1F*+*T+QAB.N-X!(SQD<9!'4&OCO5=0O\
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MR+3NKA11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_\ YN%_[E3_
M -NZ] KS_P#YN%_[E3_V[KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#0\?\ E)C_ /BZ]/HK.6)G*3E9?<O\B74;=_T/,/\ A5_B'_H>/_*3'_\
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MG.*DV[K[D7:/8\ ^(7PX\3Z;X7:^E\4ZGX@@MY1)+;3!R(DVMF7#2-G'0X'
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M]NZ] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#Z;HKQ__ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J /8**\?\
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M?\,X^#_^@EKG_?\ A_\ C5 'L%%>/_\ #./@_P#Z"6N?]_X?_C5'_#./@_\
MZ"6N?]_X?_C5 'L%%>/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\
MA_\ C5 'L%%>/_\ #./@_P#Z"6N?]_X?_C5<)JOPFT&Q^,NA^#XKO4CI]_9-
M<2R-(GFA@)CA3LQC]VO4'J: /INBO'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M:H_X9Q\'_P#02US_ +_P_P#QJ@#V"BO'_P#AG'P?_P!!+7/^_P##_P#&J/\
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M!1D\#)(ZT <7I.I?%G6=&L=4MU\%+!>V\=Q&L@N@P5U# '!(S@^IJY_Q=_\
MZD;_ ,FZZCPG8W&F>#=#L+R/R[JUT^"&9-P.UUC4,,C@X(/2MB@#S_\ XN__
M -2-_P"3='_%W_\ J1O_ ";KT"B@#S__ (N__P!2-_Y-T?\ %W_^I&_\FZ]
MHH \_P#^+O\ _4C?^3='_%W_ /J1O_)NO0** //_ /B[_P#U(W_DW1_Q=_\
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M;O$%W>V_SJV^%]NUOE)QG!X.#[5V% 'G_P#Q=_\ ZD;_ ,FZ/^+O_P#4C?\
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M,/\ 2O\ A*_[#_@^S?V5YWONW^9_P'&/>N@HHH **** "BBB@ HHHH ****
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MHXQD,.."3Y#X*EN_!_Q/\*:IXG+Q075LDD4TDR-B"6)HHG)+85%&."055>G
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M0 4444 %%%% !1110 4444 %%%% &9XBT"Q\4:!>:+J2N;2Z3:_EMM92""K
M^H(!YR..01Q7F_AGX'Q:/KVDZCJNOR:I%I"8LK=;40!&$C2*68.2P#NS8]2,
MG VGUNB@ HHHH **** "BBB@ HHHH **** .0^(W@?\ X3_P[!I/]H_8/*NE
MN/-\CS<X5UQC<O\ ?ZY[5E^*/A18^*/!6B:'/?R0WFCV\<-M?+'D8"JK[H]V
M"&" ]<@@<XR#Z'10!PG@;X:P^$=8U37+S5)-5UK478RW1A$"A68.P" D9+#)
M/L  .<]W110 4444 %%%% !1110 4444 ><?$KX6W/Q$U"QF;Q#]AM;.)ECM
M_L0E^=CEGW;U/("#'.-ON:H:O\';[Q)H26&N^+/M4UF4&F2PZ9';I:)T=/+1
M@'5@$QTV[!C@D'U:B@#A/ WPUA\(ZQJFN7FJ2:KK6HNQENC"(%"LP=@$!(R6
M&2?8  <Y[NBB@ HHHH **** "BBB@ HHHH XSXB_#JQ^(6EV\$]U)9WEHY:V
MNE7>$#8WJ4R P(4=P00.<9!Y1?@'I=W9ZS+K6L3W^MZC*TR:BD/DB!R=Q(B#
M%6RQ.<GIPNT\UZ]10!YIX,^$47AGQ,OB#4M:DU:_@MTM[0BW%NL*K&(AD!CN
M/E@*,^Y.201Z7110 4444 %%%% !1110 4444 8_B/POHWBW3H[#7+/[7:QR
MB94\UX\. 0#E"#T8_G7FMC^SSH$.LZE<7EX]QI]RDJVMI&C1M:%FRK"3>=Y5
M<CY@0>I%>Q44 >2>&?@?%H^O:3J.JZ_)JD6D)BRMUM1 $82-(I9@Y+ .[-CU
M(R<#:?6Z** "BBB@ HHHH **** "BBB@#G/''@VQ\=>&I='OI)(3O$L$Z<F*
M4 @-CHPP2"#U!/0X(Y#PU\%;+3-6GU+7M6DUN9K(6,2B#[,L<7E>20=K$L?+
MPH.1CD\G!'J5% 'C-I^S[:1WEK#>>(9[O0K6[EN8]/-J$<[PH(:4-DY$<8)
M'0XVDYKV:BB@ HHHH **** "BBB@ HHHH S/$6@V/BC0+S1=25S:72!7\MMK
M*0058'U! /.1QR".*\PT?X!6,-]9-X@UN36+&QMV@M[-;;[, "[/\SJY8@-(
MY[')'.!@^Q44 >,VG[/MI'>6L-YXAGN]"M;N6YCT\VH1SO"@AI0V3D1Q@D =
M#C:3FO9J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,N'PWH5MJAU2#1--BU NSF[2U192S9W'>!G)R<G/.36I110 4444 %%%%
M !1110 4444 %9D/AO0K?5#JD&BZ=%J!9G-VEJBREFSN.\#.3DY.><FM.B@#
M+U+PWH6L7"W&J:)IM].J;%DNK5)6"Y)P"P)QDGCW-:E%% !1110 4444 %%%
M% !1110!AW'@SPM=7$MQ<>&M&FGE<O)+)81,SL3DDDKDDGO5BS\-Z%IUO=6]
MEHNG6T%VFRXB@M419EP1AP!AA@D8/J:U** ,_3-"T?1/-_LG2K&P\['F?9;=
M(M^,XSM SC)Z^IK0HHH **** "BBB@ HHHH **** ,>R\)^'--O$O+#P_I5K
M=1YV306<:.N00<,!D9!(_&K&IZ%H^M^5_:VE6-_Y.?+^U6Z2[,XSC<#C.!T]
M!1K>MZ=X=TB?5=5N/L]C!M\R78S[=S!1PH)/) X%<A_PNSX>?]##_P"25Q_\
M;H [N""&UMXK>WB2&") D<<:A510,  #@ #M4E1P3PW5O'<6\J30RH'CDC8,
MKJ1D$$<$$=ZDH **** "BBB@ HHHH *CG@ANK>2WN(DFAE0I)'(H974C!!!X
M(([5)10!GZ9H6D:+YO\ 96E6-AYN/,^RVZ1;\9QG:!G&3^9J/3?#>A:/<-<:
M7HFFV,[)L:2UM4B8KD'!*@'&0./85J44 %%%% !1110 4444 %%%% !6/_PB
M?AS^T?[1_P"$?TK[=YOG_:?L<?F>9G._=C.[/.>N:V** *>I:3INL6ZV^J:?
M:7T"N'6.ZA650P!&0&!&<$\^YJ2RL;/3+..SL+2"TM8\[(8(PB+DDG"C@<DG
M\:L44 %%%% !1110 4444 %%%% %>]L;/4[.2SO[2"[M9,;X9XPZ-@@C*G@\
M@'\*CTW2=-T:W:WTO3[2Q@9][1VL*Q*6( R0H S@#GV%7** ,N'PWH5MJAU2
M#1--BU NSF[2U192S9W'>!G)R<G/.36I110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y9:?'?0M0@NI[+P[XGNH;1=]Q)!9(ZPK@G+D28484\GT/I7J=?-WP"\2:+X
M<@\4S:SJEI8J1;N@GE"M(%$I;8O5R,CA03R/6@#W;PKXLTCQGHPU31IGD@#^
M7(LD91HY-JL4.>"0&'()'H36W7Q)87DFG^$M0BN8KXZ?JT_EQFWNTA1Y8%W?
MO%*,SJOG(<94'U) *II_AZ37[CQ&=.:#;IMK+?HEON\IXTD4-L,A#!0C%ANR
MQ"XQDT ?;E%?)<$]W\1+OQ!XIUC5Y],CTW2H8#>[RZ+,X6+8R(NX1R_OB0BX
M7><YZ,WX8ZC9Z#\0]&1GFW7,JVL5WI5V-DZM*ZYGBD4DJQV#;^[9557VEL$@
M'UM1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y__ (07PA_T*FA_^"Z+_P")KH** ,^ZT+2+[3H=/O-*L;BQ@V^3;36Z
M/''M&U=JD8& 2!CH*YSQ!\/;.\T>XLO#8T[PY/=(T%S=6NEQ,TMNRD/$?ND
MG:<@Y^45V=% '(>!/ %GX*\)3:"]Q_:4=S+)+<M-" DF]0I79S\NU0""3GGU
MP->Q\)^'-,O$O+#P_I5I=1YV306<<;KD8.& R,@D?C6Q10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4M)TW6+=;?5-
M/M;Z!7#K%=0K*H8 C.&!&<$\^YJY10!7LK"STRSCL["T@M+6/.R&",1HN22<
M*.!DDG\:L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gjnp4w4lrub1000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gjnp4w4lrub1000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0(!^D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"2.,V]Q;O*S$?,""!_6NLH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEP7R:G_8\31KMVQ+(9#CDD'IGK7/6P#?!-@1D'/\VKU/PV OAK30!@?9H_\
MT$4 <MH6OZSI?BG_ (1O7Y1=-(GF078 !<9QR!P*T?%GBJZTR[MM)TFW6YU.
MZSM4G 0=R3].:R/%WR_$7PZR\$LH)]LFF[UT_P"+\LM\P5+F%1;,W3(7YL4
M7%\/^-EB^T-XJ+2@;OLWV9-N?3=65X4\7^(=1^(,NB:M&L AC8O$O()QP0<5
MZ=N&,Y&/6O,M.OK.\^-4RVQW/' PD8="=HH ]'O;N&PLY;J=@L42[F)K@;"]
M\4^- ][IU_\ V/II;$$@C#M(/4J>G-=#X^M)[WP3J<%L"96C& ._(--\!W]K
M>^$;$VNU0B;60=5.30!R'B;5/&?@K2Y9I[T:E Q4"Z*!6CY_NBO0O#MW-?\
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M"KOP?OK6;PQ<6\;*LL=[/N3O]\\T .U%O%WA"V.I7&J?VU9Q?-.K1+&RKW(
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M3$8E  [8%<I\6)XIM%MM,C DOKJ7; HZ@C!S^0H AUA@_P 8-%93D&QE(/\
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M#SZ^U=8_PQTB20M_:6MJI/\ JUOV"_3'I72Z3HEAHEMY-C L8_B;'S-]3WH
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MPW?BNTU\W,BR6T+1"(*-I#$'.?PINN^$;76+E;V&=[+4%&%NHAEA^!XKHJ*
M.'_X5_=7C*FM^);W5;8'/D2Q*@/XK70:KX>M]2T0:9'(]JBA?+>/JF.E;%%
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M\X*%SOX(Q^M+XI\,+XETVWM&N3!Y,\<VX+G.PYQ0!)JNBV_B#PN^GW"!EDB
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M10 4444 %%<UX^U.[T?P;J-]8RF*XBB+(X&<&M30KF6[T2TGG;=(\8+'U.*
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M444 %%%<=\0]9O\ 1=*LYK"<Q227D,;$ '*LV"* .QHJ*V=GMHW8Y8J"34M
M!1110 45QGQ UJ_T:VL6L)S$TEPB.0 <@L :[)3E030 M%%% !1110 4444
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M_P#7)?Y4 9GQ%NI[+P'JMS;2O'-'$"K(<$?,.AKE_"-KKOB^.SU34[FZLK"
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MD;T(SP:FD\-_#RQ\06NGQZ1%)?D^8BQNS%"N#D_-Q0!Z.#D9%%(  ,#H*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D 9- "T
M5GSZS:PD@-YC#LE9LOB";#>7$HYXW5A/$TH;LASBCHJ*Y$^(=0!^[#^9JU%X
MG(91-%QWV]:S6.HM[V%[6)TE%4K/5+6^'[J0;O[AZBKM=,9*2O%EII[!1115
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM=?HW45S]M\,M!MIQ*TVIW !SY=S>/(G_?)XKLJ* &0PQ6\2Q0QK'&HPJJ,
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M6C!S0 GA#3'TCPS:6D@PX7>1Z$\UI:CI]OJEA+972EH95VL <&K5% '*Z/\
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MJL8)SY4=\ZI_WR.,5TVEZ18Z-:BWL8%C3N0.6^I[U>J.:>*W3?*X5?4T-VW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &2RI#&7=@ *YR]U&2[)092+/8\D4FL7_GW
M1A4YCC_)C5%6R<UYF(Q+E+DCL8RE=V0_9QP*B=:GW<5"YKDDE8@JN*KO5F2J
MSUS3(9$)7C.58J0<\'%0ZY\2KCPOIT>^T^TLQP&SC%/>N.^(5M)<>'BT?1&!
M;\ZVR^HX8F*;T;"+:>AWG@KXJ6?BB[%E/#]FN6^XN<@UZ+7QOX<U"33->LKR
M(9:.0$#UK[#M7,EI#(>K1J3^(KZBO34'H=,7<EHHHK L**** "BBB@ HHHH
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MV_BS5FNA\P22;,9/IC'2L;P=KFO7OC/5]/UB9LVRE?+!^3[HY H 8?&^N?\
M"(:IJ'VA/M%O?-#&WEC 42 =/I7IVG3/<:?!-(<NZ DUX>?^2?:Y_P!A1_\
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M@EN=T9'IC'2NJM=/MK*Q6SMHEB@5=H51B@#AOA@!YOB'C_E^_P#916Q\1/\
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M\@)P1]0: .;@M)IOA+HEY$C.EC(MQ(JC)*C/;O7KFAZI::KI5O/:3)(OEJ"
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M7X\P=<C/4<UW&I:K9:1:FXO9TBC'3<1D_2LW7/!^F:[,MQ-YMO=*,"XMVV2
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M].U>KEN+<OW4_D;49_99MT445[!T!1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH *JW-C'=2Q.Y.8SD8JU4$]Y%;/&DA(+G"\4 3T444 %%%% !1110
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M(>/;\ZVP0PRI!'J*^NI5(5(W@[G=&2:T%HHHK4H**** "BBB@ HHHH ****
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M+AR\CG))IL43SS)#&,NYP!21QO-(L<2EG8X"BO4?"/A&/3(EO;Q0UTPR%/\
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MR=I?RV;G:V4)Y0UTUM<QW4(DC.0?TKT*.(C5TZFD9IDU%%%;EA1110 4444
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M!3L!^=^P%>PZ1H]KHUDMM;H.GS/CEC5YGF,<-'DA\;_ )2L6+"TM]/LTM[5
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MV\IQ',C?0U[>'KJK34NIT0FI(FHHZT5T%A1110 4444 %%%% !1110 4444
M%%%% !1110!6O;2*\MVCE7(QP?2O/9(A;2M&#D UZ6>1BO/==1;;4[@'Y(PW
M!/3%>5F<%RJ:,*RV97#TKSI"A>6144=237(ZQXYTS2@R1N+B8?PKR*\TUGQ/
MJ>M2L9IV6$GY8U/ %9X3+:U?5^ZO,S2;/1?$7Q%M-/0PZ:1/<="W85YCJNN:
MAK4OF7LY89R%' 'X5GT5]%AL%2PZ]U:]RD@J:UM9KVY2WMT+R.<  5K:+X5U
M#6FRB&*$=7;C\J]/T/P[9:);*D<:O./O2D<FN?'9I2PRY5K+M_F*4DC*\+^#
MHM'_ -)N]LMT?N\<+76445\A7Q%2O/GJ.[,F[C'^\OUI]-V-)(%7/'/%+B8$
M[HC@=\5GRNUR1:*C$FXXVD'W%2!9"<!#^-%F,*3/8<GTJ9;5VY=MH]JLQQ1P
M\@9;U-4J;ZCLR*"VQB23J.@J9S0SUC>(/$%KH-DTTS RD?NX^Y-;P@Y-0@KM
ME6&>(->M="LFFF8&0CY$SR37C&JZM=:S>M<W3DDGY5[**75=5NM:OGN;ER23
M\J]E%)IVF3ZE=I;P(69CS[5]5@<##"0YY_%U?8M*QK^"-+DO]?CF&1'!\Q;W
M[5]3:-<FZTV)FSN PQ/<UY-HVDV^CV*00( V 7;N37I'A*X:73Y%( V/@5YL
M,?\ 6<6[?#:R'3E>9T-%%%>B=(4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5+N_2TEBC923(<#!Z5;K$UO_ (_++_?'\Z -NBBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*Z4O:3*.IC8#\JEHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RJ,L0 .Y-5KW4+>
MPCWS.!GH/6O,_&_BF^.FN;>0Q(6  4\XK*5>$:D:=]61*:3L=S-XOT6"Z-LU
MT#*#C"C/-*_B>S5L*&(]=IKYXT^9CJ]O+(YYDRS&O6%.0I!R"!6&95IX>45#
MJ9SJ26QKZ]KD%[;1HBL#D]17F7BG13,OVRU0;E'S@=Z[2Z7=;GN1TJEPRX/(
M(YKQ_KM6G75;J8N3YKL\@9NH/:NF\*>(%LYOL=U(?*<X0GM4?B;PX]FS7EHI
M:%CEE':N2+Y'6OJ?W./H:;/\&::21[DC@J"""#T(J4/7F7A_QE)9>7:7N7AS
M@.?X:]#BG2:-98G#(PR".]?*XK"U,+/EGMT9FTT7-]&^J^^C?7/SBN3%ZC9J
MC+TQFXJ'(+C[??ABL9(SUJTLNTX=67\*MV"%+6,'@D<U<\H.,,H/UKKA2T*C
M%V*<;@C@YJPKU%+9*#NB.QOTJ%92K;).''ZU>L=Q[;ETO43M4>^F,])S'<EC
MG:&59$.&4\5V]K<+=6T<R'AAFO/6;FNI\,7&^TEB8CY&PH]L5UX"K:HX=RJ4
MO>L;]%5;S4K.PB,MW<QQ(.I8UR&M?%;PWI (2Y%VX_@B;G]:]I1;V1NVD=S3
M7D2,9D=5'JQQ7@VJ_'2^E1ETZT2,[N#(,\?@:X?5_B#XBUA\S7\L:[MP2-B
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MA48Q^(->@:/X#\/Z*J_9K%"P R9/FS^==+16$JDI;LM12,+5O#L-VN^V58G
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MTC%1V"BBBM"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MS4[R:VN;9(S@2, WYUIUC:Q&[W=F54D!QG'UH V:*** "BBB@ HHHH ****
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MQ2@SYNT3X6^(]896%L(8B 2TIVG'T->@Z+\#+6)O,U2[:3#9\M0,$?6O8@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %)@'M2UD:O-)%=VBHY 9P#[\T :]%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSG78/)U.5=N
MWOCZUZ-7*>+;%F:.Y13CHY'Z5Y^94G.C==#&LKQN<C0***^<.4D4U(IJ$&G@
MU28SGO%7A:/6(#<VRA+M1V_BKR>XCEMYGAG0I(IP5->^AJQ/$7ABUU^U("K%
M<C[L@&/SKW,NS1T;4ZNL?R-(R///#'C*Y\//Y3YEM6/*'^'WKU_2]5M=7LDN
MK20,K#)&>17@NLZ->Z+>-;W49XZ.!P:32=<O]$N5GLYB,?P$Y4_A7J8K 4\5
M'VM)ZO[F5:Y]!9WW:@\@"F:DIV1OV!KEO"WC>QU@E+EA!=' .[H:[*9!-;L@
M(.1P:^=JT)T[PJ*S(MH9%%(,]#U%+7GF96O=/M-1B,=W DBGU'2N%UGX=D;I
MM,DSW\MJ]#HKJPV-K89_NWIVZ#4FCP6\L+O3Y3'=P/$P_O#K4"LR.'1BK#H1
M7NNH:9::I;M#=0JP88W <_G7G^L_#VXM@TVG/YL8YV'J*^DPF<T:WNU?=?X&
MBFGN5="\>:CIKI%=N;BWS@[CR![5Z/IGB+3M7C!MKA=YZH3S7ATD<D,ACE1D
M8'!##%$4LD#AX9&1AT*G%:XO*J.(]Z'NORV&XIGT!*3MQW-;ND>'I[O9)(I2
M+U/4_2O-?AAXI>]\06VG:HPDW'$1V]3[U]"J J@* !V KR:64.G/]]J.%*[N
MR*VMHK2!8HE 4?K4U%%>JDDK(Z0HHHI@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5!=6D-Y"8ID#*?6IZ*32:LPW.(U7PU-;L7MU,D>,\=:P'
MB>-]CJ5;T/6O5JK3V%K<#$D*_4#!KRJ^5PD[TW8PE1['F&TCM1M/I7H,WAO3
MYE V,,'/#4Z/P]I\:@",G'JU<O\ 956^Z(]C(X&&VEG;$2%SZ+70Z5X8DD82
MW647LO<_6NLAM(($"QQ(,#&<<U-790RN$'>;N7&BEN,AAC@B6.-0JJ, "GT4
M5ZB5C<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K*U6UFGNK5HUR$8%O;FM6D+*#@L!GIDT +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %#68?/TR5=N[ SCZ5YLPP:]7=0Z,IZ,,&O-M6LWM+Z
M52I"EB5^E>+FU)^[47H<]=;,H4X&FT5XQSDP-.94EC:.10R,,$&H@:>#6D64
M>9^+O"<FF2->62%K5CDJ!]RN.$K)(LB,5=3D$=C7T 0KKM=593U##(K@?%?@
M0SO)?:7A>,O%_A7TF7YJFE3K_?\ YFBD3^%/B"LQAT_5"%?A5F)Z_6O1!("F
M]2"I&017S5(LL4A21&C=3T(P173^'O'-_HP%O.QGM3U#<D?C6F,ROF_>4/N_
MR!KL>V6G(9SU8UGW"E+J0'N<TNAZW8:O9I):3*3MR4)Y%6-1C/RS#MP:^>K4
MY*/+)6:(:T*5%%%<9!BZOX6TS5U)DA$<O:11S7G^L>!M1TW=);@W,([KR:]:
MH]CR/0UZ.%S.OA]$[KLRE)H^?F5D8HZE6'4&I[*_N].F$MI.\3#^Z>M>M:YX
M1T_6AO*B&8#AD&!^5>=:UX4U#1<NZ&6'/#J,_I7TN%S+#XI<CT;Z,T4DSJ]
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M7S/5FL*2CJPHHHKO-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L76687EG@D9<9_.MJL[4;&2ZN+=T(Q&P)_.@#1HHHH **** "BBB@
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MH)XY%SC*MFIZ0FFM&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(/?'-:=>4U9V/S6<7"3B]T%%%%(D**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ_:)"Y'7;Q6U;:=:6@Q%$HXQDC)JU16M/#4J?P1*4(K9!1129K<H6BFYHS0
MZLW7KPV.B74X!)$; 8/L:T,UB>+C_P 4Q>?[A_D:<=T:T$I58I]T?/%Q,UQ<
M23-G<[;CFHJ3/%%>R?JZLE9#J*;13'<4@$8IJHJCU^M.HI"LKW%XHI**8Q>*
MC8^7R!D'M3Z*0GJ-WD]%HW/_ ':=10%GW&^8.X(IV:#SUIA^3ITH%=K<DS24
M44R@HHHH **** "F'YGQV%.)P*2/[N?6D2]78=112$@=33*N+13/,7MS1O/]
MPTB>9#Z*9YGJ"*<&!Z'- U),6BBBF,**** "ES25K^'=&FUO5X;6.,LI;+X'
M1>YI-I*[,ZM6-*#G+9'M/P\@EM_","RKM9G9A]#TKJJ@LK5+*RAMHQ\L:!1^
M J>O'D[ML_+,14]K5E4[NX4445)B%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5B:W_ ,?EE_OC^=;=5KFQBNI(W?.8SD4 6:*** "BBB@
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M6<Y=K+U/7J***\D_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.VD]6I:* MW$V>YHPXZ'-+118+(0/G@\&E)P*0@'K34R>3SZ4!=["G>PX&*
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M5=20^(VB0C;,N'X],U[?7E8B/+49^=YW05'&22V>OWA1116)Y(4444 %%%%
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M^7=G&.O-/$.T+'3!:G3T445Q&H456NKZWM(R\L@'M6!=^(I9SY5FA&3C.,T
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MX[;?<%%%%9'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN16M7%^(=>DMO%6FVT,4#Q3X.]XP6Z=C3M=\2:K9>*(-*L(5E\^$E1@?*V<
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M **** "BBB@ HHHH **** "BBB@ HHHH \NUW_DLNC_[J_UK8U[_ )*5HO\
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M1DJ5\M549R0!FJG)N*B=.,K3J8>G2BM9=#A/ ?B62X\>ZAYX98[MBR[E/WN
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M@?NY7DFEN;'"!S-Y4R+]Y3@,?I5#3_[3N(5GGC+[/N[NM/-_"M[Y6J.2\9R
M/NUI*A7]J[24FM^6WY?F7RROO<JQVUW?-(6<0;\*6/&X"K]E!IUA)M$3$I\L
MDIZ#W%0ZU+%<2VLMO)Y@4Y$:>E,OKR[EBDEB0Q6\9R4DX+>U=3]KB*<5\,9=
M-K=%YORZ&GO22Z7(K*XLWN+F!69%D.5P:BAC6"Z1KZ<R6X<JBDYS4+1HNG^?
ML,=U*PP<=!GFJ4H@@$BF9GD RA7D9KTH4(SE+E;UT[O32Z?3U-N1-NQ)JDS2
MS-$[JD2_ZL!< U<\-:K+X9E;5%4,Q&$!]?\ )K)O7WI"QG,K%>0?X:AEC80H
MQD# ] #TKT:5*U*,$[?\#_,<J49T^26S-O6_%3:_?/=7EN"YC*+@ 8S5S0_B
M!?Z#H3:7#"IB;?R5&?FKEX_(\A_,W>9_#@<42S-<JB"( J/X>]:>SBI.RTZ_
M\ QEA*4H*FX^Z@MM2N+&[^V6SF.96W @UW-I\7]:AMDCECCD<<;M@YKSQQ@X
M([T8K1TXRW%6PE&L_P!Y&]C=\2^*M6\13 WTF(L[DC7@"MK0?B;J&@Z1#I\,
M*-'%G!*BN*9)"@=@=O0&F8R:2A%QLR98.C.FJ;BK(]*_X7+JO_/O'_WR*YKQ
M)XZU?Q(IBGD$<&<[$&/SKG9(C&0"0<C/%,Q1&G#=$T\!AZ<N:$5<['PY\0KO
MPWI?V&TMTQDDL0#R:YC5-1GU?4Y[^XQYLS;FP,<U5Q1BJ4$G=&L,-3A-SBM6
M7='U.;1]2BO8/OQ]!70^*/'UYXFL8[>X@10C[@0HS7)8H(^6FX)NXYX:G.:J
M26J.]G^*.HW&CG3F@C\LQ>7G:.F,5P@% '%.%.,%'8NAAJ=%/V:M<!3A24M6
M=2%I:2EIEHNZ5I\NJ:E!9P@EY7"BOI;1=-BTK2H+2)0H11D>_>O)OA+HPN=2
MEU%S\L/"C_:KVFO/Q4[RY>Q\;Q!BG4K*BMH_F%%%%<I\^%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *I7M@+N:&3?M\M@<8ZU=JO<7D5M)&DAP7.!0!8HHHH **** "BBB@ HHHH
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M&K5>G=-71Z5[JZ$KS+XU_P#(L6O_ %W_ *&O3:\R^-?_ "+%K_UW_H:VPO\
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MQU&-.$90O*&VNF]S"5";E)J5DS1O-:\_7([M1^ZB;"CVK7U;2QKPBO+29=Q
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MF_>/@L14JSJ-UF[^84445)@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8FM?\?EE_OC^=;=5KFRBNI(WDSF,Y&#0!9HHHH ****
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M?0TG(Z<TM%*PB:TMY+RY6"(#>QP,UW&B_"[5[YTDN0D,!;D[OFQ]*X2.5X9
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MT4*KI2YD>O\ _"3:-_S_ $7_ 'T*EDUW2XHDE>]B"O\ =^:O&P!_='Y4\DL
M&.0.@/2MI8^4>AV_VD_Y3UK_ (271_\ G^C_ .^A527QEI,;,H:1\=U&0:\P
M"@G 53]!4FQU&=I 'M7)4S6JE[L3.695'M$[:Y\>_NS]GM5+YXWY'%8=YXNU
M6Z5U$QA#=D/2L,_4?G337*LPKU=W8YI8ZM/K85Y'EE,DC%G8Y9CWJ^O"K]*S
M>^?>M)"&52/2M'=HS3;U8M-[T.ZJ,DU5DN"W"\"LG%L3)F=5ZFH6E#=!4/)Z
MTO:L:E/0S9)YK=J3<3WIM KGFD0Q:ZWP/.5NKBWQPXWY_2N2KJ/!/_(5D_ZY
M&MLO;6(1U8%M5D=Y7)?$J"6X\$7RQ(6(0D@5UM9'BE&D\+:DB*68P$ #O7TM
M)\M1/S/=6Y\GX(.#U%:.@RI#KEG)(P5%D!)-49@1/(",$.<_G1%_KD_WA7TI
M9]HV4BRV4#H05,:X(^E3UE^')$D\/V31L&4Q#D5J5YCW.@****0"$9&#TJK-
M"RQ%(\ FK=-/0Y':LZD%-6*C*S,GR%9>4*D<,R]ZCF,DA!"D]AQ6FI+K^Z&!
MG!R*ADB8[G20 = -M>9/#/E]UG3&IKJ8<D;1OA@1@\T$*V,'&!R:UQ;,%,G$
MC=""*I_9W61DVCKZ5P3PTH/R9T1JJ12\@L&(YV\FA;<G!]?6KA_=KL P>_'6
MD6,GY65CD?+@U"I1;L/G9"R>5'@*"!_$*H72HUN=ZAG_ (%/<UL;%$#KAL^]
M87B*:ZM]-WZ?$&N6;:-PR![U2I-SBE^)='WI67<HP:NQ0_;K)K?'RHS [2>U
M<V)==@U&]F$$BQGE0@RK#-:FEG59M+^T7UQ#(&;E60?(0:PYM=U6PUEUA7S7
MG^1$/(QUX%>AAZ/OSC!1?STT/5I4[2DHI,U-&$7B._74K@)'); QF$GC<>A_
M2J&J3FZLKRQ50MY%*S;O]DGBJ9US4MV5A@@=)1N4*H)-9NL22W,@FF<IJ$TF
MTB(X!7MP*[J6&E[6[T71;VM^ATPHOGN]NGD67TW4+'3H(KJZS:W RT8/S(>G
M2G6NCW5A/MLI(7=5W NV&PWM5>_L1I]PL4M\]Q,$\QCN.$QVQ5">\O[AA>'=
ME<!7CXX'J!77",ZD;J2L_*R?;0Z(J4EHUKY&M:W+Z1?3K+Y5Q>LA97=N5;TK
ME[MYKJ]=G0^:QY4"K&I23M>"\<DR2?,6V%>:K0^?/,TD9RX&2<UV4*2A^\ZM
M?U\CHI04??ZB0P;Y_+D81D==W&*A(PQ'7!IS;Y"TK<Y/)IE=:N=""BBBF,*3
M/-+2'F@!PZBM :C $"?88ON;<Y/YU5@LKBX1V1.$&6R<57R*QG"G6=F]O/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%W2UW*<Y-6(FMT:0.>W:N$^(6M/X>2W>&-625\.I]*] KRKXR_\ 'I9_[_\
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MLJU&-1=4+129HS5G0+129HH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
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MP(STI2@\H/O&2?N]Z:79L9.<4.I0X)'3/!H 2BDHI@+1244 +1244 +1244
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MK6!!&0<BO+%=E.0<5N:=XCGMML;_ #(..>U%AG<452LM3MKU1Y<@W=U[U=I
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M0(Q 9P#[\UKUG:C8R75Q;R(P C8$Y^M &C1110 4444 %%%% !1110 4444
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MD-P^U%"E<'IS0!SZZ_=-<'8I&\8V]:M:?'J-MMD*$AU.!GI4T<MNTH:RL_-
M. <"ND3.P9&..E,"C;2W0TYGG'[X$X'\J=I\LMU91O)E9.^15V@# P*0$%T
MT6QHPZMP0:JIHUK"\;Q+M9&W"M&B@!D2L(\2'<?6G!5 P  /3%+10!'Y05=L
M>$Y["GXI<XZU2N-6L[8X>9<YQBIE*,5>3$VEN7:0@'J :QV\0Q9_=V\DB]F4
MCFA?$,>?WEM)&O=B1@5E]9I7MS$\\>YK-&CD%E!QTR*?5&#5K.X("S#). #5
MT$$9!!K6,HR5TRDT]@P/2JMO:QV)F?S/ED.3N/2IYID@A:5SA5&37&:GJ\M[
M(5#,L>>%!_G6&(Q,:"UW)G-1-J\\1)&YCMD\PCJ2<#\*RGU2]F9LW!"M_"%K
M+0YJRE>5+%5:CU=C%R;W+*NQZN__ 'T:D#RIS'*ZL.ASFHDJ;C%5&_<+%F#5
M[N%AO82J.N>*V++5(+SY5)5_0C%<P]0^:T;A@Q!!X(/-:PQ4Z;UU0U-H[NBL
M32-7$Y$$Y_>=F]:VZ].G4C4CS1-XR35T%%%%:#"BBB@ HHHH **** "BBB@
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M445UF@4444 %%%% !1110 4444 %%%% !1110!RND?\ (<;_ 'FKJJY72/\
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M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;1Z5'N_B&1]*U*BMXA!;QQ*,!!@5+7UM./)!1['=%65@HHHJQA1110 4444
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MH=(4444@"BBB@ HHHH **** "BBB@ HHHH **** .5TC_D.-_O-755RND?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ97JBLT?_/5/^^JF5]PRI!'J*(RL-,M%^*PIY3-=.^<@' K3E9A$Q&<XK%!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J]Q>16TD:2'!D.!5BL36_\ C]LO]\?SH VZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'\Z\DOY(_MTWV:5V@+?)D]J]W+H591<*J:ML:QFUH?3#?%KPFI(_M!3CV/\
MA6/<?''0HIWCCM)I44X#JX ;WZ5\ZT5ZBP\"N=GO6H?'>Q$'^A:?+YF?XG!%
M9?\ POB?_H'G]*\9I0I/052HP707,SV1_CM=,C!+'#$<$XX-9/\ PN7Q.S$@
MVP&>/W7_ ->O-4C;T-6HXV]*/9070.9GHJ_&#Q,?XK;_ +]?_7J5?BYXE/\
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M_BS7,$?;6Q]35"YU_5+A!')>2;1_=)%67\-:SDC[%(<'^Z:@/AK66; LI/\
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M** "BBB@ HHHH XWQJ8KC99S1AXV3)S7A?B'P)/:N]SIO[V,G)C[K7N/B_\
MY"47_7+^M<W7A5,=6PV*DX/3L<<Y-39\_P D<D+E)8V1AU!%-]^_K7N5_H6F
M:IG[5:HSD8WXYKCM0^&I^9["Y]]CU[.'SJA4TG[K_ I33.*M=5U"S*^1>3*
M<@;SBMRU^('B"WG$C3I( ,;2E4[OPAK=F1OLW<'N@K&D@FASYL3I@X)(KT+8
M>NKZ2'H=K_PM/6L_ZJ+_ +X%:*_%<^6H>P)?')##FO-=RGH:,CUK.678:6\
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M_P"^J7^K\_YU]P>S/;G,9',B?@U0_;;=.)+F$$<$;QQ7B?\ :^I9_P"/Z?\
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M0 4444 %%%% !6?J%\]I<6\:KD2, ?SK0K'UB*22[LRB%@'&2.W- &Q1110
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M%!)-=!I/AN:X82W \N,'H>IK:C1G5ERP0U%R=D,\/Z.UW.LLJ?N5.3GO7<@
M# Z"F0PI!$L<:A5'0"I*^EPN&C0ARK<[(0Y4%%%%=)84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %5[Z8064KG^Z15BJ.K_\@R7Z
M5%1V@VA2V/-Y&+.2>3W-*K4QOO&D!KX^_4X"8QQ28+QHV/515"Z\-Z5>J0]N
M%).215U6J0-713KSAK%V*3.?G\!:3+"5C+(YZ-UQ6>?AK:G_ )?G_P"^:[,/
M2[Z[(YCB8K2;*YF<.WPQM#_R_/\ ]\5$WPNM#_R_O_WQ7>EZ87IO-,5_.',S
MB;7X::9"[&XG>93T&,8J=O .B1%7",<'.,FNK+5#(?D:L)YCB9/XV2Y,I)X8
MT,!3]A3(QWK22QLD"A;6(;>GRBFQM\@J3?6+KU)?%)L+EC*CHJCZ**0O[U!O
MI-]1S!<E9ZB9J:6II.:AR%<U_#QSJL'^^*]!KA/"T(EU09_@7>/K7=U[^5IJ
MC?S.FA\(4445Z1L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %)@'J*6LO5+N:WN;9(R '8!OS
MH U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ!
MHANE-S !O ^9?6NBHK*M1C5@X2)E%25F>4.C(V&!&/44VN_U/P[;WV9(_DEZ
M^QKDKW1;NS.6B;9_>KYW$8&K1>UT<DJ<HF;13S$X/W3^5)Y;_P!T_E7&0-HJ
MS#8W$Y BB9R>P%=!IOA61V\R[.U?[G>MZ6&JU7:**C%RV.;6TN)8F>.-F5>I
M J+9L&VO4H;."W@\F.-53&" .M<[K'AD.?.LP<]T_P *[:V63A!.#N^II*BT
MKHX^BI9;>2%]KJ0?I45>6TUHS$***,&D 4Y$:1PJ@DDU-;V<]T^V*-F/H*[+
M1O#RV9$UQAY,<#'2NK#82I7EIMW+A!R>@[P[I/V*#SI5Q*XX]A6[117TU*E&
ME!0CT.R,5%604445H,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N9\73XMXH1G[VX^XKIJY+Q?]Z/Z5QX]M8>5C.K\!RF>:E5O7
M!^M0TH.*^93L<@Z2RM)T*2P(0W7BLR?P?H]S)O,13C& 36L&IX>NJEB:L/AD
MT4F<O=?#S3YG!@G>)<<C&<U5/PSM3_R_/_WS7:AZ-]=2S+$I6YQ\S.%;X86A
M_P"7Y_\ O@5$WPNM/^?]_P#OBN^+TPM0\TQ7\X<S.0B^'.C1PJLI>1QU;IFK
M%EX*T2TN3^X\P$=&)KHF:HF/[U37/+'XF6CFR7)D-KH&D6DOF0V2!O4\UH10
M6T+;HX(U/J%%,#4N^LG6G+XG<+EC<!T 'T&*:7/K4.^D+5#D%QY:HBU(6I!R
M:AR%<[;PF<VLWU%=%6'X6B"Z4LO>0\CZ5N5]1A$U0BGV.RG\""BBBNDL****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CF@BN(]D
MR!U]#6-=^%[.<'RLQ9/1>E;M%9U*-.HO?5R7%2W.1F\'N/\ 4S ^N^G1>#OE
M_>SX;_9Z5UE%<W]GX>]^4CV,##M/#%E !YH,I!S\U;,4,<";(D"KZ"GT5TTZ
M,*:M!6+44M@HHHK0H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I"ZJ0"<9Z4M8NM$B\L\$CYQT/O0!M4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 4[K3+2\R9H59B/O$<BL:?PA \FY)G48Z5TM%85
M,-2J?%$APB]T<<?!\_F<31[/UJRG@^($%IWKJ**Q67X=?9%[*!G6NB6-J=RP
MJS_WB.:T>@Q1177"$8*T58M)+8****H84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !137XC8CT->3+\1[G1?%%]9WV9;1)"J^JUK3I2J7Y>
MAE5K1I6YNIZW163HWB/3==A#V<X8XY0\$?A6M6;33LS2,E)704444AA1110
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MI\0_]"S<_P#?Q*[3 ]*,#THYX_RBYEV.+_X2GQ#_ -"S<_\ ?Q*/^$I\0_\
M0LW/_?Q*[3 ]*,#THYX_RBNNQQ?_  E/B'_H6;G_ +^)1_PE/B'_ *%FY_[^
M)7:8'I1@>E'/'^45SB_^$I\0_P#0LW/_ '\2C_A*?$/_ $+-S_W\2NTP/2C
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M_P#OM:/^$@UK_H!3_P#?:UT^!Z48'I3]G/\ F?X%<K[G+_\ "0:U_P! &?\
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M'_H6KC_OXM=E@>E&!Z"G==A^VA_(OQ_S.,_X2GQ#_P!"S<_]_%I/^$I\0_\
M0LW/_?Q*[3 ]!1@>@I\R[#]M3_Y]K\?\SB_^$J\1?]"Q<_\ ?Q*/^$J\1?\
M0L7/_?Q*[3 ]*,#TI\\>P_;TO^?:_'_,XK_A*O$7_0L7/_?Q*/\ A*O$7_0L
M7/\ W\2NUP/2C ]*.>/\H>WI_P#/M?C_ )G%_P#"5>(O^A8N?^_B4?\ "5>(
MO^A8N?\ OXE=I@>E&!Z4<\?Y1>VI_P#/M?C_ )G%_P#"5>(O^A8N?^_B4?\
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M9N?^_B4?\)3XA_Z%FY_[^)79X'I1@>E'/'^47*^YQG_"4^(?^A9N?^_B4?\
M"4^(?^A9N?\ OXE=G@>E&!Z4<\?Y1<K[G&?\)3XA_P"A9N?^_B4?\)3XA_Z%
MFY_[^)79X'I1@>E'/'^47)+^8\N\8>(-9N_#EU#<Z%-;Q,A#2,ZD#\J\=[U]
M%?$/_D3K[_KF:\:\.^"M4U^Y4)"T<)Y,K# KT,+.*IMO1'EXRG)U%%:L;X>\
M6:SHTZ"TE>1!_P LV!8?E7O?AW5)]7TB*ZN+=H)&'*M6-X9^'^FZ"/-=?M$Y
M'WG'2NN"A1A0 !V%<N)JTYOW5\SKPE"K37OOY"T445R':%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'D8JK!IUI;2R2Q01
MK)(=S-M&2?K5JBG=BL@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JUQ>Q6TD:2'!D.!5FL36_\ C]LO]\?S
MH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7U!S65XF9E\,WS*2"(3@BN=T757T[P ER7S*795+>YQ2 [1[B"-MKS1JWHS
M&I 01D'(]JXZQ\,#5M-2[O[F9KB5=P;=]VIM*FU/25O(KSS&MHE)CEDYS@4
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MC]7O/%&CV#WDUS$T:$ @*O>NYKE_'W_(K3_[R_SH J6$GBO4+&&[2YB"2KN
MVK75Q2^7$BW$L8EQ\V6 JCX8_P"19T__ *XBN7UZ%[SQC%:^<\:,O.TX[4P.
M[CFBE_U<B/\ [K TUKF!7V--&&]"XS6,VCOI>G2QZ63YKCJW:L=O#]FUL7O-
M2?[?R2Y;H>U(#MLC&<\5']H@VEO.CV@X)W# KE/"6JSW5M>V4\IF>WW8E)ZC
MI6+X4TZ369+])[F06Z2X* \DXXH ]&26.49CD1Q_LL#2NZ1KN=E4>I.*X94?
M0/%D%G;32-;R#E&/'2I?$]\TVN6NFW$Q@M'.68'&>: .RCN(93B.6-S_ ++
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO4_[-U"+#D?*S#&?QK2N-%M+G4H[^0-YR# P>*34M#LM5 -Q&=X& Z\,/QH
MY'5;:+P[<VT^F7I^:0*8MV>":G\11_9_$>DZQ+GRD(#\<#K6Y:>$M-M9A*1+
M,PZ><V[%:UU9V]Y;F">)7C(Z$4 07&KV5M:&X>XCV[=P&X9-9&J:E'JG@V]N
M8D94*8&Y<=Q4B>#=,682,9I .B.^5_*M>?3[>XT][%DVP,NTJO'%(#&\$?\
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M0;'5L&XC(<='3AA^- &1XRU* :6+2.17DF;;A3DCI6+KL3PW7A^-QAEQD?\
M JZ>R\*:;9W'GXEF?L9FW8JY?Z+::C<P3SAM\'W-IQ0!#KW_ "+TW^X*I>"?
M^1?CK=N;2*[M6MY<^6PP<5'I^GP:9:BWM]VP=-QS0!;HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=:!-Y9
MX!/SCI]:VJ:T:.064$CID4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*=2 8  [4M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" P
MP0"/>EHH SGT'3))3(]I&7)SFKZ(L:A44*H[ 4ZB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O]AMA<FY\I?./\
M7>K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9^H7SVD]O&J@B1@#GZUH5
MBZT";RSP"?G';WH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J*>VANHS'-&KJ>""*EHH SX=#TV"0216D:L.AK0  & ,444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M5;K3K2](-S"LF.F:GAAC@B6.)0J+T I]% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4UD5B"P!QTIU9>IW<UO<VR1D
M .P#<>] &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6/J\4DEW:%$+!7&2.W-;%(<=\4 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !61J\TD=W:!'*AG (!Z\UKUE:I:S7%S:O&H*HP+?G0!JT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A9
M5(!(&>E%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>39
<FILENAME>cccc-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4797453+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:cccc="http://c4therapeutics.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="cccc-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_ccccSEGMENT">
    <xbrli:measure>cccc:SEGMENT</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccTarget">
    <xbrli:measure>cccc:Target</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccExchange">
    <xbrli:measure>cccc:Exchange</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccMaterialRight">
    <xbrli:measure>cccc:MaterialRight</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccPerformanceobligation">
    <xbrli:measure>cccc:Performanceobligation</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccProtein">
    <xbrli:measure>cccc:Protein</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ccccTargetProtein">
    <xbrli:measure>cccc:TargetProtein</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001662579_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20210301">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-06</xbrli:startDate>
      <xbrli:endDate>2020-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ccccUnderwritersMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cccc:UnderwritersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-06</xbrli:startDate>
      <xbrli:endDate>2020-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200925">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapClassOfWarrantOrRightAxis_ccccWarrantExercisableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200925_20200925">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cccc:WarrantExercisableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-25</xbrli:startDate>
      <xbrli:endDate>2020-09-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeEquipmentFurnitureAndFixturesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:OfficeEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapClassOfWarrantOrRightAxis_ccccWarrantExercisableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cccc:WarrantExercisableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-06</xbrli:startDate>
      <xbrli:endDate>2020-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapStatementEquityComponentsAxis_ccccRedeemableConvertiblePreferredStockWarrantMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cccc:RedeemableConvertiblePreferredStockWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeAndLaboratorySpaceMember_20170701_20170731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeAndLaboratorySpaceMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cccc:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapBalanceSheetLocationAxis_ccccRestrictedCashMember_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">cccc:RestrictedCashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cccc:WatertownLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtCounterpartyNameAxis_ccccJointResearchCommitteeMember_srtProductOrServiceAxis_ccccResearchAndDevelopmentLicenseMember_us-gaapTypeOfArrangementAxis_ccccOriginalRocheAgreementMember_20160301_20160331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:OriginalRocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cccc:JointResearchCommitteeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:ResearchAndDevelopmentLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccLeadSeriesIdentificationAchievementMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:LeadSeriesIdentificationAchievementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccGoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchDevelopmentAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ResearchDevelopmentAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:OneTimeSalesBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ProgressedUpToPhase1OrThroughGLPToxStudiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ProgressedUpToPhase1OrThroughGLPToxStudiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ProgressedUpToPhase1OrThroughGLPToxStudiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-22</xbrli:startDate>
      <xbrli:endDate>2018-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOptionToLicenseMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:OptionToLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOptionToInitiateResearchPlanMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:OptionToInitiateResearchPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchServicesPerformanceObligationsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ResearchServicesPerformanceObligationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccCommercialLicenseForSixTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:CommercialLicenseForSixTargetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchServicesForUninitiatedThreeTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ResearchServicesForUninitiatedThreeTargetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetTwoMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetTwoMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetsOneToThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetsOneToThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetsThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetsThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetsThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetsThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtProductOrServiceAxis_ccccTargetsFourToSixMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cccc:TargetsFourToSixMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:RocheAgreementAccountingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchAndDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:ResearchAndDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:OneTimeSalesBasedPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200601_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:BiogenLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccPotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cccc:CalicoLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cccc:OneTimeSalesBasedPaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheOneMember_20200605">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cccc:TrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20200605">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cccc:TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheOneMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cccc:TrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-05</xbrli:startDate>
      <xbrli:endDate>2020-06-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cccc:CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cccc:TermLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20201006_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-06</xbrli:startDate>
      <xbrli:endDate>2020-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-06</xbrli:startDate>
      <xbrli:endDate>2020-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeStatementLocationAxis_ccccOtherIncomeExpenseMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cccc:OtherIncomeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cccc:TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cccc:TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20200925_20200925">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-25</xbrli:startDate>
      <xbrli:endDate>2020-09-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200601_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccFFPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:FFPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20151228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201230_20201230">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-30</xbrli:startDate>
      <xbrli:endDate>2020-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandAndTwentyStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20201230">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20201230_20201230">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-30</xbrli:startDate>
      <xbrli:endDate>2020-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cccc:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_20200303_20200303">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-03-03</xbrli:startDate>
      <xbrli:endDate>2020-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapUnusualRiskOrUncertaintyByNatureAxis_ccccCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">cccc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cccc:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccOptionsToPurchaseCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cccc:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccOptionsToPurchaseCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cccc:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccWarrantToPurchaseCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cccc:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001662579_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001662579_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001662579_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001662579_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001662579_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001662579_20200101_20201231">CCCC</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001662579_20200101_20201231">C4 Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001662579_20200101_20201231">0001662579</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus id="F_000008" contextRef="C_0001662579_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000009" contextRef="C_0001662579_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:CurrentFiscalYearEndDate id="F_000010" contextRef="C_0001662579_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000011" contextRef="C_0001662579_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000012" contextRef="C_0001662579_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory id="F_000013" contextRef="C_0001662579_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000014" contextRef="C_0001662579_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000015" contextRef="C_0001662579_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000016" contextRef="C_0001662579_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:IcfrAuditorAttestationFlag id="F_000017" contextRef="C_0001662579_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityShellCompany id="F_000018" contextRef="C_0001662579_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntityCommonStockSharesOutstanding id="F_000019" contextRef="C_0001662579_20210301" decimals="INF" unitRef="U_xbrlishares">43119385</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000020" contextRef="C_0001662579_20200630" decimals="INF" unitRef="U_iso4217USD">0</dei:EntityPublicFloat>
  <dei:EntityFileNumber id="F_000021" contextRef="C_0001662579_20200101_20201231">001-39567</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000022" contextRef="C_0001662579_20200101_20201231">47-5617627</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000023" contextRef="C_0001662579_20200101_20201231">490 Arsenal Way</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000024" contextRef="C_0001662579_20200101_20201231">Suite 200</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000025" contextRef="C_0001662579_20200101_20201231">Watertown</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000026" contextRef="C_0001662579_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000027" contextRef="C_0001662579_20200101_20201231">02472</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000028" contextRef="C_0001662579_20200101_20201231">617</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000029" contextRef="C_0001662579_20200101_20201231">231-0700</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000030" contextRef="C_0001662579_20200101_20201231">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000031" contextRef="C_0001662579_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000032" contextRef="C_0001662579_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:DocumentAnnualReport id="F_000033" contextRef="C_0001662579_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000034" contextRef="C_0001662579_20200101_20201231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">181727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">90549000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:MarketableSecuritiesCurrent id="F_000037" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">189962000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000038" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">4484000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000039" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">4623000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000040" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">4836000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000041" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">1595000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000042" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">381009000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">96767000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000044" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3323000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">4463000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000046" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">13229000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000047" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">14453000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000048" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2577000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="F_000049" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">2577000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:Assets id="F_000050" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">400138000</us-gaap:Assets>
  <us-gaap:Assets id="F_000051" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">118260000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000052" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">5683000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000053" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">5385000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000054" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">9524000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000055" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">6671000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:DeferredRevenueCurrent id="F_000056" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">27603000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000057" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">20705000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000058" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">1042000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000059" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">880000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000060" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">43852000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000061" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">33641000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000062" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">53617000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000063" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">72718000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000064" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">11826000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000065" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">12869000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000066" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">10052000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:Liabilities id="F_000067" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">119347000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000068" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">119228000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000069" xsi:nil="true" contextRef="C_0001662579_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000070" xsi:nil="true" contextRef="C_0001662579_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000071" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">110995000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockValue id="F_000072" xsi:nil="true" contextRef="C_0001662579_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000073" xsi:nil="true" contextRef="C_0001662579_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000074" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000075" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">464597000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000076" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">5525000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000077" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000078" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">-183823000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000079" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">-117488000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000080" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">280791000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000081" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">-111963000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000082" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">400138000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000083" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">118260000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000084" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000085" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000086" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000087" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000088" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000089" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000090" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000091" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000092" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000093" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000094" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000095" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">21343452</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000096" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">43059632</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000097" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">1426641</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000098" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">43059632</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000099" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">1426641</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer id="F_000100" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">33195000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
  <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer id="F_000101" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21381000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000102" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">78440000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000103" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">48059000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000104" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">15204000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000105" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8774000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000106" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">93644000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000107" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">56833000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000108" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-60449000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000109" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-35452000</us-gaap:OperatingIncomeLoss>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000110" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5676000</us-gaap:FairValueAdjustmentOfWarrants>
  <cccc:InterestExpenseAndAmortizationOfLongTermDebtRelatedParty id="F_000111" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1229000</cccc:InterestExpenseAndAmortizationOfLongTermDebtRelatedParty>
  <us-gaap:InterestAndOtherIncome id="F_000112" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">393000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000113" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2157000</us-gaap:InterestAndOtherIncome>
  <us-gaap:NonoperatingIncomeExpense id="F_000114" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-6512000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000115" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2157000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000116" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66961000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000117" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-33295000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000118" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-626000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000119" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">804000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000120" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66335000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000121" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-34099000</us-gaap:NetIncomeLoss>
  <us-gaap:MarketableSecuritiesUnrealizedGainLoss id="F_000122" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000123" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66322000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000124" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-34099000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000125" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8468000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <cccc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="F_000126" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66335000</cccc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <cccc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="F_000127" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-42567000</cccc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000128" contextRef="C_0001662579_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-5.83</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000129" contextRef="C_0001662579_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-31.03</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000130" contextRef="C_0001662579_20200101_20201231" decimals="0" unitRef="U_xbrlishares">11370328</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000131" contextRef="C_0001662579_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1371905</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000132" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">113145900</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000133" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">110995000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000134" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">1338956</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000135" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">3639000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000136" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-83389000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000137" contextRef="C_0001662579_20181231" decimals="-3" unitRef="U_iso4217USD">-79750000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000138" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">93797</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000139" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000140" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000141" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000142" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockRepurchasedDuringPeriodShares id="F_000143" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6112</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:StockRepurchasedDuringPeriodValue id="F_000144" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodValue id="F_000145" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:NetIncomeLoss id="F_000146" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-34099000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000147" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">113145900</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000148" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">110995000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000149" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1426641</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000150" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">5525000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000151" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-117488000</us-gaap:StockholdersEquity>
  <cccc:IssuanceOfConvertiblePreferredStockShares id="F_000152" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">142857142</cccc:IssuanceOfConvertiblePreferredStockShares>
  <cccc:IssuanceOfConvertiblePreferredStockValue id="F_000153" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">145525000</cccc:IssuanceOfConvertiblePreferredStockValue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000154" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-256003042</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000155" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-256520000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000156" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">30355379</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000157" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000158" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">256517000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000159" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">256520000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <cccc:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity id="F_000160" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8001000</cccc:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity>
  <cccc:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity id="F_000161" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8001000</cccc:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000162" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">11040000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000163" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000164" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">191172000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000165" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">191173000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000166" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">281584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000167" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">887000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000168" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">887000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000169" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000170" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockRepurchasedDuringPeriodShares id="F_000171" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">43972</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:StockRepurchasedDuringPeriodValue id="F_000172" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">210000</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:StockRepurchasedDuringPeriodValue id="F_000173" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">210000</us-gaap:StockRepurchasedDuringPeriodValue>
  <cccc:VestedStockOptionSettlement id="F_000174" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-727000</cccc:VestedStockOptionSettlement>
  <cccc:VestedStockOptionSettlement id="F_000175" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-727000</cccc:VestedStockOptionSettlement>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000176" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000177" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000178" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66335000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000179" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">43059632</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000180" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000181" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">464597000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000182" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000183" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-183823000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000184" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000185" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">18600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:ProfitLoss id="F_000186" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66335000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000187" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-34099000</us-gaap:ProfitLoss>
  <us-gaap:DepreciationAndAmortization id="F_000188" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1617000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000189" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1595000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000190" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3432000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000191" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</us-gaap:ShareBasedCompensation>
  <us-gaap:GainLossOnDispositionOfAssets id="F_000192" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-16000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000193" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">95000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000194" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-334000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="F_000195" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1224000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense id="F_000196" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1144000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium id="F_000197" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">409000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000198" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-139000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000199" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-81815000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000200" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000201" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">814000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000202" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">467000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000203" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4231000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000204" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2558000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="F_000205" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3719000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <cccc:IncreaseDecreaseInOperatingLeaseLiability id="F_000206" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-881000</cccc:IncreaseDecreaseInOperatingLeaseLiability>
  <cccc:IncreaseDecreaseInOperatingLeaseLiability id="F_000207" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-734000</cccc:IncreaseDecreaseInOperatingLeaseLiability>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000208" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-12203000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000209" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-3235000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000210" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-67249000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000211" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">55614000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000212" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">104000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000213" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">78666000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000214" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">293855000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000215" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">79000000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000216" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">650000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000217" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1349000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000218" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">63000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000219" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-190505000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000220" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1620000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000221" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">145525000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <cccc:ProceedsFromIssuanceOfLongTermDebtAndWarrant id="F_000222" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">11973000</cccc:ProceedsFromIssuanceOfLongTermDebtAndWarrant>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000223" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">195074000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering id="F_000224" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3606000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000225" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">887000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000226" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">274000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000227" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">194000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000228" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">30000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <cccc:PaymentsForVestedStockOptionSettlement id="F_000229" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">727000</cccc:PaymentsForVestedStockOptionSettlement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000230" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">348932000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000231" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000232" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">91178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000233" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000234" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">93126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000235" contextRef="C_0001662579_20181231" decimals="-3" unitRef="U_iso4217USD">38888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000236" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">184304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000237" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2577000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000238" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">2577000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000239" contextRef="C_0001662579_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="F_000240" contextRef="C_0001662579_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsForUnderwritingExpense id="F_000241" contextRef="C_0001662579_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">14700000</us-gaap:PaymentsForUnderwritingExpense>
  <us-gaap:InterestPaidNet id="F_000242" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">820000</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid id="F_000243" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">143000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid id="F_000244" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1088000</us-gaap:IncomeTaxesPaid>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000245" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">256520000</us-gaap:ConversionOfStockAmountConverted1>
  <cccc:ReclassificationOfWarrantLiabilityToEquity id="F_000246" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">8001000</cccc:ReclassificationOfWarrantLiabilityToEquity>
  <cccc:InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses id="F_000247" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">296000</cccc:InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000248" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">172000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <cccc:StockOptionRepurchasesIncludedInAccruedExpenses id="F_000249" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16000</cccc:StockOptionRepurchasesIncludedInAccruedExpenses>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000250" contextRef="C_0001662579_20200101_20201231">
&lt;p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the registrant&amp;#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&amp;#8217;s fiscal year ended December&amp;#160;31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000251" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 1. Nature of the business and basis of presentation&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;C4 Therapeutics, Inc., or, together with its subsidiary, the Company, is a biopharmaceutical company focused on harnessing the body&amp;#8217;s natural regulation of protein levels to develop novel therapeutic candidates to target and eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company was incorporated in Delaware on October 7, 2015 and has its principal office in Watertown, Massachusetts. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and capital resources&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company&amp;#8217;s primary activities have been focused around research and development activities, building the Company&amp;#8217;s intellectual property, recruiting personnel and raising capital to support these activities. To date, the Company has funded its operations primarily with proceeds received from the sales of redeemable convertible preferred stock, sales of common stock through an initial public offering, through its collaboration agreements, and debt financing.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred recurring losses since its inception, including net losses of $66.3&amp;#160;million and $34.1&amp;#160;million for the years ended December 31, 2020 and 2019, respectively. In addition, as of December 31, 2020, the Company had an accumulated deficit of $183.8&amp;#160;million. To date, the Company has not generated any revenue from product sales as none of its product candidates has been approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 6, 2020, the Company completed its initial public offering, or the IPO, at which time the Company issued 11,040,000 shares of its common stock at a price to the public of $19.00 per share, which number includes 1,440,000 shares of common stock that were issued to the underwriters for the IPO when they exercised in full their overallotment option. Upon the closing of the IPO, all outstanding shares of the Company&amp;#8217;s redeemable convertible preferred stock automatically converted into 30,355,379 shares of common stock. Net proceeds from the IPO, including the exercise in full of the underwriters&amp;#8217; option to purchase additional shares, were $191.2 million, after deducting underwriting discounts and commissions of $14.7 million and expenses of $3.9 million.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects that its cash, cash equivalents and marketable securities of $371.7&amp;#160;million as of December 31, 2020&lt;font style="color:#000000;"&gt; will be sufficient to fund its operations for at least the next twelve months from the date of issuance of these consolidated financial statements. &lt;/font&gt;Accordingly, the&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt; &lt;/font&gt;consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 25, 2020, the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock and stock options, and a proportional adjustment to the existing conversion ratios for the Company&amp;#8217;s redeemable convertible preferred stock. Additionally, upon closing of the IPO a warrant issued to purchase up to 2,857,142 shares of the Company&amp;#8217;s Series B redeemable convertible preferred stock converted into a warrant exercisable for 338,784 shares of the Company&amp;#8217;s common stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented, except as otherwise stated.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks common to other life science companies in the early development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with the Food and Drug Administration, or the FDA, and other government regulations. If the Company does not successfully advance its programs into and through human clinical trials and/or enter into collaborations for its programs and commercialize any of its product candidates, the Company may be unable to produce product revenue or achieve profitability. There can be no assurance that the Company&amp;#8217;s research and development efforts will be successful, adequate protection for the Company&amp;#8217;s intellectual property will be obtained, any products developed will obtain necessary government regulatory approval, or any approved products will be commercially viable. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;COVID-19 Pandemic &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The impact of the coronavirus, or COVID-19, pandemic on the Company&amp;#8217;s business, results of operations and financial condition is uncertain and will depend on future developments, including the duration and spread of the outbreak, the impact of vaccines and new strains of COVID-19, and any governmental advisories and restrictions. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000252" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 2. Summary of significant accounting policies&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America, or U.S.&amp;#160;GAAP. &lt;font style="color:#000000;"&gt;Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&amp;#160;no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company&amp;#8217;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&amp;#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&amp;#8217;s long-lived assets are held in the United States. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with a maturity of three&amp;#160;months or less when purchased to be cash equivalents. The Company&amp;#8217;s cash equivalents are measured at fair value on a recurring basis.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&amp;#8217; equity (deficit) until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&amp;#8217;s lease agreements for its Watertown, Massachusetts facility (see Note 6, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;). &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, t&lt;font style="color:#000000;"&gt;he Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;, or ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&amp;#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC&amp;#160;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs other than Level&amp;#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, cash equivalents and restricted cash are Level&amp;#160;1 assets which are&amp;#160;comprised of funds held in checking and money market accounts.&amp;#160;Marketable securities are Level 2 assets which are comprised of US treasury funds with maturity dates of less than one year. The carrying amounts of accounts receivable, which relate to the Company&amp;#8217;s collaboration agreements, accounts payable, and accrued expenses approximate their fair values due to their short-term nature. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset category&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment, furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for leases in accordance with ASC Topic&amp;#160;842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, or ASC&amp;#160;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if any, and the Company&amp;#8217;s control over the use of the identified asset(s), if applicable. As provided by ASC 842, the Company elected to combine lease and non-lease components as a single component for all leases. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over&amp;#160;the expected lease term. &lt;font style="color:#000000;"&gt;Certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company&amp;#160;typically only includes&amp;#160;an initial lease term in&amp;#160;its&amp;#160;assessment of a lease arrangement; options to renew a lease are not included in the assessment unless there is reasonable certainty that&amp;#160;the Company&amp;#160;will renew. &lt;/font&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, in calculating the lease liability, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease expense is recognized over the expected lease term on a straight-line basis. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&amp;#160;reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue in accordance with ASC Topic&amp;#160;606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, or ASC&amp;#160;606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&amp;#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC&amp;#160;606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&amp;#160;non-refundable, upfront license fees; (2)&amp;#160;reimbursement of certain costs; (3)&amp;#160;customer option fees for additional goods or services; (4)&amp;#160;development milestone payments, (5)&amp;#160;regulatory and commercial milestone payments; and (6)&amp;#160;royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&amp;#160;identification of the promised goods or services in the contract; (ii)&amp;#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&amp;#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&amp;#160;allocation of the transaction price to the performance obligations; and (v)&amp;#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&amp;#160;the number of performance obligations based on the determination under step (ii)&amp;#160;above; (b)&amp;#160;the transaction price under step (iii)&amp;#160;above; (c)&amp;#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&amp;#160;above; and (d)&amp;#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&amp;#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&amp;#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&amp;#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&amp;#160;months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12&amp;#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Upfront License Fees &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if&amp;#160;necessary, adjusts the measure of performance and related revenue recognition. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Customer Options &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises under the Company&amp;#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&amp;#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further discussion of accounting for collaboration revenues, see Note&amp;#160;8, &lt;font style="font-style:italic;"&gt;Collaboration and License Agreements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&amp;#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology are expensed as&amp;#160;incurred and are included in research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which payments made to the Company&amp;#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes stock-based compensation expense based on the grant date fair value of the awards, which consist of option grants. The fair value of each share option grant was determined using the expected term, expected volatility, risk-free interest rate, dividend rate, and the fair value of the common stock underlying the share-based award. Prior to the IPO, the fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&amp;#8217;s board of directors. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;font style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/font&gt;. Each of these inputs is subjective and generally requires judgment and estimation by management. Subsequent to the IPO, the fair value of the common stock underlying shared based awards is the quoted market price of the Company&amp;#8217;s common stock on the date of the grant. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&amp;#8217; payroll costs are classified or in which the award recipients&amp;#8217; service payments are classified.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Warrant Liability Expense&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&amp;#8217;s completion of a financing involving the sale of shares of Series B redeemable convertible preferred stock, or the Series B Financing, in June and July 2020 and the entry into the Term Loan (see Note 9, &lt;font style="font-style:italic;"&gt;Long-term debt and warrant liability&lt;/font&gt;), the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability, determined using Black-Scholes, as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon completion of the IPO, the warrant converted into a warrant to purchase shares of the Company&amp;#8217;s common stock, as described in Note 9, &lt;font style="font-style:italic;"&gt;Long-term debt and warrant liability&lt;/font&gt;. Upon conversion into a warrant exercisable for shares of the Company&amp;#8217;s stock, management concluded that the warrant meets the definition of an equity instrument and the fair value of the warrant at the time of conversion, determined using Black-Scholes, was recorded as an increase in additional paid-in capital.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As noted above, the Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible Series B Preferred Stock or common stock issuable upon exercise of the warrant, remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequence of events that have been recognized in the consolidated financial statements or the Company&amp;#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) which includes certain changes in equity that are excluded from net loss. The Company&amp;#8217;s only element of other comprehensive income is unrealized gains and losses on marketable securities. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss per share attributable to common stockholders is calculated using the&amp;#160;two-class&amp;#160;method, which is an earnings allocation formula that determines net loss per share for the holders of shares of the Company&amp;#8217;s common stock and participating securities. The Company&amp;#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share is computed using the more dilutive of (a)&amp;#160;the&amp;#160;two-class&amp;#160;method or (b)&amp;#160;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&amp;#8217;s plans or when its plans alleviate substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The Company&amp;#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&amp;#8217;s cash needs and comparing those needs to the current cash and cash equivalent balance. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This standard became effective for the Company on January 1, 2020 and, based on the composition of the Company&amp;#8217;s receivables and available-for-sale debt securities, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on its consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No.&amp;#160;2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (Topic 740): &lt;font style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes, or &lt;/font&gt;ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2020, with early adoption permitted. The adoption of ASU 2019-12 is not expected to have a material effect on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;font style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/font&gt;, which provides temporary optional guidance for a limited time to ease the potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as the London Interbank Offered Rate (LIBOR). Optional expedients in Topic 848 are generally available until December 31, 2022. The adoption of ASU 2020-04 is not expected have a material effect on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000253" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Note 3. Fair value measurements&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&amp;#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,040&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the fair value of the Company&amp;#8217;s financial assets by level within the fair value hierarchy at December&amp;#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its money market funds, which are valued based on quoted market prices in active markets, with no valuation adjustment, as Level 1 assets within the fair value hierarchy. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of U.S. Treasury securities and are classified as available-for-sale pursuant to ASC 320, &lt;font style="font-style:italic;"&gt;Investments &amp;#8211; Debt and Equity Securities&lt;/font&gt;. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies on a recurring basis.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As further discussed in Note 9, &lt;font style="font-style:italic;"&gt;Long-term debt and warrant liability,&lt;/font&gt; during the year ended December 31, 2020, the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock to Perceptive Credit Holdings III, LP, an affiliate of Perceptive Advisors LLC, or Perceptive. Perceptive is a considered a related party to the Company based on its ownership of the Company&amp;#8217;s common stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date. The warrant is considered within Level 3 of the fair value hierarchy because the fair value uses management&amp;#8217;s own assumptions about the assumptions that market participants would use in pricing the liability. Upon the completion of the Company&amp;#8217;s IPO on October 6, 2020, the warrant was automatically converted into a warrant exercisable for 338,784 shares of the Company&amp;#8217;s common stock and was reclassified as equity. The fair value of the warrant was determined on October 6, 2020 using the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the changes in Level 3 instruments, redeemable convertible preferred stock warrant, for the year ended December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the warrant has not been exercised.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no transfers between fair value levels during the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="F_000254" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 4. Marketable securities&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities at December&amp;#160;31, 2020 consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, none of the Company&amp;#8217;s marketable securities were in an unrealized loss position. During the year ended December&amp;#160;31, 2020, the Company did not recognize any other-than-temporary impairment losses. The contractual maturity dates of the Company&amp;#8217;s marketable securities are less than one year.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not have any marketable securities at December&amp;#160;31, 2019.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000255" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 5. Property and equipment&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment as of December&amp;#160;31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,207&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense related to property and equipment for the years ended December&amp;#160;31, 2020 and 2019 is as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:LesseeOperatingLeasesTextBlock id="F_000256" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 6. Leases&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the Company entered into a lease of office and laboratory space for its headquarters in Watertown, Massachusetts, or the Watertown Lease. The Watertown Lease has a non-cancelable term of ten years with an option to extend for one additional five-year period and is subject to rent escalation throughout the term. Additionally, the Watertown Lease required the Company to provide collateral in the amount of $2.6 million, which is recorded as restricted cash on the accompanying consolidated balance sheets. The Watertown Lease commenced in April 2018, with rent commencing in May 2018. The Watertown Lease was classified as an operating lease and, upon the commencement in April 2018, the Company recorded a lease liability of $15.1&amp;#160;million and a right-of-use asset of $16.7 million, which is inclusive of $1.5 million of construction costs funded by the Company. In calculating the lease liability and the right-of-use asset, the Company did not include the additional five-year period option as management does not believe there is reasonable certainty the Company will exercise the option. In addition to rent, the Company is also responsible for paying its pro rata share of costs incurred for common area maintenance, real estate taxes and property insurance related to the leased space, which are accounted for as variable lease costs.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The elements of lease costs for the years ended December&amp;#160;31, 2020 and 2019 were as follows (in thousands):&lt;font style="font-size:9.5pt;font-family:Arial;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for operating liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future lease payments under non-cancelable leases as of December&amp;#160;31, 2020 for each of the years ending December 31 are as follows (in thousands):&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,483&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,471&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,868&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000257" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 7. Accrued expenses and other current liabilities&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following as of December&amp;#160;31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,724&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;728&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,524&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000258" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 8. Collaboration and license agreement&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&amp;#160;31, 2020 (in thousands): &amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net of Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roche Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;776&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calico License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,958&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,220&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&amp;#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net of Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roche Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,164&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calico License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,540&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial information related to the collaboration and license agreements for the years ended December&amp;#160;31, 2020 and 2019 are (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in the contract liability at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized from performance obligations fully or partially satisfied in previous periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,137&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Roche Collaboration and License Agreement &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Original Roche Agreement Structure &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the Company entered into a license agreement, or the Original Roche Agreement, with Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche. Pursuant to the terms of the Original Roche Agreement, the Company and Roche agreed to collaborate on research activities to develop novel treatments in the field of targeted protein degradation using the Company&amp;#8217;s degrader technology. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In exchange for a $15.0&amp;#160;million nonrefundable upfront payment and additional fees for dedicated personnel, the Company performed initial research and development services for drug discovery and preclinical development, provided a non-exclusive research and development license to its technology and participated on the joint research committee, or the Roche JRC. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restated Roche Agreement Structure &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December&amp;#160;22, 2018, the Company and Roche executed the Amended and Restated Roche License Agreement, or the Roche Agreement. Under the Roche Agreement, the Company has a more active role in the manufacturing and commercialization of the targets, whereby if certain co-development and co-detailing rights are opted into by the Company, the parties will split future development costs in return for the rights to a larger share of future earnings from commercialization of the target. The target structure was revised to six potential targets, three of which were nominated as of the execution of the Roche Agreement and represent continuations of the initial preclinical research and development efforts begun under the Original Roche Agreement and three additional targets that were not nominated as of the execution of the Roche Agreement. Roche maintained its option rights to license and commercialize these six targets. For certain targets, Roche is required to pay the Company fees of $2.0&amp;#160;million and $3.0&amp;#160;million upon the progression of targets to the lead series identification achievement and GLP toxicology, or Tox, study phase, respectively. For each target option exercised by Roche, the Company is eligible to receive up to $275.0&amp;#160;million in research and development milestones per target and commercial milestone payments, with the commercial milestones being dependent on underlying net sales. Roche is also required to pay the Company up to $150.0&amp;#160;million per target in one-time sales-based payments if the target achieves certain levels of net sales. In addition, Roche is required to pay the Company royalties, at percentages from the mid-single digits to the low double-digits, on a licensed product-by licensed product basis, on worldwide net product sales. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Roche Agreement: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company received additional upfront consideration of $40.0&amp;#160;million from Roche; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company has an option for co-development and co-detailing rights, whereby it would be required to provide additional financial support in return for the rights to a larger share of future earnings from commercializing one or more of the six targets; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roche will no longer provide FTE reimbursement; rather, it will make annual research plan payments of $1.0&amp;#160;million for each active research plan; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments were made to the option exercise fees, whereby certain targets now have option exercise fees of $7.0&amp;#160;million to $12.0&amp;#160;million (those progressed up to Phase 1 or through the GLP Tox studies, respectively) and others have $20.0&amp;#160;million (those progressed through clinical trials). &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The collaboration is managed by a joint research committee. The Company has control over the committee and may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&amp;#160;days&amp;#8217; prior written notice. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company signed an amendment to the Roche Agreement that provides a mechanism through which the Company and Roche can mutually agree to terminate the Roche Agreement on a target-by-target basis by entry into a mutual target termination agreement. Upon a termination of this nature, the Roche Agreement, as amended, provides that all rights in know-how and intellectual property in support of products that use inhibition as their mode of action, referred to as the Roche Field, will revert to Roche and all rights in respect of know-how and intellectual property in support of products that use degradation as their mode of action, referred to as the C4T Field, will revert to the Company. Further, this amendment states that, following the entry into a mutual target termination agreement, Roche will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the Roche Field and the Company will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the C4T Field. In support of this allocation of rights, under the amendment, Roche provided the Company, and the Company provided Roche, with a perpetual, irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the know-how and intellectual property rights that are allocated to a party under the mutual target termination agreement. Finally, through the entry into this amendment, the Company and Roche mutually agreed to terminate the Roche Agreement as to the target EGFR.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Roche Agreement Accounting &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Roche Agreement is a modification of the Original Roche Agreement under ASC 606 as both the scope and price of the contract were changed under the Roche Agreement and new, distinct performance obligations were created for targets that have different standalone selling prices based on the Company&amp;#8217;s revised obligations. The Roche Agreement was not determined to be a separate contract for accounting purposes. The modification was accounted for as if it were a termination of the existing contract and the creation of a new contract, for which the unrecognized consideration from the Original Roche Agreement is added to the new transaction price promised as part of the Roche Agreement and will be recognized as revenue prospectively, as the new performance obligations are satisfied. The Company made this determination after considering the performance obligations under the Roche Agreement. When the amendment was signed, the contract was restructured such that the Company would pursue some of the same targets, but would have additional material responsibility to potentially develop the targets beyond the option exercise point, to either Phase 1 completion or to a point where the Company will exercise its co-development and co-detailing options and more fully share in the costs and future revenues. The $40.0&amp;#160;million upfront payment, $13.5 million of expected research plan funding payments, plus $6.4&amp;#160;million of remaining deferred revenue from the Original Roche Agreement represent the transaction price as of the outset of the arrangement. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Roche, is a customer. The Company identified the following promises at the outset of the Roche Agreement: (1)&amp;#160;a non-exclusive royalty-free license to use the Company&amp;#8217;s intellectual property to conduct research and development activities; (2)&amp;#160;research and development services under the research plan for the three initial targets; (3)&amp;#160;participation on the Roche JRC; (4)&amp;#160;option rights to initiate a research plan for three additional targets; (5) an option to obtain a non-exclusive commercial license to intellectual property and know-how generated from the collaboration, subject to certain exclusivity requirements; (6) option rights to develop, commercialize and manufacture products related to any of the six targets; and (7)&amp;#160;rights for Roche to substitute targets prior to completion of a research plan, limited to six exchanges in total across the arrangement and subject to approval by the Roche JRC. The Roche JRC has equal representation from both parties, but the Company holds final decision-making authority in the event of a disagreement until the time at which Roche licenses a target and leads development efforts. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The six potential targets were determined to be distinct from one another, as Roche can derive benefit from each target independent of the others. For each target, the Company determined that the research and development license and research and development services were not distinct from one another, because the research and development services are essential to the license. Roche would receive little to no economic benefit from the license if it did not obtain the research services. Participation on the Roche JRC to oversee the research and development activities and the technology transfer associated with the Original Roche Agreement were determined to be quantitatively and qualitatively immaterial. The Company evaluated Roche&amp;#8217;s option rights to initiate a research plan for three additional targets as well as the option rights to license and commercialize each target to determine whether they provide Roche with any material rights. The Company concluded that each of the options were issued with an option exercise fee that represented a significant and incremental discount and therefore provide material rights for six of the six targets&amp;#8212;three material rights from the option to license the three initial targets at the end of their research terms and three material rights from the option to initiate a research plan for the three additional targets along with the option to license such at the end of their research terms. The consideration allocated to the option rights to initiate the three additional targets is deferred until the underlying option is exercised, at which point the Company will begin recognizing revenue for these targets. The non-exclusive, limited commercial license to the intellectual property and know-how generated from the collaboration was determined to be immaterial and, as such, no consideration was allocated to it. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on these assessments, the Company identified twelve performance obligations, including three research services performance obligations, six material rights for the options to purchase a commercial license for six targets, and three material rights for the option to initiate research services for the uninitiated three targets as of the outset of the arrangement. The first three performance obligations primarily comprise: (1)&amp;#160;the non-exclusive research and development license and (2)&amp;#160;the research and development services for the target, including the related substitution rights. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company included the $40.0&amp;#160;million upfront payment, $13.5 million of expected research plan funding payments ($1.0&amp;#160;million per active target per year, for a maximum of $3.0 million per target), and $6.4&amp;#160;million of remaining deferred revenue from the Original Roche Agreement in the transaction price as of the outset of the arrangement. The Company also achieved a milestone for the identification of lead series for target 2 in April 2019, resulting in a milestone payment of $2.0 million, which was added to the transaction price and recognized cumulatively. The transaction price of $61.9 million was allocated to the performance obligations based on the estimated stand-alone selling prices at the time of the amendment. For each performance obligation, the stand-alone selling price was determined considering the expected cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&amp;#8217;s estimated probability of the options&amp;#8217; exercise as of the time of the amendment. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company allocated the following amounts of the total transaction price to the performance obligations as of the amendment date, including the $2.0 million milestone achieved in April 2019: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$29.0&amp;#160;million to the research and development performance obligations for targets&amp;#160;1-3; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$4.1&amp;#160;million to the three material rights, related to the three targets initiated at the outset of the Roche Agreement, which will not begin revenue recognition until the option is exercised or expires; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$28.8&amp;#160;million to the option to nominate targets 4-6 and the three material rights related to these options. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&amp;#8217;s consolidated balance sheet. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Biogen Collaboration Research and License Agreement &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&amp;#160;2018, the Company entered into a collaboration research and license agreement, or the Biogen License Agreement, with Biogen MA, Inc., or Biogen. Pursuant to the terms of the Biogen License Agreement, the Company and Biogen agreed to collaborate on research activities to develop novel treatments in the field of TPD using the Company&amp;#8217;s degrader technology. In February 2020, the Company entered into an amendment to the Biogen Agreement that provided further clarity around Biogen&amp;#8217;s ownership of target binding moieties, which are portions of molecules, and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provides that Biogen licenses to the Company the rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement. Under the terms of the Biogen License Agreement, the Company will initially develop TPD therapeutics that utilize degrader technology for up to five target proteins over a period of 54 months. On a target-by-target basis, after successful completion of a defined target evaluation period, Biogen assumes full rights and responsibility to each degrader to meet certain criteria against a target. Biogen also has the option to pay an additional $62.5&amp;#160;million to extend the contract and select up to five additional targets for development. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In exchange for the non-exclusive research license from Biogen as well as a $45.0&amp;#160;million nonrefundable upfront payment, the Company will grant a license to develop, commercialize and manufacture products related to each of the targets, which is contingent on not cancelling the contract, will perform initial research services for drug discovery, provide a non-exclusive research and commercial license to its intellectual property and will participate on the joint steering committee, or the Biogen JSC. The Company will also be obligated to participate in early research activities for other potential targets, referred to as sandbox activities at Biogen&amp;#8217;s election up to a maximum amount; any work performed for these services will be reimbursed by Biogen, and Biogen will reimburse the Company for certain FTE costs. Biogen is also required to pay the Company up to $35.0&amp;#160;million per target in development milestones and $26.0&amp;#160;million per target in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay the Company royalties on a licensed product-by-licensed product basis, on worldwide net product sales. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The collaboration is managed by the Biogen JSC, which Biogen has control over, and Biogen may terminate the Biogen License Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&amp;#160;days&amp;#8217; prior written notice. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The nonrefundable upfront cash payment of $45.0&amp;#160;million is not creditable against any of the target development milestone fees. The research will be performed by the Company over 54 months according to the research plan approved by the Biogen JSC. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Biogen License Agreement Accounting &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed this arrangement in accordance with ASC&amp;#160;606 and concluded that the contract counterparty, Biogen, is a customer. The Company identified the following promises under the arrangement: (1)&amp;#160;a non-exclusive, royalty-free license to use the Company&amp;#8217;s intellectual property to conduct research activities; (2)&amp;#160;an upfront license to develop, commercialize and manufacture products related to each of the targets (which is contingent on not cancelling the contract); (3)&amp;#160;research services for preclinical activities under the research plan; (4)&amp;#160;participation on the Biogen JSC; and (5)&amp;#160;substitution rights for Biogen via sandbox activities to replace targets prior to a program reaching completion of a research plan, limited to five exchanges in total. Substitution is dependent on the original target failing to meet certain criteria; Biogen may only replace a target in this specific scenario. The Company also determined that Biogen&amp;#8217;s ability to terminate the Agreement at-will with 90 days&amp;#8217; notice is not representative of a substantive purchase option to continue to the research and does not provide a material right in the form of a continuous renewal option. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the licenses and research activities were not distinct from one another, as the licenses have limited value without the performance of the research activities by the Company. Participation on the Biogen JSC to oversee the research activities and the technology transfer associated with the Biogen License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on these assessments, the Company identified one performance obligation at the outset of the Biogen License Agreement, representing a combined performance obligation consisting of (1)&amp;#160;the licenses, (2)&amp;#160;the research activities for the target evaluation phase for all five targets and (3)&amp;#160;the joint research plan phase for each target. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize the transaction price as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen also has the option to fund sandbox activities in exchange for consideration, whereby the Company will perform discovery-type research at Biogen&amp;#8217;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or two additional targets under the Biogen Agreement. Revenues earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price. Sandbox research activities will be reimbursed on an FTE basis at market rates, which is adjusted for changes in the &amp;#8220;Consumer Price Index&amp;#8221; each year. The sandbox activities constitute additional research that can be purchased on an a la carte basis at an amount consistent with standalone selling price. The Company recognizes revenue as the services performed for the sandbox activities are performed and recognized $2.8 and $0.5&amp;#160;million of revenue for the years ended December&amp;#160;31, 2020 and 2019, respectively, related to the sandbox activities. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes FTE reimbursement related to sandbox activities as revenue as the hours are incurred each quarter. Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&amp;#8217;s consolidated balance sheet.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company achieved $4.0 million in milestones under the Biogen Agreement in June 2020, which amount was recorded as accounts receivable and deferred revenue at that time. The Company received payment of these milestones from Biogen in August 2020. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Calico Collaboration and License Agreement &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&amp;#160;2017, the Company entered into a collaboration and license agreement, or the Calico License Agreement, with Calico Life Sciences LLC, or Calico, whereby the Company and Calico agreed to collaborate to develop and commercialize small molecule protein degraders for diseases of aging, including cancer for a five-year period ending in March 2022, the research term. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Calico License Agreement, the Company will initially develop and commercialize small molecule protein degraders for up to five target proteins over the research term. On a target-by-target basis, after successful completion of a defined target evaluation period, Calico has an exclusive option to pursue further pre-clinical development and commercialization via a joint research plan for each target. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Calico License Agreement, Calico paid an upfront amount of $5.0&amp;#160;million and certain annual payments totaling $5.0&amp;#160;million through December 31, 2020 and pays target initiation fees and reimburses the Company for a number of FTEs, depending on the stage of the research, at specified market rates. Upon completion of the required discovery research and development services on any target, Calico is entitled to pursue commercial development of that target. The Company will perform initial research services for drug discovery and preclinical development, provide a non-exclusive research and commercial license to its IP and will participate on the Calico joint research committee, or the CJRC. For each target, the Company is eligible to receive up to $132.0&amp;#160;million in potential research, development and commercial milestone payments, on sales of all products resulting from the collaboration efforts. Calico is also required to pay the Company up to $65.0&amp;#160;million in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Calico is required to pay the Company royalties, at percentages in the mid-single digits, on a licensed product-by-licensed product basis, on worldwide net product sales. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Calico License Agreement is managed by CJRC. Calico has control over the CJRC and may terminate the Calico License Agreement on a target-by-target or product-by-product basis under several scenarios, upon prior written notice. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The nonrefundable upfront and certain annual payments are not creditable against any other payments. Calico will reimburse the Company for a contractually defined number of FTEs per target depending on the phase of development, unless otherwise agreed upon by the CJRC. The research will be performed by the Company over the research term in accordance with the research plan. For the year ended December&amp;#160;31, 2019 the Company received $2.0&amp;#160;million in cash consideration for milestone revenue and no additional consideration in the form of cash received for target initiation fees. The Company recorded an accounts receivable of $1.0&amp;#160;million for additional target initiation fees in 2019 and received payment in 2020.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Calico License Agreement Accounting &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed this arrangement in accordance with ASC&amp;#160;606 and concluded that the contract counterparty, Calico, is a customer. The Company identified the following promises under the arrangement: (1)&amp;#160;the non-exclusive, royalty-free research license and commercial license, which function for purposes of the arrangement as a license and are therefore analyzed together; (2)&amp;#160;the target evaluation research services for all five targets; (3)&amp;#160;the joint research plan research services related to targets 1 and 2, which were nominated at the execution of the Calico License Agreement; (4)&amp;#160;the target initiation rights or options associated with targets 3, 4 and 5, subject to nomination; and (5)&amp;#160;the joint research plan services associated with targets 3, 4 and 5, subject to nomination and payment of the target initiation fees from (4). The Company determined that the license and research activities were not distinct from one another, as the license has limited value without the performance of the research activities by the Company. Participation on the CJRC to oversee the R&amp;amp;D activities and the technology transfer associated with the Calico License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. The Company determined that the option rights to nominate the targets were not distinct from one another or from the other promises in the arrangement, specifically the research license and research services. The Company evaluated the target initiation rights for targets 3, 4 and 5 and the research services associated with the joint research plan nomination for these targets to determine whether they provide Calico with any material rights. The Company concluded that these options were not issued at a significant and incremental discount and therefore do not provide material rights. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on these assessments, the Company identified one performance obligation at the outset of the Calico License Agreement, which consists of: (1)&amp;#160;the non-exclusive license and (2)&amp;#160;the research activities for the target evaluation phase for all five targets and the joint research plan phase for targets 1 and 2. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Calico License Agreement, the transaction price determined by the Company is the upfront amount plus the committed anniversary payments and the target initiation fees related to the targets nominated at the execution of the Calico License Agreement. Based on the ability of Calico to cancel the arrangement for any reason, Calico effectively has an option for continued access to the Company&amp;#8217;s research license and procurement of research services that they can cancel at any time. Under the Calico License Agreement, the Company amortized the upfront fee received on a straight-line basis over the period services are available to the counterparty (i.e., the contractual term of five years). Straight-line amortization of the upfront payment was considered the best measure of progress because the customer has access to research and development services throughout the period. Incremental fees for research and development services are paid at agreed upon FTE rates and recognized in the period incurred.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&amp;#8217;s consolidated balance sheet. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <cccc:LongTermDebtAndWarrantLiabilityTextBlock id="F_000259" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 9. Long-term debt and warrant liability&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 5, 2020, contemporaneously with the completion of the Series B Financing (see Note 10, &lt;font style="font-style:italic;"&gt;Stockholders&amp;#8217; equity&lt;/font&gt;), the Company entered into a Credit Agreement, or the Credit Agreement, with Perceptive, which is a related party as previously noted, that provides for an aggregate principal borrowing amount of up to $20.0&amp;#160;million, available in two tranches of $12.5&amp;#160;million and $7.5&amp;#160;million, or the Term Loan. In June 2020, the Company drew down on the first tranche of $12.5&amp;#160;million. The borrowing bears interest at a variable rate using the greater of LIBOR or 1.75%, plus 9.50%. If LIBOR cannot be determined, an alternate rate of interest will be established giving consideration to then-prevailing market convention for determining a rate of interest. The Credit Agreement is secured by a lien on substantially all of the Company&amp;#8217;s assets, including, but not limited to, shares of the Company&amp;#8217;s subsidiaries, its current and future intellectual property, insurance, trade and intercompany receivables, inventory and equipment and contract rights. The Credit Agreement requires the Company to maintain a minimum aggregate cash balance of $3.0 million in one or more controlled accounts and contains various affirmative and negative covenants that limit its ability to engage in specified types of transactions.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to make interest-only payments until December&amp;#160;5, 2022, after which point the Company will be required to make payments of principal equal to 2% of the Term Loan until maturity on June 5, 2024, or the Maturity Date. If the Company pays off the Term Loan prior to the Maturity Date, it will be required to pay a prepayment fee. Per the terms of the Credit Agreement, the prepayment fee is $5.0 million less any interest paid through the prepayment period. As of December&amp;#160;31, 2020, the prepayment fee would be $4.2 million. The Company paid issuance costs of $0.5&amp;#160;million in connection with its entry into the Credit Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Credit Agreement, the Company issued a warrant to purchase up to 2,857,142 shares of the Company&amp;#8217;s Series B preferred stock to Perceptive at an exercise price per share of $1.05. The fair value of the warrant at the time of issuance was determined to be $2.3 million. The warrant is exercisable at any time prior to the ten-year anniversary of the closing date of the Credit Agreement. At issuance, the Company determined that the warrant is liability-classified and would be remeasured to fair value each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the Company&amp;#8217;s IPO on October 6, 2020, the warrant was effected for one-for-8.4335 reverse stock split and automatically converted into a warrant to purchase up to 338,784 shares of the Company&amp;#8217;s common stock at an exercise price per share of $8.86. Based on information available at that time, the fair value of the warrant was determined to be $8.0 million on October 6, 2020. Upon the conversion into a warrant exercisable for shares of the Company&amp;#8217;s common stock, management concluded that the warrant meets the definition of an equity instrument and the warrant was recorded, at its fair value on October 6, 2020, as an increase to additional paid-in capital. For the year ended December 31, 2020, the Company recognized $5.7 million in change in the fair value of the warrant liability as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the outstanding long-term debt was $12.5&amp;#160;million. The outstanding amount is reduced by the unamortized portions of 1) issuance costs, and 2) the issuance date fair value of the warrant to arrive at the carrying value of long-term debt as of December&amp;#160;31, 2020, which was determined to be $10.1 million.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had met the criteria to draw down on the second tranche of $7.5 million. It has the ability, but not the obligation, to draw down the second tranche until June 30, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anticipated future minimum payments on long-term debt for the years ending December 31 are (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum long-term debt payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Unamortized debt issuance costs, and debt discount related to warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying value of long-term debt&amp;#8212;related party at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,052&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</cccc:LongTermDebtAndWarrantLiabilityTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000260" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 10. Stockholders&amp;#8217; equity&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Certificate of Incorporation&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the IPO, the terms of the Company&amp;#8217;s equity securities were defined in the Company&amp;#8217;s Fourth Amended and Restated Certificate of Incorporation, which was filed with the Secretary of the State of Delaware on June 3, 2020, or the Fourth Charter. Under the Fourth Charter, the Company was authorized to issue Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock, each of which had a par value of $0.0005 per share and which are referred to collectively as Preferred Stock. On October 6, 2020, in connection with the consummation of the IPO, the Company filed its Fifth Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware. The summary below relates to the Company&amp;#8217;s Fourth Charter.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As described in Note 1, &lt;font style="font-style:italic;"&gt;Nature of the business and basis of presentation&lt;/font&gt;, on September 25, 2020 the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock, stock options and common stock warrant and a proportional adjustment to the existing conversion ratios for the Company&amp;#8217;s convertible preferred stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Fourth Charter, the Company&amp;#8217;s common stock had a par value of $0.0001 and the holders of common stock were entitled to one vote for each share held at all meetings of stockholders and written actions in lieu of meetings provided. The Fourth Charter also provided that all dividends shall be declared and paid pro rata according to the number of shares held by each holder of common stock. In the event of a liquidation, dissolution or winding up of the Company, the common stock ranks behind the Preferred Stock in terms of distribution of assets. The holders of the common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such stock. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June and July 2020, the Company closed a $150.0&amp;#160;million Series B Financing with existing and new investors. As part of the Series B Financing, the Company issued 142,857,142 shares of its Series B preferred stock at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&amp;#160;million. Of the amounts above, 138,571,428 shares were issued for gross proceeds of $145.5&amp;#160;million, less related offering costs of $4.5&amp;#160;million in June 2020, and 4,285,714 shares were issued for proceeds of $4.5&amp;#160;million in July 2020.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the Company&amp;#8217;s IPO on October 6, 2020, all outstanding shares of the Company&amp;#8217;s Preferred Stock were converted into 30,355,379 shares of common stock using the exchange rate set forth in the Fourth Charter, as amended, which provided that every 8.4335 shares of Preferred Stock converted into one share of common stock. As a result, as of December&amp;#160;31, 2020, no shares of Preferred Stock are presently outstanding.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, Preferred Stock consisted of the following (in thousands, except share data): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Issued and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuable Upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,145,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,941,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FF Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,760,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,760,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113,145,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,416,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000261" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 11. Stock-based compensation&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2015 Incentive Stock Option and Grant Plan&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December&amp;#160;28, 2015, the Company&amp;#8217;s board of directors adopted the 2015 Incentive Stock Option and Grant Plan, or the&amp;#160;2015 Plan, and reserved 2,525,327 shares of common stock for issuance under this plan. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2015 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options and restricted stock awards to eligible employees, outside directors and consultants of the Company. Options generally vest over a period of five or eight&amp;#160;years with a cliff vesting at one&amp;#160;year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again. The contractual life of all options is ten&amp;#160;years from the date of grant. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2020 Stock Option and Incentive Plan&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 8, 2020, the Company&amp;#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan, or the 2020 Plan, which became effective on September 30, 2020. Upon adoption there were 6,567,144 shares of common stock reserved for issuance under the 2020 Plan. The Company&amp;#8217;s Board of Directors, the Compensation Committee of the Board of Directors, and the Chief Executive Officer of the Company are authorized to grant a broad range of equity-based awards under the 2020 Plan, including stock options, stock appreciation rights, or SARs, restricted stock awards, or RSAs, restricted stock units, or RSUs, performance awards and stock bonus awards to the Company&amp;#8217;s officers, employees, directors and other key persons, including consultants. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following the effectiveness of the 2020 Plan, the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2020 Plan. &lt;font style="color:#000000;"&gt;As of December&amp;#160;31, 2020, the Company had 8,880,367 shares reserved under the 2020 Plan and 2015 Plan, and 3,851,003 shares available for future issuance under the 2020 Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing until the expiration of the 2020 Plan, equal to the lesser of (i) 5% of the outstanding shares of common stock on the immediately preceding December 31st, or (ii) lesser number of shares determined by the administrator of the 2020 Plan, which is the Company&amp;#8217;s Board of Directors or the Compensation Committee of the Board of Directors. On January 1, 2021, the annual increase for the 2020 Plan resulted in an additional 2,152,981 shares authorized for issuance being added to the 2020 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for the year ended December&amp;#160;31, 2020 and 2019 was classified in the consolidated statement of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock option activity under the Company&amp;#8217;s equity awards plans for the year ended December&amp;#160;31, 2020&lt;font style="color:#000000;"&gt;: &amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,222,179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(281,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,222,117&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;455,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to the option activity of the Company is as follows for the years ended December&amp;#160;31, 2020 and 2019:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic value of options exercised (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the unrecognized compensation cost related to outstanding options was $37.5&amp;#160;million, which is expected to be recognized over a weighted-average period of 3.7 years. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees for the years ended December&amp;#160;31, 2020 and 2019:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected option life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.23 - 6.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32% - 0.57%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.71% - 2.36%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.54% - 83.76%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65.50% - 76.80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2020 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 8, 2020, the Company&amp;#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective on September 30, 2020 for use by the Company following its IPO. Upon adoption there were 437,809 shares of common stock reserved for issuance under the 2020 ESPP. The 2020 ESPP provides for an annual increase to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing thereafter through January 1, 2030, equal to the lesser of (i) 1% of the outstanding shares of common stock on the immediately preceding December 31st, (ii) 656,714 shares, or (ii) lesser number of shares determined by the administrator of the 2020 ESPP. On January 1, 2021, the annual increase for the 2020 ESPP resulted in an additional 430,596 shares authorized for issuance being added to the 2020 ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To participate in the 2020 ESPP, eligible employees may authorize payroll deductions of up to 15% of their eligible compensation during an offering period. The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the 2020 ESPP. As of December&amp;#160;31, 2020, the Company had not held any offering periods and no shares had been issued under the 2020 ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;President and Chief Executive Officer Termination &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&amp;#160;3, 2020, or the Separation Date, the employment of the Company&amp;#8217;s then current president and chief executive officer, or the Former CEO, terminated. The Company repurchased all of the Former CEO&amp;#8217;s outstanding shares of common stock, which had been issued upon his exercise of previously granted stock options, for total consideration of $0.1&amp;#160;million. The Former CEO also relinquished his right to purchase shares of common stock upon the exercise of stock options that were vested as of his Separation Date, in exchange for total consideration paid by the Company of $0.7&amp;#160;million. The Company recognized the repurchase price of these shares of common stock and the relinquishment of these vested options in additional-paid-in-capital.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000262" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 12. Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax (benefit) expense consists of the following for the years ended December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current federal provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current state provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred federal provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred state provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(a) Tax Rate Reconciliation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax (benefit) expense computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows for the years ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit computed at federal statutory tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&amp;#8212;net of federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryback benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax attributes true up due to net operating loss carryback&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(b) Significant Components of Deferred Taxes &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of (a)&amp;#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and (b)&amp;#160;operating losses and tax credit carryforwards. Significant components of the Company&amp;#8217;s deferred tax assets and deferred tax liabilities are as follows as of December&amp;#160;31, 2020 and 2019 (in thousands): &lt;font style="font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D and investment tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,578&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,157&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain/loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of the deferred tax assets. As of December&amp;#160;31, 2020 and 2019, based on the Company&amp;#8217;s historical operating losses, the Company has concluded that it is more-likely-than-not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December&amp;#160;31, 2020 and 2019. The valuation allowance for deferred tax assets as of December&amp;#160;31, 2020 and 2019 was $49.9&amp;#160;million and $27.1&amp;#160;million, respectively. The net valuation allowance increase of $22.8 million during the year ended December 31, 2020 was primarily due to the increase in net operating loss and tax credits carryforward and a decrease in deferred revenue recognized during the year. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company had $58.8 million and no gross United States federal net operating loss, or NOL, carryforwards, respectively, which may be available to offset future income tax liabilities. The Tax Cuts and Jobs Act, or TCJA, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&amp;#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended, or IRC). In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&amp;#8217;s NOL carryover or 100% of a corporation&amp;#8217;s taxable income and be available for twenty years from the period the loss was generated. For U.S. federal income tax purposes, the Company has federal NOLs generated after 2017 of &lt;font style="font-weight:bold;"&gt;$&lt;/font&gt;58.8 million, which do not expire. The Company does not have any available NOLs generated prior to 2018 as they were fully utilized in 2019. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA. The Company is anticipated to carryback a portion of FY2020 NOL to the tax year ended December 31, 2019 which will result in a refund of approximately $0.6 million. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020 and 2019, the Company has total gross United States state net operating loss carryforwards of $105.1 million and $8.2&amp;#160;million, respectively, which may be available to offset future income tax liabilities that expire at various dates through 2040. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2020 and 2019, the Company has United States federal research credit carryforwards of $4.7 million and $0.4&amp;#160;million, respectively, which are available to offset future federal income tax liabilities, which expire at various dates through 2040. At December&amp;#160;31, 2020 and 2019, the Company has United States state research credit carryforwards of $1.1 million and $0.1 million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2035. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the IRC, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. In 2020, the Company completed a study of ownership changes from inception through December 31, 2020, to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The result of this study indicated that the Company experienced ownership changes as defined by IRS Section&amp;#160;382 of the Code, however there are no net operating loss carryforwards that will be limited and expire unused as a result of such ownership changes. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize interest and/or penalties related to uncertain tax benefits in income tax expense as they arise. As of December&amp;#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax benefits. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the United States, California, and Massachusetts. The federal and state income tax returns are generally subject to tax examinations for the tax years ended December&amp;#160;31, 2017 through present. To the extent that the Company has tax attribute carryforwards, the tax years in which the attributes were generated may still be adjusted upon examination by the Internal Revenue Services or State tax authorities to the extent utilized in a future period. The Company is not currently under examination by any tax authorities. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CARES Act was enacted on March&amp;#160;27, 2020. The CARES Act contains a significant number of provisions that may impact on the Company&amp;#8217;s accounting for income taxes. The Company has considered several key corporate provisions within the CARES Act, has evaluated its potential impact and as a result recorded a tax benefit of $0.6 million related to an anticipated refund to be received for federal taxes incurred for the tax year ended December 31, 2019. The refund is expected to be received in 2021 after the Company files the tax year 2020 net operating loss carryback claim upon the completion of its tax year 2020 tax returns, which are due October 15, 2021. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000263" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 13. Loss per share&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As noted in Note 2, &lt;font style="font-style:italic;"&gt;Summary of significant accounting policies&lt;/font&gt;, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for each of the years ended December 31 because including them would have had an anti-dilutive effect:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,941,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;338,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,368,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,727,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All redeemable, convertible preferred stock, including those that were outstanding as of December 31, 2019, as shown above, were converted to shares of the Company&amp;#8217;s common and effected for a one-for-8.4335 reverse stock split.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding for the years ended December&amp;#160;31, 2020 and 2019 (in thousands, except share and per share data):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrual of preferred stock dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common stock outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,370,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,371,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DefinedBenefitPlanTextBlock id="F_000264" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note 14. Defined contribution plan&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a 401(k) retirement plan, the&amp;#160;401(k)&amp;#160;Plan, whereby all full-time employees may contribute up to 90% of their pre-tax compensation, up to the maximum allowable amount set by the Internal Revenue Service. The Company, at its discretion, matches 100% of contributions to the 401(k)&amp;#160;Plan up to a maximum of $6,000 per year for each full-time employee. During each of the years ended December&amp;#160;31, 2020 and 2019, the Company contributed approximately $0.5 million and $0.4&amp;#160;million, respectively, to the 401(k)&amp;#160;Plan. &lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000265" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America, or U.S.&amp;#160;GAAP. &lt;font style="color:#000000;"&gt;Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000266" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <cccc:EmergingGrowthCompanyPolicyPolicyTextBlock id="F_000267" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&amp;#160;no longer an emerging growth company or (ii)&amp;#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;</cccc:EmergingGrowthCompanyPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000268" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S.&amp;#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company&amp;#8217;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000269" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&amp;#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&amp;#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&amp;#8217;s long-lived assets are held in the United States. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000270" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with a maturity of three&amp;#160;months or less when purchased to be cash equivalents. The Company&amp;#8217;s cash equivalents are measured at fair value on a recurring basis.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000271" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&amp;#8217; equity (deficit) until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000272" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&amp;#8217;s lease agreements for its Watertown, Massachusetts facility (see Note 6, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;). &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000273" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, t&lt;font style="color:#000000;"&gt;he Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000274" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt;, or ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&amp;#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC&amp;#160;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs other than Level&amp;#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.57%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, cash equivalents and restricted cash are Level&amp;#160;1 assets which are&amp;#160;comprised of funds held in checking and money market accounts.&amp;#160;Marketable securities are Level 2 assets which are comprised of US treasury funds with maturity dates of less than one year. The carrying amounts of accounts receivable, which relate to the Company&amp;#8217;s collaboration agreements, accounts payable, and accrued expenses approximate their fair values due to their short-term nature. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000275" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset category&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment, furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000276" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for leases in accordance with ASC Topic&amp;#160;842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, or ASC&amp;#160;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if any, and the Company&amp;#8217;s control over the use of the identified asset(s), if applicable. As provided by ASC 842, the Company elected to combine lease and non-lease components as a single component for all leases. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over&amp;#160;the expected lease term. &lt;font style="color:#000000;"&gt;Certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company&amp;#160;typically only includes&amp;#160;an initial lease term in&amp;#160;its&amp;#160;assessment of a lease arrangement; options to renew a lease are not included in the assessment unless there is reasonable certainty that&amp;#160;the Company&amp;#160;will renew. &lt;/font&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, in calculating the lease liability, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease expense is recognized over the expected lease term on a straight-line basis. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000277" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December&amp;#160;31, 2020 and 2019. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesPolicyTextBlock id="F_000278" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&amp;#160;reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
  <us-gaap:RevenueRecognitionSalesOfServices id="F_000279" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue in accordance with ASC Topic&amp;#160;606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, or ASC&amp;#160;606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&amp;#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC&amp;#160;606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&amp;#160;non-refundable, upfront license fees; (2)&amp;#160;reimbursement of certain costs; (3)&amp;#160;customer option fees for additional goods or services; (4)&amp;#160;development milestone payments, (5)&amp;#160;regulatory and commercial milestone payments; and (6)&amp;#160;royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&amp;#160;identification of the promised goods or services in the contract; (ii)&amp;#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&amp;#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&amp;#160;allocation of the transaction price to the performance obligations; and (v)&amp;#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&amp;#160;the number of performance obligations based on the determination under step (ii)&amp;#160;above; (b)&amp;#160;the transaction price under step (iii)&amp;#160;above; (c)&amp;#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&amp;#160;above; and (d)&amp;#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&amp;#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&amp;#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&amp;#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&amp;#160;months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12&amp;#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Upfront License Fees &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if&amp;#160;necessary, adjusts the measure of performance and related revenue recognition. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Customer Options &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Services &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promises under the Company&amp;#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&amp;#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For further discussion of accounting for collaboration revenues, see Note&amp;#160;8, &lt;font style="font-style:italic;"&gt;Collaboration and License Agreements.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionSalesOfServices>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000280" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&amp;#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology are expensed as&amp;#160;incurred and are included in research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which payments made to the Company&amp;#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000281" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes stock-based compensation expense based on the grant date fair value of the awards, which consist of option grants. The fair value of each share option grant was determined using the expected term, expected volatility, risk-free interest rate, dividend rate, and the fair value of the common stock underlying the share-based award. Prior to the IPO, the fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&amp;#8217;s board of directors. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;font style="font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/font&gt;. Each of these inputs is subjective and generally requires judgment and estimation by management. Subsequent to the IPO, the fair value of the common stock underlying shared based awards is the quoted market price of the Company&amp;#8217;s common stock on the date of the grant. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&amp;#8217; payroll costs are classified or in which the award recipients&amp;#8217; service payments are classified.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:FuturePolicyBenefitsLiabilityPolicy id="F_000282" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Warrant Liability Expense&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&amp;#8217;s completion of a financing involving the sale of shares of Series B redeemable convertible preferred stock, or the Series B Financing, in June and July 2020 and the entry into the Term Loan (see Note 9, &lt;font style="font-style:italic;"&gt;Long-term debt and warrant liability&lt;/font&gt;), the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability, determined using Black-Scholes, as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon completion of the IPO, the warrant converted into a warrant to purchase shares of the Company&amp;#8217;s common stock, as described in Note 9, &lt;font style="font-style:italic;"&gt;Long-term debt and warrant liability&lt;/font&gt;. Upon conversion into a warrant exercisable for shares of the Company&amp;#8217;s stock, management concluded that the warrant meets the definition of an equity instrument and the fair value of the warrant at the time of conversion, determined using Black-Scholes, was recorded as an increase in additional paid-in capital.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As noted above, the Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible Series B Preferred Stock or common stock issuable upon exercise of the warrant, remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock.&lt;/p&gt;</us-gaap:FuturePolicyBenefitsLiabilityPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000283" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequence of events that have been recognized in the consolidated financial statements or the Company&amp;#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000284" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) which includes certain changes in equity that are excluded from net loss. The Company&amp;#8217;s only element of other comprehensive income is unrealized gains and losses on marketable securities. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000285" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss per share attributable to common stockholders is calculated using the&amp;#160;two-class&amp;#160;method, which is an earnings allocation formula that determines net loss per share for the holders of shares of the Company&amp;#8217;s common stock and participating securities. The Company&amp;#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share is computed using the more dilutive of (a)&amp;#160;the&amp;#160;two-class&amp;#160;method or (b)&amp;#160;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <cccc:GoingConcernPolicyTextBlock id="F_000286" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&amp;#8217;s plans or when its plans alleviate substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The Company&amp;#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&amp;#8217;s cash needs and comparing those needs to the current cash and cash equivalent balance. &lt;/p&gt;</cccc:GoingConcernPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000287" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;font style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This standard became effective for the Company on January 1, 2020 and, based on the composition of the Company&amp;#8217;s receivables and available-for-sale debt securities, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on its consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No.&amp;#160;2019-12, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (Topic 740): &lt;font style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes, or &lt;/font&gt;ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2020, with early adoption permitted. The adoption of ASU 2019-12 is not expected to have a material effect on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;font style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/font&gt;, which provides temporary optional guidance for a limited time to ease the potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as the London Interbank Offered Rate (LIBOR). Optional expedients in Topic 848 are generally available until December 31, 2022. The adoption of ASU 2020-04 is not expected have a material effect on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock id="F_000288" contextRef="C_0001662579_20200101_20201231">Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset category&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment, furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Lesser of useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000289" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&amp;#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;370,040&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the fair value of the Company&amp;#8217;s financial assets by level within the fair value hierarchy at December&amp;#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,902&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="F_000290" contextRef="C_0001662579_20200101_20201231">The fair value of the warrant was determined on October 6, 2020 using the following assumptions:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000291" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the changes in Level 3 instruments, redeemable convertible preferred stock warrant, for the year ended December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:MarketableSecuritiesTextBlock id="F_000292" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities at December&amp;#160;31, 2020 consisted of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,949&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,962&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000293" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment as of December&amp;#160;31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,207&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,766&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,954&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,323&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <cccc:ScheduleOfDepreciationExpenseTableTextBlock id="F_000294" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense related to property and equipment for the years ended December&amp;#160;31, 2020 and 2019 is as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</cccc:ScheduleOfDepreciationExpenseTableTextBlock>
  <us-gaap:LeaseCostTableTextBlock id="F_000295" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The elements of lease costs for the years ended December&amp;#160;31, 2020 and 2019 were as follows (in thousands):&lt;font style="font-size:9.5pt;font-family:Arial;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,550&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for operating liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="F_000296" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future lease payments under non-cancelable leases as of December&amp;#160;31, 2020 for each of the years ending December 31 are as follows (in thousands):&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,483&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,339&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,471&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,868&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000297" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following as of December&amp;#160;31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,799&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,724&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,532&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;728&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,524&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <cccc:FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock id="F_000298" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&amp;#160;31, 2020 (in thousands): &amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net of Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roche Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;776&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,913&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,991&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calico License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,958&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,603&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,617&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,220&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&amp;#160;31, 2019 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net of Current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roche Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,164&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,141&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calico License Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,540&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,400&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</cccc:FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock>
  <cccc:OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock id="F_000299" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other financial information related to the collaboration and license agreements for the years ended December&amp;#160;31, 2020 and 2019 are (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized that was included in the contract liability at the beginning of the period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,570&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized from performance obligations fully or partially satisfied in previous periods&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;348&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,137&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</cccc:OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="F_000300" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anticipated future minimum payments on long-term debt for the years ending December 31 are (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum long-term debt payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Unamortized debt issuance costs, and debt discount related to warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying value of long-term debt&amp;#8212;related party at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,052&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:TemporaryEquityTableTextBlock id="F_000301" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, Preferred Stock consisted of the following (in thousands, except share data): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Issued and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuable Upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,145,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,941,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FF Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,760,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146,760,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113,145,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,995&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,416,155&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000302" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for the year ended December&amp;#160;31, 2020 and 2019 was classified in the consolidated statement of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,460&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,642&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000303" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock option activity under the Company&amp;#8217;s equity awards plans for the year ended December&amp;#160;31, 2020&lt;font style="color:#000000;"&gt;: &amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,222,179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(281,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/expired&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,222,117&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;455,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,635&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to the option activity of the Company is as follows for the years ended December&amp;#160;31, 2020 and 2019:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic value of options exercised (in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,587&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000304" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees for the years ended December&amp;#160;31, 2020 and 2019:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected option life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.23 - 6.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.32% - 0.57%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.71% - 2.36%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.54% - 83.76%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65.50% - 76.80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000305" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax (benefit) expense consists of the following for the years ended December&amp;#160;31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current federal provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;669&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current state provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred federal provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred state provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000306" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax (benefit) expense computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows for the years ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit computed at federal statutory tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&amp;#8212;net of federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rate change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryback benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax attributes true up due to net operating loss carryback&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000307" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of (a)&amp;#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and (b)&amp;#160;operating losses and tax credit carryforwards. Significant components of the Company&amp;#8217;s deferred tax assets and deferred tax liabilities are as follows as of December&amp;#160;31, 2020 and 2019 (in thousands): &lt;font style="font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,821&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,344&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D and investment tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,578&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,157&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(744&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(726&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain/loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000308" contextRef="C_0001662579_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series Seed Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,298&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,941,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,029,364&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;338,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,368,148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,727,041&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000309" contextRef="C_0001662579_20200101_20201231">
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All redeemable, convertible preferred stock, including those that were outstanding as of December 31, 2019, as shown above, were converted to shares of the Company&amp;#8217;s common and effected for a one-for-8.4335 reverse stock split.&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding for the years ended December&amp;#160;31, 2020 and 2019 (in thousands, except share and per share data):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrual of preferred stock dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,468&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(42,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average common stock outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,370,328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,371,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <cccc:InitialPublicOfferingClosingDate id="F_000310" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">2020-10-06</cccc:InitialPublicOfferingClosingDate>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000311" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="INF" unitRef="U_xbrlishares">11040000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000312" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="INF" unitRef="U_iso4217USD_xbrlishares">19.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000313" contextRef="C_0001662579_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ccccUnderwritersMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="INF" unitRef="U_xbrlishares">1440000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000314" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="INF" unitRef="U_xbrlishares">30355379</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <cccc:NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares id="F_000315" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="-5" unitRef="U_iso4217USD">191200000</cccc:NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares>
  <us-gaap:PaymentsForUnderwritingExpense id="F_000316" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="-5" unitRef="U_iso4217USD">14700000</us-gaap:PaymentsForUnderwritingExpense>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000317" contextRef="C_0001662579_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="-5" unitRef="U_iso4217USD">3900000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments id="F_000318" contextRef="C_0001662579_20201231" decimals="-5" unitRef="U_iso4217USD">371700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000319" contextRef="C_0001662579_20200101_20201231">one-for-8.4335</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000320" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200925" decimals="INF" unitRef="U_xbrlishares">2857142</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments id="F_000321" contextRef="C_0001662579_us-gaapClassOfWarrantOrRightAxis_ccccWarrantExercisableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200925_20200925" decimals="INF" unitRef="U_xbrlishares">338784</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:NumberOfOperatingSegments id="F_000322" contextRef="C_0001662579_20200101_20201231" decimals="INF" unitRef="U_ccccSEGMENT">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000323" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000324" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000325" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeEquipmentFurnitureAndFixturesMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000326" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Lesser of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf id="F_000327" contextRef="C_0001662579_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf id="F_000328" contextRef="C_0001662579_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000329" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" unitRef="U_iso4217USD">180078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000330" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" unitRef="U_iso4217USD">180078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000331" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">189962000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000332" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" unitRef="U_iso4217USD">189962000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000333" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">370040000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000334" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" unitRef="U_iso4217USD">180078000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000335" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" unitRef="U_iso4217USD">189962000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000336" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">80902000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000337" contextRef="C_0001662579_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" unitRef="U_iso4217USD">80902000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000338" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">80902000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000339" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" unitRef="U_iso4217USD">80902000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments id="F_000340" contextRef="C_0001662579_us-gaapClassOfWarrantOrRightAxis_ccccWarrantExercisableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="INF" unitRef="U_xbrlishares">338784</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:SharePrice id="F_000341" contextRef="C_0001662579_20201006" decimals="2" unitRef="U_iso4217USD_xbrlishares">26.96</us-gaap:SharePrice>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000342" contextRef="C_0001662579_20201006" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.86</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:WarrantsAndRightsOutstandingTerm id="F_000343" contextRef="C_0001662579_20201006">P9Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000344" contextRef="C_0001662579_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201006" decimals="4" unitRef="U_xbrlipure">0.7500</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000345" contextRef="C_0001662579_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201006" decimals="4" unitRef="U_xbrlipure">0.0076</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000346" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapStatementEquityComponentsAxis_ccccRedeemableConvertiblePreferredStockWarrantMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">2325</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000347" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapStatementEquityComponentsAxis_ccccRedeemableConvertiblePreferredStockWarrantMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">5676</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <cccc:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity id="F_000348" contextRef="C_0001662579_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapStatementEquityComponentsAxis_ccccRedeemableConvertiblePreferredStockWarrantMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-8001</cccc:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity>
  <cccc:NumberOfWarrantsExercised id="F_000349" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_xbrlishares">0</cccc:NumberOfWarrantsExercised>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000350" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000351" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000352" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000353" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000354" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000355" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000356" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000357" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <cccc:FairValueAssetsLevel1ToLevel3TransfersAmount id="F_000358" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel1ToLevel3TransfersAmount>
  <cccc:FairValueAssetsLevel1ToLevel3TransfersAmount id="F_000359" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel1ToLevel3TransfersAmount>
  <cccc:FairValueAssetsLevel3ToLevel1TransfersAmount id="F_000360" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel3ToLevel1TransfersAmount>
  <cccc:FairValueAssetsLevel3ToLevel1TransfersAmount id="F_000361" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel3ToLevel1TransfersAmount>
  <cccc:FairValueLiabilitiesLevel1ToLevel3TransfersAmount id="F_000362" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel1ToLevel3TransfersAmount>
  <cccc:FairValueLiabilitiesLevel1ToLevel3TransfersAmount id="F_000363" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel1ToLevel3TransfersAmount>
  <cccc:FairValueLiabilitiesLevel3ToLevel1TransfersAmount id="F_000364" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel3ToLevel1TransfersAmount>
  <cccc:FairValueLiabilitiesLevel3ToLevel1TransfersAmount id="F_000365" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel3ToLevel1TransfersAmount>
  <cccc:FairValueAssetsLevel2ToLevel3TransfersAmount id="F_000366" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel2ToLevel3TransfersAmount>
  <cccc:FairValueAssetsLevel2ToLevel3TransfersAmount id="F_000367" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel2ToLevel3TransfersAmount>
  <cccc:FairValueAssetsLevel3ToLevel2TransfersAmount id="F_000368" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel3ToLevel2TransfersAmount>
  <cccc:FairValueAssetsLevel3ToLevel2TransfersAmount id="F_000369" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueAssetsLevel3ToLevel2TransfersAmount>
  <cccc:FairValueLiabilitiesLevel2ToLevel3TransfersAmount id="F_000370" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel2ToLevel3TransfersAmount>
  <cccc:FairValueLiabilitiesLevel2ToLevel3TransfersAmount id="F_000371" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel2ToLevel3TransfersAmount>
  <cccc:FairValueLiabilitiesLevel3ToLevel2TransfersAmount id="F_000372" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel3ToLevel2TransfersAmount>
  <cccc:FairValueLiabilitiesLevel3ToLevel2TransfersAmount id="F_000373" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:FairValueLiabilitiesLevel3ToLevel2TransfersAmount>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000374" contextRef="C_0001662579_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">189949000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000375" contextRef="C_0001662579_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000376" contextRef="C_0001662579_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">189962000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:ImpairmentOfInvestments id="F_000377" contextRef="C_0001662579_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfInvestments>
  <cccc:ContractualMaturityDatesOfMarketableSecurities id="F_000378" contextRef="C_0001662579_20200101_20201231">less than one year</cccc:ContractualMaturityDatesOfMarketableSecurities>
  <us-gaap:MarketableSecurities id="F_000379" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:MarketableSecurities>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000380" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">7207000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000381" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccLaboratoryEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">6766000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000382" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">805000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000383" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">797000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000384" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">541000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000385" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">520000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000386" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">223000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000387" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000388" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">179000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000389" contextRef="C_0001662579_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdsAndLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000390" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">8955000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000391" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">8417000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000392" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">5632000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000393" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">3954000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:Depreciation id="F_000394" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1617000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000395" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1595000</us-gaap:Depreciation>
  <cccc:LesseeOperatingLeaseCommencementDate id="F_000396" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeAndLaboratorySpaceMember_20170701_20170731">2018-04</cccc:LesseeOperatingLeaseCommencementDate>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000397" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeAndLaboratorySpaceMember_20200101_20201231">In July 2017, the Company entered into a lease of office and laboratory space for its headquarters in Watertown, Massachusetts, or the Watertown Lease. The Watertown Lease has a non-cancelable term of ten years with an option to extend for one additional five-year period and is subject to rent escalation throughout the term. Additionally, the Watertown Lease required the Company to provide collateral in the amount of $2.6 million, which is recorded as restricted cash on the accompanying consolidated balance sheets. The Watertown Lease commenced in April 2018, with rent commencing in May 2018.</us-gaap:LesseeOperatingLeaseDescription>
  <cccc:RentCommencingDate id="F_000398" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ccccOfficeAndLaboratorySpaceMember_20170701_20170731">2018-05</cccc:RentCommencingDate>
  <cccc:LeaseCollateralAmount id="F_000399" contextRef="C_0001662579_us-gaapBalanceSheetLocationAxis_ccccRestrictedCashMember_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231" decimals="-5" unitRef="U_iso4217USD">2600000</cccc:LeaseCollateralAmount>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000400" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231" decimals="-5" unitRef="U_iso4217USD">16700000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability id="F_000401" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231" decimals="-5" unitRef="U_iso4217USD">15100000</us-gaap:OperatingLeaseLiability>
  <us-gaap:ConstructionPayableCurrent id="F_000402" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:OperatingLeaseCost id="F_000403" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2550000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000404" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2550000</us-gaap:OperatingLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000405" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1066000</us-gaap:VariableLeaseCost>
  <us-gaap:VariableLeaseCost id="F_000406" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1020000</us-gaap:VariableLeaseCost>
  <us-gaap:LeaseCost id="F_000407" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3616000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost id="F_000408" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3570000</us-gaap:LeaseCost>
  <us-gaap:OperatingLeasePayments id="F_000409" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2206000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments id="F_000410" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2141000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000411" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000412" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20191231">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000413" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20201231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000414" contextRef="C_0001662579_us-gaapLeaseContractualTermAxis_ccccWatertownLeaseMember_20191231" decimals="2" unitRef="U_xbrlipure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000415" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2272000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000416" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2340000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000417" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2410000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000418" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2483000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000419" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000420" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">6277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000421" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">18339000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000422" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">5471000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseLiability id="F_000423" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">12868000</us-gaap:OperatingLeaseLiability>
  <cccc:AccruedResearchAndDevelopmentCurrent id="F_000424" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3799000</cccc:AccruedResearchAndDevelopmentCurrent>
  <cccc:AccruedResearchAndDevelopmentCurrent id="F_000425" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">2615000</cccc:AccruedResearchAndDevelopmentCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000426" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3724000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000427" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">3048000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000428" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">1532000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000429" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">728000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000430" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">469000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000431" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">280000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000432" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">750000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000433" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">776000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000434" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">2958000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000435" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">4484000</us-gaap:ReceivablesNetCurrent>
  <cccc:CollaborationRevenue id="F_000436" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9051000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000437" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9913000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000438" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14231000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000439" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">33195000</cccc:CollaborationRevenue>
  <us-gaap:DeferredRevenueCurrent id="F_000440" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">11238000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000441" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">13965000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000442" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">2400000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000443" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">26991000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000444" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">26026000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000445" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">600000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenue id="F_000446" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">38229000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000447" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">39991000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000448" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000449" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">81220000</us-gaap:DeferredRevenue>
  <us-gaap:ReceivablesNetCurrent id="F_000450" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">4348000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent id="F_000451" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">4348000</us-gaap:ReceivablesNetCurrent>
  <cccc:CollaborationRevenue id="F_000452" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6409000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000453" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2432000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000454" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">12540000</cccc:CollaborationRevenue>
  <cccc:CollaborationRevenue id="F_000455" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">21381000</cccc:CollaborationRevenue>
  <us-gaap:DeferredRevenueCurrent id="F_000456" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">12164000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000457" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">6141000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000458" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">2400000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000459" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">32784000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000460" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">36934000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000461" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenue id="F_000462" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">44948000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000463" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">43075000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000464" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">5400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue id="F_000465" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">93423000</us-gaap:DeferredRevenue>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000466" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17570000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000467" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">11948000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod id="F_000468" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">348000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
  <cccc:TransactionPriceAllocatedToPerformanceObligation id="F_000469" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">91137000</cccc:TransactionPriceAllocatedToPerformanceObligation>
  <cccc:TransactionPriceAllocatedToPerformanceObligation id="F_000470" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">103923000</cccc:TransactionPriceAllocatedToPerformanceObligation>
  <cccc:NonrefundableUpfrontPaymentAndAdditionalFees id="F_000471" contextRef="C_0001662579_srtCounterpartyNameAxis_ccccJointResearchCommitteeMember_srtProductOrServiceAxis_ccccResearchAndDevelopmentLicenseMember_us-gaapTypeOfArrangementAxis_ccccOriginalRocheAgreementMember_20160301_20160331" decimals="-5" unitRef="U_iso4217USD">15000000</cccc:NonrefundableUpfrontPaymentAndAdditionalFees>
  <cccc:NumberOfPotentialTargets id="F_000472" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="INF" unitRef="U_ccccTarget">6</cccc:NumberOfPotentialTargets>
  <cccc:NumberOfTargetNominated id="F_000473" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfTargetNominated>
  <cccc:NumberOfTargetNotNominated id="F_000474" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfTargetNotNominated>
  <cccc:UpfrontFees id="F_000475" contextRef="C_0001662579_srtProductOrServiceAxis_ccccLeadSeriesIdentificationAchievementMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">2000000</cccc:UpfrontFees>
  <cccc:UpfrontFees id="F_000476" contextRef="C_0001662579_srtProductOrServiceAxis_ccccGoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">3000000</cccc:UpfrontFees>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts id="F_000477" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchDevelopmentAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="-5" unitRef="U_iso4217USD">275000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <us-gaap:ContractsReceivableClaimsAndUncertainAmounts id="F_000478" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="-5" unitRef="U_iso4217USD">150000000</us-gaap:ContractsReceivableClaimsAndUncertainAmounts>
  <cccc:AdditionalUpfrontConsideration id="F_000479" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">40000000</cccc:AdditionalUpfrontConsideration>
  <cccc:AnnualResearchPlanPaymentsReceivables id="F_000480" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222" decimals="-5" unitRef="U_iso4217USD">1000000</cccc:AnnualResearchPlanPaymentsReceivables>
  <cccc:OptionExerciseFee id="F_000481" contextRef="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">7000000</cccc:OptionExerciseFee>
  <cccc:OptionExerciseFee id="F_000482" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">12000000</cccc:OptionExerciseFee>
  <cccc:OptionExerciseFee id="F_000483" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccProgressedUpToPhase1OrThroughGLPToxStudiesMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20181222_20181222" decimals="-5" unitRef="U_iso4217USD">20000000</cccc:OptionExerciseFee>
  <cccc:CollaborationDescription id="F_000484" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementMember_20200101_20201231">The Company has control over the committee and may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90 days&#8217; prior written notice.</cccc:CollaborationDescription>
  <cccc:UpfrontPayment id="F_000485" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">40000000</cccc:UpfrontPayment>
  <cccc:ExpectedResearchPlanFundingPayments id="F_000486" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">13500000</cccc:ExpectedResearchPlanFundingPayments>
  <us-gaap:ContractWithCustomerLiability id="F_000487" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="-5" unitRef="U_iso4217USD">6400000</us-gaap:ContractWithCustomerLiability>
  <cccc:NumberOfInitialTargets id="F_000488" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfInitialTargets>
  <cccc:NumberOfAdditionalTargets id="F_000489" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfAdditionalTargets>
  <cccc:NumberOfTargets id="F_000490" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">6</cccc:NumberOfTargets>
  <cccc:NumberOfExchanges id="F_000491" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccExchange">6</cccc:NumberOfExchanges>
  <cccc:NumberOfPotentialTargets id="F_000492" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">6</cccc:NumberOfPotentialTargets>
  <cccc:NumberOfMaterialRights id="F_000493" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOptionToLicenseMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_ccccMaterialRight">3</cccc:NumberOfMaterialRights>
  <cccc:NumberOfMaterialRights id="F_000494" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOptionToInitiateResearchPlanMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_ccccMaterialRight">3</cccc:NumberOfMaterialRights>
  <cccc:NumberOfAdditionalTargets id="F_000495" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOptionToInitiateResearchPlanMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfAdditionalTargets>
  <cccc:NumberOfAdditionalTargetsDeferred id="F_000496" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfAdditionalTargetsDeferred>
  <cccc:NumberOfPerformanceObligation id="F_000497" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">12</cccc:NumberOfPerformanceObligation>
  <cccc:NumberOfPerformanceObligation id="F_000498" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchServicesPerformanceObligationsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">3</cccc:NumberOfPerformanceObligation>
  <cccc:NumberOfPerformanceObligation id="F_000499" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccCommercialLicenseForSixTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">6</cccc:NumberOfPerformanceObligation>
  <cccc:NumberOfPerformanceObligation id="F_000500" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchServicesForUninitiatedThreeTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">3</cccc:NumberOfPerformanceObligation>
  <cccc:NumberOfTargets id="F_000501" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccCommercialLicenseForSixTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">6</cccc:NumberOfTargets>
  <cccc:NumberOfTargets id="F_000502" contextRef="C_0001662579_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchServicesForUninitiatedThreeTargetsMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="INF" unitRef="U_ccccTarget">3</cccc:NumberOfTargets>
  <cccc:AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear id="F_000503" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1000000</cccc:AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear>
  <cccc:AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget id="F_000504" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">3000000</cccc:AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget>
  <cccc:MilestonePaymentReceived id="F_000505" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetTwoMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2000000</cccc:MilestonePaymentReceived>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000506" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetTwoMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="-5" unitRef="U_iso4217USD">61900000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000507" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetsOneToThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="-5" unitRef="U_iso4217USD">29000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000508" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetsThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="-5" unitRef="U_iso4217USD">4100000</us-gaap:RevenueRemainingPerformanceObligation>
  <cccc:NumberOfMaterialRights id="F_000509" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetsThreeMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20200101_20201231" decimals="INF" unitRef="U_ccccMaterialRight">3</cccc:NumberOfMaterialRights>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000510" contextRef="C_0001662579_srtProductOrServiceAxis_ccccTargetsFourToSixMember_us-gaapTypeOfArrangementAxis_ccccRocheAgreementAccountingMember_20201231" decimals="-5" unitRef="U_iso4217USD">28800000</us-gaap:RevenueRemainingPerformanceObligation>
  <cccc:AgreementDate id="F_000511" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231">2018-12</cccc:AgreementDate>
  <cccc:NumberOfTargetedProteinDegradation id="F_000512" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231" decimals="INF" unitRef="U_ccccProtein">5</cccc:NumberOfTargetedProteinDegradation>
  <cccc:ResearchAndDevelopmentAgreementPeriod id="F_000513" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231">P54M</cccc:ResearchAndDevelopmentAgreementPeriod>
  <cccc:AdditionalPaymentOnExtensionOfContract id="F_000514" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231" decimals="-5" unitRef="U_iso4217USD">62500000</cccc:AdditionalPaymentOnExtensionOfContract>
  <cccc:AdditionalTargetsForDevelopment id="F_000515" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20181201_20181231" decimals="INF" unitRef="U_ccccTarget">5</cccc:AdditionalTargetsForDevelopment>
  <cccc:NonRefundableUpfrontPayment id="F_000516" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">45000000</cccc:NonRefundableUpfrontPayment>
  <us-gaap:ProceedsFromCollaborators id="F_000517" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccResearchAndDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">35000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="F_000518" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">26000000</us-gaap:ProceedsFromCollaborators>
  <cccc:NoticePeriodForTerminationOfAgreement id="F_000519" contextRef="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">P90D</cccc:NoticePeriodForTerminationOfAgreement>
  <cccc:ResearchAndDevelopmentAgreementPeriod id="F_000520" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">P54M</cccc:ResearchAndDevelopmentAgreementPeriod>
  <cccc:NoticePeriodForTerminationOfAgreement id="F_000521" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231">P90D</cccc:NoticePeriodForTerminationOfAgreement>
  <cccc:NumberOfPerformanceObligation id="F_000522" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">1</cccc:NumberOfPerformanceObligation>
  <cccc:NumberOfTargets id="F_000523" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20201231" decimals="INF" unitRef="U_ccccTarget">5</cccc:NumberOfTargets>
  <cccc:NumberOfAdditionalTargets id="F_000524" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_ccccTarget">2</cccc:NumberOfAdditionalTargets>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000525" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000526" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <cccc:MilestonePaymentReceived id="F_000527" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccBiogenLicenseAgreementMember_20200601_20200630" decimals="-5" unitRef="U_iso4217USD">4000000</cccc:MilestonePaymentReceived>
  <cccc:ResearchTerm id="F_000528" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231">P5Y</cccc:ResearchTerm>
  <cccc:NumberOfTargetProteins id="F_000529" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="INF" unitRef="U_ccccTargetProtein">5</cccc:NumberOfTargetProteins>
  <cccc:UpfrontPayment id="F_000530" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</cccc:UpfrontPayment>
  <cccc:AnnualPayments id="F_000531" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</cccc:AnnualPayments>
  <us-gaap:ProceedsFromCollaborators id="F_000532" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccPotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">132000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="F_000533" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ccccOneTimeSalesBasedPaymentsMember_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">65000000</us-gaap:ProceedsFromCollaborators>
  <cccc:CashConsiderationReceivedForMilestoneRevenue id="F_000534" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">2000000</cccc:CashConsiderationReceivedForMilestoneRevenue>
  <cccc:AdditionalConsiderationReceivedInCashForTargetInitiationFees id="F_000535" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</cccc:AdditionalConsiderationReceivedInCashForTargetInitiationFees>
  <cccc:AccountsReceivableForAdditionalTargetInitiationFees id="F_000536" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">1000000</cccc:AccountsReceivableForAdditionalTargetInitiationFees>
  <cccc:NumberOfTargets id="F_000537" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="INF" unitRef="U_ccccTarget">5</cccc:NumberOfTargets>
  <cccc:NumberOfPerformanceObligation id="F_000538" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20201231" decimals="INF" unitRef="U_ccccPerformanceobligation">1</cccc:NumberOfPerformanceObligation>
  <cccc:ContractualTerm id="F_000539" contextRef="C_0001662579_us-gaapTypeOfArrangementAxis_ccccCalicoLicenseAgreementMember_20200101_20201231">P5Y</cccc:ContractualTerm>
  <us-gaap:DebtInstrumentFaceAmount id="F_000540" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605" decimals="INF" unitRef="U_iso4217USD">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="F_000541" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheOneMember_20200605" decimals="-5" unitRef="U_iso4217USD">12500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="F_000542" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20200605" decimals="-5" unitRef="U_iso4217USD">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:LineOfCredit id="F_000543" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapLongtermDebtTypeAxis_ccccTrancheOneMember_20200630" decimals="-5" unitRef="U_iso4217USD">12500000</us-gaap:LineOfCredit>
  <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis id="F_000544" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200101_20201231">greater of LIBOR or 1.75%, plus 9.50%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000545" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605" decimals="4" unitRef="U_xbrlipure">0.0950</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <cccc:CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding id="F_000546" contextRef="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605" decimals="INF" unitRef="U_iso4217USD">3000</cccc:CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding>
  <cccc:DateUntilWhichInterestOnlyPaymentsAreMade id="F_000547" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605">2022-12-05</cccc:DateUntilWhichInterestOnlyPaymentsAreMade>
  <us-gaap:DebtInstrumentMaturityDate id="F_000548" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605">2024-06-05</us-gaap:DebtInstrumentMaturityDate>
  <cccc:DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity id="F_000549" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605" decimals="2" unitRef="U_xbrlipure">0.02</cccc:DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity>
  <us-gaap:PaymentsOfDebtExtinguishmentCosts id="F_000550" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
  <us-gaap:PaymentsOfDebtExtinguishmentCosts id="F_000551" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4200000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
  <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts id="F_000552" contextRef="C_0001662579_us-gaapCreditFacilityAxis_ccccCreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_20200605_20200605" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000553" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">2857142</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000554" contextRef="C_0001662579_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000555" contextRef="C_0001662579_us-gaapDebtInstrumentAxis_ccccTermLoanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000556" contextRef="C_0001662579_20201006_20201006" decimals="9" unitRef="U_xbrlipure">0.118574732</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000557" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="INF" unitRef="U_xbrlishares">338784</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000558" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.86</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000559" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="-5" unitRef="U_iso4217USD">8000000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000560" contextRef="C_0001662579_us-gaapIncomeStatementLocationAxis_ccccOtherIncomeExpenseMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">5700000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000561" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">12500000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:LongTermDebt id="F_000562" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">10052000</us-gaap:LongTermDebt>
  <us-gaap:LineOfCredit id="F_000563" contextRef="C_0001662579_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20201231" decimals="-5" unitRef="U_iso4217USD">7500000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000564" contextRef="C_0001662579_us-gaapLongtermDebtTypeAxis_ccccTrancheTwoMember_20200101_20201231">2021-06-30</us-gaap:LineOfCreditFacilityExpirationDate1>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="F_000565" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour id="F_000566" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">9500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet id="F_000567" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">2448000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000568" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0005</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000569" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0005</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000570" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.0005</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000571" contextRef="C_0001662579_20200925_20200925" decimals="9" unitRef="U_xbrlipure">0.118574732</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:CommonStockVotingRights id="F_000572" contextRef="C_0001662579_20200101_20201231">one vote for each share</us-gaap:CommonStockVotingRights>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000573" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">150000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:TemporaryEquitySharesIssued id="F_000574" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">142857142</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000575" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:TemporaryEquitySharesIssued id="F_000576" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200630" decimals="INF" unitRef="U_xbrlishares">138571428</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000577" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200731" decimals="INF" unitRef="U_xbrlishares">4285714</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000578" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200601_20200630" decimals="-5" unitRef="U_iso4217USD">145500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000579" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000580" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesBRedeemableConvertiblePreferredStockMember_20200601_20200630" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:PaymentsOfStockIssuanceCosts>
  <cccc:InitialPublicOfferingClosingDate id="F_000581" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006">2020-10-06</cccc:InitialPublicOfferingClosingDate>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000582" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="INF" unitRef="U_xbrlishares">30355379</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <cccc:NumberOfPreferredStockConvertedInToOneCommonStock id="F_000583" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006_20201006" decimals="4" unitRef="U_xbrlishares">8.4335</cccc:NumberOfPreferredStockConvertedInToOneCommonStock>
  <us-gaap:PreferredStockSharesOutstanding id="F_000584" contextRef="C_0001662579_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201006" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000585" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">4000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000586" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">110000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000587" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccFFPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">32760000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000588" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">146760000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000589" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">4000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000590" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">109145900</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000591" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">113145900</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000592" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">4000000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000593" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">109145900</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000594" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">113145900</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000595" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">1000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000596" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">109995000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000597" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">1000000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000598" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">109995000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000599" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">110995000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000600" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">474298</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000601" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">12941857</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000602" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_xbrlishares">13416155</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000603" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20151228" decimals="INF" unitRef="U_xbrlishares">2525327</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000604" contextRef="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000605" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">P8Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights id="F_000606" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">Options generally vest over a period of five or eight years with a cliff vesting at one year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000607" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000608" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200930" decimals="INF" unitRef="U_xbrlishares">6567144</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000609" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">8880367</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000610" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">8880367</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000611" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3851003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <cccc:PercentageOfOutstandingSharesOfCommonStock id="F_000612" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201230_20201230" decimals="2" unitRef="U_xbrlipure">0.05</cccc:PercentageOfOutstandingSharesOfCommonStock>
  <us-gaap:CommonStockSharesAuthorized id="F_000613" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131" decimals="INF" unitRef="U_xbrlishares">2152981</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000614" contextRef="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">972000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000615" contextRef="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">395000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000616" contextRef="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2460000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000617" contextRef="C_0001662579_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1247000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000618" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3432000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000619" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1642000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000620" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">2310886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000621" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">4222179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000622" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">281584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000623" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1222117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000624" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">5029364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000625" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">455633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000626" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">5029364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000627" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000628" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000629" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000630" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000631" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000632" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000633" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000634" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231">P8Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000635" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P9Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000636" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P7Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000637" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P9Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000638" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">4801000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000639" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">102635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000640" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">13144000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000641" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="-3" unitRef="U_iso4217USD">102635000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000642" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000643" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000644" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2587000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000645" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000646" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20201231" decimals="-5" unitRef="U_iso4217USD">37500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000647" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000648" contextRef="C_0001662579_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000649" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000650" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000651" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000652" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000653" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000654" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000655" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.6954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000656" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.6550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000657" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.8376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000658" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.7680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000659" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000660" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandAndTwentyStockOptionAndIncentivePlanMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000661" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20200930" decimals="INF" unitRef="U_xbrlishares">437809</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockSharesOutstanding id="F_000662" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20201230" decimals="INF" unitRef="U_xbrlishares">656714</us-gaap:CommonStockSharesOutstanding>
  <cccc:PercentageOfOutstandingSharesOfCommonStock id="F_000663" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20201230_20201230" decimals="2" unitRef="U_xbrlipure">0.01</cccc:PercentageOfOutstandingSharesOfCommonStock>
  <us-gaap:CommonStockSharesAuthorized id="F_000664" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210131" decimals="INF" unitRef="U_xbrlishares">430596</us-gaap:CommonStockSharesAuthorized>
  <cccc:MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees id="F_000665" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.15</cccc:MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000666" contextRef="C_0001662579_us-gaapPlanNameAxis_ccccTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000667" contextRef="C_0001662579_20200303_20200303" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <cccc:PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions id="F_000668" contextRef="C_0001662579_20200303_20200303" decimals="-5" unitRef="U_iso4217USD">700000</cccc:PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000669" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-673000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000670" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">669000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000671" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">47000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000672" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">135000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000673" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-626000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000674" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">804000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000675" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000676" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000677" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000678" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000679" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000680" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <cccc:EffectiveIncomeTaxRateReconciliationStateTaxCredit id="F_000681" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.012</cccc:EffectiveIncomeTaxRateReconciliationStateTaxCredit>
  <cccc:EffectiveIncomeTaxRateReconciliationStateTaxCredit id="F_000682" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.006</cccc:EffectiveIncomeTaxRateReconciliationStateTaxCredit>
  <cccc:EffectiveIncomeTaxRateReconciliationFederalTaxCredit id="F_000683" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.035</cccc:EffectiveIncomeTaxRateReconciliationFederalTaxCredit>
  <cccc:EffectiveIncomeTaxRateReconciliationFederalTaxCredit id="F_000684" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.011</cccc:EffectiveIncomeTaxRateReconciliationFederalTaxCredit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000685" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.341</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000686" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.321</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate id="F_000687" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate id="F_000688" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <cccc:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits id="F_000689" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.010</cccc:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits>
  <cccc:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits id="F_000690" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</cccc:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_000691" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements id="F_000692" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000693" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000694" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000695" contextRef="C_0001662579_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000696" contextRef="C_0001662579_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.024</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <cccc:DeferredTaxAssetsCapitalizedStartUpCosts id="F_000697" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">1075000</cccc:DeferredTaxAssetsCapitalizedStartUpCosts>
  <cccc:DeferredTaxAssetsCapitalizedStartUpCosts id="F_000698" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">1151000</cccc:DeferredTaxAssetsCapitalizedStartUpCosts>
  <cccc:DeferredTaxAssetsOperatingLeaseLiability id="F_000699" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3859000</cccc:DeferredTaxAssetsOperatingLeaseLiability>
  <cccc:DeferredTaxAssetsOperatingLeaseLiability id="F_000700" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">3821000</cccc:DeferredTaxAssetsOperatingLeaseLiability>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000701" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">1344000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000702" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">542000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000703" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">19399000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000704" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">575000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000705" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">5578000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000706" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">441000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000707" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">23157000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000708" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">25271000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther id="F_000709" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">168000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000710" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">54580000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000711" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">31801000</us-gaap:DeferredTaxAssetsGross>
  <cccc:DeferredTaxLiabilitiesRightOfUseAsset id="F_000712" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3967000</cccc:DeferredTaxLiabilitiesRightOfUseAsset>
  <cccc:DeferredTaxLiabilitiesRightOfUseAsset id="F_000713" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">4017000</cccc:DeferredTaxLiabilitiesRightOfUseAsset>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000714" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">744000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000715" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">726000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities id="F_000716" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000717" contextRef="C_0001662579_20201231" decimals="-3" unitRef="U_iso4217USD">49866000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000718" contextRef="C_0001662579_20191231" decimals="-3" unitRef="U_iso4217USD">27058000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000719" contextRef="C_0001662579_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">22800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000720" contextRef="C_0001662579_20201231" decimals="-5" unitRef="U_iso4217USD">58800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000721" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:TaxCreditCarryforwardDescription id="F_000722" contextRef="C_0001662579_20200101_20201231">The Tax Cuts and Jobs Act, or TCJA, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended, or IRC).</us-gaap:TaxCreditCarryforwardDescription>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration id="F_000723" contextRef="C_0001662579_20201231" decimals="-5" unitRef="U_iso4217USD">58800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority id="F_000724" contextRef="C_0001662579_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
  <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate id="F_000725" contextRef="C_0001662579_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.80</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000726" contextRef="C_0001662579_20201231" decimals="-5" unitRef="U_iso4217USD">105100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000727" contextRef="C_0001662579_20191231" decimals="-5" unitRef="U_iso4217USD">8200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000728" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" unitRef="U_iso4217USD">4700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000729" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000730" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000731" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <cccc:NetOperatingLossAndTaxCreditCarryforwardsDescription id="F_000732" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20200101_20201231">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%</cccc:NetOperatingLossAndTaxCreditCarryforwardsDescription>
  <cccc:NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges id="F_000733" contextRef="C_0001662579_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</cccc:NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000734" contextRef="C_0001662579_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000735" contextRef="C_0001662579_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000736" contextRef="C_0001662579_us-gaapUnusualRiskOrUncertaintyByNatureAxis_ccccCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">-600000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000737" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_ccccSeriesSeedRedeemableConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">474298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000738" contextRef="C_0001662579_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">12941857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000739" contextRef="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccOptionsToPurchaseCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">5029364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000740" contextRef="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccOptionsToPurchaseCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2310886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000741" contextRef="C_0001662579_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ccccWarrantToPurchaseCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">338784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000742" contextRef="C_0001662579_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">5368148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000743" contextRef="C_0001662579_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">15727041</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000744" contextRef="C_0001662579_20200101_20201231" decimals="9" unitRef="U_xbrlipure">0.118574732</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000745" contextRef="C_0001662579_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-66335000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000746" contextRef="C_0001662579_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-42567000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasic id="F_000747" contextRef="C_0001662579_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-5.83</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="F_000748" contextRef="C_0001662579_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-31.03</us-gaap:EarningsPerShareBasic>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000749" contextRef="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000750" contextRef="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000751" contextRef="C_0001662579_srtRangeAxis_srtMaximumMember_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedBenefitPlanContributionsByEmployer id="F_000752" contextRef="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
  <us-gaap:DefinedBenefitPlanContributionsByEmployer id="F_000753" contextRef="C_0001662579_us-gaapRetirementPlanTypeAxis_us-gaapPensionPlansDefinedBenefitMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>40
<FILENAME>cccc-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4797453+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:cccc="http://c4therapeutics.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://c4therapeutics.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://c4therapeutics.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100110 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100150 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiability" id="Role_DisclosureLongTermDebtAndWarrantLiability">
        <link:definition>100160 - Disclosure - Long-term Debt and Warrant Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquity" id="Role_DisclosureStockholderSEquity">
        <link:definition>100170 - Disclosure - Stockholder&#8217;s Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100180 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100200 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100210 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100240 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100250 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100260 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100270 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" id="Role_DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>100290 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityTables" id="Role_DisclosureLongTermDebtAndWarrantLiabilityTables">
        <link:definition>100300 - Disclosure - Long-term Debt and Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityTables" id="Role_DisclosureStockholderSEquityTables">
        <link:definition>100310 - Disclosure - Stockholder&#8217;s Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100320 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100330 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100340 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Summary of Assumptions to Determine Fair Value of Warrant (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>100420 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100440 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
        <link:definition>100450 - Disclosure - Property and Equipment - Summary of Depreciation Expense Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails" id="Role_DisclosureLeasesSummaryOfLeaseCostsDetails">
        <link:definition>100470 - Disclosure - Leases - Summary of Lease Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails" id="Role_DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails">
        <link:definition>100480 - Disclosure - Leases - Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails2" id="Role_DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails2">
        <link:definition>100490 - Disclosure - Leases - Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100500 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
        <link:definition>100510 - Disclosure - Collaboration and License Agreements - Schedule of Financial Information Related to Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
        <link:definition>100520 - Disclosure - Collaboration and License Agreements - Schedule of Other Financial Information Related to Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails" id="Role_DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Long-term Debt and Warrant Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails" id="Role_DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails">
        <link:definition>100550 - Disclosure - Long-term Debt and Warrant Liability - Summary of Anticipated Future Minimum Payments of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails" id="Role_DisclosureStockholderSEquityAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Stockholder&apos;s Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails" id="Role_DisclosureStockholderSEquityScheduleOfPreferredStockDetails">
        <link:definition>100570 - Disclosure - Stockholder&apos;s Equity - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100590 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100600 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails">
        <link:definition>100610 - Disclosure - Stock-based Compensation - Summary of Other Information Related to the Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails">
        <link:definition>100620 - Disclosure - Stock-based Compensation - Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" id="Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Summary of Income Tax (Benefit) Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails">
        <link:definition>100640 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" id="Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
        <link:definition>100650 - Disclosure - Income Taxes - Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100670 - Disclosure - Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" id="Role_DisclosureLossPerShareAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails" id="Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails">
        <link:definition>100690 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" name="InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_IssuanceOfConvertiblePreferredStockShares" name="IssuanceOfConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_IssuanceOfConvertiblePreferredStockValue" name="IssuanceOfConvertiblePreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_VestedStockOptionSettlement" name="VestedStockOptionSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" name="ProceedsFromIssuanceOfLongTermDebtAndWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_PaymentsForVestedStockOptionSettlement" name="PaymentsForVestedStockOptionSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" name="InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_StockOptionRepurchasesIncludedInAccruedExpenses" name="StockOptionRepurchasesIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LongTermDebtAndWarrantLiabilityTextBlock" name="LongTermDebtAndWarrantLiabilityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_LongTermDebtAndWarrantLiabilityAbstract" name="LongTermDebtAndWarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" name="EmergingGrowthCompanyPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_ScheduleOfDepreciationExpenseTableTextBlock" name="ScheduleOfDepreciationExpenseTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_WatertownLeaseMember" name="WatertownLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" name="FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" name="OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_UnderwritersMember" name="UnderwritersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_WarrantExercisableMember" name="WarrantExercisableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_InitialPublicOfferingClosingDate" name="InitialPublicOfferingClosingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" name="NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OfficeEquipmentFurnitureAndFixturesMember" name="OfficeEquipmentFurnitureAndFixturesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_RedeemableConvertiblePreferredStockWarrantMember" name="RedeemableConvertiblePreferredStockWarrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" name="FairValueAssetsLevel1ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" name="FairValueAssetsLevel3ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" name="FairValueLiabilitiesLevel1ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" name="FairValueLiabilitiesLevel3ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" name="FairValueAssetsLevel2ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" name="FairValueAssetsLevel3ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" name="FairValueLiabilitiesLevel2ToLevel3TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" name="FairValueLiabilitiesLevel3ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_ContractualMaturityDatesOfMarketableSecurities" name="ContractualMaturityDatesOfMarketableSecurities" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_LesseeOperatingLeaseCommencementDate" name="LesseeOperatingLeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_RentCommencingDate" name="RentCommencingDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_LeaseCollateralAmount" name="LeaseCollateralAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_RestrictedCashMember" name="RestrictedCashMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OtherInformationAbstract" name="OtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LeaseCostsLineItems" name="LeaseCostsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LeaseCostsTable" name="LeaseCostsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_CollaborationRevenue" name="CollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_RocheAgreementMember" name="RocheAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_BiogenLicenseAgreementMember" name="BiogenLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_CalicoLicenseAgreementMember" name="CalicoLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TransactionPriceAllocatedToPerformanceObligation" name="TransactionPriceAllocatedToPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" name="NonrefundableUpfrontPaymentAndAdditionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_OriginalRocheAgreementMember" name="OriginalRocheAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_JointResearchCommitteeMember" name="JointResearchCommitteeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ResearchAndDevelopmentLicenseMember" name="ResearchAndDevelopmentLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LeadSeriesIdentificationAchievementMember" name="LeadSeriesIdentificationAchievementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" name="GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" name="ResearchDevelopmentAndCommercialMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OneTimeSalesBasedPaymentsMember" name="OneTimeSalesBasedPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" name="ProgressedUpToPhase1OrThroughGLPToxStudiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_RocheAgreementAccountingMember" name="RocheAgreementAccountingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OptionToLicenseMember" name="OptionToLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OptionToInitiateResearchPlanMember" name="OptionToInitiateResearchPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ResearchServicesPerformanceObligationsMember" name="ResearchServicesPerformanceObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_CommercialLicenseForSixTargetsMember" name="CommercialLicenseForSixTargetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ResearchServicesForUninitiatedThreeTargetsMember" name="ResearchServicesForUninitiatedThreeTargetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TargetTwoMember" name="TargetTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TargetsOneToThreeMember" name="TargetsOneToThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TargetsThreeMember" name="TargetsThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TargetsFourToSixMember" name="TargetsFourToSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_ResearchAndDevelopmentMilestonesMember" name="ResearchAndDevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" name="PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_NumberOfPotentialTargets" name="NumberOfPotentialTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfTargetNominated" name="NumberOfTargetNominated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfTargetNotNominated" name="NumberOfTargetNotNominated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_UpfrontFees" name="UpfrontFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AdditionalUpfrontConsideration" name="AdditionalUpfrontConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AnnualResearchPlanPaymentsReceivables" name="AnnualResearchPlanPaymentsReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_OptionExerciseFee" name="OptionExerciseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_CollaborationDescription" name="CollaborationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_ExpectedResearchPlanFundingPayments" name="ExpectedResearchPlanFundingPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_NumberOfInitialTargets" name="NumberOfInitialTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfAdditionalTargets" name="NumberOfAdditionalTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfTargets" name="NumberOfTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfExchanges" name="NumberOfExchanges" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfMaterialRights" name="NumberOfMaterialRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfAdditionalTargetsDeferred" name="NumberOfAdditionalTargetsDeferred" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfPerformanceObligation" name="NumberOfPerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" name="AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" name="AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AgreementDate" name="AgreementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfTargetedProteinDegradation" name="NumberOfTargetedProteinDegradation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_AdditionalPaymentOnExtensionOfContract" name="AdditionalPaymentOnExtensionOfContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_AdditionalTargetsForDevelopment" name="AdditionalTargetsForDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_ResearchAndDevelopmentAgreementPeriod" name="ResearchAndDevelopmentAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NonRefundableUpfrontPayment" name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_NoticePeriodForTerminationOfAgreement" name="NoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_ResearchTerm" name="ResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NumberOfTargetProteins" name="NumberOfTargetProteins" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cccc_AnnualPayments" name="AnnualPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_CashConsiderationReceivedForMilestoneRevenue" name="CashConsiderationReceivedForMilestoneRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" name="AdditionalConsiderationReceivedInCashForTargetInitiationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_AccountsReceivableForAdditionalTargetInitiationFees" name="AccountsReceivableForAdditionalTargetInitiationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_ContractualTerm" name="ContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" name="CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_LongTermDebtAndWarrantLiabilityLineItems" name="LongTermDebtAndWarrantLiabilityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_LongTermDebtAndWarrantLiabilityTable" name="LongTermDebtAndWarrantLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" name="CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TermLoanMember" name="TermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TrancheOneMember" name="TrancheOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TrancheTwoMember" name="TrancheTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" name="DateUntilWhichInterestOnlyPaymentsAreMade" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" name="DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_StockholdersEquityLineItems" name="StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_StockholdersEquityTable" name="StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" name="SeriesSeedRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" name="NumberOfPreferredStockConvertedInToOneCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_FFPreferredStockMember" name="FFPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" name="TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" name="TwoThousandAndTwentyStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_PercentageOfOutstandingSharesOfCommonStock" name="PercentageOfOutstandingSharesOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" name="MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" name="PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" name="EffectiveIncomeTaxRateReconciliationStateTaxCredit" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" name="EffectiveIncomeTaxRateReconciliationFederalTaxCredit" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" name="DeferredTaxAssetsCapitalizedStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cccc_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" name="CoronavirusAidReliefAndEconomicSecurityActMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" name="NetOperatingLossAndTaxCreditCarryforwardsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" name="NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cccc_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cccc_WarrantToPurchaseCommonStockMember" name="WarrantToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>41
<FILENAME>cccc-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4797453+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cccc-20201231.xsd#TemplateLink" roleURI="http://c4therapeutics.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" xlink:type="locator" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndOtherIncome" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForVestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_PaymentsForVestedStockOptionSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" xlink:type="locator" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cccc_PaymentsForVestedStockOptionSettlement" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cccc_IncreaseDecreaseInOperatingLeaseLiability" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails2" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="cccc_AccruedResearchAndDevelopmentCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="cccc_DeferredTaxLiabilitiesRightOfUseAsset" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cccc_DeferredTaxAssetsOperatingLeaseLiability" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>42
<FILENAME>cccc-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4797453+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="cccc-20201231.xsd#TemplateLink" roleURI="http://c4therapeutics.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_VestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_VestedStockOptionSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_IssuanceOfConvertiblePreferredStockValue" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_IssuanceOfConvertiblePreferredStockShares" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_VestedStockOptionSettlement" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingClosingDate" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingClosingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantExercisableMember" xlink:type="locator" xlink:label="cccc_WarrantExercisableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UnderwritersMember" xlink:type="locator" xlink:label="cccc_UnderwritersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cccc_UnderwritersMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cccc_WarrantExercisableMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfitLoss" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cccc_InitialPublicOfferingClosingDate" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="11130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeEquipmentFurnitureAndFixturesMember" xlink:type="locator" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="cccc_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cccc_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_LaboratoryEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_OfficeEquipmentFurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11060.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="cccc_NumberOfWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantExercisableMember" xlink:type="locator" xlink:label="cccc_WarrantExercisableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cccc_WarrantExercisableMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_NumberOfWarrantsExercised" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RedeemableConvertiblePreferredStockWarrantMember" xlink:type="locator" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cccc_RedeemableConvertiblePreferredStockWarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="cccc_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCollateralAmount" xlink:type="locator" xlink:label="cccc_LeaseCollateralAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RentCommencingDate" xlink:type="locator" xlink:label="cccc_RentCommencingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LesseeOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="cccc_LesseeOperatingLeaseCommencementDate" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="cccc_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RestrictedCashMember" xlink:type="locator" xlink:label="cccc_RestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="cccc_RestrictedCashMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_OfficeAndLaboratorySpaceMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_LesseeOperatingLeaseCommencementDate" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_RentCommencingDate" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_LeaseCollateralAmount" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ConstructionPayableCurrent" order="10640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherInformationAbstract" xlink:type="locator" xlink:label="cccc_OtherInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsTable" xlink:type="locator" xlink:label="cccc_LeaseCostsTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsLineItems" xlink:type="locator" xlink:label="cccc_LeaseCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cccc_LeaseCostsLineItems" xlink:to="cccc_LeaseCostsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LeaseCostsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LeaseCostsLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LeaseCostsLineItems" xlink:to="cccc_OtherInformationAbstract" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationRevenue" xlink:type="locator" xlink:label="cccc_CollaborationRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CalicoLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_CalicoLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_BiogenLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_BiogenLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementMember" xlink:type="locator" xlink:label="cccc_RocheAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_BiogenLicenseAgreementMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_CalicoLicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CollaborationRevenue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ContractualTerm" xlink:type="locator" xlink:label="cccc_ContractualTerm" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccountsReceivableForAdditionalTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashConsiderationReceivedForMilestoneRevenue" xlink:type="locator" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualPayments" xlink:type="locator" xlink:label="cccc_AnnualPayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetProteins" xlink:type="locator" xlink:label="cccc_NumberOfTargetProteins" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchTerm" xlink:type="locator" xlink:label="cccc_ResearchTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NoticePeriodForTerminationOfAgreement" xlink:type="locator" xlink:label="cccc_NoticePeriodForTerminationOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="cccc_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalTargetsForDevelopment" xlink:type="locator" xlink:label="cccc_AdditionalTargetsForDevelopment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalPaymentOnExtensionOfContract" xlink:type="locator" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentAgreementPeriod" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetedProteinDegradation" xlink:type="locator" xlink:label="cccc_NumberOfTargetedProteinDegradation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AgreementDate" xlink:type="locator" xlink:label="cccc_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MilestonePaymentReceived" xlink:type="locator" xlink:label="cccc_MilestonePaymentReceived" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="cccc_NumberOfPerformanceObligation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargetsDeferred" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargetsDeferred" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfMaterialRights" xlink:type="locator" xlink:label="cccc_NumberOfMaterialRights" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfExchanges" xlink:type="locator" xlink:label="cccc_NumberOfExchanges" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargets" xlink:type="locator" xlink:label="cccc_NumberOfTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargets" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfInitialTargets" xlink:type="locator" xlink:label="cccc_NumberOfInitialTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ExpectedResearchPlanFundingPayments" xlink:type="locator" xlink:label="cccc_ExpectedResearchPlanFundingPayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontPayment" xlink:type="locator" xlink:label="cccc_UpfrontPayment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationDescription" xlink:type="locator" xlink:label="cccc_CollaborationDescription" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionExerciseFee" xlink:type="locator" xlink:label="cccc_OptionExerciseFee" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualResearchPlanPaymentsReceivables" xlink:type="locator" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalUpfrontConsideration" xlink:type="locator" xlink:label="cccc_AdditionalUpfrontConsideration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontFees" xlink:type="locator" xlink:label="cccc_UpfrontFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNotNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNotNominated" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNominated" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPotentialTargets" xlink:type="locator" xlink:label="cccc_NumberOfPotentialTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonrefundableUpfrontPaymentAndAdditionalFees" xlink:type="locator" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CalicoLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_CalicoLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentMilestonesMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_BiogenLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_BiogenLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsFourToSixMember" xlink:type="locator" xlink:label="cccc_TargetsFourToSixMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsThreeMember" xlink:type="locator" xlink:label="cccc_TargetsThreeMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsOneToThreeMember" xlink:type="locator" xlink:label="cccc_TargetsOneToThreeMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetTwoMember" xlink:type="locator" xlink:label="cccc_TargetTwoMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesForUninitiatedThreeTargetsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CommercialLicenseForSixTargetsMember" xlink:type="locator" xlink:label="cccc_CommercialLicenseForSixTargetsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesPerformanceObligationsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesPerformanceObligationsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToInitiateResearchPlanMember" xlink:type="locator" xlink:label="cccc_OptionToInitiateResearchPlanMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToLicenseMember" xlink:type="locator" xlink:label="cccc_OptionToLicenseMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementAccountingMember" xlink:type="locator" xlink:label="cccc_RocheAgreementAccountingMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" xlink:type="locator" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OneTimeSalesBasedPaymentsMember" xlink:type="locator" xlink:label="cccc_OneTimeSalesBasedPaymentsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" xlink:type="locator" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeadSeriesIdentificationAchievementMember" xlink:type="locator" xlink:label="cccc_LeadSeriesIdentificationAchievementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementMember" xlink:type="locator" xlink:label="cccc_RocheAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentLicenseMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_JointResearchCommitteeMember" xlink:type="locator" xlink:label="cccc_JointResearchCommitteeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OriginalRocheAgreementMember" xlink:type="locator" xlink:label="cccc_OriginalRocheAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_OriginalRocheAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cccc_JointResearchCommitteeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_ResearchAndDevelopmentLicenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_LeadSeriesIdentificationAchievementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OneTimeSalesBasedPaymentsMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementAccountingMember" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OptionToLicenseMember" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OptionToInitiateResearchPlanMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchServicesPerformanceObligationsMember" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_CommercialLicenseForSixTargetsMember" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchServicesForUninitiatedThreeTargetsMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetTwoMember" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsOneToThreeMember" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsThreeMember" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsFourToSixMember" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_BiogenLicenseAgreementMember" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchAndDevelopmentMilestonesMember" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_CalicoLicenseAgreementMember" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" order="13680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfPotentialTargets" order="13730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetNominated" order="13750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetNotNominated" order="13770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_UpfrontFees" order="13810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" order="13850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalUpfrontConsideration" order="13920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AnnualResearchPlanPaymentsReceivables" order="13970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_OptionExerciseFee" order="14020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CollaborationDescription" order="14170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_UpfrontPayment" order="14220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ExpectedResearchPlanFundingPayments" order="14240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="14260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfInitialTargets" order="14310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfAdditionalTargets" order="14330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargets" order="14350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfExchanges" order="14370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfMaterialRights" order="14500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfAdditionalTargetsDeferred" order="14560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfPerformanceObligation" order="14610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" order="14840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" order="14860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_MilestonePaymentReceived" order="14900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AgreementDate" order="15100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetedProteinDegradation" order="15120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ResearchAndDevelopmentAgreementPeriod" order="15140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalPaymentOnExtensionOfContract" order="15160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalTargetsForDevelopment" order="15180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NonRefundableUpfrontPayment" order="15230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="15250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NoticePeriodForTerminationOfAgreement" order="15320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="15600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ResearchTerm" order="15720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetProteins" order="15770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AnnualPayments" order="15880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CashConsiderationReceivedForMilestoneRevenue" order="16090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" order="16110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AccountsReceivableForAdditionalTargetInitiationFees" order="16130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ContractualTerm" order="16300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" xlink:type="locator" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DateUntilWhichInterestOnlyPaymentsAreMade" xlink:type="locator" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" xlink:type="locator" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="cccc_OtherIncomeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheTwoMember" xlink:type="locator" xlink:label="cccc_TrancheTwoMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheOneMember" xlink:type="locator" xlink:label="cccc_TrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TermLoanMember" xlink:type="locator" xlink:label="cccc_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" xlink:type="locator" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityTable" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_LongTermDebtAndWarrantLiabilityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cccc_TermLoanMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cccc_TrancheOneMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cccc_TrancheTwoMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="cccc_OtherIncomeExpenseMember" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LineOfCredit" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LongTermDebt" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="12350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPreferredStockConvertedInToOneCommonStock" xlink:type="locator" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingClosingDate" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingClosingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityTable" xlink:type="locator" xlink:label="cccc_StockholdersEquityTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityLineItems" xlink:type="locator" xlink:label="cccc_StockholdersEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_StockholdersEquityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesARedeemableConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_InitialPublicOfferingClosingDate" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquityScheduleOfPreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FFPreferredStockMember" xlink:type="locator" xlink:label="cccc_FFPreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesARedeemableConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_FFPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" xlink:type="locator" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" xlink:type="locator" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_PercentageOfOutstandingSharesOfCommonStock" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" order="11940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" xlink:type="locator" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" xlink:type="locator" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxTable" xlink:type="locator" xlink:label="cccc_IncomeTaxTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxLineItems" xlink:type="locator" xlink:label="cccc_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_WarrantToPurchaseCommonStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cccc_OptionsToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cccc_WarrantToPurchaseCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:type="locator" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>43
<FILENAME>cccc-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4807449+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt&#8212;related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 6 and Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock (See Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value of $0.0001 per share; 10,000,000 and no shares authorized, and no shares issued or outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value of $0.0001 per share; 150,000,000 and 21,343,452 shares authorized, and 43,059,632 and 1,426,641 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" xlink:type="locator" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense and amortization of long term debt related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" xlink:to="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income (loss) available to common stockholders, basic and diluted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from collaboration agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability&#8212;related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense and amortization of long-term debt&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense And Amortization Of Long Term Debt Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (expense) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Unrealized Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of net loss to net loss attributable to common stockholders:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrual of preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends Income Statement Impact</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common stock outstanding&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital share based compensation requisite service period recognition, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares" />
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_IssuanceOfConvertiblePreferredStockShares" xlink:to="cccc_IssuanceOfConvertiblePreferredStockShares_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_IssuanceOfConvertiblePreferredStockValue" xlink:to="cccc_IssuanceOfConvertiblePreferredStockValue_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification of warrant liability to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_VestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_VestedStockOptionSettlement" />
    <link:label xml:lang="en-US" xlink:label="cccc_VestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested stock option settlement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_VestedStockOptionSettlement" xlink:to="cccc_VestedStockOptionSettlement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable convertible preferred stock, Beginning balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Redeemable convertible preferred stock, Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $4.5 million</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $4.5 million, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Convertible Preferred Stock Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability To Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon closing of initial public offering, net of issuance costs of $18.6 million</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon closing of initial public offering, net of issuance costs of $18.6 million, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_VestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested Stock Option Settlement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_VestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vested Stock Option Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable convertible preferred stock, Ending balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Redeemable convertible preferred stock, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="cccc_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" xlink:type="locator" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" />
    <link:label xml:lang="en-US" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Issuance of Long-term debt and warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" xlink:to="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForVestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_PaymentsForVestedStockOptionSettlement" />
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForVestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for vested stock option settlement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_PaymentsForVestedStockOptionSettlement" xlink:to="cccc_PaymentsForVestedStockOptionSettlement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to cash (used in) provided by operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of (premium) discount on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in carrying amount of right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds received from maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series B shares, net of issuance costs of $4.5 million</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from long-term debt and warrant, net of issuance costs of $0.5 million</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt And Warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount of $14.7 million</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForVestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested stock option settlement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForVestedStockOptionSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Vested Stock Option Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt and warrant, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Underwriting Expense</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="cccc_ReclassificationOfWarrantLiabilityToEquity" />
    <link:label xml:lang="en-US" xlink:label="cccc_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ReclassificationOfWarrantLiabilityToEquity" xlink:to="cccc_ReclassificationOfWarrantLiabilityToEquity_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:to="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockOptionRepurchasesIncludedInAccruedExpenses" xlink:type="locator" xlink:label="cccc_StockOptionRepurchasesIncludedInAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="cccc_StockOptionRepurchasesIncludedInAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option repurchases included in accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_StockOptionRepurchasesIncludedInAccruedExpenses" xlink:to="cccc_StockOptionRepurchasesIncludedInAccruedExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital expenditures in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_StockOptionRepurchasesIncludedInAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option repurchases included in accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_StockOptionRepurchasesIncludedInAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Repurchases Included In Accrued Expenses</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cccc_CollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CollaborationAndLicenseAgreementsAbstract" xlink:to="cccc_CollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityTextBlock" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term debt and warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTextBlock" xlink:to="cccc_LongTermDebtAndWarrantLiabilityTextBlock_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term debt and warrant liability abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:to="cccc_LongTermDebtAndWarrantLiabilityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Warrant Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt and Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Warrant Liability [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholder&#8217;s Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:type="locator" xlink:label="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:to="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionSalesOfServices" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionSalesOfServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionSalesOfServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionSalesOfServices" xlink:to="us-gaap_RevenueRecognitionSalesOfServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionSalesOfServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Sales Of Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:type="locator" xlink:label="us-gaap_FuturePolicyBenefitsLiabilityPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FuturePolicyBenefitsLiabilityPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:to="us-gaap_FuturePolicyBenefitsLiabilityPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FuturePolicyBenefitsLiabilityPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Future Policy Benefits Liability Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_GoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="cccc_GoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_GoingConcernPolicyTextBlock" xlink:to="cccc_GoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_GoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Indefinite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions to Determine Fair Value of Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ScheduleOfDepreciationExpenseTableTextBlock" xlink:type="locator" xlink:label="cccc_ScheduleOfDepreciationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="cccc_ScheduleOfDepreciationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Depreciation Expense Related to Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_WatertownLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Watertown lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_WatertownLeaseMember" xlink:to="cccc_WatertownLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_WatertownLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Watertown Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_WatertownLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Watertown Lease [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:type="locator" xlink:label="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial information related to the collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:to="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Information Related to Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Information Related To Collaboration And License Agreements Table [Text Block]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:type="locator" xlink:label="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial information related to the collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:to="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Financial Information Related to Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Information Related To Collaboration And License Agreements Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Anticipated Future Minimum Payments of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax (Benefit) Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Expected Income Tax (Benefit) Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UnderwritersMember" xlink:type="locator" xlink:label="cccc_UnderwritersMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_UnderwritersMember" xlink:to="cccc_UnderwritersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters for IPO Exercised in full Overallotment Option</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_UnderwritersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantExercisableMember" xlink:type="locator" xlink:label="cccc_WarrantExercisableMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantExercisableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_WarrantExercisableMember" xlink:to="cccc_WarrantExercisableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantExercisableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantExercisableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercisable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingClosingDate" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingClosingDate" />
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering closing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_InitialPublicOfferingClosingDate" xlink:to="cccc_InitialPublicOfferingClosingDate_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" />
    <link:label xml:lang="en-US" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds including exercise in full of underwriters option to purchase additional shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" xlink:to="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering closing date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_InitialPublicOfferingClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Issued shares of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Outstanding shares of preferred stock automatically converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds including exercise in full of underwriters option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Including Exercise In Full Of Underwriters Option To Purchase Additional Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants converted into shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Number Of Equity Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cccc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cccc_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="cccc_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LaboratoryEquipmentMember" xlink:to="cccc_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeEquipmentFurnitureAndFixturesMember" xlink:type="locator" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office equipment, furniture and fixtures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OfficeEquipmentFurnitureAndFixturesMember" xlink:to="cccc_OfficeEquipmentFurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment, Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets to be disposed of</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Quantitative Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Measurement Input</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:to="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RedeemableConvertiblePreferredStockWarrantMember" xlink:type="locator" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_RedeemableConvertiblePreferredStockWarrantMember" xlink:to="cccc_RedeemableConvertiblePreferredStockWarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2020</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="cccc_NumberOfWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfWarrantsExercised" xlink:to="cccc_NumberOfWarrantsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Exercised</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 1 to level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:to="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 3 to level 1 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:to="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value liabilities level 1 to level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" xlink:to="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value liabilities level 3 to level 1 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 2 to level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:to="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level 3 to level 2 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:to="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value liabilities level 2 to level 3 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" xlink:to="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value liabilities level 3 to level 2 transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 2 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 1 to level 2 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 2 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 3 to level 1 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 1 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 3 to level 1 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level3 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 3 to level 2 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level3 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 2 to level 3 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level3 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities, level 3 to level 2 transfers, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level3 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ContractualMaturityDatesOfMarketableSecurities" xlink:type="locator" xlink:label="cccc_ContractualMaturityDatesOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualMaturityDatesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual maturity dates of marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ContractualMaturityDatesOfMarketableSecurities" xlink:to="cccc_ContractualMaturityDatesOfMarketableSecurities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualMaturityDatesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturity dates of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualMaturityDatesOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Maturity Dates Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds And Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LesseeOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="cccc_LesseeOperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="cccc_LesseeOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LesseeOperatingLeaseCommencementDate" xlink:to="cccc_LesseeOperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RentCommencingDate" xlink:type="locator" xlink:label="cccc_RentCommencingDate" />
    <link:label xml:lang="en-US" xlink:label="cccc_RentCommencingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent commencing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_RentCommencingDate" xlink:to="cccc_RentCommencingDate_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCollateralAmount" xlink:type="locator" xlink:label="cccc_LeaseCollateralAmount" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCollateralAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease collateral amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LeaseCollateralAmount" xlink:to="cccc_LeaseCollateralAmount_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RestrictedCashMember" xlink:type="locator" xlink:label="cccc_RestrictedCashMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_RestrictedCashMember" xlink:to="cccc_RestrictedCashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="cccc_OfficeAndLaboratorySpaceMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OfficeAndLaboratorySpaceMember" xlink:to="cccc_OfficeAndLaboratorySpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LesseeOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LesseeOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RentCommencingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent commencing date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RentCommencingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rent Commencing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCollateralAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease collateral amount</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCollateralAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Collateral Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities under lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Payable Current</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherInformationAbstract" xlink:type="locator" xlink:label="cccc_OtherInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="cccc_OtherInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OtherInformationAbstract" xlink:to="cccc_OtherInformationAbstract_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsLineItems" xlink:type="locator" xlink:label="cccc_LeaseCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LeaseCostsLineItems" xlink:to="cccc_LeaseCostsLineItems_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsTable" xlink:type="locator" xlink:label="cccc_LeaseCostsTable" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease costs table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LeaseCostsTable" xlink:to="cccc_LeaseCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeaseCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease cost:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OtherInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other information:</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OtherInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for operating liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liability at December 31, 2020</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AccruedResearchAndDevelopmentCurrent" xlink:to="cccc_AccruedResearchAndDevelopmentCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationRevenue" xlink:type="locator" xlink:label="cccc_CollaborationRevenue" />
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CollaborationRevenue" xlink:to="cccc_CollaborationRevenue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementMember" xlink:type="locator" xlink:label="cccc_RocheAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_RocheAgreementMember" xlink:to="cccc_RocheAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Roche Agreement [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_BiogenLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_BiogenLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_BiogenLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_BiogenLicenseAgreementMember" xlink:to="cccc_BiogenLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_BiogenLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_BiogenLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen License Agreement [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CalicoLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_CalicoLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_CalicoLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Calico license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CalicoLicenseAgreementMember" xlink:to="cccc_CalicoLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CalicoLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calico License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CalicoLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Calico License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Net Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred Revenue, Net of Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TransactionPriceAllocatedToPerformanceObligation" xlink:type="locator" xlink:label="cccc_TransactionPriceAllocatedToPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="cccc_TransactionPriceAllocatedToPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TransactionPriceAllocatedToPerformanceObligation" xlink:to="cccc_TransactionPriceAllocatedToPerformanceObligation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized that was included in the contract liability at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized from performance obligations fully or partially satisfied in previous periods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Performance Obligation Satisfied In Previous Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TransactionPriceAllocatedToPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TransactionPriceAllocatedToPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Performance Obligation</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonrefundableUpfrontPaymentAndAdditionalFees" xlink:type="locator" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" />
    <link:label xml:lang="en-US" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonrefundable upfront payment and additional fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" xlink:to="cccc_NonrefundableUpfrontPaymentAndAdditionalFees_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OriginalRocheAgreementMember" xlink:type="locator" xlink:label="cccc_OriginalRocheAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OriginalRocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original Roche agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OriginalRocheAgreementMember" xlink:to="cccc_OriginalRocheAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OriginalRocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Roche Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OriginalRocheAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Roche Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_JointResearchCommitteeMember" xlink:type="locator" xlink:label="cccc_JointResearchCommitteeMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_JointResearchCommitteeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Joint research committee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_JointResearchCommitteeMember" xlink:to="cccc_JointResearchCommitteeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_JointResearchCommitteeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche JRC</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_JointResearchCommitteeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Joint Research Committee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentLicenseMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchAndDevelopmentLicenseMember" xlink:to="cccc_ResearchAndDevelopmentLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development License</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development License [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeadSeriesIdentificationAchievementMember" xlink:type="locator" xlink:label="cccc_LeadSeriesIdentificationAchievementMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeadSeriesIdentificationAchievementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lead series identification achievement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LeadSeriesIdentificationAchievementMember" xlink:to="cccc_LeadSeriesIdentificationAchievementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_LeadSeriesIdentificationAchievementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lead Series Identification Achievement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LeadSeriesIdentificationAchievementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lead Series Identification Achievement [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" xlink:type="locator" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Good laboratory practice (&#8220;GLP&#8221;) toxicology (&#8220;Tox&#8221;) study phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" xlink:to="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Good Laboratory Practice (&#8220;GLP&#8221;) Toxicology (&#8220;Tox&#8221;) Study Phase</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Good Laboratory Practice Glp Toxicology Tox Study Phase [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research, development and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:to="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research, Development and Commercial Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Commercial Milestone Payments [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OneTimeSalesBasedPaymentsMember" xlink:type="locator" xlink:label="cccc_OneTimeSalesBasedPaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OneTimeSalesBasedPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One-time sales-based payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OneTimeSalesBasedPaymentsMember" xlink:to="cccc_OneTimeSalesBasedPaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OneTimeSalesBasedPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-Time Sales-Based Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OneTimeSalesBasedPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time Sales Based Payments [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" xlink:type="locator" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Progressed up to phase 1 or through GLP Tox studies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" xlink:to="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Progressed Through Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Progressed Up To Phase1 Or Through G L P Tox Studies [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementAccountingMember" xlink:type="locator" xlink:label="cccc_RocheAgreementAccountingMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementAccountingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche agreement accounting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_RocheAgreementAccountingMember" xlink:to="cccc_RocheAgreementAccountingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementAccountingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche Agreement Accounting</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_RocheAgreementAccountingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Roche Agreement Accounting [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToLicenseMember" xlink:type="locator" xlink:label="cccc_OptionToLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OptionToLicenseMember" xlink:to="cccc_OptionToLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to License</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To License [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToInitiateResearchPlanMember" xlink:type="locator" xlink:label="cccc_OptionToInitiateResearchPlanMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToInitiateResearchPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to initiate research plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OptionToInitiateResearchPlanMember" xlink:to="cccc_OptionToInitiateResearchPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToInitiateResearchPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Initiate Research Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OptionToInitiateResearchPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To Initiate Research Plan [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesPerformanceObligationsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesPerformanceObligationsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesPerformanceObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services performance obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchServicesPerformanceObligationsMember" xlink:to="cccc_ResearchServicesPerformanceObligationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesPerformanceObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Services Performance Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesPerformanceObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Performance Obligations [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CommercialLicenseForSixTargetsMember" xlink:type="locator" xlink:label="cccc_CommercialLicenseForSixTargetsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_CommercialLicenseForSixTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial license for six targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CommercialLicenseForSixTargetsMember" xlink:to="cccc_CommercialLicenseForSixTargetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CommercialLicenseForSixTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial License for Six Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CommercialLicenseForSixTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial License For Six Targets [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesForUninitiatedThreeTargetsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services for the uninitiated three targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchServicesForUninitiatedThreeTargetsMember" xlink:to="cccc_ResearchServicesForUninitiatedThreeTargetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Services for Uninitiated Three Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services For Uninitiated Three Targets [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetTwoMember" xlink:type="locator" xlink:label="cccc_TargetTwoMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Target two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TargetTwoMember" xlink:to="cccc_TargetTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Target Two</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TargetTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Target Two [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsOneToThreeMember" xlink:type="locator" xlink:label="cccc_TargetsOneToThreeMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsOneToThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Targets one to three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TargetsOneToThreeMember" xlink:to="cccc_TargetsOneToThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsOneToThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Targets 1-3</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsOneToThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Targets One To Three [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsThreeMember" xlink:type="locator" xlink:label="cccc_TargetsThreeMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Targets three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TargetsThreeMember" xlink:to="cccc_TargetsThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Targets 3</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Targets Three [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsFourToSixMember" xlink:type="locator" xlink:label="cccc_TargetsFourToSixMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsFourToSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Targets four to six.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TargetsFourToSixMember" xlink:to="cccc_TargetsFourToSixMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsFourToSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Targets 4-6</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TargetsFourToSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Targets Four To Six [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentMilestonesMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchAndDevelopmentMilestonesMember" xlink:to="cccc_ResearchAndDevelopmentMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Milestones [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential research, development and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:to="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Research, Development and Commercial Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Research Development And Commercial Milestone Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable upfront payment and additional fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable Upfront Payment And Additional Fees</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPotentialTargets" xlink:type="locator" xlink:label="cccc_NumberOfPotentialTargets" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPotentialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of potential targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfPotentialTargets" xlink:to="cccc_NumberOfPotentialTargets_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNominated" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of target nominated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfTargetNominated" xlink:to="cccc_NumberOfTargetNominated_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNotNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNotNominated" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNotNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of target not nominated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfTargetNotNominated" xlink:to="cccc_NumberOfTargetNotNominated_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontFees" xlink:type="locator" xlink:label="cccc_UpfrontFees" />
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_UpfrontFees" xlink:to="cccc_UpfrontFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPotentialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of potential targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPotentialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Potential Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of target nominated as of the execution of the Restated Roche Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Target Nominated</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNotNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of target not nominated as of the execution of the Restated Roche Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetNotNominated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Target Not Nominated</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount eligible to receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contracts Receivable Claims And Uncertain Amounts</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalUpfrontConsideration" xlink:type="locator" xlink:label="cccc_AdditionalUpfrontConsideration" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalUpfrontConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional upfront consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdditionalUpfrontConsideration" xlink:to="cccc_AdditionalUpfrontConsideration_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalUpfrontConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional upfront consideration received</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalUpfrontConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Upfront Consideration</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualResearchPlanPaymentsReceivables" xlink:type="locator" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables" />
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual research plan payments receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AnnualResearchPlanPaymentsReceivables" xlink:to="cccc_AnnualResearchPlanPaymentsReceivables_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual research plan payments receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Research Plan Payments Receivables</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionExerciseFee" xlink:type="locator" xlink:label="cccc_OptionExerciseFee" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionExerciseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OptionExerciseFee" xlink:to="cccc_OptionExerciseFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionExerciseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OptionExerciseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationDescription" xlink:type="locator" xlink:label="cccc_CollaborationDescription" />
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CollaborationDescription" xlink:to="cccc_CollaborationDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration description</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CollaborationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Description</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontPayment" xlink:type="locator" xlink:label="cccc_UpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_UpfrontPayment" xlink:to="cccc_UpfrontPayment_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ExpectedResearchPlanFundingPayments" xlink:type="locator" xlink:label="cccc_ExpectedResearchPlanFundingPayments" />
    <link:label xml:lang="en-US" xlink:label="cccc_ExpectedResearchPlanFundingPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected research plan funding payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ExpectedResearchPlanFundingPayments" xlink:to="cccc_ExpectedResearchPlanFundingPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ExpectedResearchPlanFundingPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected research plan funding payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ExpectedResearchPlanFundingPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Research Plan Funding Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfInitialTargets" xlink:type="locator" xlink:label="cccc_NumberOfInitialTargets" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfInitialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of initial targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfInitialTargets" xlink:to="cccc_NumberOfInitialTargets_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargets" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargets" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfAdditionalTargets" xlink:to="cccc_NumberOfAdditionalTargets_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargets" xlink:type="locator" xlink:label="cccc_NumberOfTargets" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfTargets" xlink:to="cccc_NumberOfTargets_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfExchanges" xlink:type="locator" xlink:label="cccc_NumberOfExchanges" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfExchanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of exchanges.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfExchanges" xlink:to="cccc_NumberOfExchanges_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfInitialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of initial targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfInitialTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Initial Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfExchanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of exchanges</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfExchanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Exchanges</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfMaterialRights" xlink:type="locator" xlink:label="cccc_NumberOfMaterialRights" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfMaterialRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of material rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfMaterialRights" xlink:to="cccc_NumberOfMaterialRights_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargetsDeferred" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargetsDeferred" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargetsDeferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional targets deferred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfAdditionalTargetsDeferred" xlink:to="cccc_NumberOfAdditionalTargetsDeferred_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfMaterialRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of material rights</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfMaterialRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Material Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargetsDeferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional targets</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfAdditionalTargetsDeferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Targets Deferred</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="cccc_NumberOfPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfPerformanceObligation" xlink:to="cccc_NumberOfPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Performance Obligation</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" />
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expected research plan funding payments of per active target per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" />
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expected research plan funding payments of per target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MilestonePaymentReceived" xlink:type="locator" xlink:label="cccc_MilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="cccc_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_MilestonePaymentReceived" xlink:to="cccc_MilestonePaymentReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of expected research plan funding payments of per active target per year</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Expected Research Plan Funding Payments Of Per Active Target Per Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of expected research plan funding payments of per target</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Expected Research Plan Funding Payments Of Per Target</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AgreementDate" xlink:type="locator" xlink:label="cccc_AgreementDate" />
    <link:label xml:lang="en-US" xlink:label="cccc_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AgreementDate" xlink:to="cccc_AgreementDate_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetedProteinDegradation" xlink:type="locator" xlink:label="cccc_NumberOfTargetedProteinDegradation" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetedProteinDegradation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of targeted protein degradation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfTargetedProteinDegradation" xlink:to="cccc_NumberOfTargetedProteinDegradation_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalPaymentOnExtensionOfContract" xlink:type="locator" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment on extension of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdditionalPaymentOnExtensionOfContract" xlink:to="cccc_AdditionalPaymentOnExtensionOfContract_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalTargetsForDevelopment" xlink:type="locator" xlink:label="cccc_AdditionalTargetsForDevelopment" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalTargetsForDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional targets for development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdditionalTargetsForDevelopment" xlink:to="cccc_AdditionalTargetsForDevelopment_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentAgreementPeriod" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development agreement period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchAndDevelopmentAgreementPeriod" xlink:to="cccc_ResearchAndDevelopmentAgreementPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetedProteinDegradation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of targeted protein degradation</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetedProteinDegradation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Targeted Protein Degradation</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement, period</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Agreement Period</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment on extension of contract</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payment On Extension Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalTargetsForDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional targets for development</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalTargetsForDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Targets For Development</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="cccc_NonRefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="cccc_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NonRefundableUpfrontPayment" xlink:to="cccc_NonRefundableUpfrontPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NoticePeriodForTerminationOfAgreement" xlink:type="locator" xlink:label="cccc_NoticePeriodForTerminationOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="cccc_NoticePeriodForTerminationOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice period for termination of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NoticePeriodForTerminationOfAgreement" xlink:to="cccc_NoticePeriodForTerminationOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NoticePeriodForTerminationOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NoticePeriodForTerminationOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notice Period For Termination Of Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchTerm" xlink:type="locator" xlink:label="cccc_ResearchTerm" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ResearchTerm" xlink:to="cccc_ResearchTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research term</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Term</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetProteins" xlink:type="locator" xlink:label="cccc_NumberOfTargetProteins" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetProteins_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of target proteins.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfTargetProteins" xlink:to="cccc_NumberOfTargetProteins_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetProteins_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of target proteins</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfTargetProteins_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Target Proteins</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualPayments" xlink:type="locator" xlink:label="cccc_AnnualPayments" />
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AnnualPayments" xlink:to="cccc_AnnualPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AnnualPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Payments</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashConsiderationReceivedForMilestoneRevenue" xlink:type="locator" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue" />
    <link:label xml:lang="en-US" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash consideration received for milestone revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CashConsiderationReceivedForMilestoneRevenue" xlink:to="cccc_CashConsiderationReceivedForMilestoneRevenue_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" />
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional consideration received in cash for target initiation fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" xlink:to="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccountsReceivableForAdditionalTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees" />
    <link:label xml:lang="en-US" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable for additional target initiation fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_AccountsReceivableForAdditionalTargetInitiationFees" xlink:to="cccc_AccountsReceivableForAdditionalTargetInitiationFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration received for milestone revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Consideration Received For Milestone Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration received in cash for target initiation fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Consideration Received In Cash For Target Initiation Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable for additional target initiation fees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable For Additional Target Initiation Fees</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ContractualTerm" xlink:type="locator" xlink:label="cccc_ContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_ContractualTerm" xlink:to="cccc_ContractualTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_ContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Term</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" xlink:type="locator" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash balance to be maintained in bank account while debt is outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" xlink:to="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term debt and warrant liability line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_LongTermDebtAndWarrantLiabilityLineItems_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityTable" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term debt and warrant liability table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="cccc_LongTermDebtAndWarrantLiabilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Debt And Warrant Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Warrant Liability [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" xlink:type="locator" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit agreement with Perceptive Life Sciences Master Fund LTD.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" xlink:to="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Agreement with Perceptive Life Sciences Master Fund LTD</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement With Perceptive Life Sciences Master Fund L T D [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TermLoanMember" xlink:type="locator" xlink:label="cccc_TermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TermLoanMember" xlink:to="cccc_TermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheOneMember" xlink:type="locator" xlink:label="cccc_TrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TrancheOneMember" xlink:to="cccc_TrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheTwoMember" xlink:type="locator" xlink:label="cccc_TrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TrancheTwoMember" xlink:to="cccc_TrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="cccc_OtherIncomeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OtherIncomeExpenseMember" xlink:to="cccc_OtherIncomeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OtherIncomeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Debt And Warrant Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt And Warrant Liability [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withdrawn</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Variable Rate Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description Of Variable Rate Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applicable margin rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance to be maintained in bank account while debt is outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Balance To Be Maintained In Bank Account While Debt Is Outstanding</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DateUntilWhichInterestOnlyPaymentsAreMade" xlink:type="locator" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" />
    <link:label xml:lang="en-US" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Date until which interest only payments are made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" xlink:to="cccc_DateUntilWhichInterestOnlyPaymentsAreMade_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" xlink:type="locator" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" />
    <link:label xml:lang="en-US" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument. percentage of principal payment until maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" xlink:to="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date until which interest only payments are made</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Date Until Which Interest Only Payments Are Made</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of principal payments until maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Of Principal Payment Until Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Extinguishment Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost in connection with entry into Credit Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Related Commitment Fees And Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding long term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Date1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt By Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum long-term debt payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt issuance costs, and debt discount related to warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Carrying value of long-term debt&#8212;related party at December 31, 2020</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityLineItems" xlink:type="locator" xlink:label="cccc_StockholdersEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_StockholdersEquityLineItems_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityTable" xlink:type="locator" xlink:label="cccc_StockholdersEquityTable" />
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_StockholdersEquityTable" xlink:to="cccc_StockholdersEquityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Table]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series seed redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series Seed Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series Seed Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="cccc_SeriesARedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_StockholdersEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, par value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPreferredStockConvertedInToOneCommonStock" xlink:type="locator" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" />
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of preferred stock converted in to one common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" xlink:to="cccc_NumberOfPreferredStockConvertedInToOneCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Outstanding shares of preferred stock converted</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted in to one common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Converted In To One Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Preferred stock, outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series Seed Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FFPreferredStockMember" xlink:type="locator" xlink:label="cccc_FFPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_FFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FF preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_FFPreferredStockMember" xlink:to="cccc_FFPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_FFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FF Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_FFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">F F Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Issuable Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2015 incentive stock option and grant plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" xlink:to="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Incentive Stock Option and Grant Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Incentive Stock Option And Grant Plan [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 stock option and incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Option and Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Stock Option And Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, common stock shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, options vesting description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life of options from the date of grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, common stock shares available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_PercentageOfOutstandingSharesOfCommonStock" xlink:to="cccc_PercentageOfOutstandingSharesOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation, common stock shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, Outstanding as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Forfeited/expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Outstanding as of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Vested and expected to vest as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-average exercise price, Outstanding as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, Forfeited/expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-average exercise price, Outstanding as of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, Exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price, Vested and expected to vest as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, Outstanding as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, Outstanding as of December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised (in thousands)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be recognized over a weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected option life (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation, common stock shares outstanding</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" xlink:type="locator" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" />
    <link:label xml:lang="en-US" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum authorized payroll deduction percentage of eligible compensation for eligible employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" xlink:to="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum authorized payroll deduction percentage of eligible compensation for eligible employees</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Authorized Payroll Deduction Percentage Of Eligible Compensation For Eligible Employees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" xlink:type="locator" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" />
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for relinquishment of right to purchase common stock upon exercise of stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" xlink:to="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for relinquishment of right to purchase common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Relinquishment Of Right To Purchase Common Stock Upon Exercise Of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current tax provision:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current federal provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current state provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax provision:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred federal provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred state provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total tax provision</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" />
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation state tax credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" />
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation federal tax credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" />
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation net operating loss carryback benefits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit computed at federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax&#8212;net of federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State credits</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State Tax Credit</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal credits</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Federal Tax Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryback benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax attributes true up due to net operating loss carryback</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" />
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized start-up costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="cccc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="cccc_DeferredTaxAssetsOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="cccc_DeferredTaxLiabilitiesRightOfUseAsset_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized start-up costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D and investment tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain/loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Unrealized Gains On Trading Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxLineItems" xlink:type="locator" xlink:label="cccc_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxTable" xlink:type="locator" xlink:label="cccc_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_IncomeTaxTable" xlink:to="cccc_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Jurisdiction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service (IRS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service I R S [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk Or Uncertainty By Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk Or Uncertainty Nature [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus aid relief, and economic security act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="cccc_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;)</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Aid Relief And Economic Security Act [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets, valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net valuation allowance increases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards do not expire</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refund due to anticipated carryback portion of net operating loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of taxable income limitation under TCJA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Increase Decrease In Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" xlink:type="locator" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" />
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit carryforwards description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" xlink:to="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription_lbl" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" xlink:type="locator" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" />
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards limited and expire due to ownership changes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" xlink:to="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss and tax credit carryforwards description</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Tax Credit Carryforwards Description</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards limited and expire due to ownership changes</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Limited And Expire Due To Ownership Changes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_OptionsToPurchaseCommonStockMember" xlink:to="cccc_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_WarrantToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cccc_WarrantToPurchaseCommonStockMember" xlink:to="cccc_WarrantToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cccc_WarrantToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock split conversion ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:type="locator" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension Plans Defined Benefit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-tax compensation of employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employer discretion contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary contribution amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined benefit plan, contributions by employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Contributions By Employer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>44
<FILENAME>cccc-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T05:38:12.4807449+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c1be03ae4fa04fda91d889f25fb265ab -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/role/TemplateLink" xlink:href="cccc-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cccc-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:type="locator" xlink:label="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" xlink:type="locator" xlink:label="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="locator" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_li0l2" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_VestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_VestedStockOptionSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockShares" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockShares" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IssuanceOfConvertiblePreferredStockValue" xlink:type="locator" xlink:label="cccc_IssuanceOfConvertiblePreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_IssuanceOfConvertiblePreferredStockValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_IssuanceOfConvertiblePreferredStockShares" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cccc_VestedStockOptionSettlement" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockOptionRepurchasesIncludedInAccruedExpenses" xlink:type="locator" xlink:label="cccc_StockOptionRepurchasesIncludedInAccruedExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ReclassificationOfWarrantLiabilityToEquity" xlink:type="locator" xlink:label="cccc_ReclassificationOfWarrantLiabilityToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForVestedStockOptionSettlement" xlink:type="locator" xlink:label="cccc_PaymentsForVestedStockOptionSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" xlink:type="locator" xlink:label="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cccc_IncreaseDecreaseInOperatingLeaseLiability" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cccc_PaymentsForVestedStockOptionSettlement" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cccc_ReclassificationOfWarrantLiabilityToEquity" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cccc_StockOptionRepurchasesIncludedInAccruedExpenses" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="cccc-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="cccc-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="cccc-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="cccc-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cccc_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiability" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiability" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiability">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityTextBlock" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:to="cccc_LongTermDebtAndWarrantLiabilityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquity" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShare" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="cccc-20201231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_GoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="cccc_GoingConcernPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:type="locator" xlink:label="us-gaap_FuturePolicyBenefitsLiabilityPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionSalesOfServices" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionSalesOfServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" xlink:type="locator" xlink:label="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cccc_EmergingGrowthCompanyPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionSalesOfServices" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FuturePolicyBenefitsLiabilityPolicy" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cccc_GoingConcernPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ScheduleOfDepreciationExpenseTableTextBlock" xlink:type="locator" xlink:label="cccc_ScheduleOfDepreciationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="cccc_ScheduleOfDepreciationExpenseTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:type="locator" xlink:label="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" xlink:type="locator" xlink:label="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="cccc_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_CollaborationAndLicenseAgreementsAbstract" xlink:to="cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_CollaborationAndLicenseAgreementsAbstract" xlink:to="cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityTables" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiabilityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityTables" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareTables" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:type="locator" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" xlink:type="locator" xlink:label="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingClosingDate" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingClosingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantExercisableMember" xlink:type="locator" xlink:label="cccc_WarrantExercisableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UnderwritersMember" xlink:type="locator" xlink:label="cccc_UnderwritersMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cccc_UnderwritersMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cccc_WarrantExercisableMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfitLoss" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cccc_InitialPublicOfferingClosingDate" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeEquipmentFurnitureAndFixturesMember" xlink:type="locator" xlink:label="cccc_OfficeEquipmentFurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="cccc_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cccc_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cccc_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_LaboratoryEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_OfficeEquipmentFurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cccc_SummaryOfSignificantAccountingPoliciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" xlink:type="locator" xlink:label="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfWarrantsExercised" xlink:type="locator" xlink:label="cccc_NumberOfWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantExercisableMember" xlink:type="locator" xlink:label="cccc_WarrantExercisableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cccc_WarrantExercisableMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_NumberOfWarrantsExercised" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel1ToLevel3TransfersAmount" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel3ToLevel1TransfersAmount" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel2ToLevel3TransfersAmount" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueAssetsLevel3ToLevel2TransfersAmount" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RedeemableConvertiblePreferredStockWarrantMember" xlink:type="locator" xlink:label="cccc_RedeemableConvertiblePreferredStockWarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cccc_RedeemableConvertiblePreferredStockWarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ContractualMaturityDatesOfMarketableSecurities" xlink:type="locator" xlink:label="cccc_ContractualMaturityDatesOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_ImpairmentOfInvestments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="cccc_ContractualMaturityDatesOfMarketableSecurities" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="cccc_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="cccc-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCollateralAmount" xlink:type="locator" xlink:label="cccc_LeaseCollateralAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RentCommencingDate" xlink:type="locator" xlink:label="cccc_RentCommencingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LesseeOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="cccc_LesseeOperatingLeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="cccc_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RestrictedCashMember" xlink:type="locator" xlink:label="cccc_RestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="cccc_RestrictedCashMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cccc_OfficeAndLaboratorySpaceMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_LesseeOperatingLeaseCommencementDate" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_RentCommencingDate" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cccc_LeaseCollateralAmount" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ConstructionPayableCurrent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherInformationAbstract" xlink:type="locator" xlink:label="cccc_OtherInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsLineItems" xlink:type="locator" xlink:label="cccc_LeaseCostsLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WatertownLeaseMember" xlink:type="locator" xlink:label="cccc_WatertownLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeaseCostsTable" xlink:type="locator" xlink:label="cccc_LeaseCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="cccc_LeaseCostsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LeaseCostsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cccc_WatertownLeaseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LeaseCostsTable" xlink:to="cccc_LeaseCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LeaseCostsLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LeaseCostsLineItems" xlink:to="cccc_OtherInformationAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccruedResearchAndDevelopmentCurrent" xlink:type="locator" xlink:label="cccc_AccruedResearchAndDevelopmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cccc_AccruedResearchAndDevelopmentCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationRevenue" xlink:type="locator" xlink:label="cccc_CollaborationRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CalicoLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_CalicoLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_BiogenLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_BiogenLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementMember" xlink:type="locator" xlink:label="cccc_RocheAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_BiogenLicenseAgreementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_CalicoLicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CollaborationRevenue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TransactionPriceAllocatedToPerformanceObligation" xlink:type="locator" xlink:label="cccc_TransactionPriceAllocatedToPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="cccc_TransactionPriceAllocatedToPerformanceObligation" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ContractualTerm" xlink:type="locator" xlink:label="cccc_ContractualTerm" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AccountsReceivableForAdditionalTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AccountsReceivableForAdditionalTargetInitiationFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" xlink:type="locator" xlink:label="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashConsiderationReceivedForMilestoneRevenue" xlink:type="locator" xlink:label="cccc_CashConsiderationReceivedForMilestoneRevenue" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualPayments" xlink:type="locator" xlink:label="cccc_AnnualPayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetProteins" xlink:type="locator" xlink:label="cccc_NumberOfTargetProteins" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchTerm" xlink:type="locator" xlink:label="cccc_ResearchTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NoticePeriodForTerminationOfAgreement" xlink:type="locator" xlink:label="cccc_NoticePeriodForTerminationOfAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="cccc_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalTargetsForDevelopment" xlink:type="locator" xlink:label="cccc_AdditionalTargetsForDevelopment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalPaymentOnExtensionOfContract" xlink:type="locator" xlink:label="cccc_AdditionalPaymentOnExtensionOfContract" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentAgreementPeriod" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentAgreementPeriod" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetedProteinDegradation" xlink:type="locator" xlink:label="cccc_NumberOfTargetedProteinDegradation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AgreementDate" xlink:type="locator" xlink:label="cccc_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MilestonePaymentReceived" xlink:type="locator" xlink:label="cccc_MilestonePaymentReceived" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" xlink:type="locator" xlink:label="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPerformanceObligation" xlink:type="locator" xlink:label="cccc_NumberOfPerformanceObligation" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargetsDeferred" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargetsDeferred" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfMaterialRights" xlink:type="locator" xlink:label="cccc_NumberOfMaterialRights" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfExchanges" xlink:type="locator" xlink:label="cccc_NumberOfExchanges" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargets" xlink:type="locator" xlink:label="cccc_NumberOfTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfAdditionalTargets" xlink:type="locator" xlink:label="cccc_NumberOfAdditionalTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfInitialTargets" xlink:type="locator" xlink:label="cccc_NumberOfInitialTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ExpectedResearchPlanFundingPayments" xlink:type="locator" xlink:label="cccc_ExpectedResearchPlanFundingPayments" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontPayment" xlink:type="locator" xlink:label="cccc_UpfrontPayment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CollaborationDescription" xlink:type="locator" xlink:label="cccc_CollaborationDescription" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionExerciseFee" xlink:type="locator" xlink:label="cccc_OptionExerciseFee" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AnnualResearchPlanPaymentsReceivables" xlink:type="locator" xlink:label="cccc_AnnualResearchPlanPaymentsReceivables" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_AdditionalUpfrontConsideration" xlink:type="locator" xlink:label="cccc_AdditionalUpfrontConsideration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractsReceivableClaimsAndUncertainAmounts" xlink:type="locator" xlink:label="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_UpfrontFees" xlink:type="locator" xlink:label="cccc_UpfrontFees" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNotNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNotNominated" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfTargetNominated" xlink:type="locator" xlink:label="cccc_NumberOfTargetNominated" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPotentialTargets" xlink:type="locator" xlink:label="cccc_NumberOfPotentialTargets" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NonrefundableUpfrontPaymentAndAdditionalFees" xlink:type="locator" xlink:label="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CalicoLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_CalicoLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentMilestonesMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentMilestonesMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_BiogenLicenseAgreementMember" xlink:type="locator" xlink:label="cccc_BiogenLicenseAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsFourToSixMember" xlink:type="locator" xlink:label="cccc_TargetsFourToSixMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsThreeMember" xlink:type="locator" xlink:label="cccc_TargetsThreeMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetsOneToThreeMember" xlink:type="locator" xlink:label="cccc_TargetsOneToThreeMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TargetTwoMember" xlink:type="locator" xlink:label="cccc_TargetTwoMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesForUninitiatedThreeTargetsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesForUninitiatedThreeTargetsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CommercialLicenseForSixTargetsMember" xlink:type="locator" xlink:label="cccc_CommercialLicenseForSixTargetsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchServicesPerformanceObligationsMember" xlink:type="locator" xlink:label="cccc_ResearchServicesPerformanceObligationsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToInitiateResearchPlanMember" xlink:type="locator" xlink:label="cccc_OptionToInitiateResearchPlanMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionToLicenseMember" xlink:type="locator" xlink:label="cccc_OptionToLicenseMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementAccountingMember" xlink:type="locator" xlink:label="cccc_RocheAgreementAccountingMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" xlink:type="locator" xlink:label="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OneTimeSalesBasedPaymentsMember" xlink:type="locator" xlink:label="cccc_OneTimeSalesBasedPaymentsMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" xlink:type="locator" xlink:label="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LeadSeriesIdentificationAchievementMember" xlink:type="locator" xlink:label="cccc_LeadSeriesIdentificationAchievementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_RocheAgreementMember" xlink:type="locator" xlink:label="cccc_RocheAgreementMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_ResearchAndDevelopmentLicenseMember" xlink:type="locator" xlink:label="cccc_ResearchAndDevelopmentLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_JointResearchCommitteeMember" xlink:type="locator" xlink:label="cccc_JointResearchCommitteeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OriginalRocheAgreementMember" xlink:type="locator" xlink:label="cccc_OriginalRocheAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_OriginalRocheAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cccc_JointResearchCommitteeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_ResearchAndDevelopmentLicenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_LeadSeriesIdentificationAchievementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OneTimeSalesBasedPaymentsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_RocheAgreementAccountingMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OptionToLicenseMember" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_OptionToInitiateResearchPlanMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchServicesPerformanceObligationsMember" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_CommercialLicenseForSixTargetsMember" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchServicesForUninitiatedThreeTargetsMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetTwoMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsOneToThreeMember" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsThreeMember" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cccc_TargetsFourToSixMember" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_BiogenLicenseAgreementMember" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_ResearchAndDevelopmentMilestonesMember" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cccc_CalicoLicenseAgreementMember" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="13660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NonrefundableUpfrontPaymentAndAdditionalFees" order="13670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfPotentialTargets" order="13720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetNominated" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetNotNominated" order="13760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_UpfrontFees" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractsReceivableClaimsAndUncertainAmounts" order="13840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalUpfrontConsideration" order="13910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AnnualResearchPlanPaymentsReceivables" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_OptionExerciseFee" order="14010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CollaborationDescription" order="14160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_UpfrontPayment" order="14210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ExpectedResearchPlanFundingPayments" order="14230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="14250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfInitialTargets" order="14300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfAdditionalTargets" order="14320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargets" order="14340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfExchanges" order="14360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfMaterialRights" order="14490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfAdditionalTargetsDeferred" order="14550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfPerformanceObligation" order="14600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear" order="14830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget" order="14850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_MilestonePaymentReceived" order="14890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AgreementDate" order="15090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetedProteinDegradation" order="15110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ResearchAndDevelopmentAgreementPeriod" order="15130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalPaymentOnExtensionOfContract" order="15150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalTargetsForDevelopment" order="15170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NonRefundableUpfrontPayment" order="15220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="15240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NoticePeriodForTerminationOfAgreement" order="15310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="15590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ResearchTerm" order="15710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_NumberOfTargetProteins" order="15760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AnnualPayments" order="15870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_CashConsiderationReceivedForMilestoneRevenue" order="16080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees" order="16100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_AccountsReceivableForAdditionalTargetInitiationFees" order="16120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="cccc_ContractualTerm" order="16290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" xlink:type="locator" xlink:label="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DateUntilWhichInterestOnlyPaymentsAreMade" xlink:type="locator" xlink:label="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" xlink:type="locator" xlink:label="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OtherIncomeExpenseMember" xlink:type="locator" xlink:label="cccc_OtherIncomeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheTwoMember" xlink:type="locator" xlink:label="cccc_TrancheTwoMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TrancheOneMember" xlink:type="locator" xlink:label="cccc_TrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TermLoanMember" xlink:type="locator" xlink:label="cccc_TermLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" xlink:type="locator" xlink:label="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityTable" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityTable" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:type="locator" xlink:label="cccc_LongTermDebtAndWarrantLiabilityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityAbstract" xlink:to="cccc_LongTermDebtAndWarrantLiabilityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cccc_TermLoanMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cccc_TrancheOneMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cccc_TrancheTwoMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="cccc_OtherIncomeExpenseMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityTable" xlink:to="cccc_LongTermDebtAndWarrantLiabilityLineItems" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LineOfCredit" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_DateUntilWhichInterestOnlyPaymentsAreMade" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LongTermDebt" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_LongTermDebtAndWarrantLiabilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NumberOfPreferredStockConvertedInToOneCommonStock" xlink:type="locator" xlink:label="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_InitialPublicOfferingClosingDate" xlink:type="locator" xlink:label="cccc_InitialPublicOfferingClosingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityLineItems" xlink:type="locator" xlink:label="cccc_StockholdersEquityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_StockholdersEquityTable" xlink:type="locator" xlink:label="cccc_StockholdersEquityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cccc_StockholdersEquityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesARedeemableConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesBRedeemableConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityTable" xlink:to="cccc_StockholdersEquityLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_InitialPublicOfferingClosingDate" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="cccc_NumberOfPreferredStockConvertedInToOneCommonStock" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockholderSEquityScheduleOfPreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_FFPreferredStockMember" xlink:type="locator" xlink:label="cccc_FFPreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesARedeemableConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_FFPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" xlink:type="locator" xlink:label="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" xlink:type="locator" xlink:label="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_PercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="cccc_PercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_PercentageOfOutstandingSharesOfCommonStock" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" xlink:type="locator" xlink:label="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="cccc_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsOperatingLeaseLiability" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="locator" xlink:label="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="cccc_DeferredTaxAssetsCapitalizedStartUpCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="cccc_DeferredTaxAssetsOperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="cccc_DeferredTaxLiabilitiesRightOfUseAsset" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" xlink:type="locator" xlink:label="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" xlink:type="locator" xlink:label="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxLineItems" xlink:type="locator" xlink:label="cccc_IncomeTaxLineItems" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_IncomeTaxTable" xlink:type="locator" xlink:label="cccc_IncomeTaxTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cccc_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="cccc_CoronavirusAidReliefAndEconomicSecurityActMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxTable" xlink:to="cccc_IncomeTaxLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cccc_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_WarrantToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_WarrantToPurchaseCommonStockMember" />
    <link:loc xlink:href="cccc-20201231.xsd#cccc_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cccc_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cccc_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cccc_WarrantToPurchaseCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cccc_SeriesSeedRedeemableConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="cccc-20201231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:type="locator" xlink:label="us-gaap_PensionPlansDefinedBenefitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509527000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CCCC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">C4 Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001662579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,119,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5617627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-0700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511946424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 181,727<span></span>
</td>
<td class="nump">$ 90,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">189,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">4,484<span></span>
</td>
<td class="nump">4,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">381,009<span></span>
</td>
<td class="nump">96,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,323<span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">13,229<span></span>
</td>
<td class="nump">14,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">400,138<span></span>
</td>
<td class="nump">118,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,524<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">27,603<span></span>
</td>
<td class="nump">20,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,852<span></span>
</td>
<td class="nump">33,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current</a></td>
<td class="nump">53,617<span></span>
</td>
<td class="nump">72,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current</a></td>
<td class="nump">11,826<span></span>
</td>
<td class="nump">12,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt&#8212;related party</a></td>
<td class="nump">10,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">119,347<span></span>
</td>
<td class="nump">119,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 6 and Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock (See Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.0001 per share; 10,000,000 and no shares authorized, and no shares issued or outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.0001 per share; 150,000,000 and 21,343,452 shares authorized, and 43,059,632 and 1,426,641 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">464,597<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(183,823)<span></span>
</td>
<td class="num">(117,488)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">280,791<span></span>
</td>
<td class="num">(111,963)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 400,138<span></span>
</td>
<td class="nump">$ 118,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511908536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">21,343,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,059,632<span></span>
</td>
<td class="nump">1,426,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,059,632<span></span>
</td>
<td class="nump">1,426,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216599814936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaboration agreements</a></td>
<td class="nump">$ 33,195<span></span>
</td>
<td class="nump">$ 21,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">78,440<span></span>
</td>
<td class="nump">48,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,204<span></span>
</td>
<td class="nump">8,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">93,644<span></span>
</td>
<td class="nump">56,833<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(60,449)<span></span>
</td>
<td class="num">(35,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability&#8212;related party</a></td>
<td class="num">(5,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty', window );">Interest expense and amortization of long-term debt&#8212;related party</a></td>
<td class="num">(1,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(6,512)<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(66,961)<span></span>
</td>
<td class="num">(33,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">626<span></span>
</td>
<td class="num">(804)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,335)<span></span>
</td>
<td class="num">(34,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(66,322)<span></span>
</td>
<td class="num">(34,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Reconciliation of net loss to net loss attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,335)<span></span>
</td>
<td class="num">(34,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Accrual of preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (66,335)<span></span>
</td>
<td class="num">$ (42,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (5.83)<span></span>
</td>
<td class="num">$ (31.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common stock outstanding&#8212;basic and diluted</a></td>
<td class="nump">11,370,328<span></span>
</td>
<td class="nump">1,371,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense and amortization of long term debt related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_InterestExpenseAndAmortizationOfLongTermDebtRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to common stockholders, basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118644919&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510778984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (79,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83,389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,145,900<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,995<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">$ (111,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,488)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">113,145,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,145,900<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 110,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,995<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IssuanceOfConvertiblePreferredStockValue', window );">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $4.5 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IssuanceOfConvertiblePreferredStockShares', window );">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $4.5 million, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,857,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">256,520<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">256,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,355,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,003,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon closing of initial public offering, net of issuance costs of $18.6 million</a></td>
<td class="nump">191,173<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">191,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon closing of initial public offering, net of issuance costs of $18.6 million, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_VestedStockOptionSettlement', window );">Vested Stock Option Settlement</a></td>
<td class="num">(727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 280,791<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 464,597<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">$ (183,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,059,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_IssuanceOfConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_IssuanceOfConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_IssuanceOfConvertiblePreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_IssuanceOfConvertiblePreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_VestedStockOptionSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested stock option settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_VestedStockOptionSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216618810808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 18.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510606744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66,335)<span></span>
</td>
<td class="num">$ (34,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,432<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of (premium) discount on investments</a></td>
<td class="num">(95)<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in carrying amount of right-of-use assets</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">5,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">81,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,257)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(881)<span></span>
</td>
<td class="num">(734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(12,203)<span></span>
</td>
<td class="num">(3,235)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(67,249)<span></span>
</td>
<td class="nump">55,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds received from maturities of marketable securities</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">78,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(293,855)<span></span>
</td>
<td class="num">(79,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(190,505)<span></span>
</td>
<td class="num">(1,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series B shares, net of issuance costs of $4.5 million</a></td>
<td class="nump">145,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant', window );">Proceeds from long-term debt and warrant, net of issuance costs of $0.5 million</a></td>
<td class="nump">11,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discount of $14.7 million</a></td>
<td class="nump">195,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of initial public offering costs</a></td>
<td class="num">(3,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_PaymentsForVestedStockOptionSettlement', window );">Vested stock option settlement</a></td>
<td class="num">(727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">348,932<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">91,178<span></span>
</td>
<td class="nump">54,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">93,126<span></span>
</td>
<td class="nump">38,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">184,304<span></span>
</td>
<td class="nump">93,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">184,304<span></span>
</td>
<td class="nump">93,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Less: restricted cash</a></td>
<td class="num">(2,577)<span></span>
</td>
<td class="num">(2,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">181,727<span></span>
</td>
<td class="nump">90,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering</a></td>
<td class="nump">256,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses', window );">Initial public offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockOptionRepurchasesIncludedInAccruedExpenses', window );">Stock option repurchases included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_InitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_PaymentsForVestedStockOptionSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for vested stock option settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_PaymentsForVestedStockOptionSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Long-term debt and warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ProceedsFromIssuanceOfLongTermDebtAndWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_StockOptionRepurchasesIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option repurchases included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_StockOptionRepurchasesIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516782984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Long-term debt and warrant, net of issuance costs</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discount</a></td>
<td class="nump">$ 14.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513152920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 1. Nature of the business and basis of presentation</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc., or, together with its subsidiary, the Company, is a biopharmaceutical company focused on harnessing the body&#8217;s natural regulation of protein levels to develop novel therapeutic candidates to target and eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company was incorporated in Delaware on October 7, 2015 and has its principal office in Watertown, Massachusetts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company&#8217;s primary activities have been focused around research and development activities, building the Company&#8217;s intellectual property, recruiting personnel and raising capital to support these activities. To date, the Company has funded its operations primarily with proceeds received from the sales of redeemable convertible preferred stock, sales of common stock through an initial public offering, through its collaboration agreements, and debt financing.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred recurring losses since its inception, including net losses of $66.3&#160;million and $34.1&#160;million for the years ended December 31, 2020 and 2019, respectively. In addition, as of December 31, 2020, the Company had an accumulated deficit of $183.8&#160;million. To date, the Company has not generated any revenue from product sales as none of its product candidates has been approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 6, 2020, the Company completed its initial public offering, or the IPO, at which time the Company issued 11,040,000 shares of its common stock at a price to the public of $19.00 per share, which number includes 1,440,000 shares of common stock that were issued to the underwriters for the IPO when they exercised in full their overallotment option. Upon the closing of the IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into 30,355,379 shares of common stock. Net proceeds from the IPO, including the exercise in full of the underwriters&#8217; option to purchase additional shares, were $191.2 million, after deducting underwriting discounts and commissions of $14.7 million and expenses of $3.9 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its cash, cash equivalents and marketable securities of $371.7&#160;million as of December 31, 2020<font style="color:#000000;"> will be sufficient to fund its operations for at least the next twelve months from the date of issuance of these consolidated financial statements. </font>Accordingly, the<font style="Background-color:#FFFFFF;color:#000000;"> </font>consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2020, the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock and stock options, and a proportional adjustment to the existing conversion ratios for the Company&#8217;s redeemable convertible preferred stock. Additionally, upon closing of the IPO a warrant issued to purchase up to 2,857,142 shares of the Company&#8217;s Series B redeemable convertible preferred stock converted into a warrant exercisable for 338,784 shares of the Company&#8217;s common stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented, except as otherwise stated.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks and Uncertainties </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the early development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with the Food and Drug Administration, or the FDA, and other government regulations. If the Company does not successfully advance its programs into and through human clinical trials and/or enter into collaborations for its programs and commercialize any of its product candidates, the Company may be unable to produce product revenue or achieve profitability. There can be no assurance that the Company&#8217;s research and development efforts will be successful, adequate protection for the Company&#8217;s intellectual property will be obtained, any products developed will obtain necessary government regulatory approval, or any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Pandemic </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of the coronavirus, or COVID-19, pandemic on the Company&#8217;s business, results of operations and financial condition is uncertain and will depend on future developments, including the duration and spread of the outbreak, the impact of vaccines and new strains of COVID-19, and any governmental advisories and restrictions. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517042216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 2. Summary of significant accounting policies</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America, or U.S.&#160;GAAP. <font style="color:#000000;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in consolidation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company&#8217;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. The Company&#8217;s cash equivalents are measured at fair value on a recurring basis.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity (deficit) until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&#8217;s lease agreements for its Watertown, Massachusetts facility (see Note 6, <font style="font-style:italic;">Leases</font>). </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, t<font style="color:#000000;">he Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC&#160;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash are Level&#160;1 assets which are&#160;comprised of funds held in checking and money market accounts.&#160;Marketable securities are Level 2 assets which are comprised of US treasury funds with maturity dates of less than one year. The carrying amounts of accounts receivable, which relate to the Company&#8217;s collaboration agreements, accounts payable, and accrued expenses approximate their fair values due to their short-term nature. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset category</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment, furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of useful life or remaining lease term</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. As provided by ASC 842, the Company elected to combine lease and non-lease components as a single component for all leases. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over&#160;the expected lease term. <font style="color:#000000;">Certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company&#160;typically only includes&#160;an initial lease term in&#160;its&#160;assessment of a lease arrangement; options to renew a lease are not included in the assessment unless there is reasonable certainty that&#160;the Company&#160;will renew. </font>The interest rate implicit in lease contracts is typically not readily determinable. As such, in calculating the lease liability, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease expense is recognized over the expected lease term on a straight-line basis. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commitments and Contingencies </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&#160;reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue in accordance with ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC&#160;606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees; (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (ii)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Upfront License Fees </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if&#160;necessary, adjusts the measure of performance and related revenue recognition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further discussion of accounting for collaboration revenues, see Note&#160;8, <font style="font-style:italic;">Collaboration and License Agreements.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology are expensed as&#160;incurred and are included in research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes stock-based compensation expense based on the grant date fair value of the awards, which consist of option grants. The fair value of each share option grant was determined using the expected term, expected volatility, risk-free interest rate, dividend rate, and the fair value of the common stock underlying the share-based award. Prior to the IPO, the fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&#8217;s board of directors. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font>. Each of these inputs is subjective and generally requires judgment and estimation by management. Subsequent to the IPO, the fair value of the common stock underlying shared based awards is the quoted market price of the Company&#8217;s common stock on the date of the grant. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrant Liability Expense</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s completion of a financing involving the sale of shares of Series B redeemable convertible preferred stock, or the Series B Financing, in June and July 2020 and the entry into the Term Loan (see Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>), the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability, determined using Black-Scholes, as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of the IPO, the warrant converted into a warrant to purchase shares of the Company&#8217;s common stock, as described in Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>. Upon conversion into a warrant exercisable for shares of the Company&#8217;s stock, management concluded that the warrant meets the definition of an equity instrument and the fair value of the warrant at the time of conversion, determined using Black-Scholes, was recorded as an increase in additional paid-in capital.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible Series B Preferred Stock or common stock issuable upon exercise of the warrant, remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequence of events that have been recognized in the consolidated financial statements or the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive income is unrealized gains and losses on marketable securities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss per share attributable to common stockholders is calculated using the&#160;two-class&#160;method, which is an earnings allocation formula that determines net loss per share for the holders of shares of the Company&#8217;s common stock and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the&#160;two-class&#160;method or (b)&#160;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balance. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016 the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This standard became effective for the Company on January 1, 2020 and, based on the composition of the Company&#8217;s receivables and available-for-sale debt securities, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on its consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12, <font style="font-style:italic;">Income Taxes</font> (Topic 740): <font style="font-style:italic;">Simplifying the Accounting for Income Taxes, or </font>ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of ASU 2019-12 is not expected to have a material effect on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <font style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</font>, which provides temporary optional guidance for a limited time to ease the potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as the London Interbank Offered Rate (LIBOR). Optional expedients in Topic 848 are generally available until December 31, 2022. The adoption of ASU 2020-04 is not expected have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513061288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Note 3. Fair value measurements</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,040</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its money market funds, which are valued based on quoted market prices in active markets, with no valuation adjustment, as Level 1 assets within the fair value hierarchy. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of U.S. Treasury securities and are classified as available-for-sale pursuant to ASC 320, <font style="font-style:italic;">Investments &#8211; Debt and Equity Securities</font>. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies on a recurring basis.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further discussed in Note 9, <font style="font-style:italic;">Long-term debt and warrant liability,</font> during the year ended December 31, 2020, the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock to Perceptive Credit Holdings III, LP, an affiliate of Perceptive Advisors LLC, or Perceptive. Perceptive is a considered a related party to the Company based on its ownership of the Company&#8217;s common stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date. The warrant is considered within Level 3 of the fair value hierarchy because the fair value uses management&#8217;s own assumptions about the assumptions that market participants would use in pricing the liability. Upon the completion of the Company&#8217;s IPO on October 6, 2020, the warrant was automatically converted into a warrant exercisable for 338,784 shares of the Company&#8217;s common stock and was reclassified as equity. The fair value of the warrant was determined on October 6, 2020 using the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in Level 3 instruments, redeemable convertible preferred stock warrant, for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,676</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,001</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the warrant has not been exercised.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no transfers between fair value levels during the years ended December&#160;31, 2020 and 2019. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513041032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Marketable securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities at December&#160;31, 2020 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,949</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, none of the Company&#8217;s marketable securities were in an unrealized loss position. During the year ended December&#160;31, 2020, the Company did not recognize any other-than-temporary impairment losses. The contractual maturity dates of the Company&#8217;s marketable securities are less than one year.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any marketable securities at December&#160;31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216519016248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Property and equipment</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment as of December&#160;31, 2020 and 2019 consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,207</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,766</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,955</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,417</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,954</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,323</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,617</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511831288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Leases</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the Company entered into a lease of office and laboratory space for its headquarters in Watertown, Massachusetts, or the Watertown Lease. The Watertown Lease has a non-cancelable term of ten years with an option to extend for one additional five-year period and is subject to rent escalation throughout the term. Additionally, the Watertown Lease required the Company to provide collateral in the amount of $2.6 million, which is recorded as restricted cash on the accompanying consolidated balance sheets. The Watertown Lease commenced in April 2018, with rent commencing in May 2018. The Watertown Lease was classified as an operating lease and, upon the commencement in April 2018, the Company recorded a lease liability of $15.1&#160;million and a right-of-use asset of $16.7 million, which is inclusive of $1.5 million of construction costs funded by the Company. In calculating the lease liability and the right-of-use asset, the Company did not include the additional five-year period option as management does not believe there is reasonable certainty the Company will exercise the option. In addition to rent, the Company is also responsible for paying its pro rata share of costs incurred for common area maintenance, real estate taxes and property insurance related to the leased space, which are accounted for as variable lease costs.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The elements of lease costs for the years ended December&#160;31, 2020 and 2019 were as follows (in thousands):<font style="font-size:9.5pt;font-family:Arial;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,616</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,570</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future lease payments under non-cancelable leases as of December&#160;31, 2020 for each of the years ending December 31 are as follows (in thousands):&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,272</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,483</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,339</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,471</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,868</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216519070120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Accrued expenses and other current liabilities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2020 and 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,799</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,724</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,048</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">469</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,524</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216508636104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Collaboration and license agreement</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2020 (in thousands): &#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,913</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,965</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,026</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,958</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,195</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,617</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,220</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,409</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,164</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,432</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,540</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,423</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial information related to the collaboration and license agreements for the years ended December&#160;31, 2020 and 2019 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in the contract liability at the beginning of the period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,570</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized from performance obligations fully or partially satisfied in previous periods</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,137</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Roche Collaboration and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Original Roche Agreement Structure </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Company entered into a license agreement, or the Original Roche Agreement, with Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche. Pursuant to the terms of the Original Roche Agreement, the Company and Roche agreed to collaborate on research activities to develop novel treatments in the field of targeted protein degradation using the Company&#8217;s degrader technology. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for a $15.0&#160;million nonrefundable upfront payment and additional fees for dedicated personnel, the Company performed initial research and development services for drug discovery and preclinical development, provided a non-exclusive research and development license to its technology and participated on the joint research committee, or the Roche JRC. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restated Roche Agreement Structure </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2018, the Company and Roche executed the Amended and Restated Roche License Agreement, or the Roche Agreement. Under the Roche Agreement, the Company has a more active role in the manufacturing and commercialization of the targets, whereby if certain co-development and co-detailing rights are opted into by the Company, the parties will split future development costs in return for the rights to a larger share of future earnings from commercialization of the target. The target structure was revised to six potential targets, three of which were nominated as of the execution of the Roche Agreement and represent continuations of the initial preclinical research and development efforts begun under the Original Roche Agreement and three additional targets that were not nominated as of the execution of the Roche Agreement. Roche maintained its option rights to license and commercialize these six targets. For certain targets, Roche is required to pay the Company fees of $2.0&#160;million and $3.0&#160;million upon the progression of targets to the lead series identification achievement and GLP toxicology, or Tox, study phase, respectively. For each target option exercised by Roche, the Company is eligible to receive up to $275.0&#160;million in research and development milestones per target and commercial milestone payments, with the commercial milestones being dependent on underlying net sales. Roche is also required to pay the Company up to $150.0&#160;million per target in one-time sales-based payments if the target achieves certain levels of net sales. In addition, Roche is required to pay the Company royalties, at percentages from the mid-single digits to the low double-digits, on a licensed product-by licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Roche Agreement: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company received additional upfront consideration of $40.0&#160;million from Roche; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company has an option for co-development and co-detailing rights, whereby it would be required to provide additional financial support in return for the rights to a larger share of future earnings from commercializing one or more of the six targets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche will no longer provide FTE reimbursement; rather, it will make annual research plan payments of $1.0&#160;million for each active research plan; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments were made to the option exercise fees, whereby certain targets now have option exercise fees of $7.0&#160;million to $12.0&#160;million (those progressed up to Phase 1 or through the GLP Tox studies, respectively) and others have $20.0&#160;million (those progressed through clinical trials). </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is managed by a joint research committee. The Company has control over the committee and may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&#160;days&#8217; prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company signed an amendment to the Roche Agreement that provides a mechanism through which the Company and Roche can mutually agree to terminate the Roche Agreement on a target-by-target basis by entry into a mutual target termination agreement. Upon a termination of this nature, the Roche Agreement, as amended, provides that all rights in know-how and intellectual property in support of products that use inhibition as their mode of action, referred to as the Roche Field, will revert to Roche and all rights in respect of know-how and intellectual property in support of products that use degradation as their mode of action, referred to as the C4T Field, will revert to the Company. Further, this amendment states that, following the entry into a mutual target termination agreement, Roche will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the Roche Field and the Company will have rights in and responsibility for any know-how and intellectual property generated as a result of the collaboration that fits within the C4T Field. In support of this allocation of rights, under the amendment, Roche provided the Company, and the Company provided Roche, with a perpetual, irrevocable, fully paid up, exclusive (even as to party granting the license), sublicensable (including in multiple tiers) license to the know-how and intellectual property rights that are allocated to a party under the mutual target termination agreement. Finally, through the entry into this amendment, the Company and Roche mutually agreed to terminate the Roche Agreement as to the target EGFR.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roche Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Roche Agreement is a modification of the Original Roche Agreement under ASC 606 as both the scope and price of the contract were changed under the Roche Agreement and new, distinct performance obligations were created for targets that have different standalone selling prices based on the Company&#8217;s revised obligations. The Roche Agreement was not determined to be a separate contract for accounting purposes. The modification was accounted for as if it were a termination of the existing contract and the creation of a new contract, for which the unrecognized consideration from the Original Roche Agreement is added to the new transaction price promised as part of the Roche Agreement and will be recognized as revenue prospectively, as the new performance obligations are satisfied. The Company made this determination after considering the performance obligations under the Roche Agreement. When the amendment was signed, the contract was restructured such that the Company would pursue some of the same targets, but would have additional material responsibility to potentially develop the targets beyond the option exercise point, to either Phase 1 completion or to a point where the Company will exercise its co-development and co-detailing options and more fully share in the costs and future revenues. The $40.0&#160;million upfront payment, $13.5 million of expected research plan funding payments, plus $6.4&#160;million of remaining deferred revenue from the Original Roche Agreement represent the transaction price as of the outset of the arrangement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Roche, is a customer. The Company identified the following promises at the outset of the Roche Agreement: (1)&#160;a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities; (2)&#160;research and development services under the research plan for the three initial targets; (3)&#160;participation on the Roche JRC; (4)&#160;option rights to initiate a research plan for three additional targets; (5) an option to obtain a non-exclusive commercial license to intellectual property and know-how generated from the collaboration, subject to certain exclusivity requirements; (6) option rights to develop, commercialize and manufacture products related to any of the six targets; and (7)&#160;rights for Roche to substitute targets prior to completion of a research plan, limited to six exchanges in total across the arrangement and subject to approval by the Roche JRC. The Roche JRC has equal representation from both parties, but the Company holds final decision-making authority in the event of a disagreement until the time at which Roche licenses a target and leads development efforts. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The six potential targets were determined to be distinct from one another, as Roche can derive benefit from each target independent of the others. For each target, the Company determined that the research and development license and research and development services were not distinct from one another, because the research and development services are essential to the license. Roche would receive little to no economic benefit from the license if it did not obtain the research services. Participation on the Roche JRC to oversee the research and development activities and the technology transfer associated with the Original Roche Agreement were determined to be quantitatively and qualitatively immaterial. The Company evaluated Roche&#8217;s option rights to initiate a research plan for three additional targets as well as the option rights to license and commercialize each target to determine whether they provide Roche with any material rights. The Company concluded that each of the options were issued with an option exercise fee that represented a significant and incremental discount and therefore provide material rights for six of the six targets&#8212;three material rights from the option to license the three initial targets at the end of their research terms and three material rights from the option to initiate a research plan for the three additional targets along with the option to license such at the end of their research terms. The consideration allocated to the option rights to initiate the three additional targets is deferred until the underlying option is exercised, at which point the Company will begin recognizing revenue for these targets. The non-exclusive, limited commercial license to the intellectual property and know-how generated from the collaboration was determined to be immaterial and, as such, no consideration was allocated to it. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified twelve performance obligations, including three research services performance obligations, six material rights for the options to purchase a commercial license for six targets, and three material rights for the option to initiate research services for the uninitiated three targets as of the outset of the arrangement. The first three performance obligations primarily comprise: (1)&#160;the non-exclusive research and development license and (2)&#160;the research and development services for the target, including the related substitution rights. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company included the $40.0&#160;million upfront payment, $13.5 million of expected research plan funding payments ($1.0&#160;million per active target per year, for a maximum of $3.0 million per target), and $6.4&#160;million of remaining deferred revenue from the Original Roche Agreement in the transaction price as of the outset of the arrangement. The Company also achieved a milestone for the identification of lead series for target 2 in April 2019, resulting in a milestone payment of $2.0 million, which was added to the transaction price and recognized cumulatively. The transaction price of $61.9 million was allocated to the performance obligations based on the estimated stand-alone selling prices at the time of the amendment. For each performance obligation, the stand-alone selling price was determined considering the expected cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the amendment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocated the following amounts of the total transaction price to the performance obligations as of the amendment date, including the $2.0 million milestone achieved in April 2019: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.0&#160;million to the research and development performance obligations for targets&#160;1-3; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4.1&#160;million to the three material rights, related to the three targets initiated at the outset of the Roche Agreement, which will not begin revenue recognition until the option is exercised or expires; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.8&#160;million to the option to nominate targets 4-6 and the three material rights related to these options. </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biogen Collaboration Research and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2018, the Company entered into a collaboration research and license agreement, or the Biogen License Agreement, with Biogen MA, Inc., or Biogen. Pursuant to the terms of the Biogen License Agreement, the Company and Biogen agreed to collaborate on research activities to develop novel treatments in the field of TPD using the Company&#8217;s degrader technology. In February 2020, the Company entered into an amendment to the Biogen Agreement that provided further clarity around Biogen&#8217;s ownership of target binding moieties, which are portions of molecules, and any related intellectual property that are directed at or bind to collaboration targets. This amendment further provides that Biogen licenses to the Company the rights to use these Biogen target binding moieties and any related intellectual property as needed in order to conduct the research and development activities contemplated under the Biogen Agreement. Under the terms of the Biogen License Agreement, the Company will initially develop TPD therapeutics that utilize degrader technology for up to five target proteins over a period of 54 months. On a target-by-target basis, after successful completion of a defined target evaluation period, Biogen assumes full rights and responsibility to each degrader to meet certain criteria against a target. Biogen also has the option to pay an additional $62.5&#160;million to extend the contract and select up to five additional targets for development. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for the non-exclusive research license from Biogen as well as a $45.0&#160;million nonrefundable upfront payment, the Company will grant a license to develop, commercialize and manufacture products related to each of the targets, which is contingent on not cancelling the contract, will perform initial research services for drug discovery, provide a non-exclusive research and commercial license to its intellectual property and will participate on the joint steering committee, or the Biogen JSC. The Company will also be obligated to participate in early research activities for other potential targets, referred to as sandbox activities at Biogen&#8217;s election up to a maximum amount; any work performed for these services will be reimbursed by Biogen, and Biogen will reimburse the Company for certain FTE costs. Biogen is also required to pay the Company up to $35.0&#160;million per target in development milestones and $26.0&#160;million per target in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay the Company royalties on a licensed product-by-licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is managed by the Biogen JSC, which Biogen has control over, and Biogen may terminate the Biogen License Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90&#160;days&#8217; prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nonrefundable upfront cash payment of $45.0&#160;million is not creditable against any of the target development milestone fees. The research will be performed by the Company over 54 months according to the research plan approved by the Biogen JSC. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Biogen License Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Biogen, is a customer. The Company identified the following promises under the arrangement: (1)&#160;a non-exclusive, royalty-free license to use the Company&#8217;s intellectual property to conduct research activities; (2)&#160;an upfront license to develop, commercialize and manufacture products related to each of the targets (which is contingent on not cancelling the contract); (3)&#160;research services for preclinical activities under the research plan; (4)&#160;participation on the Biogen JSC; and (5)&#160;substitution rights for Biogen via sandbox activities to replace targets prior to a program reaching completion of a research plan, limited to five exchanges in total. Substitution is dependent on the original target failing to meet certain criteria; Biogen may only replace a target in this specific scenario. The Company also determined that Biogen&#8217;s ability to terminate the Agreement at-will with 90 days&#8217; notice is not representative of a substantive purchase option to continue to the research and does not provide a material right in the form of a continuous renewal option. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the licenses and research activities were not distinct from one another, as the licenses have limited value without the performance of the research activities by the Company. Participation on the Biogen JSC to oversee the research activities and the technology transfer associated with the Biogen License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified one performance obligation at the outset of the Biogen License Agreement, representing a combined performance obligation consisting of (1)&#160;the licenses, (2)&#160;the research activities for the target evaluation phase for all five targets and (3)&#160;the joint research plan phase for each target. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize the transaction price as the research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen also has the option to fund sandbox activities in exchange for consideration, whereby the Company will perform discovery-type research at Biogen&#8217;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or two additional targets under the Biogen Agreement. Revenues earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price. Sandbox research activities will be reimbursed on an FTE basis at market rates, which is adjusted for changes in the &#8220;Consumer Price Index&#8221; each year. The sandbox activities constitute additional research that can be purchased on an a la carte basis at an amount consistent with standalone selling price. The Company recognizes revenue as the services performed for the sandbox activities are performed and recognized $2.8 and $0.5&#160;million of revenue for the years ended December&#160;31, 2020 and 2019, respectively, related to the sandbox activities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes FTE reimbursement related to sandbox activities as revenue as the hours are incurred each quarter. Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company achieved $4.0 million in milestones under the Biogen Agreement in June 2020, which amount was recorded as accounts receivable and deferred revenue at that time. The Company received payment of these milestones from Biogen in August 2020. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Calico Collaboration and License Agreement </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, the Company entered into a collaboration and license agreement, or the Calico License Agreement, with Calico Life Sciences LLC, or Calico, whereby the Company and Calico agreed to collaborate to develop and commercialize small molecule protein degraders for diseases of aging, including cancer for a five-year period ending in March 2022, the research term. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Calico License Agreement, the Company will initially develop and commercialize small molecule protein degraders for up to five target proteins over the research term. On a target-by-target basis, after successful completion of a defined target evaluation period, Calico has an exclusive option to pursue further pre-clinical development and commercialization via a joint research plan for each target. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Calico License Agreement, Calico paid an upfront amount of $5.0&#160;million and certain annual payments totaling $5.0&#160;million through December 31, 2020 and pays target initiation fees and reimburses the Company for a number of FTEs, depending on the stage of the research, at specified market rates. Upon completion of the required discovery research and development services on any target, Calico is entitled to pursue commercial development of that target. The Company will perform initial research services for drug discovery and preclinical development, provide a non-exclusive research and commercial license to its IP and will participate on the Calico joint research committee, or the CJRC. For each target, the Company is eligible to receive up to $132.0&#160;million in potential research, development and commercial milestone payments, on sales of all products resulting from the collaboration efforts. Calico is also required to pay the Company up to $65.0&#160;million in one-time sales-based payments for the first product to achieve certain levels of net sales. In addition, Calico is required to pay the Company royalties, at percentages in the mid-single digits, on a licensed product-by-licensed product basis, on worldwide net product sales. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Calico License Agreement is managed by CJRC. Calico has control over the CJRC and may terminate the Calico License Agreement on a target-by-target or product-by-product basis under several scenarios, upon prior written notice. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nonrefundable upfront and certain annual payments are not creditable against any other payments. Calico will reimburse the Company for a contractually defined number of FTEs per target depending on the phase of development, unless otherwise agreed upon by the CJRC. The research will be performed by the Company over the research term in accordance with the research plan. For the year ended December&#160;31, 2019 the Company received $2.0&#160;million in cash consideration for milestone revenue and no additional consideration in the form of cash received for target initiation fees. The Company recorded an accounts receivable of $1.0&#160;million for additional target initiation fees in 2019 and received payment in 2020.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Calico License Agreement Accounting </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC&#160;606 and concluded that the contract counterparty, Calico, is a customer. The Company identified the following promises under the arrangement: (1)&#160;the non-exclusive, royalty-free research license and commercial license, which function for purposes of the arrangement as a license and are therefore analyzed together; (2)&#160;the target evaluation research services for all five targets; (3)&#160;the joint research plan research services related to targets 1 and 2, which were nominated at the execution of the Calico License Agreement; (4)&#160;the target initiation rights or options associated with targets 3, 4 and 5, subject to nomination; and (5)&#160;the joint research plan services associated with targets 3, 4 and 5, subject to nomination and payment of the target initiation fees from (4). The Company determined that the license and research activities were not distinct from one another, as the license has limited value without the performance of the research activities by the Company. Participation on the CJRC to oversee the R&amp;D activities and the technology transfer associated with the Calico License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. The Company determined that the option rights to nominate the targets were not distinct from one another or from the other promises in the arrangement, specifically the research license and research services. The Company evaluated the target initiation rights for targets 3, 4 and 5 and the research services associated with the joint research plan nomination for these targets to determine whether they provide Calico with any material rights. The Company concluded that these options were not issued at a significant and incremental discount and therefore do not provide material rights. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these assessments, the Company identified one performance obligation at the outset of the Calico License Agreement, which consists of: (1)&#160;the non-exclusive license and (2)&#160;the research activities for the target evaluation phase for all five targets and the joint research plan phase for targets 1 and 2. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Calico License Agreement, the transaction price determined by the Company is the upfront amount plus the committed anniversary payments and the target initiation fees related to the targets nominated at the execution of the Calico License Agreement. Based on the ability of Calico to cancel the arrangement for any reason, Calico effectively has an option for continued access to the Company&#8217;s research license and procurement of research services that they can cancel at any time. Under the Calico License Agreement, the Company amortized the upfront fee received on a straight-line basis over the period services are available to the counterparty (i.e., the contractual term of five years). Straight-line amortization of the upfront payment was considered the best measure of progress because the customer has access to research and development services throughout the period. Incremental fees for research and development services are paid at agreed upon FTE rates and recognized in the period incurred.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216518970840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt and Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityAbstract', window );"><strong>Long Term Debt And Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityTextBlock', window );">Long-term Debt and Warrant Liability</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Long-term debt and warrant liability</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 5, 2020, contemporaneously with the completion of the Series B Financing (see Note 10, <font style="font-style:italic;">Stockholders&#8217; equity</font>), the Company entered into a Credit Agreement, or the Credit Agreement, with Perceptive, which is a related party as previously noted, that provides for an aggregate principal borrowing amount of up to $20.0&#160;million, available in two tranches of $12.5&#160;million and $7.5&#160;million, or the Term Loan. In June 2020, the Company drew down on the first tranche of $12.5&#160;million. The borrowing bears interest at a variable rate using the greater of LIBOR or 1.75%, plus 9.50%. If LIBOR cannot be determined, an alternate rate of interest will be established giving consideration to then-prevailing market convention for determining a rate of interest. The Credit Agreement is secured by a lien on substantially all of the Company&#8217;s assets, including, but not limited to, shares of the Company&#8217;s subsidiaries, its current and future intellectual property, insurance, trade and intercompany receivables, inventory and equipment and contract rights. The Credit Agreement requires the Company to maintain a minimum aggregate cash balance of $3.0 million in one or more controlled accounts and contains various affirmative and negative covenants that limit its ability to engage in specified types of transactions.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to make interest-only payments until December&#160;5, 2022, after which point the Company will be required to make payments of principal equal to 2% of the Term Loan until maturity on June 5, 2024, or the Maturity Date. If the Company pays off the Term Loan prior to the Maturity Date, it will be required to pay a prepayment fee. Per the terms of the Credit Agreement, the prepayment fee is $5.0 million less any interest paid through the prepayment period. As of December&#160;31, 2020, the prepayment fee would be $4.2 million. The Company paid issuance costs of $0.5&#160;million in connection with its entry into the Credit Agreement.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Credit Agreement, the Company issued a warrant to purchase up to 2,857,142 shares of the Company&#8217;s Series B preferred stock to Perceptive at an exercise price per share of $1.05. The fair value of the warrant at the time of issuance was determined to be $2.3 million. The warrant is exercisable at any time prior to the ten-year anniversary of the closing date of the Credit Agreement. At issuance, the Company determined that the warrant is liability-classified and would be remeasured to fair value each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the Company&#8217;s IPO on October 6, 2020, the warrant was effected for one-for-8.4335 reverse stock split and automatically converted into a warrant to purchase up to 338,784 shares of the Company&#8217;s common stock at an exercise price per share of $8.86. Based on information available at that time, the fair value of the warrant was determined to be $8.0 million on October 6, 2020. Upon the conversion into a warrant exercisable for shares of the Company&#8217;s common stock, management concluded that the warrant meets the definition of an equity instrument and the warrant was recorded, at its fair value on October 6, 2020, as an increase to additional paid-in capital. For the year ended December 31, 2020, the Company recognized $5.7 million in change in the fair value of the warrant liability as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the outstanding long-term debt was $12.5&#160;million. The outstanding amount is reduced by the unamortized portions of 1) issuance costs, and 2) the issuance date fair value of the warrant to arrive at the carrying value of long-term debt as of December&#160;31, 2020, which was determined to be $10.1 million.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had met the criteria to draw down on the second tranche of $7.5 million. It has the ability, but not the obligation, to draw down the second tranche until June 30, 2021.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt for the years ending December 31 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum long-term debt payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Unamortized debt issuance costs, and debt discount related to warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,448</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value of long-term debt&#8212;related party at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LongTermDebtAndWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and warrant liability abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LongTermDebtAndWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LongTermDebtAndWarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LongTermDebtAndWarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516784536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder&#8217;s Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder&#8217;s Equity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Stockholders&#8217; equity</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certificate of Incorporation</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the terms of the Company&#8217;s equity securities were defined in the Company&#8217;s Fourth Amended and Restated Certificate of Incorporation, which was filed with the Secretary of the State of Delaware on June 3, 2020, or the Fourth Charter. Under the Fourth Charter, the Company was authorized to issue Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock, each of which had a par value of $0.0005 per share and which are referred to collectively as Preferred Stock. On October 6, 2020, in connection with the consummation of the IPO, the Company filed its Fifth Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware. The summary below relates to the Company&#8217;s Fourth Charter.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 1, <font style="font-style:italic;">Nature of the business and basis of presentation</font>, on September 25, 2020 the Company effected a one-for-8.4335 reverse stock split of its issued and outstanding common stock, stock options and common stock warrant and a proportional adjustment to the existing conversion ratios for the Company&#8217;s convertible preferred stock. Accordingly, all issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Fourth Charter, the Company&#8217;s common stock had a par value of $0.0001 and the holders of common stock were entitled to one vote for each share held at all meetings of stockholders and written actions in lieu of meetings provided. The Fourth Charter also provided that all dividends shall be declared and paid pro rata according to the number of shares held by each holder of common stock. In the event of a liquidation, dissolution or winding up of the Company, the common stock ranks behind the Preferred Stock in terms of distribution of assets. The holders of the common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June and July 2020, the Company closed a $150.0&#160;million Series B Financing with existing and new investors. As part of the Series B Financing, the Company issued 142,857,142 shares of its Series B preferred stock at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&#160;million. Of the amounts above, 138,571,428 shares were issued for gross proceeds of $145.5&#160;million, less related offering costs of $4.5&#160;million in June 2020, and 4,285,714 shares were issued for proceeds of $4.5&#160;million in July 2020.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the Company&#8217;s IPO on October 6, 2020, all outstanding shares of the Company&#8217;s Preferred Stock were converted into 30,355,379 shares of common stock using the exchange rate set forth in the Fourth Charter, as amended, which provided that every 8.4335 shares of Preferred Stock converted into one share of common stock. As a result, as of December&#160;31, 2020, no shares of Preferred Stock are presently outstanding.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, Preferred Stock consisted of the following (in thousands, except share data): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,145,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FF Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,760,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,760,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,145,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,416,155</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216625335208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Stock-based compensation</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2015 Incentive Stock Option and Grant Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;28, 2015, the Company&#8217;s board of directors adopted the 2015 Incentive Stock Option and Grant Plan, or the&#160;2015 Plan, and reserved 2,525,327 shares of common stock for issuance under this plan. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options and restricted stock awards to eligible employees, outside directors and consultants of the Company. Options generally vest over a period of five or eight&#160;years with a cliff vesting at one&#160;year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again. The contractual life of all options is ten&#160;years from the date of grant. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Stock Option and Incentive Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 8, 2020, the Company&#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan, or the 2020 Plan, which became effective on September 30, 2020. Upon adoption there were 6,567,144 shares of common stock reserved for issuance under the 2020 Plan. The Company&#8217;s Board of Directors, the Compensation Committee of the Board of Directors, and the Chief Executive Officer of the Company are authorized to grant a broad range of equity-based awards under the 2020 Plan, including stock options, stock appreciation rights, or SARs, restricted stock awards, or RSAs, restricted stock units, or RSUs, performance awards and stock bonus awards to the Company&#8217;s officers, employees, directors and other key persons, including consultants. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the effectiveness of the 2020 Plan, the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2020 Plan. <font style="color:#000000;">As of December&#160;31, 2020, the Company had 8,880,367 shares reserved under the 2020 Plan and 2015 Plan, and 3,851,003 shares available for future issuance under the 2020 Plan.</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing until the expiration of the 2020 Plan, equal to the lesser of (i) 5% of the outstanding shares of common stock on the immediately preceding December 31st, or (ii) lesser number of shares determined by the administrator of the 2020 Plan, which is the Company&#8217;s Board of Directors or the Compensation Committee of the Board of Directors. On January 1, 2021, the annual increase for the 2020 Plan resulted in an additional 2,152,981 shares authorized for issuance being added to the 2020 Plan.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the year ended December&#160;31, 2020 and 2019 was classified in the consolidated statement of operations and comprehensive loss as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">972</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans for the year ended December&#160;31, 2020<font style="color:#000000;">: &#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,222,179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281,584</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,222,117</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455,633</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.34</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to the option activity of the Company is as follows for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the unrecognized compensation cost related to outstanding options was $37.5&#160;million, which is expected to be recognized over a weighted-average period of 3.7 years. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.23 - 6.35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32% - 0.57%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71% - 2.36%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.54% - 83.76%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.50% - 76.80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Employee Stock Purchase Plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 8, 2020, the Company&#8217;s board of directors adopted the C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan, or the 2020 ESPP, which became effective on September 30, 2020 for use by the Company following its IPO. Upon adoption there were 437,809 shares of common stock reserved for issuance under the 2020 ESPP. The 2020 ESPP provides for an annual increase to be added on the first day of each fiscal year, beginning with January 1, 2021 and continuing thereafter through January 1, 2030, equal to the lesser of (i) 1% of the outstanding shares of common stock on the immediately preceding December 31st, (ii) 656,714 shares, or (ii) lesser number of shares determined by the administrator of the 2020 ESPP. On January 1, 2021, the annual increase for the 2020 ESPP resulted in an additional 430,596 shares authorized for issuance being added to the 2020 ESPP.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To participate in the 2020 ESPP, eligible employees may authorize payroll deductions of up to 15% of their eligible compensation during an offering period. The Company may hold one or more offering periods each year during which employees will be able to purchase shares under the 2020 ESPP. As of December&#160;31, 2020, the Company had not held any offering periods and no shares had been issued under the 2020 ESPP.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">President and Chief Executive Officer Termination </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;3, 2020, or the Separation Date, the employment of the Company&#8217;s then current president and chief executive officer, or the Former CEO, terminated. The Company repurchased all of the Former CEO&#8217;s outstanding shares of common stock, which had been issued upon his exercise of previously granted stock options, for total consideration of $0.1&#160;million. The Former CEO also relinquished his right to purchase shares of common stock upon the exercise of stock options that were vested as of his Separation Date, in exchange for total consideration paid by the Company of $0.7&#160;million. The Company recognized the repurchase price of these shares of common stock and the relinquishment of these vested options in additional-paid-in-capital.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516797032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Income Taxes</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense consists of the following for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current tax provision:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current federal provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">669</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current state provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred federal provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred state provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total tax provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a) Tax Rate Reconciliation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) expense computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows for the years ended December&#160;31, 2020 and 2019: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at federal statutory tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax&#8212;net of federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate change</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax attributes true up due to net operating loss carryback</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b) Significant Components of Deferred Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of (a)&#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and (b)&#160;operating losses and tax credit carryforwards. Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows as of December&#160;31, 2020 and 2019 (in thousands): <font style="font-size:9pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start-up costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,859</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and investment tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,578</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,157</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,580</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(744</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain/loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,866</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the positive and negative evidence bearing upon the realizability of the deferred tax assets. As of December&#160;31, 2020 and 2019, based on the Company&#8217;s historical operating losses, the Company has concluded that it is more-likely-than-not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December&#160;31, 2020 and 2019. The valuation allowance for deferred tax assets as of December&#160;31, 2020 and 2019 was $49.9&#160;million and $27.1&#160;million, respectively. The net valuation allowance increase of $22.8 million during the year ended December 31, 2020 was primarily due to the increase in net operating loss and tax credits carryforward and a decrease in deferred revenue recognized during the year. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company had $58.8 million and no gross United States federal net operating loss, or NOL, carryforwards, respectively, which may be available to offset future income tax liabilities. The Tax Cuts and Jobs Act, or TCJA, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended, or IRC). In addition, there will be no carryback for losses generated after 2017. Losses generated prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#8217;s NOL carryover or 100% of a corporation&#8217;s taxable income and be available for twenty years from the period the loss was generated. For U.S. federal income tax purposes, the Company has federal NOLs generated after 2017 of <font style="font-weight:bold;">$</font>58.8 million, which do not expire. The Company does not have any available NOLs generated prior to 2018 as they were fully utilized in 2019. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA. The Company is anticipated to carryback a portion of FY2020 NOL to the tax year ended December 31, 2019 which will result in a refund of approximately $0.6 million. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, the Company has total gross United States state net operating loss carryforwards of $105.1 million and $8.2&#160;million, respectively, which may be available to offset future income tax liabilities that expire at various dates through 2040. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020 and 2019, the Company has United States federal research credit carryforwards of $4.7 million and $0.4&#160;million, respectively, which are available to offset future federal income tax liabilities, which expire at various dates through 2040. At December&#160;31, 2020 and 2019, the Company has United States state research credit carryforwards of $1.1 million and $0.1 million, respectively, which are available to reduce future tax liabilities which expire at various dates through 2035. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the IRC, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. In 2020, the Company completed a study of ownership changes from inception through December 31, 2020, to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The result of this study indicated that the Company experienced ownership changes as defined by IRS Section&#160;382 of the Code, however there are no net operating loss carryforwards that will be limited and expire unused as a result of such ownership changes. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize interest and/or penalties related to uncertain tax benefits in income tax expense as they arise. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax benefits. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, California, and Massachusetts. The federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2017 through present. To the extent that the Company has tax attribute carryforwards, the tax years in which the attributes were generated may still be adjusted upon examination by the Internal Revenue Services or State tax authorities to the extent utilized in a future period. The Company is not currently under examination by any tax authorities. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CARES Act was enacted on March&#160;27, 2020. The CARES Act contains a significant number of provisions that may impact on the Company&#8217;s accounting for income taxes. The Company has considered several key corporate provisions within the CARES Act, has evaluated its potential impact and as a result recorded a tax benefit of $0.6 million related to an anticipated refund to be received for federal taxes incurred for the tax year ended December 31, 2019. The refund is expected to be received in 2021 after the Company files the tax year 2020 net operating loss carryback claim upon the completion of its tax year 2020 tax returns, which are due October 15, 2021. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516917512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 13. Loss per share</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted in Note 2, <font style="font-style:italic;">Summary of significant accounting policies</font>, for periods in which the Company reports a net loss attributable to common stockholders, potentially dilutive securities have been excluded from the computation of diluted net loss per share as their effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for each of the years ended December 31 because including them would have had an anti-dilutive effect:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338,784</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,368,148</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,727,041</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All redeemable, convertible preferred stock, including those that were outstanding as of December 31, 2019, as shown above, were converted to shares of the Company&#8217;s common and effected for a one-for-8.4335 reverse stock split.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding for the years ended December&#160;31, 2020 and 2019 (in thousands, except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual of preferred stock dividends</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,468</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common stock outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,370,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371,905</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516829480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 14. Defined contribution plan</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) retirement plan, the&#160;401(k)&#160;Plan, whereby all full-time employees may contribute up to 90% of their pre-tax compensation, up to the maximum allowable amount set by the Internal Revenue Service. The Company, at its discretion, matches 100% of contributions to the 401(k)&#160;Plan up to a maximum of $6,000 per year for each full-time employee. During each of the years ended December&#160;31, 2020 and 2019, the Company contributed approximately $0.5 million and $0.4&#160;million, respectively, to the 401(k)&#160;Plan. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235042<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216599815432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America, or U.S.&#160;GAAP. <font style="color:#000000;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements include the accounts of C4 Therapeutics, Inc. and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_EmergingGrowthCompanyPolicyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts and timing of revenues recognized under the Company&#8217;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. The Company&#8217;s cash equivalents are measured at fair value on a recurring basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income as a component of stockholders&#8217; equity (deficit) until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&#8217;s lease agreements for its Watertown, Massachusetts facility (see Note 6, <font style="font-style:italic;">Leases</font>). </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. Additionally, t<font style="color:#000000;">he Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <font style="font-style:italic;">Fair Value Measurement</font>, or ASC 820, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC&#160;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash are Level&#160;1 assets which are&#160;comprised of funds held in checking and money market accounts.&#160;Marketable securities are Level 2 assets which are comprised of US treasury funds with maturity dates of less than one year. The carrying amounts of accounts receivable, which relate to the Company&#8217;s collaboration agreements, accounts payable, and accrued expenses approximate their fair values due to their short-term nature. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset category</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment, furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of useful life or remaining lease term</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for leases in accordance with ASC Topic&#160;842, <font style="font-style:italic;">Leases</font>, or ASC&#160;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. As provided by ASC 842, the Company elected to combine lease and non-lease components as a single component for all leases. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over&#160;the expected lease term. <font style="color:#000000;">Certain adjustments to the right-of-use asset may be required for items such as incentives received. The Company&#160;typically only includes&#160;an initial lease term in&#160;its&#160;assessment of a lease arrangement; options to renew a lease are not included in the assessment unless there is reasonable certainty that&#160;the Company&#160;will renew. </font>The interest rate implicit in lease contracts is typically not readily determinable. As such, in calculating the lease liability, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Lease expense is recognized over the expected lease term on a straight-line basis. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December&#160;31, 2020 and 2019. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commitments and Contingencies </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&#160;reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesOfServices', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue in accordance with ASC Topic&#160;606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC&#160;606. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&#160;606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC&#160;606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1)&#160;non-refundable, upfront license fees; (2)&#160;reimbursement of certain costs; (3)&#160;customer option fees for additional goods or services; (4)&#160;development milestone payments, (5)&#160;regulatory and commercial milestone payments; and (6)&#160;royalties on net sales of licensed products. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&#160;the number of performance obligations based on the determination under step (ii)&#160;above; (b)&#160;the transaction price under step (iii)&#160;above; (c)&#160;the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)&#160;above; and (d)&#160;the contract term and pattern of satisfaction of the performance obligations under step (v)&#160;above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Upfront License Fees </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if&#160;necessary, adjusts the measure of performance and related revenue recognition. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Customer Options </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Services </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company&#8217;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further discussion of accounting for collaboration revenues, see Note&#160;8, <font style="font-style:italic;">Collaboration and License Agreements.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology are expensed as&#160;incurred and are included in research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes stock-based compensation expense based on the grant date fair value of the awards, which consist of option grants. The fair value of each share option grant was determined using the expected term, expected volatility, risk-free interest rate, dividend rate, and the fair value of the common stock underlying the share-based award. Prior to the IPO, the fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&#8217;s board of directors. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font>. Each of these inputs is subjective and generally requires judgment and estimation by management. Subsequent to the IPO, the fair value of the common stock underlying shared based awards is the quoted market price of the Company&#8217;s common stock on the date of the grant. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. Stock-based compensation expense is classified in the consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#8217; payroll costs are classified or in which the award recipients&#8217; service payments are classified.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy', window );">Warrant Liability Expense</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrant Liability Expense</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s completion of a financing involving the sale of shares of Series B redeemable convertible preferred stock, or the Series B Financing, in June and July 2020 and the entry into the Term Loan (see Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>), the Company issued a warrant to purchase shares of its Series B redeemable convertible preferred stock. Upon issuance, the Company classified the warrant as a liability on its consolidated balance sheet and remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability, determined using Black-Scholes, as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon completion of the IPO, the warrant converted into a warrant to purchase shares of the Company&#8217;s common stock, as described in Note 9, <font style="font-style:italic;">Long-term debt and warrant liability</font>. Upon conversion into a warrant exercisable for shares of the Company&#8217;s stock, management concluded that the warrant meets the definition of an equity instrument and the fair value of the warrant at the time of conversion, determined using Black-Scholes, was recorded as an increase in additional paid-in capital.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted above, the Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the warrant. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible Series B Preferred Stock or common stock issuable upon exercise of the warrant, remaining contractual term of the warrant, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequence of events that have been recognized in the consolidated financial statements or the Company&#8217;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) which includes certain changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive income is unrealized gains and losses on marketable securities. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss per share attributable to common stockholders is calculated using the&#160;two-class&#160;method, which is an earnings allocation formula that determines net loss per share for the holders of shares of the Company&#8217;s common stock and participating securities. The Company&#8217;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is computed using the more dilutive of (a)&#160;the&#160;two-class&#160;method or (b)&#160;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balance. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016 the FASB issued ASU No. 2016-13, <font style="font-style:italic;">Financial Instruments - Credit Losses</font> (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This standard became effective for the Company on January 1, 2020 and, based on the composition of the Company&#8217;s receivables and available-for-sale debt securities, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on its consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12, <font style="font-style:italic;">Income Taxes</font> (Topic 740): <font style="font-style:italic;">Simplifying the Accounting for Income Taxes, or </font>ASU 2019-12, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020, with early adoption permitted. The adoption of ASU 2019-12 is not expected to have a material effect on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <font style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</font>, which provides temporary optional guidance for a limited time to ease the potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as the London Interbank Offered Rate (LIBOR). Optional expedients in Topic 848 are generally available until December 31, 2022. The adoption of ASU 2020-04 is not expected have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_EmergingGrowthCompanyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_EmergingGrowthCompanyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121643868&amp;loc=d3e14931-158439<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121643868&amp;loc=d3e14937-158439<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=121643868&amp;loc=d3e14931-158439<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FuturePolicyBenefitsLiabilityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for sales of a service. The entity also may disclose how it recognizes cost of sales for such a service transaction and its treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516877960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation on equipment is calculated using the straight-line method over the estimated useful lives of the assets as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset category</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment, furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5 years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lesser of useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517030776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370,040</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,078</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy at December&#160;31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,902</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Assumptions to Determine Fair Value of Warrant</a></td>
<td class="text">The fair value of the warrant was determined on October 6, 2020 using the following assumptions:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the changes in Level 3 instruments, redeemable convertible preferred stock warrant, for the year ended December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,676</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,001</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216600548536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities at December&#160;31, 2020 consisted of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,949</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,962</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513173944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment as of December&#160;31, 2020 and 2019 consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,207</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,766</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,955</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,417</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,954</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,323</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ScheduleOfDepreciationExpenseTableTextBlock', window );">Summary of Depreciation Expense Related to Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense related to property and equipment for the years ended December&#160;31, 2020 and 2019 is as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,617</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ScheduleOfDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ScheduleOfDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513456120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future lease payments under non-cancelable leases as of December&#160;31, 2020 for each of the years ending December 31 are as follows (in thousands):&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,272</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,483</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,277</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,339</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,471</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,868</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember', window );">Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The elements of lease costs for the years ended December&#160;31, 2020 and 2019 were as follows (in thousands):<font style="font-size:9.5pt;font-family:Arial;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,550</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,616</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,570</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remaining lease term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517077032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2020 and 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,799</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,724</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,048</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">469</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,524</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513181272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock', window );">Schedule of Financial Information Related to Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2020 (in thousands): &#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,991</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,913</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,965</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,026</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,991</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,958</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,195</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,603</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,617</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,220</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information related to the collaboration and license agreements consisted of the following as of and for the year ended December&#160;31, 2019 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net of Current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,409</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,164</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen License Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,432</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,141</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calico License Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,540</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,400</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,705</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,423</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock', window );">Schedule of Other Financial Information Related to Collaboration and License Agreements</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financial information related to the collaboration and license agreements for the years ended December&#160;31, 2020 and 2019 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized that was included in the contract liability at the beginning of the period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,570</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,948</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized from performance obligations fully or partially satisfied in previous periods</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">348</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,137</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial information related to the collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial information related to the collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_OtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216590333768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt and Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityAbstract', window );"><strong>Long Term Debt And Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Summary of Anticipated Future Minimum Payments of Long-term Debt</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anticipated future minimum payments on long-term debt for the years ending December 31 are (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum long-term debt payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Unamortized debt issuance costs, and debt discount related to warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,448</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying value of long-term debt&#8212;related party at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,052</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LongTermDebtAndWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and warrant liability abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LongTermDebtAndWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516890200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder&#8217;s Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, Preferred Stock consisted of the following (in thousands, except share data): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Issued and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,000,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,145,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FF Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,760,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,760,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,145,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,995</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,416,155</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513134856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the year ended December&#160;31, 2020 and 2019 was classified in the consolidated statement of operations and comprehensive loss as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">972</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,460</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,432</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,642</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans for the year ended December&#160;31, 2020<font style="color:#000000;">: &#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,222,179</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281,584</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/expired</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,222,117</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455,633</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.34</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,144</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,635</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to the option activity of the Company is as follows for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value of options granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic value of options exercised (in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees for the years ended December&#160;31, 2020 and 2019:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option life (years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.23 - 6.35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.35</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.32% - 0.57%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.71% - 2.36%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.54% - 83.76%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.50% - 76.80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513168680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax (Benefit) Expense</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense consists of the following for the years ended December&#160;31, 2020 and 2019 (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current tax provision:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current federal provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">669</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current state provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred federal provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred state provision</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total tax provision</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(626</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Expected Income Tax (Benefit) Expense</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) expense computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows for the years ended December&#160;31, 2020 and 2019: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit computed at federal statutory tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax&#8212;net of federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rate change</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax attributes true up due to net operating loss carryback</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of (a)&#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and (b)&#160;operating losses and tax credit carryforwards. Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows as of December&#160;31, 2020 and 2019 (in thousands): <font style="font-size:9pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized start-up costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,859</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,821</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,344</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and investment tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,578</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,157</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,271</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,580</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,801</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(744</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(726</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain/loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,866</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511831288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series Seed Preferred Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,298</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred Stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,941,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,029,364</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338,784</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,368,148</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,727,041</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All redeemable, convertible preferred stock, including those that were outstanding as of December 31, 2019, as shown above, were converted to shares of the Company&#8217;s common and effected for a one-for-8.4335 reverse stock split.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding for the years ended December&#160;31, 2020 and 2019 (in thousands, except share and per share data):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrual of preferred stock dividends</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,468</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common stock outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,370,328</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371,905</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509877848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 25, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,335<span></span>
</td>
<td class="nump">$ 34,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,823<span></span>
</td>
<td class="nump">$ 117,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock automatically converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,416,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-8.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_InitialPublicOfferingClosingDate', window );">Initial public offering closing date</a></td>
<td class="text">Oct.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock automatically converted | shares</a></td>
<td class="nump">30,355,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrant Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Number of warrants converted into shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_InitialPublicOfferingClosingDate', window );">Initial public offering closing date</a></td>
<td class="text">Oct.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock | shares</a></td>
<td class="nump">11,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock automatically converted | shares</a></td>
<td class="nump">30,355,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares', window );">Net proceeds including exercise in full of underwriters option to purchase additional shares | $</a></td>
<td class="nump">$ 191,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discount | $</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses | $</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Initial Public Offering | Warrant Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Number of warrants converted into shares | shares</a></td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cccc_UnderwritersMember', window );">Underwriters for IPO Exercised in full Overallotment Option | Common Stock | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock | shares</a></td>
<td class="nump">1,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_InitialPublicOfferingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_InitialPublicOfferingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds including exercise in full of underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NetProceedsIncludingExerciseInFullOfUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cccc_WarrantExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cccc_WarrantExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cccc_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cccc_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513232120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>SEGMENT</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | SEGMENT</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets to be disposed of | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510811464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_OfficeEquipmentFurnitureAndFixturesMember', window );">Office Equipment, Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, plant and equipment, useful life</a></td>
<td class="text">Lesser of useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_OfficeEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_OfficeEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509852680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 370,040<span></span>
</td>
<td class="nump">$ 80,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">180,078<span></span>
</td>
<td class="nump">80,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury securities</a></td>
<td class="nump">189,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">180,078<span></span>
</td>
<td class="nump">80,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">180,078<span></span>
</td>
<td class="nump">$ 80,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">189,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">U.S. Treasury securities</a></td>
<td class="nump">$ 189,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509633928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 25, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfWarrantsExercised', window );">Number of warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value, assets, level 1 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value, assets, level 2 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value, liabilities, level 1 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value, liabilities, level 2 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueAssetsLevel1ToLevel3TransfersAmount', window );">Fair value, assets, level 1 to level 3 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueAssetsLevel3ToLevel1TransfersAmount', window );">Fair value, assets, level 3 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount', window );">Fair value, liabilities, level 1 to level 3 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount', window );">Fair value, liabilities, level 3 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueAssetsLevel2ToLevel3TransfersAmount', window );">Fair value, assets, level 2 to level 3 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueAssetsLevel3ToLevel2TransfersAmount', window );">Fair value, assets, level 3 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount', window );">Fair value, liabilities, level 2 to level 3 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount', window );">Fair value, liabilities, level 3 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Warrant Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Number of warrants converted into shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock | Warrant Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Number of warrants converted into shares | shares</a></td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueAssetsLevel1ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 1 to level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueAssetsLevel1ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueAssetsLevel2ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 2 to level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueAssetsLevel2ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueAssetsLevel3ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 3 to level 1 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueAssetsLevel3ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueAssetsLevel3ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level 3 to level 2 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueAssetsLevel3ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value liabilities level 1 to level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueLiabilitiesLevel1ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value liabilities level 2 to level 3 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueLiabilitiesLevel2ToLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value liabilities level 3 to level 1 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueLiabilitiesLevel3ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value liabilities level 3 to level 2 transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueLiabilitiesLevel3ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cccc_WarrantExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cccc_WarrantExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511963640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assumptions to Determine Fair Value of Warrant (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 26.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 8.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text">9 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.7500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513115880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant (Details) - Redeemable Convertible Preferred Stock Warrant - Level 3<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of warrant</a></td>
<td class="nump">$ 2,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">5,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">$ (8,001)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=cccc_RedeemableConvertiblePreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=cccc_RedeemableConvertiblePreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517065832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - U.S. Treasury Securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 189,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 189,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517055400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other-than-temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ContractualMaturityDatesOfMarketableSecurities', window );">Contractual maturity dates of marketable securities</a></td>
<td class="text">less than one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ContractualMaturityDatesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual maturity dates of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ContractualMaturityDatesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509868680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 8,955<span></span>
</td>
<td class="nump">$ 8,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,632)<span></span>
</td>
<td class="num">(3,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,323<span></span>
</td>
<td class="nump">4,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,207<span></span>
</td>
<td class="nump">6,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511972856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Summary of Depreciation Expense Related to Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,617<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509548200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,229<span></span>
</td>
<td class="nump">$ 14,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Liabilities under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember', window );">Watertown Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Liabilities under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember', window );">Watertown Lease | Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LesseeOperatingLeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">2018-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2017, the Company entered into a lease of office and laboratory space for its headquarters in Watertown, Massachusetts, or the Watertown Lease. The Watertown Lease has a non-cancelable term of ten years with an option to extend for one additional five-year period and is subject to rent escalation throughout the term. Additionally, the Watertown Lease required the Company to provide collateral in the amount of $2.6 million, which is recorded as restricted cash on the accompanying consolidated balance sheets. The Watertown Lease commenced in April 2018, with rent commencing in May 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_RentCommencingDate', window );">Rent commencing date</a></td>
<td class="text">2018-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember', window );">Watertown Lease | Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LeaseCollateralAmount', window );">Lease collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LeaseCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease collateral amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LeaseCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LesseeOperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LesseeOperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_RentCommencingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent commencing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_RentCommencingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cccc_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=cccc_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=cccc_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216511999624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs (Details) - Watertown Lease - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_OtherInformationAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating liabilities</a></td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cccc_WatertownLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509568856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">18,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability at December 31, 2020</a></td>
<td class="nump">$ 12,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216687198840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 3,799<span></span>
</td>
<td class="nump">$ 2,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">3,724<span></span>
</td>
<td class="nump">3,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,524<span></span>
</td>
<td class="nump">$ 6,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509655384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Financial Information Related to Collaboration and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts Receivable</a></td>
<td class="nump">$ 4,484<span></span>
</td>
<td class="nump">$ 4,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationRevenue', window );">Collaboration Revenue</a></td>
<td class="nump">33,195<span></span>
</td>
<td class="nump">21,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">27,603<span></span>
</td>
<td class="nump">20,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Net of Current</a></td>
<td class="nump">53,617<span></span>
</td>
<td class="nump">72,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue, Total</a></td>
<td class="nump">81,220<span></span>
</td>
<td class="nump">93,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts Receivable</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationRevenue', window );">Collaboration Revenue</a></td>
<td class="nump">9,051<span></span>
</td>
<td class="nump">6,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">11,238<span></span>
</td>
<td class="nump">12,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Net of Current</a></td>
<td class="nump">26,991<span></span>
</td>
<td class="nump">32,784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue, Total</a></td>
<td class="nump">38,229<span></span>
</td>
<td class="nump">44,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts Receivable</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationRevenue', window );">Collaboration Revenue</a></td>
<td class="nump">9,913<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">13,965<span></span>
</td>
<td class="nump">6,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Net of Current</a></td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">36,934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue, Total</a></td>
<td class="nump">39,991<span></span>
</td>
<td class="nump">43,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember', window );">Calico License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts Receivable</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">4,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationRevenue', window );">Collaboration Revenue</a></td>
<td class="nump">14,231<span></span>
</td>
<td class="nump">12,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Net of Current</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue, Total</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513028952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Other Financial Information Related to Collaboration and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was included in the contract liability at the beginning of the period</a></td>
<td class="nump">$ 17,570<span></span>
</td>
<td class="nump">$ 11,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performance obligations fully or partially satisfied in previous periods</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_TransactionPriceAllocatedToPerformanceObligation', window );">Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period</a></td>
<td class="nump">$ 91,137<span></span>
</td>
<td class="nump">$ 103,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_TransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_TransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216502938152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2018 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Protein</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Exchange </div>
<div>MaterialRight </div>
<div>Performanceobligation </div>
<div>TargetProtein</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_OriginalRocheAgreementMember', window );">Original Roche Agreement | Roche JRC | Research and Development License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NonrefundableUpfrontPaymentAndAdditionalFees', window );">Nonrefundable upfront payment and additional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPotentialTargets', window );">Number of potential targets | Target</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargetNominated', window );">Number of target nominated as of the execution of the Restated Roche Agreement | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargetNotNominated', window );">Number of target not nominated as of the execution of the Restated Roche Agreement | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AdditionalUpfrontConsideration', window );">Additional upfront consideration received</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AnnualResearchPlanPaymentsReceivables', window );">Annual research plan payments receivables</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CollaborationDescription', window );">Collaboration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has control over the committee and may terminate the Roche Agreement on a target-by-target or product-by-product basis under several scenarios, upon at least 90 days&#8217; prior written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Progressed Through Clinical Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_OptionExerciseFee', window );">Option exercise fees</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Minimum | Progressed Through Clinical Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_OptionExerciseFee', window );">Option exercise fees</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Maximum | Research, Development and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Amount eligible to receive</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Maximum | One-Time Sales-Based Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts', window );">Amount eligible to receive</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Maximum | Progressed Through Clinical Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_OptionExerciseFee', window );">Option exercise fees</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Lead Series Identification Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_UpfrontFees', window );">Upfront fees</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember', window );">Roche Agreement | Good Laboratory Practice (&#8220;GLP&#8221;) Toxicology (&#8220;Tox&#8221;) Study Phase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_UpfrontFees', window );">Upfront fees</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPotentialTargets', window );">Number of potential targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ExpectedResearchPlanFundingPayments', window );">Expected research plan funding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Remaining deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfInitialTargets', window );">Number of initial targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfAdditionalTargets', window );">Number of additional targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfExchanges', window );">Number of exchanges | Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfAdditionalTargetsDeferred', window );">Number of additional targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear', window );">Amount of expected research plan funding payments of per active target per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Option to License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfMaterialRights', window );">Number of material rights | MaterialRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Option to Initiate Research Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfAdditionalTargets', window );">Number of additional targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfMaterialRights', window );">Number of material rights | MaterialRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Research Services Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Commercial License for Six Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Research Services for Uninitiated Three Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget', window );">Amount of expected research plan funding payments of per target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Target Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_MilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Targets 1-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Targets 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfMaterialRights', window );">Number of material rights | MaterialRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember', window );">Roche Agreement Accounting | Targets 4-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfAdditionalTargets', window );">Number of additional targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_MilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AgreementDate', window );">Agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ResearchAndDevelopmentAgreementPeriod', window );">Research agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">54 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">54 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AdditionalPaymentOnExtensionOfContract', window );">Additional payment on extension of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NonRefundableUpfrontPayment', window );">Nonrefundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NoticePeriodForTerminationOfAgreement', window );">Written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NoticePeriodForTerminationOfAgreement', window );">Written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargetedProteinDegradation', window );">Number of targeted protein degradation | Protein</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AdditionalTargetsForDevelopment', window );">Additional targets for development | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement | Maximum | One-Time Sales-Based Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember', window );">Biogen License Agreement | Maximum | Research And Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember', window );">Calico License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPerformanceObligation', window );">Number of performance obligation | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ResearchTerm', window );">Research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AnnualPayments', window );">Annual Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CashConsiderationReceivedForMilestoneRevenue', window );">Cash consideration received for milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees', window );">Additional consideration received in cash for target initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_AccountsReceivableForAdditionalTargetInitiationFees', window );">Accounts receivable for additional target initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_ContractualTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember', window );">Calico License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfTargetProteins', window );">Number of target proteins | TargetProtein</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember', window );">Calico License Agreement | Maximum | One-Time Sales-Based Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember', window );">Calico License Agreement | Maximum | Potential Research, Development and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AccountsReceivableForAdditionalTargetInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable for additional target initiation fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AccountsReceivableForAdditionalTargetInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional consideration received in cash for target initiation fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AdditionalConsiderationReceivedInCashForTargetInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AdditionalPaymentOnExtensionOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment on extension of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AdditionalPaymentOnExtensionOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AdditionalTargetsForDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional targets for development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AdditionalTargetsForDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AdditionalUpfrontConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional upfront consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AdditionalUpfrontConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected research plan funding payments of per active target per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerActiveTargetPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected research plan funding payments of per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AmountOfExpectedResearchPlanFundingPaymentsOfPerTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AnnualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AnnualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_AnnualResearchPlanPaymentsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual research plan payments receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_AnnualResearchPlanPaymentsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CashConsiderationReceivedForMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration received for milestone revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CashConsiderationReceivedForMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CollaborationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CollaborationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ExpectedResearchPlanFundingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected research plan funding payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ExpectedResearchPlanFundingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NonrefundableUpfrontPaymentAndAdditionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront payment and additional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NonrefundableUpfrontPaymentAndAdditionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfAdditionalTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfAdditionalTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfAdditionalTargetsDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional targets deferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfAdditionalTargetsDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfExchanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exchanges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfExchanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfInitialTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of initial targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfInitialTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfMaterialRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of material rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfMaterialRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfPotentialTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfPotentialTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfTargetNominated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of target nominated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfTargetNominated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfTargetNotNominated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of target not nominated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfTargetNotNominated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfTargetProteins">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of target proteins.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfTargetProteins</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfTargetedProteinDegradation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targeted protein degradation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfTargetedProteinDegradation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ResearchAndDevelopmentAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development agreement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ResearchAndDevelopmentAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_ResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_ResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_UpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_UpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsReceivableClaimsAndUncertainAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of billed or unbilled claims or other similar items subject to uncertainty concerning their determination or ultimate realization under long-term contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119991564&amp;loc=SL119991585-234733<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsReceivableClaimsAndUncertainAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_OriginalRocheAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_OriginalRocheAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cccc_JointResearchCommitteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cccc_JointResearchCommitteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_ResearchAndDevelopmentLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_ResearchAndDevelopmentLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ProgressedUpToPhase1OrThroughGLPToxStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchDevelopmentAndCommercialMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OneTimeSalesBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OneTimeSalesBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_LeadSeriesIdentificationAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_LeadSeriesIdentificationAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_GoodLaboratoryPracticeGlpToxicologyToxStudyPhaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_RocheAgreementAccountingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OptionToLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OptionToLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OptionToInitiateResearchPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_OptionToInitiateResearchPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchServicesPerformanceObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchServicesPerformanceObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_CommercialLicenseForSixTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_CommercialLicenseForSixTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchServicesForUninitiatedThreeTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchServicesForUninitiatedThreeTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_TargetTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_TargetTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_TargetsOneToThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_TargetsOneToThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_TargetsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_TargetsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cccc_TargetsFourToSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cccc_TargetsFourToSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_BiogenLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchAndDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_ResearchAndDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cccc_CalicoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cccc_PotentialResearchDevelopmentAndCommercialMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216506038200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt and Warrant Liability - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th">
<div>Jun. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 8.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-8.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.118574732<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 8.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Other Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cccc_TrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cccc_TermLoanMember', window );">Term Loan | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cccc_TermLoanMember', window );">Term Loan | Maximum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember', window );">Credit Agreement with Perceptive Life Sciences Master Fund LTD | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">greater of LIBOR or 1.75%, plus 9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Applicable margin rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_DateUntilWhichInterestOnlyPaymentsAreMade', window );">Date until which interest only payments are made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  05,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity', window );">Percentage of principal payments until maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Issuance cost in connection with entry into Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember', window );">Credit Agreement with Perceptive Life Sciences Master Fund LTD | Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember', window );">Credit Agreement with Perceptive Life Sciences Master Fund LTD | Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding', window );">Balance to be maintained in bank account while debt is outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember', window );">Credit Agreement with Perceptive Life Sciences Master Fund LTD | Term Loan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember', window );">Credit Agreement with Perceptive Life Sciences Master Fund LTD | Term Loan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_LongTermDebtAndWarrantLiabilityLineItems', window );"><strong>Long Term Debt And Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash balance to be maintained in bank account while debt is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_CashBalanceToBeMaintainedInBankAccountWhileDebtIsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_DateUntilWhichInterestOnlyPaymentsAreMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date until which interest only payments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_DateUntilWhichInterestOnlyPaymentsAreMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument. percentage of principal payment until maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_DebtInstrumentPercentageOfPrincipalPaymentUntilMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_LongTermDebtAndWarrantLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term debt and warrant liability line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_LongTermDebtAndWarrantLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cccc_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cccc_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cccc_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cccc_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cccc_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cccc_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cccc_CreditAgreementWithPerceptiveLifeSciencesMasterFundLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cccc_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cccc_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216517001016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt and Warrant Liability - Summary of Anticipated Future Minimum Payments of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long Term Debt By Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum long-term debt payments</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt issuance costs, and debt discount related to warrant</a></td>
<td class="num">(2,448)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of long-term debt&#8212;related party at December 31, 2020</a></td>
<td class="nump">$ 10,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216506267080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-8.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.118574732<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote for each share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,145,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,416,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_InitialPublicOfferingClosingDate', window );">Initial public offering closing date</a></td>
<td class="text">Oct.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock converted</a></td>
<td class="nump">30,355,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NumberOfPreferredStockConvertedInToOneCommonStock', window );">Number of preferred stock converted in to one common stock</a></td>
<td class="nump">8.4335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,145,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding shares of preferred stock converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,941,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 145,500<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,714<span></span>
</td>
<td class="nump">138,571,428<span></span>
</td>
<td class="nump">142,857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_InitialPublicOfferingClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_InitialPublicOfferingClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NumberOfPreferredStockConvertedInToOneCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock converted in to one common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NumberOfPreferredStockConvertedInToOneCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216506242904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Schedule of Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">146,760,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">113,145,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">113,145,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="nump">$ 110,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="nump">$ 110,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">13,416,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">474,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">110,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">109,145,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">109,145,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="nump">$ 109,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="nump">$ 109,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">12,941,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_FFPreferredStockMember', window );">FF Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">32,760,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_FFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_FFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510422728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Mar. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 28, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Stock-based compensation, common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">21,343,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Stock-based compensation, common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,059,632<span></span>
</td>
<td class="nump">1,426,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions', window );">Payments for relinquishment of right to purchase common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember', window );">2015 Incentive Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock-based compensation, common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,880,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,525,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Stock-based compensation, options vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options generally vest over a period of five or eight years with a cliff vesting at one year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of options from the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember', window );">2015 Incentive Stock Option and Grant Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember', window );">2015 Incentive Stock Option and Grant Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember', window );">2020 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock-based compensation, common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,880,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,567,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based compensation, common stock shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,851,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember', window );">2020 Stock Option and Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Stock-based compensation, common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock-based compensation, common stock shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_PercentageOfOutstandingSharesOfCommonStock', window );">Percentage of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Stock-based compensation, common stock shares outstanding</a></td>
<td class="nump">656,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees', window );">Maximum authorized payroll deduction percentage of eligible compensation for eligible employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Stock-based compensation, common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum authorized payroll deduction percentage of eligible compensation for eligible employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_MaximumAuthorizedPayrollDeductionPercentageOfEligibleCompensationForEligibleEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for relinquishment of right to purchase common stock upon exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_PaymentsForRelinquishmentOfRightToPurchaseCommonStockUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_PercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_PercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandFifteenIncentiveStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513267960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,432<span></span>
</td>
<td class="nump">$ 1,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 1,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216506023576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity (Details) - 2020 Stock Option and Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding as of December 31, 2019</a></td>
<td class="nump">2,310,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">4,222,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="num">(281,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited/expired</a></td>
<td class="num">(1,222,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding as of December 31, 2020</a></td>
<td class="nump">5,029,364<span></span>
</td>
<td class="nump">2,310,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable as of December 31, 2020</a></td>
<td class="nump">455,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, Vested and expected to vest as of December 31, 2020</a></td>
<td class="nump">5,029,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Outstanding as of December 31, 2019</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Granted</a></td>
<td class="nump">14.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Exercised</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, Forfeited/expired</a></td>
<td class="nump">4.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Outstanding as of December 31, 2020</a></td>
<td class="nump">12.72<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, Exercisable as of December 31, 2020</a></td>
<td class="nump">4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Vested and expected to vest as of December 31, 2020</a></td>
<td class="nump">$ 12.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Options outstanding</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">8 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable</a></td>
<td class="text">7 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Vested and expected to vest</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2019</a></td>
<td class="nump">$ 4,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2020</a></td>
<td class="nump">102,635<span></span>
</td>
<td class="nump">$ 4,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable as of December 31, 2020</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2020</a></td>
<td class="nump">$ 102,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216516946184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Other Information Related to the Option Activity (Details) - 2020 Stock Option and Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised (in thousands)</a></td>
<td class="nump">$ 2,587<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510531864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted (Details) - 2020 Stock Option and Incentive Plan<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.32%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">69.54%<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">83.76%<span></span>
</td>
<td class="nump">76.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cccc_TwoThousandAndTwentyStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509536440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Tax (Benefit) Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current federal provision</a></td>
<td class="num">$ (673)<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state provision</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="num">(626)<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="num">$ (626)<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510554888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Expense (Benefit) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax&#8212;net of federal</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit', window );">State credits</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit', window );">Federal credits</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34.10%)<span></span>
</td>
<td class="num">(32.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Rate change</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits', window );">Net operating loss carryback benefits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax attributes true up due to net operating loss carryback</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other permanent differences</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation federal tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_EffectiveIncomeTaxRateReconciliationFederalTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating loss carryback benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation state tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_EffectiveIncomeTaxRateReconciliationStateTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513739848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">$ 1,075<span></span>
</td>
<td class="nump">$ 1,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">3,859<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">19,399<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D and investment tax credits</a></td>
<td class="nump">5,578<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">23,157<span></span>
</td>
<td class="nump">25,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">54,580<span></span>
</td>
<td class="nump">31,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(3,967)<span></span>
</td>
<td class="num">(4,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain/loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (49,866)<span></span>
</td>
<td class="num">$ (27,058)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start-up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216510377832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 49,866,000<span></span>
</td>
<td class="nump">$ 27,058,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net valuation allowance increases</a></td>
<td class="nump">22,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 58,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">The Tax Cuts and Jobs Act, or TCJA, which was enacted in December 2017, will generally allow federal losses generated after 2017 to be carried over indefinitely, but will generally limit the NOL deduction to the lesser of the NOL carryover or 80% of a corporation&#8217;s taxable income (subject to Section 382 of the Internal Revenue Code of 1986, as amended, or IRC).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards do not expire</a></td>
<td class="nump">$ 58,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority', window );">Refund due to anticipated carryback portion of net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate', window );">Percentage of taxable income limitation under TCJA</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 105,100,000<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(626,000)<span></span>
</td>
<td class="nump">804,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=cccc_CoronavirusAidReliefAndEconomicSecurityActMember', window );">Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription', window );">Net operating loss and tax credit carryforwards description</a></td>
<td class="text">Under the provisions of the IRC, the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges', window );">Net operating loss carryforwards limited and expire due to ownership changes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cccc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and tax credit carryforwards description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NetOperatingLossAndTaxCreditCarryforwardsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards limited and expire due to ownership changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cccc_NetOperatingLossCarryforwardsLimitedAndExpireDueToOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase (decrease) in effective tax rate for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=cccc_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=cccc_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216509603720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">5,368,148<span></span>
</td>
<td class="nump">15,727,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,941,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">5,029,364<span></span>
</td>
<td class="nump">2,310,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_WarrantToPurchaseCommonStockMember', window );">Warrant to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">338,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cccc_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_WarrantToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cccc_WarrantToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216513090824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-8.4335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.118574732<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
<td class="nump">0.118574732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216592541288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,335)<span></span>
</td>
<td class="num">$ (34,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Accrual of preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,468)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (66,335)<span></span>
</td>
<td class="num">$ (42,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common stock outstanding&#8212;basic and diluted</a></td>
<td class="nump">11,370,328<span></span>
</td>
<td class="nump">1,371,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (5.83)<span></span>
</td>
<td class="num">$ (31.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140216600194088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - 401(k) Plan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Pre-tax compensation of employees</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employer discretion contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan, contributions by employer</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC&KSYFQSH^6R?G%S*[6617VYX"SCE3& [^^DU$\WYEW0]OWEZ?]02P,$%
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M5AO \RWGZNV''F#\GN?ZOU!+ P04    " !U@FM2@B)P>&<"  "*!0  &
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M.NB*=&[Z(QG@>$>*!^[CN:'2:P@E7LA5.C61F!0)S%#PJC]90_]&'7B:QNO
MPPL=<Z+G@&MGTCZ=HW@^&4SHB4T'XT@F*DE%N$ZL1RGFVN2IIT2Q63H ]N6L
M]FV#K[$>[QEA1NU$4'EI;&4W?"#4!F<VF8J[4#4-ADQ;1CRBYW93?I94TT"'
MX+?4EES WM:92LN51@+W63S(Y;U3(X8+4#8.,9T-!..XG%,A]; _=6-S&Q=
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M"_!^;0&.=$,*NO^N7/T74$L#!!0    ( '6":U+&C6#,."(  #AM   9
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M-_^@0.<+S2>R($E4)<"?E^SI+L"%HH"#^-U0U#!2,-*&+!%;V(#/0:(VC%S
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M09L9Y8"9.F L0[E)LL0@#=58TM96EH$O>4*+R0L,[K1A(L[OI6[(1>Y-FW8
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MT]$UYQK&83]0JQWOR L$PZL4.E7L+G2#6^[<;N'/U;?+#I; OREY]U;!$@^
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M;+U967/;.!)^YZ] >9.MI(JF15*4Y&SB*MLY)ELU8Y>=S#QL[0-$@A(V),$
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MUJJ2+M>"@W%Q ;S/E;+=#3+HOYN?_0]02P,$%     @ =8)K4EA1(0CU"P
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M-10'MMS/+A^RA='0T4*2M\N*BA05E=#0U <JM"*38ZJL1[,NTJJH\M DAU,
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M=@NQY0 (/S.4W& P)F&K\N :@]4:6NF<HS*A=&I6<TQ,;<9*H:^VVJGOV9'
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M]G)S<L( [8Z"$D>85OU4"!N^YIK-(Z<.9*D$)R=G0[:*:C22;3)M4F5KF.S
M7JD%D5H5;0R-^>)M@00X@"Z*%>DC4>$VQSAGT7I:&(;.)0[A8C>VI<6^(1AQ
M_ML37XT1\'<TNS+6R%Z%TFY/E IT,B414DU/D O<27+"#B9P%-PG>AB>GPI>
M43IX0RC4H$8&2"0B4C+: 4]203+2FH\^PI9\WA>(*6? JHY,%2QD'3G7) R8
M$@Y3-I*GE (OP3 &+"]/1M":#HA&%"<2'P#$GN8ELC7:8W(SI9#ZHW&4><8(
MSI92E2_(Z9W[$7"8]V7(;CU@=,ZKDW1"<A/)5,E;^)NFXX.5^90M1S :8T&7
M2CW6#OWDP9/SS.7EGPOUB\-D/R,K>\^(\*)QAD$\#+0OS9&?>HP;NB#@BL8N
MT0CN&EINB?<!17T=8]/Y6B_R+:8.3TIJ)*,W3@14:S.+BMC::5LE)]P0,]Y_
M'LD1H]127L72#HG/AB"H7Q:!X2</H;:7EX^% Z".2@_YKH0D)W2YCBL2.R/,
MUNV%W9)Z@K$ ;R]2Z89"R'JRD]=])!.:T4W$L&D-JN AU VG41^^WSYP*[SN
MU5#]IS<HOPXR%T#K.;ZI3O;".-B!YPLM30K:%;]/YN<R<#H?+9/BNDJTWX$=
M^SL(X&CB^_\-I#XH,[)VT%(36*G('#7*9['R/HB5]P[MM/=K*2+B[T82"QC3
M+C%SA_6T>PV64_[9EQ%YWYSUO(\\LUP2BX*X<=1\.!+@D8*;W<?IM."894LV
M:2*,XEU[\:!?P,Y(G EJY7%OZ*K_Z+] 22=72RAL6:%,K<S:1GB0N<G:9!\X
M-I1RQ= X@@C?]Z WQ5(HK]22?PV8,L^J.Q.\& #IV(_AU8M\'QQ^E4>"@-<R
M(57PL/;#]6_ ^!/W*4UWO@XN.!<"^CB:!'UJS"E(9@K(UWD9(5=8)9-'Y5J,
M4?$UQA 06[?^V-CQC\XIG((69OG2$:WE1;ZERP"T81"+>V^CA6A^.(YXW22R
MI0L1$V%"R;#=VE)QHU<\^EPR4\."0#0^C/6W.;C&7:Y1#0-%J-?).':BM6[H
M7@H/<L6W$MG1)//L'=4]%)PWC-39;DG2@)SS*=K43'AJY$@1.)FEE%4,FD\F
M'N&-00/I(0-Q^Q[9G(?":X%HN&,8:5_;BIT6RS68,[SCX9^;'3F+FM%:BP\C
M2 -5[?2.'A&2W!%B,<9EX:)*AB/AN(YX162JZY1D5/6O$GE *X,%9WF#%SPI
MUW(\4826.,<XH-'G/G:3_2%YC_<<J YB^E@IH(5#$8,T3*!$@PHOY4HD@X)2
M/9,1!$8]?XV >P^5;+G2FR9'ZVIJYBCP/::7)*P,7.],<,ABU<02]> M.KEM
M1D:<1$64WJ?.]PA4I!>]L**2M&[BK--#,$73K*D41:A:\PASU?^#2$K/L3%[
M;E7 A?@13'P2Z7><T(H-GSR4U(ZPXGUX[ET'$FWNQOWW/NH2/S9U-@9\#0TD
MIA2=S!%9+*'66S0;!Z19L85DD^*9TGA*$[SMO3C^>C$KME;Z*/=$/&Q<4EWZ
M3!'*UWV=G)/0(]U3EF*DN?!Q^(G-6*U5TBVU>;,Q=+0: M L49*=Q.82I?$W
MBSR(=,DCJ)(@8<K8*.MM="P^\C&^._9+%$>\5JK_%+2LF[C$-NI384!8HZVC
M-]4\CR4BY+B^"UD0_Z'!L<W+==^"FF=7$L/DNH H[.JB4@VOD1]\%<^L8>G(
M0PS$0M&6@;">'+AP.Q-[CE>_G9/[34M3Y)V0;=1>@*E>BVK)*T9S4R# (TMV
MQ187Q5 .20E T 1J5HBYBC=,*1,?G=FM<C)(K:W=AQLB.LN,*N!,OI*A.GD\
M*M12%O5IC#TJ -6"\+Z/#9\P@"SFQ_V7&7_S\6I_UA?,H5B_L%?+F31ZK%*Y
MO$Y+%NZ+F;>#ZB4VB:*X42\![)-H ,;24+X%[]'="DF$NL\V9,\D:7QO_"B4
M .UJ+".T-]0L@"=AJXGDT' Z+RXM#((#S# 'I,;EHBBS:KR.Z^NFU(L(:/(E
ME??"&Q]7(% E2%PK\N IBE/W[_)I4PPQDZ.*W3BG@;8C@"4$UC-,)@Y$VSF@
M4^(G42(=*($)M##D#+K"2EIAEA6@ S';-(O@G,6)EY"5Q9L&>F\ 0\Y+OIA$
MMX'(.B%@63)0?2],%P4N$?N[_(8)P\85-P0[U\7X2";BP3L+MKJMRUL^P#AY
MDWHV_PH9S94[3;7R?!FU&ND;W?T(16K;Q>8 U7@29GQQ45G&;.GOO]1Q5F/"
MJ(_[!"@54H4*S#M VGA/C4\_*L!*Y!M?;>4J0Y2Q8(D4V]-NKP%8-HT88]*G
M(6UXD#<57<6P/O!JV2T*2[(3J:%D-* ZYS1\D.8[4B6M*P%#Z:6HES/ ?#]M
MK)&N"Z_4)V\^A&NRY].76\=LC\'T^^14PX47H[;-Q_$+]ZZ=*CBX9Z":.< %
M>2.9 9CLE(U=K%<R%)(0O#+OF]V^K _&^!"*EA'/,C@';]:Y#KM_);4<_@JU
MKZSHV8 /MFYB_1RR@<%TUNMSI[I *'6FKAR8N_% 8.X<? ^,G&A0Q52;?./]
M6,KC/P 6<)3Y/((*XAH1C9<@AYIB6]5EO3F,'MO@A<O[S(PH]Q6"Y[XQ!.TQ
M7&"72%]T'Y;+>GO)1VWT07$'=.+BE.MD'XI4)MKHQB3F@U1@M511_M"N$*Y_
M'^LF[0GA$Z:]VG;GA?A 8'T(:X.--;S_MZ:2%L)@4F%X4]5WXLOB?^QN($")
M5\NYJ!5M4ZU,%*'JK0UL$C+&$4J@XD?Z$CI_.\-;]KZGDMRMT#8M?)2'.,4>
MD1"#4F I*RL*]4I)26A#$FU1:'N,)3>M)0.A17SO*SX5[MU X%%@OF>S)D8F
MA=U4>=R:T+I"=D?[7_9]EP03['^(G4I@"BMI/M**Y<ED0SF.T!&E[6<-(]2J
M?==;Z99D:/#5=$?I/N-X'*$%EM4TM2\X.<9NN&2$E8I52'; A+<$H:<?5)S'
MP2"?E.*,GMX XA)3'-(Q!3Q SFG;$>.E59'O;2OWSFWU-<2!+!V/C@DN%HX^
M=..K4Q@(+!"6*Q3CCNUDY=TB=&E83'=7N,;> *=O2!)<1LIQ2/]_XU2IB.-P
MK4O#*8Y[% PI:67D)%BU:=#J)6DW4&A[A]=*U:[3^].D+6A&&BS'E(YFLWA+
M"8GHV>PN3^)FP?T+Z5'X;18^@CT/T*.VGI%?<4HAR^0:XPRL1!1FB ;ZJ,Q^
MO"%T5^J*4=0/"<?&#6U\GEUI8AM_?W_UQVQ@VK$ICZ9SR=TY;+^CF@XT N$K
M.HLT4.0%_!([C>*J?/439'VJ]N+@[#:^.+/'PA(ZCA1Z2RV0HAWDK>\(QF6)
MZFA)?UG0>-A@LS+X!%,>.+EX-YD\ G\-<_#>!Q&<]GJ5-M*A?RNWD:WH_B[>
M/B< \5((QU*ON*&>=&!%PH/S0;$#<UU8<(+^[J^ 4@==ZG18'D[_ ^ON%4%O
MN5E'U%GT/7>+S-TXIWT-<Y&+E%YGXO"8O\U$QHZSK1='D1L4F(XC9?Q 0D51
M #IT[J5$(IYVU#?N^CY0T8L.50/_NH6H4[A\AY9,57&GIU"10QM ;-H]QA5\
M!Q7030VX:9&_$L%5/W 2CTQ5=.D\4S[>(C0?64RW#OF3(G"M+W,_\+T_9P:%
M_#?.A291OY!\.$8-OI;QJ76U3($$. SB!5O.H2+B?[)WKPW9(F\P5@D^L):&
MW2*OX=_[1M4WT;MOY.K'O=.ET,'*?NTJ#NK_V@$M^IL-'"5IFP,7<./'3U@A
M]Z$&)@^=2WZ8\<4?JIY;F24G2^X$.Z%B_S/FS=(])V)91\A&B*0I2:(_8.]6
M[;,3<#&"62\19VF-&VSWJZ"^H+0)<B]6\Z7&7H>*[9\BJ]^4.;#K=;&MJ229
ME.8I1F:HRQ+>8_><7VF78W)@HIZ"<31VAOME.1]A9QZU]>RW%,3[+46K5#-\
M1SOI\AP]$O2+H#32A"-$YHGIRE,;B:R,N^$&E83M*;CQY#Y*F>I"LK%9E$.*
MRN>X)O/HT3%#PIL=WJ+@[@C:K;-GD@17V!9?L?,>>_4W/"FJ0@N?Q73+G??<
M?>E3_F7X[L_T\)'K>M&<X_<^I>]32T\%"X\OKL5-5@\2X0_WV*6' JO)I(+:
M.Q0P[5C#5BWH]2<E_@L.0;U&(5H^*+D4&%HHTUV@^!;;0UW_>CB!B&N":=0U
ME0MMK^EJ'._X(?OII=O3@FMI^8S>S-*T=\8\%& 2S;#H4E\V,+*Z=/7 GMD"
M)DL<])$YMJOXQDMNJ9*.H5-?38L?.;)NYMEEN([Y4&SX2+3O!%O?<@/'/N&-
M= GES,L-.(9;<!,EB=:Z00 TBB"7/(U<G ]$)06TVHAMYON,<UN2J(GNK%_
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MFY8HF3W7%2JRY-I(YFAKBMA6!ED6@J2(DW[_?2P95]%L$L[69C;1M1-<X=J
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M]*8MH7P-$*"Z46+\+/$R/HIX#<4932*?QF$<'L%+QI 3AY?\5\@KP3#4Y:O
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MHSQ9C:<<<7:QS#+=0$[N=_C,!@QA,B??; F:W#9:@[3D*V<I%]QR/+U\9JD
M<S6++(H[BBC;"ZU:(7I"**'D04E;&G(O<\C_)XC0=6>='JROZ%G&.\BN23_I
M$1K3^ Q?OTM%W_/U3_"MV9N_'%EB"GQ>F##DUS(U5N//\_N,Q*"3&'B)P0F)
MI_;7)ZH@'TO\>_D^+W7@AV-^Y?FS/;\X>MA,89T9BP#TAE&D4 (+ELL-8<;M
M8;:A2A%]R+@GI'$R)9=<(D0U!G?,U4W@3@-W$AQ,:## =%9Z3 ZOV MJK&P;
M7 3]WG@ZQ9'V1LFP V2J<K996[D(2D%"P:UQ\72 WW@PZ:)KK0HPKD\P00H
M$R2]89\&8SH)?$J#P6@:T$D</"N+(>Q#N4%ST]X012^"46\T3M[[#Z*C"JQ
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M?OVF%\#Z)V$V(D*F<5C&Q(@2X25T565AGF87.EBQ[V#%JSO8KUAD\__UL<M
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M)C98[T#G2V-P9WB"]C]@^A=02P,$%     @ =8)K4K8F$-#; @  208  !D
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M^N>]CD-D-;@J18O"#HNET#AZK)C@K =I#/!\)83>*B9 \^\Q_@]02P,$%
M  @ =8)K4CUP/ZDQ!0  CPP  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&ULI5=+<]LV$+[S5V#4I!//T!0)/B2YMF=DY]$<4GMLQSUT>H#)E80Q22@
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MSCME\0+K7A?XCP$T">#WF5)VNR '_7^0TW\!4$L#!!0    ( '6":U('97Y
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M:W-H965T<R]S:&5E=#,U+GAM;*56VV[C-A!]UU<0;E$D &/=;3GK&' V6[1
M-PW6;?-0](&6QA81B=225)S\?8>4K'B-V-BB+S8O,V?.G!F2FN^D>M(E@"$O
M=27TS:@TIKGV?9V74#,]E@T(W-E(53.#4[7U=:. %<ZIKOPH""9^S;@8+>9N
M[4$MYK(U%1?PH(ANZYJIUUNHY.YF%([V"U_XMC1VP5_,&[:%%9@_FP>%,W]
M*7@-0G,IB(+-S6@97M^FUMX9_,5AIP_&Q&:REO+)3GXM;D:!)005Y,8B,/Q[
MAH]0518(:7SM,4=#2.MX.-ZC_^QRQUS63,-'63WRPI0WHVQ$"MBPMC)?Y.X7
MZ/-Q!'-9:?=+=KUM,")YJXVL>V=D4'/1_;.77H?O<8AZA\CQ[@(YEG?,L,5<
MR1U1UAK1[,"EZKR1'!>V*"NC<)>CGUG\)K4F#Z#(JF0*R,4?;%V!OIS[!L&M
MB9_W0+<=4'0"*(S(9RE,J<DG44#Q+8"/K 9JT9[:;706\0[R,8E#2J(@"L[@
MQ4.JL<.+3^!]8DIPL3U,]^_E6AN%G?'/&?QDP$\<?G("?X4'IF@K(')#/LJZ
M:0USC8?3.UZU!@IRCZ?L2/&E,8JOT19U)T9:SQJ=5D;F3Z6L"E#ZO6*<IV(5
M\Z(@G'DK4!PT60%&?\"&!Z5PY-"]GW[(HC#ZX"73A$:S;&^[/&D81G26A#1+
MI][OC<U-6\9-J_(2#P;).^K:^:0TB&8TGB1>1.,PH%DV\1Z94DR8TTYQG-%I
ME@P!4P3(:)AD7IC2:32E01*>J50Z5"K][DK=,LUSPD0Q%.G; KTG_GGT957A
M=54 WIY84XH9BF=0AML"-X.R+F%*N,BKML"V)*:4*(<IF2$[P,; &U0;Y&7W
MF'9=!#G4:R36'8IP1NV&+N4.;[>U?,98SK,/B$%0:&V3<.ZF!->73+PZ?:<?
M]%Y]FSYL-GA3HA/>](01*> *1U?9.(GC%!-"2.3G:!/=5-R,#[0K>NTJJUV#
M%%U8PEV$QFVM7]'JF;M\!)X#9\J.NO^P&_KNMXZ6^LY=L%!<,62"[\5@VR=X
M()?-P+J\ D-_L/?1L7A1X'A;%<D%%U;]5N.*I@1><FA,GX$U>LNGP"OV\MI[
M.U[W;8UDC%37WGV?D_>C=S&94!3-N[3C.*'!;(;C99ZKEE6V%$=MT F#//70
M^1<93289>MW_!ZEZY_5Q68XI)1%-)U,<WX&0^*AT"3R>$MA1/-#W9)@PI/$T
MH'&$YQ5'(9T%Z5L";S+^SU32<1;WVH;C (?O70G^P9N(-=JZE]^V8RM,]SP.
MJ\/'Q;)[4]_,NR^3STQM.=YU%6S0-1A/\?RK[K7O)D8V[H5=2X/OM1N6^($$
MRAK@_D9*LY_8 ,,GU^)?4$L#!!0    ( '6":U)F\\Q0T 4  "\9   9
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M+*R1R,L#E/;ZAMDSEH81AY9>LUK2;O0QZ4H*:AE,W0S^GHW8K/;URIT8;9T
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MRM%M6JQ(Z^R;&6C*N'H[\K49WZ+X43G6=3$6.3+67:0[*.A?(!*00*VI!'4
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M(CM8_+*TDQRU"[#O"Z5HMW$$W7]#^A-02P,$%     @ =8)K4BS3::=  @
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MEH:ND.L6]&:AL@6TGDMIW@;V'G6O8/P/4$L#!!0    ( '6":U)C&5TD<0(
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M=S^&FTJ84AV[5,?.\SE_4V<4$57QS8?Z?STJ-'J0$(O?+6LYY5I.OI9[R$[
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MJJMR/ERHKQG@&J#>SQB3FXF^+Y??1X,_4$L#!!0    ( '6":U*[%A9,4P(
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M@CXHT$66$;6_H5SNKGI![_#@D6U38Q]XBWE.MO2)FL_Y@\([K[:2L(P*S:0
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M&CR!N$O;>*BR OA^(Z4YW%B ^IRZ^!=02P,$%     @ =8)K4L'E-B/T @
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M*]T1[6.F/UI0F #]?LZYV@S, O5GT/ ?4$L#!!0    ( '6":U++5PR8T@(
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M]%J.<^@A&@H4?X-IG:$(%)&#/XO(\D$[LSP($%T%BL@!3N23)%_PK%L @(V
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M-??P"=*+YB'&&QI4K^L;*>S3HH<!.2'"B<5KU-'I=L=)[BZ+VP;.A5_0GDK
M07$U"(\4 <HTIUY[6PO6R3"9R;CGB3RJEPK2$5C+];.PO^')@/=A,ADTOH_4
M" ZY#Z,8GNJ5@'1:&XE4JP:D;#^0-U&\ OIP '_>=&["=:T.D(X4 HXKYB6Q
MLE8&2-G$8F6M2)"R5XB569?E'@YSK1B0CE0#&JGILBW9>/VB5ZK5"U(VL4A:
M*R2D[!4B:=;#9KO?[<VTGVD2/_3U#>:QF-$K?@MMK?=B$[;8_G36]D.5K^M?
M;KK)JRI/Z\LEC\#UB1O@[[<Y:%%^$#\&U?Z"V?'_ 5!+ P04    " !U@FM2
MS:*-=;$&   =(   &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6R]FE]/
MXS@0P)_W/H55[4J[TM(F3M*6%2 !!1TG$ C8W8?3/;BIVUHD=LYQ*4CWX6^<
MI'$6TBG+LD6B-&WFC\?CWXP=]I9*W^5SS@UY2!.9[W?FQF1?>KT\GO.4Y5V5
M<0G?3)5.F8%+/>OEF>9L4@BE28]Z7K^7,B$[!WO%9U?Z8$\M3"(DO](D7Z0I
MTX]'/%'+_8[?67UP+69S8S_H'>QE;,9ON/F:76FXZM5:)B+E,A=*$LVG^YU#
M_\MI5 @4=WP3?)DWWA,[E+%2=_;B;++?\:Q'/.&QL2H8_+GGQSQ)K";PX]]*
M::>V:06;[U?:3XO!PV#&+.?'*ODN)F:^WQEVR(1/V2(QUVKY)Z\&%%E]L4KR
MXI4LJWN]#HD7N5%I)0P>I$*6?]E#%8B&0#!8(T K ?I$P _7" 250/!$@/IK
M!,)*('SJTG"-0%0)1"^UT*\$^D7LRV 5D1XQPP[VM%H2;>\&;?9-,5V%- 18
M2)M9-T;#MP+DS,&YDK,=PW5*1GQL"),3\IUIS:0AYX*-12+,(]DAAY.)L)G
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M$RR7L64Y+!SXA18'EM:8R3O"XKC<_<P%%"A[=@9-$%'N3*]U_L+G&\KU<^<
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M^,\IX 'VAU$7A6%-8=B+PN="2:7W \M7;3R&?7D$-8_ RF-&A7C02=$WFA:
M?J.3MO1;C& OO1=%P_;<89T[M.;^R+1P8EKZC#5]V"O]J$X_LI?.LTQG;K8
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M\'(SM7)(CT6XC^!HS2JTY_Q1K*W)5? K2WR@DHUIY?)7KY'2QCXOK6V^O#O
M=K1F"7H$2W05G*=1!*TI@KX2BJ U1=#_CB)HDR**-[)[ 1MN?>\Q7QB_,+D(
MX4@3\3D K9,QS""+CW;%0(LT_P1T+[06<7X9< ;I9 3@^5P(O1F8KTK5I].S
M?P!02P,$%     @ =8)K4K2*7/7G @  [0@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&ULS59=3]LP%/TK5L0#2(-\MJ4HK=0/MB$-K6IA>YCV8)+;
MQL*Q,]MI8;]^MI.&4-IJ+TB\-+9SS_&Y][B^B3=</,H,0*&GG#(Y<#*EBBO7
ME4D&.987O "FWRRYR+'24[%R92$ IQ:44S?PO*Z;8\*<86S79F(8\U)1PF F
MD"SS'(OG,5"^&3B^LUV8DU6FS(([C N\@@6H^V(F],QM6%*2 Y.$,R1@.7!&
M_M7$]PS 1OP@L)&M,3*I/'#^:"8WZ<#QC"*@D"A#@?5C#1.@U#!I'7]J4J?9
MTP#;XRW[9YN\3N8!2YAP^I.D*ALXEPY*88E+JN9\\Q7JA#J&+^%4VE^TJ6,]
M!R6E5#ROP5I!3ECUQ$]U(5H OWL $-2 8!<0'0"$-2"TB5;*;%I3K/ P%GR#
MA(G6;&9@:V/1.AO"C(T+)?1;HG%JN% \>3PWA4C1A.?Z=$ALZWN.%OK(I"4%
MQ)?H8-CUDQD#.IV"PH3*,PV\7TS1Z<D9.D&$H;N,EQ*S5,:NTGK-KFY2:QM7
MVH(#VOP W7*F,HFN60KI:P)7)]ID&VRS'0='&:>07*#0_X0"+_#V")K\-]SO
M'Y$3-L4/+5]X@.\Z+RA_!D +$&N2Z&>&!:#QVS*/*.5)-?R^1'-(^(J1OSIJ
M!H)P$RR51+^^Z0W0C8)<_CXB+VKD159>=$#>'5>8(MFR/FEK@LKZ?;Y6O%W+
M:RZ2]3",PB!VU^U:OPWRN]%+T"O)G49RYZCD.4C (LF0/G%H"FM]317ZTE%'
MJM%MJ+L?T:Q>(Z_W3F95O)V6#_W>KE=O8\)^9[]5EXW@RZ."OP #H24;IT:I
MOMJ(5 *;2_U(-?H->?\CFN5[+]>N]TYVU<3M_TT0=;T=P_9$^4'4V[',;36.
M',3*]E.II91,5;=JL]KT[)'M5#OK8]/+;4-ZH:D^!&ZQ6!$F$86EIO0N>OH0
MB:JW5A/%"]N>'KC2S<X.,_T] L($Z/=+SM5V8C9HOG"&_P!02P,$%     @
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MH"5R104'B?-!,$H^3)*V!;@57RENU,$U6"MW0MS;P74Q"&*K"!GFVE(0\_>
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ML5 "*:YR^<*VOZ#Q,])\,<N%^:)M$^M8**Z$9$4#5@H*0NL_WC5Y. "XP1F
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MMV.U%;RNZG5'LM(4QG<F59DUS4P]A,!U@)I/&9/[CEZ@?5JC3U!+ P04
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MQM>ZO,OVT-\V4-3VW+P1J$_A]G&G+TH@S0?Z?2$$'AHF0'_U6GX'4$L#!!0
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M94Q:\5FRL3^^E<T5/Q';R0$DJZJ!M01^+[=),(V[^\-F%GHX&2C!^0+ XS?
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M2 9S5A?Z3JR^0)-0Q_"EHE#VDZR:6,\A::VT*!LP*BAYM?YF3XT16P!,]##
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MP,W.7LB::#.5!ZP:":1T4,UP% 0/N":4>UGJUM8R2\5),\IA+9$ZU361OY^
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" !U@FM2+"J=L%(%  "6+@  #P   'AL+W=O<FMB;V]K+GAM;,6:6U/;.!2
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M-OY9<?$"4$L! A0#%     @ =8)K4@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !U@FM2N;&LBNX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ =8)K4H V:N[+ @
M50D  !@              ("!7A4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( '6":U(R5 ';304  +<2   8              " @5\8
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !U@FM2\QDN
M/$0&  #+'   &               @('B'0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ =8)K4C&],7E< @  7P4  !@
M ("!7"0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '6"
M:U)]1[JYCP@  -LC   8              " @>XF  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !U@FM2@B)P>&<"  "*!0  &
M        @(&S+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( '6":U(_TK_,_P(  ,4&   9              "
M@7UG  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ =8)K
M4LC;;:5P!0  5@P  !D              ("!LVH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !U@FM2U?"):ZT"   /!@  &0
M        @(%:<   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( '6":U+W*\G;VAT  *EU   9              " @3YS  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ =8)K4OSC"1K4!@  9A$
M !D              ("!3Y$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !U@FM2OFF,/*@&  "I$   &0              @(%:F
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '6":U+LZPPB
MSPH  $,?   9              " @3F?  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ =8)K4EA1(0CU"P  R2$  !D
M ("!/ZH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !U
M@FM2CS1H]?@#  #A"   &0              @(%KM@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( '6":U*&A RU$0,  *L&   9
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M970R-BYX;6Q02P$"% ,4    " !U@FM2CW#MH" #  !O!P  &0
M    @(%@[   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M '6":U+)L>;9B ,  )P(   9              " @;?O  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ =8)K4GJ4Z82N @  [ 4  !D
M             ("!=O,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !U@FM29@WSODP$  "@"P  &0              @(%;]@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( '6":U)7TG<RT (
M  \&   9              " @=[Z  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ =8)K4K8F$-#; @  208  !D              ("!
MY?T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !U@FM2
M/7 _J3$%  "/#   &0              @('W  $ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( '6":U('97Y A 4  -T-   9
M      " @5\& 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ =8)K4L'O\R,'!   ?@D  !D              ("!&@P! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !U@FM29O/,4- %   O&0
M&0              @(%8$ $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( '6":U('/D&@?P(  -P%   9              " @5\6 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ =8)K4EN'IM_]
M @  % H  !D              ("!%1D! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !U@FM2]P#>%RD#   K#   &0
M@(%)' $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '6"
M:U+2X:NIX ,  !X2   9              " @:D? 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ =8)K4BT!W;+. @  = @  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( '6":U*[%A9,4P(  %H%   9
M  " @4XR 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M=8)K4GM_)B.@!   LPX  !D              ("!V#0! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " !U@FM2P>4V(_0"   2"0  &0
M            @(&O.0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( '6":U++5PR8T@(  -T'   9              " @=H\ 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ =8)K4CQ 3RVW @
M;@<  !D              ("!XS\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " !U@FM2>G2Q894$  #&%   &0              @('1
M0@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( '6":U(@
M-K% 1 ,  .<'   9              " @9U' 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ =8)K4D0 "\?#"P  S4P  !D
M     ("!&$L! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '6":U)[0)H;-P8  $8=   9              "
M@5YJ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ =8)K
M4K2*7/7G @  [0@  !D              ("!S' ! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " !U@FM2/J3'X;P$  #'$P  &0
M        @('J<P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( '6":U+N@:WVT@(  )(&   9              " @=UX 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ =8)K4@:SG_>0 P  ] P
M !D              ("!YGL! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " !U@FM20\C4;9\"  !F!P  &0              @(&M?P$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( '6":U)Y,*[K
MJ0,  (8-   9              " @8." 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ =8)K4KFD'P"S P  U L  !D
M ("!8X8! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !U
M@FM26O/-F"T&  "S%   &0              @(%-B@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( '6":U*)K5Z'-@,  *X+   9
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M;',O+G)E;'-02P$"% ,4    " !U@FM2+"J=L%(%  "6+@  #P
M    @ %EH $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ =8)K4MMVL'$Q
M @  B2D  !H              ( !Y*4! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ =8)K4J3(PW?Z 0  M"@  !,
M ( !3:@! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X 3@!9%0  >*H!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>182</ContextCount>
  <ElementCount>486</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Long-term Debt and Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiability</Role>
      <ShortName>Long-term Debt and Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stockholder???s Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquity</Role>
      <ShortName>Stockholder???s Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Long-term Debt and Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityTables</Role>
      <ShortName>Long-term Debt and Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiability</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stockholder???s Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityTables</Role>
      <ShortName>Stockholder???s Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfDepreciationOnEquipmentCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Depreciation on Equipment Calculated Using Straight-Line Method Over Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Summary of Assumptions to Determine Fair Value of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssumptionsToDetermineFairValueOfWarrantDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assumptions to Determine Fair Value of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInLevel3InstrumentsRedeemableConvertiblePreferredStockWarrantDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Level 3 Instruments, Redeemable Convertible Preferred Stock Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment - Summary of Depreciation Expense Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Depreciation Expense Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Leases - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLeasesUndiscountedMinimumFutureLeasePaymentsUnderNonCancelableLeasesDetails</Role>
      <ShortName>Leases - Undiscounted Minimum Future Lease Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Collaboration and License Agreements - Schedule of Financial Information Related to Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Financial Information Related to Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Collaboration and License Agreements - Schedule of Other Financial Information Related to Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfOtherFinancialInformationRelatedToCollaborationAndLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Other Financial Information Related to Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Long-term Debt and Warrant Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilityAdditionalInformationDetails</Role>
      <ShortName>Long-term Debt and Warrant Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Long-term Debt and Warrant Liability - Summary of Anticipated Future Minimum Payments of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLongTermDebtAndWarrantLiabilitySummaryOfAnticipatedFutureMinimumPaymentsOfLongTermDebtDetails</Role>
      <ShortName>Long-term Debt and Warrant Liability - Summary of Anticipated Future Minimum Payments of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stockholder's Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholder's Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stockholder's Equity - Schedule of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockholderSEquityScheduleOfPreferredStockDetails</Role>
      <ShortName>Stockholder's Equity - Schedule of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-based Compensation - Summary of Other Information Related to the Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOtherInformationRelatedToOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Other Information Related to the Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock-based Compensation - Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfSignificantAssumptionsUsedInBlackScholesPricingModelToDetermineFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Significant Assumptions Used in the Black-scholes Pricing Model to Determine the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Summary of Income Tax (Benefit) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes - Summary of Income Tax (Benefit) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Significant Components of Deferred Tax Assets and Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Loss Per Share - Schedule of Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cccc-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cccc-20201231.xml</File>
    <File>cccc-20201231.xsd</File>
    <File>cccc-20201231_cal.xml</File>
    <File>cccc-20201231_def.xml</File>
    <File>cccc-20201231_lab.xml</File>
    <File>cccc-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001564590-21-012531-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-012531-xbrl.zip
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M$W%@#=N!ZWA:4"ST72DJCGZ3ERR-C+^]+7SM3&R1A7<M<;QX!7',,\VG?\8
MZ+4_GO@>_!FJC /?CGVOD0Q2M.R42686KIEA<F7;#@8MIGMO.O:M=VU.G,AT
M#XLQYB)!,PF8FLAT/&9_,@//\9["P^*.XM4WE"UV2-/:XV9M([MSC_D@K.T^
M.OEKF>B#8JM:V.JFL5BY@3\HWMJMI=]'IMI(<J(9K+6?R8G7R!6N[S<U@D%J
MZB[5F!D6>SX'P!BU<'AJS"1S?)<#X([:)"=VP1:;\#YV7Y!PL&[(/M15K.N[
M-(V]:NK$-(V5%GD^A\56M7"!&L=BEA6/8Q>NM.^P+ARO"M@(2?3,;CW+'[-#
M9;=E,:-9;\,N^V'Q67W2C4U@JF+OZP#8J :9HU<IQ]RL_W0 C%$+MZG.3%+)
M SH$AJF;XU-CYIGCPQP I]0E[;@3MIA).U+S(+R#A1]TZE%-/?*>R8J8T0[P
M+.O%@]"Q'3.8/I@N*\AXW][?-8ZMRM:<:J%DU9IE9ECF,S-#E+0H,*TH-MU'
M%HP39?4G-LQ&_HM'5S6-<\J6+O11T>(U VTJZ%Y-8W4[G;/DP[[RW;;B]89I
MS2[VM59D>O661C&]YO5F\7HV-%'9=INAR3=&0?L]R-+T,3"]$ P?3OSZ,%5_
M2<S_=\]FP4O@@!T,<QRLE7Y%)EP>]<+]F$7^1F5"RV5C;- &\PR7O=-]%;!]
M32]D!WE<'O=.7\,2""3]:0:@BZ*[@$8B*7$???WI)PLL)T1D;43]2Q;;>UXK
MQ5X2.A;C;Q\T^+9"6)6SE].DF5NVJ4GO Q\>%$WO72#:E6<C1B>X^ _3Q^F$
M)6+QV1SX-+9NFES1M)S($J@0/%Z*#)TC68G!4JTYB<'G.VP.4[17$38TBZVL
MP^Z&0\=BR:\W<> Y41PPN.7&^8F?&E=FM;Q.6QHYF@'7T7&44!_YKGT[G@3^
M,WDQA\EUF:V(8HQH5IL-7LQP!!C%_R!6GTTW'WM\ 5=X^L4,?C 08L]N2M5%
M^<)35BI>>K-++E9F"/'KC>D$?YANS#Y,DX__";0S VLT_<R>F:L^*[GDU@/G
M)*3?NPWAL.4PD7+;'%QL,MC5C+\JXW]_> QH%//T@5EQX$0..R1M6+Y\S1BE
MC+$QK=AK"*=M0BOV=J,5#U4 M$G?@4D_=);1^JZROMMOEEDC$MWOL2/[Y)"_
MYLR1.D6B^\UA.A+=*\;7C-L(?^M5=>4N:E .N 1QD_5VE=Y;@UK#;57L'%+=
MX0[Y?]UXX+4*K+_P4^^0%4B;YW<^\[_?!X[%_O!=,W)<6%A#BO[+L*!X2,O@
M83>A8UU9Y9L3_K@)&'@)$0M8&'T#^3Y8?BE'1K.99GTONU_%BT+3N$3!M#">
M3:O@6."WD-]0%3N;]&DV$6CT=9%)B:C= CG#"%>;U\P-WE*=7;3>2=I,=?@^
M<\4>%87O+XOL=])K+UGD-9-=&VH!:#R/U*3RO[YZ9"&3'( BJ1V3U%23+.CN
M.!@^V7TC1^WUR5Q6.2"54B=6J:E6R75)':)"*42!UB4+&.2 U$A-&*2F&B1I
M=POAND7=@ ?#,\MB1>N9ZFQT0*JGOFSTFMJH^ES3E1KI$<5)0NMA8EKIGFSW
MO'/.ST2&#_O+>UN8DKJ=Q.)\@NQBAZM[?MPYKW@Z,]U2U]&_FQ:1AFP4:Q%9
M641JO@G\P02<6NQAQ%CTV;=,'-FH5$:$4>!8$:-J\*R(K#966PO!RD)01JFD
M3F.65LWVHS4'UFB>^_ZP0/=2F.3]CIAJS L9#_&RLOG+!U'U\A UWS0LCD8/
M\FYXA26,3Y0]2-T?'VAV]10PUJ!=@,+E2A^B8,'--B#EQ/_@^$_,^PS1A!<>
M%!/,6_BA,L.U":OU#Y 9YBW\4)FAU"PT(M535_NP1SF5-8Q*XUFH#M:E$:RT
MT"0UGI7J8)L.@97V.]ZM.P?M2=#;D*S9/G@W-4^9K>S='  +U<V[V5M66FB2
M&L]*=;!-C6"E4H/65,ZI1Q:W'M[,0I/45":H@R5Z968(@^C:CW%>R@1/&OUJ
MCM-"K;_[CA=]8R'#T1$XA\N)(B:W].#&^\"W8RNZ"QY8\(P51$H)#-US!;H+
MQTGX5'<D\)JMB"GGPKO >7(\TRU316>=/K=F\*&9[#@/ YLHD@$2OBLBOGC]
M//)OZO5%+)36YBQBHIV8]+/C3K^B2:=;ZFK2+[J]7J^)XE,3DWZ!6KS7V[86
M+U7&GYEI\U-N;P4)1!F<-7+8L\H,Z[&0YJ7-Z\"E:;<339CC[&4T8>Z6K6C"
M><+PN^\K5<[W6,X#/__N3A[]GQ YNO[3%#X]1+$]O1_-5+AKR:B-9*Q&2"TF
M&3'YAO0D'H8_OI@_G7$\SG)\L1.F<((LBGOT[UDP](/QC1_<12,6A+FN#_DD
M]3&>C6XESM8UW2^.R\+(]]B].<4?PXV(GI:X:A*7<,31;_AGAB<V\0ZYOHWP
M52Y0J,A9S74%7U.L[SSV".3%T>'A!]"SMA9?+;Z5Q'<!!S543+5'6<NX?2\=
M-\?;IH8')QQH$8)@?@?GFISI[EWP. K\^&GT^^=[X6;/G!.I67NWNE_EBKKJ
M_JJ\I=7 SAP]K0;V4PWL@PNHU<#:CJ06]$,2="V$M13"947@RK)PV]WQG@ZI
M]6 ^#G;!3GO;?+ $.VDN:EY[Y0;3MA/<1GZ4I;*K67*MQJHSX,ZRK$4$USKW
M%43LUG,B!\"53\9Y;%K>#D7>RJFOA6^+PB>?) I'0G$YSH*[&[C.$U51K1C
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M>IWSSFEE$+,&32)[6@#J!BU3%[S<.68U#\6J$&_0 EU<=%8&6.'@62#/-FF
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MUU=C],6O(HCX!C&EBQ_]>S,G2><;#:(ZE[GT7F709A*52AMO?G?@O%<W#EH
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M#!Q_,C+AT18]"P3,XK^#<K%BW& "28,+$,>H5@CGOCW-R+Z')(%;@U27$!&
M8J!+7/;,7%) -G[R)[ 6^"\^2B[!L'!> @@4H^LBP#W$1TA2YCIC$"@@O>V$
MF-0[MLR8(!&/#TD+(EA1P$QJ@,*76Q@_ CX\%@>^S9Z81P5PH$1!U'@/+^<9
MG[ E'AZV$;$21<:+&6;5%*SF(W/-%]1?L,@[*_)!P1GGJ-:ZI_2\$=X#:)^
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M?,5;-J*<'X9;^#/0"Z^>/A*H(B-?BI),]G] 6P>C[!/67:R,-=*Z_&3Y>,>
M!T9I,C/-9,KNL.Q^#O!@FD<!9DQ"'-QC3_G*#,76M2A>Y],&*.QR(OX7UA^+
M[J\$?MIJ$*,#:)&TRR1FM*!]8*Y+LS/D0O%T8JIJ( G%;1EE[;RF'A0_PVXB
MI88GX?$"[(JM\S0W*=-./'S/7Y\A(3H@*0[&J2R#V1#"FY-=BO./(RPWR$OP
M'-'D@S/0/,%O[_*ZTW:>#1JY^.N1RX;14?(#=[0&A)!?CW"N(Z SG)C(/\G?
M$VP/$G\+M<7O.*9]FDG(WLD/V&)N1R/0M*!XE=<$Z4<;ET6@@+Y.'LAOZ[=/
MS__Z'FQNQ(X1"M2Y+X$Y.5K!"NQ6[9-$>(-PHIAK^A39.T*%6/M_F.!HO,]A
M@'^IHNP4;D.W[7C$T=+MPA?IRO[]9Z_3ZRV_MKVCWV=4CD8W4<V]]_\G]C'R
MD/*.^DHXDN34\N]%O$T*D'IL^+:#HG^=[#Z#@C?^,4@_HFPF?X$(:W'6XJS%
M>0UQ[BGB?,L]*IYDI00[79-Z,MV,TX4.$W,B/HT1_(_(I2(^\ :3OQ+7KR7K
M." .G-49K33]'"0U&U,'<P%6'#QK];"'[*750Q/40U]1#T6A7!HP\7T=I8YH
MF"W^2B.KJ1KHR712&@,F$:Q9%$@D4=W:*F%/DR>/F='9^#&MHW'4'(1OXQ!?
M4LA9G4V[^0HIX9)<CH$>RY'/.TWE_EV2RTX#N% I2?7AZ?\3VZ*4)C^X"IZ"
M>S!XN[Q(&6*790M>[,-?BGRE!(RP2+X)'$8S^1NL!7KR [[)&>;-5Q]@RF66
M^8VY[2)D?#%6G6+(HLR1BFK:%_5?$"!^,Q5*33GB16(\S*3!18=!<1B\X<VB
MW0V]+A_PEMNV(+:<\35$H,#U UR1_D8;ZXZH".#I:UG!9(V8]4..ZA@#@%-E
M9 AM(RH5U87E&"DP1F\&!B/SZN\/-,,:"#<58%#>/"E?L*4F))$CCPK+SG"$
M*D_(8^D!=7&H==ARNY.G=+CW))6D2VT6_IR)2:43<N5C)_R0DE:F;#0IJ*:1
M$C])A^-+@#]54;=C^78'!R;Y ; #R"B?)[[IF:0[ZTX4,SP0/^DA\LLMK5-S
MF<PLCB6+XS75J*YY[MOR0U!#ZD$PI&JQ>MP)E#TFYM%N$44"G(-([\HAQ6WC
MSQ'SU$+#@$6T?<_+5?@6H3]LI7E9J1]X'4UV^N\$0'1D_3.:$Z6J.AF\*/D\
M'7? BY6IXPCWQ##QX(?8]Y4I+2DT<W)H<MOXJ+X=_I?BSD&SXUH"2J6\!4<P
M .F.T8N412U)'4U:IP^^S#!V#:S)3,H8)"I"D< ,WZW$?G,/4#G+^+,Y3UT&
M3:O'2<+WY>?9;#9LXHL],@9/M/'ZZY&8=)"\1<!QC*$>(4%^\8UDJ=,^/U6^
M?$1,9;_ZD**3PW5RV3[YZWNQ?HEMJM$U^*U&9O>W(HW$GPFX6:+A%S,*L:S8
M;ZEC<=;9NZ,]!>%G39<*?[9'+L$S[>[%?-K0ZG >@A<UG3X5PVXM2KLCU:=9
M$S!DY51[JRK#\G122LGKFYO.S?6K41(I\(ID7&_NSH9S)=SEQAEMB5^PHOAM
MG6A<6S:?)FLK0BT^KT4JXY2?*K)!W?=*5JSYM,$D0XP-%^LJMJU31"NVNE#B
M4&3#Z&]<;[V2T6D^;7CO;:JU6L8P#CS*98G9G3\IKU57YT!KL[I0XE D1GMA
M]:4-]91ABRC._,61W[2I4U?[KW5772AQ*/)A?,8Q-C2,3LFE\6EKLJF<MX'B
M!L]R&BXM'7F5'9<5ZU/*7KBK(X6I^;4A!0R924ER^WQ(\S#X-+'9EKFDM4EI
M_SCIK=,[+'N:,@]L&U>R"48<]2J&\RASH;*',"0=^#3(0U1X,O5ZW,CDC1R\
M-= 4$I.4N23]^CCP3!P*HK:]R%.*6D9R)!83![3@ ;^R T8,GGD3_D+G1?#!
MH7,:HA"@P'?3K=,X3"<0E#TTF05-C2K) ,C!E'>8($E4["@3."U_/, -6]$U
MCO/T?=2#XMPH.0N)QCB(CL1TFH,\M\D59Y.GXY7X _*#]7@A!; 0GI;K\^.K
M MHT]H?'N,[,UKG8G\_4'0F<R\$I0WG  '_?Q)SRPBA$7LI!G#X3ON94+RXU
MAOM:GFV0'((6)B=9S4 N#W])VO9YZST;ATD]L$-=TK3Y+7N8"H;($-33B3A(
MU/?<:7+(JC(P-#U&.ET4?)5>X43JY30E2@YXE>RN2,1[]?"P@.'\SO0J/@(N
M7T&@/#/V1-4//]U5G5F7GK^$Q6%9NLPLFPZ0H+?G#H:D(R_4NFET#ETZ(1E;
M?P7'8@>Z1<??&2D"$70\5\)Q4\V02 M2ID6U5**L058T9'EXFA6A.')P $@H
M3Z#FM6S8F0S<32U8!A_LQTN9'''F(X$MS[3&+FZZ6H[!<K&H(A"317BS&:D!
M%#VP F; 28R*CS?%X=D]KN3'G P@TR;W@3!Y/IX!HAPFTS9(_R9#3YS,W+ZT
M=&-6<CB\V8H//K6H$251MV.L^Y&2\AE'B'VF9L,KKIZ:9^[%<#K!SK-#TTB/
MI5C!.44X()&F5O+F)M[2R<>Z9JPD]D=8R;3D:+8*4)KR1(&*8</(BWBV,\GI
M-_D';^),Y[?R20A\CH)GB^F?2F<SF$!3S"UV0F4,Z!P8Z#Q<LBJQ)X<,,9N*
MHZAZ<X@52JE8< C2L]9%92\]BXXWDR,]I663O:/)O1RS>&J6/.9&X%E.5$V$
M,K<RI3UV,)6G@!>O3BFSPJ$7XJ@,=0B9>DU;LCJ'0*E=$[99#JR-DFK@H!2U
M:DTE+PW%>KM0MNZVC:^^LNB0'T.MUKKQ68"I>R",#Z5O##XF0IZ%K%0_BT.1
MB2UZG>YE,W33M7+V+XWX\\5T8JLYQT9^5MS&H:Q?M#(+E3._J [2<DUGC!60
MB3<"?^#]3^+LAV%R6!18.M--_%'>^I6,TE2]3AK%QN>[@#L]X#//>9M&VDN.
MHT[HS(?$I$O/7O ^/\,O9<K$*9JF%9%HAI_H4*TP2FM)Q7QL3QS)1]%6(1[*
M2E&;P.S?Q(%YW[@R:.:)*:FJ"Y,3 I<+M<\ZRX_I^J:>/7B=N,GTZ&N(;/PQ
M"Q9%XO ^,;M;3K7AD:<XD$@<@JX\V)(/3L[Q%;,3Q$5)CX[2?@+V=D+62 BG
MG)\CC\?(0]020WI1'@LP*>0X3& 10SV40)M.21U3D\.3C\</ XS8'21;-15_
M6YW?$2;SQ-&8\TKIU 0+B+B7("(J"O?$V"D^ 8.;-FP!FWES4]IB,FXFAF]A
MP2&L8J2^A;,CT7-(A]<1']'9LNP)PA?LC?.(H=(>E2+FF>42/D%/1&/<T00R
MN''(S]O@+Q=!O: 7'RV>'/%+@XUCS :!_]4J."6V^'A8'IXY.+X*&_ODB2CJ
M'+]L'*Y&KO)\)!'5Y7IA2$P\2OQ2,YKPP)0I(&^ZF7-)O&-@7L $[XB))Z -
MO"A9^Y"Q\+WQIO>+:K"<\2 .0B:C(7G6(UDKN+BO7)R*&,_1X?-XCB@]7'B&
MS^$9)\HSU!GNP*)@)7&!,JAM&6].,]"EA\5FJ%%PZWNZY,V9>KL_%<Z [Y%[
MSX]VQ@8FCI'TI-FF2.-MML^07)4)/R2:QIDG\8+4GS,A"(VQ@P#)'3JNR^-%
M?^ *5RL48L9,D#)Q8++:E:7RKAA7'F99%M#*)N&[[($ZN8FI@LW+M;9RB#U9
MFO>YHW9F&E_4'/&<QZ*V4::L9Q:>'FJJ/&S*.W=H7H\5J6 !U90C*5(H53"5
M)DEYK3JO2 Q,RIZFBO:(#D.-Y)D=/ 6GFBE\T;-Z\I"8K)ZB=N8U4O&4K%X(
MUW-&-E.?3>$GLL=O4">$OV38(80GA30QBIBG^$4\O8WG:\EP-3U52 D3%5V:
M.YP;-!2?D06,F73EPMJ2_0+@//.7;(K2BS&R)#^AA/:9%'66N;@\(%/GCWL:
M^,\,*#'(O6T6]=E'%#W#RCV#G*9CTT7]AR$V/W0)GT4G$93C5]UAR,E0,I(_
MQRTSX.)L6P[K\RRHQ"9V#MSD%2*[B98R@L_T LX7II61_!(ZJ)B:>7EV)F2,
M.UJ%')#(;V)#PO2 EV*!RKBWB55I8<NHF%>63YS/HHT.DPNMP!E@RB,.Z'4#
ML(4OPE^81728' A!F:1Y=!4CYL7XS7+^H"QN2SGI0I6> O?:)-R04"\F3(;6
M=,*ZD/E-AZN[&_4H^IK3QN$$>8A2OMYI>H031Z*J*H$!Z'09?CJ@"(\DTF)^
MZ$PL=RGCB= YF:'094W1N;;7L*CU6O+GPM,\Q0!68'&&:4ZY\&0N'["3'_#I
MK<NO.0^@C6?8!G3,3Q(75X<N3,'+)6VS;DUBHM)XHMN;.1\B]51H5*+Z(G[\
M%Q%,G@' SY3!E QHF?QR4KCD>-[7ART/4XL<873T!=!TRMC&CRY=-7]4(+,5
MC^ 3,<]G$?/<L,:D36^Y^,MH;L[8!-Q&=3&'@;N'$]DC3\.)DX,+DLP_=UV3
MAG-N!X633-J_U".>\25*RS4*+ N]L"QBI<@R8_S4E2?F2'Z!NZ]B%FB07IZ$
MJS)IFWR!EE4<<AF+JH@!\]C04? @GMTV;CV1>%9]?U-BJ!Q!A.\%Z,UB*3WK
M1I[!)ZL*N&:5^8HT30$@S28J^-LM<Y)FV:7E$ AX+QY( ^!EL<W4^ 'QC,B/
M9,?7O$_SWGQ2;+)+)[:4?!PE(.9N@#H)$TTN3EH70TOH= 2.49$Q*$. &K E
M9./9=H5.*17D&0C)7'%YL!0J5#EBEXS7)(DMTEJZE!SJ>S/[9O)%)$3)=&"^
MR-A+'!UY7>9) 5?,PL.$>Y/C%?F!<Z*>IQ@H0KU\&-^PD$=+8/Y(R" _ADPR
MV<Q#VL8-#:BT^%04Q?&@ZB";I^'F\::<;)1UJL7)9!1%T<R4U$<1#RZ1C4*'
M?)D;<?D)LGD- QY9C $G[MU,?,?C<;C#3WVA^JGDNM9,1D0.LAB*C5>!-'"J
M0GE^,#&2.+23JS%^1IFP\<7[[/@>$=^+##1_)#GQ^;,]):!**H_AP05F@,5D
M5)DT^T0%/^J,D0('K"FV7>YC&'>BCJDQ=CU;ZCAKJ445HY'+P$I)1J\PJRI1
M-BTJ4IN;G.7RP+]&)DHR8130N8E7/_->63 V4^M0YBR(2@)0Q2%+LSNJO\#-
MW#0)B!Q^)B_%0"+A+)70/*&; 16%6![I*<V;'ZBU<,M@BAXSI'EO0M7(TA&J
M 2E%4I:.R?!S?E2= A.G1/:[7,46K]&4QPJ5Z,=%>,X=F"I<K+ \*YA'7287
MELTX%"0<E/HX!1.99RAN9'KDEW W^-8\]S;2^B*)9RHEE#S!EST1641Y?*WJ
M0N91GC!Q<2A&QY.U)$+Y^?"AH)/@1SK87DS\(S8P/>4G'O3)@8!R21%H(D:D
ME6E$61@DB4++@MB=N2PY@S0!D;9A4_N>:GM7]91S"RU+MC;#+'Q3SPC^J.PO
M/4C9;8:=>$S=T'#!L<NE*2+<%I5[CJ5G*R<Z+Z/29X=:HDK$_Z%7/C+=83[,
M:!OW2<$VMJXH6XVA,L8L<5LK'2#-AO!Z)>F5"C!ER NV=(00"@W,%9!I/ 58
M=<.+<0?,,F.A2I+)G:'01/)H(DKT85PF(,#BQ<S*>&A"6>YIIJ \M<[2_Q9Q
M'9Z-3C7;"MV>I78%2S)R)ND!CO(I+9KXR4Q;W"H?KMZ5SJFV_&,5>S327AZ\
ME4\;PE^X*2K\],5'<#=#C7Q)MI03KFV&WBCJK:$P1'4Y^5A7T8-@+-JECPK=
M+S6.4S97<C6Q2;D=@#%@5 Z"IU$_"_%,1RY':9V=J*-=N,F2CBL<^SB^UOF!
M0;)X" _UR$X7%_ZI(VU3PPJQ8PABSR<UHTWW+2L.DAF/,O61HBF9Z[L0WK;Q
M90:YJ7+ =RGY8*6>246_+P\RI=A>F4RO%D]@P M@"6'/.>YS",*/:.453,E#
MI,*8;6Y1>*$H@Q5:CMCG;QD6^(A8 ]-2X&RI%1YI_2:>KB</1L+]W0$_OY4.
M327OG8#E6II&:\?8$9'2PZ%3S3EC.*%214JP\VZ69+L/\9!D.!SOV7>?.0'5
MLHIL.F8=-DHZWYAG)W(9QH.0_3-F='\V4Y!/JV9C']5=IM&[A)FD)<AU5;%,
MSGSTU:("F3(I2$!@?DU*I^1"*MJ'YQ:P-A[GRZFOM%9E; WOBN$34='>@:=N
MC8[CB=REY*$#QY@Y'"*P I\\6@6SA.1(RD%$,@67FKRR*3N/F+^3N\88)L5A
M*#.WV1*)K.LG\05J01S]JC1>+EU<>CU3RR>W5ZX2U[)Y)QB6Q17-8*AO96X=
MKU,O+SQ?<*.,+D#9P6MYE00\[)C'_-BIPRA=+AB)JW@VGKC^E+$DO2\'>+<,
M8+PDN@UC48Z<WNE/1(U&4F&?"X4K!16J6YS67:59!'F2\K%\23IH'/713RQJ
M20#!XLTX0K.2)/V9]V0^)2D]*B1= I8V+()HDGH;O%] YO-1&3-KY/FN_S3-
MDTXILU.[&/)GD2]R\Y5ZH70?/HS@/]*^)*0(Y9:4<EP\'SN=J^X">R7/YYW@
M,.Y K7)+7I(><9"\+N>".LI)VE@H(XU41/W(<BC\HA6&^5-E?[ P>P)(Q"O2
M<B/FP\1P%^S(%V&M:$%I3JRL'?V'1V=I"E<==S-F=](")EN4,3:4#7K"D"8>
MYMBTYVX?2VX5^;6DFRPY#2*)KI-.='$* @:RU)=*Y)RJE8T*&W%P+.PVY0Z"
MS-:1<S 4S>MFR)_BY*2,R[TL7Y#];+<>IPR5F'+P:!<Y%ZMD@@O:(Y).PW-2
M/9ZLCM8_R.</,IC@.0 1GQ"80IQDL98C(@[..K0A#Z]%*(MJW1342K\^]Z9G
M4JIISD2N*+M.=<^(T *OE>5]20GP+';3$TZP:<]+=^;A@<\$8<)#Z&K,)LF3
MTA9>)"1/'.'=EGB+.+]T":4GLN=B2Y_$P9R0R?\7?W(%YD"Q5N]6&4XU<DE*
M.ZD.YD!@KZP8\U^>7&I&2]9#Y%L_CC^0,KI6C74SO)Z,@N>;J6$VP8[-3XB"
M G]%JK#,]L53@'$>Z?J";ML7;&V2D0P%F:&PE?1$NEDP:/9N'@B.J&Y N=9X
M,3,[*6G"(RTO@]]:Z9\0P9J1&'" D?0Q;6)E!BVT(*) -8YHH#^EFIM=$ ;H
M.#L%493?)%3]/%IXV[B758+X^^W]7:O@L66/G'E<F#FE"+O"I)T'>TCX4FB1
M355GS-O Q\XV>#,_V \L7=;PJUMV(_5HBPD6'Q-)LBN@]C-U%2;7TWX<BC-S
MU..$J3M@#&&]Z3&\@G-?%/@XD(;BX.0$K,*9/,1TL<._ 0?3)4B%JKT:PTNP
M3@:/67>BF$?J..2$[[#=QP-0'W26%6A .ECZ'BM/T5Q>.?;2$>$?R2%=\'B@
M\C.5HQS_)_;I2SSB83/1U'A(CR*ZQ;/N2=.JJB43.+:-3Z*W)*):?W':EY/D
M*Q!!B#)16>1.TP.[DKR-DD>D@Y_1F?-,N0'ZD*97YG/F/(8G/I [F2E[XBT%
M1T+FDG:YO1KE#;+'0$FQ$%,W)8VARED5E5LVD"0=8T)<$#I18IZ5=%"JBOGN
M#;\@HUN4C>J4L_"^9Q8J^3?@GD6@8C8Q+<%=/VJ2CPC-,7KWGH>)1[45E1:
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M7TY%=FJN(E$0E*--N,,N!R4['HW'X$5I<[.(,[%^TL\$*D%MK>!G):&G3YE
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MY:BVE-&VIBZ4T#)24\IH6[-/U-)RM,%]M<T>/_C*@]UZY^W^:>WI]@5^GAH
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MV8,Q\MT!=2W<WW9^XK33[N\\F5L'[ZH.&< YI]Z^,D5F=%F9=W6QC*W;/FT
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M)JN\0!&W([ZL?BEF;@H#@0F=>V[DR9#*J^"2.0XKDY&N[+H+LAD,3\0+2GO
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M84Q%P;0V 2 @RB:B2L9]=7FY#P1>,HV3,D^Y/&JB+.J<5;-G](Q3I%^YM9"
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M4,$U<& ,UB+%,F1?'J!F[?6"1T%Y6D,6ZD)57;EPL<#U!###XL0#.]*F"\#
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M)=^T. 7%(#RPQE<\F606:(26W2Y4'(6;B\>7@4DI3\11G<(5]0QD5UZBC[=
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M%N;4LRV6AC-FIXL,^P"&#S#FLUMMPV37").MR^GHL!,5C18@P];%M"[]D;5
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M;J[857ID'R6[UB")CB5OYOW_[/UK;]M(TC>,OU]@OT/#>\V#!) 5'6SYD,D
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MSR8R]EVG(X!K_^Q>=,L]_^^SLV]ZS^/;Y=2OF@ZZQ2B\FFHM*D-7F@<E$JB
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M- %5D2+/X1Y0ND%]Y^O["_Q#%S2N)ZN_ZRQYN.(E6)HG S@_.%XT5>HG!,+
M76-YZR=5]9X4BLE/DLSPLOQO)K5>Q6?*$#A,'6Z,ALL7(? >P*H9&.+*1H?W
M!LT+>KN\*RKN&=X)[(A;X,ARG94CAK)K9 !&-)HUD0 ) ;<",@-$VJQ7./GZ
M1 GF1N2I0P+>+5"FCS)EUGG/] 9.,TI6@+97%D<J)/R@['?A*:,&;SW-K@(3
M>KZW=O/FBCI.'/B CJ$-?E\_PD]QF[SRK2- &(D@"J_AZN6[!]?_RK>_Y8S'
M/FQ#?;S0 CB&-XS0'(++IRBNLP*<%02#HPUV:R\W9;'!SO P"X9S%J0=8WH]
MK#CPA H&&HA<O?;8BN@;,BE":(PT0/C8Y2#! D/XV34/<)0>,CCDY)F#JBK/
M'RFEJU;3GXG\.OZ8I.KTE]@2_+@M$AQ(@"0OB= <T:T/3=KDT^Z*QY^4[A]N
M8!?_-_-CY:\)G6OM P(6F#@_@!4+,B+3@ND#2L"X1Y O'+63%4O VJ)8';PF
MA?T%U\M4?S7PG2L_T):23H5)W"!*LECFGA?8[OCD9=])*N+)_/PP"92)M61Y
ML788Z8OD3_1 P0=/^V;*+RFV5N*G*N^O'+P<+<GE5 *D0 6D$1XN _6,V%?G
MP[L;,/*<6\</M%L+O@?7(O11!L(;U%44)X44O@)S$!:KSI%7N"XGB4+UQ:S0
MJZX?N]D$E82K-9./Q^S(126-<D[+1MP3<'.<A:%_D1@=@F^)[P![#ZWB<1Q-
MC";,WZZD79:4$GAN4ZZ'BC\V(KJZ!OW4Q00#<1O!=^(*>;U(B>\TBT.E0#1Y
M4/\#&5(_]PADL3KE(MSX:*7M[=M@3I=%4X7-Q/%D5UQ8-OQRE.'H;O1^<>Q?
M^]#2$5>P<%P!O@E:_=I^Z!345EL83P/7E4T;2S>"Q?U?N+K<!(O.3^A-<F)\
M9>0[^'H03163NW#^<:[,F066 ++HVF(;!V>FP-V7?M^P3)4KD'_Q?Q:YE.<1
M_O\ZPG? =+CDK;B)[N!6<6=^-X(F#3Q[)]I;H[HAD\4GH:H2K"K("WF-2_^>
M,_:#)Y^3MNA-0YFFZ,NO(#@<;3;G+X8\EI]IG$198W"/7%6!-8MG=+"388>A
M\7QWX\.>3[1TDX72BF6*WCU<@^8;/$@5<EQY_6^=(--_,R$*]\:78S!S\R5Y
MTO43^/L^ZM@8A0;^!@.GR!;*61C 1L3' EM$6>R60D?J3%3U_' NRJ&.(/!.
MUJ/,VU<NJWI7EJQ-Z7]@3]1OY^J:CS^EFRFS]2N8\R[^45L,R5+18VYK-*%3
ME8I*$"B**3V2Q=-(VV[FY7$UQ>MKEXI1,(L>A:>2_0!6YQ4F!.!](P-OH=-W
ML>A82SS,.2J=Y.8L]/"?CV!' ?:XI99+E*->6R0*DD3M6O6#19R&B!B;\7!C
M^YCWK8*A-_ 8T%R!#^^,VP\LMU3+(&6#8]PP1;?A3&_H6%JAU@D\[R9!<R=
M5E>V"/"&"ZRM_0IX5D6"RI*@*[A[[DK%%!,P=3(,OH!Q.7;\&)- ,JDY-$:'
M9ESHZ>Y"5^,Z6[[*);\[\0^I<A=*SZK^@LT:_;:P1DD.RX.\+:Y8D-9"@T<"
M$,Q@3*N3YH+WSYDCEA/'#\UY1+/)'!< UUR#O9XJH]<)-0L)PSF.I8_W88W[
M">Q/4!_W?F<_&MG"!0O8O\<5A<\G"^&1@;*WKV%]YH@:*5O7V/*>/EW!,2P+
ME(K3)Q:T-&()KY"@\H1K(^UH=$H;!%]I8?G(T5O%OD"#5VB[N'[ZVGCN\M7
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M-A) ?3:RQ87GRKB0)$8,P$X(G&DB3_,?W@HC*GH]NQ_(XER'YY97+UPHOEA
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M_X\_9>SZB7R2!? "G>C8 B""1$O%&%FO%UL =O)$]WA3 X YITX& )__MV<
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M>G.U-&3M??9>4$%BC4%^+/UH0E>U1)X(7]/-D/YQ9S@\(8LELR%[2)J"&19
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M08(E&E5DV"JPZJ([A\--9Y(S#[67AUC/4$&">80J,JQG2KB.!I2;;S '48N
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MT3 #U2E$\^P!M39I_P'9J"9K?RI(L/"BB@R; 9RI41=H:I>IT28S@*Y3E\T
M*DBP\***#)L!5EE I[?S*=K,0W7R U2T_6Y;E%'"#*R"@QT;TK8)P,#4Z%RZ
M7KLX%H4TT=/FQ/80;+K)<=(YW-CD>.XV]4OE)#-?VQP1_6'WB#Q"EU'J!$6V
MRUR&2Y[\0M:\9V<%%22XM5)MH:N:']QC:75.[N )Q@?[.^ID9["_XUDQ^R*3
MY%3\&3H3+!/%ODO*YO"3)%.%J&Z4I$E'S9]1?_#\Q%5UK=;0FSLGAL>E-,X"
M[#:IV\&;W29U1H_=)H^#]-6@<[#S'D[L-UD'JM<$W26KS)AGFWY;"Q_*.5@A
M,RS^ 00RB?TOJGX4*U,JMUVPH88:N;!\\MZ.SQ@KC!J>=4SY.,^SCIM;@,+#
MCK=87-WI'6Z:C;]E(<O#CE^BX'K3HNAJ2?6EG$RCV(EG'_^;^>EL>?UTOT7U
MTZK_US)3IG_2$=]B.99Q#);/18IT LHD?H*6D.D6-HZ"(+I#(ZI2,=T1\J<K
M@0F2&ZRF]IS4>7TJRGU NHKZN4]1!P?=(X)SA^MNHFW;+=A[&D9;0,2F,OD)
M@G0F<1X_Z-%M[2#.0I[/B>*6O+Y28NU\];,,E'.,\1JRCF%B;GTRT)'4C$QS
MUGAU )(U'AS;/B=)AOV>PY92X6N6)JFC.GVQ]JL9=JS]R-*<M1]U(/,09SO%
M_E\8UV6!7S/46."3I3D+?.I ?O'_F_F>:CK,,I]E?EU0(RGS.?C#NJ%)0)Y'
MDTE;U4*+(S_H_%/9%7].VXK^>13>RCBI&$5L&=0"NGJV(C I/LW/O+V0L0^/
MO)#2FT\6(YN3^XP'>DK0-"/GO97Y[/2A.ZJ8V=Q\8"6<!]AKD7B_16;$>C(B
M:S,R2# 3U14ZUF:LS9@1*4#'VHP*$LQ$-:LU9B7VF#)B5F U1*T&8I,5&!4D
MF(E8@;$"8]ZCA%H-Q"8K,"I(,!/5%3K69(_Q)QX== 8GFS:X9#:DS(;TAI:W
M+3/G;$MI.2\PR)P-#R)(\#0"HLAHNX+-!G4 [O>>&(AD1FHM([&R(8,$\PA1
M9%C96,JF=]+I'QQV3EC94(.&/B.QLB&#!/,(4618V525S<G)(56HF(G((L.*
MA@H2S"-$D6%%PXJ&."STF8@5#1DDF$>((L.*QE(T@\[)0;]S?'A$%2WFHRTF
M<6QWS-K3QR4U#+-/GXBU6J'3-(\23/33%*DUG6+T-D\R?3J 33="AH/.T:@N
MA>O,CU3YD94=:7B8N1J)'BN[#1#]U_&@/R +*3-D#1B2M1UI>)BY&HD>:SO6
M=LR0K.T8'F:NYJ/'VHZU'3,D:SN&AYFK^>BQMF-MQPQ)HTO,J@0C+\IP:-J@
MRRIP9^EZ*RP4AF?W\*PC$)?VS%J%)TM,TO"NV=YN>P@WW<;I'XR>F)O$+$T9
M7S(LS0J5-#S,?>V$EQ7JUIO##6O0KX=9NO8LS0J5-#S,?<\![Z831%B/U@UI
M;+)*NT,$<W'MA33K4-+P,/>Q#F4=RCJ4N9BPD&8=2AH>YKYVPLO*=-O*=-@Y
MZ(\Z_4/6I\_(T1K"',%58.\V6>Q-Z@#ABJL\_Q9__O5-ENQ?.\[T]%).IE'L
MQ+./_\W\=':)5U_"BMX'D?OCMW_^0XA?\TLOW!OI98'\.OXXF0;13,H+&=_Z
MKKRX 6WYWDFD=QY-IC),G-2/PK, ;J%^^CK^+MWH.@22>=]D[$=P79(FQ6.$
M[[W;^_0WT';8&^P)%UX>_O1=CM_MG>-O^Z/1X/#HY.]!;P ?>GWU0W\P[._]
MM@KJ415J_%A!]I<=,ZKJ2[5_A72#=RX))^1/_%D*N(E(;Z2822<6$E;MB0_2
ME9,K&>N4S_ZH]W;8[PBDAW!"#W[HGX@[)Q%NX"2)/_;A*WZH;@)458SFI/"[
M)(5_)D %$8U%-)6Q>G"B[H%+B>4-K,"_E2*($OAU FL!..\2\4K=+LH2N#1Y
M?5IN0H6$V5Y:QN!6,FS\;J\'N,H@0&8%F5!\-C)"?38"R85ER;@0/T8.  L&
MSC21I_D/;X41)KV>W6=S!\F1HU'W9.?U 6QG5*W\T6#7B-A4OHH";ZD6.5Y'
MBSP_-K \( B  R)XE\;!L'O\ #?E)%QMW&DYL@WKC@R2*.=K8-21R/ G QI)
MT<@T9Y%7"R31HF615S/02+=,7@JGL>.;[Q3\+A,X4;HWZKCGR5L91%,\#&[(
M9\]?//B,*HL2+O0K<]?QW+72S[YIK/KY$1M4;(LGHM9TW_G)T8 LD,QZM96:
MK+^H(,%,Q/JKP?IKN'$2%;,>9:FYX_8?)")<E##[MPQE[ 3J .UX$S_TDQ1C
MJ+>2D(^7X2+G@J^-*Y'1>X*1\G0$FVZG##H'(XYDUA X,KS(BHXT/,Q<S42/
M%=TCD[$[@P/*$WV9%^L8PEYU*F]Q+=-EE,*9/'D@K7K'#K(5ADN+H6M&Z(!Z
MT0J'%S8-+W#YV=HAB,[!L-9!=&9BZC*:52AI>)C[6(6R"GV2TV!TP"J4B[<?
M+-Y^MHKL987?B^^K"IF_3E4)\9F;^K?W"LGM"N_A2U9X+P6_]_+H7]Y(4T8-
MC"5T>7223> %8$6)*M)6O@L1*5(*QY!29/ ZNA(<J>Z$LV+@S]';1$A5N"^<
M.R?V$C$-8#6/JQQ' N.J<QI7:::6?BK*KZFMB-<7^[+E]=^'O>[P@7E57/_]
MTG'!P<[C@C:5R5=C$2J&['7[7 RY&,D_,I3@(AK/B=V6O+XQ,3B<5C/<2"H'
MICD+_5H@^1^U!NGMG]W*V+F6[93]'W_*V/43*;[%<+YE%5 S^%@%D*4YJP#R
M2+(*P'?]+B>.'\+F:>?KG\-?8L=-,R=H)P$N93Q1_2?1JYF\9AN@9OBQ#4"6
MYFP#D$?R[/HZEM=.VE+E_QF4GQ\FOMO.U__+";*6(E_M.,U:OV;PD2ZD6 JG
MB>DV/ZWL:Y8F*7 6IB0X";:#SQ,%A,X/V+C]Y@NT57H^ XX21,U([&QETB9]
MZ$XJ%C>W5WJ@;<&PW^L<'X^HHLF,6%M&9&U&!@EFHIJ5(+ 2>P2*!]UZ%Q>T
MDO5J(#59?U%!@IFHKM"Q(GL$G,?=?I\JD,R#M>5!5F1DD& FXH-8<_770>>X
MQPJL;JB1;M?.\<Q_PX6I],BF";!Q006)7UA^T41&&Q%L(V@;83 8=/I'E&>@
M,AO11(95#14DF$>((L.JQNHZ=M =4&Y5SBQ$$QE6,U208!XAB@RKF3JAQ7Q$
M%AG6-5208!XAB@SKFCJAQ7RTQ2@:5P5N"YZ\V]:F<31.TJ$BP5XB48 E&$ED
MV!*PF@@,CON=P^,#JEBUE8LV[>? "J8U8JRMK$$?&58P)5K#;O^0*D[,0621
M82U#!0GF$:+(L):I$UK,1V2185U#!0GF$:+(L*ZI$UK,1UL,GC5P)B(ES#Y%
M\5C"7O7>R)]3/]YYA1J=.8F44*I%P@"I/L.,WN/MB^T!V'0;Y%5?U[_U*1<F
M,#]N.;C'.JX54G(M!K*Q:243$8/K80WV>,2:KL4.NH?'),!C7JL5K['FH@T/
M<U.=X&+-57L(F>/J!1?K+]+P,#?5"2[67[6'D#FNQE6!JP*;7I1=!5(,NNU3
M:@\.$!ST=IP_L,(8:3%NM4CO>+ %\2H\6QU[H0_OFKW"MX=PTXV=PTYO<-(9
MCB@7.3)#UYZA69W6 9[UL6DE-^UZ@L:*(_T3@6JZENL/ND>[GE_(/%9'D<@:
MBS0\S$UU@HM5U^,A/.D.=MTC@'FMAKS&FHLV/,Q-?-9JI,+J]P:=T9!U5AVP
MJFU1:(L5F6FSZN#[;S=V^@*)7"W&C4Q:R;JAEH5A% ZUU!;>^['39T:XZ9;.
MP>$A6#I#JG@S.S>!G5F9U@$>/F<\RVG^!9*A^33_0!GJ@&H9*K,898G("HLT
M/,Q-=8*+-=?C(3SJ#C=-:F5>:S&OL>:B#0]S$Q^U&JFP^L-._X!55AV@XIK3
M^F'VETQ2Z0DG](3\.94N?D@C<0N_YAK4&N%()I&+ R_MA)?CJ"VO066&KB5#
MLSJM SQ\\N"\Z$9J.:Y!K0M2U$0B:RS2\# WU0DN5EU<@\J\QIJ+X6%NXK-6
M0Q46UZ ^&BN-1P['*N1V&TI]DV+E8W&5Y]\^1*%1E4+XL4*07Q9NR)>CP-?T
M1L;"#_%:)_6C4,0R<$QX$OXFHJGZK>.F_JV?SC!4B;\^CR93)YP)/\'XY3@*
M@N@._XW57V?2B1,AX1V](K"I:/VO_JCW-H]PJG#HH-<_.2VIKVAITU51W.SA
M=WN]/>'*(,!="ON]^&SVO_IL.,L%\LJXX"/#!+#W F>:R-/\A[?",$JO9X\:
M7QPS?^[,A]&H>_*(CNFK9:LFP#:$:]T-EVVGZ(V>-B/B63"RZ7X5!=Y2*7N\
MCHQY?K1@>4 B@&NPM],RQ6'W>,WYIJU#DDXQ_PM.32=#_:9)O19BPS*./))H
M?=+@+Y9QQ#)9E_*3L=*;[X+ZC[J;]/:=6QD[UU*,'3]&LF<2CX'Z9)B(:[@?
M7$4V?TIIKN:C1<:_NVXF&X^=I^+K78[8H&(Z/!&UICM^3[H#REFDK62M&DA%
MUD]4D&#]Q/JIP?KIH-O?M%\<ZZ<=2L6=-<'E(_#G,(W],/'=^\=>J5OA2D^\
M\D.1WD19XH1>\GK'[B2V,Z@XSEG6$>L.\9 9P5:"<HEW#H^/R"+54M:I@5!C
M]4(%B9;R"*N7.J T'+)R:6(2[*]OLF3_VG&FIQ?NC?2R0'X=7]PXL7SOP!D)
MTT5EF*@,TXLT<G]\U:>H,Y-6>HFWO(1EOP_@C[_]\Q]"_+KJ?M^<V01H>7;G
MQ)Y]O[_@E*8><I8DV43_KGIOX7OO]C[]#50?]@[VA MD@3]]E^-W>^?XV_YH
M-#@\.OD;LY]Z_5Y?_= ?#/M[O]4YS_?R1IHL7=CZ0B?5 H5@R; BS.$MR"4R
M/-.J(ZT4[P/'_;$/"$0!7&5R@:>QC]FW8A)Y,L \84^F,I[XH53?J4:)$T1G
M/E:,7Y*3:1#-I.2LX:=F#1\N:K:U\XQ4MM.J^7-']""J52+0CFV#@P<3(%N<
M1+?S1.%U8GJK,./<NYK+QQ9"0R6]F"7C"LFX\_1BEHPD0K+/GY6L3P'-=_-]
MS/OGFM-HX(^E>*7.CIO&7E\@Q^NH#=#4(,6KJJR6)@R]E*:BA-YA=S 4^V+4
MW7GO L[0:R#GL0@D @3S4&VA&ZZGO1X=:6RF0F--5D/0:IH0VY;3UW<_^;$_
MCJ44/HH,G%\2.ZDDZ^1@JX,($ ?+\L,:KX9ZW>'@%SA8];J'1[^0Q:>E26,U
MX!P6862#'FT49[ ?^RC.!MWAB,49,7 X=D$:GB)V<1L%3NH'?CHC>T!EM4,$
MB/:JFM%)]_  =<WQL'NTL;+AVN7V\@X+L4?;SBS0GE&@'78/>RC0CD;=XQX+
M-&+PL.^9-#R%]>SYMSXLT1,S7P:;-AYDQPT1*X"=-<_I>^YMK&;82=->CF'1
MQ3YG0D"Q&%L.2I/+QC<O\UY60HZ%Z/!>89I\'7\.W6@B+YV?:%B&B7PO0SGV
MT^7UXH?MJ1?7M!&I\U.\NM)T>2VDIA,2(?&3-,F'096%Y1N6<L^U4#L5Y98B
M7=K]3$>];4V#XBIN:E-0FEWN5C-[BN>B+$622[IK"!I)8<DT9Y%7"R0)U&KS
M**BZ)2ZUI0_V>1:C2:O.@],XNO43.'*?;L@N/%*#RNF(RYP8NJ70\6R-9N')
MK%A;Z%B?44&"F:BVT+$^:Q:>G#U2IR3%[9R4^\/N$7F$\L/R6(*@<8+RP$S6
MH\[V!14D6BK4>'9''5!Z-3K:=( D<\XS8<+S!EFI,&NP4JDM2J/1KL.NS#AU
M"L;N)#FR5N?.)'52^>13YW;Q>G+F9 M9;.?^-5)I=HS>$[S=3T>PZ6;(P:9C
M*9D1F1%9RQ&'AYFKF>BQEGMD\\:==T1?B^UL*<FLU[8@[^"H.SPD#]%EE#J!
M<,V9FV.\1&"IA3N><\AJ"AWGD#TJ7#P8D462F9#CR20!J($49-ZI+72LP!Z!
MYW'O@"R0')JF%YI^[H,Q?7@^R+&$ [''A<*D8*F!)Y?E&55D.%FM5G Q(U%%
MAI4-%2281Z@BP\JF5G Q([4O/%N+7.CB(,I%N,20J8&3E*4:5638/)B#ZU_'
M@_Z +E[,252186U#!0GF$:K(L+9A;5,7:*C&1+E<]\$C*M?K-H/'=NZ+XTJF
M^J+'E4PO;8\P1^X:/@H<R>J.-#S,7,U$C]5=7=4=%_#6/D*\ZDSN11G.5QUT
MMZWTZE356\E>WK&[:X6!\FQ8-8._=NZ-?+#,9A6>K;9@J+?N?$%DFV[9U+U*
MF'F8:"4Q*TY6G*UC.E:<K5&<NZ].7N8*6"I>=\F2&HL<BE6H[=83\"9U@'C%
M59Y_BS__^B9+]J\=9WIZX=Y(+PODU_%Y-)G"L\,T^3K^'+K11%XZ/S_^G,HP
MD>]E*,=^>HGWNH3UO@\B]\=O__R'$+_>O]''\5BZJ7\KB[M\=U+Y7;I1Z/J!
M[Z1P"J[>2?C>N[U/?P-QA[W1GH +D2C?Y?C=WCG^MC\:#0Z/3OX>] ;PH==7
M/_0'P_[>;ZNP'E6QQH\5:']9R%8OA^69B"M$$=%8I#=22""ZFTI/^(J RG_P
MZDI#\%K]%2 !*DVF&5[EI.I;&/?/TBB>%4GJ,28"I)%U&W@C)X&GCH/\ >JK
ML @E/1W\W=@/'5@3?%]E$DQP1PA??7$<!4%TA__&ZGLSZ<2)D$!.3WR0KIQ<
MR5B[%ONCWMMAOR,0*.&$GL!YZ*>BW+,*-[,;M8C!'6$X_]U>#W:!#'#*O0M2
MHOALI(;Z;.21GAU?2!\C.H!C V>:R-/\A[?"B)=>STY47.PH>VX9]_3\%4L;
M:0)L0QVQ+4DMB&=3^2H*O*6:Z'@=Z?7\V,#R@"  SF!OI];A<.UXT$OQ%ADD
M42*3M>J)16')@$92-#+-6>35 DFT/5GDU0PTTFGHSUT43=]=]+D\FIJ3:>5
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M7:;MHVOO%C>>^X(NF9]!*L+@R3L'EW:P]@(POUN0&-'\/"XE13HOA-/"3)0
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MQIL9HPY0(!]%<E*US[1W24W5"X5!2[Z<C:RJ':.]Y\EI9!DSHX(LO,+&Y0-
M5MD#*TQT< 2X%M:6A1*5,P97)7E&MG)'&?S$R1;HD(?>=Q=?E<]_Y*L1@=1[
MMK)[1-5-MXI] M>H:O(!!1C@I^G)<)1$%5AXSDNN[(Y+$%B^O2X*D\&E.3Q
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M/"YN65"9*(E)7,/GED:,6"IM"^62)S*1I[J$K:W76<*90%^9;_#RL+C#P=Z
M$LD;M0YVUU(K1OSV,_+ES5HB:G*L--J1%L1*2M@N,QG)?(%8:FGL0PN((21[
MB^JPP"MP1<8<8YWZ<[&'].1Q!O%%3]X<&KMS. \6%YH,+IQX-&.U&@+29!XK
MM#0+0"T<_B'0;6)U=JY),Q)(A-MV$(4RF3)0ILHK-FE9RI:WSBA!I)<1B5;J
M1?U>M:/+RC2#;R@^ )_LDP2EU-5<MXN&O#C4A"'.X+.*0WR[N9'85]2BT7Y+
M9DL_D-[Q7<0@;;#4PVYO;,/KOKEV8BCFN,Y7KU"O.[YW;+#!4I/[G8YH_O51
M"7P,ZX@/,$SIJ0NYK32\N8;6;95A(3RLSZS0?DVXNH\KG9'P"\P_$1< R^]'
M-6>X 7SQ<TC$:"L:IAV6;KSC_4D.]2 @,"QF"L3[@J3?;%#+IM.21N*7/7WW
MNL",.5]F'\?%8XU);FQ2B;?21-?-K&D#))Y@K3HK1&N9.&\(5D4J3058 <JH
M\+"&/PQHVJR82]$%:!4I+56@'1"O4;'+" =<3+$I@UJ-_@#@M!U6JCN(J!7M
M&7!"Y7"?/.BE'FCB3:<-1U)&2KX7E<%2[+[^(::IJL6)V--XGQI].LE"(3F:
M]GK:N,I@"&SW$KSXYGQ'LHVS182Q5[6,B]GX]-DH=9#+^,QU%"M=0*1$%0^>
M&"SU[L4)]MX8W6:-P1@(+<VK2QR3._<+ZG&'JDK>+=)E$<E9FT5P*#*E>1-:
M;KN;C:52##)]XQ/@D<Q7.*7]&>[I<M#8 :64Q_QAEH<]1R]()!J%M1M4NZ/8
M^YTC)/OXV&E4; $P#ZY\;[7->O%\TM)3"]X?* T[_Z1L@<$<>*@O!.I*<2<-
M>R^^-<3PGA*LV\$_:8_(CG\R65#N5VP=(,-/27H:UIC;O#1"$!6>;W5:KC!<
M/M_/AI?9G&=@HX%9I_8;$,]8?;/.*T]JUX$^28QU\X+:<J Y0TWV(H5M'%";
M$G3#8]'-J [@4[(1#&K;@@[U*<E9<>=X3UY 8648Z]K=!,0O;Y83H?@HZMZ*
MDK"?S#<2@$:)LZUX5=J>M2\/AT(A:M/QI)TDWP]1L=MK;8188^/4_@T"ALDX
M&2;#,>H-P)-=S13MSEDTI/%)UKHL,PTM[!\% XO(V:M\DQ!!3F5Q.4)\*T+N
MBI;[]5A%]"-EC"&YWZ"VBQ M(9X)6)G9'Y]+VTWB-ZCM)?K 4IYR_G43M3U%
MUX>ZTM3:UHX3UQ<(;6&EZMF.7@LK6VJOC6-;V;8C@#%O9 %/G0LS6.8.VJ:V
M"'*?C;"=RE5&J^U!ZKD9^0UE'KY*8YVE-U^[Z+EH(8;M0I*H"R_(EW0PJ/U%
M6H2'-CYVX[_\+.9;E^%#Z-LSR_">HO>_'Z!&;BI_+3?F7!A^KIC6HLVZGPCT
M='C6HE5!A)9[GG081$AU?]),F.2QT1FP^@YW@:)B1<%G. B#T(_0XZY,"Q1[
M2AK41BA,!O/"!W#8PX?C$X%;EO#7&2]HY88['Z]14MB-O0"/E@T@SL&M&83
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MU!QJY.E30QT.=0'6H0(/8M^?+$5!Q#*3X.:B=,-_3&T0U@J(P^P#:^6--!&
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MH[SA-L=1C7)6?%I3,K_C31I(PBM<<[R 7%TG4B@-]QX:NG]LYUE'I^2YWHY
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MBMBA3?S9I,3N]</C_K*DWZ!_ZV-O>.U[KW: DR52__CA8H _N"!4O)0[O![
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M'JW7#N[K+LIISVEC TE6K3MHV"7G>VKXZYY0,'1G>([^]G]02P,$%     @
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M/C[)5?W?\H___(H2<I3B.;K%<;S.KH">-SA:?1@XCRA@%DS5@V\UX#JF++_
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MY%>G!_C:\2,V,_4+$7CR;R;G/*/MV@^=T/6=(//GY3_R1DGQW#B\IP$!FB/
M>M')^7+[1L,.KVQO5&JX'6<X%9APHB!WX@8@6OH,\)AE1T+:(.F@YHL3_23O
MG]QQ2F-@'V/6219"2S,<73WUB";=B#9W?$4 H.9HE'E?;9!T4%.[D64($@"F
M@Z9O#Y.(J=PEWP=P-W@3%"U: 8=HF6WIZS3T)"BH@Z"G.I^\<=\E1E2UE%=_
M"J>QVSH'3F3K:.N.5:WQH.VQ&J#HH*)0<#?A(DWB6_2,@C/X"VL$8XJ.4S5T
MG)JFXT0-'2=&Z"C?*HH/_\LGMY3(G4DT:0$"WA]:=>F]8OWSY38J3-"@.E 4
MHE;J,ON/J.;5@ -F,F67W]*-E_S@*PZCM0LPN*.-PD6'PJ-M;Y8F/MT:[K?3
M#_-P+\+$(RL"+O7A16W[V_-5KZ-%N7%>?[ FEMD4V04> U4<$3W5[(EM"H5Y
M-7%F6(%/.1NIBC=5%NV0PJ"]<.)TB%'07CAQ9ET\U(YSJ,G1P%DUC+-'P/6"
MU3F3) :8&6T"H8TY9=;8?P(I\5V6.%?GD>:Q=?O/(M4\:8HS<+X,Z&3JZY(F
M$%TJ^/7.=-^==GZ)1][:3Z1M!KRW-W\'&$AMI;XR$CRD!B92DM <[.=-'>S?
M"$+I#^6&>BTI&[R(W_X](/7J&Y)O>+VVL%5J/$E-X9Q8:?@6IY7)3X&MJ=\I
M5BF=S]DU<(*SBS'K:SE%43R:TX1*$7>S+&2I"J3:=4[S=<Z44U /N1L%V5Y6
MS'XAH,KP5L=T(:!J)6;%GY/>9'X;LEH*3GJ3^7K(RF6^._N%@"K#6QW3A8!J
MC5#6J3Z9=]0!N%&:3SKHX@[ #42BU;]B(;BF*%7Z8H7@2NF<52>B54>F5?LZ
M3UC!-$#0P7N9'DOB;T &^F$^[([-A]4V5?4PW? PW5!VNN%AKFK%= P1IA_F
MJEJ5>WC(SSSD9^Y8?N9.=M71DA<C,L_*HF8[1N99&<^[U#G/RG0RI27;XC#%
M\##%\) [V7K;MC%U4N^$J &D_BF>$#6 Q+[>K=@N?><!78=VCX%M#FW.)/OW
ME>Z[4DMT@H\DW6/YD@MA<=;9GV>FCW7BP<XA)>N:XY^ _+TS;4:9/AI@R13V
M3"*VD6_UR3.<;WM\5,AF3 TI,=\0\P0DS_@X96N8)Y0JR?EV."$@J;%#&OMK
M:+,*"-T *F\,:[HFR1,^)HS7;Q2MF D3TSG#+I[@2Y2@:$YXPWO>KJ[N*CL+
M=US;XKH/:=(T1,M7/ABR'[))D>,TB1,GI)-V2S2P%@.08#@,KHZ\@":,Z/14
M5=1EL(SETJV<:6Q*-O>QK0:!GG3.LVM?0$LV#YWGS%  I>^4GM+2^75#TNE$
M9EIO?ND_^Q[1//=. DA#E8%J@LI[/_YY'2%T$Q(-A^)$#95-4$U0R<3H.PZ<
MA!H$R^X$U@ T09O<X+@F*+M A:X>DU480!,5ZV$,)0>//L\J9"?(G87^7RE@
M?IX>/ ;,R>VKCCENWNY SJ,0BQ6G0=8+YB$S4IV6P2(ZU<9<R:868JTG3 O5
M@QU"J(;P826'"IA%#5376*76)(SVSH"F>\>0.F]VXT+3'7-(>:$F#ONRU\&>
MC$D[>27I<AK"M$.3;&UW6/+,N_V(E*GDX+9#FW-3.,YM3_3G8N:$3RB^";,0
M5RF+]1YY",VI?5S*>;TCUUT4$8ZS)/H>(T,]X#6$J)%*LCMUS2EA]\-/9M]"
M_!BCZ)FNG[6@)AL.AR[9AVQCW6\$5[,=NB0?4QW/)KVR_8>S9&D13X1>?$Q-
MS^E S!TB>L:["5W:B!9=HNQ/*2=/OP@-D+<W<9PB.8>96@1LYEU<@SN#I8-W
M+0@<ILH-;;+7?L_UJCF3Q4]^8)<C..!#]YJ63(4=ZEY3E0=7<=]BFG=+4:_K
M:?E8GK*U!\:Q;C$[I>N;C=/UP<J6 IYN@K9O\3C5VD&B,X-%@3B=G1D&$(YJ
M[<P@:8=8$Y&R:K^(6J$#:VD"--<53!D<4FQKMR?*03BARU10ZZ089#3+4E:W
M^-(&&?8:%JOK7, 2,;*=9;W>P(9$*QJ=T<FJ,5)%-*SJ2[E@8]=E[(@=2E.A
MP?DQ>B8KT=6O<41;%):1>$SXOR .#7&8.MP[F]BLXS!RW72>!N2.Y_T1X9AH
M!J+Z O]?R+LE_SI'4QRAB?/2A7S)!6WFS1]$&6OES<:"%O!FCLF%EV!V@>.$
M*76%;*B K8/BIN&HXK0U0='2OKV86$C3)R^(,#V1@_-?['R5Z.LN &T7J=)5
M2+6."33>4O6TEH"1.T->2AOZUI]UX.@) *@M-$K%.X" C00RY(C'4B\3Y! ?
M;N@!OF<JQ]!65?28]JB+5?0TJ+I:2NM4,Z?=M/M)R!>LBG2;G.#M'@G F0T=
M47]BOS^FLPJ%&\E#\G_WS1[1J]20VF0;X]G&U9P[Y^R/."GG6;TWA[-%^$#6
MZ;.\BS Q59+E*/2HEW5!%7/AAJOZ4LYGV749.WR6TE1HN)FLEK\+G# IX_ 5
M@1I@-</1XF/B&N<2+2+D^OG >?+NF8X(O?R<8Y_7(@SR/2E;4P>':I=G&EK)
MV\XAZ:#FEH;59CCP6$'<ZA\W\T6$G[-< +@O1QRF#@K'TZGOHH*W<')J &A)
M!$TCHEZ)\B.,O/9?Z-\DWD<3%$VC3Q=I@J(.[Z 6A%0B_*WSB".ZVE("I38(
M1G607/<J(7!&Z3I?RCACA<#I]5S6LUK>.=L&T^B;DW+(BD SXH4%D%GI>FU[
M5=R+)G"/VP7/J^!^P,!-S?EHNF.&D#<2HO=$6%'==<A^=PKD7,/M1_&0.NT
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M^G$&& Y(JE=U[74TQ\9'SYJMHSD6C\(-OX[F^,Q>/0^Q=\"^#5Y[;7G '<@
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M_ 5W3TUOZ<$%&L$^*L[K?9L K]_C>NA#H3."P$O+3=O#N\SM+=E^?T@.Z2W
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M*=AK3Z>[OSMEV[$NR]NN8P6#.,[R'CO( AVS$#2+$WMC+[M!75?<8&_:X1'
M,4D8[@T^T"3CW4L69/I3HV$9DPX$.F7Z.Q>0<*C$0Q(02JB.T$1U30>5$C*1
M#7<!<1DS]PAD"D^0!;DJ9@'1)V.*];ME>@L(!8YO1@0%)U "8H0FJFLZJ)20
MB6PX.0:4(-6F@.'V9__W+0\'>^2Y#X*B U*W*N!LA([R0G7L!9$#,L7\[L:
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M=Q8.AFJ:(44U5.J&&E^0ZB&N'RH47*IV9#Z[3&W&M $A#FH.-H7ZK!%9O/D
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M8(QF^O0UY\3CEH1+5=>,5X'K6LL""BO]5PY,I/EARTEW:AA9 )>A>DQJAMC
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MBO'V#,?LAXQ?'+/;KQD2,V$IWB_60]UG"<8K"69)='\4WLDQ87B?#E/4P'2
M62%U0G(@P<62G;VH3;K9-8J9O<A_6H6-KD1[KO00W <3X#JNAC12.V.N@S*B
MLK79M8KFO13_6G2.I51VG1!LPW(F/>;5*]?'+?TH#J,#D<\KUK!AA)<67=3$
M?)"I*6>T:O7A*3'3DZ3Y?H^3!Q:6OR3T2_;(IY)!_&(]_AB+M,SPTX?PDJU9
MP".)CW(%(.1E6O!)+8VZ$N[43JZ'N.G9BG,WB@RV!\X8^SG%F]W[-(OV0893
MDU&U^4W[SKHNR;U3,?E\R"P18 R7/9:GPW:!9652&7BC96 _29;X@??]-_A
M$R>K,TV!$W+S=  \))1(6" !8$8;M;+>*B@B-790"0EGE#@/TD=>-9']B^=T
M/@6$N]&4)9F>P"F//&H ^'BM,WT4%R[$#PHRC) SXY%:F7,5G!&%KM,.N@#$
M7%?I8JF52: -27%;E5I*_5V5WM6@:*06M6HTN'20 2;R2 $Q(-W@-$NBD.=J
M#G0ET\<I71S77:$>KOL0K'!%1PDC^)RXP.@09V+R-=,].B V?&!HU)S_F"!D
MZ++LQDV4_G:>X&V4\9\,3PGZQ4S:B>X3ZZ,"B0(FSPD$&N)P0,)6@RUJ8#[
MS) .4@03>JSX?2=(>;CQ,F:A+1]0-A\A-04Z>)UF",#K^T%4?4)2@8814&:,
M=KTI-&[85;!'6L1M>HA;9ISJ+0\^81]%7Z:'LN8S''FOL#"]QFZ*F477PAQI
MD-95C'[Y;159W5F6=)X0>(-BII:Y[A3[>Z@W/DQ+J]CX@)T 4T *ZXLRXWEQ
M\>4#XW)_8",GC])-<A&E!YH&9+/C!7>NHB>\E8\.38@8._D3+G]9X'FXH%=J
MP:>1HC*3@,\?<8(1?).HIRY,OD::28OA38(*%?C<4Q2K4MD&$.7G=+^/Y"-D
M?$.)BI1/'(?1I-'01.JD6RN:*#YV5DIL>;ZGHL.(8@MJJ;UQUT,C:3-XVF00
M0&3>X"<<'_$-#NE#'/&]HMN X'2SN\7)4Q2:)6=I"+,G<%2XCQ,( 8D43!A!
MI\\:-38@>(9(+SE(X/%!L$"</9I2S&CDIR873#U"Q?HS?SO#?)=32]P4OD;%
M>SG5$Z!B/%-@H026/H'4PI(K((LT>#JM\U2\!+/4J5MW@:1ILT@]D6XN/@]
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MG(&Z-/Z:B<\#OE($]<?^0*^PS.#YD<;XY:.HQ/SA&&\M(KY/@CVEW1+=1ZG
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MF?N*1JW)Q:,4+R8C7Z^("7<%ND5Z" 3E%8YCO,6)'.I@C&YCW%!-@P'EH9C
M-X:O$F7F2#BG<9HEQU!D$ 4O_%;G^3%)#%/JAJ38\] OU4OYB1*+#1$IE'L8
M&OQ0?8O!Y8)TT)#CH!QH\BX5+V=S&>]HLI<'/O>IJ,"AOS_5*\!V]Z-'H)\]
M*0Z&H@H-Q$[4&"=4RU13D@M8J%^9W([I_^ZTQ )5EM>T @8$@?HA\],QTTPD
M7+N*1_?W)A/ML')#/\E(5%.!176KK$:_82 9N;V*% @.RV#XT)K,HK#C3JO7
MU%>ZM_,65;_+YEJ:^[N3S;4PF>L,?'GB75U5F+_MG33[&<;<O=_ZS<O2;<.
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M6EET=11.B%>N!."(_<!LX2M@I>QYR.987L+UA_6%:XU3RVBM[+DV_NQCE>L
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M;ZC::LH#GVF01EN<R.FP[LQ^3(SEQ'18K)?YO[+W5FQ#ABHHA#6!)FG4P(J
M":IU<B/L%%V>@[G '$TCK585PV\-;'*0Q_&Q.O#@-X:+ X2JE]%?Q6M*L_4H
M'>E^(E\@UR_UEZ>3N6,)=!!=@!&EU-RX\.FK]0NZW#GH%^9K(:DUKG[EOSP"
MO-%IG$G]C_?/_+PQQ6P%H-TG='QS4L$(19+/8AXXA^%K,@A1W4\ '38/+&-W
M%.-0+>VBIJ8?Q4E-YT(\7PM/O_=.B'S(CTF^P&F81 >C&7:_ .NKTMT"/=UI
M5\#0MD*#$'6CW% MDX'DH7Y-O8<$%[?3?3:"=.E_H:._T5E6/J2:'F>57YMV
MHI6+\7JHE<^(( 1=C\WI@%&LSBG?/Q]PF.&M.F'[<(RW4?Q03*&T"=>29>D%
M&K*]N$:!VY@[[R0TJ.Q,$RJIJ5D!!6_7H4'.@[-S Z<*-XX.KEWI.EM,J!;7
M#(@5M8XT&E9?2.:0&BFV7@]]?HVRQ_-CFM$]3JZBX#XB4?9B<\K3(VCZ84"G
M8!]W0/CS0IR1+=[A)!&>^(3C([!SG&'".@YN!NP'FIS&T0SB4*C 0B68JRQ=
M6>+1.D>W^?6)*4%U<9YS[61-%Y#9N3VL-%/LNLPU*0NS.AJP=8@."1-]HB71
MLULHJ?\ /:.?H:9S]-C-09:NN5>X\H5Y/  @[6-DNZ/X_7/XR%\H-"=9^>9$
MFDM)GHG&!0XDJML$-,ENF ?@F-N=0-@8<-WE ?IH JEIO]GEQ; ]I-]Z&N"Z
M.6B/;N ;TF)"26#PE OME0+G=O=K;><F=MR[=QNY[-K!ZMTR]/MQE<V&\H\!
MLPV_>QP]/%I,VII?GSC.U,5Y'MGW.1A*!!JD\;V'E>8@WV4NMVN[BWS#9_H:
MKY+D>JU72)Y]S5=NAT%RG7$*1Q>!=8,"#.GN[KP1S^XZ=1]-:/7L!0BZ<:R]
MYW@!,(5TVR"-J20J$)W50>AZ7L.XS^V1,O4*9I=4WV41.A^J@=3-#C/6*I#0
M;T.X[/3<DNVDQN%567\-:D5V]],RDW/;Q3T8OA88/4T5S3T-L^@IKU?/_O.O
M[(^U0]\)EFUB]71L/UGS\MJ96.!I'9SG;HT"H6!QAY5_\L*^!:'7<>E2U#5]
M5BL.4W2)ZRTN"O$SA8*$@^7]TNW7Z.T-W[!U<)44*Y]NUF>[R6]^:7MMOP!+
MO^P3Z,7S/C8+*)97WR XU2@Y5,MF:Q\K.^YGNQHH'5QD@F(E4C.0V'?5RE3+
M)Y5(*E:4A."?_'41 [D<9YQXCG29=1MBJG/<.;*!W\Y=I;N_9X?>"M)L0%'4
M\F:T 5YR2V]DWF2946F]\6,HT#Z=40O PRL#21"G?)RA,3HD$5N@!T18@K\7
M2/M>,H:1CVI&,K6R]2H(S:,O1T15'K&GC9>B>M0%<Q/]I6+]6[83/%6*GX5=
M@8"V# +"E+K;WK3?(@[R"O'V.J$9CN(+_) $6[N-\B%13K(/NT3/DI#(>L>#
M1$;;"AJ"LQC0V)VXV&]3NPVH\E0GGQ)LXO?/&8Y3]MEF5Z36Z_<BFN(F5[49
M$N^[_% Q^Q.WYW-T[GMAC@_!SPQY;5<D&C?P1'\KWSQ*E,KZ%H[6(V>RAW7*
M]>U:14H%?SA8>:0#ED<-,]=VI0%+6OE0L;ZLOY-3#K1L5A51_=U&36E.'RQJ
M2)_WK:F@G$$=!#H$YS*C=/C!J4[CPIG/UC:0:I-9!_M![M4E34TOG&@ZUT1Q
M**^X>Y:XGK:U#O(+0)0CH@N7S9JQ*^M\>JWLMU[E'=>JFD0:K6D^N%8%V+6C
MQLTY6>XI!3DV4UY7(TFK?<4VZH;7I"K:QP+QW$/[/,Y'>]CKF8RNI%%MMJHG
M4!,U]"9G+]+XIN>]*OTMF2$9MGLQ_3+];,*(*J]];X5!F&7J,$5UK0>5%>W7
MVYR\U.:W+:1L!KKI?9EMYK,K-K<*,=ZF'YA?587/:&)4^7Y B/V11J]0#^]%
M&AV SG7B-$X-U;866!KRF"A0$(=!-9SI UH6A5A.0]E8>8<3\8Z'F%&5TU2#
MH4U+FG5WJB'=TW#'D?.EB)@C916XN/Q1P,,8^DPXI>;6A<^?VG_]FD09FZ_S
M%WHT270Q6L[6U'+<%*V3D&+:JX"*.SWCK?.9_R%[R':=J/?/(3GRI*'3-,7L
M_[9WP;-%-HB9^,FI!"9P/K9)9'8!&Y'I0QS]'<J8/(7J=DZ(N8U72&LC7R0?
MX#N+G)5*H$(+MLI]GCH!*#:I>&]A?(XBOS3QN(0+\7LJPOMY" -SIZV;!QR5
M.<#8M7.+EAO5W:ZL.V6;FZ]W@WK:).3D.^ZV];ZJKSM)O"G$S?,$;WZ( JIT
M1 \KW3DU=7,!9&#PE<G"_*X/KMPVH>>PJCBJFOY>FGB+Q;AR>/-KDU[7\5H/
M/']L!E+=[QZ;TP&C +)OQS-%XZ66EU28&.JJ^0!*D#[6'C4K[@2P]6)Y82"?
MBVJ'E9E0VP<Z#$#\/)["%.AYYD[L)>S+^Q9YH6@(06O%-[4V^<0LP4ZPRYCK
MP?=0Q!@BRPWR/S!Z]'X:R.3\0G-0W\F'/9X<Q2CDCBYVQ^2@'95ZB6>C(+BU
M$Y=IYR[:LF3G]F$HWHZM7HYC&,W#<EMOMY%MZ^3F6'Y\.]=#>6=0>'&K+!-(
MAY[@#'0J$:L9D6O/:)D.QPZ>UYJ]P41I:PVYO,LI-OJKJYXWKMJZ_-#5DZ=D
M/6Y]#38A+7/T>,5EC(33B&,@:8Y*'_Z2H@MS+-7QUSS#MM=?<?M)H^G*(_6<
M[U82G#[UNJ]HRN,)MC U.C1H?<_ZK<::'$]/99888$X/^NQ.A^P"R<;U9S#K
M!G;Q^J4'E4E;6Q?G";QS/@L(OPQ^1\_PQR!BGA?%?! Y"^+?\M#^]9$-[!?X
M/KM,-\<LS0)17,-H7\8>9,*LT!;4W[[-O=2(EU&XQVA?*L7G#?=,+11(O= 7
MKAC:,LU0E"):Z0:B W#A-=0945;+WBL:/_ (XC)/X^VO09($<5:^WW7%-+C,
M\%Y_K:LOT-*C=0&\>"\'?\W[1^F3_'K?%ZD (H4&["<V]8^X#A"\U)AA:F5H
M']YWQR=1KCPO%^;'ZX3PY3PNX_ K<+8ZH9J.IM@6/'GJE(JCBMD)XKCBTEF.
M7+V/B/XFP/_W].G6?&TD+IOGY_G4!+,UUX<@%$J</D=&]P.ZOCWA+<Z6- ^3
M=X&!"A 8R8<#)-!Q\\ S..FT-?H;1UC6P2\HGT';NWCQ?5<VE_)^EV[>H*+7
MT543031[G[-+#'UW[UMO"[EE!CS/J[W&"3=U](2OHAV^#2/,3)]^#%+F ;R,
MY=7=Q4?,\Y?TU]N30&S7VQ- _:RW)855X9$O/(FYT@EQI5"A%9)JB<*AB"D&
M84[IQ%FH,WY6ZQ@=7>FIG5<XV!Q<W!JDQQ"_ZAL"W:$+]#>IU-PS +$'%*=9
M(F+==(K;]6W[8:@MS;W#BC5&!0)C[!\@@8Z;!Y[!2:>MEYGBUMOX*=AC\VEN
MOPQ7MJ]D>G?Y5XB#073\#G)ZW;]I,*A$](0"AW$V"^:;)U<TB WGM<VO64Y(
MZF*\S#W%[A!A&!"FD3W6I@/F &396F%R;E8.,'T>YD-5TM!RJ2D2WZ#,\AW1
M.]8:TTE2]_?M.ZPN>7YVG>5Y <=YA3@2C$%CD ^J8R>(ME=VPTNK"Z,O,VUJ
M-M1\TM0GP9WQ?4V8UN/Z_;.E(5O!9& @ %S-DY(@#A_Q)L:F,Z76%VU'](8@
M/[,E"8)H#.(HM]?J=- HH"S<?,Z%FY=!.)@W>5&7M#0UGSL-Q]#=%VH70\H7
MIS%<"O(:0]D7"BB&VE:G@T8!9>&N&&(0SF+(L;JDI>E2ZX];G$0X/;M.\I?:
M;S,:_J8??5IB[*<$ V+=^XT$0V>HA$,"#\;L3(<H:F YP*2083Z6"I7+.*1[
M?,MZ<7$(<\4#@O7GIBOV03'VK R(=1\J$@R5:*B @Q$K.DQ1 ],!9H6,$++,
M K^GV>;K_!%!SHGQM>I?9\#T[P!HF \T-^-AXVA;8),]XD3"\.=OX]1T>Z!?
M@.4$O$^@EZ6. $.1-#.6<" N'(SR0K7,!9(#M>.1!.1^_DT.]NWT=9'?%I .
MY7,8C=F?;AOFO:1CGG7/%4!"@]4UECAOYPSY&Q^"$,O7RNWS-U09KM(&*ID^
M'AA[2/ #&_[XZ]%Q&!T"@@*!!6-F,LI0;Q)'TVI0V<A#I9G$P6'0Z0@3?D[G
M6#AN=C+GT.A,KO:]">= BAP/#K^7=W:C['&;!%^ 3, [;4Z'; +)OD5OS_MQ
M_KB5$+UH5WZ!TS")#K)V_E^").(WO&Y8-W<6I%.R4,?DNNIDAG%\I/&5>+QP
M;(&(."02F##BQ(KEWB%"Q\IK8K1G*%')W1B2.T.L"@UN#PD.MIM8M<R)?9P.
MR73%:#^&AU'K<"!1*%C;!\E#%*-D])7596)2@\W>>!RSZ%J8ZXE# 8LD+G\1
MLA:()VYJS2U;1D5UV;/)Y5.^!HODKB *RA06N:/H#*-*&5YYC:N#<GV04$@N
MF2]3M-&QB-YN)'^:^7.<180AA(^7,>,+I]DF)B]%L>C3A%EIJU_/PD"BY5Z9
M-H*7#4R.CHX<GOMI^,B\5RJ *-.@++:._O_VKOTW<AM)_RO$+1!D <]N9O8.
MMTF !=JOP N/V[ ]"1;!X:!NL6UMU&)'#X_[_OKC4Z*Z]2 I4J+:R0^3F7:;
M];&^JN*K6 Q28N.A%TE1^BPC,UT;E5.IAV)ZB0UK^QDO2>[%#@071I%\#O(B
MC?*]ND6:MF]JGV;RW%@K#:(EF+^0=\LX'#*MK[9XQ+O+S+*W'),7QCO0/) -
M6N81JFH+.,TX-7QL';FSL=1/*A90N4 (!D1R^>8!P++!Y\Y^CK"R$49%0)NO
M9>JMV)H#RZW:-T?1.@@]7:8T4M.Z,#E6EK\TM"P^2D8N>QGQ?M23+>V^>X3+
M#H:XF?>\A5Q)"<L-*'&(<,@#YN=>';AY#YLSL=P0V%=O.5[(%%'V0CZ\0)G:
M6TP:C0UXF+FO<0?FFT(Q%]M 3R*E.F%(6W?>D\,]K)Q(8'^BWE87"*C$"287
M#S#&\3N\0-MME-/C2 BS11*R[8NL(!L,VDZEV?"PL4]9D(,L/-X\6./V:?E_
ME"1P33?&:6T9C";=DZDS H<U5_QP33,30(,8F!7=\@#)18-*-BUE3]-0^.8:
MMX<>;];H\D4<9#A$\2R79?H0/;_@8(7'YRB#>&!>P_*'&?]IYN"\0$@D$R+V
M?#G(7O#:;^S;)21?_P7%(89V]7N!YQYW*(?TT\=='.&XG;SB'Y$',<@.AM:!
MCW[; ZX\:,IR<#F%WGS(B# 2M;@T0-_P\",T&7.-ANIY;KS&$J5<.&#2 1'/
M;[E0 *!" !B$23<T+G#DVI,7S0=FR1VV8VLU76_7039M=10#8I+;6-:\]L,'
ME=AJW>5HTI[/S+0LAH6HB;+GI#Q;K>RYVN\-JZ(@VG&4N.R9T3=J''5IQ"?M
MQI)BRTSI"3,^11G=J[==Q%X(N]1-Q5%JSD[^8DOS+B;40H!'6]HZO+4DDW8J
M< 8<"?>II9Y6M: EVBZ[DVR<#P;G>['_NEAE]&$HT^&AJ24[(>VX99?70<[W
MU:G$KT)@SU67*0:5#N9:AIDV/78G3-BW.8XB@MF#V&;.I'.*F^0.ON5/7V'\
M"C^C)'_1+CTW0) =B]46;']HP#ST).]-8;3FU+?8M*&F9TUS<]RJP( *3?W@
M[28!!!%@D ##-.'@TZN_?\$@??J*G/E_V?Y(]L#E.?'V3S/T]D-^39V\IM<Y
M<CG$I0F0[K)2GC@REJZ5<&0J84P#(!*=N//?YNK.-98'.72EVWDR.MRI"1;?
MW?H:Z\6I5S,!(YH $>C$I_]SICY=HWB(2U>:G26=@QV:0+%RH#_" 1/*@YB;
M[A/Y.]A&2;0MMO2(27I65?1XTB/ +TFP16D>_1\,+Z.,WE>Z3^$V*K9-21UW
M<, IH8$H6\=5VJ('FL+WS!026HHC%(<M,,M^ !(4<4E.RF+*SNAKN_0'(4<*
M4I[XDB/Q#*\?X="6);6>8!K2-E>KZ3X'E0U'P $<3UL.%,"@K(1-!\>04I@L
MCWA?@[B@B=_U4/G-G_[^Z>.G'X4?[((TWX. W(1?T^)1X&\?SP )=T,O5!XG
MD-QJ/T;?V8;A3:2.-IU</*OELD JT(?+9"KT(%65&=UV/&Y5[[WXUM^W9ACN
M7H6?C5$TO_C>J2H?U7^4+WB07&;M&7>GO>C(CM-]J+W-)VEAZ4<(PP<80K@E
MC;(\NSS"?S6MA6[>MJDQZ<MRX^>L4'>&@>"IIT#"TU0I%+ K2WAG!(P786"
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MGJ?1JLC)Y.H)W>/.VKJ>56>LO'E 3]:FC=RW$?Y?2.<C3/<P60\Y[VYISUJ
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M<;L2YT-7KV,V7MX;FM1_M(EU$>PB;"ND7NIC'J3YEQTY=5;/&U5OT# U5%6
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MGKRK2Q6FIAXY[U#^6*S^#=?Y$[IZVT7LM51'XVB;L%$";;/PZ<98$"*0H!Q
M@L63K5Y[AF,V_G9Q-'LC,1V;,2; 08$G!"I84R7T7+T%VRBA$,J'L1[@IDC"
M1?CO@CV#<(WMZA'F>0S)OWZ)\A?\B[B#99Z%40J0)<D64E.L('&1BTH@@+"
M($<@2/"4+MJ1JD<L]JR"]6]@AU*Z]D.;AACE1QQR9&I-^4L6B3PMLSK>MY3
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M]-??CG[_QP?VV^=?OW[]A?UK]JNA6_:+A.SY+__[V_VSO48;ZSU9*K(+;#I
MZ/XC9#^\QS9;(P&^WE7^!OW;^_VOO:<_>G]^\?[#^<]OH?,30>/=NP2/ 'OH
M"2W?T?]^?[K+QK0_1FL46%M$T+63;436X.S\XL/Y+_1W?UF@S=8CF^@^F3,C
MM@[0\I\_V>3_WN]_F8[W7\I^-]IMR;X/7?(O9/:_M&0ILMZPCS>[A+?]P=C_
M=^8[-W[D1KL[?XF##4.WB><G0NA/"*'J"6T#LA/]B/TVA:#P 7J+D.\@9T^&
M3J"K*3.>]EQYV"Y 0(<,R9AL'X7(_GF%7W]QD,M&I']@^+P_.T]WT7\A/\H
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M_5M-1,]>2!#;)R,E+,"6L9R"E!:T)\93^F<;'$3NWVQ#S)?Y,.\GQ&):'JU
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M<LBG>U4%Y W.Z SN7Z?K507<D$<-CKW9-I/$\U$MHF7/8+R_B>GEJE6C*?:
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M=)/>T2OE(KE]7=I[]LH*U^!&"V4?Z\#WTB)(V.AYC5!TCY/R8?#M4D>EKUE
MMT8U#:G]\ >]:R/\PV=""[@?RC_6%D67"V^G73#A^Z&.2E^S@.Z':AK]W9W@
MT)I:,MI60BK!YO#+WKT)%5/!@FB/I:>#R,X]?(XK/69C29II%%8-:(VM,X/
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MC9+S\42T"!\6,7/TJ0Z%\&#0!^S;< V\AD@/<Y P(:HH2)D.A>T(V <U'^M
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M D/"U!-E[1SF[X;2UN/*/^2*IC&1 \(9:S?)$G*3.TVO.TUD3;B18':_GG;
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M+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !U@FM2:T;=WI^>   'J0D
M%0              @ &3] $ 8V-C8RTR,#(P,3(S,5]L86(N>&UL4$L! A0#
M%     @ =8)K4EC^@R!17P  <TT' !4              ( !99," &-C8V,M
F,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!  #I\@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
